

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 August 2000 (31.08.2000)

PCT

(10) International Publication Number
WO 00/50639 A3

(51) International Patent Classification⁷: C12Q 1/68

(21) International Application Number: PCT/US00/01392

(22) International Filing Date: 20 January 2000 (20.01.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/121,047 22 February 1999 (22.02.1999) US
60/139,440 15 June 1999 (15.06.1999) US
09/357,743 20 July 1999 (20.07.1999) US

(71) Applicant (for all designated States except US): VARIA-
GENICS, INC. [US/US]; 60 Hampshire Street, Cam-
bridge, MA 02139-1562 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): STANTON, Vincent,
Jr. [US/US]; 32 Royal Road, Belmont, MA 02173 (US).

(74) Agent: AMES, Wesley, B.; Brobeck, Phleger & Harrison
LLP, 12390 El Camino Real, San Diego, CA 92130 (US).

(81) Designated States (*national*): AL, AM, AT, AU, AZ, BA,
BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES,
FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG,
MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN,
YU, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
10 May 2002

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: GENE SEQUENCE VARIATIONS WITH UTILITY IN DETERMINING THE TREATMENT OF DISEASE

(57) Abstract: The present disclosure describes the use of genetic variance information for genes involved in gene pathways in the selection of effective methods of treatment of a disease or condition. The variance information is indicative of the expected response of a patient to a method of treatment. Methods of determining relevant variance information and additional methods of using such variance information are also described.

WO 00/50639 A3

INTERNATIONAL SEARCH REPORT

International Application No

PC./US 00/01392

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

MEDLINE, EPO-Internal, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MARSHALL ET AL.: "Getting the right drug into the right patient" NATURE BIOTECHNOLOGY, vol. 15, November 1997 (1997-11), pages 1249-1252, XP002178096 page 1249, middle column -page 1250, left-hand column	1
X	VUORISTO ET AL.: "Expression and therapeutic response related to apolipoprotein E polymorphism in primary biliary cirrhosis" JOURNAL OF HEPATOLOGY, vol. 27, no. 1, July 1997 (1997-07), pages 136-142, XP001024390 page 139, right-hand column -page 141, left-hand column	1

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

24 September 2001

Date of mailing of the international search report

09/10/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

van Klompenburg, W

INTERNATIONAL SEARCH REPORT

International Application No

PC/US 00/01392

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>ARRANZ ET AL.: "Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine"</p> <p>MOLCECULAR PSYCHIATRY, vol. 3, no. 1, January 1998 (1998-01), pages 61-66, XP001024470 abstract; tables 1-3 page 64, right-hand column -page 65, right-hand column page 61, left-hand column -page 62, left-hand column</p>	1
X	<p>STEEN ET AL.: "The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness"</p> <p>PHARMACOGENETICS, vol. 8, no. 3, June 1998 (1998-06), pages 259-268, XP001024444 abstract; tables 1-3</p>	1

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Claims Nos.: 145-149

Claims 145-149 relate to methods for providing contract research and methods for recruiting a clinical trial or study population which are considered as methods for doing business under the provisions of Article 17(2)(a)(i) and Rule 39.1(iii), PCT. These methods are therefore excluded from search.

Continuation of Box I.2

Claims Nos.: 1-149

The present application relates to gene sequence variations which are useful in selecting suitable treatments of various diseases. The application provides extensive listings and tables relating to human genes, gene sequence variations, diseases and compounds. No individual links are provided between the gene sequence variations and the suitable compound for treating the corresponding disease.

In view of the large number and also the wording of the claims presently on file, which render it difficult, if not impossible, to determine the matter for which protection is sought, the present application fails to comply with the clarity and conciseness requirements of Article 6 PCT (see also Rule 6.1(a) PCT) to such an extent that a meaningful search is impossible.

Additionally, present claims 1-149 relate to an extremely large number of possible compounds and methods. In fact, the claims contain so many options and possible combinations of elements from the different tables, that a lack of clarity and conciseness within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible.

Independently from the above, because of the large number of elements raising from the various tables, non-unity objections will almost certainly be made when in a later EP regional stage a search is required.

Present claims 58-66 also lack clarity (Article 6 PCT), since they relate to pharmaceutical compositions defined by reference to a desirable characteristic or property, namely having a differential effect in patients having at least one copy of a particular form of an identified gene.

An attempt is made to define the pharmaceutical compositions by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search of the claimed scope impossible.

Claims 89-110, 123, 124, 131, 132, 135, 136, 139, 141-144 relate to methods of treatment of the human body. Normally the search would be based and

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

performed on the alleged effects of the compounds. However, considering the shortcomings, especially the lack of conciseness and clarity mentioned above, no search could be performed.

Since for the reasons stated above a complete search was impossible, a limited search for the general principle underlying the first independent claim (claim 1), i.e. a method of selecting a treatment on basis of gene variance, was performed. The many documents retrieved also feature some of the genes mentioned in the many tables of the present application.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

synthetase mRNA, complete cds	601002	U34683	ARG283CYS
Human glutathione synthetase mRNA, complete cds	601002	U34683	ARG125CYS
Human glutathione synthetase mRNA, complete cds	601002	U34683	PRO314LEU
Human glutathione synthetase mRNA, complete cds	601002	U34683	6-BP DEL VAL-GLN del
Human glutathione synthetase mRNA, complete cds	601002	U34683	ASP219GLY
Human kidney mRNA for catalase	115500	X04076	IVS4, G-A, +5
Human kidney mRNA for catalase	115500	X04076	A to T -21
Human kidney mRNA for catalase	115500	X04076	C to A -20
Human kidney mRNA for catalase	115500	X04076	C to T -18
Human kidney mRNA for catalase	115500	X04076	T to C 4
Human kidney mRNA for catalase	115500	X04076	T to C 44
Human kidney mRNA for catalase	115500	X04076	T to C 49

Human kidney mRNA for catalase	115500	X04076	C to T 12
Human kidney mRNA for catalase	115500	X04076	C to A 27
Human kidney mRNA for catalase	115500	X04076	358 T-->del
Human kidney mRNA for catalase	115500	X04076	MspI
Human messenger RNA for serum albumin (HSA)	103600	V00494	ARG-2HIS
Human messenger RNA for serum albumin (HSA)	103600	V00494	ARG-1GLN
Human messenger RNA for serum albumin (HSA)	103600	V00494	ARG-1PRO
Human messenger RNA for serum albumin (HSA)	103600	V00494	ASP1VAL
Human messenger RNA for serum albumin (HSA)	103600	V00494	HIS3GLN
Human messenger RNA for serum albumin (HSA)	103600	V00494	ARG114GLY
Human messenger RNA for serum albumin (HSA)	103600	V00494	GLU119LYS
Human messenger RNA for serum	103600	V00494	ASP269GLY

albumin (HSA) Human messenger RNA for serum albumin (HSA)	103600	V00494	LYS313ASN
Human messenger RNA for serum albumin (HSA)	103600	V00494	ALA320THR
Human messenger RNA for serum albumin (HSA)	103600	V00494	ARG-2CYS
Human messenger RNA for serum albumin (HSA)	103600	V00494	GLU321LYS
Human messenger RNA for serum albumin (HSA)	103600	V00494	GLU354LYS
Human messenger RNA for serum albumin (HSA)	103600	V00494	GLU358LYS
Human messenger RNA for serum albumin (HSA)	103600	V00494	ASP365HIS
Human messenger RNA for serum albumin (HSA)	103600	V00494	LYS372GLU
Human messenger RNA for serum albumin (HSA)	103600	V00494	ASP375ASN
Human messenger RNA for serum albumin (HSA)	103600	V00494	GLU376LYS

Human messenger RNA for serum albumin (HSA)	103600	V00494	GLU382LYS
Human messenger RNA for serum albumin (HSA)	103600	V00494	GLU501LYS
Human messenger RNA for serum albumin (HSA)	103600	V00494	LYS541GLU
Human messenger RNA for serum albumin (HSA)	103600	V00494	ASP550GLY
Human messenger RNA for serum albumin (HSA)	103600	V00494	ASP563ASN
Human messenger RNA for serum albumin (HSA)	103600	V00494	GLU565LYS
Human messenger RNA for serum albumin (HSA)	103600	V00494	GLU570LYS
Human messenger RNA for serum albumin (HSA)	103600	V00494	LYS573GLU
Human messenger RNA for serum albumin (HSA)	103600	V00494	LYS574ASN
Human messenger RNA for serum albumin (HSA)	103600	V00494	IVS6, A-G, -2
Human messenger RNA for serum albumin (HSA)	103600	V00494	EX14DEL

RNA for serum albumin (HSA)	103600	V00494	LYS536GLU
Human messenger RNA for serum albumin (HSA)	103600	V00494	ARG-2CYS
Human messenger RNA for serum albumin (HSA)	103600	V00494	ARG-1LEU
Human messenger RNA for serum albumin (HSA)	103600	V00494	GLN580LYS
Human messenger RNA for serum albumin (HSA)	103600	V00494	GLU60LYS
Human messenger RNA for serum albumin (HSA)	103600	V00494	GLU82LYS
Human messenger RNA for serum albumin (HSA)	103600	V00494	ASP494ASN
Human messenger RNA for serum albumin (HSA)	103600	V00494	ASP365VAL
Human messenger RNA for serum albumin (HSA)	103600	V00494	HIS128ARG
Human messenger RNA for serum albumin (HSA)	103600	V00494	IVS13DS, G-C, +1

albumin (HSA) Human messenger RNA for serum albumin (HSA)	103600	V00494	LYS240GLU
Human messenger RNA for serum albumin (HSA)	103600	V00494	AAT267AAAAT frameshift
Human messenger RNA for serum albumin (HSA)	103600	V00494	ARG218HIS
Human messenger RNA for serum albumin (HSA)	103600	V00494	HIS3TYR
Human messenger RNA for serum albumin (HSA)	103600	V00494	LYS225GLN
Human messenger RNA for serum albumin (HSA)	103600	V00494	LYS276ASN
Human messenger RNA for serum albumin (HSA)	103600	V00494	TGC567GC frameshift
Human messenger RNA for serum albumin (HSA)	103600	V00494	TYR140CYS
Human messenger RNA for serum albumin (HSA)	103600	V00494	ASP63ASN
Human messenger RNA for serum albumin (HSA)	103600	V00494	CYS177PHE

Human messenger RNA for serum albumin (HSA)	103600	V00494	GLN268ARG
Human messenger RNA for serum albumin (HSA)	103600	V00494	ASN318LYS
Human messenger RNA for serum albumin (HSA)	103600	V00494	GLU333LYS
Human messenger RNA for serum albumin (HSA)	103600	V00494	GLU376ASN
Human messenger RNA for serum albumin (HSA)	103600	V00494	GLU479LYS
Human messenger RNA for serum albumin (HSA)	103600	V00494	GLU505LYS
Human messenger RNA for serum albumin (HSA)	103600	V00494	ARG218PRO
Human messenger RNA for serum albumin (HSA)	103600	V00494	LEU66PRO
Human messenger RNA for serum albumin (HSA)	103600	V00494	Arg218His
Human messenger RNA for serum albumin (HSA)	103600	V00494	HaeIII intron 7
Human mitochondrial	600125	L13286	none found

1,25-dihydroxyvitamin D3 24-hydroxylase mRNA, complete cds Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709	4-BP DEL	
Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709	7-BP DEL	
Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709		ARG378HIS
Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709		LYS313DEL
Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709	2-BP DEL frameshift	
Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709	20-BP DEL, EX11DEL	
Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709	21-BP INS	

SD-144141.1

Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709	ARG234GLY
Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709	ARG302CYS
Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709	4-BP INS frameshift
Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709	ASP258ALA
Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709	PHE205LEU
Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709	TYR243ASN
Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709	ASP315ASN
Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709	MET282LEU

1.2.4.1) Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709	-BP INS FS141TER
Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709	ARG10PRO
Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709	13-BP INS, EX10
Human mRNA for brain pyruvate dehydrogenase (EC 1.2.4.1)	312170	X52709	36-BP INS
Human mRNA for dipeptidase	179780	D13138	none found
Human mRNA for glutathione reductase (EC 1.6.4.2)	138300	X15722	none found
Human mRNA for pancreatic gamma- glutamyltransferase	231950	X60069	none found
Human multidrug resistance-associated protein homolog (MRP3)	CMOAT2	U83659	none found
Human Na/taurocholate	182396	L21893	none found

cotransporting
polypeptide mRNA,
complete cds

Monoamine Oxidase A; MAOA	309850	M69226	23-bp VNTR
Monoamine Oxidase A; MAOA	309850	M69226	3rd base of codon 941 941 G>T
Monoamine Oxidase A; MAOA	309850	M69226	A1026T ProlineProline
Monoamine Oxidase A; MAOA	309850	M69226	A1559G LysineArginine
Monoamine Oxidase A; MAOA	309850	M69226	A385C ArginineArginin e
Monoamine Oxidase A; MAOA	309850	M69226	C1410T Aspartic AcidAspartic Acid
Monoamine Oxidase A; MAOA	309850	M69226	C886T GlutamineTermi nation codon
Monoamine Oxidase A; MAOA	309850	M69226	C886T Glutamine296T ermination codon
Monoamine Oxidase A; MAOA	309850	M69226	exon 14 -- RFLP (EcoRV enzyme) length of (CA) _n repeat
Monoamine Oxidase A; MAOA	309850	M69226	RFLP (EcoRV enzyme)
Monoamine Oxidase A; MAOA	309850	M69226	RFLP (Pst I)
Monoamine Oxidase A; MAOA	309850	M69226	T891G

Monoamine Oxidase A; MAOA	309850	M69226	T891G Arginine
Monoamine Oxidase B; MAOB	309860	M69177	e (GT)n repeat
Monoamine Oxidase B; MAOB	309860	M69177	36 bases upstream from intron 13-exon 14 boundary
Monoamine Oxidase B; MAOB	309860	M69177	A at position 644 of intron 13
Monoamine Oxidase B; MAOB	309860	M69177	G at position 644 of intron 13
Multidrug resistance associated protein MRP1	158343	L05628	RFLP (MaeIII enzyme) none found
Multidrug resistance associated protein MRP2	601107	U83659	none found
Multidrug resistance protein MDR1	171050	X96395	HindIII
Multidrug resistance protein MDR1	171050	X96395	Ser893Ala
Multidrug resistance protein MDR1	171050	X96395	GLY185VAL
Multidrug resistance protein MDR3/P- glycoprotein 3/PGY3	602347	X06181	none found
Myeloperoxidase/MPO	254600		ARG569TRP
Myeloperoxidase/MPO	254600		TYR173CYS
Myeloperoxidase/MPO	254600		MET251THR

myeloperoxidase/MPO	254600	G to A in the promoter -463 G/A
myeloperoxidase/MPO	254600	Dinucleotide repeat
myeloperoxidase/MPO	254600	EcoRV RFLP
myeloperoxidase/MPO	254600	PstI
N-acetyltransferase 1/arylamine acetylase 1/NAT1	108345	NM_000662 POLYADENYLATION SIGNAL VARIANT
N-acetyltransferase 1/arylamine acetylase 1/NAT1	108345	NM_000662 VAL149ILE
N-acetyltransferase 1/arylamine acetylase 1/NAT1	108345	NM_000662 C1095A
N-acetyltransferase 1/arylamine acetylase 1/NAT1	108345	NM_000662 T1088A
N-acetyltransferase 1/arylamine acetylase 1/NAT1	108345	NM_000662 C1095A
N-acetyltransferase 1/arylamine acetylase 1/NAT1	108345	NM_000662 9 bp deletion
N-acetyltransferase 1/arylamine acetylase 1/NAT1	108345	NM_000662 G560A
N-acetyltransferase 1/arylamine acetylase 1/NAT1	108345	NM_000662 C559T
N-acetyltransferase 1/arylamine acetylase 1/NAT1	108345	NM_000662 C190T

1/arylamide acetylase 1/NAT1	2				
N-acetyltransferase 1/arylamide acetylase 1/NAT1	108345	NM_00066 2	350-351 (GG to CC)		
N-acetyltransferase 1/arylamide acetylase 1/NAT1	108345	NM_00066 2	497-499 (GGG to CCC)		
N-acetyltransferase 1/arylamide acetylase 1/NAT1	108345	NM_00066 2	C97T		
N-acetyltransferase 1/arylamide acetylase 1/NAT1	108345	NM_00066 2	C190T		
N-acetyltransferase 1/arylamide acetylase 1/NAT1	108345	NM_00066 2	T402C		
N-acetyltransferase 1/arylamide acetylase 1/NAT1	108345	NM_00066 2	G445A		
N-acetyltransferase 1/arylamide acetylase 1/NAT1	108345	NM_00066 2	G459A		
N-acetyltransferase 1/arylamide acetylase 1/NAT1	108345	NM_00066 2	T640G		
N-acetyltransferase 1/arylamide acetylase 1/NAT1	108345	NM_00066 2	C559T		
N-acetyltransferase 1/arylamide acetylase 1/NAT1	108345	NM_00066 2	G560A		

1/NAT1	108345	NM_000662	A613G	
N-acetyltransferase 1/arylamide acetylase				
1/NAT1	108345	NM_000662	A752T	
N-acetyltransferase 1/arylamide acetylase				
1/NAT1	108345	NM_000662	T777C	
N-acetyltransferase 1/arylamide acetylase				
1/NAT1	108345	NM_000662	G781A	
N-acetyltransferase 1/arylamide acetylase				
1/NAT1	108345	NM_000662	A787G	
N-acetyltransferase 1/arylamide acetylase				Arg187 to a stop codon
1/NAT1	108345	NM_000662		Arg187 to Gln
N-acetyltransferase 1/arylamide acetylase				
1/NAT1	108345	NM_000662	-344 (C-->T)	
N-acetyltransferase 1/arylamide acetylase				
1/NAT1	108345	NM_000662	640 T-->G Ser-->Ala	
N-acetyltransferase 1/arylamide acetylase				
1/NAT1	243400	NM_000015	ARG197GLN	
N-acetyltransferase 2/arylamide acetylase				
2/NAT2				

N-acetyltransferase 2/arylamide acetylase 2/NAT2	243400	NM_00001 5	ILE114THR
N-acetyltransferase 2/arylamide acetylase 2/NAT2	243400	NM_00001 5	LYS268ARG
N-acetyltransferase 2/arylamide acetylase 2/NAT2	243400	NM_00001 5	857G-A GLY-GLU
N-acetyltransferase 2/arylamide acetylase 2/NAT2	243400	NM_00001 5	191G-A Arg64-->Gln
N-acetyltransferase 2/arylamide acetylase 2/NAT2	243400	NM_00001 5	C282T (silent)
N-acetyltransferase 2/arylamide acetylase 2/NAT2	243400	NM_00001 5	T341C Ile114-->Thr
N-acetyltransferase 2/arylamide acetylase 2/NAT2	243400	NM_00001 5	481C-->T silent
N-acetyltransferase 2/arylamide acetylase 2/NAT2	243400	NM_00001 5	590 G-->A Arg197-->Gln
N-acetyltransferase 2/arylamide acetylase 2/NAT2	243400	NM_00001 5	803 A-->G Lys268-->Arg
N-acetyltransferase 2/arylamide acetylase 2/NAT2	243400	NM_00001 5	857 G-->A Gly286-->Glu
N-acetyltransferase 2/arylamide acetylase 2/NAT2	243400	NM_00001	C759T

2/arylamide acetylase 2/NAT2	5			
NAD(P)H menadione oxidoreductase 1, dioxin- inducible/NMOR1/diaphorase 4/DIA4	125860	NM_000903	609C>T pro187ser	
NAD(P)H menadione oxidoreductase 2, dioxin- inducible/NMOR2	160998	NM_000904	none found	
NEUROPATHY TARGET ESTERASE	603197		none found	
nicotinamide N-methyltransferase/NNMT	600008	NM_006169	eight SNPs within intron 1	
O6 alkylguanine-DNA alkyltransferase	156569	M60761	GGA to AGA gly160arg	
O6 alkylguanine-DNA alkyltransferase	156569	M60761	1034A>G	
O6 alkylguanine-DNA alkyltransferase	156569	M60761	1099C>T	
O6 alkylguanine-DNA alkyltransferase	156569	M60761	79G>T	
paraoxonase 1/PON1 (arylesterase)	168820	AH004193	GLN192ARG	
paraoxonase 1/PON1 (arylesterase)	168820	AH004193	MET54LEU	
paraoxonase 1/PON1 (arylesterase)	168820	AH004193	Leu55Met	
paraoxonase 1/PON1	168820	AH004193	CA repeat intron 4.	

(arylesterase)	601250	none found	
PEPTIDE			
METHIONINE			
SULFOXIDE			
REDUCTASE			
Peroxisome	170998	NM_00503 6	none found
proliferative activated			
receptor, alpha/PPARA			
Peroxisome	600409	NM_00623 8	none found
proliferative activated			
receptor, delta/PPARD			
Peroxisome	601487	NM_00503 7	PRO115GLN
proliferative activated			
receptor,			
gamma/PPARG			
Peroxisome	601487	NM_00503 7	PRO12ALA
proliferative activated			
receptor,			
gamma/PPARG			
Peroxisome	601487	NM_00503 7	1-BP DEL, 472A Frameshift
proliferative activated			
receptor,			
gamma/PPARG			
Peroxisome	601487	NM_00503 7	GLN286PRO
proliferative activated			
receptor,			
gamma/PPARG			
Peroxisome	601487	NM_00503 7	LYS319TER
proliferative activated			
receptor,			
gamma/PPARG			

Peroxisome proliferative activated receptor, gamma/PPARG	601487	NM_00503 7	ARG288HIS
Phenol-preferring sulfotransferase, family 1A, member 1/SULT1A1	171150	NM_00105 5	Arg213His
Phenol-preferring sulfotransferase, family 1A, member 2/SULT1A2	601292	NM_00105 4	none found
Phenol-preferring sulfotransferase, family 1A, member 3/SULT1A3	600641	L19956	none found
phenylethanolamine N- methyltransferase/PN MT	171190	NM_00268 6	BANI
PHOSPHOADENOSI NE-	603262		none found
PHOSPHOSULFATE SYNTHETASE I			
Pyruvate dehydrogenase (lipoamide) beta	179060	M34479	none found
RAR related orphan receptor A/RORA	600825	NM_00294 3	none found
RAR related orphan receptor C/RORC	602943	NM_00506 0	none found
reduced folate carrier	600424	U19720	none found

RFC1

renal microsomal dipeptidase/DPEP1 (b-lactam ring hydrolysis)	179780	NM_004413	none found
renal transport of beta-amino acids/AABT	109660		none found
retinoic acid receptor alpha/RARA	180240	NM_000964	7-base deletion frameshift
retinoic acid receptor alpha/RARA	180240	NM_000964	codon 411 C to T
retinoic acid receptor alpha/RARA	180240	NM_000964	Arg272Gln
retinoic acid receptor alpha/RARA	180240	NM_000964	Met297Leu
retinoic acid receptor beta/RARB	180220	NM_000965	none found
retinoic acid receptor gama/RARG	180190	M57707	none found
retinoid X receptor alpha/RXRA	180245	NM_002957	none found
retinoid X receptor beta/RXRB	180246	X66424	none found
retinoid X receptor gamma/RXRG	180247	U38480	none found
serotonin transporter	182138	X70697	PstI promoter 44-bp ins/del
serotonin transporter	182138	X70697	tandem repeat close to the promoter
serotonin transporter	182138	X70697	two polyadenylation sites

serotonin transporter	182138	X70697	VNTR intron 2	silent
serotonin transporter	182138	X70697		polymorphism
Solute Carrier Family 1, Member 1; Slc1a1	133550	U08989	none found	
Solute Carrier Family 1, Member 2; Slc1a2	600300	U03505	none found	
Solute Carrier Family 1, Member 3; Slc1a3	600111	U03504	none found	
Solute carrier family 1, member 4/SLC1A4 (glutamate)	600229	NM_003038	none found	
Solute carrier family 1, member 5/SLC1A5 (neutral AA)	109190	AF105230	none found	
Solute carrier family 1, member 6 (GABA/GLU)/SLC1A6	600637	NM_005071	none found	
Solute carrier family 10, member 1/SLC10A1 (taurocholate)	182396	NM_003049	none found	
Solute carrier family 10, member 2/SLC10A2 (taurocholate)	601295	NM_000452		LEU243PRO
Solute carrier family 10, member 2/SLC10A2 (taurocholate)	601295	NM_000452		THR262MET

Solute carrier family 10, member 2/SLC10A2 (taurocholate)	601295	NM_00045 2	A171S
Solute carrier family 12, member 2/SLC12A2 (dicarboxylic acids)	604148	NM_00398 4	none found
Solute carrier family 15, member 1/SLC15A1 (peptides)	600544	U13173	none found
Solute carrier family 15, member 2/SLC15A2 (peptides)	602339	S78203	none found
Solute carrier family 16, member 1/SLC16A1 (monocarboxylic acids)	600682	NM_00305 1	none found
Solute carrier family 16, member 2/SLC16A2 (monocarboxylic acids)	300095	NM_00651 7	none found
Solute carrier family 16, member 3/SLC16A3 (monocarboxylic acids)	603877	NM_00420 7	none found
Solute carrier family 16, member 4/SLC16A4 (monocarboxylic acids)	603878	*****	none found
Solute carrier family	603879	NM_00469	none found

SD-144141.1

16, member 5/SLC16A5 (monocarboxylic acids) Solute carrier family 16, member 6/SLC16A6 (monocarboxylic acids) Solute carrier family 16, member 7/SLC16A7 (monocarboxylic acids) Solute carrier family 21, member 2/SLC21A2 (prostaglandin) Solute carrier family 21, member 3/SLC21A3 (organic anion) Solute carrier family 22, member 1- like/SLC22A1 (organic cation) Solute carrier family 22, member 1- like/SLC22A1 (organic cation) Solute carrier family 22, member 1/SLC22A2 (organic cation)	603880	NM_004694	none found
	603654	AF049608	none found
	601460	NM_005630	none found
	602883	NM_005075	none found
	602631	AF037064	111-BP INS
	602631	AF037064	688G-A
	602607	NM_003058	none found

Solute carrier family 22, member 2/SLC22A2 (organic cation)	602608	NM_00305 8	
Solute carrier family 22, member 5/SLC22A5 (carnitine)	603377		113-BP DEL
Solute carrier family 22, member 5/SLC22A5 (carnitine)	603377		1-BP INS, 226C
Solute carrier family 22, member 5/SLC22A5 (carnitine)	603377		TRP132TER
Solute carrier family 22, member 5/SLC22A5 (carnitine)	603377		G-to-A transition in the last nucleotide of intron 8 1394-BP DEL
Solute carrier family 22, member 5/SLC22A5 (carnitine)	603377		19-BP INS
Solute carrier family 22, member 5/SLC22A5 (carnitine)	603377		171-BP DEL
Solute carrier family 22, member 5/SLC22A5 (carnitine)	603377		ARG282TER
Solute carrier family 22, member 5/SLC22A5 (carnitine)	603377		TYR401TER

Solute carrier family 22, member 5/SLC22A5 (carnitine)	603377	1-BP DEL, 1345G	
Solute carrier family 22, member 5/SLC22A5 (carnitine)	603377		PRO478LEU
Solute carrier family 22, member 5/SLC22A5 (carnitine)	603377		TYR211CYS
Solute carrier family 22, member 5/SLC22A5 (carnitine)	603377		Arg169Gln
Solute carrier family 25, member 1/SLC25A1 (tricarboxylic acids)	190315	X96924	none found
Solute carrier family 29 (nucleosides), member 1/SLC29A1/ENT1	602193	NM_004955	none found
Solute carrier family 29 (nucleosides), member 2/SLC29A2/ENT2	602110	X86681	none found
Solute carrier family 3 member 1/SLC3A1 (aa transporter)	104614	*****	none found
Solute carrier family 5 member 6/SLC5A6 (folate, biotin, lipoate)	604024	*****	none found
Solute carrier family 6 (GABA), member 1/SLC6A1	137165	X54673	none found

Solute carrier family 6 (betaine/GABA), member 12	603080	U27699	none found
Solute carrier family 6, member	163970	NM_00104 3	none found
5/SLC6A2/NAT1/NET 1 (glycine)	604159	NM_00421 1	none found
Solute carrier family 6, member 5/SLC6A5 (glycine)	186854	U16120	Dinucleotide repeat
Solute carrier family 6, member 6/SLC6A6 (taurine)	601019	S70612	none found
Solute carrier family 7, Member 9; SLC6A9 (glycine)	104615	*****	TaqI
Solute carrier family 7, member 1/SLC7A1 (cationic AA)	601872	D29990	none found
Solute carrier family 7, member 2/SLC7A2 (cationic AA)	603752	*****	none found
Solute carrier family 7, member 4/SLC7A4 (cationic AA)	600182	M80244	none found
Solute carrier family 7, member 5/SLC7A5 (neutral AA)	603593	Y18474	1181, A-T, -2 A->T
Solute carrier family 7, member 7/SLC7A7 (dibasic AA)			

Solute carrier family 7, member 7/SLC7A7 (dibasic AA)	603593	Y18474	543-BP DEL	
Solute carrier family 7, member 7/SLC7A7 (dibasic AA)	603593	Y18474	4-BP INS	
Solute carrier family 7, member 9/SLC7A9 (neutral AA)	604144	*****		VAL170MET
Solute carrier family 7, member 9/SLC7A9 (neutral AA)	604144	*****		GLY105ARG
Solute carrier family 7, member 9/SLC7A9 (neutral AA)	604144	*****		ALA182THR
Solute carrier family 7, member 9/SLC7A9 (neutral AA)	604144	*****		GLY195ARG
Solute carrier family 7, member 9/SLC7A9 (neutral AA)	604144	*****		GLY259ARG
Solute carrier family 7, member 9/SLC7A9 (neutral AA)	604144	*****	2-BP DEL, 596TG	
Solute carrier family 7, member 9/SLC7A9 (neutral AA)	604144	*****	1-BP INS, 520T	
sterol-O-acyl transferase 1/SOAT1	102642	L21934	none found	
sterol-O-acyl transferase 2/SOAT2	601311	*****	none found	

Succinic semialdehyde dehydrogenase	271980	L34820	IVS9, G-T, +I
Succinic semialdehyde dehydrogenase	271980	L34820	IVS5, G-A, +I
SULFONYLUREA RECEPTOR 2	601439		none found
Sulfotransferase, family 1C, member 3/SULT1C1	602385	U66036	none found
Sulfotransferase, family 2B, member 1/SULT2B1	604125	NM_004605	none found
Superoxide Dismutase 1/SOD1 (soluble)	147450	NM_000454	GLY37ARG
Superoxide Dismutase 1/SOD1 (soluble)	147450	NM_000454	LEU38VAL
Superoxide Dismutase 1/SOD1 (soluble)	147450	NM_000454	GLY41SER
Superoxide Dismutase 1/SOD1 (soluble)	147450	NM_000454	GLY41ASP
Superoxide Dismutase 1/SOD1 (soluble)	147450	NM_000454	HIS43ARG
Superoxide Dismutase 1/SOD1 (soluble)	147450	NM_000454	GLY85ARG
Superoxide Dismutase 1/SOD1 (soluble)	147450	NM_000454	GLY93CYS
Superoxide Dismutase 1/SOD1 (soluble)	147450	NM_000454	GLY93ALA
Superoxide Dismutase 1/SOD1 (soluble)	147450	NM_000454	GLU100GLY
Superoxide Dismutase 1/SOD1 (soluble)	147450	NM_000454	LEU106VAL

SD-144141.J

1/SOD1 (soluble)	4		
Superoxide Dismutase	147450	NM_00045	ILE113THR
1/SOD1 (soluble)	4		
Superoxide Dismutase	147450	NM_00045	ALA4VAL
1/SOD1 (soluble)	4		
Superoxide Dismutase	147450	NM_00045	HIS46ARG
1/SOD1 (soluble)	4		
Superoxide Dismutase	147450	NM_00045	ALA4THR
1/SOD1 (soluble)	4		
Superoxide Dismutase	147450	NM_00045	ASP90ALA
1/SOD1 (soluble)	4		
Superoxide Dismutase	147450	NM_00045	ILE104THE
1/SOD1 (soluble)	4		
Superoxide Dismutase	147450	NM_00045	LEU144SER
1/SOD1 (soluble)	4		
Superoxide Dismutase	147450	NM_00045	ALA145THR
1/SOD1 (soluble)	4		
Superoxide Dismutase	147450	NM_00045	T-G, -10, 9-BP INS
1/SOD1 (soluble)	4		
Superoxide Dismutase	147450	NM_00045	CYS6PHE
1/SOD1 (soluble)	4		
Superoxide Dismutase	147450	NM_00045	THR151ILE
1/SOD1 (soluble)	4		
Superoxide Dismutase	147450	NM_00045	GLU21LYS
1/SOD1 (soluble)	4		
Superoxide Dismutase	147450	NM_00045	SER134ASN
1/SOD1 (soluble)	4		
Superoxide Dismutase	147450	NM_00045	LEU84VAL
1/SOD1 (soluble)	4		
Superoxide Dismutase	147450	NM_00045	GLY16SER
1/SOD1 (soluble)	4		

Superoxide Dismutase 1/SOD1 (soluble)	147450	NM_00045 4	LEU126TER
Superoxide Dismutase 1/SOD1 (soluble)	147450	NM_00045 4	VS4AS, A-G, -I1
Superoxide Dismutase 1/SOD1 (soluble)	147450	NM_00045 4	GLY72SER
Superoxide Dismutase 1/SOD1 (soluble)	147450	NM_00045 4	Val7-->Glu
Superoxide Dismutase 2/SOD2 (mitochondrial)	147460	X65965	ALA16VAL
Superoxide Dismutase 3/SOD3 (extracellular)	185490	NM_00310 2	ARG213GLY
Superoxide Dismutase 3/SOD3 (extracellular)	185490	NM_00310 2	A241G
Superoxide Dismutase 3/SOD3 (extracellular)	185490	NM_00310 2	C280T
Thiopurine methyltransferase (6- mercaptopurine detoxification)	187680	U12387	ALA80PRO
Thiopurine methyltransferase (6- mercaptopurine detoxification)	187680	U12387	ALA154THR
Thiopurine methyltransferase (6- mercaptopurine detoxification)	187680	U12387	TYR240CYS
Thiopurine methyltransferase (6- mercaptopurine detoxification)	187680	U12387	IVS9AS, G-A, -I

mercaptapurine detoxification)	187680	U12387	ALA154THR
Thiopurine			
methyltransferase (6-			
mercaptapurine			
detoxification)			
Thiopurine	187680	U12387	TYR240CYS
methyltransferase (6-			
mercaptapurine			
detoxification)			
Thiopurine	187680	U12387	ARG215HIS
methyltransferase (6-			
mercaptapurine			
detoxification)			
Thiopurine	187680	U12387	G460 to A
methyltransferase (6-			
mercaptapurine			
detoxification)			
Thiopurine	187680	U12387	A719 to G
methyltransferase (6-			
mercaptapurine			
detoxification)			
Thiopurine	187680	U12387	VNTR promoter
methyltransferase (6-			
mercaptapurine			
detoxification)			
Thiopurine	187680	U12387	G644A
methyltransferase (6-			
mercaptapurine			
detoxification)			
Thiopurine	187680	U12387	G238C

methytransferase (6- mercaptopurine detoxification)	187680	U12387	T681G	
Thiopurine				
methytransferase (6- mercaptopurine detoxification)	187680	U12387	C-->T at nucleotide - 178	
Thiopurine				
methytransferase (6- mercaptopurine detoxification)	187680	U12387	T-->G681	
Thiopurine				
methytransferase (6- mercaptopurine detoxification)	164014	L19067		494, Glu-Asp
TRANSCRIPTION FACTOR P65				
UDP	191740	NM_00107 2	13-BP DEL	
glycosyltransferase 1/UGT1				
UDP	191740	NM_00107 2		SER-PHE
glycosyltransferase 1/UGT1				
UDP	191740	NM_00107 2		GLN331TER
glycosyltransferase 1/UGT1				
UDP	191740	NM_00107 2		ARG341TER
glycosyltransferase 1/UGT1				
UDP	191740	NM_00107 2		GLN331ARG
glycosyltransferase				

1/UGT1	191740	NM_00107	PHE170DEL
UDP		2	
glycosyltransferase			
1/UGT1	191740	NM_00107	SER376PHE
UDP		2	
glycosyltransferase			
1/UGT1	191740	NM_00107	GLY309GLU
UDP		2	
glycosyltransferase			
1/UGT1	191740	NM_00107	CYS-TER
UDP		2	
glycosyltransferase			
1/UGT1	191740	NM_00107	PRO229GLN
UDP		2	
glycosyltransferase			
1/UGT1	191740	NM_00107	2-BP INS, TA, TATAA ELEMENT
UDP		2	
glycosyltransferase			
1/UGT1	191740	NM_00107	1-BP INS, 470T
UDP		2	
glycosyltransferase			
1/UGT1	191740	NM_00107	IVS1, G-C, +1
UDP		2	
glycosyltransferase			
1/UGT1	191740	NM_00107	145C-T
UDP		2	
glycosyltransferase			
1/UGT1	191740	NM_00107	IVS3, A-G, -2
UDP		2	
glycosyltransferase			
1/UGT1			

UDP glycosyltransferase 8/UGT8	601291	U30930	none found	
UDP glycosyltransferase family 2, member B10/UGT2B10	600070	NM_00107 5	none found	
UDP glycosyltransferase family 2, member B15/UGT2B15	600069	U06641		asp85tyr
UDP glycosyltransferase family 2, member B17/UGT2B17	601903	NM_00107 7	none found	
UDP glycosyltransferase family 2, member B4/UGT2B4	600067	NM_00107 3		asp458glu
UDP glycosyltransferase family 2, member B4/UGT2B4	600067	NM_00107 3		leu109phe
UDP glycosyltransferase family 2, member B4/UGT2B4	600067	NM_00107 3		leu396phe
UDP glycosyltransferase family 2, member B7/UGT2B7	600068	NM_00107 4	none found	

UDP-glucuronosyltransferase	218800	AJ005162	none found
Vesicular acetylcholine transporter	600336	NM_003055	none found
Vesicular Amine Transporter 1; VAT1	193002	*****	none found
Vesicular Amine Transporter 2; VAT2	193001	L09118	TaqI XX
Table 21. Identified Variances in Genes or Related Pathways involved in Inflammation and Immune Disease			
3,5 cyclic nucleotide phosphodiesterase (HSPDE1A3A)	171890	U40370	none found
activated leucocyte cell adhesion molecule/CD6 ligand/ALCAM	601662	L38608	none found
alpha-2-macroglobulin	103950	M11313	VAL1000ILE
alpha-2-macroglobulin	103950	M11313	CYS972TYR
alpha-2-macroglobulin	103950	M11313	deletion of the intron
alpha-2-macroglobulin	103950	M11313	ARG681HIS
alpha-2-macroglobulin	103950	M11313	EX18DEL
alpha-2-macroglobulin	103950	M11313	5-BP DEL
alpha-2-macroglobulin	103950	M11313	intronic

alpha-2-macroglobulin	103950	M11313	polymorphism EcoRI	
antigen peptide transporter 1/MHC 1/TAP1	170260	X57522		ILE333VAL
antigen peptide transporter 1/MHC 1/TAP1	170260	X57522		ASP637GLY
antigen peptide transporter 1/MHC 1/TAP1	170260	X57522		ARG659GLN
antigen peptide transporter 1/MHC 1/TAP1	170260	X57522	518 (GTC-->ATC) Val-->Ile	
antigen peptide transporter 1/MHC 1/TAP1	170260	X57522	G-->T substitution in the promoter region	
antigen peptide transporter 1/MHC 1/TAP1	170260	X57522	10-bp insert in intron 9	
antigen peptide transporter 1/MHC 1/TAP1	170260	X57522	G-->T 80bp 3' of termination codon	
antigen peptide transporter 2/MHC 2/TAP2	170261	Z22935		Ala665Thr
antigen peptide transporter 2/MHC 2/TAP2	170261	Z22935		Gln687Stop
antigen peptide transporter 2/MHC	170261	Z22935		ILE379VAL

SD-144141.1

2/TAP2	147678	X65019	none found
apoptosis-related			
cystein protease			
1/interleukin 1-beta			
converting			
enzyme/ICE/caspase			
1/CASPI			
beta-1-adrenergic	109630	J03019	C1165G ARG389GLY
receptor; Adrb1			
beta-1-adrenergic	109630	J03019	Bgl I.
receptor; Adrb1			
Beta-2-Adrenergic	109690	M15169	val 34 met
Receptor; Adrb2			
Beta-2-Adrenergic	109690	M15169	A-->G -1343
Receptor; Adrb2			
Beta-2-Adrenergic	109690	M15169	C-->G -468
Receptor; Adrb2			
Beta-2-Adrenergic	109690	M15169	G-->A -1023
Receptor; Adrb2			
Beta-2-Adrenergic	109690	M15169	G-->A -654
Receptor; Adrb2			
Beta-2-Adrenergic	109690	M15169	T-->A -1429
Receptor; Adrb2			
Beta-2-Adrenergic	109690	M15169	T-->C -367
Receptor; Adrb2			
Beta-2-Adrenergic	109690	M15169	Fnu4HI
Receptor; Adrb2			
Beta-2-Adrenergic	109690	M15169	T-->C -20
Receptor; Adrb2			
Beta-2-Adrenergic	109690	M15169	T-->C -47
Receptor; Adrb2			

Beta-3-Adrenergic Receptor; Adrb3	109691	X70811	TRP64ARG
Beta-3-Adrenergic Receptor; Adrb3	109691	X70811	intron 1 g1856t
Beta-Adrenergic Receptor Kinase 2; Adrbk2	109636	X69117	none found
bradykinin receptor B1/BDKRB1 G	600337	U12512	9-base pair deletion
protein-coupled bradykinin receptor B1/BDKRB1 G	600337	U12512	A1098-->G
protein-coupled bradykinin receptor B1/BDKRB1 G	600337	U12512	C181-->T
protein-coupled bradykinin receptor B1/BDKRB1 G	600337	U12512	G-699-->C
protein-coupled bradykinin receptor B2/BDKRB2 G	113503	X86164	-845C/T
protein-coupled bradykinin receptor B2/BDKRB2 G	113503	X86165	-704C/T
protein-coupled bradykinin receptor B2/BDKRB2 G	113503	X86166	-649insG
protein-coupled bradykinin receptor B2/BDKRB2 G	113503	X86167	-640T/C

bradykinin receptor B2/BDKRB2 G	113503	X86168	-536C/T	
protein-coupled				
bradykinin receptor B2/BDKRB2 G	113503	X86169	-412C/G	
protein-coupled				
bradykinin receptor B2/BDKRB2 G	113503	X86170	-143C/T	
protein-coupled				
bradykinin receptor B2/BDKRB2 G	113503	X86171	-78C/T	
protein-coupled				
bradykinin receptor B2/BDKRB2 G	113503	X86172		T21M
protein-coupled				
bradykinin receptor B2/BDKRB2 G	113503	X86173	9 bp de (-)21'-29	
protein-coupled				
bradykinin receptor B2/BDKRB2 G	113503	X86174	C>T promoter 54	
protein-coupled				
bradykinin receptor B2/BDKRB2 G	113503	X86175	tandem repeat near promoter	
protein-coupled				
bradykinin receptor B2/BDKRB2 G	113503	X86176		R14C
protein-coupled				
bradykinin receptor B2/BDKRB2 G	113503	X86177	repeat 3'UTR	
protein-coupled				
Ca Channel alpha1a	601011	AF004884		ARG192GLN

(alt. splice) L-Type Ca Channel alpha	601011	AF004884	THR666MET
(alt. splice) L-Type Ca Channel alpha	601011	AF004884	VAL714ALA
(alt. splice) L-Type Ca Channel alpha	601011	AF004884	ILE1811LEU
(alt. splice) L-Type Ca Channel alpha	601011	AF004884	1-BP DEL, 4073C frameshift
(alt. splice) L-Type Ca Channel alpha	601011	AF004884	G-to-A first nucleotide of intron 24 (CAG)n
Ca Channel alpha (alt. splice) L-Type	601011	AF004884	GLY293ARG
Ca Channel alpha (alt. splice) L-Type	601011	AF004884	ASP715GLU
Ca Channel alpha (alt. splice) L-Type	601011	AF004884	C4914T premature stop
Ca Channel gamma L-Type	114209	L07738	none found
Ca ²⁺ -dependent phospholipase A2	601192	U03090	none found
CD3E antigen, epsilon polypeptide (TiT3 complex)	186830	X03884	T-to-C splice change
CD3E antigen, epsilon polypeptide (TiT3 complex)	186830	X03884	TRP59TER
CD3E antigen, epsilon	186830	X03884	TaqI

polypeptide (TiT3 complex)	186740	X04145	METIVAL
CD3G antigen, gamma polypeptide (TiT3 complex)	186740	X04145	17-BP DEL
CD3G antigen, gamma polypeptide (TiT3 complex)	186740	X04145	MspI
Complement C1S component precursor (C1 esterase)	120580	J04080	4-BP DEL
Cyclooxygenase 1 COX1	176805	M59979	none found
Cyclooxygenase 2 COX2	600262	M90100	none found
H.sapiens ACTH-R gene for adrenocorticotrophic hormone receptor	None	X65633	none found
Histamine receptor H1	600167	AF026261	none found
Histamine receptor H2	142703	M64799	A649G
Histamine receptor H3	None	U31332	none found
Human DP prostanoid receptor (PTGDR) gene, 5' region and partial cds	600022	D38128	none found
Human IP gene for prostacyclin receptor,			

SD-144141.1

Human leukotriene-C4 synthase mRNA, complete cds	246530	U11552	promoter polymorphism
Human mRNA for prostacyclin synthase, complete cds	601699	D38145	none found
Human prostaglandin receptor ep1 subtype mRNA, complete cds	176802	L22647	none found
Intercellular adhesion molecule 1	147840	M24283	K/E 469
Intercellular adhesion molecule 1	147840	M24283	Dinucleotide repeat 3'
Intercellular adhesion molecule 2	146630	X15606	none found
Intercellular adhesion molecule 3	146631	X69819	LYS29MET
interferon-gamma receptor 2/IFNGR2	147569	U05875	Gln64Arg
interferon-gamma receptor 2/IFNGR2	147569		2-BP DEL, AG, NT278-279
interferon-gamma receptor 1/IFNGR1	107470	J03143	395C-A SER-TER
interferon-gamma receptor 1/IFNGR1	107470		1-BP DEL frameshift
interferon-gamma receptor 1/IFNGR1	107470		ILE87THR
interferon-gamma receptor 1/IFNGR1	107470		4-BP INS, 107TTAC
interferon-gamma	107470		G-A, +1

SD-144141.1

receptor 1/IFNGRI	107470	4-BP DEL, NT818	
interferon-gamma			
receptor 1/IFNGRI	107470		Val14Met
interferon-gamma			
receptor 1/IFNGRI	107470		TaqI
interferon-gamma			
receptor 1/IFNGRI	147720		TaqI
interleukin 1 beta			
(IL1b)			
interleukin 1 beta	147720	+5887 C --> T	
(IL1b)			
interleukin 1 beta	147720	exon 5 (position	
(IL1b)		+3953)	
interleukin 1 beta	147720	position -511	
(IL1b)			
interleukin 1 beta	147720		Asp106Asn
(IL1b)			
Interleukin 1 receptor	147679	86-bp tandem repeat	
antagonist			
Kallikrein Inhibitor	147935		
Kallikrein KLK1	147910	none found	
Kallikrein KLK1	147910	A1166-->C	
Kallikrein KLK2	147960	TaqI	
L-Type Ca Channel	114204	C to T at base 792	
alpha 2/delta		none found	
L-Type Ca Channel	114206	none found	
alpha1d			
L-type voltage	114205	none found	
dependent calcium			
channel alpha 1C			
subunit/CACNA1C			

SD-144141.1

L-type voltage dependent calcium channel alpha 1S subunit/CACNA1S	114208	L33798	ARG1086HIS
L-type voltage dependent calcium channel alpha 1S subunit/CACNA1S	114208	L33798	ARG1239GLY
L-type voltage dependent calcium channel alpha 1S subunit/CACNA1S	114208	L33798	ARG1239HIS
L-type voltage dependent calcium channel alpha 1S subunit/CACNA1S	114208	L33798	ARG528HIS
Leukocyte integrin alpha-4	192975	L12002	none found
Leukocyte integrin alpha-d	602453	U40274	none found
Leukocyte integrin alpha-l	153370	Y00796	none found
Leukocyte integrin alpha-m	120980	J04145	none found
Leukocyte integrin alpha-x	151510	M81695	none found
Leukocyte integrin beta-1	135630	U28252	none found
Leukocyte integrin beta-2	600065	M15395	ARG593CYS
Leukocyte integrin	600065	M15395	LYS196THR

SD-144141.1

Leukocyte integrin beta-2	600065	M15395	LEU149PRO
Leukocyte integrin beta-2	600065	M15395	GLY169ARG
Leukocyte integrin beta-2	600065	M15395	ATG-to-AAG initiation codon
Leukocyte integrin beta-2	600065	M15395	ARG586TRP
Leukocyte integrin beta-2	600065	M15395	12-bp insertion pro-ser-ser-gln
Leukocyte integrin beta-2	600065	M15395	ASN351SER
Leukocyte integrin beta-2	600065	M15395	PRO178LEU
Leukocyte integrin beta-2	600065	M15395	ASP128ASN
Leukocyte integrin beta-2	600065	M15395	G-A, splice/donor site
Leukocyte integrin beta-2	600065	M15395	GLY284SER
Leukocyte integrin beta-2	600065	M15395	SER138PRO
Leukocyte integrin beta-2	600065	M15395	GLY273ARG
Leukocyte integrin beta-2	600065	M15395	S138P
Leukocyte integrin beta-2	173470	M35999	ARG214GLN
Leukocyte integrin beta-3	173470	M35999	ASP119TYR

SD-144141.1

Leukocyte integrin beta-3	173470	M35999	ARG214TRP
Leukocyte integrin beta-3	173470	M35999	SER752PRO
Leukocyte integrin beta-3	173470	M35999	ARG143GLN
Leukocyte integrin beta-3	173470	M35999	LEU33PRO
Leukocyte integrin beta-3	173470	M35999	PRO407ALA
Leukocyte integrin beta-3	173470	M35999	G-T, EXiDEL
Leukocyte integrin beta-3	173470	M35999	ARG489GLN
Leukocyte integrin beta-3	173470	M35999	CYS374TYR
Leukocyte integrin beta-3	173470	M35999	11.2-KB DEL
Leukocyte integrin beta-3	173470	M35999	ARG724TER
Leukocyte integrin beta-3	173470	M35999	GLU616TER
Leukocyte integrin beta-4	147557	X51841	1-BP INS, 3801T
Leukocyte integrin beta-4	147557	X51841	1-BP DEL, 1150G
Leukocyte integrin beta-4	147557	X51841	LEU156PRO
Leukocyte integrin beta-4	147557	X51841	ARG554TER
Leukocyte integrin beta-4	147557	X51841	CYS61TYR

SD-144141.1

Leukocyte integrin beta-4	147557	X51841	CYS562ARG
Leukocyte integrin beta-4	147557	X51841	IVS30DS, G-A, +1
Leukocyte integrin beta-4	147557	X51841	TRP1478TER
Leukocyte integrin beta-4	147557	X51841	CYS38ARG
Leukocyte integrin beta-4	147557	X51841	1-BP DEL, 4776G
Leukocyte integrin beta-4	147557	X51841	3434delT
Leukocyte integrin beta-4	147557	X51841	8-bp deletion
Leukocyte integrin beta-7	147559	M68892	none found
Leukotriene A4 hydrolase	151570	J03459	none found
Leukotriene C4 receptor			none found
Leukotriene D4/E4 receptor			none found
lipocortin 1/annexin 1	151690	X05908	none found
lipocortin 2/annexin 2	151740	D00017	none found
lipocortin 3/annexin 3	106490	M20560	BglII
lipocortin 3/annexin 3	106490	M20560	Sall
lipocortin 3/annexin 3	106490	M20560	tandem repeat
Lipoxygenases: 12- lipoxygenase (platelet)	152391	M62982	TAAA none found

Lipoxygenases: 5-lipoxygenase (leukocytes)	152390	J03571	none found
lymphotoxin beta receptor (TNFR superfamily, member 3/LTBR)	600979	L04270	none found
N-acylamino acid aminohydrolase	104620	L07548	none found
P2Y7 purinoceptor/leukotriene B4 receptor/G protein-coupled	601531	D89078	none found
Phospholipase A-2 (PLA-2) lung	172410	M21054	none found
Phospholipase C beta-3	600230	Z26649	none found
Phospholipase C delta-1	602142	U09117	none found
Phospholipase C epsilon	600597	D42108	none found
Phospholipase C gamma-1	172420	M34667	none found
Phospholipase C gamma-2	600220	M37238	none found
Phospholipase C, beta 4	600810	L41349	none found
Platelet-activating factor receptor	173393	M76674	none found
Prostaglandin 15-OH dehydrogenase (PGDH)	601688	J05594	none found

SD-144141.1

Prostaglandin E receptor 2 (subtype EP2), 53kD	601586	L28175	none found	
Prostaglandin E receptor 3 (subtype EP3) {alternative products}	176806	X83861	none found	
PROSTAGLANDIN E2 RECEPTOR, EP2 SUBTYPE	176804	U19487	none found	
PROSTAGLANDIN F RECEPTOR	600563	L24470	none found	
PROSTAGLANDIN F2 ALPHA RECEPTOR		U26664	none found	
prostaglandin transporter hPGT	601460	U70867	none found	
recombination activating gene 1/RAG1	179615	M29474		GLU722LYS
recombination activating gene 1/RAG1	179615	M29474		GLU774TER
recombination activating gene 1/RAG1	179615	M29474		TYR938TER
recombination activating gene 1/RAG1	179615	M29474		ALA156VAL
recombination activating gene	179615	M29474		ARG561HIS

SD-144141.1

1/RAG1 recombination activating gene 1/RAG1	179615	M29474	ARG396CYS
recombination activating gene 1/RAG1	179615	M29474	TYR912CYS
recombination activating gene 1/RAG1	179615	M29474	ARG396HIS
recombination activating gene 1/RAG1	179615	M29474	ASP429GLY
recombination activating gene 1/RAG1	179615	M29474	ARG561CYS
recombination activating gene 1/RAG1	179615	M29474	ARG737HIS
recombination activating gene 1/RAG1	179615	M29474	13-BP DEL, NT1723
recombination activating gene 1/RAG1	179615	M29474	2-BP DEL, NT368
recombination activating gene 2/RAG2	179616		CYS476TYR
recombination activating gene 2/RAG2	179616		ARG220GLN

SD-144141.1

recombination activating gene 2/RAG2	179616		CYS41TRP
recombination activating gene 2/RAG2	179616		MET285ARG
regulator of G-protein signalling 1/RGS1	600323	X73427	none found
Retinoic acid receptor, alpha/RARA	180240	X06538	7-base deletion frameshift
Retinoic acid receptor, alpha/RARA	180240	X06538	Arg272Gln
Retinoic acid receptor, alpha/RARA	180240	X06538	Met297Leu
Retinoic acid receptor, alpha/RARA	180240	X06538	codon 411 C to T
Retinoic acid receptor, beta/RARB	180220	X07282	none found
Retinoic acid receptor, gamma/RARG	180190	M24857	none found
serotonin 5-HT receptors 5-HT3, gated ion channel	182139	D49394	none found
signaling lymphocytic activation molecule/SLAM	603492	U33017	none found
small inducible cytokine subfamily A (Cys-Cys), member 2/monocyte chemotactic protein	158105	M28226	-2518 (G or A)

SD-144141.1

1/MCP1/SCYA2 small inducible cytokine subfamily A (Cys-Cys), member 2/monocyte chemotactic protein 1/MCP1/SCYA2	158105	M28226	-2076 (A or T)	
small inducible cytokine subfamily A (Cys-Cys), member 3/macrophage inflammatory protein 1A/MIPIA/SCYA3	182283	M25315	none found	
Solute carrier family 4, anion exchanger, member 1 (MEDIATES EXCHANGE OF INORGANIC ANIONS ACROSS THE MEMBRANE)	109270	M27819		LYS56GLU
Solute carrier family 4, anion exchanger, member 1 (MEDIATES EXCHANGE OF INORGANIC ANIONS ACROSS THE MEMBRANE)	109270	M27819	24-BP DEL CODONS 400- 408	
Solute carrier family 4, anion exchanger,	109270	M27819		PRO327ARG

SD-144141.1

BNSDOCID: <WO_____0050639A2_I_>

anion exchanger, member 1 (MEDIATES EXCHANGE OF INORGANIC ANIONS ACROSS THE MEMBRANE) Solute carrier family 4, anion exchanger, member 1 (MEDIATES EXCHANGE OF INORGANIC ANIONS ACROSS THE MEMBRANE)	109270	M27819	GLN330TER
Solute carrier family 4, anion exchanger, member 1 (MEDIATES EXCHANGE OF INORGANIC ANIONS ACROSS THE MEMBRANE)	109270	M27819	ARG150TER
Solute carrier family 4, anion exchanger, member 1 (MEDIATES EXCHANGE OF INORGANIC ANIONS ACROSS THE MEMBRANE)	109270	M27819	89G-A

SD-144141.1

Solute carrier family 4, anion exchanger, member 1 (MEDIATES EXCHANGE OF INORGANIC ANIONS ACROSS THE MEMBRANE)	109270	M27819	VAL557MET
Solute carrier family 4, anion exchanger, member 1 (MEDIATES EXCHANGE OF INORGANIC ANIONS ACROSS THE MEMBRANE)	109270	M27819	ARG589HIS
Solute carrier family 4, anion exchanger, member 1 (MEDIATES EXCHANGE OF INORGANIC ANIONS ACROSS THE MEMBRANE)	109270	M27819	ARG589CYS
Solute carrier family 4, anion exchanger, member 1 (MEDIATES EXCHANGE OF INORGANIC ANIONS ACROSS THE MEMBRANE)	109270	M27819	SER613PHE

SD-144141.1

THE MEMBRANE) Solute carrier family 4, anion exchanger, member 1 (MEDIATES EXCHANGE OF INORGANIC ANIONS ACROSS THE MEMBRANE)	109270	M27819	ARG589SER
Solute carrier family 4, anion exchanger, member 1 (MEDIATES EXCHANGE OF INORGANIC ANIONS ACROSS THE MEMBRANE)	109270	M27819	GLY701ASP
Solute carrier family 4, anion exchanger, member 1 (MEDIATES EXCHANGE OF INORGANIC ANIONS ACROSS THE MEMBRANE)	109270	M27819	PRO854LEU
Solute carrier family 4, anion exchanger, member 1 (MEDIATES EXCHANGE OF INORGANIC ANIONS ACROSS THE MEMBRANE)	109270	M27819	GLY130ARG

SD-144141.1

SD-144141.1

factor, beta receptor I (activin A receptor type II-like kinase, 53kD)/TGFBRI	190182	M85079	2-BP INS frameshift
transforming growth factor, beta receptor II (70-80kD)/TGFBRI2	190182	M85079	THR315MET
transforming growth factor, beta receptor II (70-80kD)/TGFBRI2	190182	M85079	GG to TT Stop codon
transforming growth factor, beta receptor II (70-80kD)/TGFBRI2	190182	M85079	a7g intron 2
transforming growth factor, beta receptor II (70-80kD)/TGFBRI2	190182	M85079	a-4t intron 3
transforming growth factor, beta receptor II (70-80kD)/TGFBRI2	190182	M85079	codon 128
transforming growth factor, beta receptor II (70-80kD)/TGFBRI2	190182	M85079	ACA to GCA Thr to Ala
transforming growth factor, beta receptor II (70-80kD)/TGFBRI2	190182	M85079	base in the polyadenine tract of exon 3 none found
transforming growth factor, beta receptor III (betaglycan,	600742	L07594	

SD-144141.1

300kD)/TGFB β 3				
tumor necrosis factor alpha (TNFa)	191160	X01394	C-850T	
tumor necrosis factor alpha (TNFa)	191160	X01394	C-ins 5'UTR of exon 1	
tumor necrosis factor alpha (TNFa)	191160	X01394	G -238 A	
tumor necrosis factor alpha (TNFa)	191160	X01394	G -376 A	
tumor necrosis factor alpha (TNFa)	191160	X01394	-1,031 T-->C	
tumor necrosis factor alpha (TNFa)	191160	X01394	-863 C-->A	
tumor necrosis factor alpha (TNFa)	191160	X01394	-308 G/A	
tumor necrosis factor alpha (TNFa)	191160	X01394	ARG32TRP	
tumor necrosis factor alpha (TNFa)	191160	X01394	LEU29SER	
tumor necrosis factor alpha (TNFa)	191160	X01394	G-376A	
tumor necrosis factor alpha (TNFa)	191160	X01394	NcoI	
tumor necrosis factor alpha (TNFa)	191160	X01394	C to T, -857T	
TUMOR NECROSIS FACTOR RECEPTOR 1 PRECURSOR	191190	M58286	CYS33TYR	
TUMOR NECROSIS FACTOR RECEPTOR 1 PRECURSOR	191190	M58286	THR50MET	

SD-144141.1

TUMOR NECROSIS FACTOR RECEPTOR 1 PRECURSOR	191190	M58286	CYS30ARG
TUMOR NECROSIS FACTOR RECEPTOR 1 PRECURSOR	191190	M58286	CYS52PHE
TUMOR NECROSIS FACTOR RECEPTOR 1 PRECURSOR	191190	M58286	CYS88ARG
TUMOR NECROSIS FACTOR RECEPTOR 1 PRECURSOR	191190	M58286	CYS88TYR
Tumor necrosis factor receptor 2 (75kD)	191191	M32315	M196R
tumor necrosis factor type 1 receptor associated protein (TRAP1)	None	U12595	none found
tumor necrosis factor type 2 receptor associated protein (TRAP3)	601895	U12597	none found
Vascular cell adhesion molecule 1	192225	M60335	none found
vitamin D (1,25- dihydroxyvitamin D3) receptor/VDR	601769	J03258	GLY30ASP
vitamin D (1,25- dihydroxyvitamin D3) receptor/VDR	601769	J03258	ARG-GLY
vitamin D (1,25- dihydroxyvitamin D3) receptor/VDR	601769	J03258	TYR292TER

SD-144141.1

dihydroxyvitamin D3) receptor/VDR	601769	J03258	ARG77GLN
vitamin D (1,25- dihydroxyvitamin D3) receptor/VDR	601769	J03258	ARG47GLN
vitamin D (1,25- dihydroxyvitamin D3) receptor/VDR	601769	J03258	GLN149TER
vitamin D (1,25- dihydroxyvitamin D3) receptor/VDR	601769	J03258	ARG27ILEU
vitamin D (1,25- dihydroxyvitamin D3) receptor/VDR	601769	J03258	GLY46ASP
vitamin D (1,25- dihydroxyvitamin D3) receptor/VDR	601769	J03258	HIS305GLN
vitamin D (1,25- dihydroxyvitamin D3) receptor/VDR	601769	J03258	ILE314SER
vitamin D (1,25- dihydroxyvitamin D3) receptor/VDR	601769	J03258	ARG391CYS
vitamin D (1,25- dihydroxyvitamin D3) receptor/VDR	601769	J03258	ARG30TER
vitamin D (1,25- dihydroxyvitamin D3) receptor/VDR	601769	J03258	BsmI

SD-144141.1

receptor/VDR	601769	J03258	ATG to ACG initiation codon
vitamin D (1,25-dihydroxyvitamin D3) receptor/VDR	601769	J03258	Apa I
vitamin D (1,25-dihydroxyvitamin D3) receptor/VDR	601769	J03258	Taq I
vitamin D (1,25-dihydroxyvitamin D3) receptor/VDR	601769	J03258	codon 79 silent
vitamin D (1,25-dihydroxyvitamin D3) receptor/VDR	601769	J03258	base change in intron 3
vitamin D (1,25-dihydroxyvitamin D3) receptor/VDR	601769	J03258	EcoRV xx
2,3-cyclic nucleotide 3-phosphodiesterase	M19650	123830	none found
3beta hydroxysteroid dehydrogenase	M27137	109715	none found
a-glucosidase	Y00839	232300	EX18DEL

Table 22. Identified
Variances in Genes or
Related Pathways
involved in Endocrine
and Metabolic Disease

SD-144141.1

a-glucosidase	Y00839	232300	1-BP DEL	frameshift
a-glucosidase	Y00839	232300	T-G, -13 intron 1	
a-glucosidase	Y00839	232300		ARG725TRP
a-glucosidase	Y00839	232300		PRO545LEU
a-glucosidase	Y00839	232300		SER529VAL
a-glucosidase	Y00839	232300		GLY643ARG
a-glucosidase	Y00839	232300		GLU521LYS
a-glucosidase	Y00839	232300		GLU689LYS
a-glucosidase	Y00839	232300		ARG854TER
a-glucosidase	Y00839	232300		LEU299ARG
a-glucosidase	Y00839	232300		LYS903DEL
a-glucosidase	Y00839	232300		MET318THR
a-glucosidase	Y00839	232300		ASP91ASN
a-glucosidase	Y00839	232300		ASP645GLU
a-glucosidase AB	D42041	None	none found	
ACAT1	D90228	203750	1-BP INS, 1083A	
ACAT1	D90228	203750	1163 + 2	
ACAT1	D90228	203750	4-BP INS	
ACAT1	D90228	203750	828 + 1	
ACAT1	D90228	203750	IVS10, A-C, -2	
ACAT1	D90228	203750	IVS10, G-C, -1	
ACAT1	D90228	203750	IVS8, G-T, +1	
ACAT1	D90228	203750		ALA347THR
ACAT1	D90228	203750		GLY150ARG
ACAT1	D90228	203750		MET1LYS
ACAT1	D90228	203750		GLY379VAL
ACAT1	D90228	203750		GLN272TER
ACAT1	D90228	203750		GLU345DEL
ACAT1	D90228	203750		ASN93SER
ACAT1	D90228	203750		ILE312THR
ACAT1	D90228	203750		ALA333PRO

SD-144141.1

ACAT1	D90228	203750	N158D
ACAT2	S70154	100678	
ACAT2	S70154	100678	
ACAT2	S70154	100678	
ACAT2	S70154	100678	
ACAT2	S70154	100678	N158D Q272X
Adrenocorticotrophic hormone (ACTH)	M28636	176830	
Adrenocorticotrophic hormone (ACTH)	M28636	176830	3804C-A
Adrenocorticotrophic hormone (ACTH)	M28636	176830	7013G-T
Adrenocorticotrophic hormone (ACTH)	M28636	176830	7133C DEL
aldose reductase	M34720	103880	(AC)n
Alpha Amylase 2A; pancreatic	M28443	104650	none found
androgen receptor	M20132	313700	Hind III
androgen receptor	M20132	313700	(CAA)n
androgen receptor	M20132	313700	(CAG)n
androgen receptor	M20132	313700	(GGN)n
androgen receptor	M20132	313700	5-KB DEL, EX F,G
androgen receptor	M20132	313700	5-KB DEL, EX E
androgen receptor	M20132	313700	C>T within exon B
androgen receptor	M20132	313700	CAG340TAG
androgen receptor	M20132	313700	Del T at 3286
androgen receptor	M20132	313700	del1893
androgen receptor	M20132	313700	G Codon 210 A
androgen receptor	M20132	313700	G Codon 211 A
androgen receptor	M20132	313700	G2314A
androgen receptor	M20132	313700	G2677A
androgen receptor	M20132	313700	HhaI
androgen receptor	M20132	313700	HpaII

silent
Gln>Ter
frameshift
frameshift

ala>thr
glu629arg

androgen receptor	M20132	313700	Insert of 69 nucleotides MaeIII PARTIAL DEL Stu I	VAL730MET
androgen receptor	M20132	313700		ALA721THR
androgen receptor	M20132	313700		GLN902ARG
androgen receptor	M20132	313700		HIS874TYR
androgen receptor	M20132	313700		SER647ASN
androgen receptor	M20132	313700		THR877SER
androgen receptor	M20132	313700		ARG607GLN
androgen receptor	M20132	313700		VAL865LEU
androgen receptor	M20132	313700		VAL865MET
androgen receptor	M20132	313700		LYS588TER
androgen receptor	M20132	313700		CYS579PHE
androgen receptor	M20132	313700		PHE582TYR
androgen receptor	M20132	313700		pro892ser
androgen receptor	M20132	313700		PRO546SER
androgen receptor	M20132	313700		ILE869MET
androgen receptor	M20132	313700		GLU2LYS
androgen receptor	M20132	313700		ARG839CYS
androgen receptor	M20132	313700		ARG839HIS
androgen receptor	M20132	313700		GLN60TER
androgen receptor	M20132	313700		TRP794TER
androgen receptor	M20132	313700		LEU172TER
androgen receptor	M20132	313700		LEU707ARG
androgen receptor	M20132	313700		MET786VAL
androgen receptor	M20132	313700		TYR761CYS
androgen receptor	M20132	313700		ARG772CYS
androgen receptor	M20132	313700		598 or 599 ter

SD-144141.1

androgen receptor	M20132	313700	gly743val
androgen receptor	M20132	313700	Gln798Glu
androgen receptor	M20132	313700	arg726leu
androgen receptor	M20132	313700	LEU676PRO
androgen receptor	M20132	313700	ARG608LYS
androgen receptor	M20132	313700	val 581 phe
androgen receptor	M20132	313700	G214R
androgen receptor	M20132	313700	THR877ALA
androgen receptor	M20132	313700	Arg615His
androgen receptor	M20132	313700	Arg752Gln
androgen receptor	M20132	313700	arg840his
androgen receptor	M20132	313700	ALA771THR
androgen receptor	M20132	313700	LYS882TER
androgen receptor	M20132	313700	ARG846HIS
androgen receptor	M20132	313700	ARG773HIS
androgen receptor	M20132	313700	TRP717TER
androgen receptor	M20132	313700	ARG773CYS
androgen receptor	M20132	313700	VAL866MET
androgen receptor	M20132	313700	ARG855HIS
androgen receptor	M20132	313700	MET780ILE
Arginine Vasopressin	AF030625	600821	none found
Receptor 1A/AVPR1A			
Arginine Vasopressin	AF030512	600264	none found
Receptor 1B/AVPR1B			
Arginine vasopressin	AF030626	304800	1-BP DEL
receptor 2			
Arginine vasopressin	AF030626	304800	1-BP DEL, 102G
receptor 2			
Arginine vasopressin	AF030626	304800	1-BP INS frameshift
receptor 2			
Arginine vasopressin	AF030626	304800	1-BP INS 804 frameshift

SD-144141.1

receptor 2					
Arginine vasopressin receptor 2	AF030626	304800	15delC		
Arginine vasopressin receptor 2	AF030626	304800	28-bp del		
Arginine vasopressin receptor 2	AF030626	304800	786delG frameshift		
Arginine vasopressin receptor 2	AF030626	304800	CpG dinucleotides		
Arginine vasopressin receptor 2	AF030626	304800	TYR280CYS		
Arginine vasopressin receptor 2	AF030626	304800	P322H		
Arginine vasopressin receptor 2	AF030626	304800	P322S		
Arginine vasopressin receptor 2	AF030626	304800	ARG113TRP		
Arginine vasopressin receptor 2	AF030626	304800	TRP71TER		
Arginine vasopressin receptor 2	AF030626	304800	ALA132ASP		
Arginine vasopressin receptor 2	AF030626	304800	ARG203CYS		
Arginine vasopressin receptor 2	AF030626	304800	GLY185CYS		
Arginine vasopressin receptor 2	AF030626	304800	TYR205CYS		
Arginine vasopressin receptor 2	AF030626	304800	ASP85ASN		
Arginine vasopressin receptor 2	AF030626	304800	GLY201ASP		

SD-144141.1

Arginine vasopressin receptor 2	AF030626	304800	ARG337TER
Arginine vasopressin receptor 2	AF030626	304800	G107E
Arginine vasopressin receptor 2	AF030626	304800	L43P
Arginine vasopressin receptor 2	AF030626	304800	W193X
Arginine vasopressin receptor 2	AF030626	304800	ARG181CYS
Arginine vasopressin receptor 2	AF030626	304800	R137H
ATP-sensitive inwardly rectifying K-channel	U24660	600877	none found
Beta-3-Adrenergic Receptor; Adrb3	X70811	109691	intron 1 g1856t
Beta-3-Adrenergic Receptor; Adrb3	X70811	109691	TRP64ARG
BONE MORPHOGENETIC PROTEIN RECEPTOR, TYPE IB; BMPRIB		603248	none found
Calcitonin Receptor	U26553	114131	PRO463LEU
Calcitonin Receptor	U26553	114131	pro447leu
Calcitonin Related Peptide Receptor	U17473	114190	none found
Calcitonin Related Polypeptide Alpha	M26095	114130	1-BP INS, IVS4
Calcium-activated	U02632	600150	none found

SD-144141.1

potassium channel				
calpain, large	NM_0000	114240		ARG572GLN
polypeptide	70			
L3/CAPN3				
calpain, large	NM_0000	114240		ARG110TER
polypeptide	70			
L3/CAPN3				
calpain, large	NM_0000	114240		ARG769GLN
polypeptide	70			
L3/CAPN3				
calpain, large	NM_0000	114240		PRO319LEU
polypeptide	70			
L3/CAPN3				
calpain, large	NM_0000	114240		SER86PHE
polypeptide	70			
L3/CAPN3				
Carnitine	X78706	600184	none found	
Acetyltransferase				
Carnitine	D87812	600528		ASP454GLY
Palmitoyltransferase I				
(muscle)				
Carnitine	U09648	600650	413 delAG	
Palmitoyltransferase II				
Carnitine	U09648	600650		ARG631CYS
Palmitoyltransferase II				
Carnitine	U09648	600650		E174K
Palmitoyltransferase II				
Carnitine	U09648	600650		F352C
Palmitoyltransferase II				
Carnitine	U09648	600650		M647V
Palmitoyltransferase II				

SD-144141.1

Carnitine Palmitoyltransferase II	U09648	600650	V368I
Carnitine Palmitoyltransferase II	U09648	600650	SER113LEU
Carnitine Palmitoyltransferase II	U09648	600650	R124Stop
Carnitine Palmitoyltransferase II	U09648	600650	ASP553ASN
Carnitine Palmitoyltransferase II	U09648	600650	PRO50HIS
Carnitine Palmitoyltransferase II	U09648	600650	GLU174LYS
Carnitine Palmitoyltransferase II	U09648	600650	PHE383TYR
Carnitine Palmitoyltransferase II	U09648	600650	F448L
Carnitine Palmitoyltransferase II	U09648	600650	G549D
Carnitine Palmitoyltransferase II	U09648	600650	ARG503CYS
Carnitine Palmitoyltransferase II	U09648	600650	TYR628SER
CCAAT/ENHANCER- BINDING PROTEIN, GAMMA; CEBPG		138972	none found
Cell surface receptor for sulfonyleureas on pancreatic b cells	L78207	600509	EX35, G-A
Cell surface receptor for sulfonyleureas on pancreatic b cells	L78207	600509	G-A, -9 EXON ALPHA DEL

SD-144141.1

Cell surface receptor for sulfonyleureas on pancreatic b cells	L78207	600509	3-BP DEL	PHE1388DEL
Cell surface receptor for sulfonyleureas on pancreatic b cells	L78207	600509	ACC-->ACT	Thr759Thr
Cell surface receptor for sulfonyleureas on pancreatic b cells	L78207	600509	BRANCH POINT, A-G, -20	
Cell surface receptor for sulfonyleureas on pancreatic b cells	L78207	600509	Exon 16 -3c-->t	
Cell surface receptor for sulfonyleureas on pancreatic b cells	L78207	600509	G-A, -1	splice change
Cell surface receptor for sulfonyleureas on pancreatic b cells	L78207	600509	G-A, -1 exon 5	
Cell surface receptor for sulfonyleureas on pancreatic b cells	L78207	600509		ARG1353PRO
Cell surface receptor for sulfonyleureas on pancreatic b cells	L78207	600509		ARG1421CYS
Cell surface receptor for sulfonyleureas on pancreatic b cells	L78207	600509		ARG1494TRP
Cell surface receptor for sulfonyleureas on pancreatic b cells	L78207	600509		R275Q
Cell surface receptor for sulfonyleureas on pancreatic b cells	L78207	600509		V560M

SD-144141.1

for sulfonylureas on pancreatic b cells	L78207	600509	F591L
Cell surface receptor for sulfonylureas on pancreatic b cells	L78207	600509	G1382S
Cell surface receptor for sulfonylureas on pancreatic b cells	L78207	600509	H125Q
Cell surface receptor for sulfonylureas on pancreatic b cells	L78207	600509	N188S
Cell surface receptor for sulfonylureas on pancreatic b cells	L78207	600509	R1215Q
Cell surface receptor for sulfonylureas on pancreatic b cells	L78207	600509	R1394H
Cell surface receptor for sulfonylureas on pancreatic b cells	L78207	600509	T1139M
Cell surface receptor for sulfonylureas on pancreatic b cells	L78207	600509	S1370A
Cell surface receptor for sulfonylureas on pancreatic b cells	L78207	600509	GLY716VAL
cytochrome P450 aromatase (CYP19)	X13589	107910	(TTTA) _n in intron 5

SD-144141.1

cytochrome P450 aromatase (CYP19)	X13589	107910	1-BP DEL, 408C	frameshift
cytochrome P450 aromatase (CYP19)	X13589	107910	G-->A at Val80	silent
cytochrome P450 aromatase (CYP19)	X13589	107910	G-1094 -A	ARG365GLN
cytochrome P450 aromatase (CYP19)	X13589	107910	G-to-A	Val370-to-Met
cytochrome P450 aromatase (CYP19)	X13589	107910	GT to AT exon and intron 3	
cytochrome P450 aromatase (CYP19)	X13589	107910	splice donor (GT>GC) of intron 6	29 extra amino acids ARG435CYS
cytochrome P450 aromatase (CYP19)	X13589	107910		CYS437TYR
cytochrome P450 aromatase (CYP19)	X13589	107910		Arg264cys
cytochrome P450 aromatase (CYP19)	X13589	107910		ARG375CYS
Cytochrome P450 reductase	S90469	124015	none found	
Cytochrome P450, subfamily IIB (phenobarbital- inducible), polypeptide 6	M29874	None	none found	
Cytochrome P450, subfamily XIA (cholesterol side chain cleavage)	M14565	118485	5' UTR pentanucleotide repeat	

Cytochrome P450, subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia	M14564	202110	1-BP DEL	frameshift
Cytochrome P450, subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia	M14564	202110	1-bp C del codon 131	
Cytochrome P450, subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia	M14564	202110	1-BP DEL	frameshift
Cytochrome P450, subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia	M14564	202110	4-BP DUP, EX8	
Cytochrome P450, subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia	M14564	202110	469-BP INS	
Cytochrome P450, subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia	M14564	202110	518-BP DEL	
Cytochrome P450, subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia	M14564	202110	7-BP DUP, EX2	

SD-144141.1

subfamily XVII (steroid 17-alpha- hydroxylase), adrenal hyperplasia	M14564	202110	IVS2, G-T, +5	
Cytochrome P450, subfamily XVII (steroid 17-alpha- hydroxylase), adrenal hyperplasia	M14564	202110	IVS7+5G to A	
Cytochrome P450, subfamily XVII (steroid 17-alpha- hydroxylase), adrenal hyperplasia	M14564	202110	T-->C promoter	
Cytochrome P450, subfamily XVII (steroid 17-alpha- hydroxylase), adrenal hyperplasia	M14564	202110		ARG347HIS
Cytochrome P450, subfamily XVII (steroid 17-alpha- hydroxylase), adrenal hyperplasia	M14564	202110		
Cytochrome P450, subfamily XVII (steroid 17-alpha- hydroxylase), adrenal hyperplasia	M14564	202110		ARG358GLN
Cytochrome P450, subfamily XVII (steroid 17-alpha- hydroxylase), adrenal hyperplasia	M14564	202110		TRP17TER

SD-144141.1

(steroid 17-alpha-hydroxylase), adrenal hyperplasia	M14564	202110	PHE417CYS
Cytochrome P450, subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia	M14564	202110	PHE53/54 DEL
Cytochrome P450, subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia	M14564	202110	ARG239TER
Cytochrome P450, subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia	M14564	202110	PRO342THR
Cytochrome P450, subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia	M14564	202110	SER106PRO
Cytochrome P450, subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia	M14564	202110	PHE53DEL

SD-144141.1

hydroxylase), adrenal hyperplasia				
Cytochrome P450, subfamily XVII	M14564	202110		his373leu
(steroid 17-alpha- hydroxylase), adrenal hyperplasia				
Cytochrome P450, subfamily XVII	M14564	202110		Arg496Cys
(steroid 17-alpha- hydroxylase), adrenal hyperplasia				
Cytochrome P450, subfamily XVII	M14564	202110		Gln461Stop
(steroid 17-alpha- hydroxylase), adrenal hyperplasia				
Cytochrome P450, subfamily XVII	M14564	202110		ARG96TRP
(steroid 17-alpha- hydroxylase), adrenal hyperplasia				
DOLICHOL- PHOSPHATE		603503	none found	
MANNOSYLTRANSF ERASE 1				
DOLICHYL- PHOSPHATE		603564	none found	
MANNOSYLTRANSF ERASE 2				
REGULATORY				

SD-144141.1

SUBUNIT				
Endothelin Receptor Type A	D90348	131243	none found	
Endothelin Receptor Type B	L06623	131244	1-BP INS, 878T	
Endothelin Receptor Type B	L06623	131244		TRP275TER
Endothelin Receptor Type B	L06623	131244		ALA183GLY
Endothelin Receptor Type B	L06623	131244		TRP276CYS
Endothelin Receptor Type B	L06623	131244		SER305ASN
Endothelin Receptor Type B	L06623	131244		GLY57SER
estrogen receptor 1 (ESR1)	X03635	133430	RFLP (Pssl enzyme)	
estrogen receptor 1 (ESR1)	X03635	133430	RFLP (PvuII enzyme)	
Estrogen-preferring sulfotransferase/STE	NM_005420	600043	none found	
FATTY ACID COENZYME A LIGASE, LONG-CHAIN 2		152426	none found	
Folic Acid (Folate Receptor)	M28099	136430	none found	
follicle stimulating hormone-beta (FSH)	M16646	136530		CYS51GLY
follicle stimulating hormone-beta (FSH)	M16646	136530		FS87TER

SD-144141.1

FSH receptor	M65085	136435	566C-->T	ARG573CYS
FSH receptor	M65085	136435	BsmI	ILE160THR
FSH receptor	M65085	136435	HindIII	PHE591SER
FSH receptor	M65085	136435	PstI	Thr307Ala
FSH receptor	M65085	136435		Asp567Gly
FSH receptor	M65085	136435		Ser680Asn
FSH receptor	M65085	136435		Asp334Gly
FSH receptor	M65085	136435		ALA189VAL
G PROTEIN- COUPLED RECEPTOR 24; GPR24		601751	none found	
Glucagon	J04040	138030	Dinucleotide repeat	
glucagon receptor/GCGR	NM_0001 60	138033	Alu-repeat	
glucagon receptor/GCGR	NM_0001 60	138033		GLY40SER
glucagon-like peptide 1 receptor/GLPIR	U01156	138032	silent substitution in exon 6	
glucagon-like peptide 1 receptor/GLPIR	U01156	138032	simple tandem repeat DNA	
glucagon-like peptide 2 receptor/GLP2R	*****	603659	polymorphism none found	
glucocorticoid receptor	M11050	138040	4-BP DEL	2 bases of the exon and the first 2

SD-144141.1

glucocorticoid receptor	M11050	138040	A to G 3'-splice junction of intron G	nucleotides of intron 6 frameshift
glucocorticoid receptor	M11050	138040	Base-pair deletion in exon 9	32 amino acid deletion
glucocorticoid receptor	M11050	138040	BcII	
glucocorticoid receptor	M11050	138040	T insertion 1188 and 1189	frameshift
glucocorticoid receptor	M11050	138040	trinucleotide insertion	Arg453
glucocorticoid receptor	M11050	138040	TthIII	LEU753PHE
glucocorticoid receptor	M11050	138040		CYS736SER
glucocorticoid receptor	M11050	138040		CYS736THR
glucocorticoid receptor	M11050	138040		ILE747THR
glucocorticoid receptor	M11050	138040		ASP641VAL
glucocorticoid receptor	M11050	138040		L753F
glucocorticoid receptor	M11050	138040		Q710X
glucocorticoid receptor	U25029	138040		ASN363SER
glucocorticoid receptor alpha	X03348	138040	none found	
glucocorticoid receptor beta			none found	
GLUCOCORTICOID RECEPTOR- INTERACTING PROTEIN 1		601993	none found	
glycogen synthase [human, liver, mRNA, 2912 nt]	S70004	138571	IVS6, G-C, +1	

SD-144141.1

glycogen synthase [human, liver, mRNA, 2912 nt]	S70004	138571	ALA339PRO
glycogen synthase [human, liver, mRNA, 2912 nt]	S70004	138571	ARG246TER
glycogen synthase [human, liver, mRNA, 2912 nt]	S70004	138571	ASN39SER
glycogen synthase [human, liver, mRNA, 2912 nt]	S70004	138571	HIS446ASP
glycogen synthase [human, liver, mRNA, 2912 nt]	S70004	138571	MET491ARG
glycogen synthase [human, liver, mRNA, 2912 nt]	S70004	138571	SER483PRO
glycogen synthase [human, liver, mRNA, 2912 nt]	S70004	138571	PRO479GLN
gonadotropin releasing hormone receptor/G protein- coupled/LHRHR/GNR HR	NM_0004 06	138850	ARG262GLN
gonadotropin releasing hormone receptor/G protein- coupled/LHRHR/GNR HR	NM_0004 06	138850	GLN106ARG

SD-144141.1

gonadotropin releasing hormone receptor/G protein-coupled/LHRHR/GNR HR	NM_000406	138850	TYR284CYS
gonadotropin releasing hormone receptor/G protein-coupled/LHRHR/GNR HR	NM_000406	138850	Mae III
Gonadotropin-releasing hormone (leutinizing-releasing hormone)	M12578	152760	none found
GROWTH FACTOR RECEPTOR-BOUND PROTEIN 2; GRB2		108355	none found
Growth hormone 1	V00519	139250	G-T, +1 intron 4
Growth hormone 1	V00519	139250	1-BP DEL, 371C
Growth hormone 1	V00519	139250	18-BP DEL, +28-45 intron 3
Growth hormone 1	V00519	139250	FSI32TER
Growth hormone 1	V00519	139250	2-BP DEL
Growth hormone 1	V00519	139250	6.7-KB DEL
Growth hormone 1	V00519	139250	BglII
Growth hormone 1	V00519	139250	G-A, +1 intron 3
Growth hormone 1	V00519	139250	G-A, +28
Growth hormone 1	V00519	139250	G-C, +1 intron 3
Growth hormone 1	V00519	139250	G-C, +1 intron 4
Growth hormone 1	V00519	139250	HincII
Growth hormone 1	V00519	139250	MspI
Growth hormone 1	V00519	139250	T-C, +6 intron 3
Growth hormone 1	V00519	139250	ARG77CYS

Growth hormone 1	V00519	139250	ASPI112GLY
Growth hormone 1	V00519	139250	TRP20TER
Growth hormone receptor	X06562	600946	none found
growth hormone releasing hormone receptor/G protein-coupled/GHRHR	U34195	139191	IVS8DS, G-C, -1 alternative splice
growth hormone releasing hormone receptor/G protein-coupled/GHRHR	U34195	139191	1-BP DEL frameshift
growth hormone releasing hormone receptor/G protein-coupled/GHRHR	U34195	139191	2-BP DEL frameshift
growth hormone releasing hormone receptor/G protein-coupled/GHRHR	U34195	139191	C to T codon 236. silent
growth hormone releasing hormone receptor/G protein-coupled/GHRHR	U34195	139191	EX4,6DEL
growth hormone releasing hormone receptor/G protein-coupled/GHRHR	U34195	139191	GAA180GAG silent
growth hormone releasing hormone receptor/G protein-coupled/GHRHR	U34195	139191	IVS4DS, G-A, +1 alternative splice

SD-144141.1

coupled/GHRHR growth hormone releasing hormone receptor/G protein- coupled/GHRHR	U34195	139191	IVS6AS, G-T, -1
growth hormone releasing hormone receptor/G protein- coupled/GHRHR	U34195	139191	IVS8AS, G-C, -1
growth hormone releasing hormone receptor/G protein- coupled/GHRHR	U34195	139191	IVS9DS, G-A, +1 frameshift
growth hormone releasing hormone receptor/G protein- coupled/GHRHR	U34195	139191	ARG161CYS
growth hormone releasing hormone receptor/G protein- coupled/GHRHR	U34195	139191	GLU224ASP
growth hormone releasing hormone receptor/G protein- coupled/GHRHR	U34195	139191	GLU44LYS
growth hormone releasing hormone receptor/G protein- coupled/GHRHR	U34195	139191	PHE96SER
growth hormone releasing hormone receptor/G protein- coupled/GHRHR	U34195	139191	ASP152HIS

SD-144141.1

receptor/G protein-coupled/GHRHR growth hormone releasing hormone	U34195	139191	GLN154PRO
receptor/G protein-coupled/GHRHR growth hormone releasing hormone	U34195	139191	ILE153THR
receptor/G protein-coupled/GHRHR growth hormone releasing hormone	U34195	139191	VAL155GLY
receptor/G protein-coupled/GHRHR growth hormone releasing hormone	U34195	139191	VAL144ILE
receptor/G protein-coupled/GHRHR growth hormone releasing hormone	U34195	139191	PRO131GLN
receptor/G protein-coupled/GHRHR growth hormone releasing hormone	U34195	139191	GLU224TER
receptor/G protein-coupled/GHRHR growth hormone releasing hormone	U34195	139191	P561T
receptor/G protein-coupled/GHRHR growth hormone	U34195	139191	ARG217TER

SD-144141.1

releasing hormone receptor/G protein- coupled/GHRHR	U34195	139191	ARG43TER
growth hormone releasing hormone receptor/G protein- coupled/GHRHR	U34195	139191	CYS38TER
growth hormone releasing hormone receptor/G protein- coupled/GHRHR	L29177		none found
growth hormone- releasing factor (GRF)	X63282	601244	none found
Guanylate cyclase 1, soluble, alpha 2	X66534	139396	none found
Guanylate cyclase soluble, alpha-3 chain	X66533	139397	none found
Guanylate cyclase soluble, beta-1 chain	X65633	202200	C818A
H.sapiens ACTH-R gene for adrenocorticotrophic hormone receptor	X65633	202200	Ser74Ile
H.sapiens ALK-3 mRNA	Z22535	601299	none found
H.sapiens encoding PC1/PC3	X64810	162150	IVS5DS, A-C, +4

SD-144141.1

H.sapiens encoding PC1/PC3	X64810	162150	GLY483ARG
H.sapiens HNF4 mRNA for hepatocyte nuclear factor 4	X76930	600281	1-BP DEL PHE75T
H.sapiens HNF4 mRNA for hepatocyte nuclear factor 4	X76930	600281	GLN268TER
H.sapiens HNF4 mRNA for hepatocyte nuclear factor 4	X76930	600281	ARG154TER
H.sapiens HNF4 mRNA for hepatocyte nuclear factor 4	X76930	600281	ARG127TRP
H.sapiens HNF4 mRNA for hepatocyte nuclear factor 4	X76930	600281	VAL393ILE
H.sapiens HNF4 mRNA for hepatocyte nuclear factor 4	X76930	600281	Val/Met255
H.sapiens IL-1R2 mRNA for type II interleukin-1 receptor, (cell line CB23)	X59770	147811	none found
H.sapiens mRNA for beta subunit of epithelial amiloride- sensitive sodium channel	X87159	600760	1-BP INS, 592C
H.sapiens mRNA for beta subunit of	X87159	600760	32-BP DEL

SD-144141.1

•

epithelial amiloride-sensitive sodium channel	X87159	600760	ARG564TER
H.sapiens mRNA for beta subunit of epithelial amiloride-sensitive sodium channel	X87159	600760	PRO616LEU
H.sapiens mRNA for beta subunit of epithelial amiloride-sensitive sodium channel	X87159	600760	GLY37SER
H.sapiens mRNA for beta subunit of epithelial amiloride-sensitive sodium channel	X87159	600760	TYR618HIS
H.sapiens mRNA for beta subunit of epithelial amiloride-sensitive sodium channel	X87159	600760	PRO615SER
H.sapiens mRNA for beta subunit of epithelial amiloride-sensitive sodium channel	Y10319	212138	1-BP INS frameshift
H.sapiens mRNA for carnitine carrier	Y10319	212138	110-BP DEL

caritine carrier					
H.sapiens mRNA for	Y10319	212138	128-BP DEL		
caritine carrier					
H.sapiens mRNA for	Y10319	212138			ARG166TER
caritine carrier					
H.sapiens mRNA for	X82153	601105			TER330TRP
cathepsin O					
H.sapiens mRNA for	X82153	601105			GLY146ARG
cathepsin O					
H.sapiens mRNA for	X82153	601105			ARG241TER
cathepsin O					
H.sapiens mRNA for	X82153	601105			ALA277VAL
cathepsin O					
H.sapiens mRNA for	X77383	600550	none found		
cathepsin-O					
H.sapiens mRNA for	Y11525	116897	none found		
CCAAT/enhancer					
binding protein alpha					
H.sapiens mRNA for	X95520	602047	1389 (A/G)		
cyclic nucleotide					
phosphodiesterase					
H.sapiens mRNA for	X95520	602047	dinucleotide repeat		
cyclic nucleotide			introns 12		
phosphodiesterase					
H.sapiens mRNA for	X95520	602047	dinucleotide repeat		
cyclic nucleotide			introns 5		
phosphodiesterase					
H.sapiens mRNA for	X87160	600761	none found		
gamma subunit of					
epithelial amiloride-					
sensitive sodium					

SD-144141.1

channel				
H.sapiens mRNA for GlcNac-1-P transferase	Z82022	191350		none found
H.sapiens mRNA for glucose-dependant insulinotropic polypeptide receptor gene	X81832	147940		539G del
H.sapiens mRNA for glucose-dependant insulinotropic polypeptide receptor gene	X81832	147940		A-230C
H.sapiens mRNA for growth factor receptor tyrosine kinase	X61656	191306		none found
H.sapiens mRNA for microsomal triglyceride transfer protein	X75500	157147		-164 T->C
H.sapiens mRNA for microsomal triglyceride transfer protein	X75500	157147		-400 A->T
H.sapiens mRNA for microsomal triglyceride transfer protein	X75500	157147		-493T/G
H.sapiens mRNA for microsomal triglyceride transfer protein	X75500	157147		1-BP DEL, 215C

SD-144141.1

H.sapiens mRNA for protein microsomal triglyceride transfer protein	X75500	157147	IVS, G-A, +5	
H.sapiens mRNA for microsomal triglyceride transfer protein	X75500	157147	IVS9AS, G-A, -1	
H.sapiens mRNA for microsomal triglyceride transfer protein	X75500	157147		ARG215TER
H.sapiens mRNA for parathyroid hormone receptor	X68596	168468	33-BP DEL	
H.sapiens mRNA for parathyroid hormone receptor	X68596	168468		HIS223ARG
H.sapiens mRNA for parathyroid hormone receptor	X68596	168468		THR410PRO
H.sapiens mRNA for parathyroid hormone receptor	X68596	168468		ARG383GLN
H.sapiens mRNA for parathyroid hormone receptor	X68596	168468		PRO132LEU
H.sapiens mRNA for phosphoenolpyruvate carboxykinase	X92720	261650	none found	

SD-144141.1

H.sapiens oculorhombin (aniridia) mRNA, complete cds	M77844	106210	IVS12DS, G-C, -1	
H.sapiens oculorhombin (aniridia) mRNA, complete cds	M77844	106210	2-BP INS	
H.sapiens oculorhombin (aniridia) mRNA, complete cds	M77844	106210	dinucleotide repeat promoter	
H.sapiens oculorhombin (aniridia) mRNA, complete cds	M77844	106210	EXON G DEL	
H.sapiens oculorhombin (aniridia) mRNA, complete cds	M77844	106210	IVS10AS, A-T, -2	
H.sapiens oculorhombin (aniridia) mRNA, complete cds	M77844	106210	IVS11DS, A-G, -2	
H.sapiens oculorhombin (aniridia) mRNA, complete cds	M77844	106210		ARG103TER
H.sapiens oculorhombin (aniridia) mRNA, complete cds	M77844	106210		SER353TER

SD-144141.1

complete cds H.sapiens oculorhombin (aniridia) mRNA, complete cds	M77844	106210	ARG26GLY
H.sapiens oculorhombin (aniridia) mRNA, complete cds	M77844	106210	I29V
H.sapiens oculorhombin (aniridia) mRNA, complete cds	M77844	106210	N17S
H.sapiens oculorhombin (aniridia) mRNA, complete cds	M77844	106210	Q178H
H.sapiens oculorhombin (aniridia) mRNA, complete cds	M77844	106210	R44Q
H.sapiens oculorhombin (aniridia) mRNA, complete cds	M77844	106210	Q422R
H.sapiens oculorhombin (aniridia) mRNA, complete cds	M77844	106210	ARG203TER
H.sapiens oculorhombin (aniridia) mRNA, complete cds	M77844	106210	ARG240TER

(aniridia) mRNA, complete cds	M77844	106210	GLY64VAL
H.sapiens oculorhombin (aniridia) mRNA, complete cds	M77844	106210	VAL126ASP
H.sapiens oculorhombin (aniridia) mRNA, complete cds	M77844	106210	GLN116TER
H.sapiens oculorhombin (aniridia) mRNA, complete cds	M77844	106210	I87R
H.sapiens oculorhombin (aniridia) mRNA, complete cds	M77844	106210	ARG125CYS
H.sapiens oculorhombin (aniridia) mRNA, complete cds	M77844	106210	VAL54ASP
H.sapiens PPP1R3 mRNA for protein phosphatase 1, glycogen-binding regulatory subunit	X78578	600917	5-BP INS/DEL 3'UTR

SD-144141.1

H.sapiens PPP1R3 mRNA for protein phosphatase 1, glycogen-binding regulatory subunit	X78578	600917	ASP905TYR
HEPATOCYTE NUCLEAR FACTOR 3-BETA; HNF3B		600288	none found
HEPATOCYTE NUCLEAR FACTOR 3-GAMMA; HNF3G		602295	none found
HEPATOCYTE NUCLEAR FACTOR		604164	none found
HMG CoA synthase (HSH1) mitochondrial	U12789	600234	none found
HMG CoA synthase soluble	X66435	142940	none found
HMGCoA reductase/HMGCR	NM_000859	142910	HgiAI
HMGCoA reductase/HMGCR	NM_000859	142910	ScrFI polymorphism in the 2nd intron
Homo sapiens (clone lamda-hPEC-3) phosphoenolpyruvate carboxykinase (PCK1) mRNA, complete cds	L05144	261680	none found
Homo sapiens (clone PEBP2aA1) core-binding factor, runt domain, alpha subunit	L40992	600211	16-BP INS

SD-144141.1

1 (CBFA1) mRNA, 3' end of cds				
Homo sapiens (clone PEBP2aA1) core-binding factor, runt domain, alpha subunit 1 (CBFA1) mRNA, 3' end of cds	L40992	600211	ALA REPEAT	
Homo sapiens (clone PEBP2aA1) core-binding factor, runt domain, alpha subunit 1 (CBFA1) mRNA, 3' end of cds	L40992	600211		MET175ARG
Homo sapiens (clone PEBP2aA1) core-binding factor, runt domain, alpha subunit 1 (CBFA1) mRNA, 3' end of cds	L40992	600211		SER191ASN
Homo sapiens (clone PEBP2aA1) core-binding factor, runt domain, alpha subunit 1 (CBFA1) mRNA, 3' end of cds	L40992	600211		TRP283TER
Homo sapiens acyl-CoA synthetase 4 (ACS4) mRNA, complete cds	AF030555	300157	none found	
Homo sapiens low	M28219	143890		ATn

SD-144141.1

density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	EX2-6DEL
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	-19(CGG)n
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	1-BP DEL, 197G
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	1061-8T-->C
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	1650delG frameshift

SD-144141.1

receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	165delG
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	18-BP DUP
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	1846-1G-->A
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	2-BP DEL, 694AC
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	2199delCA

SD-144141.1

causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	2201delCA	
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	313 + 1G-->A	
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	335del10	frameshift
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	347delGCC	
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	4-BP INS, EX8	frameshift

SD-144141.1

hypercholesterolemia) mRNA, 3 end	M28219	143890	7-BP DEL	frameshift
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	785insG	
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	9-BP DEL	
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	AGG450AGA	silent
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	C766T	

SD-144141.1

mRNA, 3 end Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	EX13-14DEL
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	EX13-15DEL
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	EX13-15DUP
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	EX15DEL
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	EX16-17DEL

SD-144141.1

Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	EX16-18DEL
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	EX16DEL
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	EX17-18DEL
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	EX17DEL
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	EX2-12DEL
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	EX2-3DEL

SD-144141.1

density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	EX2-5DUP
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	EX2-8DUP
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	EX3-8DEL
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	EX4-6DEL
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	EX5DEL

SD-144141.1

receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	EX7-14DEL
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	EX7-8DEL
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	EX7DEL
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	EX9-10DEL
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	EX9DUP

SD-144141.1

causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	HhaI intron 9
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	HincII
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	IVS3, G-A, +1
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	IVS4, T-C, +2
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	null allele

SD-144141.1

hypercholesterolemia) mRNA, 3 end					
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	PvuII		
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	StuI		
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	T --> A28		
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890		ALA410THR	
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890			VAL502MET

SD-144141.1

mRNA, 3 end Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	ASP283ASN
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	GLY27DEL
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	GLU207LYS
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	D154N
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	D206E

SD-144141.1

Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	V408M
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	GLY197DEL
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	C127W
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	C139G
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	E397X
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	GLN12TER

SD-144141.1

density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	GLY525ASP
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	GLY528ASP
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	CYS163TYR
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	ASP206GLU
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	CYS646TYR

SD-144141.1

receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	TRP66GLY
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	SER156LEU
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	GLY544VAL
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	R329X
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	ASN543HIS

SD-144141.1

causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	ASP154ASN
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	N543H
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	Glu119-Lys
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	C152R
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	T705I

SD-144141.1

hypercholesterolemia) mRNA, 3 end	M28219	143890	Cys297-->Phe
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end			
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	asp147his
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end			
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	Trp469Stop
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end			
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	ASP412HIS
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end			
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	PRO664LEU

SD-144141.1

mRNA, 3 end Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	Ala370-->Thr
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	C356-->Y
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	CYS240PHE
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	Asp200-->Gly
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	Cl22X

Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	Pro84-->Ser
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	pro664leu
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	Cys646-->Tyr
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	Glu207-->Lys
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	Trp66-->Gly
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	CYS660TER

SD-144141.1

density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	TYR807CYS
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	TRP792TER
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	CYS210TER
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	GLY823ASP
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	LEU380HIS

SD-144141.1

receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	TYR167TER
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	VAL408MET
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	C331C
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	E119K
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	N494 N

SD-144141.1

causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	T383P
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	T7051
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	W23X
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	W556S
Homo sapiens low density lipoprotein receptor (FH 10 mutant causing familial hypercholesterolemia) mRNA, 3 end	M28219	143890	W66G

SD-144141.1

hypercholesterolemia) mRNA, 3 end					
Homo sapiens mRNA for Acyl-CoA synthetase 3, complete cds	D89053	602371	none found		
Homo sapiens mRNA for estrogen receptor beta, complete cds	AB006590	601663	none found		
Homo sapiens mRNA for perilipin, complete cds	AB005293	170290	none found		
Homo sapiens mRNA for transient receptor potential protein TRP6	AJ006276	603652	none found		
Homo sapiens mRNA for very-long-chain acyl-CoA synthetase, complete cds	D88308	603247	none found		
Homo sapiens muscle glycogen phosphorylase (PYGM) mRNA, complete cds	AF066859	232600	IVS14, G-A, +1, 67- BP DEL		
Homo sapiens muscle glycogen phosphorylase (PYGM) mRNA, complete cds	AF066859	232600		ARG49TER	
Homo sapiens muscle glycogen	AF066859	232600			GLY204SER

SD-144141.1

phosphorylase (PYGM) mRNA, complete cds	AF066859	232600	LYS542THR
Homo sapiens muscle glycogen phosphorylase (PYGM) mRNA, complete cds	AF066859	232600	METIGLY
Homo sapiens muscle glycogen phosphorylase (PYGM) mRNA, complete cds	AF066859	232600	GLU654LYS
Homo sapiens muscle glycogen phosphorylase (PYGM) mRNA, complete cds	AF066859	232600	LEU396PRO
Homo sapiens muscle glycogen phosphorylase (PYGM) mRNA, complete cds	AF066859	232600	GLY685ARG
Homo sapiens muscle glycogen phosphorylase (PYGM) mRNA, complete cds	AF066859	232600	ARG575TER

SD-144141.1

(PYGM) mRNA, complete cds	Homo sapiens muscle glycogen phosphorylase (PYGM) mRNA, complete cds	AF066859	232600	GLN665GLU
Homo sapiens muscle glycogen phosphorylase (PYGM) mRNA, complete cds	Homo sapiens muscle glycogen phosphorylase (PYGM) mRNA, complete cds	AF066859	232600	LYS753, DEL A
Homo sapiens muscle glycogen phosphorylase (PYGM) mRNA, complete cds	Homo sapiens muscle glycogen phosphorylase (PYGM) mRNA, complete cds	AF066859	232600	METVAL
Homo sapiens muscle glycogen phosphorylase (PYGM) mRNA, complete cds	Homo sapiens muscle glycogen phosphorylase (PYGM) mRNA, complete cds	AF066859	232600	GLU540TER
Homo sapiens somatostatin receptor (SSTR4) gene, complete cds	Homo sapiens somatostatin receptor (SSTR4) gene, complete cds	L07833	182454	none found
Homo sapiens sorbitol dehydrogenase gene, complete cds	Homo sapiens sorbitol dehydrogenase gene, complete cds	U07361	182500	none found
HOMOLOG OF SONIC HEDGEHOG	HOMOLOG OF SONIC HEDGEHOG		600725	GLY31ARG

HOMOLOG OF SONIC HEDGEHOG	600725	GLN100TER
HOMOLOG OF SONIC HEDGEHOG	600725	LYS105TER
HOMOLOG OF SONIC HEDGEHOG	600725	TRP117GLY
HOMOLOG OF SONIC HEDGEHOG	600725	TRP117ARG
Human (HepG2) glucose transporter gene mRNA, complete cds	K03195 138140	GCT15GCC silent
Human (HepG2) glucose transporter gene mRNA, complete cds	K03195 138140	XbaI
Human (HepG2) glucose transporter gene mRNA, complete cds	K03195 138140	DEL
Human (HepG2) glucose transporter gene mRNA, complete cds	K03195 138140	LYS456TER
Human (HepG2) glucose transporter gene mRNA, complete cds	K03195 138140	TYR449TER
Human activin receptor-like kinase (ALK-5) mRNA,	L11695 190181	S387Y

SD-144141.1

complete cds				
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	ALU INS	
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943		CYS342TYR
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943		CYS342ARG
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943		CYS342SER
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943		TYR340HIS
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943		SER354CYS
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943		ALA344ALA
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943		ALA344GLY
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943		TYR328CYS
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943		SER347CYS

SD-144141.1

Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	SER252TRP
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	PRO253ARG
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	THR341PRO
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	CYS342TRP
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	GLN289PRO
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	TYR375CYS
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	SER372CYS
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	SER252PHE
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	PRO253SER
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	TRP290CYS
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	LYS292GLU

SD-144141.1

fibroblast growth factor receptor-BEK	X52832	176943	TRP290ARG
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	TRP290GLY
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	LYS292GLU
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	TRP290ARG
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	TRP290GLY
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	VAL-VAL DEL
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	SER351CYS
Human bek mRNA for fibroblast growth factor receptor-BEK	X52832	176943	SER252PHE
Human beta-LH gene (luteinizing hormone gene beta subunit)	X00264	152780	ILE15THR
Human beta-LH gene (luteinizing hormone)	X00264	152780	TRP8ARG

SD-144141.1

gene beta subunit)					
Human beta-LH gene (luteinizing hormone gene beta subunit)	X00264	152780			GLN54ARG
Human brain glycogen phosphorylase mRNA, complete cds	J03544	138550	none found		
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	1-BP INS, CODON 443		frameshift
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	1305G-C		
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	C1644i		frameshift
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	EX4-10DEL		
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	HindIII		
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160			VAL458ALA
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160			R338L
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160			GLY340ARG

Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	ALA229THR
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	THR332DEL
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	ARG383HIS
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	LYS438GLU
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	GLY340SER
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	ARG320LEU
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	ARG311HIS
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	ARG438HIS
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	ARG320CYS
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	ARG338TRP
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	ALA312THR

SD-144141.1

for thyroid hormone receptor	Human c-erb-A mRNA	X04707	190160	GLY327ARG
for thyroid hormone receptor	Human c-erb-A mRNA	X04707	190160	GLY340VAL
for thyroid hormone receptor	Human c-erb-A mRNA	X04707	190160	GLY342GLU
for thyroid hormone receptor	Human c-erb-A mRNA	X04707	190160	MET437VAL
for thyroid hormone receptor	Human c-erb-A mRNA	X04707	190160	PRO448THR
for thyroid hormone receptor	Human c-erb-A mRNA	X04707	190160	PRO448HIS
for thyroid hormone receptor	Human c-erb-A mRNA	X04707	190160	THR337ALA
for thyroid hormone receptor	Human c-erb-A mRNA	X04707	190160	CYS434TER
for thyroid hormone receptor	Human c-erb-A mRNA	X04707	190160	CYS446ARG
for thyroid hormone receptor	Human c-erb-A mRNA	X04707	190160	LEU445HIS

SD-144141.1

receptor Human c-erb-A mRNA for thyroid hormone	X04707	190160	GLY340ASP
receptor Human c-erb-A mRNA for thyroid hormone	X04707	190160	GLN335HIS
receptor Human c-erb-A mRNA for thyroid hormone	X04707	190160	pro453ser
receptor Human c-erb-A mRNA for thyroid hormone	X04707	190160	R316H
receptor Human c-erb-A mRNA for thyroid hormone	X04707	190160	met313thre
receptor Human c-erb-A mRNA for thyroid hormone	X04707	190160	L346V
receptor Human c-erb-A mRNA for thyroid hormone	X04707	190160	MET310THR
receptor Human c-erb-A mRNA for thyroid hormone	X04707	190160	LEU325PHE
receptor Human c-erb-A mRNA for thyroid hormone	X04707	190160	ARG243GLN
receptor Human c-erb-A mRNA for thyroid hormone	X04707	190160	ARG243TRP

SD-144141.1

Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	ASP317HIS
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	PHE454CYS
Human c-erb-A mRNA for thyroid hormone receptor	X04707	190160	ARG315HIS
Human c-erbA-1 mRNA for thyroid hormone receptor alpha	X55005	190120	LYS370ASN
Human c-erbA-1 mRNA for thyroid hormone receptor alpha	X55005	190120	SER377LEU
Human c-erbA-1 mRNA for thyroid hormone receptor alpha	X55005	190120	SER45ILE
Human cGMP- inhibited cAMP phosphodiesterase mRNA, complete cds	M91667	123805	none found
Human colipase mRNA, complete cds	J02883	120105	none found
Human collagen type XVIII alpha 1 (COL18A1) mRNA, partial cds	L22548	120328	none found
Human CYP11B2 gene for steroid 18- hydroxylase, complete	D13752	124080	-344C/T

SD-144141.1

Human CYP11B2 gene for steroid 18- hydroxylase, complete cds	D13752	124080	5-BP DEL	frameshift
Human CYP11B2 gene for steroid 18- hydroxylase, complete cds	D13752	124080	T4986C	
Human CYP11B2 gene for steroid 18- hydroxylase, complete cds	D13752	124080		GLU198ASP
Human CYP11B2 gene for steroid 18- hydroxylase, complete cds	D13752	124080		GLU255TER
Human CYP11B2 gene for steroid 18- hydroxylase, complete cds	D13752	124080		LYS173ARG
Human CYP11B2 gene for steroid 18- hydroxylase, complete cds	D13752	124080		THR185ILE
Human CYP11B2 gene for steroid 18- hydroxylase, complete cds	D13752	124080		LEU461PRO
Human CYP11B2 gene for steroid 18- hydroxylase, complete cds	D13752	124080		ARG181TRP

SD-144141.1

[illegible]

P450c21 mRNA, 3' end	M17252	201910	GG dinucleotide to a C in exon 10	
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	HaeIII	
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	IVS2AS A/C-G, -13	
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	IVS7DS, G-C, +1	
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	NcoI	
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	Rsa I	
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	T-A exon 4	
Human cytochrome P450c21 mRNA, 3' end	M17252	201910		ILE172ASN
Human cytochrome P450c21 mRNA, 3' end	M17252	201910		VAL281LEU
Human cytochrome P450c21 mRNA, 3' end	M17252	201910		PRO30LEU
Human cytochrome P450c21 mRNA, 3' end	M17252	201910		SER268THR
Human cytochrome P450c21 mRNA, 3' end	M17252	201910		GLY292SER
Human cytochrome P450c21 mRNA, 3' end	M17252	201910		PRO453SER
Human cytochrome P450c21 mRNA, 3' end	M17252	201910		TYR102ARG
Human cytochrome P450c21 mRNA, 3' end	M17252	201910		ILE235ASN

SD-144141.1

Human cytochrome P450c21 mRNA, 3' end	M17252	201910	VAL236GLU
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	MET238LYS
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	GLN318TER
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	ARG339HIS
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	TRP406TER
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	GLU380ASP
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	Q318X
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	R356W
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	I236N
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	V237E
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	M239K
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	GLY524SER
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	R356Q
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	Y97X
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	Arg357Trp
Human cytochrome P450c21 mRNA, 3' end	M17252	201910	D183E

SD-144141.1

P450c21 mRNA, 3' end	MI7252	201910	W23X	
Human cytochrome				
P450c21 mRNA, 3' end	U26644	600212	none found	
Human fatty acid				
synthase (fas) mRNA,				
complete cds				
Human gene for	X52560	189965	none found	
nuclear factor NF-IL6				
Human glucagon-like	U01157	138032	none found	
peptide-1 receptor				
mRNA with CA				
dinucleotide repeat,				
complete cds				
Human heparin-	M32977	192240	none found	
binding vascular				
endothelial growth				
factor (VEGF) mRNA,				
complete cds				
Human hepatic lipase	J03540	151670	SER267PHE	
mRNA, complete cds				
Human hepatic lipase	J03540	151670	THR383MET	
mRNA, complete cds				
Human hepatic nuclear	M57732	142410	A-C, -58	
factor 1 (TCF1)				
mRNA, complete cds,				
clones HCL10,				
HCL12, HCL17, and				
HCL20				
Human hepatic nuclear	M57732	142410	1-BP DEL	frameshift
factor 1 (TCF1)				
mRNA, complete cds,				

SD-144141.1

clones HCL10, HCL12, HCL17, and HCL20	M57732	142410	1-BP INS	frameshift
Human hepatic nuclear factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20	M57732	142410	RsaI promoter	
Human hepatic nuclear factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20	M57732	142410	PRO447LEU	
Human hepatic nuclear factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20	M57732	142410	E619K	
Human hepatic nuclear factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20	M57732	142410	R537T	

SD-144141.1

HCL12, HCL17, and HCL20	M57732	142410	Ala ² /Val ⁹⁸
Human hepatic nuclear factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20			
Human hepatic nuclear factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20	M57732	142410	TYR122CYS
Human hepatic nuclear factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20	M57732	142410	THR620ILE
Human hepatic nuclear factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20	M57732	142410	Gly574Ser
Human hepatic nuclear factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20	M57732	142410	Cys241Gly

SD-144141.1

HCL20 Human hepatic nuclear factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20	M57732	142410	Glu48Lys
HCL20 Human hepatic nuclear factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20	M57732	142410	Pro291fsdelA
HCL20 Human hepatic nuclear factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20	M57732	142410	ARG272HIS
HCL20 Human hepatic nuclear factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20	M57732	142410	ARG583GLY
HCL20 Human hepatic nuclear factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20	M57732	142410	K205Q

Human hepatic nuclear factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20	M57732	142410	R131Q
Human hepatic nuclear factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20	M57732	142410	T392fsdelA
Human hepatic nuclear factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20	M57732	142410	L12H
Human hepatic nuclear factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20	M57732	142410	L584S585fsinsT C
Human hepatic nuclear factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20	M57732	142410	P379fsdelCT
Human hepatic nuclear factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20	M57732	142410	R263C

SD-144141.1

factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20	M57732	142410	G191D
Human hepatic nuclear factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20	M57732	142410	GLY319SER
Human hepatic nuclear factor 1 (TCF1) mRNA, complete cds, clones HCL10, HCL12, HCL17, and HCL20	U39840	602294	none found
Human hepatocyte nuclear factor-3 alpha (HNF-3 alpha) mRNA, complete cds	U40002	151750	dinucleotide repeat
Human hormone- sensitive lipase testicular isoform mRNA, complete cds	U40002	151750	Arg309Cys
Human hormone- sensitive lipase testicular isoform mRNA, complete cds	D83260	601125	none found
Human HXC-26 mRNA, complete cds			

SD-144141.1

Human insulin promoter factor 1 (IPF1) mRNA, complete cds	U30329	600733	1-BP DEL	frameshift
Human insulin- degrading enzyme (IDE) mRNA, complete cds	M21188	146680	none found	
Human insulin- responsive glucose transporter (GLUT4) mRNA, complete cds	M20747	138190		VAL383ILE
Human liver glycogen phosphorylase type IV mRNA, 3' end	M36807	232700	IVS13DS, G-A, +1	
Human liver glycogen phosphorylase type IV mRNA, 3' end	M36807	232700	IVS14DS, G-A, +1	
Human liver glycogen phosphorylase type IV mRNA, 3' end	M36807	232700	IVS4AS, G-C, -1	
Human liver glycogen phosphorylase type IV mRNA, 3' end	M36807	232700		ASN338SER
Human liver glycogen phosphorylase type IV mRNA, 3' end	M36807	232700		ASN376LYS
Human liver glycogen phosphorylase type IV mRNA, 3' end	M36807	232700		VAL221ILE
Human long-chain	L09229	152425	A-->T	new initiation

SD-144141.1

acyl-coenzyme A synthetase (FACL1) mRNA, complete cds				codon +18 amino acids
Human luteinizing hormone- choriogonadotropin receptor mRNA, complete cds	M63108	152790	6-BP DEL, NT1822	
Human luteinizing hormone- choriogonadotropin receptor mRNA, complete cds	M63108	152790	LEU-GLN INS, CODON 19-20	
Human luteinizing hormone- choriogonadotropin receptor mRNA, complete cds	M63108	152790		SER616TYR
Human luteinizing hormone- choriogonadotropin receptor mRNA, complete cds	M63108	152790		ARG554TER
Human luteinizing hormone- choriogonadotropin receptor mRNA, complete cds	M63108	152790		ALA593PRO
Human luteinizing hormone- choriogonadotropin receptor mRNA, complete cds	M63108	152790		ASP578GLY

SD-144141.1

receptor mRNA, complete cds Human luteinizing hormone- choriogonadotropin receptor mRNA, complete cds	M63108	152790	ILE625LYS
Human luteinizing hormone- choriogonadotropin receptor mRNA, complete cds	M63108	152790	ILE542LEU
Human luteinizing hormone- choriogonadotropin receptor mRNA, complete cds	M63108	152790	ALA373VAL
Human luteinizing hormone- choriogonadotropin receptor mRNA, complete cds	M63108	152790	GLU354LYS
Human luteinizing hormone- choriogonadotropin receptor mRNA, complete cds	M63108	152790	ARG133CYS
Human luteinizing hormone- choriogonadotropin receptor mRNA, complete cds	M63108	152790	ASP578GLY

complete cds Human luteinizing hormone- choriogonadotropin receptor mRNA, complete cds	M63108	152790	ALA572VAL
Human luteinizing hormone- choriogonadotropin receptor mRNA, complete cds	M63108	152790	THR577ILE
Human luteinizing hormone- choriogonadotropin receptor mRNA, complete cds	M63108	152790	ASP582GLY
Human luteinizing hormone- choriogonadotropin receptor mRNA, complete cds	M63108	152790	MET575ILE
Human luteinizing hormone- choriogonadotropin receptor mRNA, complete cds	M63108	152790	MET398THR
Human luteinizing hormone- choriogonadotropin receptor mRNA, complete cds	M63108	152790	CYS545TER

Human metalloendopeptidase homolog (PEX) mRNA, partial cds	U60475	307800	2-BP DEL	frameshift
Human metalloendopeptidase homolog (PEX) mRNA, partial cds	U60475	307800	A-G, NT-429	
Human metalloendopeptidase homolog (PEX) mRNA, partial cds	U60475	307800	IVS1AS, G-A, -1	
Human metalloendopeptidase homolog (PEX) mRNA, partial cds	U60475	307800	IVS1AS, G-C, -1	
Human metalloendopeptidase homolog (PEX) mRNA, partial cds	U60475	307800		LEU555PRO
Human metalloendopeptidase homolog (PEX) mRNA, partial cds	U60475	307800		CYS82TYR
Human metalloendopeptidase homolog (PEX) mRNA, partial cds	U60475	307800		LEU274TER
Human metalloendopeptidase homolog (PEX) mRNA, partial cds	U60475	307800		MET250ILE

SD-144141.1

mRNA, partial cds	U60475	307800	PHE249SER
Human metalloendopeptidase homolog (PEX)			
mRNA, partial cds			
Human molecular marker (EPC-1) gene, complete cds	M90439	172860	G to A 5
Human molecular marker (EPC-1) gene, complete cds	M90439	172860	Met72Thr
Human molecular marker (EPC-1) gene, complete cds	M90439	172860	Thr130Thr
Human molecular marker (EPC-1) gene, complete cds	M90439	172860	Tyr321Tyr
Human mRNA for alpha-tocopherol transfer protein, complete cds	D49488	600415	1-BP DEL 744
Human mRNA for alpha-tocopherol transfer protein, complete cds	D49488	600415	1-BP DEL, 485T
Human mRNA for alpha-tocopherol transfer protein, complete cds	D49488	600415	frameshift
Human mRNA for alpha-tocopherol transfer protein, complete cds	D49488	600415	2-BP INS, 513TT
Human mRNA for alpha-tocopherol transfer protein, complete cds	D49488	600415	552G-A

SD-144141.1

transfer protein, complete cds	D49488	600415	HIS101GLN
Human mRNA for alpha-tocopherol transfer protein, complete cds	D49488	600415	ARG192HIS
Human mRNA for alpha-tocopherol transfer protein, complete cds	D49488	600415	ARG134TER
Human mRNA for carboxypeptidase E (EC 3.4.17.10)	X51405	114855	none found
Human mRNA for cytochrome P-450 (11 Beta)	X55764	202010	2-BP INS, CODON 394 frameshift
Human mRNA for cytochrome P-450 (11 Beta)	X55764	202010	28bp deletion
Human mRNA for cytochrome P-450 (11 Beta)	X55764	202010	5 bp duplication
Human mRNA for cytochrome P-450 (11 Beta)	X55764	202010	CHIMERA
Human mRNA for cytochrome P-450 (11 Beta)	X55764	202010	MspI

SD-144141.1

Beta) Human mRNA for cytochrome P-450 (11	X55764	202010	PvuII	
Beta) Human mRNA for cytochrome P-450 (11	X55764	202010		ARG448HIS
Beta) Human mRNA for cytochrome P-450 (11	X55764	202010		TRP116TER
Beta) Human mRNA for cytochrome P-450 (11	X55764	202010		N133H
Beta) Human mRNA for cytochrome P-450 (11	X55764	202010		P42S
Beta) Human mRNA for cytochrome P-450 (11	X55764	202010		Y423X
Beta) Human mRNA for cytochrome P-450 (11	X55764	202010		arg384gly
Beta) Human mRNA for cytochrome P-450 (11	X55764	202010		ARG374GLN
Beta) Human mRNA for cytochrome P-450 (11	X55764	202010		THR318MET
Beta) Human mRNA for cytochrome P-450 (11	X55764	202010		C494F

SD-144141.1

Human mRNA for cytochrome P-450 (11 Beta)	X55764	202010	G267D
Human mRNA for cytochrome P-450 (11 Beta)	X55764	202010	G267R
Human mRNA for cytochrome P-450 (11 Beta)	X55764	202010	Q356X
Human mRNA for cytochrome P-450 (11 Beta)	X55764	202010	R427H
Human mRNA for glioblastoma-derived T-cell suppressor factor G-TsF (transforming growth factor-beta2, TGF-beta2)	Y00083	190220	none found
Human mRNA for plasminogen	X05199	173350	IVS17, 1-BP DEL, G, +1 TaqI
Human mRNA for plasminogen	X05199	173350	
Human mRNA for plasminogen	X05199	173350	GLU460TER
Human mRNA for plasminogen	X05199	173350	ALA600THR
Human mRNA for plasminogen	X05199	173350	ARG216HIS
Human mRNA for plasminogen	X05199	173350	GLY732ARG
Human mRNA for plasminogen	X05199	173350	LYS19GLU

SD-144141.1

Human plasminogen mRNA for plasminogen	X05199	173350	LYS212DEL
Human mRNA for plasminogen	X05199	173350	SER572PRO
Human mRNA for plasminogen	X05199	173350	TRP597TER
Human mRNA for plasminogen	X05199	173350	VAL355PHE
Human mRNA for plasminogen	X05199	173350	D676N
Human mRNA for plasminogen	X05199	173350	Ala675Thr
Human mRNA for transforming growth factor-beta (TGF-beta)	X02812	190180	713-8delC
Human mRNA for transforming growth factor-beta (TGF-beta)	X02812	190180	Leu10-->Pro
Human mRNA for transforming growth factor-beta (TGF-beta)	X02812	190180	713-8delC
Human mRNA for transforming growth factor-beta (TGF-beta)	X02812	190180	Arg25-->Pro
Human mRNA for transforming growth factor-beta 3 (TGF-beta 3)	X14149	190230	none found
Human mRNA for variant hepatic nuclear factor 1 (vHNF1)	X58840	189907	75-BP DEL, NT409
Human mRNA for variant hepatic nuclear factor 1 (vHNF1)	X58840	189907	ARG177TER

factor 1 (vHNF1)				
Human mRNA	X02404	114160	none found	
fragment for second				
calcitonin gene related				
peptide (CGRP) from				
medullary thyroid				
carcinoma (MTC)				
Human mRNA for	X12451	116880	none found	
pro-cathepsin L (major				
excreted protein MEP)				
Human muscle	J04501	138570	TTC342TTT	
glycogen synthase				
mRNA, complete cds				Gln71His
Human muscle	J04501	138570		
glycogen synthase				
mRNA, complete cds				Gly464Ser
Human muscle	J04501	138570		
glycogen synthase				Met416Val
mRNA, complete cds				
Human myeloid-	U80982	600749	none found	
specific C/EBP-epsilon				
transcription factor				
(CEBPE) gene,				
complete cds				
Human neurokinin A	M57414	162321	none found	
receptor (NK-2R)				
mRNA, complete cds				
Human NF-IL6-beta	M83667	116898	none found	

SD-144141.1

protein mRNA, complete cds	U18915	164160	-1387 G/A	
Human obese (ob) mRNA, complete cds	U18915	164160	1-BP DEL	frameshift
Human obese (ob) mRNA, complete cds	U18915	164160	A --> G + 19 exon1	
Human obese (ob) mRNA, complete cds	U18915	164160	C(-188)A	
Human obese (ob) mRNA, complete cds	U18915	164160		ARG105TRP
Human obese (ob) mRNA, complete cds	U18915	164160		Glu-126-Gln
Human obese (ob) mRNA, complete cds	U18915	164160		Ser-91-Ser
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079	CCC[Pro]-- >CCG[Pro] at codon 145	
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079	intron 1 a variant (C-->T)	
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079	(-258) G-to-A	
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079	(TAC-->TAT) in codon 215	
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079	-120 (G-->T)	

SD-144141.1

Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079	-194 (A-->G)
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079	-282 (C-->T)
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079	-30 G/A
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079	10-bp (base pair) deletion in exon 3;
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079	33-bp deletion at the exon 5/intron 5 junction 403 (C-->G)
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079	603 (G-->T)
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079	A--> G 244
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079	C--> T 8 bp 3' to the exon 9
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079	compound imperfect dinucleotide repeat
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079	G--> A 13

SD-144141.1

beta-cell glucokinase mRNA, complete cds	M88011	138079	IVS4DS, 15-BP DEL	
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079	TGG257-->CGG257	
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079		ARG186TER
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079		GLU265TER
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079		GLU279TER
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079		GLY261ARG
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079		GLY299ARG
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079		SER131PRO
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079		THR228MET
Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079		VAL455MET

SD-144141.1

mRNA, complete cds				
Human pancreatic	M88011	138079		Val62Ala
beta-cell glucokinase				
mRNA, complete cds				
Human pancreatic	M88011	138079		Thr209--
beta-cell glucokinase				>Met209
mRNA, complete cds				
Human pancreatic	M88011	138079		Gly261--
beta-cell glucokinase				>Glu261
mRNA, complete cds				
Human pancreatic	M88011	138079		Arg36-->Trp36
beta-cell glucokinase				
mRNA, complete cds				
Human pancreatic	M88011	138079		Glu70-->Lys
beta-cell glucokinase				
mRNA, complete cds				
Human pancreatic	M88011	138079		Ser131-->Pro
beta-cell glucokinase				
mRNA, complete cds				
Human pancreatic	M88011	138079		Ala188-->Thr
beta-cell glucokinase				
mRNA, complete cds				
Human pancreatic	M88011	138079		Trp257-->Arg
beta-cell glucokinase				
mRNA, complete cds				
Human pancreatic	M88011	138079		Lys414-->Glu
beta-cell glucokinase				
mRNA, complete cds				
Human pancreatic	M88011	138079		Asp4-->Asn
beta-cell glucokinase				
mRNA, complete cds				

SD-144141.1

Human pancreatic beta-cell glucokinase mRNA, complete cds	M88011	138079	Ala11Thr
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	(CA)n
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	2-BP DEL/1-BP INS
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	ALU INS, CODON 877
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	T/C fifth intron
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	ARG796TRP
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	GLU298LYS
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	ARG185GLN

SD-144141.1

Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	GLU128ALA
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	ARG227LEU
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	CYS582TYR
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	GLU681HIS
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	ALA116THR
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	PHE806SER
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	THR151MET
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	ASN118LYS

SD-144141.1

complete cds Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	PHE128LEU
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	THR151MET
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	GLU191LYS
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	PHE612SER
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	LEU773ARG
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	ARG185TER
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	GLY670GLU
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	PRO40ALA

SD-144141.1

receptor mRNA, complete cds Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	ARG228GLN
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	THR139MET
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	GLY144GLU
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	ARG63MET
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	ARG67CYS
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	PHE788CYS
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	LYS47ASN
Human parathyroid cell calcium-sensing receptor mRNA, complete cds	U20759	601199	A986S

SD-144141.1

calcium-sensing receptor mRNA, complete cds	U43148	601309	1148G-A	
Human patched homolog (PTC) mRNA, complete cds	U43148	601309	1-BP DEL	
Human patched homolog (PTC) mRNA, complete cds	U43148	601309	1-BP INS	
Human patched homolog (PTC) mRNA, complete cds	U43148	601309	11-BP DEL	frameshift
Human patched homolog (PTC) mRNA, complete cds	U43148	601309	2-BP INS	
Human patched homolog (PTC) mRNA, complete cds	U43148	601309	3340A-T	
Human patched homolog (PTC) mRNA, complete cds	U43148	601309	37-BP DEL	
Human patched homolog (PTC) mRNA, complete cds	U43148	601309	451C-T	Pro-Ser
Human patched homolog (PTC) mRNA, complete cds	U43148	601309	9-BP INS	CODON 815, PRO-ASN-ILE INS nonsense
Human patched mRNA, complete cds	U43148	601309	CAG to TAG at	

SD-144141.1

homolog (PTC) mRNA, complete cds	U43148	601309	codon 361	GLN210TER
Human patched homolog (PTC) mRNA, complete cds	U43148	601309		Gln816Leu
Human PTH2 parathyroid hormone receptor mRNA, complete cds	U25128	601469	none found	
Human putative calcium influx channel (htrp3) mRNA, complete cds	U47050	602345	none found	
Human receptor for advanced glycosylation end products (RAGE) mRNA, partial cds	M91211	600214	none found	
Human serum vitamin D-binding protein (hDBP) mRNA, complete cds	M12654	139200	HaeIII	
Human serum vitamin D-binding protein (hDBP) mRNA, complete cds	M12654	139200	(TAAA)n	
Human serum vitamin D-binding protein (hDBP) mRNA, complete cds	M12654	139200	MspI	

SD-144141.1

complete cds				
Human serum vitamin D-binding protein (hDBP) mRNA, complete cds	M12654	139200	Styl	
Human serum vitamin D-binding protein (hDBP) mRNA, complete cds	M12654	139200	T to C at Cys283	
Human serum vitamin D-binding protein (hDBP) mRNA, complete cds	M12654	139200		THR420LYS
Human somatostatin I gene and flanks	J00306	182450	BamHI intron	
Human somatostatin I gene and flanks	J00306	182450	EcoRI 3'	
Human SREBP-1 mRNA, complete cds	U00968	184756	none found	
Human stanniocalcin mRNA, complete cds	U46768	601185	none found	
Human steroid 5-alpha-reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600	1-BP DEL	PRO251DEL
Human steroid 5-alpha-reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600	null allele	
Human steroid 5-alpha-reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600		ARG246TRP
Human steroid 5-alpha-reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600		GLY115ASP

SD-144141.1

reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600	GLY183SER
Human steroid 5-alpha- reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600	GLY196SER
Human steroid 5-alpha- reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600	HIS231ARG
Human steroid 5-alpha- reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600	LEU55GLN
Human steroid 5-alpha- reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600	MET157DEL
Human steroid 5-alpha- reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600	THR228ALA
Human steroid 5-alpha- reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600	ARG227TER
Human steroidogenic acute regulatory protein (StAR) mRNA, complete cds	U17280	600617	840delA
Human steroidogenic acute regulatory protein (StAR) mRNA, complete cds	U17280	600617	IVS4AS, T-A, -11

SD-144141.1

Human steroidogenic acute regulatory protein (StAR) mRNA, complete cds	U17280	600617	GLN258TER
Human steroidogenic acute regulatory protein (StAR) mRNA, complete cds	U17280	600617	ARG182LEU
Human steroidogenic acute regulatory protein (StAR) mRNA, complete cds	U17280	600617	1-BP DEL, 261T
Human steroidogenic acute regulatory protein (StAR) mRNA, complete cds	U17280	600617	IVS2, 1-BP INS, T, +3
Human steroidogenic acute regulatory protein (StAR) mRNA, complete cds	U17280	600617	D203A
Human steroid regulatory element binding protein-2 mRNA, complete cds	U02031	600481	none found
Human transforming growth factor-beta type III receptor (TGF-beta) mRNA, complete cds	L07594	600742	none found
Human type II iodothyronine deiodinase mRNA,	U53506	601413	none found

complete cds Human type II serine/threonine kinase receptor mRNA, complete cds	U20165	600799	none found
Human vascular endothelial growth factor related protein VRP mRNA, complete cds	U43142	601528	none found
Human VEGF related factor isoform VRF186 precursor (VRF) mRNA, complete cds	U43368	601398	none found
Hydroxy-delta-5- steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2	M67466	201810	1-BP INS
Hydroxy-delta-5- steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2	M67466	201810	Dinucleotide repeat
Hydroxy-delta-5- steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2	M67466	201810	ARG249TER
Hydroxy-delta-5- steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2	M67466	201810	VAL248ASN
Hydroxy-delta-5- steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2	M67466	201810	TRP171TER

steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2			none found	
hyrotropin beta (TSH- beta)	M21023			
IGF-2 receptor	Y00285	147280	17 bp deletion	
IGF-2 receptor	Y00285	147280	CA repeat	
			polymorphisms	
IGF-2 receptor	Y00285	147280	SacI	
IGF-2 receptor	Y00285	147280		Asn2020Ser
IGF-2 receptor	Y00285	147280		GLY1449VAL
IGF-2 receptor	Y00285	147280		GLY1464GLU
Insulin receptor	M10051	147670	10 base pair deletion	
Insulin receptor	M10051	147670	1058 CAC-->CAT	silent
Insulin receptor	M10051	147670	12 additional base	insertion Leu-
			pairs in exon 3	His-Leu-Val
Insulin receptor	M10051	147670	3' flanking intron (T-	
			->G at position 74)	
Insulin receptor	M10051	147670	400-bp insertion	
			intron	
Insulin receptor	M10051	147670	8-BP DEL	
Insulin receptor	M10051	147670	A-G, -2 intron 4	
Insulin receptor	M10051	147670	Alu	lys1030
Insulin receptor	M10051	147670	codon 1058 (CAC--	silent
			>CAT)	
Insulin receptor	M10051	147670	deletion of the gene	
Insulin receptor	M10051	147670	EcoRI	
Insulin receptor	M10051	147670	EX14DEL	
Insulin receptor	M10051	147670	Four RSAI	
Insulin receptor	M10051	147670	G-->T at position 13,	
			5' intron	

SD-144141.1

Insulin receptor	M10051	147670	Gln276 (CAA-->CAG)	silent
Insulin receptor	M10051	147670	Gly8 (GGA-->GGG)	silent
Insulin receptor	M10051	147670	His1068 (CAC-->CAT)	silent
Insulin receptor	M10051	147670	Insertion intron 9,	
Insulin receptor	M10051	147670	Nsil	
Insulin receptor	M10051	147670	Nsil	
Insulin receptor	M10051	147670	Short repeats in intron 2	
Insulin receptor	M10051	147670	Thr789 (ACG-->ACA)	silent
Insulin receptor	M10051	147670		GLY996VAL
Insulin receptor	M10051	147670		GLU672TER
Insulin receptor	M10051	147670		LYS460GLU
Insulin receptor	M10051	147670		Asn461Thr
Insulin receptor	M10051	147670		MET1153ILE
Insulin receptor	M10051	147670		ARG86PRO
Insulin receptor	M10051	147670		TRP1200SER
Insulin receptor	M10051	147670		TRP?SER
Insulin receptor	M10051	147670		ALA1134THR
Insulin receptor	M10051	147670		LYS121TER
Insulin receptor	M10051	147670		ILE119MET
Insulin receptor	M10051	147670		ARG735SER
Insulin receptor	M10051	147670		ARG981GLN
Insulin receptor	M10051	147670		ARG988TER
Insulin receptor	M10051	147670		TRP412SER
Insulin receptor	M10051	147670		ALA1135GLU
Insulin receptor	M10051	147670		ARG1000TER
Insulin receptor	M10051	147670		ASN462SER
Insulin receptor	M10051	147670		CODON 897

Insulin receptor	M10051	147670	nonsense
Insulin receptor	M10051	147670	HIS209ARG
Insulin receptor	M10051	147670	TRP133TER
Insulin receptor	M10051	147670	Asn281del
Insulin receptor	M10051	147670	his252arg
Insulin receptor	M10051	147670	Leu999del
Insulin receptor	M10051	147670	glyc1008val
Insulin receptor	M10051	147670	glu1131arg
Insulin receptor	M10051	147670	Leu193Pro
Insulin receptor	M10051	147670	ser462asp
Insulin receptor	M10051	147670	GLY31ARG
Insulin receptor	M10051	147670	PHE382VAL
Insulin receptor	M10051	147670	LEU233PRO
Insulin receptor	M10051	147670	Arg86ter
Insulin receptor	M10051	147670	Trp1193Leu
Insulin receptor	M10051	147670	Leu1178Pro
Insulin receptor	M10051	147670	ARG1174GLN
Insulin receptor	M10051	147670	VAL985MET
Insulin receptor	M10051	147670	GLY366ARG
Insulin receptor	M10051	147670	VAL28ALA
Insulin receptor	M10051	147670	Asp59Gly
Insulin receptor	M10051	147670	Leu62Pro
Insulin receptor	M10051	147670	ARG372TER
Insulin receptor	M10051	147670	ASN15LYS
Insulin receptor	M10051	147670	ARG1152GLN
Insulin-like growth factor 1 receptor	X04434	147370	none found
Insulin-like growth factor 2	J03242	147470	(CA)n
Insulin-like growth factor 2	J03242	147470	Apal 3'UTR

Insulin-like growth factor 2	J03242	147470	Avall
Insulin-like growth factor 2	J03242	147470	BamHI
Insulin-like growth factor 2	J03242	147470	Eco RI
Insulin-like growth factor 2	J03242	147470	Sst I
Insulin-like growth factor 2	J03242	147470	VNTR upstream
insulin-like growth factor binding protein 1	NM_000596	146730	none found
Insulin-like growth factor1	M29644	147440	(CA)n
Insulin-like growth factor1	M29644	147440	EcoRV
Insulin-like growth factor1	M29644	147440	EX4,5 DEL
Insulin-like growth factor1	M29644	147440	HindIII
Insulin-like growth factor1	M29644	147440	PvuII
interleukin 1 receptor (IL-1R)	M27492	147810	PstI
interleukin 6 receptor (IL-6R) (20)	M20566	147880	dinucleotide (CA)
inward rectifier K channel	D50582		none found
leptin receptor/LEPR	NM_002303	601007	(CTTTA)n
leptin receptor/LEPR	NM_0023	601007	3'-UTR

SD-1414141.1

leptin receptor/LEPR	03 NM_0023	601007	insertion/deletion CA microsatellite repeat in intron 3, IVS16, G-A, +1
leptin receptor/LEPR	03 NM_0023	601007	
leptin receptor/LEPR	03 NM_0023	601007	K109R
leptin receptor/LEPR	03 NM_0023	601007	K656N
leptin receptor/LEPR	03 NM_0023	601007	Ala976Asp
leptin receptor/LEPR	03 NM_0023	601007	Gln223Arg
leptin receptor/LEPR	03 NM_0023	601007	Lys109Arg
leptin receptor/LEPR	03 NM_0023	601007	Lys656Asn
leptin receptor/LEPR	03 NM_0023	601007	Pro1019Pro
leptin receptor/LEPR	03 NM_0023	601007	Ser343Ser
leptin receptor/LEPR	03 NM_0023	601007	Ser492Thr
leptin receptor/LEPR	03 NM_0023	601007	GLN23ARG
Leukocyte integrin alpha-I	Y00796	153370	none found
Leukocyte integrin alpha-x	M81695	151510	none found
Lipoprotein lipase	M15856	238600	INS
Lipoprotein lipase	M15856	238600	(TTTA)n

Lipoprotein lipase	M15856	238600	-39T-C	
Lipoprotein lipase	M15856	238600	-93T-G	
Lipoprotein lipase	M15856	238600	1-BP DEL	frameshift
Lipoprotein lipase	M15856	238600	1-BP DEL, 221G	frameshift
Lipoprotein lipase	M15856	238600	2-KB DUP	
Lipoprotein lipase	M15856	238600	6-KB DEL	
Lipoprotein lipase	M15856	238600	C-->A -3 intron 6	
Lipoprotein lipase	M15856	238600	C-to-T -480	
Lipoprotein lipase	M15856	238600	C1338-->A	Thr361 Thr
Lipoprotein lipase	M15856	238600	C1595-->G	S447X
Lipoprotein lipase	M15856	238600	G579-->A	V108V
Lipoprotein lipase	M15856	238600	HindIII	
Lipoprotein lipase	M15856	238600	IVS1, G-C, +1	
Lipoprotein lipase	M15856	238600	IVS2DS, G-A	
Lipoprotein lipase	M15856	238600	IVS2DS, G-A, +1	
Lipoprotein lipase	M15856	238600		ALA176THR
Lipoprotein lipase	M15856	238600		GLY188GLU
Lipoprotein lipase	M15856	238600		TRP64TER
Lipoprotein lipase	M15856	238600		ARG75SER
Lipoprotein lipase	M15856	238600		TYR73TER
Lipoprotein lipase	M15856	238600		SER172CYS
Lipoprotein lipase	M15856	238600		TRP382TER
Lipoprotein lipase	M15856	238600		TYR61TER
Lipoprotein lipase	M15856	238600		ASP204GLU
Lipoprotein lipase	M15856	238600		GLY142GLU
Lipoprotein lipase	M15856	238600		GLY195GLU
Lipoprotein lipase	M15856	238600		ILE194THR
Lipoprotein lipase	M15856	238600		ARG243HIS
Lipoprotein lipase	M15856	238600		ASP156GLY
Lipoprotein lipase	M15856	238600		SER447TER
Lipoprotein lipase	M15856	238600		Cys239-->stop

Lipoprotein lipase	M15856	238600	His183-->Gln
Lipoprotein lipase	M15856	238600	ARG243CYS
Lipoprotein lipase	M15856	238600	ASN291SER
Lipoprotein lipase	M15856	238600	E163G
Lipoprotein lipase	M15856	238600	E410K
Lipoprotein lipase	M15856	238600	ASP180GLU
Lipoprotein lipase	M15856	238600	ASP250ASN
Lipoprotein lipase	M15856	238600	Pro157 Arg
Lipoprotein lipase	M15856	238600	Glu118 Glu
Lipoprotein lipase	M15856	238600	Glu421Lys
Lipoprotein lipase	M15856	238600	CYS418TYR
Lipoprotein lipase	M15856	238600	LEU365VAL
Lipoprotein lipase	M15856	238600	ALA334THR
Lipoprotein lipase	M15856	238600	ASP9ASN
Lipoprotein lipase	M15856	238600	ILE225THR
Lipoprotein lipase	M15856	238600	TRP86ARG
Lipoprotein lipase	M15856	238600	SER244THR
Lipoprotein lipase	M15856	238600	GLN106TER
Lipoprotein lipase	M15856	238600	PRO207LEU
Lipoprotein lipase	M15856	238600	Tyr262-->His
MELANOCORTIN 4 RECEPTOR		155541	4-BP DEL NT631
MELANOCORTIN 4 RECEPTOR		155541	4-BP INS, NT732
MELANOCORTIN 4 RECEPTOR		155541	TYR35TER
MELANOCORTIN 4 RECEPTOR		155541	ASP37VAL
MELANOCORTIN 4 RECEPTOR		155541	Thr112Met
MELANOCORTIN 4 RECEPTOR		155541	Ile137Thr

RECEPTOR					
Mineralocorticoid receptor (aldosterone receptor)	M16801	600983	1-BP DEL	frameshift at codon 337	
Mineralocorticoid receptor (aldosterone receptor)	M16801	600983	1-BP DEL	frameshift at codon 459	
Mineralocorticoid receptor (aldosterone receptor)	M16801	600983	760-->G760	Ileu180-->Val180	
Mineralocorticoid receptor (aldosterone receptor)	M16801	600983	A DEL, +3 intron 5		
Mineralocorticoid receptor (aldosterone receptor)	M16801	600983	C944-->T944	Ala241-->Val241	
Mineralocorticoid receptor (aldosterone receptor)	M16801	600983		ARG537TER	
natriuretic peptide receptor B/guanylate cyclase B	L13436	108961	none found		
NEUROMEDIN K RECEPTOR	M89473	162332	none found		
Neuropeptide Y receptor Y5	U94320	602001	none found		
Nicotinic, Cholinergic receptor alpha 2	118502	U62431	none found		
Norepinephrine transporter	M65105	163970	none found		
Opioid Receptor,	U17298	165196	none found		

SD-144141.1

Kappa-I; Oprk1				
Oxytocin receptor	X64878	167055	C to T exon 3	
Oxytocin receptor	X64878	167055	CA repeat	
PAIRED BOX GENE		167413	none found	
4				
Pancreatic lipase (PNLIP) (Dietary supplement)	M93285	246600	C-to-T promoter	
Pancreatic lipase (PNLIP) (Dietary supplement)	M93285	246600		Ser267Phe
Pancreatic lipase (PNLIP) (Dietary supplement)	M93285	246600		Thr383Met
Parathyroid hormone	V00597	168450	Drall	
Parathyroid hormone	V00597	168450	G-C, +1	
Parathyroid hormone	V00597	168450	(AAAT)n intron 1	EX2DEL
Parathyroid hormone	V00597	168450	BstB I	
Parathyroid hormone	V00597	168450	Pst I	
Parathyroid hormone	V00597	168450	Taq I	
Parathyroid hormone	V00597	168450	XmnI	
Parathyroid hormone	V00597	168450		CYS18ARG
Peroxidase (thyroid)	Y00406	274500	1-BP INS	
Peroxidase (thyroid)	Y00406	274500	1-BP INS, 2505C	
Peroxidase (thyroid)	Y00406	274500	20-BP DUP	frameshift
Peroxidase (thyroid)	Y00406	274500	2612 (GTG-->GCG)	Val-->Ala
Peroxidase (thyroid)	Y00406	274500	4-BP INS	frameshift
Peroxidase (thyroid)	Y00406	274500	50 bp repeat in intron 10	
Peroxidase (thyroid)	Y00406	274500	Acyl intron 8	
Peroxidase (thyroid)	Y00406	274500	Eco RI	

Peroxidase (thyroid)	Y00406	274500	ARG648GLN
Peroxidase (thyroid)	Y00406	274500	GLU799LYS
Peroxidase (thyroid)	Y00406	274500	GLY590SER
Peroxidase (thyroid)	Y00406	274500	ILE447PHE
Peroxidase (thyroid)	Y00406	274500	TYR453ASP
Peroxidase (thyroid)	Y00406	274500	ARG540TER
Peroxisome proliferative activated receptor, gamma/PPARG	NM_0050 37	601487	1-BP DEL, 472A Frameshift
Peroxisome proliferative activated receptor, gamma/PPARG	NM_0050 37	601487	PRO115GLN
Peroxisome proliferative activated receptor, gamma/PPARG	NM_0050 37	601487	ARG288HIS
Peroxisome proliferative activated receptor, gamma/PPARG	NM_0050 37	601487	GLN286PRO
Peroxisome proliferative activated receptor, gamma/PPARG	NM_0050 37	601487	LYS319TER
Peroxisome proliferative activated receptor, gamma/PPARG	NM_0050 37	601487	PRO12ALA
phospholipid transfer	NM_0062	172425	TaqIB

protein/PLTP	27			
plasma cholesterol	NM_0000	118470	A1503G	
ester transfer	78			
protein/CETP				
plasma cholesterol	NM_0000	118470	G-A splice junction	alternative
ester transfer	78			splice
protein/CETP				
plasma cholesterol	NM_0000	118470	G1696A	
ester transfer	78			
protein/CETP				
plasma cholesterol	NM_0000	118470	C-T transition in	
ester transfer	78		intron 12	
protein/CETP				
plasma cholesterol	NM_0000	118470	EcoNI	
ester transfer	78			
protein/CETP				
plasma cholesterol	NM_0000	118470	G-->A intron 14	
ester transfer	78			
protein/CETP				
plasma cholesterol	NM_0000	118470	G-A transition in	
ester transfer	78		intron 15	
protein/CETP				
plasma cholesterol	NM_0000	118470	G1533A	
ester transfer	78			
protein/CETP				
plasma cholesterol	NM_0000	118470	INST alternative	
ester transfer	78		(intron/exon14) splice	
protein/CETP				
plasma cholesterol	NM_0000	118470	StuI	
ester transfer	78			
protein/CETP				

SD-144141.1

plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	T-->G tyr57stop
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	TaqIA
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	TaqIB in intron 1
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	268 Arg-- >STOP
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	G181X
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	Asp 442 to Gly
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	I405V
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	Lys309-Stop
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	Val421-Ile
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	R451Q
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	ASP442GLY

SD-144141.1

ester transfer protein/CETP	78			
potassium channel beta subunit	U25138	603951	none found	
POTASSIUM CHANNEL INWARDLY RECTIFYING SUBFAMILY J MEMBER 11; KCNJ11		600937		LEU147PRO
Potassium channel Kir3.4	X83582	600734	none found	
PRO-MELANIN- CONCENTRATING HORMONE		176795	none found	
progesterone receptor	M15716	264080	none found	
Prolactin	V00566	176760	Bg/II	
Prolactin receptor	M31661	176761	none found	
protein kinase C beta 1	X06318	176970	none found	
Pyridoxine (Pyridoxal Kinase)	U89606	179020	none found	
RAR related orphan receptor A/RORA	NM_0029 43	600825	none found	
RAR related orphan receptor B/RORB	*****	601972	none found	
RAR related orphan receptor C/RORC	NM_0050 60	602943	none found	
REGUCALCIN		300212	none found	
retinoic acid receptor alpha/RARA	NM_0009 64	180240	7-base deletion frameshift	

SD-144141.1

retinoic acid receptor alpha/RARA	NM_0009 64	180240	codon 411 C to T	
retinoic acid receptor alpha/RARA	NM_0009 64	180240	Arg272Gln	
retinoic acid receptor alpha/RARA	NM_0009 64	180240	Met297Leu	
RETINOIC ACID RECEPTOR BETA-2	X07282	180220	none found	
retinoic acid receptor gamma/RARG	M57707	180190	none found	
Retinoic acid receptor, gamma 1	M38258	180190	none found	
retinoid X receptor alpha/RXRA	NM_0029 57	180245	none found	
retinoid X receptor gamma/RXRG	U38480	180247	none found	
Retinoid X receptor- gamma	U38480	180247	none found	
serotonin 5-HT receptors 5-HT1C, G protein-coupled	U49516	312861	2831T > G in the 3'	
serotonin 5-HT receptors 5-HT1C, G protein-coupled	U49516	312861	CYS23SER	
SODIUM-IODIDE SYMPORTER		601843	THR354PRO	
SODIUM-IODIDE SYMPORTER		601843	CYS272TER	
SODIUM-IODIDE SYMPORTER		601843	GLN267GLU	
SODIUM-IODIDE		601843	TYR531TER	

SD-144141.1

SYMPORTER	601843	GLY93ARG
SODIUM-IODIDE SYMPORTER	601843	GLY543GLU
Solute carrier family 9 (sodium/hydrogen exchanger), isoform 1 (antiporter, Na ⁺ /H ⁺ , amiloride sensitive)	X76180	2-BP DEL frameshift
Solute carrier family 9 (sodium/hydrogen exchanger), isoform 1 (antiporter, Na ⁺ /H ⁺ , amiloride sensitive)	X76180	2-BP DEL ARG508TER
Somatostatin receptor 1/G protein-coupled	M81829	182451 (CA) _n 5'
Somatostatin receptor 2	M81830	182452
Somatostatin receptor 3/adenyl cyclase coupled	M96738	182453 none found
Somatostatin receptor 5	D16827	182455 2 RFLP's promoter
somatostatin receptor subtype 2	L05521	none found
Steroid 5 alpha reductase 1	M32313	184753 none found
STEROID HORMONE	X51416	601998 none found
RECEPTOR ERR1	U40396	602691 none found
Steroid receptor coactivator (SRC-1)		

Sucrase-isomaltase	X63597	222900	GLN1098PRO
Tachykinin NK1 receptor/TACR1	M81797	162323	none found
thyroid stimulating hormone receptor	NM_000369	603372	18-BP DEL, 4-BP frameshift INS
thyroid stimulating hormone receptor	NM_000369	603372	1953-1957 deletion Asp at 619 deleted
thyroid stimulating hormone receptor	NM_000369	603372	2 bases deleted of codon 655
thyroid stimulating hormone receptor	NM_000369	603372	C253A
thyroid stimulating hormone receptor	NM_000369	603372	duplication of nucleotides -346 to -330
thyroid stimulating hormone receptor	NM_000369	603372	G to C +3 intron 6
thyroid stimulating hormone receptor	NM_000369	603372	G-A -4 intron
thyroid stimulating hormone receptor	NM_000369	603372	TaqI
thyroid stimulating hormone receptor	NM_000369	603372	P52T
thyroid stimulating hormone receptor	NM_000369	603372	leu677val
thyroid stimulating hormone receptor	NM_000369	603372	Asn715Asp
thyroid stimulating hormone receptor	NM_000369	603372	Asp219Glu
thyroid stimulating hormone receptor	NM_000369	603372	Asp727Glu
thyroid stimulating hormone receptor	NM_000369	603372	Lys723 Met

SD-144141.1

hormone receptor	NM_000369	603372	Phe197Ile
thyroid stimulating hormone receptor	NM_000369	603372	LYS183ARG
thyroid stimulating hormone receptor	NM_000369	603372	ILE167ASN
thyroid stimulating hormone receptor	NM_000369	603372	PRO162ALA
thyroid stimulating hormone receptor	NM_000369	603372	PHE631LEU
thyroid stimulating hormone receptor	NM_000369	603372	CYS672TYR
thyroid stimulating hormone receptor	NM_000369	603372	VAL509ALA
thyroid stimulating hormone receptor	NM_000369	603372	ALA623ILE
thyroid stimulating hormone receptor	NM_000369	603372	ASP619GLY
thyroid stimulating hormone receptor	NM_000369	603372	ALA553THR
thyroid stimulating hormone receptor	NM_000369	603372	SER281ILE
thyroid stimulating hormone receptor	NM_000369	603372	SER281ASN
thyroid stimulating hormone receptor	NM_000369	603372	ASP633HIS
thyroid stimulating hormone receptor	NM_000369	603372	LEU629PHE
thyroid stimulating hormone receptor	NM_000369	603372	SER505ASN

thyroid stimulating hormone receptor	NM_000369	603372	TRP546TER
thyroid stimulating hormone receptor	NM_000369	603372	MET453THR
thyroid stimulating hormone receptor	NM_000369	603372	ASP36HIS
thyroid stimulating hormone receptor	NM_000369	603372	alanine 623 to valine
thyroid stimulating hormone receptor	NM_000369	603372	asp727glu
thyroid stimulating hormone receptor	NM_000369	603372	CAG
thyroid stimulating hormone receptor	NM_000369	603372	[Glu]227CAT
thyroid stimulating hormone receptor	NM_000369	603372	[His]
thyroid stimulating hormone receptor	NM_000369	603372	GCG
thyroid stimulating hormone receptor	NM_000369	603372	[Ala]460GCA
thyroid stimulating hormone receptor	NM_000369	603372	[Ala]
thyroid stimulating hormone receptor	NM_000369	603372	GGT[Arg]201C
thyroid stimulating hormone receptor	NM_000369	603372	AT [His]
thyroid stimulating hormone receptor	NM_000369	603372	ARG109GLN
thyroid stimulating hormone receptor	NM_000369	603372	CYS41SER
thyroid stimulating hormone receptor	NM_000369	603372	ASP410ASN
thyroid stimulating hormone receptor	NM_000369	603372	CYS390TRP
thyroid stimulating hormone receptor	NM_000369	603372	GLN324TER
thyroid stimulating hormone receptor	NM_000369	603372	PHE525LEU
Transferrin receptor	X01060	190010	Bcll

(p90, CD71)					
Transferrin receptor	X01060	190010	RsaI		
(p90, CD71)					
Transferrin receptor	X01060	190010	Ser142-->Gly		
(p90, CD71)					
transforming growth	M85079	190182	2-BP INS frameshift		
factor, beta receptor II					
(70-80kD)/TGFB2					
transforming growth	M85079	190182	a-4t intron 3		
factor, beta receptor II					
(70-80kD)/TGFB2					
transforming growth	M85079	190182	a7g intron 2		
factor, beta receptor II					
(70-80kD)/TGFB2					
transforming growth	M85079	190182	ACA to GCA Thr to Ala		
factor, beta receptor II					
(70-80kD)/TGFB2					
transforming growth	M85079	190182	base in the		
factor, beta receptor II			polyadenine tract of		
(70-80kD)/TGFB2			exon 3		
transforming growth	M85079	190182	GG to TT Stop codon		
factor, beta receptor II					
(70-80kD)/TGFB2					
transforming growth	M85079	190182	THR315MET		
factor, beta receptor II					
(70-80kD)/TGFB2					
transforming growth	M85079	190182	codon 128		
factor, beta receptor II					
(70-80kD)/TGFB2					
TUBBY, MOUSE,		601197	none found		
HOMOLOG					

SD-144141.1

type I 5 iodothyronine deiodinase [human, mRNA, 2222 nt]	S48220	147892	none found
Type V cyclic nucleotide phosphodiesterase	AJ004865	603310	none found
vitamin D receptor/VDR	NM_0003 76	601769	A(T/C)G putative translation start site
vitamin D receptor/VDR	NM_0003 76	601769	Apal
vitamin D receptor/VDR	NM_0003 76	601769	BsmI
vitamin D receptor/VDR	NM_0003 76	601769	FokI
vitamin D receptor/VDR	NM_0003 76	601769	PvuII
vitamin D receptor/VDR	NM_0003 76	601769	TaqI
vitamin D receptor/VDR	NM_0003 76	601769	XbaI
vitamin D receptor/VDR	NM_0003 76	601769	ARG-GLY
vitamin D receptor/VDR	NM_0003 76	601769	GLY30ASP
vitamin D receptor/VDR	NM_0003 76	601769	TYR292TER
vitamin D receptor/VDR	NM_0003 76	601769	ARG77GLN
vitamin D receptor/VDR	NM_0003 76	601769	ARG391CYS

SD-144141.1

vitamin D receptor/VDR	NM_0003 76	601769	ILE314SER
vitamin D receptor/VDR	NM_0003 76	601769	ARG271LEU
vitamin D receptor/VDR	NM_0003 76	601769	GLN149TER
vitamin D receptor/VDR	NM_0003 76	601769	ARG30TER
vitamin D receptor/VDR	NM_0003 76	601769	GLY46ASP
vitamin D receptor/VDR	NM_0003 76	601769	codon 352
vitamin D receptor/VDR	NM_0003 76	601769	HIS305GLN
vitamin D receptor/VDR	NM_0003 76	601769	ARG47GLN

Table 23. Identified
Variances in Genes or
Related Pathways
involved in
Cardiovascular and
Renal Disease

3beta hydroxysteroid dehydrogenase	M27137	109715	none found
5,10- METHYLENETETRA HYDROFOLATE REDUCTASE	U09806	236250	1027T-G
5,10- REDUCTASE	U09806	236250	1084C-T

METHYLENETETRA HYDROFOLATE REDUCTASE	U09806	236250	1298A-C	
5,10- METHYLENETETRA HYDROFOLATE REDUCTASE	U09806	236250	1711C-T	
5,10- METHYLENETETRA HYDROFOLATE REDUCTASE	U09806	236250	677C-T	ala --> val
5,10- METHYLENETETRA HYDROFOLATE REDUCTASE	U09806	236250	983A-G	
5,10- METHYLENETETRA HYDROFOLATE REDUCTASE	U09806	236250	exon 7	Ala-->Glu
5,10- METHYLENETETRA HYDROFOLATE REDUCTASE	U09806	236250		A225V
5,10- METHYLENETETRA HYDROFOLATE REDUCTASE	U09806	236250		ARG158GLN

SD-144141.1

5,10-METHYLENETETRAHYDROFOLATE REDUCTASE	U09806	236250	ARG184TER
Adenosine A1 Receptor; Adora1/G protein-coupled	L22214	102775	1777C/A
Adenosine A1 Receptor; Adora1/G protein-coupled	L22214	102775	1827C/T
Adenosine A1 Receptor; Adora1/G protein-coupled	L22214	102775	1904C/T
Adenosine A1 Receptor; Adora1/G protein-coupled	L22214	102775	2126G/T
Adenosine A1 Receptor; Adora1/G protein-coupled	L22214	102775	2294insT
Adenosine A1 Receptor; Adora1/G protein-coupled	L22214	102775	267 + 275C/T
Adenosine A1 Receptor; Adora1/G protein-coupled	L22214	102775	2776C/T
Adenosine A1 Receptor; Adora1/G protein-coupled	L22214	102775	2777del36
Adenosine A1 Receptor; Adora1/G protein-coupled	L22214	102775	2819T/G

SD-144141.1

Adenosine A1 Receptor; Adora1/G protein-coupled	L22214	102775	805T/G
Adenosine A1 Receptor; Adora1/G protein-coupled	L22214	102775	48T/A
Adenosine A1 Receptor; Adora1/G protein-coupled	L22214	102775	716T/G
Adenosine A2 Receptor; Adora2a/G protein-coupled	X68486	102776	1083C/T
Adenosine A2 Receptor; Adora2a/G protein-coupled	X68486	102776	405C/T
Adenosine A2 Receptor; Adora2a/G protein-coupled	X68486	102776	432C/T
Adenosine A2 Receptor; Adora2a/G protein-coupled	X68486	102776	Gly-340-Ser
Adenosine A2b Receptor; Adora2b/G protein-coupled	X68487	600446	none found
Adenosine A3 Receptor; Adora3/G protein-coupled	L20463	600445	none found
alpha-1b-adrenergic receptor; ADRA1B	L31773	104220	none found
alpha-2a-adrenergic receptor; ADRA2A	M18415	104210	-1291

SD-144141.1

alpha-2a-adrenergic receptor; ADRA2A	M18415	104210	DraI	
alpha-2a-adrenergic receptor; ADRA2A	M18415	104210	HhaI	
alpha-2a-adrenergic receptor; ADRA2A	M18415	104210	MspI promoter	
alpha-2b-adrenergic receptor; ADRA2B	AF005900	104260	none found	
alpha-2c-adrenergic receptor; ADRA2C	J03853	104250	(CA)n	
androgen receptor	M20132	313700	Hind III	
androgen receptor	M20132	313700	(CAA)n	
androgen receptor	M20132	313700	(CAG)n	
androgen receptor	M20132	313700	(GGN)n	
androgen receptor	M20132	313700	5-KB DEL, EX F, G	
androgen receptor	M20132	313700	5-KB DEL, EX E	
androgen receptor	M20132	313700	C>T within exon B	silent
androgen receptor	M20132	313700	CAG340TAG	Gln>Ter
androgen receptor	M20132	313700	Del T at 3286	frameshift
androgen receptor	M20132	313700	del1893	frameshift
androgen receptor	M20132	313700	G Codon 210 A	
androgen receptor	M20132	313700	G Codon 211 A	
androgen receptor	M20132	313700	G2314A	ala>thr
androgen receptor	M20132	313700	G2677A	glu629arg
androgen receptor	M20132	313700	HhaI	
androgen receptor	M20132	313700	HpaII	
androgen receptor	M20132	313700	Insert of 69 nucleotides	
androgen receptor	M20132	313700	MaeIII	
androgen receptor	M20132	313700	PARTIAL DEL	
androgen receptor	M20132	313700	Stu I	

SD-144141.1

androgen receptor	M20132	313700	598 or 599 ter
androgen receptor	M20132	313700	ALA721THR
androgen receptor	M20132	313700	ALA771THR
androgen receptor	M20132	313700	ARG607GLN
androgen receptor	M20132	313700	ARG608LYS
androgen receptor	M20132	313700	Arg615His
androgen receptor	M20132	313700	arg726leu
androgen receptor	M20132	313700	Arg752Gln
androgen receptor	M20132	313700	ARG772CYS
androgen receptor	M20132	313700	ARG773CYS
androgen receptor	M20132	313700	ARG773HIS
androgen receptor	M20132	313700	ARG839CYS
androgen receptor	M20132	313700	ARG839HIS
androgen receptor	M20132	313700	arg840his
androgen receptor	M20132	313700	ARG846HIS
androgen receptor	M20132	313700	ARG855HIS
androgen receptor	M20132	313700	CYS579PHE
androgen receptor	M20132	313700	G214R
androgen receptor	M20132	313700	GLN60TER
androgen receptor	M20132	313700	Gln798Glu
androgen receptor	M20132	313700	GLN902ARG
androgen receptor	M20132	313700	GLU2LYS
androgen receptor	M20132	313700	gly743val
androgen receptor	M20132	313700	HIS874TYR
androgen receptor	M20132	313700	ILE869MET
androgen receptor	M20132	313700	LEU172TER
androgen receptor	M20132	313700	LEU676PRO
androgen receptor	M20132	313700	LEU707ARG
androgen receptor	M20132	313700	LYS588TER
androgen receptor	M20132	313700	LYS882TER
androgen receptor	M20132	313700	MET780ILE

androgen receptor	M20132	313700	MET786VAL
androgen receptor	M20132	313700	PHE582TYR
androgen receptor	M20132	313700	PRO546SER
androgen receptor	M20132	313700	pro892ser
androgen receptor	M20132	313700	SER647ASN
androgen receptor	M20132	313700	THR877ALA
androgen receptor	M20132	313700	THR877SER
androgen receptor	M20132	313700	TRP717TER
androgen receptor	M20132	313700	TRP794TER
androgen receptor	M20132	313700	TYR761CYS
androgen receptor	M20132	313700	val 581 phe
androgen receptor	M20132	313700	VAL730MET
androgen receptor	M20132	313700	VAL865LEU
androgen receptor	M20132	313700	VAL865MET
androgen receptor	M20132	313700	VAL866MET
angiotensin converting enzyme/dipeptidyl carboxypeptidase	NM_000789	106180	250-bp in/del
angiotensin converting enzyme/dipeptidyl carboxypeptidase	NM_000789	106180	3 in the 3' UTR
angiotensin converting enzyme/dipeptidyl carboxypeptidase	NM_000789	106180	5 in the 5' region
angiotensin converting enzyme/dipeptidyl carboxypeptidase	NM_000789	106180	Pst I RFLP
angiotensin receptor I/AGTR1A	M87290	106165	1166A-C
Anticoagulant Protein C (inactivator of	X02750	176860	-1641-A/G

SD-144141.1

coagulation factors Va and VIIIa)					
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	(6376 G/T) in intron 7		
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	-1654 C/T		
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	1-BP DEL 42AA		frameshift
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	1432 C-->T		
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	2-BP INS, TT, NT6139		
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	3350insA		
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	3351del4		
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	40 T-->G		

C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	5-bp deletion nucleotides 3455 to 3459
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	6128 T-->C
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	6216 C-->T
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	6246 G-->A
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	7253 C-->T
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	8589 G-->A
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	8631 C-->T

SD-144141.1

Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	A/G at -641	
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	A/T at -1476	
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	A/T at -476	
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	C insertion: CAT-- >CCAT	
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	C/T at -654	
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	CCT to CCC	Pro-21Pro
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	deletion of 5 nucleotides (nt) (CCCCGC) in the end of exon VI G3079A	
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860		

SD-144141.1

Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	G8857 deletion	
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	IVS G, C-T, +9	
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	MspI	
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	T-C, -14	
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860		230 Arg-Lys
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860		254 Thr-Ile
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860		325 Val-Ala
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860		359 Asp-Asn

coagulation factors Va and VIIIa)					
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	364 Met-Trp, 378 Stop		
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Ala136-->Pro		
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	ALA259VAL		
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	ALA267THR		
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Arg 157-Stop		
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	ARG12TRP		
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	ARG169TRP		
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	ARG178GLN		

SD-144141.1

C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	ARG178TRP
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	ARG230CYS
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Arg286His
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	ARG306TER
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	arg352try
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Asn102-->Lys
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Asn329-->Thr

SD-144141.1

Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Asp359Asn
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Asp359Asn
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Cys-331 to Arg
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Cys78-->Stop
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	GLN184HIS
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	GLU20ALA
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Gly-376 Asp
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Gly282Ser

SD-144141.1

Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	GLY292SER
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	GLY301SER
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Gly350Arg
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	HIS107PRO
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	ILE403MET
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	LEU223PHE
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Lys150 deletion
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Met365Ile

SD-144141.1

coagulation factors Va and VIIIa)	X02750	176860	Phe139Val
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	PRO168LEU
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	PRO247LEU
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Pro279Leu
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Pro327Leu
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Q132X
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Ser270Pro
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Thr298-->Met

SD-144141.1

C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	TRP402CYS
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Tyr399His
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	VAL297MET
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	VAL34MET
Anticoagulant Protein C (inactivator of coagulation factors Va and VIIIa)	X02750	176860	Y124C
Anticoagulant protein S	Y00692	176880	G to T at codon Cys598 IVS11, A-G, -9
Anticoagulant protein S	Y00692	176880	+1 G to A in intron d
Anticoagulant protein S	Y00692	176880	+3 A to C in intron j

SD-144141.1

Anticoagulant protein S	Y00692	176880	1 nt (T) insertion at codon 265	Arg410 (CGA)-
Anticoagulant protein S	Y00692	176880	delete T 635	->Stop
Anticoagulant protein S	Y00692	176880	G to A at codon Trp465	Lys368stop
Anticoagulant protein S	Y00692	176880	IVS10, G-A, +5	Ala 484-->Pro
Anticoagulant protein S	Y00692	176880		Arg506-->Gln
Anticoagulant protein S	Y00692	176880		ARG520GLY
Anticoagulant protein S	Y00692	176880		ASN217SER
Anticoagulant protein S	Y00692	176880		Cys145Tyr
Anticoagulant protein S	Y00692	176880		Cys200Ser
Anticoagulant protein S	Y00692	176880		Cys408Ser
Anticoagulant protein S	Y00692	176880		Cys625Arg
Anticoagulant protein S	Y00692	176880		GLN238TER
Anticoagulant protein S	Y00692	176880		Glu26Ala

SD-144141.1

S	Anticoagulant protein	Y00692	176880	Gly340Asp
S	Anticoagulant protein	Y00692	176880	Gly54Glu
S	Anticoagulant protein	Y00692	176880	LYS155GLU
S	Anticoagulant protein	Y00692	176880	Lys155Glu
S	Anticoagulant protein	Y00692	176880	Lys9Glu
S	Anticoagulant protein	Y00692	176880	Ser283Pro
S	Anticoagulant protein	Y00692	176880	SER406PRO
S	Anticoagulant protein	Y00692	176880	Ser460Pro
S	Anticoagulant protein	Y00692	176880	TER636TYR, 649TER
S	Anticoagulant protein	Y00692	176880	Tyr595stop
S	Apolipoprotein B (including Ag(x) antigen)	J02610	107730	C2316-->A Val1703-->Ile
S	Apolipoprotein B (including Ag(x) antigen)	J02610	107730	(TG)n
S	Apolipoprotein B (including Ag(x) antigen)	J02610	107730	1-BP DEL frameshift
S	Apolipoprotein B (including Ag(x) antigen)	J02610	107730	1-BP DEL

(including Ag(x) antigen)	J02610	107730	1-BP DEL, FS1425TER
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	3'-VNTR
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	A----G second intron +722
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	ApaLI
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	AvaII
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	BalI
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	C to T -516
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	C-->T change at nucleotide 7064,
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	CTT3517-->CTG
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	EcoRI

antigen) Apolipoprotein B (including Ag(x) antigen)	J02610	107730	EX21DEL
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	GCC3527-->GCT
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	HincII
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	INS AND DEL
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Ins/Del
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	intron 20 Alu repeat
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	MspI
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	PvuII
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	StyI second intron
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	T-to-C 1981

Apolipoprotein B (including Ag(x) antigen)	J02610	107730	XbaI	
Apolipoprotein B (including Ag(x) antigen)	J02610	107730		A3371V
Apolipoprotein B (including Ag(x) antigen)	J02610	107730		Arg----Glu3611
Apolipoprotein B (including Ag(x) antigen)	J02610	107730		ARG1306TER
Apolipoprotein B (including Ag(x) antigen)	J02610	107730		ARG2058TER
Apolipoprotein B (including Ag(x) antigen)	J02610	107730		ARG2495TER
Apolipoprotein B (including Ag(x) antigen)	J02610	107730		ARG3500GLN
Apolipoprotein B (including Ag(x) antigen)	J02610	107730		ARG3531CYS
Apolipoprotein B (including Ag(x) antigen)	J02610	107730		ASN1728THR
Apolipoprotein B (including Ag(x) antigen)	J02610	107730		Asn4311----Ser
Apolipoprotein B (including Ag(x) antigen)	J02610	107730		Cys646-->Tyr

SD-144141.1

(including Ag(x) antigen)	J02610	107730	Gln 3405 Glu
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	GLN1450TER
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	GLN2252TER
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Glu207-->Lys
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	GLU4034ARG
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Glu4154
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Leu 3350 Leu
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Leu-Ala-Leu signal peptide (SP) insertion/deletion
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	LEU3041TER

SD-144141.1

Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Q3405E
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Ser 3252 Gl
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Ser 3455 Arg
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	SER1729TER
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Thr71-->Ile
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Trp66-->Gly
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Val 3396 Met
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	VAL1829CYS
Apolipoprotein B (including Ag(x) antigen)	J02610	107730	Val591-->Ala
apolipoprotein E/APOE	NM_000041	107741	7 AA insertion; tandem repeat of residues 121-127
apolipoprotein	NM_0000	107741	A178G Threonine42Ala

E/APOE	41		nine
apolipoprotein	NM_0000	107741	A490C Lysine146Gluta
E/APOE	41		mine
apolipoprotein	NM_0000	107741	A490G Lysine146Gluta
E/APOE	41		mic Acid
apolipoprotein	NM_0000	107741	A940C Serine296Argini
E/APOE	41		ne
apolipoprotein	NM_0000	107741	Aintron3G substitution
E/APOE	41		creates 2
			abnormally
			spliced mRNA
			forms
apolipoprotein	NM_0000	107741	C305G Proline84Argini
E/APOE	41		ne
apolipoprotein	NM_0000	107741	C460A Arginine136Seri
E/APOE	41		ne
apolipoprotein	NM_0000	107741	C478T Arg142142Cys1
E/APOE	41		42
apolipoprotein	NM_0000	107741	C487T Arginine145Cys
E/APOE	41		teine
apolipoprotein	NM_0000	107741	C526T Arginine158Cys
E/APOE	41		teine
apolipoprotein	NM_0000	107741	C736T Arginine228Cys
E/APOE	41		teine
apolipoprotein	NM_0000	107741	C805G Arg251251Gly2
E/APOE	41		51
apolipoprotein	NM_0000	107741	G144deletion Leucine60Termi
E/APOE	41		nation Codon
			(frameshift)
apolipoprotein	NM_0000	107741	G349A Ala9999Thr99
E/APOE	41		

SD-144141.1

apolipoprotein E/APOE	NM_0000 41	107741	G434A Gly127127Asp1 27
apolipoprotein E/APOE	NM_0000 41	107741	G455A Arginine134Glu tamine
apolipoprotein E/APOE	NM_0000 41	107741	G488A Arginine145His tidine
apolipoprotein E/APOE	NM_0000 41	107741	G568C Ala152Proline
apolipoprotein E/APOE	NM_0000 41	107741	G61A Glutamic Acid13Lysine
apolipoprotein E/APOE	NM_0000 41	107741	G683A Tryptophan210 Termination Codon
apolipoprotein E/APOE	NM_0000 41	107741	G725A Arg224224Gln2 24
apolipoprotein E/APOE	NM_0000 41	107741	G875A Arginine274His tidine
apolipoprotein E/APOE	NM_0000 41	107741	G91A Glutamic Acid13Lysine
apolipoprotein E/APOE	NM_0000 41	107741	GAG-GAG844- Glu244/Glu245 849AAG-AAG 244- 245Lys244/Lys 245
apolipoprotein E/APOE	NM_0000 41	107741	T137C Leucine28Prolin e
apolipoprotein E/APOE	NM_0000 41	107741	T388C Cysteine112Arg inine
apolipoprotein E/APOE	NM_0000 41	107741	T761A Valine236Glu mic Acid
APOLIPOPROTEIN(a); LPA		152200	-773G, +93T, +121G

SD-144141.1

APOLIPOPROTEIN(a); LPA	152200	C/T(+93)	
APOLIPOPROTEIN(a); LPA	152200	-773A, +93C, +121A	
APOLIPOPROTEIN(a); LPA	152200	C/T at -49	
APOLIPOPROTEIN(a); LPA	152200	G/A at -21	
APOLIPOPROTEIN(a); LPA	152200	G/A at -914	
APOLIPOPROTEIN(a); LPA	152200	IVS K4 TYPE 8 DS, G-A, +1	
APOLIPOPROTEIN(a); LPA	152200	TTTTTA repeat	
APOLIPOPROTEIN(a); LPA	152200		Met-->Thr 66
APOLIPOPROTEIN(a); LPA	152200		Met/Thr 4168
APOLIPOPROTEIN(a); LPA	152200		Thr12-->Pro
arachidonate 5-lipoxygenase-activating protein/FLAP/ALOX5 AP	NM_001629	603700	none found
Arginine Vasopressin Receptor 1B/AVPR1B	AF030512	600264	none found
Arginine vasopressin receptor 2	AF030626	304800	1-BP DEL
Arginine vasopressin receptor 2	AF030626	304800	1-BP DEL, 102G

SD-144141.1

Arginine vasopressin receptor 2	AF030626	304800	1-BP INS frameshift
Arginine vasopressin receptor 2	AF030626	304800	1-BP INS 804 frameshift
Arginine vasopressin receptor 2	AF030626	304800	15delC
Arginine vasopressin receptor 2	AF030626	304800	28-bp del
Arginine vasopressin receptor 2	AF030626	304800	786delG frameshift
Arginine vasopressin receptor 2	AF030626	304800	CpG dinucleotides
Arginine vasopressin receptor 2	AF030626	304800	ALA132ASP
Arginine vasopressin receptor 2	AF030626	304800	ARG181CYS
Arginine vasopressin receptor 2	AF030626	304800	ARG113TRP
Arginine vasopressin receptor 2	AF030626	304800	ARG203CYS
Arginine vasopressin receptor 2	AF030626	304800	ARG337TER
Arginine vasopressin receptor 2	AF030626	304800	ASP85ASN
Arginine vasopressin receptor 2	AF030626	304800	G107E
Arginine vasopressin receptor 2	AF030626	304800	GLY185CYS
Arginine vasopressin receptor 2	AF030626	304800	GLY201ASP
Arginine vasopressin	AF030626	304800	L43P

SD-144141.1

[illegible]

Beta-2-Adrenergic Receptor; Adrb2	M15169	109690	Fnu4HI	
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690	A-->G -1343	
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690	C-->G -468	
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690	G-->A -1023	
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690	G-->A -654	
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690	T-->A -1429	
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690	T-->C -20	
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690	T-->C -367	
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690	T-->C -47	
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690		ARG16GLY
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690		GLN27GLU
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690		Thr164Ile
Beta-2-Adrenergic Receptor; Adrb2	M15169	109690		val 34 met
Beta-Adrenergic Receptor Kinase 2; Adrbk2	X69117	109636	none found	
beta-adrenergic receptor kinase	NM_001619	109635	none found	

1/BARK1	NM_0007	600337	9-base pair deletion
bradykinin receptor B1/BDKRB1 G	10		
protein-coupled			
bradykinin receptor B1/BDKRB1 G	NM_0007	600337	A1098-->G
protein-coupled	10		
bradykinin receptor B1/BDKRB1 G	NM_0007	600337	C181-->T
protein-coupled	10		
bradykinin receptor B1/BDKRB1 G	NM_0007	600337	G-699-->C
protein-coupled	10		
bradykinin receptor B2/BDKRB2 G	NM_0006	113503	-143C/T
protein-coupled	23		
bradykinin receptor B2/BDKRB2 G	NM_0006	113503	-412C/G
protein-coupled	23		
bradykinin receptor B2/BDKRB2 G	NM_0006	113503	-536C/T
protein-coupled	23		
bradykinin receptor B2/BDKRB2 G	NM_0006	113503	-640T/C
protein-coupled	23		
bradykinin receptor B2/BDKRB2 G	NM_0006	113503	-649insG
protein-coupled	23		
bradykinin receptor B2/BDKRB2 G	NM_0006	113503	-704C/T
protein-coupled	23		

SD-144141.1

bradykinin receptor B2/BDKRB2 G	NM_0006 23	113503	-78C/T
protein-coupled			
bradykinin receptor B2/BDKRB2 G	NM_0006 23	113503	-845C/T
protein-coupled			
bradykinin receptor B2/BDKRB2 G	NM_0006 23	113503	9 bp de (-)21-29
protein-coupled			
bradykinin receptor B2/BDKRB2 G	NM_0006 23	113503	C>T promoter 54
protein-coupled			
bradykinin receptor B2/BDKRB2 G	NM_0006 23	113503	repeat 3'UTR
protein-coupled			
bradykinin receptor B2/BDKRB2 G	NM_0006 23	113503	tandem repeat near promoter
protein-coupled			
bradykinin receptor B2/BDKRB2 G	NM_0006 23	113503	R14C
protein-coupled			
bradykinin receptor B2/BDKRB2 G	NM_0006 23	113503	T21M
protein-coupled			
Ca ²⁺ -dependent phospholipase A2	U03090	601192	none found
Carbonic anhydrase II	J03037	259730	BstNI
Carbonic anhydrase II	J03037	259730	gt->tt splice donor site at the 5' end of intron 6
Carbonic anhydrase II	J03037	259730	IVS2, G-A, +1

SD-144141.1

Carbonic anhydrase II	J03037	259730	IVS5, G-C, -I TAQI	TYR40TER
Carbonic anhydrase II	J03037	259730		ASN252ASP
Carbonic anhydrase II	J03037	259730		HIS107TYR
Carbonic anhydrase II	J03037	259730		Ile31Val
Carbonic anhydrase II	J03037	259730		LYS17GLU
Carbonic anhydrase II	J03037	259730		PRO237HIS
Carbonic anhydrase IV	M83670	114760	none found	
Chloride channel 5	X91906	300008	1-BP DEL, 2085C	
Chloride channel 5	X91906	300008	tgcag --> tgaag	
Chloride channel 5	X91906	300008		Arg704Stop
Chloride channel 5	X91906	300008		GLY57VAL
Chloride channel 5	X91906	300008		ARG280PRO
Chloride channel 5	X91906	300008		Arg34Stop
Chloride channel 5	X91906	300008		ARG648TER
Chloride channel 5	X91906	300008		ARG704TER
Chloride channel 5	X91906	300008		GLY506GLU
Chloride channel 5	X91906	300008		LEU200ARG
Chloride channel 5	X91906	300008		SER244LEU
Chloride channel 5	X91906	300008		SER520PRO
Chloride channel 5	X91906	300008		TRP279TER
Chloride channel 5	X91906	300008		TRP343TER
Cholecystokinin A receptor/CCKAR	L13605	118444		GLY21ARG
Cholecystokinin A receptor/CCKAR	L13605	118444		VAL365ILE
Cholecystokinin B receptor/CCKBR	L08112	118445	1550 G-->A Val125-->Ile	
Cholecystokinin B receptor/CCKBR	L08112	118445	CAT 207 CAC His207His	

Cholecystokinin B receptor/CCKBR	L08112	118445	Arg215His
Cholecystokinin B receptor/CCKBR	L08112	118445	Val138Met
CHOLINERGIC RECEPTOR, NICOTINIC, ALPHA POLYPEPTIDE 1; CHRNA1	100690	Hae III	
CHOLINERGIC RECEPTOR, NICOTINIC, ALPHA POLYPEPTIDE 1; CHRNA1	100690		ASN217LYS
CHOLINERGIC RECEPTOR, NICOTINIC, ALPHA POLYPEPTIDE 1; CHRNA1	100690		GLY153SER
CHOLINERGIC RECEPTOR, NICOTINIC, ALPHA POLYPEPTIDE 1; CHRNA1	100690		SER269ILE
CHOLINERGIC RECEPTOR, NICOTINIC, ALPHA POLYPEPTIDE 1; CHRNA1	100690		THR254ILE
CHOLINERGIC RECEPTOR,	100690		VAL156MET

SD-144141.1

NICOTINIC, ALPHA POLYPEPTIDE 1; CHRNA1	118938	none found	
CHYMASE 1; CMA1	120580	4-BP DEL	
Complement C1S component precursor (C1 esterase)	J04080		
Copper Transport Protein HAH1	U70660	none found	
CPLA2-GAMMA	603602	none found	
Cytochrome P450, subfamily X1A (cholesterol side chain cleavage)	M14565	5' UTR pentanucleotide repeat	
dopamine beta hydroxylase	Y00096	223360	
Dopamine Receptor D1	X58987	126449	C/T Isoleucine49
Dopamine Receptor D2	X51362	126450	141 C ins/del
Dopamine Receptor D2	X51362	126450	A241G
Dopamine Receptor D2	X51362	126450	NcoI RFLP
Dopamine Receptor D2	X51362	126450	TaqI A, TaqI B, TaqI D, and (CA)n STRP
Dopamine Receptor D2	X51362	126450	Serine 311Cysteine
Endopeptidase	X07166	120520	none found
Endothelin 1	Y00749	131240	A at position 138
Endothelin 1	Y00749	131240	C at position 121
Endothelin 1	Y00749	131240	Dimucleotide repeat
Endothelin 1	Y00749	131240	Lys198Asn
Endothelin 2	M65199	131241	3'UTR A985G

SD-144141.1

Endothelin 3	X52001	131242	1-BP INS	ALA17THR
Endothelin 3	X52001	131242	1-BP INS, 262G	ALA224THR
Endothelin 3	X52001	131242	262GC-T	CYS159PHE
Endothelin 3	X52001	131242		ARG742CYS
Endothelin 3	X52001	131242		
Endothelin 3	X52001	131242		
Endothelin Converting Enzyme 1	Z35307	600423		
Endothelin Receptor Type A	D90348	131243	none found	
Endothelin Receptor Type B	L06623	131244	1-BP INS, 878T	
Endothelin Receptor Type B	L06623	131244		ALA183GLY
Endothelin Receptor Type B	L06623	131244		GLY57SER
Endothelin Receptor Type B	L06623	131244		SER305ASN
Endothelin Receptor Type B	L06623	131244		TRP275TER
Endothelin Receptor Type B	L06623	131244		TRP276CYS
eosinophil peroxidase/EPX		131399	INS G, NT1537	
eosinophil peroxidase/EPX		131399		ARG286HIS
Erythropoietin receptor	M34986	133171	7-BP DEL	frameshift
Erythropoietin receptor	M34986	133171	1-BP INS	FS444TER
Erythropoietin receptor	M34986	133171	1-BP INS, 5967T	frameshift
Erythropoietin receptor	M34986	133171	BamHI	
Erythropoietin receptor	M34986	133171	Bgl II	

Erythropoietin receptor	M34986	133171	C to T C6148T	--->435stop
Erythropoietin receptor	M34986	133171	HindIII	
Erythropoietin receptor	M34986	133171	SacI	
Erythropoietin receptor	M34986	133171		ASN487SER
Erythropoietin receptor	M34986	133171		TRP439TER
Erythropoietin receptor	M34986	133171		TYR426TER
estrogen receptor 1 (ESR1)	M12674	133430	RFLP (PssI enzyme)	
estrogen receptor 1 (ESR1)	M12674	133430	RFLP (PvuII enzyme)	
estrogen receptor 2 (ESR2)	X99101	601663	none found	
Estrogen-preferring sulfotransferase/STE	NM_005420	600043	none found	
G protein coupled potassium channel, subfamily J, member 3/KCNJ3/GIRK1	NM_002239	601534	(CA)n	
GAP JUNCTION PROTEIN, ALPHA-5		121013	none found	
GLYCOPROTEIN Ib, PLATELET, ALPHA POLYPEPTIDE		231200	(39-base pair)n	
GLYCOPROTEIN Ib, PLATELET, ALPHA POLYPEPTIDE		231200	92-BP DUP	SER399-THR411 DUP
GLYCOPROTEIN Ib, PLATELET, ALPHA POLYPEPTIDE		231200	Arg342 (A --> G)	silent
GLYCOPROTEIN Ib, PLATELET, ALPHA POLYPEPTIDE		231200	T --> C 2nd	

PLATELET, ALPHA POLYPEPTIDE		nucleotide exon 2	
GLYCOPROTEIN Ib, PLATELET, ALPHA POLYPEPTIDE	231200	Tyr492 (TAT-->T)	
GLYCOPROTEIN Ib, PLATELET, ALPHA POLYPEPTIDE	231200	ALA156VAL	
GLYCOPROTEIN Ib, PLATELET, ALPHA POLYPEPTIDE	231200	GLY233VAL	
GLYCOPROTEIN Ib, PLATELET, ALPHA POLYPEPTIDE	231200	LEU57PHE	
GLYCOPROTEIN Ib, PLATELET, ALPHA POLYPEPTIDE	231200	MET239VAL	
GLYCOPROTEIN Ib, PLATELET, ALPHA POLYPEPTIDE	231200	TRP126TER	
GLYCOPROTEIN Ib, PLATELET, ALPHA POLYPEPTIDE	231200	TRP343TER	
GLYCOPROTEIN Ib, PLATELET, ALPHA POLYPEPTIDE	231200	TRP498TER	
Granulocyte colony- stimulating factor	M64592	120420	none found
Guanine nucleotide binding protein (G protein), alpha	J03004	139360	PHE200LEU

inhibiting activity polypeptide 2	J03004	139360	ARG179CYS
Guanine nucleotide binding protein (G protein), alpha			
inhibiting activity polypeptide 2	J03004	139360	ARG179GLY
Guanine nucleotide binding protein (G protein), alpha			
inhibiting activity polypeptide 2	J03004	139360	ARG179HIS
Guanine nucleotide binding protein (G protein), alpha			
inhibiting activity polypeptide 2	M31328	139130	C825T
Guanine nucleotide binding protein (G protein), beta			
polypeptide 3			
Guanine nucleotide binding protein (G protein), q polypeptide	U40038	600998	none found
GUANINE NUCLEOTIDE- BINDING PROTEIN		139311	none found
ALPHA- ACTIVATING ACTIVITY POLYPEPTIDE O;			

SD-144141.1

GNAOI				
Guanylate cyclase I, soluble, alpha 2	X63282	601244	none found	
GUANYLATE CYCLASE 1, SOLUBLE, BETA-2		603695	none found	
Guanylate cyclase soluble, alpha-3 chain	X66534	139396	none found	
Guanylate cyclase soluble, beta-1 chain	X66533	139397	none found	
H.sapiens 40 kDa protein kinase related to rat ERK2	Z11695	176948	none found	
H.sapiens 44kDa protein kinase related to rat ERK1	Z11696	601795	none found	
H.sapiens encoding CLA-1 mRNA	Z22555	601040	none found	
H.sapiens gene for antithrombin III	X68793	107300	AAG----AAA transition at Lys 176	
H.sapiens gene for antithrombin III	X68793	107300	DdeI	
H.sapiens gene for antithrombin III	X68793	107300	Hae III	
H.sapiens gene for antithrombin III	X68793	107300	NheI	
H.sapiens gene for antithrombin III	X68793	107300	Pst I	
H.sapiens gene for antithrombin III	X68793	107300	Trinucleotide repeat	
H.sapiens gene for	X68793	107300		GLU245FS

antithrombin III				
H.sapiens gene for	X68793	107300	ILE7ASN	
antithrombin III				
H.sapiens gene for	X68793	107300	ALA382THR	
antithrombin III				
H.sapiens gene for	X68793	107300	ala382thr	
antithrombin III				
H.sapiens gene for	X68793	107300	ALA384PRO	
antithrombin III				
H.sapiens gene for	X68793	107300	ALA384SER	
antithrombin III				
H.sapiens gene for	X68793	107300	ALA387VAL	
antithrombin III				
H.sapiens gene for	X68793	107300	ALA404THR	
antithrombin III				
H.sapiens gene for	X68793	107300	ARG129TER	
antithrombin III				
H.sapiens gene for	X68793	107300	ARG24CYS	
antithrombin III				
H.sapiens gene for	X68793	107300	ARG393CYS	
antithrombin III				
H.sapiens gene for	X68793	107300	ARG393HIS	
antithrombin III				
H.sapiens gene for	X68793	107300	ARG393PRO	
antithrombin III				
H.sapiens gene for	X68793	107300	arg406met	
antithrombin III				
H.sapiens gene for	X68793	107300	ARG47CYS	
antithrombin III				
H.sapiens gene for	X68793	107300	ARG47HIS	
antithrombin III				

SD-144141.1

H.sapiens gene for antithrombin III	X68793	107300	ARG47SER
H.sapiens gene for antithrombin III	X68793	107300	ASN208LYS
H.sapiens gene for antithrombin III	X68793	107300	ASP309LYS
H.sapiens gene for antithrombin III	X68793	107300	GLY392ASP
H.sapiens gene for antithrombin III	X68793	107300	His120-->Tyr
H.sapiens gene for antithrombin III	X68793	107300	LEU-10PRO
H.sapiens gene for antithrombin III	X68793	107300	LEU99PHE
H.sapiens gene for antithrombin III	X68793	107300	LYS228FS
H.sapiens gene for antithrombin III	X68793	107300	LYS370ARG
H.sapiens gene for antithrombin III	X68793	107300	PRO407LEU
H.sapiens gene for antithrombin III	X68793	107300	PRO41LEU
H.sapiens gene for antithrombin III	X68793	107300	PRO429LEU
H.sapiens gene for antithrombin III	X68793	107300	Pro80-->Thr
H.sapiens gene for antithrombin III	X68793	107300	SER291PRO
H.sapiens gene for antithrombin III	X68793	107300	SER349PRO
H.sapiens gene for antithrombin III	X68793	107300	SER394LEU

antithrombin III	X68793	107300	Tyr158-->Cys
H.sapiens gene for antithrombin III	X68793	107300	VAL-3GLU
H.sapiens gene for antithrombin III	X68793	107300	VAL48CYS
H.sapiens HTNT4 mRNA for cardiac troponin T	X79857	191045	IVS15, G-A, +1
H.sapiens HTNT4 mRNA for cardiac troponin T	X79857	191045	Arg102Leu
H.sapiens HTNT4 mRNA for cardiac troponin T	X79857	191045	ARG278CYS
H.sapiens HTNT4 mRNA for cardiac troponin T	X79857	191045	ARG92GLN
H.sapiens HTNT4 mRNA for cardiac troponin T	X79857	191045	ILE79ASN
H.sapiens mRNA for adenosine triphosphatase, calcium	Z69881	601929	none found
H.sapiens mRNA for cyclic nucleotide phosphodiesterase	X95520	602047	1389 (A/G)
H.sapiens mRNA for cyclic nucleotide phosphodiesterase	X95520	602047	dinucleotide repeat introns 12

H.sapiens mRNA for cyclic nucleotide phosphodiesterase	X95520	602047	dinucleotide repeat introns 5	
H.sapiens mRNA for delta-sarcoglycan	X95191	601411	1-BP DEL, 656C	
H.sapiens mRNA for delta-sarcoglycan	X95191	601411		ARG165TER
H.sapiens mRNA for delta-sarcoglycan	X95191	601411		GLU262LYS
H.sapiens mRNA for delta-sarcoglycan	X95191	601411		TRP30TER
H.sapiens mRNA for growth factor receptor tyrosine kinase	X61656	191306	none found	
H.sapiens mRNA for nitric oxide synthase	X73029	163730	(CCTTT)n	
H.sapiens mRNA for platelet derived growth factor alpha receptor	X76079	173490	none found	
H.sapiens mRNA for ryanodine receptor 2	X98330	180902	none found	
H.sapiens mRNA for thrombospondin-4	Z19585	600715	none found	
H.sapiens tropomyosin isoform mRNA, complete CDS	Z24727	191010		ASP175ASN
H.sapiens tropomyosin isoform mRNA, complete CDS	Z24727	191010		GLU180GLY
Histamine receptor H1	AF026261	600167	none found	
HMGCoA	NM_0008	142910	HgiAI	

SD-144141.1

reductase/HMGCR	59			
HMGCoA	NM_0008	142910	ScrFI polymorphism	
reductase/HMGCR	59		in the 2nd intron	
Homo sapiens (clone	L17128	137167		LEU394ARG
H4/H16) gamma-				
glutamic carboxylase				
mRNA, complete cds				
Homo sapiens ADDL	D67031	601568	none found	
mRNA for adducin-				
like protein, complete				
cds				
Homo sapiens beta-	AF084040	107940	none found	
arrestin 1A mRNA,				
complete cds				
Homo sapiens beta-	M58018	160760	2.4-KB DEL	
myosin heavy chain				
(MYH7) mRNA,				
complete cds				
Homo sapiens beta-	M58018	160760		ARG249GLN
myosin heavy chain				
(MYH7) mRNA,				
complete cds				
Homo sapiens beta-	M58018	160760		ARG403GLN
myosin heavy chain				
(MYH7) mRNA,				
complete cds				
Homo sapiens beta-	M58018	160760		ARG403LEU
myosin heavy chain				
(MYH7) mRNA,				
complete cds				
Homo sapiens beta-	M58018	160760		ARG453CYS

SD-144141.1

myosin heavy chain (MYH7) mRNA, complete cds	M58018	160760	ARG719TRP
Homo sapiens beta- myosin heavy chain (MYH7) mRNA, complete cds	M58018	160760	ARG723CYS
Homo sapiens beta- myosin heavy chain (MYH7) mRNA, complete cds	M58018	160760	ASP778GLY
Homo sapiens beta- myosin heavy chain (MYH7) mRNA, complete cds	M58018	160760	GLU924LYS
Homo sapiens beta- myosin heavy chain (MYH7) mRNA, complete cds	M58018	160760	GLU949LYS
Homo sapiens beta- myosin heavy chain (MYH7) mRNA, complete cds	M58018	160760	GLY256GLU
Homo sapiens beta- myosin heavy chain (MYH7) mRNA, complete cds	M58018	160760	GLY584ARG

SD-144141.1

Homo sapiens beta-myosin heavy chain (MYH7) mRNA, complete cds	M58018	160760	GLY741ARG
Homo sapiens beta-myosin heavy chain (MYH7) mRNA, complete cds	M58018	160760	LEU908VAL
Homo sapiens beta-myosin heavy chain (MYH7) mRNA, complete cds	M58018	160760	PHE513CYS
Homo sapiens beta-myosin heavy chain (MYH7) mRNA, complete cds	M58018	160760	VAL606MET
Homo sapiens calcium-ATPase (HK1) mRNA, complete cds	M23114	108740	18-BP INS, IVS2, -12
Homo sapiens calcium-ATPase (HK1) mRNA, complete cds	M23114	108740	IVS6DS, G-A, +1
Homo sapiens calcium-ATPase (HK1) mRNA, complete cds	M23114	108740	ASN754 DEL
Homo sapiens calcium-ATPase (HK1) mRNA, complete cds	M23114	108740	ASN767SER
Homo sapiens calcium-ATPase (HK1) mRNA, complete cds	M23114	108740	CYS268PHE

SD-144141.1

Homo sapiens calcium-ATPase (HK1) mRNA, complete cds	M23114	108740	CYS560ARG
Homo sapiens calcium-ATPase (HK1) mRNA, complete cds	M23114	108740	GLN108TER
Homo sapiens calcium-ATPase (HK1) mRNA, complete cds	M23114	108740	GLY23GLU
Homo sapiens calcium-independent phospholipase A2 mRNA, complete cds	AF064594	603604	none found
Homo sapiens carbonic anhydrase precursor (CA 12) mRNA, complete cds	AF037335	603263	none found
Homo sapiens focal adhesion kinase mRNA, complete cds	L05186	600758	none found
Homo sapiens GATA-4 mRNA, complete cds	L34357	600576	none found
Homo sapiens integrin alpha 8 subunit mRNA, 3' end	L36531	604063	none found
Homo sapiens integrin alpha-7 mRNA, complete cds	AF032108	600536	1-bp frameshift deletion at cDNA nucleotide 1204
Homo sapiens integrin alpha-7 mRNA, complete cds	AF032108	600536	21-BP INS

SD-144141.1

Homo sapiens integrin alpha-7 mRNA, complete cds	AF032108	600536	98-BP DEL	
Homo sapiens mRNA for ABC transporter 7 protein, complete cds	AB005289	300135		ILE400MET
Homo sapiens mRNA for AMP-activated protein kinase alpha-1, complete cds	AB022017	602739	none found	
Homo sapiens mRNA for AMP-activated protein kinase beta 1	AJ224515	602740	none found	
Homo sapiens mRNA for AMP-activated protein kinase beta 2 subunit	AJ224538	602741	none found	
Homo sapiens mRNA for brain ryanodine receptor, complete cds	AB001025	180903	none found	
Homo sapiens p21-activated kinase 3 (PAK3) mRNA, complete cds	AF068864	300142		ARG419TER
Homo sapiens paraoxonase 2 (PON2) mRNA, complete cds	L48513	602447		ALA148GLY
Homo sapiens paraoxonase 2 (PON2) mRNA, complete cds	L48513	602447		CYS311SER
Homo sapiens	L48516	602720	none found	

SD-144141.1

paraoxonase 3 (PON3) mRNA, 3' end of cds	M95678	604114	none found	
Homo sapiens phospholipase C-beta-2 mRNA, complete cds	AF033850	602384	none found	
Homo sapiens phospholipase D2 (PLD2) mRNA, complete cds	L06139	600221		ARG849TRP
Homo sapiens receptor protein-tyrosine kinase (TEK) mRNA, complete cds	M55067	233700	1-BP DEL, 502G	frameshift
Human 47-kD autosomal chronic granulomatous disease protein mRNA, complete cds	M55067	233700	2-BP DEL, EX2, -2, GT	
Human 47-kD autosomal chronic granulomatous disease protein mRNA, complete cds	M55067	233700	2-BP INS	frameshift
Human 47-kD autosomal chronic granulomatous disease protein mRNA, complete cds	M55067	233700		ASP161VAL
Human 47-kD autosomal chronic granulomatous disease				

protein mRNA, complete cds Human 47-kD autosomal chronic granulomatous disease protein mRNA, complete cds Human 5'-AMP- activated protein kinase, gamma-1 subunit mRNA, complete cds Human activin receptor-like kinase (ALK-5) mRNA, complete cds Human alpha adducin mRNA, partial cds including alternate exons A and B Human apolipoprotein A-I mRNA, complete cds Human apolipoprotein A-I mRNA, complete cds Human apolipoprotein A-I mRNA, complete cds Human apolipoprotein A-I mRNA, complete cds	M55067 U42412 L11695 L07261 M27875 M27875 M27875 M27875 M27875	233700 602742 190181 102680 107680 107680 107680 107680 107680	LYS160GLU none found S387Y G460W 1-BP DEL, CODON 202 1-BP INS 1121 C/T in intron 3 12-BP DEL AND 2- BP INS
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------

SD-144141.1

Human apolipoprotein A-I mRNA, complete cds	M27875	107680	A/G at position 78 bp upstream
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	DELETION OF APOA1/APOC3/AP OA4 GENE COMPLEX EX4/IVS1
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	G-to-A -75 bp
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	IVS2, G-C, +1
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	Msp I
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	Pst-I
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	SstI
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	XmnI
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	Lys-107 deletion

SD-144141.1

Human apolipoprotein A-I mRNA, complete cds	M27875	107680	Ala-95-->Asp
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	ARG10LEU
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	ARG173CYS
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	ARG173PRO
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	Asp103----Asn
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	GLN-2TER
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	GLN32TER
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	GLN84TER
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	GLU136LYS
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	GLU198LYS

SD-144141.1

Human apolipoprotein A-I mRNA, complete cds	M27875	107680	GLY26ARG
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	LEU60ARG
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	LEU90PRO
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	LYS107DEL
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	PRO143ARG
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	Pro165-->Arg
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	PRO165ARG
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	PRO3ARG
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	PRO4ARG
Human apolipoprotein A-I mRNA, complete cds	M27875	107680	Trp-108-->Arg
Human apolipoprotein cds	M27875	107680	TRP50ARG

SD-144141.1

A-I mRNA, complete cds				
Human apolipoprotein A-I mRNA, complete cds	M27875	107680		VAL156GLU
Human ARF-activated phosphatidylcholine-specific phospholipase D1a (hPLD1) mRNA, complete cds	U38545	602382	none found	
Human beta 4 adducin mRNA, alternatively spliced partial cds	U43959	102681	none found	
Human bumetanide-sensitive Na-K-2Cl cotransporter (NKCC2) mRNA, complete cds	U58130	600839		ASP648ASN
Human bumetanide-sensitive Na-K-2Cl cotransporter (NKCC2) mRNA, complete cds	U58130	600839		TRP625TER
Human bumetanide-sensitive Na-K-2Cl cotransporter (NKCC2) mRNA, complete cds	U58130	600839		VAL272PHE
Human bumetanide-sensitive Na-K-Cl cotransporter (NKCC1) mRNA, complete cds	U30246	600840	none found	
Human c-sis/platelet-derived growth factor 2	M12783	190040	135-BP DEL, IVS5	

SD-144141.1

(SIS/PDGF2) mRNA, complete cds	M12783	190040	FUSION WITH COL1A
Human c-sis/platelet- derived growth factor 2 (SIS/PDGF2) mRNA, complete cds	U95301	603603	none found
Human calcium- dependent group X phospholipase A2 mRNA, complete cds	M33336	188830	none found
Human cAMP- dependent protein kinase type I-alpha subunit (PRKAR1A) mRNA, complete cds	L10844	116952	none found
Human cellular growth-regulating protein mRNA, complete cds	M91667	123805	none found
Human cGMP- inhibited cAMP phosphodiesterase mRNA, complete cds	M14058	216950	none found
Human complement C1r mRNA, complete cds	U59167	125660	21-BP DEL
Human desmin mRNA, complete cds	U59167	125660	EcoRV
Human desmin mRNA, complete cds	U59167	125660	ALA337PRO

complete cds	U59167	125660	ALA360PRO
Human desmin mRNA,			
complete cds	U59167	125660	ASN393ILE
Human desmin mRNA,			
complete cds	U59167	125660	ILE451MET
Human desmin mRNA,			
complete cds	AL023653	300145	none found
Human DNA sequence			
from clone 753P9 on			
chromosome Xq25-			
26.1. Contains the gene			
coding for			
Aminopeptidase P (EC			
3.4.11.9, XAA-Pro/X-			
Pro/Proline/Aminoacyl			
proline			
Aminopeptidase) and a			
novel gene. Contains			
ESTs, STSs, GSSs and			
a gaaa repeat			
polymorphism			
Human ERK5 mRNA,	U25278	602521	none found
complete cds			
Human ferritin H chain	M11146	134770	none found
mRNA, complete cds			
Human ferritin L chain	M11147	134790	22T-G
mRNA, complete cds			
Human ferritin L chain	M11147	134790	146A-G
mRNA, complete cds			
Human ferritin L chain	M11147	134790	147G-C
mRNA, complete cds			

SD-144141.1

Human ferritin L chain mRNA, complete cds	M11147	134790	18C-T	
Human ferritin L chain mRNA, complete cds	M11147	134790	29-BP DEL	IRE DEL
Human ferritin L chain mRNA, complete cds	M11147	134790	32G-A	
Human ferritin L chain mRNA, complete cds	M11147	134790	32G-T	
Human ferritin L chain mRNA, complete cds	M11147	134790	36C-A	
Human ferritin L chain mRNA, complete cds	M11147	134790	39C-T	
Human flt mRNA for receptor-related tyrosine kinase	X51602	165070	Dinucleotide repeat	
Human heparin-binding vascular endothelial growth factor (VEGF) mRNA, complete cds	M32977	192240	none found	
Human hepatic lipase mRNA, complete cds	J03540	151670		SER267PHE
Human hepatic lipase mRNA, complete cds	J03540	151670		THR383MET
Human hormone-sensitive lipase testicular isoform mRNA, complete cds	U40002	151750	dinucleotide repeat	
Human hormone-sensitive lipase testicular isoform mRNA, complete cds	U40002	151750		Arg309Cys

mRNA, complete cds	L24158	603963	none found	ARG387TER
Human integrin alpha 9 protein mRNA, 3'end	D38128	600022	none found	
Human IP gene for prostacyclin receptor, exon 3	X00063	179820		
Human kidney mRNA fragment for renin (aa 105-401)	U33052	602549	none found	
Human lipid-activated, protein kinase PRK2 mRNA, complete cds	D14874	103275	none found	
Human mRNA for adrenomedullin, complete cds	X52947	121014	GCG-->GTG	
Human mRNA for cardiac gap junction protein	D26309	601329	none found	
Human mRNA for LIMK (LIM kinase), complete cds	D45906	601988	none found	
Human mRNA for LIMK-2, complete cds	X15357	108960	none found	
Human mRNA for natriuretic peptide receptor (ANP-A receptor)	X05199	173350	IVS17, 1-BP DEL, G, +1 TaqI	
Human mRNA for plasminogen	X05199	173350		

Human mRNA for plasminogen	X05199	173350	GLU460TER
Human mRNA for plasminogen	X05199	173350	ALA600THR
Human mRNA for plasminogen	X05199	173350	Ala675Thr
Human mRNA for plasminogen	X05199	173350	ARG216HIS
Human mRNA for plasminogen	X05199	173350	D676N
Human mRNA for plasminogen	X05199	173350	GLY732ARG
Human mRNA for plasminogen	X05199	173350	LYS19GLU
Human mRNA for plasminogen	X05199	173350	LYS212DEL
Human mRNA for plasminogen	X05199	173350	SER572PRO
Human mRNA for plasminogen	X05199	173350	TRP597TER
Human mRNA for plasminogen	X05199	173350	VAL355PHE
Human mRNA for platelet-derived growth factor PDGF-A	X06374	173430	none found
Human mRNA for thrombospondin	X04665	188060	none found
Human mRNA for transforming growth factor-beta (TGF-beta)	X02812	190180	72
Human mRNA for	X02812	190180	-509

SD-144141.1

transforming growth factor-beta (TGF-beta)	X02812	190180	-800	
Human mRNA for transforming growth factor-beta (TGF-beta)	X02812	190180	-988	
Human mRNA for transforming growth factor-beta (TGF-beta)	X02812	190180	713-8delC intron 4	
Human mRNA for transforming growth factor-beta (TGF-beta)	X02812	190180	C788-T	thr263iso
Human mRNA for transforming growth factor-beta (TGF-beta)	X02812	190180		Arg25-->Pro
Human mRNA for transforming growth factor-beta (TGF-beta)	X02812	190180		Leu10-->Pro
Human mRNA for type I beta cGMP-dependent protein kinase (EC 2.7.1.37)	Y07512	176894	none found	
Human myoadenylate deaminase (AMPD1) mRNA, complete cds	M60092	102770	C143-->T	PRO48LEU
Human myoadenylate deaminase (AMPD1) mRNA, complete cds	M60092	102770	C34-T	Gln-->Stop
Human neuronal nitric	U17327	163731	none found	

SD-144141.1

oxide synthase (NOS1) mRNA, complete cds	M21186	233690	1-BP DEL, 272C	
Human neutrophil cytochrome b light chain p22 phagocyte b- cytochrome mRNA, complete cds	M21186	233690	10-KB DEL	
Human neutrophil cytochrome b light chain p22 phagocyte b- cytochrome mRNA, complete cds	M21186	233690	IVS4DS, G-A, +1	
Human neutrophil cytochrome b light chain p22 phagocyte b- cytochrome mRNA, complete cds	M21186	233690		ARG90GLN
Human neutrophil cytochrome b light chain p22 phagocyte b- cytochrome mRNA, complete cds	M21186	233690		HIS72TYR
Human neutrophil cytochrome b light chain p22 phagocyte b- cytochrome mRNA, complete cds	M21186	233690		HIS94ARG

complete cds	M21186	233690	PRO156GLN
Human neutrophil cytochrome b light chain p22 phagocyte b- cytochrome mRNA,			
complete cds	M21186	233690	SER118ARG
Human neutrophil cytochrome b light chain p22 phagocyte b- cytochrome mRNA,			
complete cds	M32011	233710	5-nucleotide del nts 1169-1173
Human neutrophil oxidase factor (p67- phox) mRNA,			
complete cds	M32011	233710	9-nt in-frame deletion in exon 2 (nts 55-63)
Human neutrophil oxidase factor (p67- phox) mRNA,			
complete cds	M32011	233710	C(304) --> T
Human neutrophil oxidase factor (p67- phox) mRNA,			
complete cds	M32011	233710	del A(728)
Human neutrophil oxidase factor (p67- phox) mRNA,			
complete cds	M32011	233710	intron 4 (G --> A)
Human neutrophil oxidase factor (p67- phox) mRNA,			
complete cds			

SD-144141.1

Human p21-activated protein kinase (Pak1) gene, complete cds	U24152	602590	none found	
Human phospholamban mRNA, complete cds	M63603	172405	none found	
Human platelet glycoprotein IX mRNA, 3' end	M25827	173515		Ala139(ACC)-->Thr(GCC)
Human platelet glycoprotein IX mRNA, 3' end	M25827	173515		ASN45SER
Human platelet glycoprotein IX mRNA, 3' end	M25827	173515		ASP21GLY
Human platelet glycoprotein IX mRNA, 3' end	M25827	173515		LEU40PRO
Human platelet glycoprotein IX mRNA, 3' end	M25827	173515		PHE55SER
Human platelet-derived growth factor (PDGF) receptor mRNA, complete cds	M21616	173410	none found	
Human protein kinase C iota isoform (PRKCI) mRNA, complete cds	L18964	300094	none found	
Human RASFA-PLA2 mRNA, complete cds	M22430	172411	2-BP DEL	frameshift

Human receptor for advanced glycosylation end products (RAGE) mRNA, partial cds	M91211	600214	none found	
Human steroid 5-alpha- reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600	1-BP DEL	PRO251DEL
Human steroid 5-alpha- reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600	null allele	
Human steroid 5-alpha- reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600		GLY196SER
Human steroid 5-alpha- reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600		LEU55GLN
Human steroid 5-alpha- reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600		ARG227TER
Human steroid 5-alpha- reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600		ARG246TRP
Human steroid 5-alpha- reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600		GLY115ASP
Human steroid 5-alpha- reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600		GLY183SER
Human steroid 5-alpha- reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600		HIS231ARG

Human steroid 5-alpha-reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600	MET157DEL
Human steroid 5-alpha-reductase 2 (SRD5A2) mRNA, complete cds	M74047	264600	THR228ALA
Human steroidogenic acute regulatory protein (StAR) mRNA, complete cds	U17280	600617	840delA
Human steroidogenic acute regulatory protein (StAR) mRNA, complete cds	U17280	600617	IVS4AS, T-A, -11
Human steroidogenic acute regulatory protein (StAR) mRNA, complete cds	U17280	600617	IVS2, I-BP INS, T, +3
Human steroidogenic acute regulatory protein (StAR) mRNA, complete cds	U17280	600617	I-BP DEL, 261T
Human steroidogenic acute regulatory protein (StAR) mRNA, complete cds	U17280	600617	ARG182LEU
Human steroidogenic acute regulatory protein (StAR) mRNA, complete cds	U17280	600617	D203A
Human steroidogenic acute regulatory protein (StAR) mRNA, complete cds	U17280	600617	GLN258TER

acute regulatory protein (StAR) mRNA, complete cds	M85079	190182	2-BP INS	Frameshift
Human TGF-beta type II receptor mRNA, complete cds	M85079	190182		THR315MET
Human TGF-beta type II receptor mRNA, complete cds	U44128	600968	3-BP DEL	
Human thiazide- sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968	119-bp insertion between exons 3 and 4	
Human thiazide- sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968	exon 24 was deleted	
Human thiazide- sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968	intron 24, GGT --> GTT	
Human thiazide- sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968	intron 3, CAG --> CAA	
Human thiazide- sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968	IVS15AS, G-T, -I	

SD-144141.1

cotransporter (hTSC) mRNA, complete cds Human thiazide- sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968	IVS23DS, G-T, +I	
Human thiazide- sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968		ALA588VAL
Human thiazide- sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968		ARG209TRP
Human thiazide- sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968		ARG653LEU
Human thiazide- sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968		ARG655HIS
Human thiazide- sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968		CYS421ARG
Human thiazide- sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968		GLY630VAL
Human thiazide- sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968		LEU623PRO

sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968	LEU850PRO
Human thiazide- sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U44128	600968	PRO349LEU
Human thiazide- sensitive Na-Cl cotransporter (hTSC) mRNA, complete cds	U68162	159530	none found
Human thrombopoietin receptor (MPL) gene	M81339	188061	none found
Human thrombospondin mRNA	X60957	600222	none found
Human tie mRNA for putative receptor tyrosine kinase	M12530	190000	Aval
Human transferrin mRNA, complete cds	M12530	190000	ASP277GLY
Human transferrin mRNA, complete cds	M12530	190000	GLY652GLU
Human transferrin mRNA, complete cds	M12530	190000	HIS300ARG
Human transferrin mRNA, complete cds	M12530	190000	LYS627GLU
Human transferrin mRNA, complete cds	M12530	190000	PRO570SER

Human transforming growth factor-beta type III receptor (TGF-beta) mRNA, complete cds	L07594	600742	none found	
Human urokinase gene, 3' end	K02286	191840	BamHI	
Human urokinase gene, 3' end	K02286	191840	C to T change near the beginning of exon 8	
Human urokinase gene, 3' end	K02286	191840		Leu residue by a Pro, in the kringle domain
Human vascular endothelial growth factor related protein VRP mRNA, complete cds	U43142	601528	none found	
Human VEGF related factor isoform VRF186 precursor (VRF) mRNA, complete cds	U43368	601398	none found	
Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2	M67466	201810	1-BP INS	
Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2	M67466	201810	Dinucleotide repeat	
Hydroxy-delta-5-steroid dehydrogenase,	M67466	201810		ARG249TER

3 beta- and steroid delta-isomerase 2	M67466	201810	TRP171TER
Hydroxy-delta-5- steroid dehydrogenase,			
3 beta- and steroid delta-isomerase 2	M67466	201810	VAL248ASN
Hydroxy-delta-5- steroid dehydrogenase,			
3 beta- and steroid delta-isomerase 2	K02770	147720	+5887 C --> T
interleukin 1 beta (IL1b)			
interleukin 1 beta (IL1b)	K02770	147720	exon 5 (position +3953)
interleukin 1 beta (IL1b)	K02770	147720	position -511
interleukin 1 beta (IL1b)	K02770	147720	TaqI
interleukin 1 beta (IL1b)	K02770	147720	Asp106Asn
INTERLEUKIN 1 BETA CONVERTASE PRECURSOR	X65019	147678	none found
interleukin 1 receptor (IL-1R)	M27492	147810	PstI
interleukin 12a (IL12a)	M65271	161560	none found
interleukin 12b (IL12b)	M65272	161561	4.4-KB DEL
interleukin 2 (IL2)	X01586	147680	-330
interleukin 2 (IL2)	X01586	147680	166
interleukin 2 (IL2)	X01586	147680	AUUUA motif deleted

SD-144141.1

interleukin 2 (IL2)	X01586	147680	Dinucleotide Repeat	
interleukin 2 receptor beta (IL-2Rb)	M26062	146710	CA repeat	
interleukin 2 receptor gamma (IL-2Rg)	D11086	308380	690-691 hotspot	
interleukin 2 receptor gamma (IL-2Rg)	D11086	308380	9-BP DUP	GLN-HIS-TRP INS
interleukin 2 receptor gamma (IL-2Rg)	D11086	308380	G-to-A first position of intron 3	ARG222CYS
interleukin 2 receptor gamma (IL-2Rg)	D11086	308380		ARG267TER
interleukin 2 receptor gamma (IL-2Rg)	D11086	308380		ARG285GLN
interleukin 2 receptor gamma (IL-2Rg)	D11086	308380		CYS115ARG
interleukin 2 receptor gamma (IL-2Rg)	D11086	308380		CYS62TER
interleukin 2 receptor gamma (IL-2Rg)	D11086	308380		GLY114ASP
interleukin 2 receptor gamma (IL-2Rg)	D11086	308380		ILE153ASN
interleukin 2 receptor gamma (IL-2Rg)	D11086	308380		LEU271GLN
interleukin 2 receptor gamma (IL-2Rg)	D11086	308380		LYS97TER
interleukin 2 receptor gamma (IL-2Rg)	D11086	308380		SER286TER
interleukin 4 (IL4)	M13982	147780	-285 C-T	
interleukin 4 (IL4)	M13982	147780	-81 A-G	

SD-144141.1

interleukin 4 (IL4)	M13982	147780	C-589T
interleukin 4 (IL4)	M13982	147780	Dinucleotide Repeat intron 2
interleukin 4 receptor (IL-4R)	X52425	147781	GLN576ARG
interleukin 4 receptor (IL-4R)	X52425	147781	ILE50VAL
interleukin 4 receptor (IL-4R)	X52425	147781	S503P
interleukin 6 (IL6)	M14584	147620	CA repeat
interleukin 6 (IL6)	M14584	147620	174G-C
interleukin 6 (IL6)	M14584	147620	AT repeat
interleukin 6 (IL6)	M14584	147620	BglI
interleukin 6 (IL6)	M14584	147620	BglII
interleukin 6 (IL6)	M14584	147620	MspI
interleukin 6 (IL6)	M14584	147620	NlaIII promoter
interleukin 6 receptor (IL-6R) (20)	M20566	147880	dinucleotide (CA)
interleukin receptor 11 alpha (IL-11a)	U32324	600939	none found
interleukin receptor 12 beta2 (IL-12b2)	U03187	601642	none found
K+ channel (KvLQT1)	AF000571	192500	7-BP DEL AND 8- BP INS
K+ channel (KvLQT1)	AF000571	192500	1-BP INS, 282G
K+ channel (KvLQT1)	AF000571	192500	3-BP DEL
K+ channel (KvLQT1)	AF000571	192500	9-BP DEL, NT373
K+ channel (KvLQT1)	AF000571	192500	ALA300THR
K+ channel (KvLQT1)	AF000571	192500	ALA341GLU
K+ channel (KvLQT1)	AF000571	192500	ALA341VAL
K+ channel (KvLQT1)	AF000571	192500	ALA529THR

SD-144141.1

K+ channel (KvLQT1)	AF000571	192500	ALA83PRO
K+ channel (KvLQT1)	AF000571	192500	ARG518TER
K+ channel (KvLQT1)	AF000571	192500	ARG555CYS
K+ channel (KvLQT1)	AF000571	192500	ARG95GLN
K+ channel (KvLQT1)	AF000571	192500	GLY189ARG
K+ channel (KvLQT1)	AF000571	192500	GLY211ARG
K+ channel (KvLQT1)	AF000571	192500	GLY219SER
K+ channel (KvLQT1)	AF000571	192500	GLY250GLU
K+ channel (KvLQT1)	AF000571	192500	LEU178PHE
K+ channel (KvLQT1)	AF000571	192500	PHE339DEL
K+ channel (KvLQT1)	AF000571	192500	THR217ILE
K+ channel (KvLQT1)	AF000571	192500	TRP305SER
K+ channel (KvLQT1)	AF000571	192500	VAL159MET
L-type voltage dependent calcium channel alpha 1C subunit/CACNA1C	NM_000719	114205	none found
Leukocyte integrin beta-1	U28252	135630	none found
Leukocyte integrin beta-3	M35999	173470	11.2-KB DEL
Leukocyte integrin beta-3	M35999	173470	G-T, EXiDEL
Leukocyte integrin beta-3	M35999	173470	ARG143GLN
Leukocyte integrin beta-3	M35999	173470	ARG214GLN
Leukocyte integrin beta-3	M35999	173470	ARG214TRP
Leukocyte integrin beta-3	M35999	173470	ARG489GLN

SD-144141.1

Leukocyte integrin beta-3	M35999	173470	ARG724TER
Leukocyte integrin beta-3	M35999	173470	ASP119TYR
Leukocyte integrin beta-3	M35999	173470	CYS374TYR
Leukocyte integrin beta-3	M35999	173470	GLU616TER
Leukocyte integrin beta-3	M35999	173470	LEU333PRO
Leukocyte integrin beta-3	M35999	173470	PRO407ALA
Leukocyte integrin beta-3	M35999	173470	SER752PRO
Lipoprotein lipase	M15856	238600	INS
Lipoprotein lipase	M15856	238600	(TTTA)n
Lipoprotein lipase	M15856	238600	-39T-C
Lipoprotein lipase	M15856	238600	-93T-G
Lipoprotein lipase	M15856	238600	1-BP DEL
Lipoprotein lipase	M15856	238600	1-BP DEL, 221G
Lipoprotein lipase	M15856	238600	2-KB DUP
Lipoprotein lipase	M15856	238600	6-KB DEL
Lipoprotein lipase	M15856	238600	C-->A -3 intron 6
Lipoprotein lipase	M15856	238600	C-to-T -480
Lipoprotein lipase	M15856	238600	C1338-->A
Lipoprotein lipase	M15856	238600	C1595-->G
Lipoprotein lipase	M15856	238600	G579-->A
Lipoprotein lipase	M15856	238600	HindIII
Lipoprotein lipase	M15856	238600	IVS1, G-C, +1
Lipoprotein lipase	M15856	238600	IVS2DS, G-A
Lipoprotein lipase	M15856	238600	IVS2DS, G-A, +1
Lipoprotein lipase	M15856	238600	frameshift
Lipoprotein lipase	M15856	238600	frameshift
Lipoprotein lipase	M15856	238600	Thr361 Thr
Lipoprotein lipase	M15856	238600	S447X
Lipoprotein lipase	M15856	238600	V108V

Lipoprotein lipase	M15856	238600	ILE194THR
Lipoprotein lipase	M15856	238600	ILE225THR
Lipoprotein lipase	M15856	238600	TRP382TER
Lipoprotein lipase	M15856	238600	TYR61TER
Lipoprotein lipase	M15856	238600	ALA176THR
Lipoprotein lipase	M15856	238600	ALA334THR
Lipoprotein lipase	M15856	238600	ARG243CYS
Lipoprotein lipase	M15856	238600	ARG243HIS
Lipoprotein lipase	M15856	238600	ARG75SER
Lipoprotein lipase	M15856	238600	ASN291SER
Lipoprotein lipase	M15856	238600	ASP156GLY
Lipoprotein lipase	M15856	238600	ASP180GLU
Lipoprotein lipase	M15856	238600	ASP204GLU
Lipoprotein lipase	M15856	238600	ASP250ASN
Lipoprotein lipase	M15856	238600	ASP9ASN
Lipoprotein lipase	M15856	238600	Cys239-->stop
Lipoprotein lipase	M15856	238600	CYS418TYR
Lipoprotein lipase	M15856	238600	E163G
Lipoprotein lipase	M15856	238600	E410K
Lipoprotein lipase	M15856	238600	GLN106TER
Lipoprotein lipase	M15856	238600	Glu118 Glu
Lipoprotein lipase	M15856	238600	Glu421Lys
Lipoprotein lipase	M15856	238600	GLY142GLU
Lipoprotein lipase	M15856	238600	GLY188GLU
Lipoprotein lipase	M15856	238600	GLY195GLU
Lipoprotein lipase	M15856	238600	His183-->Gln
Lipoprotein lipase	M15856	238600	LEU365VAL
Lipoprotein lipase	M15856	238600	Pro157 Arg
Lipoprotein lipase	M15856	238600	PRO207LEU
Lipoprotein lipase	M15856	238600	SER172CYS
Lipoprotein lipase	M15856	238600	SER244THR

Lipoprotein lipase	M15856	238600		SER447TER
Lipoprotein lipase	M15856	238600		TRP64TER
Lipoprotein lipase	M15856	238600		TRP86ARG
Lipoprotein lipase	M15856	238600		Tyr262-->His
Lipoprotein lipase	M15856	238600		TYR73TER
Lipoxigenases: 5-lipoxygenase (leukocytes)	J03571	152390	none found	
Mineralocorticoid receptor (aldosterone receptor)	M16801	600983	1-BP DEL	frameshift at codon 337
Mineralocorticoid receptor (aldosterone receptor)	M16801	600983	1-BP DEL	frameshift at codon 459
Mineralocorticoid receptor (aldosterone receptor)	M16801	600983	760-->G760	Ileu180-->Val180
Mineralocorticoid receptor (aldosterone receptor)	M16801	600983	A DEL, +3 intron 5	
Mineralocorticoid receptor (aldosterone receptor)	M16801	600983	C944-->T944	Ala241-->Val241
Mineralocorticoid receptor (aldosterone receptor)	M16801	600983		ARG537TER
myeloperoxidase	X04876	254600	C8089T	ARG569TRP
myeloperoxidase	X04876	254600	Dinucleotide Repeat	
myeloperoxidase	X04876	254600	EcoRV	
myeloperoxidase	X04876	254600	G to A (promoter)	
myeloperoxidase	X04876	254600	KpnI	

myeloperoxidase	X04876	254600	PstI	
myeloperoxidase	X04876	254600		MET251THR
myeloperoxidase	X04876	254600		TYR173CYS
MYOSIN-BINDING PROTEIN C, CARDIAC		600958	5-BP DEL, EX25	
MYOSIN-BINDING PROTEIN C, CARDIAC		600958	IVS, G-A, +1	
MYOSIN-BINDING PROTEIN C, CARDIAC		600958	12-BP DUP/4-BP DEL	
MYOSIN-BINDING PROTEIN C, CARDIAC		600958	18-BP DUP	
MYOSIN-BINDING PROTEIN C, CARDIAC		600958	BRANCH POINT, IVS23, A-G, TGAT- TGGT	
MYOSIN-BINDING PROTEIN C, CARDIAC		600958	IVS, A-G	
MYOSIN-BINDING PROTEIN C, CARDIAC		600958	IVS, G-C, +5	
MYOSIN-BINDING PROTEIN C, CARDIAC		600958	IVS23, G-A, +1	
MYOSIN-BINDING PROTEIN C, CARDIAC		600958	IVS7, G-A, +5	
MYOSIN-BINDING		600958		Arg654His

PROTEIN C, CARDIAC MYOSIN-BINDING	600958			Glu1096 termination codon GLU542GLN
PROTEIN C, CARDIAC MYOSIN-BINDING	600958			
PROTEIN C, CARDIAC NEPHRIN	602716		1-BP INS, 3250G	
NEPHRIN	602716		2-BP DEL, 121CT	
NEPHRIN	602716		2-BP INS, 1306AC	
NEPHRIN	602716			ARG1109TER
Neuropeptide Y receptor Y1/NPY1R	M84755	162641	none found	
Nicotinic, Cholinergic receptor beta 1	X14830	100710		LEU263MET
Nicotinic, Cholinergic receptor beta 1	X14830	100710		VAL266MET
Nicotinic, Cholinergic receptor epsilon polypeptide	X66403	100725		ARG147LEU
Nicotinic, Cholinergic receptor epsilon polypeptide	X66403	100725		ARG64TER
Nicotinic, Cholinergic receptor epsilon polypeptide	X66403	100725		LEU269PHE
Nicotinic, Cholinergic receptor epsilon polypeptide	X66403	100725		PRO121LEU
Nicotinic, Cholinergic receptor epsilon polypeptide	X66403	100725		THR264PRO

SD-144141.1

receptor epsilon polypeptide					
NITRIC OXIDE SYNTHASE 3	163729				GLU298ASP
NITRIC OXIDE SYNTHASE, MACROPHAGE, TYPE 2B	600719			none found	
NITRIC OXIDE SYNTHASE, MACROPHAGE, TYPE 2C; NOS2C	600720			none found	
paraoxonase 1/PON1 (arylesterase)	168820	AH004193		CA repeat intron 4.	
paraoxonase 1/PON1 (arylesterase)	168820	AH004193			GLN192ARG
paraoxonase 1/PON1 (arylesterase)	168820	AH004193			Leu55Met
paraoxonase 1/PON1 (arylesterase)	168820	AH004193			MET54LEU
phenylethanolamine N-methyltransferase/PNMT	171190	NM_002686		BANI	
Phospholipase A-2 (PLA-2) lung	172410	M21054		none found	
Phospholipase A2, group IV	600522	M68874		none found	
Phospholipase C beta-3	600230	Z26649		none found	
Phospholipase C, beta 4	600810	L41349		none found	
plasma cholesterol	118470	NM_0000		A1503G	

ester transfer protein/CETP	78			
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	G-A splice junction alternative splice	
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	G1696A	
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	C-T transition in intron 12	
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	EcoNI	
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	G-->A intron 14	
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	G-A transition in intron 15	
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	G1533A	
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	INS T alternative (intron/exon14) splice	
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	StuI	
plasma cholesterol ester transfer protein/CETP	NM_0000 78	118470	T-->G tyr57stop	

protein/CETP					
plasma cholesterol					
ester transfer	NM_0000	118470		TaqIA	
protein/CETP	78				
plasma cholesterol					
ester transfer	NM_0000	118470		TaqIB in intron I	
protein/CETP	78				
plasma cholesterol					
ester transfer	NM_0000	118470		268 Arg--	
protein/CETP	78			>STOP	
plasma cholesterol					
ester transfer	NM_0000	118470		Asp 442 to Gly	
protein/CETP	78				
plasma cholesterol					
ester transfer	NM_0000	118470		ASP442GLY	
protein/CETP	78				
plasma cholesterol					
ester transfer	NM_0000	118470		G181X	
protein/CETP	78				
plasma cholesterol					
ester transfer	NM_0000	118470		I405V	
protein/CETP	78				
plasma cholesterol					
ester transfer	NM_0000	118470		Lys309-Stop	
protein/CETP	78				
plasma cholesterol					
ester transfer	NM_0000	118470		R451Q	
protein/CETP	78				
plasma cholesterol					
ester transfer	NM_0000	118470		Val421-Ile	
protein/CETP	78				

SD-144141.1

Platelet glycoprotein IIb/IIIa (fibrinogen receptor)	X06831	273800	11-BP DEL, EX12	
Platelet glycoprotein IIb/IIIa (fibrinogen receptor)	X06831	273800	13-BP DEL AT INTRON-EXON BOUNDARY OF EXON 4	
Platelet glycoprotein IIb/IIIa (fibrinogen receptor)	X06831	273800	4.5-KB DEL, EX2-9	
Platelet glycoprotein IIb/IIIa (fibrinogen receptor)	X06831	273800	IVS15DS, G-A, +1	
Platelet glycoprotein IIb/IIIa (fibrinogen receptor)	X06831	273800	IVS25AS, C-G, -3	
Platelet glycoprotein IIb/IIIa (fibrinogen receptor)	X06831	273800		ARG327HIS
Platelet glycoprotein IIb/IIIa (fibrinogen receptor)	X06831	273800		ARG584TER
Platelet glycoprotein IIb/IIIa (fibrinogen receptor)	X06831	273800		ASP426DEL
Platelet glycoprotein IIb/IIIa (fibrinogen receptor)	X06831	273800		GLU324LYS
Platelet glycoprotein IIb/IIIa (fibrinogen receptor)	X06831	273800		GLY273ASP

Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800	GLY418ASP
Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800	ILE565THR
Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800	ILE843SER
Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800	LEU214PRO
Platelet glycoprotein IIb/IIIa (fibrogen receptor)	X06831	273800	VAL425DEL
Platelet-activating factor receptor	M76674	173393	none found
Potassium channel subunit (h-erg)	U04270	152427	1-BP DEL
Potassium channel subunit (h-erg)	U04270	152427	27-BP DEL
Potassium channel subunit (h-erg)	U04270	152427	IVS3, G-C, +1
Potassium channel subunit (h-erg)	U04270	152427	VAL822MET
Potassium channel subunit (h-erg)	U04270	152427	ALA561VAL
Potassium channel subunit (h-erg)	U04270	152427	ARG582CYS
Potassium channel subunit (h-erg)	U04270	152427	ASN470ASP

SD-144141.1

Potassium channel subunit (h-erg)	U04270	152427	GLY628SER
Potassium channel subunit (h-erg)	U04270	152427	ILE593ARG
POTASSIUM CHANNEL, VOLTAGE-GATED, ISK-RELATED SUBFAMILY, MEMBER 2		603796	GLN9GLU
POTASSIUM CHANNEL, VOLTAGE-GATED, ISK-RELATED SUBFAMILY, MEMBER 2		603796	ILE57THR
POTASSIUM CHANNEL, VOLTAGE-GATED, ISK-RELATED SUBFAMILY, MEMBER 2		603796	MET54THR
progesterone receptor	M15716	264080	
PROTEIN KINASE C, EPSILON		176975	none found
PROTEIN KINASE, AMP-ACTIVATED, CATALYTIC, ALPHA-2		600497	none found
PROTEIN KINASE, AMP-ACTIVATED,		602743	none found

SD-144141.1

NONCATALYTIC, GAMMA-2; PRKAG2	M61831	180960	none found
S-adenosyl homocysteine hydrolase			
serotonin 5-HT receptors 5-HT1A, G protein-coupled	X57829	109760	Rsal
serotonin 5-HT receptors 5-HT4, G protein-coupled	Y08756	602164	none found
small inducible cytokine subfamily A (Cys-Cys), member 2/monocyte	M28226	158105	-2076 (A or T)
chemotactic protein 1/MCP1/SCYA2			
small inducible cytokine subfamily A (Cys-Cys), member 2/monocyte	M28226	158105	-2518 (G or A)
chemotactic protein 1/MCP1/SCYA2			
Solute carrier family 9 (sodium/hydrogen exchanger)	M81768	107310	none found
Steroid 5 alpha reductase 1	M32313	184753	none found
Superoxide dismutase 1 (Cu/Zn)	X02317	147450	
Superoxide Dismutase	NM_0004	147450	T-G, -10, 9-BP INS

SD-144141.1

1/SOD1 (soluble)	54				
Superoxide Dismutase	NM_0004	147450	VS4AS, A-G, -11		
1/SOD1 (soluble)	54				
Superoxide Dismutase	NM_0004	147450		ALA145THR	
1/SOD1 (soluble)	54				
Superoxide Dismutase	NM_0004	147450		ALA44THR	
1/SOD1 (soluble)	54				
Superoxide Dismutase	NM_0004	147450		ALA44VAL	
1/SOD1 (soluble)	54				
Superoxide Dismutase	NM_0004	147450		ASP90ALA	
1/SOD1 (soluble)	54				
Superoxide Dismutase	NM_0004	147450		CYS6PHE	
1/SOD1 (soluble)	54				
Superoxide Dismutase	NM_0004	147450		GLU100GLY	
1/SOD1 (soluble)	54				
Superoxide Dismutase	NM_0004	147450		GLU21LYS	
1/SOD1 (soluble)	54				
Superoxide Dismutase	NM_0004	147450		GLY16SER	
1/SOD1 (soluble)	54				
Superoxide Dismutase	NM_0004	147450		GLY37ARG	
1/SOD1 (soluble)	54				
Superoxide Dismutase	NM_0004	147450		GLY41ASP	
1/SOD1 (soluble)	54				
Superoxide Dismutase	NM_0004	147450		GLY41SER	
1/SOD1 (soluble)	54				
Superoxide Dismutase	NM_0004	147450		GLY72SER	
1/SOD1 (soluble)	54				
Superoxide Dismutase	NM_0004	147450		GLY85ARG	
1/SOD1 (soluble)	54				
Superoxide Dismutase	NM_0004	147450		GLY93ALA	
1/SOD1 (soluble)	54				

Superoxide Dismutase 1/SOD1 (soluble)	NM_0004 54	147450	GLY93CYS
Superoxide Dismutase 1/SOD1 (soluble)	NM_0004 54	147450	HIS43ARG
Superoxide Dismutase 1/SOD1 (soluble)	NM_0004 54	147450	HIS46ARG
Superoxide Dismutase 1/SOD1 (soluble)	NM_0004 54	147450	ILE104THE
Superoxide Dismutase 1/SOD1 (soluble)	NM_0004 54	147450	ILE113THR
Superoxide Dismutase 1/SOD1 (soluble)	NM_0004 54	147450	LEU106VAL
Superoxide Dismutase 1/SOD1 (soluble)	NM_0004 54	147450	LEU126TER
Superoxide Dismutase 1/SOD1 (soluble)	NM_0004 54	147450	LEU144SER
Superoxide Dismutase 1/SOD1 (soluble)	NM_0004 54	147450	LEU38VAL
Superoxide Dismutase 1/SOD1 (soluble)	NM_0004 54	147450	LEU84VAL
Superoxide Dismutase 1/SOD1 (soluble)	NM_0004 54	147450	SER134ASN
Superoxide Dismutase 1/SOD1 (soluble)	NM_0004 54	147450	THR151ILE
Superoxide Dismutase 1/SOD1 (soluble)	NM_0004 54	147450	Val7-->Glu
Superoxide Dismutase 2/SOD2 (mitochondrial)	X65965	147460	ALA16VAL
Tafazzin		300069	none found
Thimet oligopeptidase	Z50115	601117	none found

SD-144141.1

Thrombopoietin	U70136	600044	1-BP DEL, 3252G
Thrombopoietin	U70136	600044	IVS3, G-C, +1
THROMBOSPONDIN		188062	none found
III			
Thromboxane synthase	M80646	274180	(CA)n intron 9
Tissue Plasminogen	M18182	173370	BglII
activator, tissue type (t-PA)			
Tissue Plasminogen	M18182	173370	EcoRI
activator, tissue type (t-PA)			
Tissue Plasminogen	M18182	173370	HincII
activator, tissue type (t-PA)			
Tissue Plasminogen	M18182	173370	polymorphic
activator, tissue type (t-PA)			dinucleotide intron 1
Tissue Plasminogen	M18182	173370	PstII
activator, tissue type (t-PA)			
Tissue Plasminogen	M18182	173370	TaqI
activator, tissue type (t-PA)			
Tissue Plasminogen	M18182	173370	XmnI
activator, tissue type (t-PA)			
Transferrin receptor	X01060	190010	BclI
(p90, CD71)			
Transferrin receptor	X01060	190010	RsaI
(p90, CD71)			
IRNA-LEU,		590050	3243A-G

MITOCHONDRIAL	590050	3250T-C	
trNA-LEU,			
MITOCHONDRIAL	590050	3251A-G	
trNA-LEU,			
MITOCHONDRIAL	590050	3252T-C	
trNA-LEU,			
MITOCHONDRIAL	590050	3256C-T	
trNA-LEU,			
MITOCHONDRIAL	590050	3260A-G	
trNA-LEU,			
MITOCHONDRIAL	590050	3271T-C	
trNA-LEU,			
MITOCHONDRIAL	590050	3303C-T	
trNA-LEU,			
MITOCHONDRIAL	590050	A3288G	
trNA-LEU,			
MITOCHONDRIAL	590050	G --> A 12301	
trNA-LEU,			
MITOCHONDRIAL	603310	none found	
Type V cyclic nucleotide phosphodiesterase	AJ004865		
type V voltage dependent sodium channel alpha subunit/SCN5A	NM_000335	600163	1-BP DEL frameshift
type V voltage dependent sodium channel alpha subunit/SCN5A	NM_000335	600163	2-BP INS
type V voltage dependent sodium channel alpha subunit/SCN5A	NM_0003	600163	

dependent sodium channel alpha subunit/SCN5A	35		LYS1505/PRO1 506/GLN1507D EL
type V voltage dependent sodium channel alpha subunit/SCN5A	NM_0003 35	600163	ARG1232TRP
type V voltage dependent sodium channel alpha subunit/SCN5A	NM_0003 35	600163	ARG1623GLN
type V voltage dependent sodium channel alpha subunit/SCN5A	NM_0003 35	600163	ARG1644HIS]
type V voltage dependent sodium channel alpha subunit/SCN5A	NM_0003 35	600163	GLU1784LYS
type V voltage dependent sodium channel alpha subunit/SCN5A	NM_0003 35	600163	THR1620MET
Vascular cell adhesion molecule 1	M60335	192225	none found
vitamin B12 receptor/cubilin/CUBN	NM_0010 81	602997	IVS6, C-G
vitamin B12 receptor/cubilin/CUBN	NM_0010 81	602997	PRO1297LEU

Table 24. Current Candidate Therapeutic Interventions for the Treatment of Cancer

Product Name	Latest Phase	Chemical Name	Action	Indication
2-chloro-2'-fluoro-vidarabine; 2-chloro-2'-fluoro-araA	Phase I			cancer
A 007	Phase I	bis(4-hydroxyphenyl)-(2,4-dinitrophenyl)-methanone, hydrazone		cancer
acemannan derivatives, Carrington	Preclinical			cancer
adozelesin; U 73975; ADOSAR	Phase II	(7bR)-N-[2-[(4,5,8,8a-tetrahydro-7-methyl-4-oxocyclopropa[c]pyrrolo[3,2-e]indol-2(1H)-yl)carbonyl]-1H-indol-5-yl]-2-benzofurancarboxamide		cancer
AG 7352	Preclinical	(3S-trans)-1,4-dihydro-7-[3-methoxy-4-(methylamino)-1-pyrrolidiny]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid		cancer
aging-related disease therapy, Chiroscience/Geron	Preclinical			atherosclerosis; cancer; osteoporosis; diabetes; eye disease

AK 2123	Phase II	N-(2-methoxyethyl)-3-nitro-1H-1,2,4-triazole-1-acetamide	cancer
alanosine	Phase II	L-2-amino-3-(hydroxynitrosoamino)-L-alanine	cancer
alkyltransferase inhibitors, National Institutes of Health	Preclinical		cancer
altretamine; hexamethylamine; hexamethylmelamine; KB 913; NSC 13875; HEXALEN; HEXASTAT; HEXINAWAS	Marketed	N,N,N',N'',N'''-hexamethyl-1,3,5-triazine-2,4,6-triamine	cancer
amonafide; nafidimide; MFA 142; FA 142	Discontinued	5-amino-2-(2-dimethylamine)ethyl-1H-benz[de]isoquinoline-1,3(2H)-dione	cancer
amsacrine; CI 880; NSC 249992; NSC 156203; AMSIDYL; AMSIDINE; AMSEDINE; AMEKRIN	Marketed	N-[4-(9-acridinylamino)-3-methoxyphenyl]methanesulfonamide	cancer
ANCER	Marketed		cancer; leukopenia
annonaceous acetogenins	Preclinical		cancer
anticancer agent, Gryphon	Preclinical		cancer

anticancer agent, Kyowa Hakko	Preclinical	[1aS-(1aalpha,8beta,8aalpha,8balpha)]-8-[[[(aminocarbonyl)oxy]methyl]-5-ethyl-1,1a,2,8,8a,8b-hexahydro-6,8a-dimethoxyazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione		cancer
anticancer agent, Paracelsian	Preclinical			cancer
anticancer agent, SOAD	Preclinical			cancer
anticancer agent, Xocyte Therapies	Preclinical			cancer
anticancer agents, Millennium	Preclinical			cancer
anticancer, Kitasato University	Preclinical	7,8-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one		cancer
anticancer, New York University	Preclinical	(1-methylethyl)carbamic acid (5,6-dihydro-8-methoxypyrrrolo[2,1-a]isoquinoline-1,2-diy)bis(methylene)ester		cancer
anticancer, Sloan Kettering	Preclinical	3-[[bis(2-chloroethyl)-amino]methyl]-1,8-dihydroxy-9,10-anthracenedione		cancer

anticancer, Southern Research Institute	Preclinical	(1-alpha, 3-beta, 4-alpha)-2-amino-1,9-dihydro-9-(3-hydroxy-4-(phosphonomethyl)cy clopen-6H-purin-6-one	cancer	
anticancer, Takeda	Discontinued	1-octadecyl-2-acetoacetyl-3-glycerol omega-trimethylammoniododecyl phosphate	cancer	
anticancer, Yale University	Preclinical	1-(2-chloroethyl)-2,2-bis(methylsulfonyl)hydrazide	cancer	
antiproliferative agents, Harvard University/Sheffield Medical	Phase I	methanesulfonic acid	cancer; restenosis; psoriasis; atherosclerosis	
antiproliferative therapy, SIDR	Preclinical		cancer	
AP 633	Discontinued		cancer	
AP 656	Discontinued		cancer	
aplidine	Phase I		cancer	
apoptosis modulators, Devgen	Preclinical		cancer; inflammation	
apoptosis regulators, Apoptosis Technology; apoptosis regulators, ICRF	Preclinical		cancer	

AQ6N	Discontinued	1-[[2-(dimethylamino-N-oxide)ethyl]-amino]-4-[[2(ethylamino)ethyl]amino]-5,8-dihydroxyanthracene-9,10-dione		cancer
arginine deaminase; CX 108	Preclinical			cancer
artificial platelets, Andaris; SYNTHOCYTES	Preclinical			thrombocytopenia; cancer
AT 3510	Preclinical			cancer
atrimustine; bestrabucil; busramustine; KM 2210; KREGAN	Discontinued	(17beta)-estra-1,3,5(10)-triene-3,17-diol 3-benzoate 17-[[4-[4-[bis(2-chloroethyl)amino]phenyl]-1-oxobutoxy]acetate] ester		cancer

ATX 70	Preclinical	(SP-4-2)-[[N,N'-[[7,12-bis[1-(decyloxy)ethyl]-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-diyl-kappaN21,kappaN22,kappaN23,kappaN24]bis(1-oxo-3,1-propanediyl)]bis[L-aspartato]](6-)]gallate (3-) trihydrogen		depression; cancer
AV 109	Discontinued			cancer
AV 21; PM 92100	Preclinical	Unspecified		cancer
azalyrosine; SF 1346	Discontinued	(S)-alpha-amino-5-hydroxy-2-pyridinepropanoic acid		cancer
azinomycin A	Discontinued	6-(3-acetoxy-4-hydroxy-1,5-methylenepyrrolidin-2-ylidene)-2,2(oxymethylene)-5,8-diaza-4,7,10-trioxo-undecyl-3-methoxy-5-methyl-1-naphthalenecarboxylate		cancer
azinomycin B	Discontinued			cancer
BCH 1184	Discontinued			cancer
BCH 1667	Discontinued			cancer
BCH 2050	Discontinued			cancer
BD 95325	Discontinued			cancer

BE 12406B	Discontinued				cancer
BE 18591	Discontinued	N-[[3-methoxy-5-(1H-pyrrol-2-yl)-2H-pyrrol-2-ylidene]methyl]-1-dodecanamine			cancer
benzeneacetic acid ester	Phase I	alpha-(benzoyloxy)-alpha-cyclopentyl-benzeneacetic acid, 1-methyl-4-piperidinyl ester			cancer
bFGF inhibitor, PharmaGenics	Discontinued				cancer; cardiovascular disease
bistratene A; bistramide A	Preclinical	tetrahydro-N-[2-hydroxy-4-[[3-[8-(6-hydroxy-3,5-dimethyl-4-heptenyl)-3-methyl-1,7-dioxaspiro[5.5]undec-2-yl]propyl]amino]-3-methyl-4-oxobutyl]-3-methyl-6-(2-oxo-3-pentenyl)-2H-pyran-2-acetamide			cancer
BMOV	Preclinical	bis(maltolato)orthovanadate			cancer

BMS 181174; BMY 25067	Discontinued	[[1aS-(1aalfa,8beta,8aalfa,8balfa)]-8-[[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-6-[[2-[(4-nitrophenyl)dithio]ethyl]amino]azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione		cancer
BMS 181175	Discontinued			cancer
BMS 181176	Discontinued			cancer
BMS 185660; BMS 18566002	Discontinued			cancer
BMY 27577	Discontinued			cancer
BN 52205	Discontinued	4-hydroxy-7-(methoxymethyl)-N,N,N,8-tetramethyl-3,5-dioxa-8-aza-4-phosphahexacosan-1-aminium 4-oxide inner salt		cancer
BN 52207	Discontinued	4-hydroxy-6-(methoxymethyl)-N,N,N,8-tetramethyl-3,5-dioxa-8-aza-4-phosphahexacosan-1-aminium 4-oxide inner salt		cancer

BN 52208	Discontinued	8-hydroxy-N,N,N-trimethyl-5-[(methyloctadecylamino)methyl]-3-oxo-4,7,9-trioxa-2-aza-8-phosphaundecan-11-aminium 8-oxide inner salt		cancer
BN 52210	Discontinued			cancer
BN 52211	Discontinued	4-hydroxy-7-methoxy-N,N,N,9-tetramethyl-3,5-dioxa-9-aza-4-phosphaheptacosan-1-aminium 4-oxide inner salt		cancer
BN 52213	Discontinued			cancer
BN 52214	Discontinued			cancer
BNP 7787, dimesna	Phase I	2,2'-dithiobisethanesulfonic acid disodium salt		cancer
brain tumor therapy, John Wayne Cancer Institute	Phase II			cancer
breast and ovarian cancer therapy, Myriad/Lilly	Preclinical			cancer
breast cancer therapy, Affymax/American Home Products	Preclinical			cancer
breast cancer therapy, Taiho/SRI International	Preclinical			cancer

BW 773U82; 773U82	Discontinued	2-[(3-fluorantheny(methyl)amino)-2-methyl-1,3-propanediol]		cancer
C 1006	Preclinical	N-hexyl-N'-(1-nitro-9-acridinyl)-1,3-propanediamine dihydrochloride		cancer
C 1210S	Discontinued			cancer
C 609	Preclinical	N,N-dimethyl-N'-(1-nitro-9-anthracenyl)-1,5-pentanediamine dihydrochloride		cancer
C 835	Preclinical	2,2'-[[2-[(1-nitro-9-acridinyl)amino]ethyl]imino]bis-ethanol		cancer
CA 102	Discontinued			cancer
cancer therapy polymers, Cornell Research Foundation	Preclinical			cancer
cancer therapy, Agouron	Preclinical			cancer
cancer therapy, ASP 05/ASP 07	Preclinical			cancer
cancer therapy, brca 2 gene, Cancer Research Campaign	Preclinical			cancer
cancer therapy, Bristol-Myers Squibb/Isys	Preclinical			cancer

cancer therapy, Cambridge Neuroscience/Repligen	Preclinical				cancer
cancer therapy, Cell Pathways/Tripos/Panlabs	Preclinical				cancer
cancer therapy, CellPath/Genzyme	Preclinical				cancer
cancer therapy, Chiroscience	Discontinued				cancer
cancer therapy, cytolognans	Phase I				cancer
cancer therapy, Duke University/Targon	Preclinical				cancer
cancer therapy, Galenica/SuperGen	Preclinical				cancer
cancer therapy, GenQuest/ArQule	Preclinical				cancer
cancer therapy, Genzyme	Preclinical				cancer
cancer therapy, Genzyme/Xenova	Preclinical				cancer
cancer therapy, Hughes Institute/Minnesota University	Preclinical				cancer
cancer therapy, ImClone/CombiChem	Preclinical				cancer
cancer therapy, Ku80, Lexicon Genetics	Preclinical				cancer

cancer therapy, Lilly; cancer therapy, Millennium	Preclinical				cancer
cancer therapy, modulators of Rad 51/Bra2 signalling pathway, Lexicon Genetics	Preclinical				cancer
cancer therapy, National Cancer Institute	Preclinical				cancer
cancer therapy, NeoGenesis	Preclinical				cancer
cancer therapy, NOVALON	Preclinical				cancer
cancer therapy, Ontogeny/Brigham & Women's Hospital	Preclinical				cancer
cancer therapy, Ontogeny/University of California San Francisco	Preclinical				cancer
cancer therapy, PharmacoPeia	Preclinical				cancer
cancer therapy, PharmaMar	Preclinical				cancer
cancer therapy, Phytora/Chiron	Preclinical				cancer
cancer therapy, polymeric prodrug	Preclinical				cancer
cancer therapy, Prolifix/BioFocus	Preclinical				cancer

cancer therapy, reovirus, SYNSORB Biotech	Preclinical			cancer
cancer therapy, Shinpoong	Preclinical			cancer
cancer therapy, spiegelmer, Noxxon	Preclinical			cancer
cancer therapy, SUGEN/Zeneca	Preclinical			cancer
cancer therapy, Toyama/Sugen	Preclinical			cancer
CaRest M3	Preclinical			cancer; contraception
CB 10200	Preclinical	5-(aziridin-1-yl)-2,4-dinitro-1-isobutylbenzoate		cancer
CB 10277; CB 10-277	Phase II	4-(3,3-dimethyl-1-triazenyl)benzoic acid		cancer
CB 7646	Preclinical	[[6-(methylamino)-1,3,5-triazine-2,4-diy]]bis(methylimino)bismethanol		cancer
CBT 1	Preclinical			malaria; cancer
CCI 779	Phase I			cancer
CD36 inhibitors, Affymax	Preclinical			cancer
CDC 25	Discontinued			cancer
CDF inhibitor, Prolifix	Preclinical			cancer; psoriasis
cell cycle inhibitors, Cortex	Discontinued			cancer
cell cycle regulators, Janssen/Rigel	Preclinical			cancer

cell cycle regulators, Onyx; cell cycle regulators, Warner Lambert	Preclinical			cancer	
CH 271	Preclinical			cancer	
chloroquinoxaline sulfonamide; chlorsulfaminoxaline ; NSC 339004; CQS	Phase I	4-amino-N-(5-chloro- 2- quinoxaliny)benzene sulfonamide		cancer	
chronic myelogenous leukemia therapy, OSI/Aston Molecules; CML therapy, OSI/Aston Molecules	Discontinued			cancer	
CHS 828	Phase I	N-[6-(4- chlorophenoxy)hexyl] -N'-cyano-N"-4- pyridiny]guanidine		cancer	
CIDI	Preclinical			cancer	
CL 329753	Discontinued	alpha-(3,4- dimethoxyphenyl)- 3,4-dihydro-6,7- dimethoxy-alpha-[(4- methylphenyl)thio]- 2(1H)- isoquinolineheptanen- trile		cancer	
clanfenur; DU 113901	Discontinued	1-(p-chlorophenyl)-3- (6-fluoro-N,N- dimethylanthraniloyl) urea		cancer	

cloturin; VUFB 15686	Suspended	(2-chloroethyl)carbamo- thioic acid, S-1H- purin-6-yl ester		cancer
colon cancer therapy, Onyx	Preclinical			cancer
combretastatin A4; NSC 817373; CRC 8709; CRC 87-09	Preclinical	(Z)-2-methoxy-5-[2- (3,4,5- trimethoxyphenyl)eth- enyl]phenol		cancer
combretastatin A4 prodrug CP 79328	Phase I			cancer
	Preclinical	2- [(aminoininomethyl) amino]-N-(5-fluoro- 2-benzothiazolyl)-4- thiazolecarboxamide		cancer

crambesidin 816; PM 92105	Preclinical	[2'aS- [2'a.alpha.,4'.alpha.(R *),7'.alpha.(S*),8'.bet a.(R*),8'a.alpha.]]-7- ethyl- 1',2',2'a,3',3"4,4",5",6 '7,8',8'a- dodecahydro-8'a- hydroxy-6"- methyldispiro[oxepin- 2(3H),4'-[4H- 5,6,8b]triazacenaphy ylene-7'(5'H),2"- [2H]pyran-8'- carboxylic acid 16- [(4-amino-2- hydroxybutyl)(3- aminopropyl)amino]- 16-oxohexadecyl ester		cancer
	Discontinued			cancer
	Discontinued			cancer
	Discontinued			cancer; restenosis
	Preclinical	2,4 dihydroxymethyl- alpha-terthiophene		cancer
curacin A	Preclinical	4,5-dihydro-4-(11- methoxy-8-methyl- 1,5,7,13- tetradecatetraenyl)-2- (2- methylcyclopropyl)- thiazole		cancer
	Preclinical			cancer
CYC 300	Preclinical			cancer

cyclin D inhibitor, Prolifix	Preclinical				cancer
cyclopentenylcytosine; CPEC	Preclinical	4-amino-1- [(1R,4R,5S)-4,5- dihydroxy-3- (hydroxymethyl)-2- cyclopent en-1-yl]- 2(1H)-pyrimidinone			cancer
D 20133	Discontinued	octadecyl-(2-(N- methylpiperidino)ethyl- l)-phosphate			cancer
D 20566	Discontinued				cancer
D 20567	Discontinued				cancer
D 21621	Discontinued				cancer
D 21663	Discontinued				cancer
D 21805	Discontinued	[2- [[hydroxy(octadecylo xy)phosphinyl]oxy]et hyl]trimethylarsoniu m inner salt			cancer
D 23980	Discontinued				cancer
DA 3030; LEUCOSTIM	Pre- registration				leukopenia; cancer
daniquidone; batracylin; BAY h 2049; NSC 320846	Discontinued	8- aminoisindolo[1,2- b]quinazolin- 12(10H)-one			cancer
dateliptium chloride; SR 95156B; NSC 311152; SR 95156	Discontinued	2-[2- (diethylamino)ethyl]- 9-hydroxy-5,11- dimethyl-6H- pyrido[4,3- b]carbolium chloride			cancer

decitabine; 5-azadeoxycytidine; 5-aza-2'-deoxycytidine; 5-CdR; AZA-DC; DAC; NSC 127716	Phase II	4-amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2 (1H)-one	cancer
dexifosfamide; D 4809	Discontinued	N,3-bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine, 2-oxide	cancer
dexverapamil; verapamil, d-; verapamil, R-(+)-; verapamil, (R)-; verapamil, (+)-; LU 33925	Phase II	(R)-alpha-[3-[[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile	cancer
diaziquone; AZQ; CI 904; NSC 182986	Phase III	[2,5-bis(1-aziridinyl)-3,6-dioxo-1,4-cyclohexadiene-1,4-diyl]biscarbamic acid diethyl ester	cancer

diazonomide A	Preclinical	2-amino-N-[1,26-dichloro-17,18,19,20-tetrahydro-12,31-dihydroxy-20-(1-methylethyl)-18-oxo-2H,16H-24,27-epoxy-10a,6,10-(methanoxymethyno)-11,15-metheno-23,21-nitro[1,4]oxaazacyclotetradecino[14,13-g]pyrrolo[2,3,4-rs][4]benzaazacyclopentadecin-17-yl]-3-methylbutanamide	cancer
differentiation-inducing compounds, Prolifix	Discontinued		cancer; psoriasis; restenosis
dihydro-5-azacytidine; DHAC	Phase II		cancer
DIP C1	Preclinical	N,N,N',N'-tetrakis(2-chloroethyl)-4,8-di-1-piperidinylpyrimido[5,4-d]pyrimidine-2,6-diamine	cancer
diphenyl spiromustine	Preclinical	3-[2-[bis(2-chloroethyl)amino]ethyl]-1,3-diazaspiro[4.5]decane-2,4-dione diphenyl derivative	cancer
distamycin A derivatives, Menarini	Discontinued		cancer

DNA binding agent, Proteus International	Discontinued			bacterial infection; viral infection; cancer; cardiovascular disease
DNA methyltransferase modulators	Preclinical			cancer
docosahexaenoic acid, Heliosynthese; docosahexaenoic acid, Scotia	Discontinued			cancer
DPPE	Phase II	N,N-diethyl-2-[4- (phenylmethyl)pheno xy]ethanamine		cancer; gastrointestinal ulcer
drug delivery system, albumin microcapsules, cytotoxic drugs; CYTOCAPS	Preclinical			cancer; delivery system
drug delivery system, aphidicolin; aphidicolin SPARTAJECT	Preclinical			cancer
drug delivery system, biodegradable polymer paste BMOV; BMOV biodegradable polymer paste	Preclinical			cancer

drug delivery system, chemotherapeutic drugs, ImaRx; MRX-ONC	Preclinical			cancer
drug delivery system, colonic polyp therapy	Phase I			cancer
drug delivery system, intravenous, SPARTAJECT temozolomide; temozolomide SPARTAJECT	Preclinical			cancer
drug delivery system, mitoxantrone; mitoxantrone delivery system; HYAL CV1282	Phase II			cancer
drug delivery system, PepTrans, cancer therapy	Preclinical			cancer
drug delivery system, Polyfunctional Molecular Modification, etoposide; etoposide Polyfunctional Molecular Modification	Preclinical			cancer
drug delivery system, SPARTAJECT busulfan; busulfan SPARTAJECT	Phase I			cancer

drug delivery system, SPARTAJECT etoposide; etoposide SPARTAJECT	Preclinical			cancer
DT 5461	Discontinued	3-[[2-deoxy-6-O-[2-deoxy-3-O-[[[(1-oxododecyl)amino]acetyl]-2-[(1-oxotetradecyl)amino]-4-O-phosphono-beta-D-glucopyranosyl]-3-O-[[[(1-oxododecyl)amino]acetyl]-2-[(1-oxotetradecyl)amino]alpha-D-glucopyranosyl]oxy]pentanedioic acid		cancer
ecomustine; NSC 609224; CY 233	Preclinical	methyl 3-[3-(2-chloroethyl)-3-nitrosoureido]-2,3-dideoxy-alpha-D-arabinohexapyranoside		cancer

ecteinascidin 722; ET 722	Preclinical	[6R-(6alpha,6beta,7beta,13beta,14beta,16alpha,20R*)]-5-(acetyloxy)-2',3',4',6,6a,7,9',13,14,16-decahydro-8,14-dihydroxy-9-methoxy-4,10-dimethylspiro[6,16-(epithiopropoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1'-[1H]pyrido[3,4-b]indol]-19-one		cancer
---------------------------	-------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	--------

<p>ecteinascidin 729; ET 729; E 729; NSC 638718</p>	<p>Preclinical</p>	<p>[6R-(6alpha,6abeta,7beta,13beta,14beta,16alpha,20R*)]-5-(acetyloxy)-3',4',6,6a,7,13,14,16-octahydro-6',8,14-trihydroxy-7',9-dimethoxy-4,10-dimethylspiro[6,16-(epithiopropoxymethano)-7,13-imino-12H-1,3-dioxolo[7,8]isoquinol-3,2-b][3]benzazocine-20,1'(2H)-isoquinolin]-19-one</p>		<p>cancer</p>
-------------------------------------------------------------	--------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	---------------

ecteinascidin 743; ecteinascidin 743 monoacetyl; ET 743; E 743	Phase II	[6R-(6alpha,6abeta,7beta,13beta,14beta,16alpha,20R*)]-5-(acetyloxy)-3',4',6,6a,7,13,14,16-octahydro-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethylspiro[6,16-(epithiopropoxy)methano]-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1'(2H)-isoquinolin]-19-one	cancer	
ED 749; J 107088	Preclinical		cancer	
eflornithine; eflornithine hydrochloride; DFMO; RMI 71782; MDL 71782; MDL 71782A; ORNIDYL	Marketed	2-(difluoromethyl)-DL-ornithine	cancer; trypanosomiasis; skin disease	
EKI 785	Preclinical		cancer	
EL 532	Phase III		anemia; cancer	
elemene	Registered		cancer	

emitefur; BOF A2; LAST-F	Pre- registration	3-[[3-(ethoxymethyl)- 5-fluoro-3,6-dihydro- 2,6-dioxo-1(2H)- pyrimidinyl]carbonyl] benzoic acid 6- (benzyloxy)-3- cyano-2-pyridinyl ester		cancer
eupenifeldin	Discontinued			cancer
FA 15	Preclinical	3-trifluoromethyl-9- (4-diethylamino-1- methylbutylamino) acridine		cancer
FCE 26492	Preclinical	4,4'- [carbonylbis[imino(1- methyl-1H-pyrrole- 4,2- diyl)carbonylimino(1- methyl-1H-pyrrole- 4,2- diyl)carbonylimino]]bis- 1,5- naphthalenedisulfonic acid		cancer

FCE 26605	Preclinical	8,8'-[carbonylbis[imino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino(1-methyl-1H-pyrrole-4,2-diyl)carbonylimino]]bis-1,3,5-naphthalenetrisulfonic acid hexasodium salt		cancer
FCE 26752	Preclinical			cancer
FD 211	Preclinical	3,5,7,7a-tetrahydro-3-hydroxy-5,7-di-1-propenyl-2H-furo[3,4-b]pyran-2-one		cancer
FJ 776	Phase I			cancer
FK 973	Discontinued			cancer
fludarabine + pentostatin; pentostatin + fludarabine	Discontinued			cancer
flurbiprofen, (R)-; E 7869	Phase II			cancer
FO 152	Discontinued	L-valine 5'-ester with 5-fluorouridine monohydrochloride		cancer

FOLLIGEN	Preclinical	6-D-phenylalanine-8-L-glutamine-9-(N-ethyl-L-prolinamide)-10-deglycinamide luteinizing hormone-releasing factor (swine)	cancer	
fosquidone; GR 63178A; NSC D 611615	Discontinued	benzyl 5,8,13,14-tetrahydro-14-methyl-8,13,dioxobenz[5,6]isobindolo[2,1-b]isoquinolin-9-yl ester	cancer	
galocitabine; neofrutulon; Ro 091390; Ro 91390	Phase III	5'-deoxy-5-fluoro-N-(3,4,5-trimethoxybenzoyl)cytidine	cancer	
GAP 31	Preclinical	N-[N-[N-[N-(N-L-lysylglycyl)-L-alanyl]-L-threonyl]-L-tyrosyl]-L-isoleucyl]-L-threonine	HIV infection; cancer	
GBC 590; NCCG	Phase I		cancer	
gene discovery, angiogenesis, Progenitor	Preclinical		cancer; cardiovascular disease; eye disease; skin ulcer	
gene discovery, breast & prostate cancer	Preclinical		cancer	
gene discovery, breast cancer, Amplicon	Preclinical		cancer	

gene discovery, cancer	Preclinical				cancer
gene discovery, cancer	Preclinical				cancer
gene discovery, cancer, AlphaGene	Preclinical				cancer
gene discovery, cancer, Chiron/Hyseq	Preclinical				cancer
gene discovery, cancer, CuraGen	Preclinical				cancer
gene discovery, cancer, deCODE genetics	Preclinical				cancer
gene discovery, cancer, Genaisance/Visible Genetics	Preclinical				cancer
gene discovery, cancer, Genetica/Mitotix	Preclinical				cancer
gene discovery, cancer, Genome Pharmaceuticals	Preclinical				cancer
gene discovery, cancer, Genos Biosciences	Preclinical				cancer
gene discovery, cancer, Genzyme	Preclinical				cancer
gene discovery, cancer, Incyte/OncorMed	Discontinued				cancer
gene discovery, cancer, LifeSpan	Preclinical				cancer

gene discovery, cancer, Micromet	Preclinical			cancer
gene discovery, cancer, Tularik/Amplicon	Preclinical			cancer
gene discovery, colorectal cancer, Myriad	Preclinical			cancer
gene discovery, connective tissue disorders	Preclinical			cancer; diabetes; obesity; autoimmune disease
gene discovery, growth factors, CuraGen	Preclinical			cancer
gene discovery, head and neck cancer	Preclinical			cancer
gene discovery, immunomodulatory genes, asthma, Genelabs	Preclinical			asthma; cancer
gene discovery, liver cancer, GeneCore	Preclinical			cancer
gene discovery, lymphoma, Myriad	Preclinical			cancer
gene discovery, p21 ras signalling pathway, Exelixis	Preclinical			cancer
gene discovery, pancreatic cancer	Preclinical			cancer
gene discovery, prostate and colon cancer, Millennium	Preclinical			cancer

gene discovery, prostate cancer, Amplicon	Preclinical				cancer
gene discovery, prostate cancer, Gene Logic	Preclinical				cancer
gene discovery, prostate cancer, GenSet/Sanofi- Synthelabo	Preclinical				cancer
gene discovery, prostate cancer, Myriad/Schering Plough	Preclinical				cancer
gene discovery, prostate cancer, Progenitor	Preclinical				cancer
genetic suppressor elements, cancer	Preclinical				cancer
GM 1603	Preclinical				cancer
granulocyte colony- stimulating factor mimetic; G-CSF mimetic	Discontinued				cancer
GRB2 antagonists	Preclinical				cancer
growth factor inhibitor, GlycoTech	Preclinical				cancer
growth hormone releasing hormone antagonists; GHRH antagonists	Preclinical				cancer

guanine derivatives, National Cancer Institute	Phase I				cancer
GW 278884; BW 668W95	Preclinical				cancer
halomon; NSC 650893	Suspended	(3S,6R)-6-bromo-3-(bromomethyl)-2,3,7-trichloro-7-methyl-1-octene			cancer
hatomarubigin A; CE 33A	Preclinical	(S)-3,4-dihydro-6-hydroxy-8-methoxy-3-methylbenz[a]anthracene-1,7,12(2H)-trione			cancer
hatomarubigin B; CE 33B	Preclinical	(S)-3,4-dihydro-11-hydroxy-8-methoxy-3-methylbenz[a]anthracene-1,7,12(2H)-trione			cancer
hatomarubigin C; CE 33C	Preclinical	(1S-cis)-1,2,3,4-tetrahydro-1,11-dihydroxy-8-methoxy-3-methylbenz[a]anthracene-7,12-dione			cancer

hatomarubigin D; CE 33D	Preclinical	[1S-[1alpha,3alpha,10(1'R*,3'R*)]]10,10'-methylenebis[1,2,3,4-tetrahydro-1,11-dihydroxy-8-methoxy-3-methylbenz[a]anthracene-7,12-dione		cancer
heat shock transcription factor modulators, ischemia; heat shock transcription factor modulators, cancer	Preclinical			stroke; ischemia; reperfusion injury; cancer
hepsulfam; NSC 329680	Discontinued	1,7-heptanediol-bis-sulfamate		cancer
HO 221	Discontinued	N-[[[4-[(5-bromo-2-pyrimidinyl)oxy]-3-chlorophenyl]amino]carbonyl]-2-nitrobenzamide		cancer
holmium 166 chitosan; DW 166HC	Phase II			cancer; rheumatoid arthritis
HPV E2 inhibitor, Signal	Preclinical			viral infection; cancer
HPV E6 inhibitors, PharmaGenics	Discontinued			cancer
HRP monomer	Preclinical			cancer
human fetal alpha fetoprotein; alpha fetoprotein; DDS-DEA	Marketed			cancer

SD-144110.1

human papilloma virus 16 inhibitor, Xenova	Discontinued			cancer; viral infection
ICC 03	Discontinued			cancer
ICI 198583	Suspended	2-desamino-2-methyl-N10-propargyl-5,8-dideazafofolic acid		cancer
ICO 15	Discontinued			cancer
ifosfamide + methylene blue; methylene blue + ifosfamide; D 7991	Discontinued			cancer
IKP 104	Preclinical	1-(2-chloro-3,5-dimethoxyphenyl)-2-(4-fluorophenyl)-3-methyl-6-phenyl-4(1H)-pyridinone		cancer
IL 101	Preclinical			cancer
IL-6 production inhibitors, Signal	Preclinical			osteoporosis; cancer
IndH (RuInd2Cl4)	Preclinical	trans-indazolium-bisindazole tetrachloro ruthenate III		cancer
inhibitor of mevalonate incorporation into cholesterol; IMIC	Discontinued			cancer; hyperlipidemia
ipomeanol, 4-; 4-ipomeanol; IPO; NSC 349438	Phase I	1-(3-furanyl)-4-hydroxy-1-pentanone		cancer
isobenzogazole	Discontinued			cancer

isohomohalicondrin B	Discontinued	51-de(carboxymethyl)-12,13-dideoxy-51-(4-hydroxy-2-oxobutyl)norhalicondrin A	cancer	
IZP 94002; PHOSPHONATE	Preclinical		cancer	
JP 7	Preclinical		cancer; surgery; heart ischemia; stroke	
kahalalide F; PM 92102	Preclinical	N-(5-methyl-1-oxohexyl)valylthreonylvalylvalyl-D-prolyl-L-ornithyl-D-alloisoleucylthreonyl-D-alloisoleucylvalyl-L-phenylalanyl-(Z)-2,3-didehydro-2-aminobutanoyl-valine rho-lactone	cancer; viral infection	
Kaposi's sarcoma-associated herpes virus (KSHV) infection therapy	Preclinical		herpes; cancer	
KI 414	Preclinical	5'-O-(N-acetyl-4,7,8,9-tetra-O-acetyl-1-methylneuraminosyl)-5-fluoro-2',3'-O-(1-methylethylidene)uridine	cancer	

kinesin modulator, Cytokinetics	Preclinical				cancer
KNK 41	Preclinical	(all-E)-5-hydroxy-4-(8-phenyl-1,3,5,7-octatetraenyl)-2(5H)-furanone			cancer
KT 6124	Discontinued	(9alpha,10alpha,12alpha)-2-amino-9,10,11,12-tetrahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-1,3(2H)-dione			cancer
KW 2149, KT 6149	Phase I	7-N-[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]mitomycin C			cancer
KW 2170	Phase I				cancer
KYN 54	Discontinued	5-hydroxy-4-(2-phenyl-(E)-ethenyl)-2(5H)-furanone			cancer
LAC 83	Preclinical				cancer

lamellarin-N triacetate	Discontinued	(+)-3,11-bis(acetyloxy)-14-[3-(acetyloxy)-4-methoxyphenyl]-2,12-dimethoxy-6H-[1]benzopyrano[4',3':4,5]pyrrolo[2,1-a]isoquinolin-6-one	cancer	
LDI 200	Phase III		cancer	
lissoclinamide 7	Preclinical	[3R-(3R*,4S*,7R*,11R*,14R*,18R*,21S*,26aS*)]-6,7,12,13,14,17,18,20,21,24,25,26,26a-decahydro-3-methyl-7-(1-methylethyl)-16,21-bis(phenylmethyl)-3H,10H-4,11,18:15-trinitrilo-1H-pyrrolo[2,1-c][1,11,18,4,7,14,21]oxadithiatetraazacyclotetracosine-5,12,19,22(4H,11H)-tetrone	cancer	
lonbricine	Discontinued	L-serine 2-[(aminoiminomethyl)amino]ethyl hydrogen phosphate (ester)	cancer	

lonidamine; dichloroacetic acid; AF 1890; KN 228; DORADAMINA	Marketed	1-(2,4-dichlorobenzyl)-1H-indazole-3-carboxylic acid	cancer
LY 195448	Discontinued	(R)-4-[3-[(2-hydroxy-2-phenylethyl)amino]-3-methylbutyl]benzamide monohydrochloride	cancer
LY 296329; 296329	Preclinical		cancer
LY 320236	Phase I	(4aR-trans)-8-[(4-ethyl-2-benzothiazolyl)thio]-1,4,4a,5,6,10b-hexahydro-4,10b-dimethylbenzo[f]quinolin-3(2H)-one	benign prostate hypertrophy; cancer
lysolecitin; lysolecithin; T 680	Discontinued		cancer
mamastatin	Phase I	Unspecified	cancer

MC 77	Preclinical	[1aS-(1aalfa,8beta,8aalfa,8balfa)]-8-[[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-6-[[4-[(2,3,4,6-tetra-O-acetyl-beta-D-glucopyranosyl)oxy]phenyl]amino]azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione	cancer
MDL 27048	Suspended	(E)-1-(2,5-dimethoxyphenyl)-3-[4-(dimethylamino)phenyl]-2-methyl-2-propen-1-one	cancer
melanoma therapy, Ventana Genetics	Preclinical		cancer
melarsoprol; RP 3854	Marketed	2-[4-[(4,6-diamino-1,3,5-triazin-2-yl)amino]phenyl]-1,3,2-dithiar solane-4-methanol	cough; cancer
MEN 10710	Discontinued		cancer
merbarone; V 1235; NSC 336628; NSC 336028	Phase II	hexahydro-4,6-dioxo-N-phenyl-2-thioxo-5-pyrimidinecarboxamide	cancer
METCYCLOR	Preclinical		cancer

MGI 222	Discontinued				cancer
MGI 650	Discontinued				hyperammonemia; cancer
MIF inhibitor, NIH; macrophage migration inhibitory factor inhibitor, NIH	Preclinical				cancer
mitoflaxone; flavone acetic acid; FAA; LM 975; NSC 347512	Discontinued	4-oxo-2-phenyl-4H-1- benzopyran-8-acetic acid			cancer
mitomycin analogues, Georgetown University	Discontinued				cancer
mitoxantrone; CL 232315; NSC 279836; NSC 301739; DHAQ; DHAD; NOVANTRONE; NOVATRON	Marketed	1,4-dihydroxy-5,8- bis[[2-[(2- hydroxyethyl)amino]e thyl]amino]-9,10- anthracenedione			cancer; multiple sclerosis
MM-COOK	Preclinical	4-(3-methyl-1- triazenyl)benzoic acid, monopotassium salt			cancer
mofarotene; Ro 408757	Discontinued	(E)-4-[2-[4-[2- (5,6,7,8-tetrahydro- 5,5,8,8-tetramethyl-2- naphthalenyl)-1- propenyl]phenoxy]eth yl]morpholine			cancer

monophosphoryl lipid A + trehalose dimycolate; trehalose dimycolade + monophosphoryl lipid A; MPL + THD; OVAMID	Discontinued			cancer
mopidamol; RA 233; OLX 102; AR 102; RAPENTON	Withdrawn	2,2',2'',2'''-[(4- piperidinopyrimido[5, 4-d]pyrimidine-2,6- diyl)dinitrilo]tetraetha nol		cancer
MPC 467	Preclinical			cancer
MS 247	Preclinical	[3-[[5-[5-[[[4-[bis(2- chloroethyl)amino]phe nyl]amino]carbonyl]- 1H-benzimidazol-2- yl]-1-methyl-1H- pyrrol-3-yl]amino]-3- oxopropyl]dimethylsu lfonium mono(4- methylbenzenesulfon ate) salt with 4- methylbenzene sulfonic acid (1:1)		cancer
MSI 1290	Discontinued			cancer
MSI 130	Discontinued			cancer; gastrointestinal disorder
MSI 1436	Discontinued			viral infection; restenosis; diabetes; cancer
MSI 511	Discontinued			cancer

MSI 58	Discontinued			cancer
MSI 782	Discontinued			cancer
MSI 99	Discontinued			cancer
MT 1	Suspended			cancer
MT 2	Preclinical			cancer
multiple drug resistance gene inhibitor, Immunex	Preclinical			cancer
mustard anticancer agent; NORPRAN	Preclinical			cancer
MX 6; MX6	Phase III			cancer
mycaperoxide B; PM 92104	Discontinued	[1R- [1alpha,1[3S*(S*),6S *],2alpha,4alpha,8ab eta]]-6-[2- (decahydro-1- hydroxy-2,5,5,8a- tetramethyl-1- naphthalenyl)ethyl]- alpha,6-dimethyl-1,2- dioxane-3-acetic acid		cancer
mycobacterial cell wall extract; MCWE; REGRESSIN	Phase II			cancer
myriaporone	Discontinued			cancer
N 1554	Discontinued	(all-E)- 3,7,11,15,19,23,27,31 ,35,39-decamethyl- 6,10,14,18,22,26,30,3 4,38- tetracontanonaen-1-ol dihydrogen phosphate		cancer

N-acetyldinaline; acetyldinaline; CI 994; GOE 5549; PD 123654	Phase II	4-(acetylamino)-N-(2-aminophenyl)benzamide	cancer
NC 381	Preclinical		cancer
NC 383	Preclinical		cancer
NC 384	Preclinical		cancer
NC 407	Preclinical		cancer
nelarabine; nelzarabine; 506U78; BW 506U; MAY; 506U	Phase III	9-beta-D-arabino-furanosyl-6-methoxy-9H-purin-2-amine	cancer
NIK 264	Phase I		cancer
NK 242	Preclinical	4-(5,6-dihydro-1,4-dioxin-2-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid bis[3-(3-pyridinyl)propyl] ester	cancer
NK 250	Preclinical	4-(5,6-dihydro-3-methyl-1,4-dithiin-2-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid bis(4-pyridinylmethyl) ester	cancer

NK 252	Preclinical	4-(5,6-dihydro-1,4-dioxin-2-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid bis[(5-ethyl-2-pyridinyl)methyl] ester	cancer	
NM 324	Phase I	2-[[hydroxy[[12-[3-(iodo-125I)phenyl]dodecyl]oxy]phosphinyl]oxy]-N,N,N-trimethylethanaminium inner salt	cancer	
noscapine; narcosine; methoxyhydrastine; opian; opianine; NSC 5366; COSCOPIN; COSCOTABS; CAPVAL; KEY-TUSSCAPINE; NOSCAPAL; TERBENOL	Marketed		cough; cancer	
notch signalling pathway modulators, Exelixis	Preclinical		stroke; cognitive defect; cancer	
NSC 242557	Preclinical	[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]propanedinitrile	cancer	

NSC 303861	Discontinued	S-(N-methylcarbamate)-L-cysteine, ethyl ester, monohydrochloride	cancer	
NSC 361456	Phase I	N-nitrosopyrazinamine, sodium salt	cancer	
NSC 639829	Preclinical	dimethyl amino benzoylphenylurea	cancer	
NSC 650573	Preclinical	(Z)-2-methyl-9-(phenylimino)naphth[2,3-d]oxazol-4(9H)-one	cancer	
NSC 686288	Preclinical	5-amino-2-(4-amino-3-fluorophenyl)-6,8-difluoro-7-methyl-4H-1-benzopyran-4-one	cancer	
OC 144093	Preclinical		cancer	
OCT 1001	Preclinical	6-amino-1,2-benzopyrone	viral infection; cancer	
okicenone	Preclinical	3,4-dihydro-4,6,9-trihydroxy-8-methyl-1(2H)-anthracenone	cancer	
OLX 516	Discontinued		septic shock; cancer; vascular leakage	
ONO FS045	Discontinued		cancer	
oracin; VUFB 16956	Phase I	6-[2-[(2-hydroxyethyl)amino]ethyl]-5H-indeno[1,2-c]isoquinoline-5,1(6H)-dione	cancer	

oral cytokine inducer, Phase I Immunex				cancer, leukopenia
p 154	Preclinical			cancer
p185 inhibitors, University of Pennsylvania	Preclinical			cancer
p53 function activators, Genzyme	Preclinical			cancer
p53 mimetic, BioNumerik	Preclinical			cancer
p53/MDM2 interaction inhibitor, Genzyme	Preclinical			cancer
PA 8	Preclinical	2,2'-[(1,1,3,3-tetrabutyl-1,3-distannoxanediyl)]bis(oxy-carbonyl)]bis[4-methoxyphenol]		cancer
palauamine	Discontinued	[3aalpha,10alpha,11beta,12beta,13beta(S*),13aalpha,13bR*]-(-)-2,2'-diamino-11-(aminomethyl)-12-chloro-1,1',3a,5',10a,11,12,13a-octahydro-5'-hydroxyspiro[8H-cyclopenta[3,4]pyrrol-6,1,2-a]imidazol[4,5-b]pyrrolo[1,2-d]pyrazine-13(10H),4'-[4H]imidazol]-8-one		cancer

palmitoyl-rhizoxin; RS 1541	Preclinical	2,3,11,12-diepoxy-8,12-dimethyl-7,13-dihydroxy-15[3-methoxy-4,8-dimethyl-9-(2-methyl-4-oxazolyl)octa-4,6-dien-2-yl]-9-pentadecenolide-5-acetic acid gamma-lactone	cancer
panaxytriol	Preclinical	1-heptadecene-4,6-diyne-3,9,10-triol	cancer
pazelliptine; BD 40; SR 95225A; SR 95225	Discontinued	N,N-diethyl-N'-(6-methyl-5H-pyrido[3',4':4,5]-pyrrolo[2,3-g]isoquinolin-10-yl)-1,3-propanediamine	cancer
PEPTIDYL MIM	Preclinical		cancer; bacterial infection
PG 2	Phase I		anemia; cancer; leukopenia
PG 266	Preclinical		anemia; cancer; leukopenia
PG 278	Discontinued		cancer
PG 349	Discontinued		cancer; anemia
PG 356	Discontinued		cancer; viral infection
PG 36	Discontinued		cancer; viral infection
PG 4336	Discontinued		cancer; viral infection

PG 488	Discontinued				cancer; anemia
phenethyl isothiocyanate	Phase I				cancer
picibanil; OK 432; OK 5; PCB 45; PICIBANIL; PICIVANYL	Marketed				cancer
piroxantrone; oxathrazole; oxantrazole; CI 942; PD 111815; NSC 349174; DUP 942	Discontinued	5-[(3-aminopropyl)amino]-7,10-dihydroxy-2-[2-[(2-hydroxyethyl)amino]ethyl]anthral[1,9-cd]pyrazol-6(2H)-one			cancer
PKH 135	Discontinued				cancer; ischemia; reperfusion injury
platinum compounds, BioNumerik	Preclinical				cancer
PM 14	Preclinical	hepta-mu-oxo-mu6-oxodioxo(penta-mu-oxotetraoxotetratungstate)divanadate(4-) tetrapotassium			cancer
PM 24	Preclinical	polyoxotungstate			cancer
PM 40; JM 1490	Preclinical	(aquanickelate)[mu12-[orthosilicato(4)-O:O:O:O':O':O":O' O":O":O":O"]tetraco-sa-mu-oxoundecaoundecalingstate(6-) hexapotassium			cancer
PM 90001	Preclinical				cancer

PM 91101	Preclinical			cancer
PM 91102	Preclinical			cancer
PM 92127	Preclinical			cancer
PM 92130	Preclinical			cancer
PM 93100	Preclinical			cancer
PM 93107	Discontinued			cancer
PM 93113	Preclinical			cancer
PM 94103	Preclinical			cancer
PM 94127	Preclinical			cancer
PM 94132	Preclinical			cancer
PNU 153429	Phase I	2,2'-[carbonylbis[imino(1-methyl-1H-pyrrole-4,2-diy)]carbonylimino(1-methyl-1H-pyrrole-4,2-diy)]carbonylimino]]bis-1,5-naphthalenedisulfonic acid tetrasodium salt		cancer
PNU 157911	Preclinical			cancer
PNU 166196	Preclinical			cancer
podophyllotoxin analogues, IGT Pharma	Preclinical			cancer
poly ADP-ribose polymerase inhibitor; PARP inhibitor	Preclinical			cancer
protein kinase RNA-activated based therapeutics, RiboGene	Preclinical			cancer; viral infection

PX 12	Preclinical				cancer
pyrazoloacridine; pyrazoloacridine hydrochloride; PD 115934; NSC 366140	Phase I	9-methoxy-N,N- dimethyl-5- nitropyrazolo[3,4- k]acridine-2(6H)- propanamine			cancer
RA 700; RA VII; TPC-B	Suspended	5-(N-methyl-L- tyrosine)-6-(3- hydroxy-N,O- dimethyl-L- tyrosine)bouvardin			cancer
raf antagonists, SUGEN	Preclinical				cancer
ras geranylgeranylation inhibitors	Preclinical				cancer
ras inhibitors, ProScript	Preclinical				cancer
ras-GAP inhibitor, Xenova	Discontinued				cancer
retelliptine; SR 95325; SR 95325B	Discontinued	1-[[3- (dimethylamino)prop yl]amino]-9-methoxy- 5,11-dimethyl-6H- pyrido[4,3- b]carbazole			cancer
retelliptine demethylated	Discontinued				cancer
rice-bran saccharide; RBS; SPR 901	Discontinued	(1-3),(1-6)-alpha-D- glucan			cancer
RL 344007; NORPRAM	Preclinical				cancer

SD-144110.1

RSR 4	Preclinical	2-[4-[2-[(3,5-dichlorophenyl)amino]-2-oxoethyl]phenoxy]-2-methylpropanoic acid	cancer; surgery; heart ischemia; stroke
RSR 46	Preclinical	2-[4-[2-[(2,3-dihydro-1H-inden-5-yl)amino]-2-oxoethyl]phenoxy]-2-methylpropanoic acid	cancer; surgery; heart ischemia; stroke
salvianolic acid A	Preclinical		cancer
sarcodictyins	Preclinical		cancer
SC 101i; SC 101c; EPAKEX	Phase III	1-(z,z,z,z,z-eicosa-5,8,11,14,17-pentaenoyloxy)-3-(z,z,z,z,z-eicosa-5,8,11,14,17-pentaenoyloxy)propane	cancer; cachexia
SC 101a; GLAMEPA	Preclinical	1-(z,z,z,z-octadeca-6,9,12-trienoyloxy)-3-(z,z,z,z,z-eicosa-5,8,11,14,17-pentaenoyloxy)-3-(z,z,z,z,z-eicosa-5,8,11,14,17-pentaenoyloxy)propane	cancer
SC 101g; MEGLUMINE-GLA	Phase I	meglumine-z,z,z-6,9,12-octadecatrienoate	cancer
SC 101i	Preclinical	meglumine-6,9,12-octadecatrienoate	cancer

SCHAL 3	Phase I			skin disease; cancer; psoriasis
Sdi 1 mimetics, SENNES	Discontinued			cancer
SDK 110	Preclinical	3-[[3-(trimethylsilyl)propylthio]-1-propanamine]		cancer
SDZ MKT 077; MKT 077; FJ 776	Phase I	1-ethyl-2-[[3-ethyl-5-(3-methyl-2(3H)-benzothiazolylidene)-4-oxo-2-thiazolidinylidene]methyl]pyridinium chloride		cancer
SE 12363	Preclinical			cancer
selenium thiosemicarbazone; NEOSTAT	Preclinical			cancer
SF 2698	Preclinical	(6S)-iminoazacyclohexa-3-ene-6-carboxylic acid		cancer
sialyl transferase inhibitor, Biota	Preclinical			cancer
SJ 3249	Preclinical	4-(3,5-dimethylphenyl)-N-(2-methoxy-5,6-dimethyl-3-pyridinyl)-1-piperazinecarboxamide		cancer
sodium phenylacetate; EL 530	Phase III	sodium phenylacetate		cancer

spirodian 3; diam 3; PE 1001	Discontinued	2,2,4,4-tetrakis(1-aziridinyl)-2,2,4,4-tetrahydro-1,3,5,7,11-pentaaza-2,4,6.lambda.5-triphosphaspiro[5.5]undeca-1,3,5-triene		cancer
spongistatin 1	Discontinued			cancer
SR 26050	Discontinued	(1-(3-diethylaminopropylamino))-9-hydroxyellipticine dihydrochloride		cancer
SR 271425	Phase I			cancer
SR 45023a; SR 45023	Phase I	[2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]ethylidene]bis-phosphonic acid tetrakis(1-methylethyl) ester		cancer
ST 30	Preclinical	(E)-4-[2-(3,4-diisopropylphenyl)-1-propenyl]benzoic acid		cancer
ST 40	Preclinical	(E)-4-[2-(3-tert-butylphenyl)ethenyl]benzoic acid		cancer

stipiamide; fenalamid A1; phenalamide A1	Preclinical	[12R- [1(S*),2E,4E,6Z,8E,1 0E,12R*,13R*,14E,1 6S*]]-13-hydroxy-N- (2-hydroxy-1- methylethyl)- 2,10,12,14,16- pentamethyl-18- phenyl-2,4,6,8,10,14- octadecahexaenamide		cancer
SU 201	Discontinued			cancer
SU 65591	Preclinical			cancer
SUN 4599	Discontinued	2-alpha-L- arabinopyranosyl-9- hydroxy-5,11- dimethyl-6H- pyrido[4,3- b]carbazolium bromide		cancer
superfibronectin	Preclinical			cancer
suramin; CI 1003; METARET	Marketed	8,8'- [carbonylbis[imino- 3,1- phenylene]carbonylimi no(4-methyl-3,1- phenylene)carbonyli mino]]bis-1,3,5- naphthalenetrisulfonic acid		parasitic infection; cancer

swainsonine; (-)-swainsonine; swainsonine hydrochloride; GD 0039	Phase II	[1S-(1alpha,2alpha,8beta,8abeta)]-octahydro-1,2,8-indolizinetriol	cancer; viral infection
T4GEN	Phase I		HIV infection; cancer
TAC 903	Preclinical	chrome-8-acetic acid	cancer
tamoxifen methiodide; PA 50300	Preclinical		cancer
TBC 1635	Preclinical		retinopathy; cancer
tBCEU	Preclinical	4-tert-butyl-[3-(2-chloroethyl)ureido]benzene	cancer
TER 286	Preclinical	(2R)-L-gamma-glutamyl-3-[[2-[[bis(bis(2-chloroethyl)amino]phosphoryl)oxy]ethyl]sulfonyl]-L-alanyl-2-phenyl-glycine	cancer

thaliblastine; taliblastine; thalicarpine; (+)- thalicarpine; TBL; thalicarpin; NSC 68075	Phase III	[S-(R*,R*)]-9-[4,5-dimethoxy-2-[(1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl)methyl]phenoxy]-5,6,6a,7-tetrahydro-1,2,10-trimethoxy-6-methyl-4H-dibenzo[de,g]quinoline	cancer
thrombopoietin mimetic, Axys	Discontinued		cancer; thrombocytopenia
TJ 14026	Discontinued		cancer
transforming growth factor beta receptor inhibitors, Affymax	Preclinical		cancer
triacetyluridine	Phase I		cancer
tricitiribine; NSC 154020; TCN	Preclinical	1,5-dihydro-5-methyl-1-beta-D-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene-3-amine	HIV infection; cancer
TRIFENS	Preclinical		diarrhea; gastrointestinal disorder; sickle cell anemia; cancer
TT 62	Discontinued	5-fluoro-2'-deoxyuridine 5'-tetradecylphosphate	cancer

tucarecol; BWA 589C; BW 589C80; BW 589C; 589C	Phase II	4-[(2-formyl-3-hydroxyphenoxy)methyl]benzoic acid	sickle cell anemia; viral infection; HIV infection; cancer; hepatitis
tumor suppressor genes, oncology, Onyx	Preclinical		cancer
tumor suppressor genes, Onyx	Preclinical		cancer
U 77863	Discontinued	trans-3-(2'-methylphenyl)-2-propene-1-carboxamide	cancer
UBC 10 inhibitors, cancer, ProScript	Preclinical		cancer
UK 21	Preclinical	N-(1-oxo-2-propylpentyl)glycine triester with 5-fluorouridine	cancer
V 489	Phase I		cancer
VA 5	Preclinical	6-(2,5-dimethoxyphenyl)-2,3-dihydroimidazo[2,1-b]thiazole	heart failure; cancer
variolin B	Discontinued		cancer; viral infection
VDacac	Preclinical		cancer; contraception
VDDTC	Preclinical		cancer; contraception
velaresol; BW 12C79; Suspended 12C	Suspended	5-(2-formyl-3-hydroxyphenoxy)-pentanoic acid	cancer; sickle cell anemia
VG 18563	Preclinical		anemia; cancer

vitamin B12 growth blockers, Receptagen	Preclinical			cancer	
WIN 33377	Discontinued	N-[[1-[[2-(diethylamino)ethyl]amino]-9-oxo-9H-thioxanthen-4-yl]methyl]-methanesulfonamide		cancer	
XK 469	Preclinical			cancer	
Y 25510	Discontinued	(+,-)-3-[4-[2-(dimethylamino)-1-methylethoxy]phenyl]-1H-pyrazolo[3,4-b]pyridine-1-acetic acid		cancer	
YM 534	Phase I	6-[4-[[5-(1H-imidazol-1-yl)pentyl]oxy]phenoxyl]-2,2-dimethylhexanoic acid ethyl ester monohydrochloride		cancer	
YW 200	Preclinical			cancer	
YW 213	Preclinical			cancer	
ZD 2767P	Phase I	N-[[4-bis(2-iodoethyl)amino]phenoxycarbonyl]-L-glutamic acid		cancer	
ZD 9063P	Preclinical			cancer	
zilascorb; ZOXXOZ	Suspended	5,6-O-((RS)-benzylidene-alpha-L)-L-ascorbic acid		cancer	

zinostatin stimalamer; drug delivery system; neocarzinostatin; neocarzinostatin delivery system; YM 881; SMANCS	Marketed	zinostatin stimalamer	cancer
ZK 119010	Preclinical	2-(4-hydroxyphenyl)- 3-methyl-1-[6-(1- pyrrolidinyl)hexyl]- 1H-indol-5-ol	cancer
ZYN 176	Suspended		cancer
ZYN-LINKER conjugated thiocolchicine analogues	Preclinical		cancer
epiristeride; SKF 105657; ONO 9302	Discontinued	17beta-[[[(1,1- dimethylethyl)amino] carbonyl]androst- 3,5-diene-3- carboxylic acid	benign prostate hypertrophy; cancer; alopecia; acne
finasteride; MK 906; MK 0906; YM 152; PROSCAR; FINASPROS; CHIBRO- PROSCAR; FINASTID; PROSTIDE; EUTIZ; PRODEL; PROPECIA	Marketed	(5alpha,17beta)-N- (1,1-dimethylethyl)- 3-oxo-4-azaandrost-1- ene-17-carboxamide	cancer; benign prostate hypertrophy; alopecia; acne
I 23	Discontinued	5 alpha reductase inhibitor	cancer; acne; hirsutism

A 63162	Preclinical	N-hydroxy-N-[1-[4-(phenylmethoxy)phenyl]ethyl]acetamide	5 lipoxygenase inhibitor	cancer
masoprocol; CHX 100; ACTINEX	Marketed	(R*,S*)-4,4'-(2,3-dimethyl-1,4-butanediyl)bis-1,2-benzenediol	5 lipoxygenase inhibitor	skin disease; cancer; psoriasis
SC 41661A	Discontinued		5 lipoxygenase inhibitor	cancer
KBR 8498	Preclinical	(1alpha,2alpha,4beta)-4-[[2-(1-piperazinyl)-4-quinazolinyl]oxy]-1,2-cyclopentanediol	5HT agonist	cancer
EF 7412	Preclinical	N-3-[4-[4-(tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butyl]-1-piperazinyl]phenylethanesulfonamide	5HT antagonist; 5HT1A antagonist; glutamate release inhibitor	neurodegeneration; depression; cancer
adecypenol; OM 3223	Preclinical	5-(7,8-dihydro-8-hydroxyimidazo[4,5-d][1,3]diazepin-3(4H)-yl)-3-(hydroxymethyl)-3-cyclopentene-1,2-diol	adenosine deaminase inhibitor	cancer

pentostatin; 2'-deoxycorformycin; covidarabine; CI 825; NSC 218321; PD 81565; CL 67310465; YK 176; NIPENT; COFORIN	Marketed	(R)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol	adenosine deaminase inhibitor	cancer
adenosine allosteric modulators, Medco	Preclinical		adenosine regulating agent	cardiovascular disease; cancer; stroke
OCT 1003	Preclinical	3-nitrosobenzamide	ADPRT ligand	cancer
OCT 1004	Preclinical	6-nitroso-1,2-benzopyrone	ADPRT ligand	cancer
forfenimex; forphenicinol; BF 121	Discontinued	(S)-alpha-amino-3-hydroxy-4-(hydroxymethyl)benzoic acid	alkaline phosphatase inhibitor; immunostimulant	bacterial infection; cancer
ambamustine; PTT 119; BLASTOP	Phase III	N-[3-[bis(2-chloroethyl)amino]-N-(4-fluoro-L-phenylalanyl)-L-phenylalanyl]-L-methionine, ethyl ester	alkylating agent	cancer
bistriazenes, NIH	Preclinical		alkylating agent	cancer
bizelesin; U 77779; NSC 615291	Phase I	[S-(R*,R*)]-6,6'-[carbonylbis(imino-1H-indole-5,2-diylcarbonyl)]bis[8-(chloromethyl)-3,6,7,8-tetrahydro-1-methylbenzo[1,2-b:4,3-b']dipyrrol-4-ol	alkylating agent	cancer

carzelesin; U 80244	Phase II	N-[2-[[1-(chloromethyl)-1,6-dihydro-8-methyl-5-[[[(phenylamino)carbo-nyl]oxy]benzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-1H-indol-5-yl]-6-(diethylamino)-2-benzofurancarboxamide	alkylating agent	cancer
CBS 5	Discontinued	4-[3-(2-chloroethyl)-1-(benzyl)-2-triazenyl]-1,4-dioxobutyl-beta-alanyl-tryptophyl-methionyl-aspartyl-phenylalaninamide	alkylating agent	cancer
DABIS maleate; NSC 262666	Preclinical	1,4-bis(2-chloroethyl)-1,4-diazoniabicyclo[2.2.1]heptane ((Z)-2-butenedioate (1:2)	alkylating agent	cancer

drug delivery system, camustine biodegradable implant; drug delivery system, sustained release BCNU; BIODOL BCNU implant; camustine delivery system; prolifeptosan 20, camustine implant; GLIADEL; GLIADEL WAFER	Marketed			alkylating agent	cancer
electrophilic alkylating agents, BioNumerik	Preclinical			alkylating agent	cancer
EO 9; NSC 382459	Phase II	(E)-5-(1-aziridinyl)-3-(hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1-methyl-1H-indole-4,7-dione		alkylating agent	cancer
estramustine analogue	Phase II			alkylating agent	cancer
glufosfamide; D 19575	Phase I	1-[N,N'-bis(2-chloroethyl)phosphorodiamidate]-beta-D-glucopyranose		alkylating agent	cancer
glutathione S-transferase-activated toxins, Telik	Discontinued			alkylating agent	cancer
isopropyl pyrrolizine derivative; IPP	Discontinued			alkylating agent	cancer
KF 22678	Preclinical			alkylating agent	cancer

mafosfamide; mefosfamide; ASTA Z 7557; NSC 345842; ASTA Z 7654; Z 7557	Discontinued	cis-(+,-)-2-[[2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorin-4-yl]thio]ethanesulfonic acid P-oxide	alkylating agent	cancer
melphalan + A-MSH; F1K	Discontinued		alkylating agent	cancer
melphalan + L-amino oxidase	Preclinical		alkylating agent	cancer
OCX 177; OCX 0177	Preclinical		alkylating agent	cancer
porfirimycin; porfirimycine; N- methylmitomycin C; ENT 50825; NSC 56410; U 14743; PROMYCIN	Phase III	[1aS- (1a.alpha.,8.beta.,8a.alpha.,8b.alpha.)]-6-amino-8- [[[(aminocarbonyl)oxy [methyl]- 1,1a,2,8,8a,8b-hexahydro-8a-methoxy-1,5-dimethyl- azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione	alkylating agent	cancer
SBR 11170; SBR 170	Preclinical		alkylating agent	cancer
temozolomide; methazolastone; SCH 52365; CCRG 81045; NSC 362856; M&B 39831; TEMODAL	Marketed	3,4-dihydro-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide	alkylating agent	cancer
treosulfan; OVASTAT; TREOSULFAN	Marketed	L-threitol 1,4-dimethanesulfonate	alkylating agent	cancer

PNU 159548	Phase I	(7S-cis)-9-acetyl-7-[[3-(1-aziridinyl)-2,3,6-trideoxy-4-O-(methylsulfonyl)-alpha-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione	alkylating agent; DNA intercalator	cancer
mitolactol; bromoalcohol; dibromodulcitol; DBD; NSC 104800; MITOLACTOL; METHOLACTOLE; ELOBROMOL	Marketed	1,6-dibromo-1,6-dideoxygalactitol	alkylating agent; peptide	cancer
bisaziridinylspermine; BAS	Preclinical	N,N'-bis[3-(1-aziridinylpropyl)]-1,4-butanediamine	alkylating agent; polyamine analogue	cancer
diarizidinylspermine; DASPM	Preclinical	N,N'-bis[3-(1-aziridinylpropyl)]-1,4-butanediamine	alkylating agent; polyamine analogue	cancer
O6-benzylguanine	Phase I		alkyltransferase inhibitor; chemosensitizer	cancer
samarium 153 Sm lexidronam; Sm 153-EDTMP; samarium 153-EDTMP; samarium EDTMP; CYT 424; QUADRAMET	Marketed	(OC-6-21)-[[[1,2-ethanediy]bis[nitrilobis(s(methylene))tetrakis(phosphonato)](8-)-N,N',OP,OP',OP'',OP''']-samarate(5-)-153Sm	analgesic; NSAID; radiotherapeutic	cancer; pain; rheumatoid arthritis

abiraterone; piraterone; CB 7630; CB 7598	Phase I	(3beta)-17-(3-pyridinyl)-androsta-5,16-dien-3-ol	androgen synthesis inhibitor	cancer
cancer therapy, Institute of Cancer Research	Preclinical		androgen synthesis inhibitor	cancer
cancer therapy, Saarbrücken University	Preclinical		androgen synthesis inhibitor	cancer
GI 111924	Suspended		androgen synthesis inhibitor	cancer
VN 851	Preclinical		androgen synthesis inhibitor	cancer
VN 871	Preclinical		androgen synthesis inhibitor	cancer
YM 116	Phase I	2-(1H-imidazol-4-ylmethyl)-9H-carbazole	androgen synthesis inhibitor	cancer
YM 53789	Preclinical	2-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl)-9H-carbazole	androgen synthesis inhibitor	cancer
YM 55208	Preclinical	2-[1-(1H-imidazol-1-yl)ethyl]-9H-carbazole	androgen synthesis inhibitor	cancer
gene therapy, cancer, Genetix	Preclinical		angiogenesis inducer; biotechnology; gene therapy	cancer
2-methyl-2-phthalimidino-glutaric acid	Preclinical		angiogenesis inhibitor	cancer

9alpha-fluoromethylprogesterone acetate; FMPA	Preclinical	(6-alpha)-17-(acetyloxy)-9-fluoro-6-methyl-pregn-4-ene-3,20-dione	angiogenesis inhibitor	cancer
ANG 453; ZD 6126	Preclinical		angiogenesis inhibitor	cancer
angiogenesis inhibitor, Boston Life Sciences	Preclinical		angiogenesis inhibitor	cancer
angiogenesis inhibitor, Merck KGaA; EMD 121974	Phase I		angiogenesis inhibitor	cancer
angiogenesis inhibitors, AstraZeneca	Preclinical		angiogenesis inhibitor	cancer
angiogenesis inhibitors, Nanodesign	Preclinical		angiogenesis inhibitor	cancer
angiogenesis inhibitors, Novartis/Schering AG	Preclinical		angiogenesis inhibitor	cancer
angiogenesis inhibitors, Repligen	Preclinical		angiogenesis inhibitor	cancer; retinopathy
CT 3577	Discontinued		angiogenesis inhibitor	cancer

FCE 26644; PNU 151484	Preclinical	7,7'- [carbonylbis[imino(1- methyl-1H-pyrrole- 4,2- diyl)carbonylimino(1- methyl-1H-pyrrole- 4,2- diyl)carbonylimino]]b is-1,3- naphthalenedisulfonic acid tetrasodium salt	angiogenesis inhibitor	cancer
FCE 27164; PNU 165897	Preclinical	7,7'- [carbonylbis[imino(1- methyl-1H-pyrrole- 4,2- diyl)carbonylimino(1- methyl-1H-pyrrole- 4,2- diyl)carbonylimino]]b is-1,3,5- naphthalenetrisulfonic acid hexasodium salt	angiogenesis inhibitor	cancer
gene discovery, tumor epithelium	Preclinical		angiogenesis inhibitor	cancer
greenstatin	Preclinical		angiogenesis inhibitor	cancer
irsogladine; irsogladine maleate; isaglidole; MN 1695; GASLON; GASLON-N	Marketed	2,4-diamino-6-(2,5- dichlorophenyl)-s- triazine	angiogenesis inhibitor	gastrointestinal ulcer; cancer
RG 8803; RG 8803B11; RG 1009	Preclinical		angiogenesis inhibitor	cancer

squalamine	Phase I	(3beta,5alfa,7alfa,24R)-3-[[3-[(4-aminobutyl)amino]propyl]amino]cholestane-7-24-diol 24-(hydrogen sulfate)	angiogenesis inhibitor	viral infection; cancer; retinopathy
SR 25989	Discontinued		angiogenesis inhibitor	cancer
SU 301	Discontinued		angiogenesis inhibitor	cancer
SU 302	Discontinued		angiogenesis inhibitor	cancer
suradista	Phase I		angiogenesis inhibitor	cancer
TAN 1120	Preclinical	8-acetyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-[[[octahydro-5-hydroxy-2-(2-hydroxypropyl)-4,10-dimethylpyrano[3,4-d]-1,3,6-dioxazin-8-yl]oxy]-5,12-naphthacenedione	angiogenesis inhibitor	cancer
TZ 93	Discontinued		angiogenesis inhibitor	cancer
VE-cadherin-2 antagonists, ImClone Systems	Preclinical		angiogenesis inhibitor	cancer
VEGF receptor modulators, Pharmacoceia	Preclinical		angiogenesis inhibitor	cancer
INGN 401	Preclinical		angiogenesis inhibitor; antiproliferative agent	cancer
soluble Tie-2	Preclinical		angiogenesis inhibitor; biotechnology	cancer

angiogenesis inhibitor, Bio-Technology General; plasminogen-related peptide Bio-Technology General	Preclinical			angiogenesis inhibitor; cancer biotechnology; peptide	angiogenesis inhibitor; cancer
SU 6668	Phase I			angiogenesis inhibitor; growth factor modulator	cancer
AE 941; NEOVASTAT; NEORETNA; PSOVASCAR; ARTHROVAS	Phase III			angiogenesis inhibitor; NSAID	cancer; psoriasis; rheumatoid arthritis; eye disease; retinopathy
FR 111142; WF 2015A	Discontinued	4,5-dihydroxy-2-hexenoic acid 5-methoxy-4-[2-methyl-3-(3-methyl-2-butenyl)oxiranyl]-1-oxaspiro[2.5]oct-6-yl ester		angiogenesis inhibitor; NSAID	cancer; rheumatoid arthritis; retinopathy
heparanase inhibitors, InSight	Preclinical			angiogenesis inhibitor; NSAID	cancer; inflammation
troponin I; cartilage derived inhibitor	Preclinical			angiogenesis inhibitor; NSAID; biotechnology	cancer; rheumatoid arthritis; eye disease
antiangiogenesis agent, Ixsys	Discontinued			angiogenesis inhibitor; peptide	cancer; restenosis
XMP 300	Preclinical			angiogenesis inhibitor; peptide	inflammation; cancer
ENDOSTATIN	Preclinical			angiogenesis inhibitor; peptide; biotechnology	cancer

thrombospondin 1 inhibitor, InKine; TSP-1 inhibitor, InKine	Preclinical		angiogenesis inhibitor; platelet antiaggregant; radiodiagnostic; contrast medium	cancer; diagnosis; thrombosis
tecogalan sodium; DS 4152; SP PG	Phase I	sulfated polysaccharide peptidoglycan	angiogenesis inhibitor; polysaccharide sulfate	cancer
SU 5416	Phase II	3-[(4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-2H-indol-2-one	angiogenesis inhibitor; tyrosine kinase inhibitor; signal transduction inhibitor	cancer
rubiginone B1	Discontinued		angucyclinone; antibiotic	cancer
aclarubicin; aclarubicin hydrochloride; aclacinomycin A; NSC 208734; MA 144A1; JACLACIN; ACLAPLASTIN; ACLACINOMYCIN; ACLACINON	Marketed	methyl(1R,2R,4S)-2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R,6S)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl]-alpha-L-lyxo-hexopyranosyl]-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl]oxy]-1-naphthacene-1-carboxylate	anthracycline; antibiotic; DNA intercalator	cancer

drug delivery system, liposome anthracycline; anthracycline liposome; AR 522; ANNAMYCIN	Phase II			anthracycline; antibiotic; DNA intercalator	cancer
IT 62B	Discontinued			anthracycline; antibiotic; DNA intercalator	cancer; bacterial infection
SO 075R1	Preclinical			anthracycline; antibiotic; DNA intercalator	bacterial infection; cancer
bisantrene hydrochloride; CL 216942; NSC 337766; ADCA; CYABIN	Phase III	bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone]-9,10-anthracenedicarboxaldehyde		anthracycline; DNA intercalator; antibiotic	cancer
daunoform	Preclinical			anthracycline; DNA intercalator; antibiotic	cancer
doxoform	Preclinical			anthracycline; DNA intercalator; antibiotic	cancer
drug delivery system, micellar doxorubicin; doxorubicin micelles	Preclinical			anthracycline; DNA intercalator; antibiotic	cancer
epidoxoform	Preclinical			anthracycline; DNA intercalator; antibiotic	cancer

memorubicin; FCE 23762	Phase II	[8S-[8 α ,10 α (R*)]]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-(2-methoxy-4-morpholinyl)- α -L-lyxohexopyranosyl]oxy]-5,12-naphthacenedione	anthracycline; DNA intercalator; antibiotic	cancer
ZYN 191	Suspended		anthracycline; DNA intercalator; antibiotic	cancer
D 26232; AN 207	Preclinical	(2S-cis)-6-[N6-[5-[2-[1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-(2,3-dihydro-1H-pyrrol-1-yl)- α -L-lyxohexopyranosyl]oxy]-2-naphthacenyl]-2-oxoethoxy]-1,5-dioxopentyl]-D-lysine]-luteinizing hormone-releasing factor (swine)	anthracycline; DNA intercalator; antibiotic; gonadorelin agonist; peptide	cancer
AN 1006	Discontinued		anthraquinone	cancer

anthraquinone prodrugs, De Montfort University	Discontinued			anthraquinone; radiosensitizer	cancer
antiandrogen, prostatic carcinoma	Discontinued			antiandrogen	cancer
bicalutamide; Zeneca 176334; ICI 176334; CASODEX	Marketed	(+,-)-N-[4-cyano-3- (trifluoromethyl)phen yl]-3-[(4- fluorophenyl)sulfony l]-2-hydroxy-2- methylpropanamide		antiandrogen	benign prostate hypertrophy; cancer
ICI 192779	Suspended			antiandrogen	cancer
LGD 1331	Preclinical			antiandrogen	cancer; benign prostate hypertrophy; acne; alopecia
nilutamide; RU 23908; RU 23908-10; ANANDRON; NILANDRON	Marketed	5,5-dimethyl-3-[4- nitro-3- (trifluoromethyl)phen yl]-2,4- imidazolidinedione		antiandrogen	cancer
osaterone; osaterone acetate; TZP 4238; HIPROS	Pre- registration	17-(acetyloxy)-6- chloro-2-oxapregna- 4,6-diene-3,20-dione		antiandrogen	benign prostate hypertrophy; cancer; osteoporosis
zanoterone; WIN 49596	Phase II	(5alpha,7alpha)-1'- (methylsulfonyl)-1'H- pregn-20-yno[3,2- c]pyrazol-17-ol		antiandrogen	benign prostate hypertrophy; cancer
albaccarin; virenomyacin M, V	Discontinued			antibiotic	cancer

ankinomycin	Discontinued	2-(4,4-anhydro-1,6-dideoxy- α -L-sorbo-2,3-oxiranosyl)-11-hydroxy-5-methyl-10-[2,3,6-trideoxy-3-(dimethylamino)-3-C-methyl- α -L-lyxohexopyranosyl]-4H-anthra[1,2-b]pyran-4,7,12-trione	antibiotic	cancer
antibiotic, Sagami	Preclinical	(7S-cis)-7-[(2,6-dideoxy- α -L-lyxohexopyranosyl)oxy]-9-(fluoroacetyl)-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione	antibiotic	cancer
anticancer, Chugai	Discontinued	3'-deoxytalopiericidin A1 (DTPA)	antibiotic	cancer
AT 2433A1	Discontinued	1-chloro-13-[6-O-[2,4-dideoxy-4-(methylamino)- α -D-threo-pentopyranosyl]-4-O-methyl-beta-D-glucopyranosyl]-12,13-dihydro-6-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione	antibiotic	cancer

azamitosenes	Preclinical		antibiotic	cancer
BE 12406A	Discontinued	12-[(6-deoxy- α -L-mannopyranosyl)oxy]-1-hydroxy-10-methoxy-8-methyl-6H-benzo[d]naphtho[1,2-b]pyran-6-one	antibiotic	cancer
betaclamycin B; BCMA	Preclinical		antibiotic	cancer
CC 1065	Discontinued	(7bR)-7-[[1,6-dihydro-4-hydroxy-5-methoxy-7-[(4,5,8a-tetrahydro-7-methyl-4-oxocyclopropa[c]pyrrolo[3,2-e]indol-2(1H)-yl)carbonyl]benzo[1,2-b:4,3-b']dopyrrol-3(2H)-yl]cabonyl-1,6-dihydro-4-hydroxy-5-methoxybenzo[1,2-b:4,3-b']dipyrrole-3(2H)-carboxamide	antibiotic	bacterial infection; cancer
collismycin A; SF 2738A	Discontinued	(E)-4-methoxy-5-(methylthio)-[2,2'-bipyridine]-6-carboxaldehyde oxime	antibiotic	cancer

collismycin B; SF 2738B	Discontinued	(Z)-4-methoxy-5-(methylthio)-[2,2'-bipyridine]-6-carboxaldehyde oxime	antibiotic	cancer
collismycin C; SF 2738C	Discontinued		antibiotic	cancer
cypemycin	Discontinued	N,N-dimethyl-L-alanyl-(E)-2,3-didehydro-2-aminobutanoyl-L-prolyl-L-alanyl-(E)-2,3-didehydro-2-aminobutanoyl-L-prolyl-(E)-2,3-didehydro-2-aminobutanoyl-L-valyl-L-alanyl-L-glutaminy-L-phenylalanyl-L-valyl-L-isoleucyl-L-glutaminyglycyl-L-seryl-(E)-2,3-didehydro-2-aminobutanoyl-L-isoleucyl-L-cysteinyl-L-leucyl-N-(2-mercaptoethenyl)-L-leucinamide cyclic (19-21)-sulfide	antibiotic	bacterial infection; cancer

dioxamycin; BE 16493	Preclinical	[2 α ,3 α ,4 α ,9[2R*,3S*[1E(2S*,4S*,5S*),3E,5E],6R*],12ba]fa)-(+)-2,4-dimethyl-5-[7-oxo-7-[[tetrahydro-2-methyl-6-(1,2,3,4,4a,7,12,12b-octahydro-2,3,4a,8,12b-pentahydroxy-3-methyl-1,7,12-trioxobenz[a]anthracen-9-yl)-2H-pyran-3-yl]oxy]-1,3,5-heptatrienyl]-1,3-dioxolane-2-carboxylic acid	antibiotic	cancer; bacterial infection
eponemycin; BMY 28647; BU 3862T	Discontinued	[2R-[2R*[S*(S*)]]]-N-[1-(hydroxymethyl)-2-[[1-[2-(hydroxymethyl)oxiranyl]carbonyl]-3-methyl-3-butenyl]amino]-2-oxoethyl]-6-methylheptanamide	antibiotic	cancer
epoxomicin	Discontinued		antibiotic	cancer

esperatrucin; esperamicin AI; esperamycin; esperamicin; BMY 28175; BBM 1675AI; BBM 1675	Discontinued	[1R-(1R*,4Z,8S*,12S*,13E)]-4,5-dimethoxy-2-[[2-methoxy-1-oxo-2-propenyl)amino]benzoic acid 3'-(12)-ester with methyl [8-[[4,6-dideoxy-2-O-[2,4-dideoxy-3-O-methyl-4-[(1-methylethyl)amino]-alfa-L-threopentopyranosyl]-4-[[2,6-dideoxy-4-S-methyl-4-thio-beta-D-ribohexopyranosyl)oxy]amino]-beta-D-glucopyranosyl]oxy]-12-[(2,6-dideoxy-alfa-L-lyxohexopyranosyl)oxy]-1-hydroxy-13-[2-(methyltrithio)ethylidene]-11-oxobicyclo[7.3.1]trideca-4,9-diene-2,6-diyn-10-yl]carbamate	antibiotic	cancer
--------------------------------------------------------------------------------------------------------	--------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------	--------

FCE 21424	Preclinical	8-acetyl-10-[[5-(hexahydro-2,4,6-trioxo-5-pyrimidinyl)octahydro-2-(2-hydroxypropyl)-4,10-dimethylpyrano[3,4-d]-1,3,6-dioxocin-8-yl]oxy]-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione	antibiotic	cancer
FCE 24366	Preclinical	8-acetyl-10-[[5-(hexahydro-1,3-dimethyl-2,4,6-trioxo-5-pyrimidinyl)octahydro-2-(2-hydroxypropyl)-4,10-dimethylpyrano[3,4-d]-1,3,6-dioxocin-8-yl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione	antibiotic	cancer

FCE 24367	Preclinical	8-acetyl-10-[[5-(hexahydro-4,6-dioxo-2-thioxo-5-pyrimidinyl)octahydro-2-(2-hydroxypropyl)-4,10-dimethylpyrano[3,4-d]-1,3,6-dioxazocin-8-yl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione	antibiotic	cancer
FK 317	Phase I		antibiotic	cancer
fluorodaunorubicin hydrochloride	Preclinical	10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-8-(fluoroacetyl)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione	antibiotic	cancer

thiomamycin; YL 0358MA	Preclinical	[2R- [2alfa,3alfa,6alfa]1R* (S*),2Z,4E(1alfaS*,7 alfaR*)]]-6-[[4-(2,3- dihydrocyclopent[b]o xireno[c]pyridin- 7(1aH)-ylidene)-1-(1- hydroxypropyl)-3- methyl-2- butenyloxy]tetrahydr o-2-methyl-2H-pyran- 3-ol	antibiotic	cancer
	Discontinued		antibiotic	bacterial infection; cancer
himastatin; BMY 40800	Discontinued		antibiotic	bacterial infection; cancer
hydramycin	Discontinued	[4S- (4alfa,4aalfa,5alfa,5aa lfa,6alfa,12alfa)]-4- (dimethylamino)- 1,4,4a,5,5a,6,11,12a- octahydro- 3,5,10,12,12a- pentahydroxy-6- methyl-1,11-dioxo-2- naphthacenecarboxam ide	antibiotic	cancer; bacterial infection
K 818B	Discontinued		antibiotic	cancer
kedarcidin	Discontinued		antibiotic	bacterial infection; cancer
KT 5432	Discontinued		antibiotic	cancer

KW 2189	Phase II	(S)-8-(bromomethyl)-3,6,7,8-tetrahydro-2-methyl-4-[[[(4-methyl-1-piperazinyl)carbonyl]oxy]-6-[(5,6,7-trimethoxy-1H-indol-2-yl)carbonyl]benzo[1,2-b:4,3-b']dipyrrole-1-carboxylic acid, methyl ester	antibiotic	cancer; bacterial infection
	Discontinued		antibiotic	cancer
leptolstatin liblomycin; NK 313	Discontinued	[2R-[2'R*,6'R*(R*),9'E,11'R*,13'E,15'Z]]-4,11'-dihydroxy-2',4,9'-trimethylspiro[1,2-dithiolane-3,6'-[19]thia[3,20]diazabicyclo[15.2.1]eicosa[1(20),9,13,15,17]pentaene]-4',5,12'-trione 2-oxide	antibiotic	cancer
	Preclinical		antibiotic	cancer
leptolstatin liblomycin; NK 313	Discontinued	N1-[3-[[3-bis[[3,4-bis(phenylmethoxy)phenyl]methyl]amino]propyl]methylamino]propyl]bleomycinamide	antibiotic	cancer; bacterial infection

nisamycin; antibiotic 106B	Preclinical	[1S- [1alfa,2beta,2(2E,4E, 6E),4(2E,4E),6alfa]]- 7-[4-[(5-cyclohexyl- 1-oxo-2,4- pentadienyl)amino]- 2-hydroxy-5-oxo-7- oxabicyclo[4.1.0]hept -3-en-2-yl]-2,4,6- heptatrienoic acid	antibiotic	bacterial infection; cancer
oligomycin E; MCI 2225	Discontinued	26-hydroxy-28- oxooligomycin A	antibiotic	cancer
oxaunomycin; D 788; R 20X2	Preclinical	[7R- (7alfa,8beta,10beta)]- 10-[(3-amino-2,3,6- trideoxy-alfa-L-lyxo- hexopyranosyl)oxy]- 8-ethyl-7,8,9,10- tetrahydro-1,6,7,8,11- pentahydroxy-5,12- naphthacenedione	antibiotic	cancer
phenazinomycin; (-)- phenazinomycin	Preclinical	[R-(E)]-5-[5-(2,2- dimethyl-6- methylenecyclohexyl)- 3-methyl-2-pent enyl]-1(5H)- phenazinone	antibiotic	bacterial infection; cancer

pyrindamycin A	Discontinued	(2R-trans)-8-(chloromethyl)-1,2,3,6,7,8-hexahydro-4-hydroxy-2-methyl-1-oxo-6-[(5,6,7-trimethoxy-1H-indol-2-yl)carbonyl]benzo[1,2-b,4,3-b']dipyrrole-2-carboxylic acid, methyl ester	antibiotic	cancer
pyrindamycin B	Discontinued	8-chloro-2,3,6,7,8,9-hexahydro-4-hydroxy-2-methyl-1-oxo-6-[(5,6,7-trimethoxy-1H-indol-2-yl)carbonyl]-1H-pyrrolo[3,2-f]quinoline-2-carboxylic acid, methyl ester	antibiotic	cancer
saintopin	Discontinued	1,3,8,10,11-pentahydroxy-5,12-naphthacenedione	antibiotic	bacterial infection; cancer

saptomycin D	Discontinued	[2alpha,3beta(Z)]-10-[4-O-acetyl-2,3,6-trideoxy-3-(dimethylamino)-3-C-methyl-alpha-L-lyxohexopyranosyl]-11-hydroxy-5-methyl-2-[2-methyl-3-(1-propenyl)oxiranyl]-4H-anthra[1,2-b]pyran-4,7,12-trione	antibiotic	cancer; bacterial infection
SPM VIII	Discontinued	4-deoxy-4-[[[(1-oxododecyl)amino]acetyl]amino]-N-1H-purin-6-yl-L-glycero-beta-L-manno-heptopyranosylamine	antibiotic	cancer
tetrazomine; Y 09194L-B	Preclinical	3-hydroxy-N-[2a,3,4,5,6,6a,7,11b-octahydro-5-(hydroxymethyl)-11-methoxy-12-methyl-3,6-imino-1H-2-oxa-11c-azanaphth[1,2,3-cd]azulen-10-yl]-2-piperidinecarboxamide	antibiotic	bacterial infection; cancer
UCA 1064B	Discontinued		antibiotic	cancer
vicenistatin	Discontinued		antibiotic	cancer

Y 05460MA	Preclinical	4-amino-4,5,6-trideoxy-N-[1-(3,4-dihydro-8-hydroxy-1H-2-benzopyran-3-yl)-3-methylbutyl]-5-methylhexonamide	antibiotic	bacterial infection; cancer
drug delivery system, mitomycin; mitomycin Therapeutic Implant; MPI 5016	Discontinued		antibiotic; alkylating agent	cancer
MGI 114; HMAF	Phase II	(R)-6'-hydroxy-3'-(hydroxymethyl)-2',4',6'-trimethylspiro[cyclopropane-1,5'-[5H]inden]-7'(6'H)-one	antibiotic; alkylating agent; terpene	cancer
AGM 1470; TNP 470	Phase II	[3R-[3alpha, 4alpha (2R*, 3R*), 5beta, 6beta]]-5-methoxy-4-[2-methyl-3-(3-methyl-2-butenyl)oxiranyl]-1-oxaspiro[2.5]oct-6-yl carbamic acid chloroacetyl ester	antibiotic; angiogenesis inhibitor	cancer

AD 143	Preclinical	hexanedioic acid (2S-cis)-mono[2-[1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-[(trifluoroacetyl)amino]-alpha-L-lyxohexopyranosyl]oxy]-2-naphthaceny]]-2-oxoethyl] ester	antibiotic; anthracycline; DNA intercalator	cancer
AD 198	Preclinical	Pentanoic acid (2S-cis)-2-[1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-[(phenylmethyl)amino]-alpha-L-lyxohexopyranosyl]oxy]-2-naphthaceny]]-2-oxoethyl ester	antibiotic; anthracycline; DNA intercalator	cancer
anthracycline analogue, BioChem Pharma	Discontinued		antibiotic; anthracycline; DNA intercalator	cancer
B 880308	Suspended	7-O-(3-N-methyl-3-N-(R)-glycidyl-alpha-L-daunosaminy)-beta-rhodomycinone	antibiotic; anthracycline; DNA intercalator	cancer

drug delivery system, ATRIGEL sustained release doxorubicin; doxorubicin ATRIGEL	Preclinical		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, doxorubicin; doxorubicin drug delivery system; AD 70; ADM OXD; GC 1004	Discontinued		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, doxorubicin; doxorubicin drug delivery system	Discontinued		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, doxorubicin; doxorubicin-tumor homing peptide; THP-doxorubicin	Preclinical		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, doxorubicin; doxorubicin Therapeutic Implant; MPI 5015	Discontinued		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, HPMA polymer-bound doxorubicin; doxorubicin HPMA polymer-bound; PK 1	Phase I		antibiotic; anthracycline; DNA intercalator	cancer

drug delivery system, liposome daunorubicin; daunorubicin liposome; VS 103; DaunoXome	Marketed		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, liposome doxorubicin; doxorubicin liposome; DOXOME	Discontinued		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, liposome doxorubicin; doxorubicin liposome; TLC D99; TLC DOX 99; DOX 99; EVACET; LIPODOX	Pre- registration		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, liposome doxorubicin; doxorubicin liposome	Clinicals		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, liposome doxorubicin; doxorubicin liposome	Phase III		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, micellar doxorubicin; doxorubicin micelles	Preclinical		antibiotic; anthracycline; DNA intercalator	cancer

drug delivery system, nanosphere doxorubicin; doxorubicin nanosphere	Phase I		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, ONCHOLAB aclarubicin; aclarubicin ONCHOLAB	Discontinued		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, ONCHOLAB AD 32; AD 32 ONCHOLAB	Discontinued		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, STEALTH liposome doxorubicin; doxorubicin STEALTH; DOXIL; DOX-SL; S-DOX; CAELYX	Marketed		antibiotic; anthracycline; DNA intercalator	cancer
drug delivery system, tetrapeptide doxorubicin; doxorubicin tetrapeptide; Super- Leu-Dox	Preclinical		antibiotic; anthracycline; DNA intercalator	cancer

epirubicin; pidorubicin; 4'-epi- doxorubicin; IMI 28; MSC 256942; FI 7701; PHARMORUBICIN; FARMORUBICIN; FARMORUBICINE	Marketed	(8S-cis)-10-[(3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione	antibiotic; anthracycline; DNA intercalator	cancer
FCE 27726	Discontinued	(7S-cis)-9-acetyl-7-[[3-[bis(2-chloroethyl)amino]-2,3,6-trideoxy-4-O-(methylsulfonyl)-alpha-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione	antibiotic; anthracycline; DNA intercalator	cancer
galarubicin; DA 125	Phase II	2-[(2S,4S)-4-[(2,6-dideoxy-2-fluoro-alpha-L-talopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-oxoethyl ester beta-alanine hydrochloride	antibiotic; anthracycline; DNA intercalator	cancer

GPX 100	Phase I			antibiotic; anthracycline; DNA intercalator	cancer
I-DOX	Phase I	4'-iodo-4'- deoxydoxorubicin		antibiotic; anthracycline; DNA intercalator	cancer
idarubicin; IMI 30; NSC 256439; IMI 22; ZAVEDOS; ZAVEDOSE; ZAVIDOS; IDAMYCIN; DAUNOBLASTINA; CERUBIDINE	Marketed	9-acetyl-7-[(3-amino- 2,3,6-trideoxy- α -L- lyxo- hexopyranosyl)oxy]- 7,8,9,10-tetrahydro- 6,9,11-trihydroxy- 5,12- naphthacenedione		antibiotic; anthracycline; DNA intercalator	cancer
iododoxorubicin; FCE 21954; IODODOX	Phase II	[2R- [2 α fa(8S*,10S*),4beta a,5beta,6beta]]-10- [(4-aminotetrahydro- 5-iodo-6-methyl-2H- pyran-2-yl)oxy]- 7,8,9,10-tetrahydro- 6,8,11-trihydroxy-8- (hydroxyacetyl)-1- methoxy-5,12- naphthacenedione		antibiotic; anthracycline; DNA intercalator	cancer

KRN 8602; MX 2	Phase II	[7R-(7 α ,8 β ,10 β)-8-ethyl-7,8,9,10-tetrahydro-1,6,7,8,11-pentahydroxy-10-[[2,3,6-trideoxy-3-(4-morpholinyl)- α -L-lyxo-hexopyranosyl]oxy]-5,12-naphthacenedione hydrochloride	antibiotic; anthracycline; DNA intercalator	cancer
ME 2303; FAD 104	Discontinued	heptanedioic acid, mono[2-[4-[(2,6-dideoxy-2-fluoro- α -L-talopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-oxoethyl] ester, (2S-cis)-	antibiotic; anthracycline; DNA intercalator	cancer

menogaril; 7-OMEN; NSC 269148; TUT 7; U 52047; TOMOSAR; TAMOSAR	Phase III	(2R,3S,4R,5R,6R,11R,13R)-4-(dimethylamino)-3,4,5,6,11,12,13,14-octahydro-3,5,8,10,13-pentahydroxy-11-methoxy-6,13-dimethyl-2,6-epoxy-2H-naphthaceno[1,2-b]oxocin-9,16-dione	antibiotic; anthracycline; DNA intercalator	cancer
pirarubicin; tirarubicin; theprubicin; THP-doxorubicin; THP-ADM; thepirubicin; THERARUBICIN; PINORUBIN; BERIRUBIN; THEPRUBICINE	Marketed	[8S-[8alfa,10alfa(S*)]]-10-[[3-amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-alfa-L-lyxohexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione	antibiotic; anthracycline; DNA intercalator	cancer

truboxyl	Phase II	(2S-cis)-4-[[1-[4[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]ethylidene]hydrazono-2,2,6,6-tetramethyl-1-piperidinyl]oxyl	antibiotic; anthracycline; DNA intercalator	cancer
valrubicin; antibiotic AD 32; NSC 246131; VALSTAR	Marketed	Pentanoic acid, (2S-cis)-2-[1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-[(trifluoroacetyl)amino]-alpha-L-lyxo-hexopyranosyl]oxy]-2-naphthacenyl]-2-oxoethyl ester	antibiotic; anthracycline; DNA intercalator	cancer
ZYN 198	Suspended		antibiotic; anthracycline; DNA intercalator	cancer
ZYN-LINKER conjugated doxorubicin	Suspended		antibiotic; anthracycline; DNA intercalator	cancer
doxorubicin + estrone; estrone + doxorubicin; DDS-DEA	Marketed		antibiotic; anthracycline; DNA intercalator; estrogen	cancer

amrubicin; SM 5887	Phase II	(7S-cis)-9-acetyl-9-amino-7-[(2-deoxy-beta-D-erythro-pentopyranosyl)oxy]-7,8,9,10-tetrahydro-6,11-dihydroxy-5,12-naphthacenedione hydrochloride	antibiotic; anthracycline; DNA topoisomerase inhibitor	cancer
MEN 10755; BMS 195615	Phase I	(7S-cis)-7-[[4-O-(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)-2,6-dideoxy-alpha-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-5,12-naphthacenedione hydrochloride	antibiotic; anthracycline; DNA topoisomerase inhibitor	cancer
BU 4704	Discontinued	1-(4-methoxyphenyl)-4-(4-hydroxysulfonyloxyphenyl)-2,3-diisocyanato-1,3-butadiene	antibiotic; antifungal	mycosis; cancer
NK 860279I	Discontinued	44-homooligomycin B	antibiotic; antifungal	mycosis; cancer
NK 860279II	Discontinued	44-homooligomycin A	antibiotic; antifungal	mycosis; cancer

reveromycin A	Preclinical	10-[9-butyl-8-[4-carboxy-3-methyl-1(E),3(E)-butadienyl]-9-(hydroxysuccinyloxy)-3-methyl-1,7-dioxaspiro-[5.5]undec-2-yl]-5-hydroxy-4,8-dimethyl-2(E),6(E),8(E)-decatricenoic acid	antibiotic; antifungal	bacterial infection; cancer; mycosis
sultricin	Discontinued	5,6-dihydro-5-hydroxy-6-(6-hydroxy-5-methyl-4-hydroxysulfonyloxy)heptadec-1,7,9,11-tetraenyl)-2H-pyran-2-one	antibiotic; antifungal	cancer; mycosis
JSM ASB001	Preclinical		antibiotic; antioxidant; cicatrizant	cancer; bacterial infection; gastrointestinal disorder; skin ulcer
JSM BCYL001	Preclinical		antibiotic; antioxidant; cicatrizant	cancer; bacterial infection; gastrointestinal disorder; skin ulcer
JSM BIAS001	Preclinical		antibiotic; antioxidant; cicatrizant	cancer; bacterial infection; gastrointestinal disorder; skin ulcer
beta lactam derivatives, Pliva	Preclinical		antibiotic; beta lactam	cancer

clavalanine; SYN 1931; Ro 22-5417	Preclinical	[3S-[3alpha(R*),5alpha]]-alpha-amino-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-3-propanoic acid	antibiotic; beta lactam	cancer
SYN 1127	Preclinical	3-(hydroxymethyl)-4-oxa-1-azabicyclo[3.2.0]heptan-7-one	antibiotic; beta lactam	cancer
SYN 1932	Preclinical	[3R-[3alpha(alphaS*,beta R*),5alpha]]-alpha-amino-7-oxo-beta-(phenylmethoxy)-4-oxa-1-azabicyclo[3.2.0]heptane-3-propanoic acid	antibiotic; beta lactam	cancer
MAb, doxorubicin conjugate	Preclinical		antibiotic; biotechnology; monoclonal antibody; anthracycline; DNA intercalator	cancer
MAb, drug delivery system, liposome doxorubicin conjugate; MAb, STEALTH doxorubicin conjugate; SPI 49	Preclinical		antibiotic; biotechnology; monoclonal antibody; anthracycline; DNA intercalator	cancer
drug delivery system, micellar doxorubicin; doxorubicin micelle	Preclinical		antibiotic; DNA intercalator; anthracycline	cancer

IST 622; A 132; NSC 639830	Phase II	3-ethoxypropanoic acid (S)-10-[[6-deoxy-2-O-(6-deoxy-3-O-methyl- α -D-galactopyranosyl)-3,4-O-(phenylmethylene)-beta-D-galactopyranosyl]oxy]-5,12-dihydro-1-methyl-5,12-dioxobenzo[h][1]benzopyrano[5,4,3-cde][1]benzopyran-6-yl ester	antibiotic; DNA topoisomerase inhibitor	cancer
NSC 655649; BMY 27557	Phase I	1,11-dichloro-6-[2-(diethylamino)ethyl]-12,13-dihydro-12-(4-O-methyl-beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazol e-5,7(6H)-dione	antibiotic; DNA topoisomerase inhibitor; DNA intercalator	cancer
WIN 58161	Preclinical	(S)-10-(2,6-dimethyl-4-pyridinyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzothiazine-6-carboxylic acid	antibiotic; DNA topoisomerase inhibitor; quinolone	cancer
MI 4337F11; MI 43	Preclinical		antibiotic; immunostimulant	cancer

gludapcin; FK 565; FK 41565	Discontinued	heptanoyl-gamma-D-glutamyl-(L)-meso-diaminopimelyl-(D)-alanine	antibiotic; immunostimulant; peptide	cancer; HIV infection
feldamycin; BMV 28565	Discontinued	(S)-N-methyl-L-histidyl-N3-[1-carboxy-2-(1H-imidazol-4-yl)ethyl]-L-threo-2,3-diaminobutanoic acid	antibiotic; melanin synthesis inhibitor	cancer
cordycepin; NSC 63984	Phase I		antibiotic; nucleoside; antimetabolite	cancer
C 1027	Preclinical	Antibiotic C	antibiotic; peptide	cancer; bacterial infection
cecropin B	Discontinued		antibiotic; peptide	bacterial infection; cancer
lytic peptides, Proteus International	Discontinued		antibiotic; peptide	bacterial infection; cancer
verucopeptin; BU 3983T; BMV 28782	Discontinued		antibiotic; peptide	cancer
placatin A	Preclinical		antibiotic; platelet antiaggregant	thrombosis; bacterial infection; cancer
placatin B	Preclinical		antibiotic; platelet antiaggregant	thrombosis; bacterial infection; cancer
MS 073	Preclinical	5-(3-(40(10,11-dihydro-5H-dibenzo(a,d)cycloheptene-5-yl)piperazin-1-yl)-2-hydroxypropoxy)quinoline	antibiotic; quinoline	cancer

A 74932	Discontinued	6-[2-[(2-amino-1-oxopentyl)amino]-1-pyrrolidiny]-5-fluoro-3-oxo-3H-pyrido[3,2,1-k]phenoxazine-2-carboxylic acid monohydrochloride	antibiotic; quinolone	cancer
E 7010	Discontinued	N-[2-[(4-hydroxyphenyl)amino]-3-pyridiny]-4-methoxybenzenesulfonamide	antibiotic; sulfonamide	cancer
E 7070	Phase I		antibiotic; sulfonamide	cancer
ER 34410	Preclinical	N-(10,11-dihydro-2-fluoro-5H-dibenzo[b,e][1,4]diazepin-6-yl)-4-methoxybenzenesulfonamide	antibiotic; sulfonamide	cancer
ER 35744	Preclinical	N-(3-chloro-1H-indol-7-yl)-1,4-benzene-disulfonamide	antibiotic; sulfonamide	cancer
HMN 214	Preclinical	(E)-N-[(4-methoxyphenyl)sulfonyl]-N-[2-[2-(1-oxido-4-pyridiny)ethenyl]phenyl]acetamide	antibiotic; sulfonamide	cancer
andrographolide	Preclinical		antibiotic; terpene	cancer
PN 271; PN 27,1; AndroCar	Phase II		antibiotic; terpene	cancer; restenosis

PN 272	Preclinical			antibiotic; terpene	cancer
PN 273	Preclinical			antibiotic; terpene	cancer
PN 274	Preclinical			antibiotic; terpene	cancer
PN 275	Preclinical			antibiotic; terpene	cancer
gircodazole; girodazole; giroline; (+)-giroline; RP 49532; RP 49532A; NSC 627434	Discontinued	[S-(R*,R*)]-2-amino- alfa-(2-amino-1- chloroethyl)-1H- imidazole-4-methanol		antibiotic; tRNA synthetase inhibitor	cancer
glycopine; glucosaminylmuramyl diptide; GMDP; LIKOPID; LIKOPID	Marketed	N2-[N-[N-acetyl-4-O- [2-(acetyl amino)-2- deoxy-beta-D- glucopyranosyl]mura moyl]-L-alanyl]-D- alpha-glutamine		antibiotic; vaccine adjuvant; immunostimulant; glycopeptide	psoriasis; cancer; leukopenia; septic shock; infectious disease; eye disease
antiestrogens, AVAX Technologies	Preclinical			antiestrogen	cancer
antiestrogens, BioNumerik	Preclinical			antiestrogen	cancer
antiestrogens, Ligand	Preclinical			antiestrogen	cancer; endometriosis
clomifene analogues	Suspended			antiestrogen	cancer
droloxifene; droloxifene citrate; 3- hydroxytamoxifen; K 21060E citrate	Pre- registration	(E)-alpha-[p-[2- (dimethylamino)ethox ylphenyl]-alpha- ethyl-3-stilbenol		antiestrogen	cancer; osteoporosis
drug delivery system, GEOMATRIX controlled release tamoxifen; tamoxifen GEOMATRIX	Discontinued			antiestrogen	cancer

EM 139	Preclinical	(7alpha,16alpha,17beta)-N-butyl-16-chloro-3,17-dihydroxy-N-methylestra-1,3,5(10)-triene-7-undecanamide	antiestrogen	cancer
EM 170	Preclinical	(7alpha,16alpha,17alpha)-N-butyl-16-chloro-3,17-dihydroxy-N-methylestra-1,3,5(10)-triene-7-undecanamide	antiestrogen	cancer
EM 800	Phase III	2,2-dimethylpropanoic acid (S)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)ethoxy]phenyl]-2H-1-benzopyran-3-yl]phenyl ester	antiestrogen	cancer
estrogen antagonists, Telik	Discontinued		antiestrogen	cancer
fulvestrant; ZD 182780; ZM 182780; Zeneca 182780; ICI 182780; FASLODEX	Phase III	(7alpha,17beta)-7-[9-[(4,4,5,5,5-pentafluoropentyl)sulphonyl]nonyl]-estra-1,3,5(10)-triene-3,17-beta-diol	antiestrogen	cancer; gynecological

iproxifene; TAT 59	Phase III	(E)-4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-[4-(1-methylethyl)phenyl]-1-butenyl]phenol dihydrogen phosphate (ester)	antiestrogen	cancer
MDL 103323	Suspended	(E)-4-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethylbutanamine	antiestrogen	cancer
panomifene; EGIS 5650; GYKI 13504	Discontinued	(E)-2-[2-[p-(3,3,3-trifluoro-1,2-diphenylpropenyl)phenoxy]ethyl]amino]ethanol	antiestrogen	cancer
R 1128B	Discontinued	1,3,6-trihydroxy-8-n-butylanthraquinone	antiestrogen	cancer
RU 53637	Discontinued	(11beta,17alpha)-3,17-dihydroxy-N-methyl-N-(methylethyl)-19-morpregna-1,3,5(10)-trien-20-yne-11-undecanamide	antiestrogen	cancer
RU 58668; RU 59428	Discontinued		antiestrogen	cancer
SH 646	Phase I		antiestrogen	cancer
toremifene; tolemifene; FC 1157a; NK 622; FARESTON; TREMIFEN	Marketed	2-(p-((Z)-4-chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethylamine	antiestrogen	cancer

zindoxifene; D 16726	Discontinued	2-[4-(acetyloxy)phenyl]-1-ethyl-3-methyl-1H-indol-5-ol acetate (ester)	antiestrogen	cancer
arxoxifene; LY 353381	Phase II	2-(4-methoxyphenyl)-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]benzo[b]thiophene-6-ol	antiestrogen; estrogen agonist	cancer
ERA 923	Preclinical		antiestrogen; estrogen agonist	cancer
estrogen receptor modulator, Genaisance; estrogen receptor modulator, Telik	Preclinical		antiestrogen; estrogen agonist	cancer; osteoporosis
estrogen receptor modulators, Nanodesign	Preclinical		antiestrogen; estrogen agonist	cancer; osteoporosis
idoxifene; SB 223030; CB 7432	Phase II	(E)-1-[2-[4-[1-(4-iodophenyl)-2-phenyl-1-butenyl]phenoxy]ethyl]pyrrolidine	antiestrogen; estrogen agonist	cancer
LY 326315	Preclinical	6-(4-hydroxyphenyl)-5-[[4-[2-(1-piperidinyl)ethoxy]phenyl]methyl]-2-naphthalenol hydrochloride	antiestrogen; estrogen agonist	cancer

raloxifene; keoxifene; LY 139481; LY 156758; EVISTA	Marketed	[6-hydroxy-2-(4- hydroxyphenyl)benzo [b]thien-3-yl][4-[2-(1- piperidinyl) ethoxy]phenyl]metha none	antiestrogen; estrogen agonist	osteoporosis; hyperlipidemia; myocardial infarction; cancer
aminopterin; aminopterin; pteramina; NSC 739; APGA	Phase II	N-[4-[(2,4-diamino- 6- pteridinyl)methyl]ami no]benzoyl]-L- glutamic acid	antifolate	cancer
anticancer agent, Eisai	Discontinued	N-[4-[3-(2,4-diamino- 6,7-dihydro-5H- cyclopenta[d]pyrimidi n-5- yl)propyl]benzoyl]-L- glutamic acid	antifolate	cancer
edatrexate; aminopterin, O-ethyl- 10-deaza; 10 EDAM; EDAM 10; CGP 30694	Discontinued	N-[p-1-(2,4- diamino-6- pteridinyl)methyl]pro pyl]benzoyl]-L- glutamic acid	antifolate	cancer
lometrexol; LY 249543; LY 264618	Phase I	(R)-N-[4-[2-(2- amino-1,4,5,6,7,8- hexahydro-4- oxopyrido[2,3- d]pyrimidin-6- yl)ethyl]benzoyl]-L- glutamic acid	antifolate	cancer

LY 254155	Phase I	N-[[5-[2-(2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl)ethyl-2-thienyl]carbonyl]-L-glutamic acid	antifolate	cancer
LY 335580	Preclinical	N-((2,4-diamino-3,4,5,6,7,8-hexahydropyrido[2,3-d]pyrimidine-6-yl)ethyl)-2-thienylcarbonyl-L-glutamic acid	antifolate	cancer
PT 523	Preclinical	(S)-2-[[[4-carboxy-4-[[4-[[[(2,4-diamino-6-pteridiny)methyl]amino]butyl]amino]carbonyl]benzoic acid	antifolate	cancer
TNP 351	Discontinued	N-[4-[3-(2,4-diamino-1H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl]benzoyl]-L-glutamic acid	antifolate; antimetabolite	cancer
piritrexim; BW 301U; NSC 351521	Phase II	6-[(2,5-dimethoxyphenyl)-methyl]-5-methylpyrido[2,3-d]pyrimidine-2,4-diamine	antifolate; dihydrofolate reductase inhibitor	cancer; pneumocystis; toxoplasmosis

translation inhibitor, Trega Biosciences/RiboGen	Preclinical		antifungal	viral infection; mycosis; cancer
liarozole; liarozole hydrochloride; liarozole fumarate; R 75251; R 85246; LIAZAL	Pre- registration	5-[(3-chlorophenyl)- 1H-imidazol-1-yl- methyl]-1H- benzimidazole	antifungal; androgen synthesis inhibitor; imidazole	cancer; psoriasis
BBR 3438	Preclinical		antifungal; anthrapyrazole	cancer
BBR 3439	Discontinued		antifungal; anthrapyrazole	cancer
DUP 942	Discontinued		antifungal; anthrapyrazole	cancer
losoxantrone; losoxantrone hydrochloride; biantrazole; CI 941; DuP 941; NSC 357885; PD 113785; BIANDA	Phase III	7-hydroxy-2-[2-[(2- hydroxyethyl)amino]e thyl]-5-[[2-[(2- hydroxyethyl)amino]e thyl]amino anthra[1,9- cd]pyrazol-6(2H)- one,	antifungal; anthrapyrazole	cancer
teloxantrone; teloxantrone hydrochloride; moxantrazole; DUP 937; CI 937; PD 113309; NSC 355644	Discontinued	7-10-dihydroxy-2-[2- [(2- hydroxyethyl)amino]e thyl]-5-[[2- (methylamino)ethyl]a mino]anthra[1,9- cd]pyrazol-6(2H)- one, dihydrochloride, monohydrate	antifungal; anthrapyrazole	cancer

cancer therapy, Lorus Therapeutics/Ion	Preclinical		antifungal; imidazole	cancer
clotrimazole; BAY 5097; CUTAMYCON; ENSCHENT; FUNGIZID; HAKUSERIN; LOTRIMIN AF; MYCO-HERMAL; MYKO CORDES; TRIGENTAX; CANESTEN; LOTRIMIN	Marketed		antifungal; imidazole	mycosis; sickle cell anemia; cancer; diarrhea
jasplakinolide; jaspamide	Preclinical	[2S-(2R*,4E,6S*,8R*)]-N-[2-bromo-N-(8-hydroxy-2,4,6-trimethyl-1-oxo-4-nonenyl)-L-alanyl]-N-methyl-D-tryptophyl]-L-3-(4-hydroxyphenyl)-beta-alanine rho-lactone	antifungal; peptide	mycosis; cancer
aminoimidazole carboxamide ribonucleotide formyltransferase inhibitors, Agouron; AICART inhibitors, Agouron	Discontinued		antifungal; ribonucleotide formyltransferase inhibitor; NSAID; imidazole	cancer; inflammation

26-epibryostatin 1	Preclinical	(2E,4E)-2,4-octadienoic acid, (1S,3S,5Z,7R,8E,11S,12S,13E,15S,17R,21R,23R,25S)-25-(acetyloxy)-1,11,21-trihydroxy-17-[(1S)-1-hydroxyethyl]-5-13-bis(2-methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-19-oxo-18,27,28,29-tetraoxatetracyclo[21.3.1.13.7.111,15]nona cos-8-en-12-yl ester	antimetabolite	cancer
capecitabine; Ro 091978; XELODA	Marketed	pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate	antimetabolite	cancer
doxifluridine; DFUR; Ro 219738; FURTOLON; FURTULON	Marketed	5-deoxy-5-fluorouridine	antimetabolite	cancer
drug delivery system, ATRIGEL sustained release fluorouracil; fluorouracil ATRIGEL	Preclinical		antimetabolite	cancer

drug delivery system, fluorouracil; fluorouracil Therapeutic Implant; MPI 5003; AccuSite	Marketed		antimetabolite	cancer; psoriasis; viral infection
drug delivery system, fluorouracil; fluorouracil Therapeutic Implant; MPI 5011; INTRADOSE-FU	Discontinued		antimetabolite	cancer
drug delivery system, fluorouracil; fluorouracil Therapeutic Adhesive	Preclinical		antimetabolite	cancer
drug delivery system, methotrexate; methotrexate delivery system; HYAL CV1281	Discontinued		antimetabolite	cancer
drug delivery system, sustained release methotrexate; methotrexate DepoFoam	Discontinued		antimetabolite	cancer
fludarabine; arabinosyl-5-azacytosine; ara-AC; NSC 281272	Phase II	4-amino-1-beta-D-arabinofuranosyl-1,3,5-triazin-2(1H)-one	antimetabolite	cancer
fludarabine + chlorambucil; chlorambucil + fludarabine	Discontinued		antimetabolite	cancer

folic acid analogue, Glaxo Wellcome	Discontinued	N-alpha-(5-deaza-5,6,7,8-tetrahydropteroyl)-L-ornithine	antimetabolite	cancer
levamisole + fluorouracil; fluorouracil + levamisole	Registered		antimetabolite	cancer
T 506	Discontinued	mono[2-(trimethylammonio)ethyl ester of 2'-deoxy-5-fluoro-5'-uridylic acid 3'-(9-octadecenoate) hydroxide inner salt	antimetabolite	cancer
TAS 102	Phase I		antimetabolite	cancer
tegafur; BMS 20060401; MJF 12264; NSC 148958; DAIYALOSE; FENTAL; FTORAFUR; FTORALON; FURAFLOL; FUTRAFUL; LAMAR; NEBERK; TORAFURIN; UFT	Marketed	5-fluoro-1-(tetrahydro-2-furanyl)-2,4(1H,3H)pyrimidin edione	antimetabolite	cancer
ZYN-LINKER conjugated fluorouracil	Suspended		antimetabolite	cancer

brequinar sodium; DUP 785; NSC 368390	Suspended	6-fluoro-2-(2'-fluoro[1,1'-biphenyl]-4-yl)-3-methyl-4-quinolinecarboxylic acid	antimetabolite; immunosuppressant	cancer; autoimmune disease; transplant rejection
ZYN-LINKER conjugated methotrexate	Suspended		antimetabolite; NSAID	cancer; rheumatoid arthritis; psoriasis
cytarabine ocfosfate; phosteabine sodium; YNK 01; C18PCA; STARASID	Marketed	4-amino-1-[5-O-[hydroxy(octadecyloxy)phosphoryl]-beta-D-arabinofuranosyl]2(1H)-pyrimidinone	antimetabolite; nucleoside analogue	cancer
drug delivery system, DepoFoam cytarabine; cytarabine DepoFoam; DTC 101; DepoCyt; SAVEDAR	Marketed		antimetabolite; nucleoside analogue	cancer
nucleotide thio analogues, Oklahoma University	Preclinical		antimetabolite; nucleoside analogue	cancer
LY 207702	Preclinical	2',2'-difluoro-2'-deoxyribofuranosyl-2,6-diaminopurine (dFdAP)	antimetabolite; ribonucleotide reductase inhibitor	cancer
antineoplaston A10	Phase II		antineoplaston; peptide	cancer
antineoplaston AS2-1	Phase II		antineoplaston; peptide	HIV infection; cancer

nitroxide antioxidant, NIH	Preclinical			antioxidant; free radical scavenger; NSAID	respiratory distress syndrome; inflammation; cancer; reperfusion injury
antioxidants, University of California	Preclinical			antioxidant; NSAID	skin disease; inflammation; cancer
naphthepin; CL 190Y2	Preclinical	(4aS-cis)-3,4a,5,12b- tetrahydro-8,10- dihydroxy-2,5,5,9- tetramethyl-4H- benzo[d]naphtho[2,3- b]pyran-7,12-dione		antioxidant; NSAID	diabetes; cardiovascular disease; cancer; inflammation
OS 535	Preclinical			antiplasmin	cancer
LG 1127	Preclinical			antiprogestogen	cancer; endometriosis
LG 1147	Preclinical			antiprogestogen	cancer; endometriosis
LG 1447	Preclinical	1,2-dihydro-2,2,4- trimethyl-6-phenyl- quinoline		antiprogestogen	cancer; endometriosis
mifepristone; RU 486; RU 4866; RU 38486; R 38486; MIFEGYNE	Marketed	(11beta,17beta)-11- [4- (dimethylamino)phen yl]-17-hydroxy-17-(1- propynyl)estra-4,9- dien-3-one		antiprogestogen	abortion; cancer; contraception

onapristone; ZK 98299; SH 549; ZK 299	Discontinued	(11beta,13alfa,17alfa)- 11-[4- (dimethylamino)phen yl]-17-hydroxy-17-(3- hydroxypropyl)estra- 4,9-dien-3-one	antiprogesterone	cancer; contraception
ORG 31710	Discontinued	(6beta,11beta,17beta)- 11-[4- (dimethylamino)phen yl]-4',5'-dihydro-6- methyl-spiro[estra- 4,9-diene-17,2'(3'H)- furan]-3-one	antiprogesterone	cancer
ORG 31806	Discontinued	(7beta,11beta,17beta)- 11-[4- (dimethylamino)phen yl]-4',5'-dihydro-7- methyl-spiro[estra- 4,9-diene-17,2'(3'H)- furan]-3-one	antiprogesterone	cancer
ORG 33245	Discontinued		antiprogesterone	cancer; abortion
ORG 33628	Discontinued	(11beta,17alpha)-11- (4-acetylphenyl)- 17,23-epoxy-19,24- dinorchola-4,9,20- trien-3-one	antiprogesterone	cancer
ORG 33832	Discontinued		antiprogesterone	cancer; abortion
RU 46556	Discontinued	(11beta,17beta)-11- [4- (methylthio)phenyl]sp iro[estra-4,9-diene- 17,2'(5'H)-furan]-3- one	antiprogesterone	cancer; endometriosis; labor induction

RU 49295	Discontinued	(11beta,17beta)-11-(4-acetylphenyl)spiro[estra-4,9-diene-17,2'(5'H)-furan]-3-one	antiprogesterone	cancer; endometriosis
SH 207	Phase I		antiprogesterone	cancer
ZK 112993	Discontinued	(11beta,17beta)-11-(4-acetylphenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one	antiprogesterone	cancer
ZK 136798	Discontinued	4-[[[11alpha,17beta,17(Z)]-9,11-dihydro-17-hydroxy-17-(3-hydroxy-1-propenyl)-3-oxo-4'Hnaphth[3',2',1':10,9,11]estra-4,9(11)-dien-6'-yl]benzonitrile	antiprogesterone	cancer
21-substituted progesterone derivatives, NIH	Preclinical		antiprogesterone; hormone replacement therapy	endometriosis; labor induction; hormone deficiency; cancer
topsentin; topsentine; topsentin B1; topsentine B1	Preclinical	(6-hydroxy-1H-indol-3-yl)[4-(1H-indol-3-yl)-1H-imidazol-2-yl]methanone	antiproliferative agent	cancer

carboxyamidotriazole ; CAI; NSC 609974; L 651582	Phase I	5-amino-1-[[[3,5-dichloro-4-(4-chlorobenzyl)phenyl]methyl]-1H-1,2,3-triazole-4-carboxamide	antiproliferative agent; imidazole	cancer	
antisense oligonucleotide, BCL-X	Preclinical		antisense; oligonucleotide; biotechnology	cancer	
antisense oligonucleotide, c-fos	Preclinical		antisense; oligonucleotide; biotechnology	cancer	
antisense oligonucleotide, c-jun	Preclinical		antisense; oligonucleotide; biotechnology	cancer	
antisense oligonucleotide, calcium binding protein in placenta; antisense oligonucleotide, CAPL	Preclinical		antisense; oligonucleotide; biotechnology	cancer	
antisense oligonucleotide, DNA methyltransferase; MG 98	Phase I		antisense; oligonucleotide; biotechnology	cancer	
antisense oligonucleotide, Epstein Barr virus; antisense oligonucleotide, EBV	Preclinical		antisense; oligonucleotide; biotechnology	cancer	

antisense oligonucleotide, jun kinase-1	Preclinical		antisense; oligonucleotide; biotechnology	cancer
antisense oligonucleotide, transforming growth factor beta; antisense oligonucleotide, TGF-beta; antisense oligonucleotide, cancer	Preclinical		antisense; oligonucleotide; biotechnology	cancer
antisense oligonucleotides, basic fibroblast growth factor	Preclinical		antisense; oligonucleotide; biotechnology	cancer
oligonucleotides, cancer, Children's Hospital of Orange County	Preclinical		antisense; oligonucleotide; biotechnology	cancer
antisense oligonucleotide, multiple drug resistance	Preclinical		antisense; oligonucleotide; biotechnology; mRNA translation inhibitor	cancer
anticancer agents, OSI/Pfizer	Preclinical		apoptosis inducer	cancer
apoptosis inhibitors, Oxford Asymmetry/LXR Biotechnology	Preclinical		apoptosis inducer	cancer; cardiac therapy; transplant rejection; gastrointestinal disorder

breast cancer therapy, Temple University; breast cancer therapy, Alliance	Preclinical			apoptosis inducer	cancer
C 857	Preclinical	2-[(1-nitro-9-acridinyl)amino]ethanol monohydrochloride		apoptosis inducer	cancer
cancer therapy, Axiom Biotechnologies/Zaiya	Preclinical			apoptosis inducer	cancer
cancer therapy, BioChem Pharma/ImmunoGen	Preclinical			apoptosis inducer	cancer
cancer therapy, Hitachi; cancer therapy, Nippon Chemiphar	Phase I			apoptosis inducer	cancer
cancer therapy, Idun/Abbott	Preclinical			apoptosis inducer	cancer
cancer therapy, Rigel	Preclinical			apoptosis inducer	cancer
DDE 313	Preclinical			apoptosis inducer	cancer
Fas modulators, Menarini	Preclinical			apoptosis inducer	cancer
K 22175; K22.175	Preclinical			apoptosis inducer	cancer
ONCODON	Preclinical			apoptosis inducer	cancer
small cell lung carcinoma therapy, Cadus	Preclinical			apoptosis inducer	cancer
E2F inhibitors, Prolifix	Preclinical			apoptosis inducer; antiproliferative agent	cancer; psoriasis; viral infection; restenosis

apoptosis inducer, IDUN	Preclinical		apoptosis inducer; caspase inhibitor	cancer
CP 461	Phase I		apoptosis inducer; phosphodiesterase inhibitor	cancer
exisulind; FGN 1; PREVATAC	Phase III	(1Z)-5-fluoro-2- methyl-1-[[4- (methylsulfonyl)phen- yl]methylene]-1H - indene-3-acetic acid	apoptosis inducer; phosphodiesterase inhibitor	cancer
apoptosis inhibitor, Biota	Discontinued		apoptosis inhibitor	cancer
apoptosis modulators, University of Colorado	Preclinical		apoptosis inhibitor; apoptosis inducer	cancer; autoimmune disease; neurodegeneration
anastrozole; ZD 1033; ICI D1033; ARIMIDEX	Marketed	alpha, alpha, alpha', alp ha'-tetramethyl-5- (1H-1,2,4-triazol-1- ylmethyl)-1,3- benzenediacetonitrile	aromatase inhibitor	cancer
aromatase inhibitor, Menarini	Preclinical		aromatase inhibitor	cancer
aromatase inhibitor, Merrell Dow	Discontinued	19-acetylenic- androstenedione	aromatase inhibitor	cancer
aromatase inhibitors, Washington Research Foundation	Preclinical		aromatase inhibitor	cancer
atamestane; SH 489; ZK 95639	Discontinued	1-methylandrosta-1,4- diene-3,17-dione	aromatase inhibitor	cancer; benign prostate hypertrophy
CGP 47645	Discontinued		aromatase inhibitor	cancer

CGS 18320B; CGS 18320	Discontinued	4,4'-(1H-imidazol-1-ylmethylene)bis(benzonitrile) compound with butanedioic acid (2:1)	aromatase inhibitor	cancer
dexamino-glutethimide; D 3967	Phase III	3-(4-aminophenyl)-3-ethyl-2,6-piperidinedione	aromatase inhibitor	cancer
exemestane; FCE 24304; PNU 971; ONC 0028; AROMASIN	Pre-registration	6-methyleneandrosta-1,4-diene-3,17-dione	aromatase inhibitor	cancer
fadrozole; CGS 16949A; AFEMA	Marketed	4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile	aromatase inhibitor	cancer
formestane; CGP 32349; AT 0931; LENTARON; LENTARE	Marketed	4-hydroxyandrostene-3,17-dione	aromatase inhibitor	cancer
letrozole; CGS 20267; FEMARA	Marketed	4,4'-(1H-1,2,4-triazol-1-ylmethylene)bisbenzonitrile	aromatase inhibitor	cancer
minamestane; FCE 24928	Discontinued	4-aminoandrosta-1,4,6-triene-3,17-dione	aromatase inhibitor	cancer
MPV 2213; MPV 2213ad	Phase I	4-[3-(4-fluorophenyl)-2-hydroxy-1-(1H-1,2,4-triazol-1-yl)propyl]benzonitrile	aromatase inhibitor	cancer; benign prostate hypertrophy

NKS 01	Discontinued	14alpha-hydroxy-4-androstene-3,6,17-trione	aromatase inhibitor	cancer
ORG 30958	Discontinued	19-(ethylthio)androst-4-ene-3,17-dione	aromatase inhibitor	cancer
ORG 33201	Discontinued	(3alphaR)-trans-1-[(3alpha-ethyl-9-(ethylthio)-2,3,3alpha,4,5,6-hexahydro-1H-phenalen-2-yl)-methyl]-1H-imidazole HCl	aromatase inhibitor	cancer; endometriosis
pentrozole; SH 582; ZK 154065	Preclinical	17-[(1-oxohexyloxy)-19-norpregn-4-ene-3,20-dione	aromatase inhibitor	cancer
rogletimide; pyridoglutethimide	Discontinued	(+,-)-3-ethyl-3-(4-pyridinyl)-2,6-piperidinedione	aromatase inhibitor	cancer
RU 54115	Discontinued	10-[2-(methylthio)ethyl]estra-4,9(11)-diene-3,17-dione	aromatase inhibitor	cancer; endometriosis
SAE 9	Discontinued		aromatase inhibitor	cancer
TAN 931	Preclinical	4-(2,6-dihydroxybenzoyl)-3-formyl-5-hydroxybenzoic acid	aromatase inhibitor	cancer

vorozole; R 76713; R 83842; JK 201; RIVIZOR	Phase III	6-[(4-chlorophenyl)-1H-1,2,4-triazol-1-ylmethyl]-1-methyl-1H-benzotriazole	aromatase inhibitor	cancer
YM 511	Phase II	4-[[[4-bromophenyl)methyl]-4H-1,2,4-triazol-4-ylamino]benzonitrile	aromatase inhibitor	cancer; endometriosis
YM 553	Preclinical	4-[[[3,5-difluorophenyl)methyl]-5-pyrimidinylamino]benzonitrile	aromatase inhibitor	cancer
sparfosic acid; sparfosate sodium; PALA; platinum complex; CI 882; NSC 224131; Pt 268; NSC 328005	Phase III	N-(phosphonoacetyl)-L-aspartic acid, disodium salt	aspartate transcarbamylase inhibitor	cancer; viral infection
AV 04	Discontinued		azaanthraquinone	cancer
AV 17	Discontinued		azaanthraquinone	cancer
AV 38	Discontinued		azaanthraquinone	cancer
AV 43	Discontinued		azaanthraquinone	cancer
AV 57	Discontinued	6,9-dihydro-4-methyl-6-(2-nitrophenyl)-pyrido[3,2-g]quinoline-2,5,10(1H)-trione	azaanthraquinone	cancer
AV 61	Discontinued		azaanthraquinone	cancer
AV 66	Discontinued		azaanthraquinone	cancer
AV 80	Discontinued		azaanthraquinone	cancer

ImuVert	Discontinued			biological response modifier	cancer
ONO 4005	Discontinued			biological response modifier	cancer
ONO 4007	Phase II	(S)-2-deoxy-2-[[1-oxo-3-[1-oxo-9-phenylonyl)oxy]tetradecyl]amino-D-glucose, 3-benzenenonanoate 4-(hydrogensulfate), monosodium salt.		biological response modifier	cancer
VIRULIZIN	Registered			biological response modifier	cancer
RS 83277	Discontinued			biological response modifier; peptide	cancer
adiposin; lipotropin	Preclinical			biotechnology	obesity; cancer
alpha mutein; mutein, alpha; HT 003	Preclinical			biotechnology	cancer
anticancer oligonucleotides, MicroProbe	Preclinical			biotechnology	cancer
ATF HI 8	Preclinical			biotechnology	cancer
B 2036PEG; PEG-B 2036; TROVERT	Phase II			biotechnology	retinopathy; acromegaly; cancer; diabetes; kidney disease
cancer immunotherapy, MedImmune	Discontinued			biotechnology	cancer

cancer therapy, University Technologies International	Preclinical		biotechnology	cancer
cell lysis factor, Texas University	Preclinical		biotechnology	cancer
colon cancer therapy, Axis Genetics	Preclinical		biotechnology	cancer
cytolytic factor; CF	Preclinical		biotechnology	cancer
DCC tumor suppressor gene	Preclinical		biotechnology	cancer
drug delivery system, HIT breast cancer	Preclinical		biotechnology	cancer
drug delivery system, ONYX 015; ONYX 015, viraMASC coating; ONYX 015	Preclinical		biotechnology	cancer
drug delivery system, ONYX 838; ONYX 838, viraMASC coating	Preclinical		biotechnology	cancer
G 207	Phase I		biotechnology	cancer
gene discovery, hereditary glioma, Myriad	Preclinical		biotechnology	cancer
gene discovery, leukemia, Myriad	Preclinical		biotechnology	cancer
gene discovery, lung cancer, Myriad	Preclinical		biotechnology	cancer
gene therapy, anti-erbB-2 single chain	Preclinical		biotechnology	cancer

gene therapy, antisense insulin-like growth factor-1; gene therapy, antisense IGF-1	Phase I		biotechnology	cancer
gene therapy, breast cancer; gene therapy, brcal, MB 200	Preclinical		biotechnology	cancer
gene therapy, interleukin-2	Preclinical		biotechnology	cancer
HER-2/neu oncogene protein	Discontinued		biotechnology	cancer
HGF/NK1	Preclinical		biotechnology	cancer
hPRL G129R	Preclinical		biotechnology	cancer
HSV 1716	Phase I		biotechnology	cancer
human chorionic gonadotropin; hCG; OVIDREL	Phase III		biotechnology	infertility; cancer
IL-2 analogue; INGN 301; F42K	Preclinical		biotechnology	cancer
iroplact; platelet factor 4; PF4; endostatin B; REPLISTATIN	Phase II		biotechnology	heparin neutralization; psoriasis; HIV infection; cancer; diabetes
mismatched double stranded RNA; poly(I)poly(C(sub12)U); AMPLIGEN	Pre-registration		biotechnology	allergy; viral infection; blood clotting disorder; cancer; chronic fatigue syndrome
neu differentiation factor; NDF	Discontinued		biotechnology	cancer
NV 1020	Preclinical		biotechnology	cancer

ONYX 015	Phase II			biotechnology	cancer
osteoprotegerin; OPG	Phase I			biotechnology	osteoporosis; cancer
p53 gene	Preclinical			biotechnology	cancer
prostate cancer therapy, Axis Genetics	Preclinical			biotechnology	cancer
protein replacement therapy, retinoblastoma protein; protein replacement therapy, Rb protein	Preclinical			biotechnology	cancer
Salmonella typhimurium, mutagenized; mutagenized S typhimurium	Preclinical			biotechnology	cancer
single chain antigen binding protein; SCA	Preclinical			biotechnology	diagnosis; cancer
transcription factor, GM-CSF	Preclinical			biotechnology	cancer
urogenital sinus-derived growth inhibitory factor; UGIF; ps20	Preclinical			biotechnology	cancer; benign prostate hypertrophy
vaccine, beta-human chorionic gonadotrophin, Vaxcel; vaccine, cancer	Preclinical			biotechnology	cancer
vaccine, cancer, Ludwig Institute/SIGA	Preclinical			biotechnology	cancer

vaccine, non-Hodgkin's B cell lymphoma	Preclinical		biotechnology	cancer
verotoxin	Preclinical		biotechnology	cancer
angiogenesis inhibitor, Genzyme	Preclinical		biotechnology; angiogenesis inhibitor	cancer
angiopoietin 2	Preclinical		biotechnology; angiogenesis inhibitor	cancer
ANGIOSTATIN	Preclinical		biotechnology; angiogenesis inhibitor	retinopathy; cancer
BST 2001; ANGIOCOL	Preclinical		biotechnology; angiogenesis inhibitor	cancer
gene therapy, endostatin	Preclinical		biotechnology; angiogenesis inhibitor	cancer
Del-1 angiogenic protein based therapies	Preclinical		biotechnology; angiogenesis inhibitor; angiogenesis inducer	cancer; ischemia; restenosis
drug delivery system, TCS, antisense oligonucleotide, VEGFR; antisense oligonucleotide, VEGFR, TCS	Preclinical		biotechnology; angiogenesis inhibitor; antisense; oligonucleotide	cancer
BST 2002	Preclinical		biotechnology; angiogenesis inhibitor; peptide	cancer
antisense oligonucleotide, -myb; LR 3001; INX 3001	Phase I		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, c-kit	Preclinical		biotechnology; antisense; oligonucleotide	cancer

antisense oligonucleotide, c- myb	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, cancer, Enzo	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, cancer, INSERM	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, chimeric 2-5A, chronic myelogenous leukemia	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, chronic myelogenous leukemia; RGA 1512	Discontinued		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, epidermal growth factor receptor; antisense oligonucleotide, EGFR	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, insulin-like growth factor-1 receptor; antisense oligonucleotide, IGF- 1R; INX 4437	Phase I		biotechnology; antisense; oligonucleotide	cancer

antisense oligonucleotide, mdm2	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, multi-drug resistance protein-1; antisense oligonucleotide, MDR-1	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, myelogenous leukemia; GT 1102	Discontinued		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, myelogenous leukemia; GT 1106	Discontinued		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, p120; ISIS 3466	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, phospholipase A2; antisense oligonucleotide, PLA2	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, protein kinase A; GEM 231	Phase II		biotechnology; antisense; oligonucleotide	cancer

antisense oligonucleotide, protein kinase C- alpha; antisense oligonucleotide, cancer; ISIS 3521; CGP 64128A; ISI 641A	Phase II		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, protein kinase type I; antisense oligonucleotide; PKA-I	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, tumor necrosis factor; AR 797	Discontinued		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, vascular endothelial growth factor; AR 639	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, vascular endothelial growth factor; antisense oligonucleotide, VEGF; GEM 220	Preclinical		biotechnology; antisense; oligonucleotide	retinopathy; cancer; skin disease
antisense oligonucleotides, cancer, Matritech	Discontinued		biotechnology; antisense; oligonucleotide	cancer

antisense oligonucleotides, human papillomavirus 16/18; antisense oligonucleotides, HPV 16/18	Preclinical		biotechnology; antisense; oligonucleotide	cancer; viral infection
antisense oligonucleotides, multi-drug resistance protein; antisense oligonucleotides, MRP	Preclinical		biotechnology; antisense; oligonucleotide	cancer
drug delivery system, antisense oligonucleotide, erbB-2	Preclinical		biotechnology; antisense; oligonucleotide	cancer
drug delivery system, antisense oligonucleotide, p27	Preclinical		biotechnology; antisense; oligonucleotide	cancer
drug delivery system, TCS antisense oligonucleotide, c- myb; antisense oligonucleotide, TCS c-myb; INX 3000, TCS	Preclinical		biotechnology; antisense; oligonucleotide	cancer
drug delivery system, TCS INX 3280; INX 3280 TCS; INXC 6295	Preclinical		biotechnology; antisense; oligonucleotide	cancer

drug delivery system, TCS, antisense oligonucleotide, IGF-1R; antisense oligonucleotide, IGF-1R, TCS; INX 4437, TCS	Preclinical		biotechnology; antisense; oligonucleotide	cancer
antisense oligonucleotide, bcl-2; G 3139	Phase II		biotechnology; antisense; oligonucleotide; chemosensitizer	cancer
antisense oligonucleotide, raf-1, Neopharm; drug delivery system, antisense oligonucleotide, raf-1, Neopharm	Preclinical		biotechnology; antisense; oligonucleotide; radiosensitizer	cancer
antisense oligonucleotide, p65 NF-kappaB	Preclinical		biotechnology; antisense; oligonucleotide; transcription factor regulator	cancer
tumor necrosis factor apoptosis inducing ligand; TRAIL	Preclinical		biotechnology; apoptosis inducer	cancer
secreted apoptosis related proteins; SARPS	Preclinical		biotechnology; apoptosis inducer; apoptosis inhibitor	cancer; myocardial infarction; stroke
keratinocyte growth factor antagonist, NeXstar; KGF antagonist	Preclinical		biotechnology; aptamer; oligonucleotide	cancer

PDGF antagonist, NeXstar	Preclinical		biotechnology; aptamer; oligonucleotide	cancer
TGF-beta antagonist, NeXstar	Preclinical		biotechnology; aptamer; oligonucleotide	cancer
NX 1838	Phase I		biotechnology; aptamer; oligonucleotide; angiogenesis inhibitor	cancer; diabetes; retinopathy
MIG	Preclinical		biotechnology; chemokine; angiogenesis inhibitor	cancer
somatomedin binding protein; insulin-like growth factor binding protein; IGF BP-1	Suspended		biotechnology; cicatrizant	skin ulcer; cancer
interleukin-1 beta; IL- 1 beta	Discontinued		biotechnology; cicatrizant; cytokine; vaccine adjuvant	cancer; infectious disease
avotermin; transforming growth factor beta-3; TGF beta-3; CGP 46614	Phase II	transforming growth factor beta3 (human), dimer	biotechnology; cicatrizant; growth factor	cancer; skin ulcer; mucositis
tumor growth factor- alpha; TGF-alpha	Discontinued		biotechnology; cicatrizant; growth factor	eye disease; cancer; skin ulcer
fibroblast anticollagenase; FIBAC; anticollagenase fibroblast	Suspended		biotechnology; cicatrizant; NSAID	arthritis; cancer; skin ulcer; arthritis

tissue inhibitor of metalloproteinase 2; TIMP-2	Discontinued		biotechnology; collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor; gene	cancer
BC 1; AS 122; AngioMab	Phase I		biotechnology; contrast medium; monoclonal antibody; radiotherapeutic; radiodiagnostic; angiogenesis inhibitor	cancer; diagnosis
senescence derived inhibitor 1; Sdi 1	Discontinued		biotechnology; cyclin dependent kinase inhibitor	cancer; psoriasis; eye disease; cancer
multiple tumor suppressor 1-based therapy	Preclinical		biotechnology; cyclin dependent kinase inhibitor; gene	cancer
AR 324	Discontinued		biotechnology; cytokine	cancer
canarypox IL-2; AL VAC-hIL-2	Phase II		biotechnology; cytokine	cancer
drug delivery system, interleukin secreting implant; interleukin secreting implant	Preclinical		biotechnology; cytokine	cancer
IL-2 conjugate, Ajinomoto; Gal3 modified IL-2	Preclinical		biotechnology; cytokine	cancer

interleukin-3/interleukin-6 mutein chimeric molecule; IL-3/IL-6 in chimeric molecule	Suspended		biotechnology; cytokine	cancer; thrombocytopenia
interleukin-6; IL-6	Suspended		biotechnology; cytokine	cancer
interleukin-6; IL-6; SDZ ILS 969; ILS 969	Discontinued		biotechnology; cytokine	cancer; thrombocytopenia; leukopenia
interleukin-6; IL-6; SIGOSIX	Phase II		biotechnology; cytokine	cancer; thrombocytopenia
interleukin-6 mutein; IL-6 mutein; FCE 27809	Phase I		biotechnology; cytokine	cancer; thrombocytopenia
nagrestipen; nagrestip; BB 10010; MIP-1alpha	Discontinued	(human clone pAT464 macrophage inflammatory reduced), 26-L-alanine-lymphokine MIP 1alpha	biotechnology; cytokine	cancer; HIV infection
SC 68420; MPO 1	Discontinued		biotechnology; cytokine	cancer
sonermin; tumor necrosis factor; TNF; PT 050; TIENEF; TINEF	Discontinued	3-157-tumor necrosis factor (human)	biotechnology; cytokine	cancer
sonermin; tumor necrosis factor; TNF; PAC 4D	Pre-registration	3-157-tumor necrosis factor (human)	biotechnology; cytokine	cancer; psoriasis

tasonermin; tumor necrosis factor alpha; TNF-alpha; FK 516; BEROMUN	Registered		biotechnology; cytokine	cancer
tumor necrosis factor; TNF	Discontinued		biotechnology; cytokine	cancer
tumor necrosis factor; TNF	Discontinued		biotechnology; cytokine	cancer
tumor necrosis factor alpha; TNF-alpha	Preclinical		biotechnology; cytokine	cancer
tumor necrosis factor alpha tip mutants; TNF-alpha tip mutants	Discontinued		biotechnology; cytokine	cancer
gene therapy, IL-12; gene therapy, cancer	Preclinical		biotechnology; cytokine; gene therapy; biotechnology; immunostimulant	cancer
gene therapy, interferon-alpha; gene therapy, cancer	Phase II		biotechnology; cytokine; gene therapy; immunostimulant; interferon	cancer

daniplestim; interleukin-3 synthokine; IL-3 synthokine; SC 55494	Discontinued	14-ala-18-ile-25-his- 29-arg-32-asn-37-pro- 42-ser-45-met-51-arg- 55-thr-59-leu-62-val- 67-his-69-glu-73-gly- 76-ala-79-arg-82-gln- 87-ser-93-ser-98-ile- 101-ala-105-gln-109- glu-116-val-120-gln- 123-glu-14-125- interleukin 3 (human clone D11)	biotechnology; cytokine; growth factor	cancer
IL-6/IL-2 fusion protein	Preclinical		biotechnology; cytokine; growth factor; hematopoietic factor	cancer
interleukin-6; IL-6; BETATROPIN	Suspended		biotechnology; cytokine; growth factor; hematopoietic factor	cancer; thrombocytopenia
aldesleukin; interleukin-2; IL-2; PROLEUKIN	Marketed	125-L-serine-2-133- interleukin 2 (human reduced)	biotechnology; cytokine; immunostimulant	cancer; HIV infection
cancer therapy, monkey vero cell line secreting IL-2; vero- IL2	Phase II		biotechnology; cytokine; immunostimulant	cancer

celmoleukin; interleukin-2; IL-2; TAKELEUKIN; CELEUK	Marketed	A-P-T-S-S-S-T-K-K- T-Q-L-Q-L-E-H-L-L- L-D-L-Q-M-I-L-N-G- I-N-N-Y-K-N-P-K-L- T-R-M-L-T-F-K-F-Y- M-P-K-K-A-T-E-L- K-H-L-Q-C-L-E-E-E- L-K-P-L-E-E-V-L-N- L-A-Q-S-K-N-F-H-L- R-P-R-D-L-I-S-N-I- N-V-I-V-L-E-L-K-G- S-E-T-T-F-M-C-E-Y- A-D-E-T-A-T-I-V-E- F-L-N-R-W-I-T-F-C- Q-S-I-I-S-T-L-T	biotechnology; cytokine; immunostimulant	viral infection; cancer
drug delivery system, aldesleukin; drug delivery system, interleukin-2; aldesleukin DepoFoam	Discontinued		biotechnology; cytokine; immunostimulant	cancer; HIV infection
drug delivery system, interleukin-2; interleukin-2 delivery system; drug delivery system, IL-2	Discontinued		biotechnology; cytokine; immunostimulant	viral infection; cancer
drug delivery system, liposome interleukin- 2; interleukin-2 liposome; OTx 287; OncoLipin-2; OncoLipin	Phase II		biotechnology; cytokine; immunostimulant	cancer

interferon alfa-N1; IFN alfa-N1; WELLFERON; SUMIFERON; HUMOFERON	Marketed		biotechnology; cytokine; immunostimulant	cancer; viral infection
interleukin-1; IL-1	Discontinued		biotechnology; cytokine; immunostimulant	cancer
interleukin-1 alpha; IL-1a	Discontinued		biotechnology; cytokine; immunostimulant	cancer
interleukin-1 alpha derivative; OCT 7000	Suspended		biotechnology; cytokine; immunostimulant	cancer
interleukin-1 beta; IL- 1 beta; OCT 43; OCTIN	Pre- registration		biotechnology; cytokine; immunostimulant	cancer
interleukin-2; IL-2	Suspended		biotechnology; cytokine; immunostimulant	cancer
interleukin-2; IL-2; NSC 600664; LEUFERON 2	Phase III		biotechnology; cytokine; immunostimulant	cancer
interleukin-2; IL-2	Discontinued		biotechnology; cytokine; immunostimulant	cancer
interleukin-5; IL-5	Discontinued		biotechnology; cytokine; immunostimulant	cancer
interleukin-6; IL-6	Suspended		biotechnology; cytokine; immunostimulant	cancer

interleukin-7; IL-7	Preclinical		biotechnology; cytokine; immunostimulant	cancer
mito flaxone + interleukin-1; interleukin-1 + mito flaxone	Discontinued		biotechnology; cytokine; immunostimulant	cancer
oprelvekin; interleukin-11; IL-11; YM 294; NEUMEGA	Marketed		biotechnology; cytokine; immunostimulant	cancer; HIV infection; mucositis; Crohn disease
polyethylene glycol interleukin 2; PEG IL-2; interleukin 2 macrogol	Phase II		biotechnology; cytokine; immunostimulant	HIV infection; cancer
SC 71858; PMP	Phase I		biotechnology; cytokine; immunostimulant	cancer
interleukin-1 beta; IL- 1 beta	Preclinical		biotechnology; cytokine; immunostimulant; cicatrizant	cancer; skin ulcer
interleukin-3; IL-3; ALLEVORIN	Suspended		biotechnology; cytokine; immunostimulant; growth factor; hematopoietic factor	cancer
interleukin-3; IL-3	Discontinued		biotechnology; cytokine; immunostimulant; growth factor; hematopoietic factor	cancer

interleukin-3; IL-3	Phase I		biotechnology; cytokine; immunostimulant; growth factor; hematopoietic factor	cancer; leukopenia
leridistim; SC 70935; MPO	Phase III		biotechnology; cytokine; immunostimulant; growth factor; hematopoietic factor	cancer
imuplestim; interleukin-3; IL-3; SDZ ILE964; ILE 964; HEMOKINE	Phase III	human interleukin 3	biotechnology; cytokine; immunostimulant; growth factor; hematopoietic factor	cancer; thrombocytopenia; leukopenia
drug delivery system, ProLease interferon alfa; interferon alfa ProLease	Discontinued		biotechnology; cytokine; immunostimulant; interferon	viral infection; cancer
MAb, ch14.18-IL-2 fusion protein	Preclinical		biotechnology; cytokine; immunostimulant; monoclonal antibody	cancer
interleukin-4; IL-4; SCH 39400; QUADRAKINE	Phase II		biotechnology; cytokine; immunostimulant; NSAID	cancer; viral infection; rheumatoid arthritis
interleukin-12; IL-12; natural killer cell stimulatory factor; NKSF; YM 01C	Phase II		biotechnology; cytokine; immunostimulant; vaccine adjuvant	viral infection; cancer

interleukin-1 deletion mutants	Preclinical		biotechnology; cytokine; vaccine adjuvant; radioprotectant; immunostimulant	cancer; infectious disease
antisense oligonucleotide, cancer; DNA binding antisense oligonucleotide	Preclinical		biotechnology; DNA transcription inhibitor; antisense; oligonucleotide	cancer
antisense oligonucleotide, epidermal growth factor receptor; triple helix oligonucleotide, EGFR; T 03101	Discontinued		biotechnology; DNA transcription inhibitor; antisense; oligonucleotide	cancer
antisense oligonucleotide, her-2; triple helix oligonucleotide, her-2	Discontinued		biotechnology; DNA transcription inhibitor; antisense; oligonucleotide	cancer
sense oligonucleotide, NF-kappaB decoy	Discontinued		biotechnology; DNA transcription inhibitor; oligonucleotide; transcription factor regulator	cancer; viral infection
methioninase; AC 9301; ONCase	Preclinical		biotechnology; enzyme	cancer

acidic fibroblast growth factor-Pseudomonas exotoxin fusion protein; aFGF-Pseudomonas exotoxin fusion protein	Discontinued		biotechnology; fusion toxin	cancer
DWP 408	Preclinical		biotechnology; fusion toxin	cancer
epidermal growth factor diphtheria toxin chimeric protein; EGF diphtheria toxin chimeric protein; EGF fusion protein; DAB 389-EGF; DAB 389-EGF	Phase II		biotechnology; fusion toxin	cancer, restenosis; psoriasis
fusion toxin, interleukin-13 fusion protein; hIL13.E13K-PE4E	Preclinical		biotechnology; fusion toxin	cancer
GM-CSF diphtheria toxin chimeric protein; DT388 GM-CSF	Discontinued		biotechnology; fusion toxin	cancer
heregulin-Pseudomonas exotoxin fusion protein	Preclinical		biotechnology; fusion toxin	cancer

IL-4 fusion toxin; IL-4(38-37)-PE38KDEL; interleukin-4 fusion toxin; NBI 3001	Phase II			biotechnology; fusion toxin	cancer
IL13-PE38QQR; interleukin-13/pseudomonas exotoxin derivative	Preclinical			biotechnology; fusion toxin	cancer
interleukin-4-pseudomonas exotoxin A; IL-4-PE	Preclinical			biotechnology; fusion toxin	cancer
interleukin-6 diphtheria toxin chimeric protein; IL-6 diphtheria toxin chimeric protein; IL-6 fusion protein	Preclinical			biotechnology; fusion toxin	HIV infection; cancer
interleukin-6-pseudomonas exotoxin 40 chimeric protein; IL-6-PE40	Preclinical			biotechnology; fusion toxin	cancer
interleukin-6-pseudomonas exotoxin 66(4Glu) chimeric protein; IL-6-PE66(4Glu)	Preclinical			biotechnology; fusion toxin	cancer
melanocyte stimulating hormone diphtheria toxin chimeric protein; MSH diphtheria toxin chimeric protein; MSH fusion protein	Preclinical			biotechnology; fusion toxin	cancer

mitotoxin fibroblast growth factor-saporin; mitotoxin, FGF-saporin; PANTARIN	Discontinued			biotechnology; fusion toxin	cancer; restenosis; eye disease
TGFalpha-PE38; TGFalpha PE38 fusion toxin	Preclinical			biotechnology; fusion toxin	cancer
transferrin-CRM107; transferrin-toxin; HN 66000	Phase II			biotechnology; fusion toxin	cancer
transforming growth factor alpha-Pseudomonas exotoxin 40 chimeric protein; TGF alpha-PE40; TGFa-PE40	Preclinical			biotechnology; fusion toxin	cancer
interleukin-4 diphtheria toxin chimeric protein; IL-4 diphtheria toxin chimeric protein; IL-4 fusion protein	Preclinical			biotechnology; fusion toxin; immunosuppressant	autoimmune disease; transplant rejection; cancer; HIV infection
denileukin difitox; interleukin-2 diphtheria toxin chimeric protein; interleukin-2 fusion protein; DAB 389-IL-2; LY 335348; DAB389IL2; ONTAK	Marketed	1-388-toxin (Corynebacterium diphtheriae strain C7), N-L-methionyl-387-L-histidine-388-L-alanine, (388.fwdarw.2')-protein with 2-133-interleukin 2 (human clone pTIL2-21a)		biotechnology; fusion toxin; NSAID	diabetes; HIV infection; rheumatoid arthritis; psoriasis; cancer

interleukin-2 diphtheria toxin chimeric protein; interleukin-2 fusion toxin; IL-2 fusion toxin; DAB 486-IL-2; D-IL-2	Discontinued		biotechnology; fusion toxin; NSAID	diabetes; HIV infection; rheumatoid arthritis; cancer
cancer therapy, int6	Preclinical		biotechnology; gene	cancer
cancer therapy, tumor suppressor, University Technologies International	Preclinical		biotechnology; gene	cancer; diagnosis
melastatin	Preclinical		biotechnology; gene	cancer
BRUSH-1 gene based therapy; cancer therapy	Preclinical		biotechnology; gene therapy	cancer
cancer therapy, modified adenovirus, Onyx; ONYX 838	Preclinical		biotechnology; gene therapy	cancer
gene therapy, adenoviral herpes simplex virus thymidine kinase; gene therapy, cancer	Preclinical		biotechnology; gene therapy	cancer
gene therapy, anti- metastasis technology	Clinicals		biotechnology; gene therapy	cancer
gene therapy, anticancer stem cell; gene therapy, cancer	Preclinical		biotechnology; gene therapy	cancer

gene therapy, anticancer T cell; gene therapy, CC49; CC 49	Phase II		biotechnology; gene therapy	cancer
gene therapy, antisense c-myc; gene therapy, prostate cancer	Preclinical		biotechnology; gene therapy	cancer
gene therapy, Bcl-xS, cancer, IDUN	Preclinical		biotechnology; gene therapy	cancer
gene therapy, BCR-ABL transcription inhibitor protein	Preclinical		biotechnology; gene therapy	cancer
gene therapy, bcr1, Vanderbilt University	Phase II		biotechnology; gene therapy	cancer
gene therapy, breast cancer; gene therapy, bcr1, MB 300	Preclinical		biotechnology; gene therapy	cancer
gene therapy, breast cancer, Bavarian Nordic Research Institute; Procon CYP2B1	Preclinical		biotechnology; gene therapy	cancer
gene therapy, c-fos; gene therapy, cancer	Phase I		biotechnology; gene therapy	cancer
gene therapy, cancer; GENECEUTICALS	Preclinical		biotechnology; gene therapy	cancer
gene therapy, cancer; gene therapy, T-body	Discontinued		biotechnology; gene therapy	cancer
gene therapy, cancer	Preclinical		biotechnology; gene therapy	cancer
gene therapy, cancer	Preclinical		biotechnology; gene therapy	cancer

gene therapy, cancer	Preclinical		biotechnology; gene therapy	cancer
gene therapy, cancer; gene therapy, cationic lipid vectors	Preclinical		biotechnology; gene therapy	cancer
gene therapy, cancer; gene therapy, immunostimulatory genes	Phase II		biotechnology; gene therapy	cancer
gene therapy, cancer, Copernicus Gene Systems	Preclinical		biotechnology; gene therapy	cancer
gene therapy, cancer, Vion	Preclinical		biotechnology; gene therapy	cancer
gene therapy, chronic myelogenous leukemia	Phase I		biotechnology; gene therapy	cancer
gene therapy, CIITA; gene therapy, MHC class II deficiency	Preclinical		biotechnology; gene therapy	cancer
gene therapy, cytosine deaminase	Phase I		biotechnology; gene therapy	cancer
gene therapy, cytotoxic T cells; gene therapy, cancer	Suspended		biotechnology; gene therapy	cancer
gene therapy, del-1; gene therapy, vascular disease; del-1	Preclinical		biotechnology; gene therapy	coronary artery disease; peripheral vascular disease; cancer
gene therapy, delta-like protein	Preclinical		biotechnology; gene therapy	cancer
gene therapy, drug activation	Preclinical		biotechnology; gene therapy	cancer

gene therapy, E1A repressor; gene therapy, cancer; RGG 0853; RGA 0853; tgDCC-E1A	Phase II			biotechnology; gene therapy	cancer
gene therapy, Egr-1 + TNF-alpha; gene therapy, Ad5.Egr-TNF; gene therapy, radiation-controlled technology	Preclinical			biotechnology; gene therapy	cancer
gene therapy, ErbB2-R; gene therapy, cancer	Preclinical			biotechnology; gene therapy	cancer
gene therapy, fas ligand; gene therapy, cancer	Preclinical			biotechnology; gene therapy	cancer
gene therapy, fasdeltaTM; gene therapy, cancer	Preclinical			biotechnology; gene therapy	cancer
gene therapy, G156A MGMT; gene therapy, cancer	Preclinical			biotechnology; gene therapy	cancer
gene therapy, glioblastoma; G207	Preclinical			biotechnology; gene therapy	cancer
gene therapy, glioma	Discontinued			biotechnology; gene therapy	cancer
gene therapy, GM-CSF	Preclinical			biotechnology; gene therapy	cancer
gene therapy, H-Nuc	Preclinical			biotechnology; gene therapy	cancer
gene therapy, H19; gene therapy, cancer	Preclinical			biotechnology; gene therapy	cancer

gene therapy, herpes simplex thymidine kinase	Phase I		biotechnology; gene therapy	cancer
gene therapy, herpes simplex tyrosine kinase; gene therapy HS-tk	Preclinical		biotechnology; gene therapy	cancer
gene therapy, HLA-B7; gene therapy, melanoma	Preclinical		biotechnology; gene therapy	cancer
gene therapy, human papillomavirus; gene therapy, HPV	Preclinical		biotechnology; gene therapy	cancer
gene therapy, IL-12 fusion protein	Preclinical		biotechnology; gene therapy	cancer; viral infection
gene therapy, interleukin-2; AdCAIL-2	Phase I		biotechnology; gene therapy	cancer
gene therapy, interleukin-7	Discontinued		biotechnology; gene therapy	cancer
gene therapy, LeIF	Discontinued		biotechnology; gene therapy	cancer
gene therapy, leukemia, Novartis; GVH 313	Phase I		biotechnology; gene therapy	cancer
gene therapy, macrophage colony-stimulating factor	Preclinical		biotechnology; gene therapy	cancer
gene therapy, mda-7; gene therapy, melanoma	Preclinical		biotechnology; gene therapy	cancer

gene therapy, MDR-1; gene therapy, cancer	Phase I		biotechnology; gene therapy	cancer
gene therapy, men1; gene therapy, cancer	Preclinical		biotechnology; gene therapy	cancer
gene therapy, multi-drug resistance	Preclinical		biotechnology; gene therapy	cancer
gene therapy, multiple drug resistance-1; gene therapy, MDR-1	Discontinued		biotechnology; gene therapy	cancer
gene therapy, p16, Introgen; gene therapy, cancer, Introgen; INGN 221	Preclinical		biotechnology; gene therapy	cancer
gene therapy, p53; gene therapy, cancer; SCH 58500	Phase II		biotechnology; gene therapy	cancer
gene therapy, p53; gene therapy, retroviral p53; INGN 101	Phase II		biotechnology; gene therapy	cancer
gene therapy, p53; gene therapy, adenovirus p53; INGN 201	Phase II		biotechnology; gene therapy	cancer
gene therapy, p53; gene therapy, cancer; p53 TCS	Preclinical		biotechnology; gene therapy	cancer
gene therapy, p53; gene therapy, cancer	Preclinical		biotechnology; gene therapy	cancer
gene therapy, p53/MDM2	Preclinical		biotechnology; gene therapy	cancer

gene therapy, p53/WAF1	Discontinued		biotechnology; gene therapy	cancer
gene therapy, pancreatic cancer, Bavarian Nordic Research Institute; Procon CYP2B1	Phase I		biotechnology; gene therapy	cancer
gene therapy, pRb2/p130; gene therapy, cancer	Preclinical		biotechnology; gene therapy	cancer
gene therapy, pro-drug activation	Preclinical		biotechnology; gene therapy	cancer
gene therapy, prostate cancer, Calydon; CN 706	Phase I		biotechnology; gene therapy	cancer
gene therapy, PTEN; gene therapy, cancer	Preclinical		biotechnology; gene therapy	cancer
gene therapy, RB 94; SG 94; RB 94	Preclinical		biotechnology; gene therapy	cancer
gene therapy, recombinant oncolytic HSV expressing CYP2B1; rRp450	Preclinical		biotechnology; gene therapy	cancer
gene therapy, retinoblastoma gene; gene therapy, Rb gene; ACNRB	Preclinical		biotechnology; gene therapy	cancer

gene therapy, ribozyme, cancer, City of Hope Medical Center; ribozyme, cancer, City of Hope Medical Center	Preclinical		biotechnology; gene therapy	cancer
gene therapy, scFv-RAS; INGN 212	Preclinical		biotechnology; gene therapy	cancer
gene therapy, solid tumors, Oxford BioMedica; MetXia	Preclinical		biotechnology; gene therapy	cancer
gene therapy, T cell chimeric receptor; gene therapy, cancer	Discontinued		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase; gene therapy, cancer; gene therapy, HS-tk; SDZ GLI328; GLI 328	Phase III		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase; gene therapy, leptomenigeal carcinomatosis; gene therapy, HS-tk gene	Discontinued		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase; gene therapy, HS-tk; gene therapy, mesothelioma	Phase I		biotechnology; gene therapy	cancer

gene therapy, thymidine kinase; gene therapy, HS-tk; gene therapy brain cancer	Phase I		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase; gene therapy, HS-tk	Discontinued		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase; gene therapy, HS-tk	Suspended		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase; gene therapy, HS-tk	Phase I		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase; gene therapy, HS-tk	Preclinical		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase; gene therapy, HS-tk; gene therapy, cancer	Preclinical		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase; gene therapy, cancer; INXC-gTK	Preclinical		biotechnology; gene therapy	cancer
gene therapy, thymidine kinase, National Institute of Neurological Disorders and Stroke; gene therapy, HS-tk, NINDS	Phase I		biotechnology; gene therapy	cancer

SD-144110.1

gene therapy, TNF alpha	Preclinical		biotechnology; gene therapy	cancer
gene therapy, tumor necrosis factor alpha; gene therapy, solid tumor	Phase II		biotechnology; gene therapy	cancer
toxigenes	Preclinical		biotechnology; gene therapy	cancer
gene therapy, epithelial cell cancer, Cobra Therapeutics; CTL 302	Preclinical		biotechnology; gene therapy; alkylating agent	cancer
gene therapy, liver cancer, Cobra Therapeutics; CTL 203	Preclinical		biotechnology; gene therapy; alkylating agent	cancer
gene therapy, prostate cancer, Cobra Therapeutics; CTL 401	Preclinical		biotechnology; gene therapy; alkylating agent	cancer
gene therapy, angiogenesis	Preclinical		biotechnology; gene therapy; angiogenesis inhibitor	cancer
gene therapy, antiangiogenesis genes, cancer	Preclinical		biotechnology; gene therapy; angiogenesis inhibitor	cancer
gene therapy, cancer; gene therapy, angiogenesis inhibition	Preclinical		biotechnology; gene therapy; angiogenesis inhibitor	cancer

gene therapy, antisense K-ras; antisense oligonucleotide, K-ras; INGN 111	Preclinical		biotechnology; gene therapy; antisense; oligonucleotide	cancer
gene therapy, chemotherapy-resistance genes; gene therapy, MDR	Preclinical		biotechnology; gene therapy; chemoprotectant; hematoprotectant	cancer
gene therapy, MDR; gene therapy, cancer; gene therapy, MDR-1; MDRx1	Phase I		biotechnology; gene therapy; chemoprotectant; hematoprotectant	cancer
gene therapy, MDR-1; gene therapy, cancer	Phase I		biotechnology; gene therapy; chemoprotectant; hematoprotectant	cancer
gene therapy, gp91phox; gene therapy chronic granulomatous disease	Preclinical		biotechnology; gene therapy; coagulation factor	cancer
gene therapy, Sdi 1; gene therapy, cancer	Discontinued		biotechnology; gene therapy; cyclin dependent kinase inhibitor	cancer
gene therapy, cancer; gene therapy, VV-GM	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer

gene therapy, cancer; gene therapy, cytokine; gene therapy, immunostimulatory cell surface molecules	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, consensus interferon; gene therapy, IFN-con1; gene therapy, cancer	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, IL-2; gene therapy, cancer; BIWB 2	Phase II		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, IL-3, IntroGene; gene therapy, cancer, IntroGene	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interferon beta; gene therapy, cancer	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-12; gene therapy, cancer	Phase II		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-12/B7-1; gene therapy, AdIL12.B7-1; gene therapy, cancer; AdIL12.B7-1	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, cancer	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer

gene therapy, interleukin-2; gene therapy, cancer	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, melanoma	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, cancer	Phase II		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, cancer; AC 9401; MetaGene	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, cancer; VCL 1102; LEUVECTIN	Phase II		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, breast cancer; AVECTIN	Discontinued		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, cancer; BIWB 1	Discontinued		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, cancer	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, cancer	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer

gene therapy, interleukin-2; gene therapy, neuroblastoma	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, colon cancer	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2; gene therapy, IL-2; gene therapy, melanoma	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2 + interferon gamma; gene therapy, cancer	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2 + thymidine kinase; gene therapy, cancer	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-2, interferon gamma, thymidine kinase; gene therapy, cancer	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-4; gene therapy, melanoma	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, interleukin-7; gene therapy, IL-7; gene therapy, malignant melanoma	Suspended		biotechnology; gene therapy; cytokine; immunostimulant	cancer

gene therapy, interleukin-7; gene therapy, IL-7	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, tumor necrosis factor; gene therapy, TNF; gene therapy, cancer	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant	cancer
gene therapy, tumor necrosis factor; gene therapy, cancer	Phase I		biotechnology; gene therapy; cytokine; immunostimulant	cancer
NV 1030	Preclinical		biotechnology; gene therapy; cytokine; immunostimulant; angiogenesis inhibitor	cancer
gene therapy, granulocyte macrophage-colony stimulating factor, Geniva; gene therapy, cancer, Geniva	Phase I		biotechnology; gene therapy; cytokine; immunostimulant; vaccine	cancer
gene therapy, MDR, GenPak; gene therapy, cancer	Phase II		biotechnology; gene therapy; hematoprotectant; chemoprotectant	cancer
gene therapy, MRP; gene therapy, cancer	Preclinical		biotechnology; gene therapy; hematoprotectant; chemoprotectant	cancer

gene therapy, HLA-B7; gene therapy, cancer; gene therapy, HLA-B7/cytotoxic complex; ALLOVECTIN-7	Phase III		biotechnology; gene therapy; immunostimulant	cancer
gene therapy, IL-2; gene therapy, small cell lung cancer; gene therapy, BPV vector	Phase I		biotechnology; gene therapy; immunostimulant	cancer
gene therapy, suicide gene + immunotherapeutic; gene therapy, cancer	Preclinical		biotechnology; gene therapy; immunostimulant	cancer
gene therapy, gamma interferon; gene therapy, cancer	Phase I		biotechnology; gene therapy; immunostimulant; cytokine	cancer
gene therapy, GM-CSF; gene therapy, cancer; vaccine, cancer; GVAX	Phase II		biotechnology; gene therapy; immunostimulant; cytokine	cancer
gene therapy, interleukin-10; gene therapy, cancer	Preclinical		biotechnology; gene therapy; immunostimulant; cytokine	cancer
gene therapy, interleukin-2; gene therapy, melanoma; gene therapy, tyrosinase promoter	Phase I		biotechnology; gene therapy; immunostimulant; cytokine	cancer

gene therapy, interleukin-2; gene therapy, melanoma	Phase I		biotechnology; gene therapy; immunostimulant; cytokine	cancer
gene therapy, interleukin-2; gene therapy, melanoma	Phase I		biotechnology; gene therapy; immunostimulant; cytokine	cancer
gene therapy, interleukin-2; gene therapy, melanoma	Phase I		biotechnology; gene therapy; immunostimulant; cytokine	cancer
gene therapy, interleukin-2; gene therapy, AdCAIL-2; gene therapy, cancer; AdCAIL-2	Phase I		biotechnology; gene therapy; immunostimulant; cytokine	cancer
gene therapy, interleukin-4; gene therapy, cancer	Phase I		biotechnology; gene therapy; immunostimulant; cytokine	cancer
gene therapy, interleukin-4; gene therapy, melanoma	Preclinical		biotechnology; gene therapy; immunostimulant; cytokine	cancer
gene therapy, leukemia; gene therapy, immunostimulatory molecules	Preclinical		biotechnology; gene therapy; immunostimulant; cytokine	cancer

gene therapy, interferon alfa	Preclinical		biotechnology; gene therapy; immunostimulant; cytokine; interferon	cancer
gene therapy, interferon gamma; gene therapy, cancer	Preclinical		biotechnology; gene therapy; immunostimulant; cytokine; interferon	cancer
gene therapy, MRP; gene therapy, cancer	Preclinical		biotechnology; gene therapy; MDR inhibitor	cancer
gene therapy, multidrug resistance; gene therapy, MDR	Discontinued		biotechnology; gene therapy; MDR inhibitor	cancer
gene therapy, herpes simplex thymidine kinase gene; gene therapy, cancer	Phase I		biotechnology; gene therapy; NSAID	rheumatoid arthritis; restenosis; cancer
gene therapy, transforming growth factor beta; oligonucleotide, TGF beta	Phase I		biotechnology; gene therapy; oligonucleotide	cancer
gene therapy, hammerhead ribozyme, cancer, Berlex Biosciences; ribozyme, c-erb-B2, Berlex Biosciences	Preclinical		biotechnology; gene therapy; oligonucleotide; ribozyme	cancer

gene therapy, Ad(GV)CD.10; gene therapy, cytosine deaminase; gene therapy, colon cancer	Phase II		biotechnology; gene therapy; radiosensitizer	cancer
gene therapy, p53; vaccine, p53; gene therapy, cancer	Preclinical		biotechnology; gene therapy; vaccine	cancer
vaccine, gene-based, B cell lymphoma	Phase I		biotechnology; gene therapy; vaccine	cancer
vaccine, gene-based, carcinoembryonic antigen; vaccine, gene-based, pGT37; vaccine, gene-based, cancer	Preclinical		biotechnology; gene therapy; vaccine	cancer
vaccine, gene-based, E7; vaccine, gene-based cancer	Preclinical		biotechnology; gene therapy; vaccine	cancer
vaccine, gene-based, gp100; vaccine, gene-based, melanoma	Phase I		biotechnology; gene therapy; vaccine	cancer
vaccine, gene-based, gp100 + MART-1; vaccine, gene-based, melanoma	Phase II		biotechnology; gene therapy; vaccine	cancer
vaccine, gene-based, MART-1; vaccine, gene-based, cancer	Phase I		biotechnology; gene therapy; vaccine	cancer

vaccine, gene-based, melanoma, Bavarian Nordic Research Institute; gene therapy, melanoma, Bavarian Nordic Research Institute; MVA TYR	Preclinical		biotechnology; gene therapy; vaccine	cancer
vaccine, gene-based, NY-ESO-1; vaccine, gene-based, cancer	Preclinical		biotechnology; gene therapy; vaccine	cancer
vaccine, gene-based, T cell cancer	Preclinical		biotechnology; gene therapy; vaccine	cancer
vaccine, human papillomavirus antigens; vaccine HPV antigens; vaccine, cervical cancer	Discontinued		biotechnology; gene therapy; vaccine	cancer
anti-dorsalizing morphogenetic protein-1	Preclinical		biotechnology; growth factor	cancer
heregulin; Neu differentiation factor; NDF	Discontinued		biotechnology; growth factor	cancer
megakaryocyte stimulating factor	Discontinued		biotechnology; growth factor	cancer
Red blood cell growth factor	Preclinical		biotechnology; growth factor	cancer
transforming growth factor beta; TGF beta; BMS 196725	Preclinical		biotechnology; growth factor	cancer; mucositis

transforming growth factor beta; TGF-beta	Preclinical		biotechnology; growth factor	mucositis; cancer; musculoskeletal disorder
keratinocyte growth factor 2; KGF 2; HG 03400	Phase II		biotechnology; growth factor; cicatrizant; chemoprotectant; cytoprotectant	cancer; mucositis; skin ulcer; alopecia; kidney disease
granulocyte macrophage colony stimulating factor muteins; GM-CSF muteins	Preclinical		biotechnology; growth factor; hematopoietic factor	cancer
polyethylene glycol hemoglobin; PEG-hemoglobin	Phase I		biotechnology; growth factor; hematopoietic factor	cancer; anemia
polyethylene glycol megakaryocyte growth and development factor; PEG-MGDF	Discontinued		biotechnology; growth factor; hematopoietic factor	cancer; thrombocytopenia
polyethylene glycol granulocyte macrophage colony stimulating factor glycol; PEG-GM-CSF; PolyMASC-GM-CSF	Preclinical		biotechnology; growth factor; hematopoietic factor	cancer
thrombopoietin; TPO; megakaryocyte growth and development factor; MGDF	Phase III		biotechnology; growth factor; hematopoietic factor	cancer; thrombocytopenia

thrombopoietin; TPO	Discontinued		biotechnology; growth factor; hematopoietic factor	cancer; thrombocytopenia
thrombopoietin; TPO	Preclinical		biotechnology; growth factor; hematopoietic factor	cancer; thrombocytopenia
milodistim; granulocyte macrophage colony stimulating factor/interleukin-3 chimeric; GM- CSF/IL-3 chimeric protein; PIXY 321; BMS 185032; PIXYKINE	Discontinued	APARSPSPST QPWEHVNAIQ EALRLDLLSR DTAAEMNEEV EWISEMFDLQ EPTCLQTRLE LYKQGLRGS TKLKGPLTMM ASHYKQHCPP TPETSCATQI ITFESFKENL KDFLLVIPFD CWEPVQEGGG GSGGGGSAD MTQTTPLKTS WVDCSNMIDE IITHLKQPPL PLLDFNNLNG EDQDILMENN LRRPNLEAFN RAVKSLQDAS AIESILKNLL PCLPLATAAP TRHPIHKDG DWNEFRRLT FYLKTLENAQ AQQTTLALF	biotechnology; growth factor; hematopoietic factor; cytokine; immunostimulant	cancer

cilmostim; macrophage colony stimulating factor; M- CSF; MACSTIM	Discontinued		biotechnology; growth factor; hematopoietic factor; immunostimulant	hyperlipidemia; bacterial infection; cancer
filgrastim; granulocyte colony stimulating factor; G- CSF; neutropoietin; KRN 8601; NEUPOGEN; GRANULOKINE; GRAN; GRIMATIN	Marketed	N-L-methionyl- colony-stimulating factor (human clone 1034)	biotechnology; growth factor; hematopoietic factor; immunostimulant; cicatrizant	cancer; HIV infection; pneumonia; leukopenia; skin ulcer
filgrastim SD01; PEG-granulocyte- colony stimulating factor; PEG-GCSF; SD-NEUPOGEN	Phase II		biotechnology; growth factor; hematopoietic factor; immunostimulant	cancer; HIV infection; pneumonia; leukopenia
granulocyte macrophage colony stimulating factor; GM-CSF; LEUCOTROPIN	Phase III		biotechnology; growth factor; hematopoietic factor; immunostimulant	cancer; leukopenia
macrophage inflammatory protein- 1alpha; MIP-1alpha	Preclinical		biotechnology; growth factor; hematopoietic factor; immunostimulant	cancer

molgramostim; granulocyte macrophage colony stimulating factor; GM-CSF; GMC 89107; SCH 39300; CSF 39300; LEUCOMAX	Marketed	colony stimulating factor 2 (human clone pHG25 protein moiety reduced)	biotechnology; growth factor; hematopoietic factor; immunostimulant	cancer; leukopenia
marogastim; granulocyte colony stimulating factor munein; G-CSF munein; KW 2228; NEU-UP	Marketed	1-(N-L-methionyl-L- alanine)-3-L- threonine-4 L- tyrosine-5-L-arginine- 17-L-serine-colony- stimulating factor (human clone 1034)	biotechnology; growth factor; hematopoietic factor; immunostimulant	cancer; leukopenia
pegnartogastim; pegylated G-CSF munein; PEG-G; Ro 258315; Ro 25-8315; Ro 25-8315/000	Suspended	Pegnartogastim	biotechnology; growth factor; hematopoietic factor; immunostimulant	cancer
polyethylene glycol granulocyte colony stimulating factor; PEG-G-CSF; granulocyte colony stimulating factor macrogol	Discontinued		biotechnology; growth factor; hematopoietic factor; immunostimulant	cancer
progenipoietin; progenipoietin G; SD 1091	Preclinical		biotechnology; growth factor; hematopoietic factor; immunostimulant	cancer

totipotent stem cell factor; T-SCF	Preclinical		biotechnology; growth factor; hematopoietic factor; immunostimulant	cancer
FLT3 ligand, DNAX Research Institute; FLT 3	Preclinical		biotechnology; growth factor; immunostimulant; hematopoietic factor	cancer
Flt3 ligand, Immunex; FLT 3; FLT 003; MOBIST	Phase II		biotechnology; growth factor; immunostimulant; hematopoietic factor; vaccine adjuvant	cancer
stem cell proliferation factor; SCPF	Preclinical		biotechnology; growth factor; immunostimulant; hematopoietic factor	cancer
DWP 404	Preclinical		biotechnology; hematopoietic factor; growth factor	cancer; thrombocytopenia
TPO-Rp	Preclinical		biotechnology; hematopoietic factor; growth factor; peptide	thrombocytopenia; cancer
thyroid stimulating hormone; TSH; THYROGEN	Marketed	thyrotropin (human .beta.-subunit) complex with chorionic gonadotropin (human .alpha.-subunit)	biotechnology; hormone	cancer; diagnosis; hypothyroidism
polyethylene glycol arginase; PEG-arginase; arginase macrogol	Discontinued		biotechnology; hydrolase; arginase; enzyme	cancer

pegaspargase; polyethylene glycol L-asparaginase; PEG- L-asparaginase; asparaginase macrogol; ONCASPAR	Marketed	pegaspargase	biotechnology; hydrolase; asparaginase; enzyme	cancer
cervical cancer therapy, Transgene	Preclinical		biotechnology; immunostimulant	cancer
immunotherapeutic, cancer, Transgene	Phase II		biotechnology; immunostimulant	cancer
mistletoe lectin; mistellektin	Preclinical		biotechnology; immunostimulant	cancer
totipotent stem cell receptor; FLK 2	Discontinued		biotechnology; immunostimulant	cancer
gene therapy, macrophage activated killer cells plus bispecific antibody; MAK therapy; MAK	Phase II		biotechnology; immunostimulant; gene therapy	cancer
ancestim; stem cell factor; SCF; STEMGEN	Pre- registration	N-L-methionyl-1- 165-hematopoietic cell growth factor KL (human clone V19.8:hSCF162) dimer	biotechnology; immunostimulant; growth factor; hematopoietic factor	cancer
granulocyte colony- stimulating factor; BM 800001	Suspended		biotechnology; immunostimulant; growth factor; hematopoietic factor	cancer

interleukin-9; IL-9	Discontinued			biotechnology; immunostimulant; growth factor; hematopoietic factor	cancer
lenograstim; granulocyte colony stimulating factor; G- CSF; pluripoiectin; NEUTROGIN; GRANOCYTE; EUPROTIN; MYELOSTIM	Marketed	133-[O-[O-(N-acetyl- alpha-neuraminosyl)- (2-3)-O-beta-D- galactopyranosyl-(1- 3)-2-(acetylamino)-2- deoxy-beta-D- galactopyranosyl]-L- threonine]-colony stimulating factor (human clone 1034)		biotechnology; immunostimulant; growth factor; hematopoietic factor	anemia; HIV infection; cancer; leukopenia
sargamostim; granulocyte macrophage colony stimulating factor; GM-CSF; BI 61012; rhu GM-CSF; LEUKINE; PROKINE; INTERBERIN	Marketed	23-L-leucine colony- stimulating factor 2 (human clone pHG25 protein moiety)		biotechnology; immunostimulant; growth factor; hematopoietic factor; vaccine adjuvant	cancer; infectious disease; HIV infection; leukopenia
stem cell factor; SCF	Discontinued			biotechnology; immunostimulant; growth factor; hematopoietic factor	cancer
ImmTher	Phase II			biotechnology; immunostimulant; peptide	cancer

vaccine, prostate cancer; JT 1001; Onco Vax-P; Onco Vax-Pr	Phase II		biotechnology; immunostimulant; vaccine	cancer
cytokine cocktail; BC-IL; leukocyte interleukin injection; MULTIKINE	Phase II		biotechnology; immunostimulant; vaccine adjuvant; cytokine	cancer; infectious disease; HIV infection
ZYN-LINKER conjugated superantigens	Suspended		biotechnology; immunosuppressant; immunostimulant; NSAID	rheumatoid arthritis; cancer
MAb, human interleukin-6 receptor; MAb, human IL-6 receptor; hPM-1; MRA	Phase I		biotechnology; immunosuppressant; monoclonal antibody	autoimmune disease; cancer
E 2 IR	Preclinical		biotechnology; immunosuppressant; NSAID	cancer; inflammation; allergy
G28-5 sFV-PE40	Preclinical		biotechnology; immunotoxin	cancer
immunotoxin, lymphoma	Discontinued		biotechnology; immunotoxin	cancer
MAb, glioma/neuroblastoma-gelatin; GLIOMAB-H	Phase I		biotechnology; immunotoxin	cancer
immunotoxin, cancer; Immunomedics/NCI	Preclinical		biotechnology; immunotoxin; monoclonal antibody	cancer

MAb, epidermal growth factor receptor-DM1; MAb, EGFR-DM1	Preclinical		biotechnology; immunotoxin; monoclonal antibody	cancer
MAb, interleukin-13-PE38QQR; immunotoxin, IL-13-PE38QQR	Preclinical		biotechnology; immunotoxin; monoclonal antibody	cancer
MAb, ricin A immunotoxin; MAb, colorectal cancer; ZD 0490; ICI D0490	Discontinued		biotechnology; immunotoxin; monoclonal antibody	cancer
MAb, SS(dsFv)-PE38	Preclinical		biotechnology; immunotoxin; monoclonal antibody	cancer
MAb, venus flytrap cluster conjugate	Preclinical		biotechnology; immunotoxin; monoclonal antibody	cancer; diagnosis

macolomab tafenatox; Phase I MAB, C242- staphylococcal enterotoxin A; FAb, C242-staphylococcal enterotoxin A; PNU 214565; LS 4565; TTMA LS 4585	20-244- immunoglobulin G1, anti-(human colorectal tumor antigen C242) Fab fragment (mouse monoclonal r- C242Fab-SEA clone pKP941 gamma1- chain) fusion protein with enterotoxin A (Staphylococcus aureus), disulfide with mouse monoclonal r- C242Fab-SEA clone pKP941 kappa-chain	biotechnology; immunotoxin; monoclonal antibody	cancer
MAB, doxorubicin conjugate; MAB, BR 96-doxorubicin; MAB, BR 96-DOX; BMS 182248; BMS 18224801	Phase II	biotechnology; immunotoxin; monoclonal antibody; anthracycline; antibiotic; DNA intercalator	cancer
MAB, B43-genistein; B43-Gen immunoconjugate	Phase I	biotechnology; immunotoxin; monoclonal antibody; tyrosine kinase inhibitor	cancer

drug delivery system, interferon alfa; interferon alfa drug delivery system; SUMIFERON MINIPLET	Pre-registration		biotechnology; interferon	viral infection; cancer
drug delivery system, interferon beta; interferon beta delivery system; drug delivery system, IFN beta	Discontinued		biotechnology; interferon	cancer; viral infection; cancer; viral infection
drug delivery system, oral interferon alfa-2a; IFN alfa-2a, oral	Suspended		biotechnology; interferon	cancer; viral infection
interferon alfa, natural; IFN-alfa, natural; EGIFERON	Marketed		biotechnology; interferon	cancer; viral infection
interferon alpha, hybrid; hybrid interferon alpha	Preclinical		biotechnology; interferon	viral infection; cancer
interferon alpha, natural; FPI 31	Pre-registration		biotechnology; interferon	viral infection; cancer
interferon beta; IFN-beta; DL 8234; FERON	Marketed		biotechnology; interferon	viral infection; cancer; retinopathy
interferon beta; IFN-beta	Discontinued		biotechnology; interferon	cancer; viral infection
interferon beta-1a; IFN beta; AVONEX	Marketed	interferon beta-1a	biotechnology; interferon	viral infection; multiple sclerosis; cancer

interferon beta-1a; interferon beta; IFN- beta; REBIF	Marketed		biotechnology; interferon	cancer; viral infection; multiple sclerosis; inflammatory bowel disease
interferon beta-1b; interferon beta-serine; SH 579; ZK 157046; BETASERON; BENESERON; BETAFERON	Marketed	2-166-interferon beta 1 (human fibroblast reduced)	biotechnology; interferon	multiple sclerosis; cancer; viral infection
interferon omega; IFN omega	Phase II		biotechnology; interferon	viral infection; cancer
polyethylene glycol interferon alfa-2b; PEG-interferon alfa- 2b; interferon alfa-2b macrogol; PEG- INTRON A	Phase III		biotechnology; interferon; cytokine	viral infection; cancer
interferon alfa-2b; IFN alfa-2b; SCH 30500; YM 1490; INTRON A; CIBIAN; VIRAFERON	Marketed		biotechnology; interferon; cytokine; immunostimulant	cancer; viral infection
tumor necrosis factor + interferon alfa-2a; interferon alfa-2a + tumor necrosis factor; TNF + IFN alfa-2a	Discontinued		biotechnology; interferon; growth factor	cancer

interferon alfa-2a; IFN alfa-2a; Ro 228181; ROFERON A; CANFERON A; ROFERON	Marketed	(human leukocyte protein moiety) interferon alpha A	biotechnology; interferon; immunostimulant	viral infection; cancer
interferon gamma-1a; SUN 4800; BIOGAMMA	Marketed		biotechnology; interferon; immunostimulant	cancer
interferon gamma-1b; interferon gamma; IFN gamma; ACTIMMUNE; IMUKIN; IMUFOR GAMMA	Marketed		biotechnology; interferon; immunostimulant	cancer; bacterial infection; chronic granulomatous disease; tuberculosis
interferon, consensus; consensus interferon; interferon alfacon-1; YM 643; INFERGEN	Marketed	interferon alpha 1 (human lymphoblast reduced), N-L- methionyl-22-L-arg- 76-L-ala-78-L-asn- 79-L-glu-86-L-tyr-90- L-tyr-156-L-thr-157- L-asn-158-L-leu-	biotechnology; interferon; immunostimulant	viral infection; cancer
3622W94; BW 3622W94	Phase II		biotechnology; monoclonal antibody	cancer
antibodies, Sdi 1	Discontinued		biotechnology; monoclonal antibody	cancer
detumomab; MAb, idiotype B cell lymphoma; MAb, B cell lymphoma; B cell lymphoma MAb; SPECIFID	Discontinued		biotechnology; monoclonal antibody	cancer

drug delivery system, liposome MAb, 273-34A; MAb, 273-34A liposome; liposome, MAb 273-34A	Preclinical			biotechnology; monoclonal antibody	cancer
edrecolomab; MAb, 17-1A; MAb, colorectal cancer; MAb, CO17-1A; 17-1A; C-I; PANOREX	Marketed	immunoglobulin G 2a (mouse monoclonal 17-1A gamma-chain anti-human colon cancer tumour-associated antigen), disulfide with mouse monoclonal 17-1A light chain dimer		biotechnology; monoclonal antibody	cancer
lintuzumab; MAb, humanized M195; MAb, humanized CD33; SMART M195; HuM195	Phase III	immunoglobulin G1 (human-mouse monoclonal HuM195.gamma.1-chain anti-human antigen CD 33), disulfide with human monoclonal HuM195.kappa.-chain, dimer		biotechnology; monoclonal antibody	cancer
lintuzumab-bismuth-213; MAb, humanized M195-213Bi	Phase I			biotechnology; monoclonal antibody	cancer
LYM 2	Preclinical			biotechnology; monoclonal antibody	cancer
MAb, 12G5	Preclinical			biotechnology; monoclonal antibody	cancer

MAB, 2A11; MAB, gastrin releasing peptide	Phase II		biotechnology; monoclonal antibody	cancer
MAB, 323A3; 323A3	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, 3F8; IgG3 anti-ganglioside GD 2; MAB, neuroblastoma	Phase I		biotechnology; monoclonal antibody	cancer
MAB, 42/6; MAB, transferrin receptor	Phase I		biotechnology; monoclonal antibody	cancer
MAB, 88BV59-rhenium 186	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, 977; MAB, bladder cancer	Preclinical		biotechnology; monoclonal antibody	cancer; diagnosis
MAB, 9D9	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, adrenomedullin	Preclinical		biotechnology; monoclonal antibody	cancer; diabetes; Alzheimer disease; diagnosis
MAB, antiganglioside GM2; KM 966	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, antinuclear auto-antibodies; MAB, cancer	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, B cell lymphoma; 1D10	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, B-E4; MAB, interleukin-6; MAB, IL-6; B-E4	Phase I		biotechnology; monoclonal antibody	cancer
MAB, B4-DC1	Discontinued		biotechnology; monoclonal antibody	cancer

MAB, B6.2/212 single chain antibody; MAB, B6.2/212 SCA	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, BCD F9- radionuclide; MAB, breast cancer; BCD F9	Phase I		biotechnology; monoclonal antibody	cancer; diagnosis
MAB, bispecific F(ab') ₂ OC/TR; OCTR	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, bispecific hu- bsF(ab') ₂	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, bladder carcinoma; RG 355	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, BR 96; BR 96	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, breast cancer antigen; Pro 1.5.3	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, BW 494	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, c-Nd2; c-Nd2	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, C215- staphylococcal enterotoxin; FAb, C215-SEA	Phase II		biotechnology; monoclonal antibody	cancer
MAB, C242; MAB, colonic adenocarcinoma	Discontinued		biotechnology; monoclonal antibody	cancer; diagnosis
MAB, C242-DM 1 conjugate; huC242- DM1	Preclinical		biotechnology; monoclonal antibody	cancer

MAb, C242-maytansine conjugate	Preclinical			biotechnology; monoclonal antibody	cancer
MAb, cancer	Phase III			biotechnology; monoclonal antibody	cancer
MAb, cancer; MAb, EpCAM	Preclinical			biotechnology; monoclonal antibody	cancer
MAb, cancer; BW 1209W95	Preclinical			biotechnology; monoclonal antibody	cancer
MAb, cancer; hybrid antibody, anti-Her-2, anti-CD3	Preclinical			biotechnology; monoclonal antibody	cancer
MAb, cancer and Fc; bispecific antibody, melanoma, glioma, neuroblastoma; MDX 260	Preclinical			biotechnology; monoclonal antibody	cancer
Mab, cancer, BioInvent	Preclinical			biotechnology; monoclonal antibody	cancer
MAb, cancer, PPL	Preclinical			biotechnology; monoclonal antibody	cancer
MAb, cancer, XTL Biopharmaceuticals; MAb, cancer, Neoprobe	Preclinical			biotechnology; monoclonal antibody	cancer
MAb, carcinoembryonic antigen; MAb, CEA	Preclinical			biotechnology; monoclonal antibody	cancer
MAb, carcinoembryonic antigen; MAb, CEA	Preclinical			biotechnology; monoclonal antibody	cancer

MAb, carcinoma; MAb, SK-1; MAb, cancer; MONOPHARM C	Phase I		biotechnology; monoclonal antibody	cancer
MAb, CC49; MAb, TAG B723; MAb, B723 second generation	Phase II		biotechnology; monoclonal antibody	cancer
MAb, CC49-interleukin-2; fusion protein, CC49-IL-2	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, CC49-lutetium 177; MAb, anti-TAG-72-lutetium 177	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, CC83; MAb, TAG B723; MAB, B723 second generation	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, CD19/CD3; bispecific antibody, cancer	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, CD28/CD30; Bi-MoAb	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, CD3/CD30; Bi-MoAb; bispecific antibody, CD3, CD30	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, CD34; anti-CD34	Phase I		biotechnology; monoclonal antibody	cancer
MAb, CD87; MAb, cancer, Willex Biotechnology	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, ch14.18	Phase II		biotechnology; monoclonal antibody	cancer

MAB, chemotherapeutic conjugates, IDEC	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, chimeric CC49; MAB, chimeric TAG B723	Phase I		biotechnology; monoclonal antibody	cancer
MAB, chimeric CC83; MAB, TAG B723	Phase I		biotechnology; monoclonal antibody	cancer
MAB, chimeric IgG1 anti CD20	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, colon-DM1	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, colorectal cancer	Phase I		biotechnology; monoclonal antibody	cancer; diagnosis
MAB, CYT 372 humanized; MAB, C46 humanized; MAB, humanized panadenocarcinoma	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, directed enzyme prodrug therapy; ADEPT, cancer therapy	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, directed enzyme prodrug therapy + CMDA; ADEPT + CMDA; ZD 2767	Phase II		biotechnology; monoclonal antibody	cancer
MAB, EGF-R and Fc; bispecific antibody, cancer; MDX 447; H 447; EMD 82633	Phase II		biotechnology; monoclonal antibody	cancer

MAB, epidermal growth factor receptor; MAB, EGF receptor; EMD 55900	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, epidermal growth factor receptor; MAB, EGF receptor; MAB, 528; MoAb528	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, epidermal growth factor receptor; MAB, EGFR; C 225	Phase III		biotechnology; monoclonal antibody	cancer
MAB, epidermal growth factor receptor; MAB, EGFR; ICR 62	Phase I		biotechnology; monoclonal antibody	cancer
MAB, epidermal growth factor, humanized; MAB, EGF, humanized; EMD 72000	Phase I		biotechnology; monoclonal antibody	cancer
MAB, erbB-2; MAB, cancer	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, erbB2	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, F(ab)2 NRC002-rhenium 186; MAB, antiCEA	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, F4	Preclinical		biotechnology; monoclonal antibody	cancer

MAb, FAb NRLU10-radionuclide; MAb, lung cancer; MAb, prostate cancer	Phase I		biotechnology; monoclonal antibody	cancer; diagnosis
MAb, fas; MAb, bladder cancer	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, FC-2.15	Phase II		biotechnology; monoclonal antibody	cancer
MAB, fibroblast growth factor receptor; MAb, FGFR	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, germ cell cancer; ImmuRAID-HCG	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, gp75; MELVAX II	Preclinical		biotechnology; monoclonal antibody	cancer
Mab, heparanase	Preclinical		biotechnology; monoclonal antibody	cancer; diagnosis
MAB, HER-2 immunoliposome	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, HER2/neu20 immunoliposomes, breast cancer; C 6.5	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, Hodgkin's lymphoma	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, human antiganglioside	Phase II		biotechnology; monoclonal antibody	cancer
MAB, human chorionic gonadotropin; MAb, hCG; CTP 103	Preclinical		biotechnology; monoclonal antibody	cancer

MAb, human chorionic gonadotropin, human; MAb, hCG, human	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, human EpCAM; UBS 54	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, humanized LL2; MAb, B cell lymphoma; LymphoCide	Phase II		biotechnology; monoclonal antibody	cancer
MAb, humanized N901-DC1	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, humanized, cancer; MAb, cancer humanized	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, IgG1 fragment	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, IGX	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, ING-1; MAb, carcinoma	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, interleukin-6; MAb, IL-6	Phase I		biotechnology; monoclonal antibody	cancer
MAb, KAI1; MAb, cancer	Preclinical		biotechnology; monoclonal antibody	cancer
MAb, KM641; KM 641	Discontinued		biotechnology; monoclonal antibody	cancer
MAb, L 6; L 6	Discontinued		biotechnology; monoclonal antibody	cancer

MAB, L6 alkaline phosphatase conjugate; L6 alkaline phosphatase MAB conjugate; MAB, carcinoma	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, Lewis Y; ABL 364; SDZ ABL 364	Phase I		biotechnology; monoclonal antibody	cancer
MAB, Lewis Y, humanized; HuABL 364; SMART ABL 364; BR 55-2	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, LL2-rhenium 188; Re-188-LL2	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, MAB fragment, REC A33-nuclide	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, mB43-technetium 99m; Tru-Scint OV	Phase II		biotechnology; monoclonal antibody	cancer; diagnosis
MAB, MDX 11; MAB, myeloid leukemia; MAB, CD15; MDX 11; PM 81	Phase II		biotechnology; monoclonal antibody	cancer
MAB, melanoma; MAB, cancer; MONOPHARM M	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, melanoma, Novartis; CGP 62360	Phase I		biotechnology; monoclonal antibody	cancer
MAB, MN-14 carcinoembryonic antigen; MAB, MN-14 CEA; CEA-Cide	Phase II		biotechnology; monoclonal antibody	diagnosis; cancer

MAB, MRK 20; MRK 20	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, multiple myeloma, U-BiSys	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, oncology, Glaxo Wellcome	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, ONS M21; ONS M21	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, P-67; MAB, acute myelogenous leukemia	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, PAM4	Phase I		biotechnology; monoclonal antibody	cancer
MAB, polymorphic epithelial mucin; MAB, PEM; AS 125	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, prostate cancer	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, prostate cancer	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, prostate cancer	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, SM3 phosphorus 32	Discontinued		biotechnology; monoclonal antibody	cancer
MAB, TAG-72	Preclinical		biotechnology; monoclonal antibody	cancer
MAB, TAG-72 and Fc; bispecific antibody, cancer; MDX 220	Phase II		biotechnology; monoclonal antibody	cancer

MAB, TB94, human; MAb, TB94, IgA1k; MAb, small cell lung cancer	Preclinical			biotechnology; monoclonal antibody	cancer
MAB, TH69	Preclinical			biotechnology; monoclonal antibody	cancer
MAB, transcobalamin II; MAB, vitamin B12 carrier protein, Receptagen	Preclinical			biotechnology; monoclonal antibody	cancer
MAB, transferrin receptor targeted immunotoxin; MAB, tfnR targeted immunotoxin; tfnR-CRM107	Preclinical			biotechnology; monoclonal antibody	cancer
MAB, tumor necrosis factor; MAB, TNF; SMA TNF	Preclinical			biotechnology; monoclonal antibody	Crohn disease; cancer; septic shock
MAB, tumor necrosis factor alpha; MAB, TNF-alpha; MAB32	Discontinued			biotechnology; monoclonal antibody	cancer
MAB, U36/E48	Discontinued			biotechnology; monoclonal antibody	cancer
MAbs, cancer, human, Medarex	Preclinical			biotechnology; monoclonal antibody	cancer
MAbs, chimeric, cancer	Preclinical			biotechnology; monoclonal antibody	cancer
MAbs, pancreatic carcinoma, B-cell tumor; bispecific antibody, cancer	Preclinical			biotechnology; monoclonal antibody	cancer

prostate carcinoma tumor antigens	Discontinued			biotechnology; monoclonal antibody	cancer; diagnosis
rituximab; MAb, CD20; MAb, pan-B; IDEC 2B8; Ro 425294; IDEC 102; RITUXAN; MabThera	Marketed	immunoglobulin G1 (human-mouse monoclonal IDEC-C2B8 gamma 1-chain anti-human antigen CD 20), disulfide with human-mouse monoclonal IDEC-C2B8 kappa-chain, dimer		biotechnology; monoclonal antibody	cancer
SDZ MMA 383; MMA 383	Phase I			biotechnology; monoclonal antibody	cancer
trastuzumab; HERCEPTIN	Marketed	immunoglobulin G1, anti-(human p185neu receptor) (human-mouse monoclonal rhuMab HER2 gamma 1-chain), disulfide with human-mouse monoclonal rhuMab HER2 light chain dimer		biotechnology; monoclonal antibody	cancer
MAb, KDR; MAb, vascular endothelial growth factor receptor; DC 101	Preclinical			biotechnology; monoclonal antibody; angiogenesis inhibitor	cancer
MAb, KDR; MAb, vascular endothelial growth factor receptor; CP1C11	Preclinical			biotechnology; monoclonal antibody; angiogenesis inhibitor	cancer

MAb, VNR integrin; LM 609; VITAXIN	Phase II		biotechnology; monoclonal antibody; angiogenesis inhibitor	cancer
MAb, CEA and doxorubicin; MAb, 26-61-10; bispecific antibody, CEA and doxorubicin	Preclinical		biotechnology; monoclonal antibody; anthracycline; DNA intercalator; antibiotic	cancer
MAb, antilaminin gamma2 chain; BST 1004	Preclinical		biotechnology; monoclonal antibody; contrast medium	cancer; diagnosis
MAb, cancer; MAb, tumor necrosis technology; MAb, TNT	Preclinical		biotechnology; monoclonal antibody; contrast medium; radiodiagnostic; radiotherapeutic	cancer
MAb, cancer, radiolabeled; NOVOMAb-G2	Phase I		biotechnology; monoclonal antibody; contrast medium; radiodiagnostic; radiotherapeutic	cancer; diagnosis
MAb, epidermal growth factor receptor; MAb, EGF α ; DiaCIM; TheraCIM; RadioTheraCIM	Phase I		biotechnology; monoclonal antibody; contrast medium; radiotherapeutic; radiodiagnostic	cancer; diagnosis
MAb, TC5-Au198	Preclinical		biotechnology; monoclonal antibody; contrast medium; radiotherapeutic; radiodiagnostic	cancer; diagnosis

MAB, B cell-cytokine fusion protein	Preclinical		biotechnology; monoclonal antibody; cytokine	cancer
interleukin-2, antiganglioside chimeric protein; G2-IL2 fusion protein; MAb-G2 IL-2 fusion protein; ch14.18-IL2	Preclinical		biotechnology; monoclonal antibody; cytokine; growth factor	cancer
MAB, L49-sFv-beta-lactamase	Preclinical		biotechnology; monoclonal antibody; enzyme	cancer
MAB, 2C11.F(ab')2 + microbeads; MAB, anti-CD3 + microbeads; PLATAR construct	Discontinued		biotechnology; monoclonal antibody; immunostimulant	bacterial infection; cancer
MAB, c-erbB-2 and CD16; bispecific antibody, c-erbB-2 and CD16; 2B1	Phase I		biotechnology; monoclonal antibody; immunostimulant	cancer
MAB, c-Mpl; MAB, thrombocytopenia; BAH 1	Preclinical		biotechnology; monoclonal antibody; immunostimulant	thrombocytopenia; cancer
MAB, CD3 F(ab')2 + microbeads; MAB, CD3 + microbeads; PLATAR construct	Discontinued		biotechnology; monoclonal antibody; immunostimulant	bacterial infection; cancer

MAb, HER-2 and Fc; bispecific antibody, ovarian and breast cancer; bispecific antibody 520C9x22; MDX 210	Phase II			biotechnology; monoclonal antibody; immunostimulant	cancer
dacalizumab; dactiliximab; MAb, Tac; MAb, humanized Tac; MAb, SMART Tac; Ro 247375; ZENAPAX	Marketed	immunoglobulin G1 (human-mouse monoclonal clone 1H4 gamma chain anti-human antigen Tac), disulfide with human-mouse monoclonal clone 1H4 light chain, dimer		biotechnology; monoclonal antibody; immunosuppressant	transplant rejection; cancer; autoimmune disease; eye disease
MAb, alpha-tubulin	Preclinical			biotechnology; monoclonal antibody; immunosuppressant	cancer; autoimmune disease; diagnosis
MAb, T cell antigen receptor; TM 29	Preclinical			biotechnology; monoclonal antibody; immunosuppressant	cancer; Crohn disease
MAbs, B cells; migis	Discontinued			biotechnology; monoclonal antibody; immunosuppressant	autoimmune disease; cancer
MAb, MHC class II	Preclinical			biotechnology; monoclonal antibody; immunosuppressant; NSAID	autoimmune disease; transplant rejection; graft versus host disease; cancer

MAB, 791T/36-ricin A immunotoxin; immunotoxin- colorectal cancer; XOMAZYME 791	Discontinued		biotechnology; monoclonal antibody; immunotoxin	cancer	
MAB, A7 mitomycin C-dextran conjugate; MAB, A7-MMCD; MAB, colon cancer mitomycin C-dextran conjugate	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer	
MAB, alpha CD80- gelonin	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer	
MAB, alphaCD86- gelonin	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer	
MAB, Anti-Tac Pseudomonas exotoxin; immunotoxin, T cell cancers	Discontinued		biotechnology; monoclonal antibody; immunotoxin	cancer	
MAB, B3- Pseudomonas exotoxin; immunotoxin B3-PE 38; LMB 1	Phase I		biotechnology; monoclonal antibody; immunotoxin	cancer	
MAB, B4-blocked ricin; MAB, B4-bR; ONCOLYSIN B	Discontinued		biotechnology; monoclonal antibody; immunotoxin	cancer	
MAB, B7- immunotoxin	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer	

MAb, BACH 250-gelonin conjugate; immunotoxin, BACH 250-gelonin	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, basic fibroblast growth factor receptor-saporin; MAb, bFGF receptor-SAP; 11A8	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, CD33-calicheamicin; CMA 676; CDP 771	Phase III		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, CMB 401-calicheamicin; MAb, ovarian cancer; CMB 401; CDP 671	Phase II		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, CYT 103-aminopterin; MAb, B72.3-aminopterin; ONCOTHER 130	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, epidermal growth factor receptor immunotoxin; immunotoxin, EGRF; OLX 103; TP 40; L 691912	Discontinued		biotechnology; monoclonal antibody; immunotoxin	cancer

MAb, erbB-2-Pseudomonas exotoxin; immunotoxin, single chain erbB-2-Pseudomonas exotoxin; OLX 209; AR 209	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAB, F(ab') ₂ HRS-3 deglycosylated ricin A; MAB, HRS-3 deglycosylated ricin A; MAB, F(ab') ₂ HRS-3 dgA; MAB, HRS-3 deglycosylated ricin A; MAB, F(ab') ₂ HRS-3 dgA; MAB, IRac dgA	Discontinued		biotechnology; monoclonal antibody; immunotoxin	cancer
MAB, F(ab') ₂ IRac deglycosylated ricin A; MAB, IRac deglycosylated ricin A; MAB, F(ab') ₂ IRac dgA	Discontinued		biotechnology; monoclonal antibody; immunotoxin	cancer
MAB, Fv B3-Pseudomonas exotoxin; immunotoxin Fv B3-PE 38; LMB 7; NSC 658931	Phase I		biotechnology; monoclonal antibody; immunotoxin	cancer

MAb, FvB1-Pseudomonas exotoxin; immunotoxin FvB1-PE33	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, LL2-Pseudomonas exotoxin	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, ME20-Pseudomonas exotoxin; immunotoxin ME20-LysPE40	Discontinued		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, N901-blocked ricin; immunotoxin, N901-bR; ONCOLYSIN S	Phase II		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, N901-DM1; immunotoxin, N901-DM1	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer
MAb, OVB3-Pseudomonas exotoxin conjugate; immunotoxin OVB3-PE	Phase I		biotechnology; monoclonal antibody; immunotoxin	cancer
MAB, RFB4(dsFv)-PE38; immunotoxin, RFB4(dsFv)-PE38; BL 22; NSC 691237	Phase I		biotechnology; monoclonal antibody; immunotoxin	cancer
MAB, RFT5-ricin A (CD25) immunotoxin; RFT5.dgA	Phase II		biotechnology; monoclonal antibody; immunotoxin	cancer

MAB, ricin A immunconjugate; immunotoxin melanoma; XOMAZYME-MEL	Discontinued		biotechnology; monoclonal antibody; immunotoxin	cancer	
MAB, SN7-ricin A; immunotoxin SN7-ricin A; SN7-RA	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer	
MAB, Tac(Fv)-PE38; immunotoxin Tac(Fv)-PE38; LMB 2	Phase I		biotechnology; monoclonal antibody; immunotoxin	cancer	
MAB, Tac(Fv)-PE40 immunotoxin	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer	
MAB, transferrin receptor targeted immunotoxin; MAB, tfnR targeted immunotoxin; 454A12-rRA	Phase I		biotechnology; monoclonal antibody; immunotoxin	cancer	
MAB, tumor immunotoxins, Menarini	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer	
MAB, UV72 immunotoxin	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer	
MAB, VEGF receptor/ligand complex-dgA; immunotoxin VEGF receptor/ligand complex-dgA	Preclinical		biotechnology; monoclonal antibody; immunotoxin	cancer	

MAbs, CD22-saporin; Phase II immunotoxin, bispecific, cancer; ITF 1265 + ITF 1269			biotechnology; monoclonal antibody; immunotoxin	cancer
MAB, doxorubicin conjugates; MAb, CC49-doxorubicin	Discontinued		biotechnology; monoclonal antibody; immunotoxin; anthracycline; antibiotic; DNA intercalator	cancer
MAB, anthracycline amine derivative	Preclinical		biotechnology; monoclonal antibody; immunotoxin; antibiotic	cancer
MAB, CD5- momordin; immunotoxin CD5- momordin; ITF 1532	Phase II		biotechnology; monoclonal antibody; immunotoxin; immunosuppressant	cancer; transplant rejection
MAB, humanized, MRK 16; MRK 16	Preclinical		biotechnology; monoclonal antibody; MDR inhibitor	cancer
MAB, MRK 17; MRK 17	Discontinued		biotechnology; monoclonal antibody; MDR inhibitor	cancer
MAB, humanized, leukemia; MAB, IgG2B; LDP 03; BW 7U; CAMPATH; CAMPATH-1H	Phase II		biotechnology; monoclonal antibody; NSAID	rheumatoid arthritis; cancer; multiple sclerosis; transplant rejection
iodine 131 tositumomab; MAB, CD20-iodine 131; BEXXAR	Phase III		biotechnology; monoclonal antibody; radiotherapeutic	cancer

MAb, 16.88-yttrium 90	Phase I		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAb, 35-67Cu; MAb, murine colon carcinoma; MAb, cancer	Phase I		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAb, 88BV59-yttrium 90	Phase I		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAb, B3-yttrium 90	Phase I		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAb, CC49-yttrium	Phase I		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAb, CD20-iodine 131	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAb, CD20-streptavidin + biotin-yttrium 90	Phase I		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAb, CEA rhenium-188; MAb, colorectal cancer; IMMURAIT-Rhenium	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAb, CG250-iodine 131	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAb, chimeric L6-iodine 131; BMS 180548	Discontinued		biotechnology; monoclonal antibody; radiotherapeutic	cancer

Mab, CYT 103- yttrium 90; Mab, B72.3-yttrium 90; ONCORAD OV103; ONCORAD CR103	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer	
Mab, ERIC1 yttrium 90	Discontinued		biotechnology; monoclonal antibody; radiotherapeutic	cancer	
Mab, F(ab)2 NRLU10-rhenium 186; Mab, F(ab)2 pancarcinoma; RHENEX	Discontinued		biotechnology; monoclonal antibody; radiotherapeutic	cancer	
Mab, G250-iodine 131	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer	
Mab, humanized MN-14; Mab, humanized carcinoembryonic antigen; MN 14; CEA-Cide	Phase I		biotechnology; monoclonal antibody; radiotherapeutic	cancer	
Mab, iodine-131, DNA-associated antigens; 131I- chTNT-1/B; COTARA; Tumor Necrosis Therapy; TNT	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer	
Mab, LL2-iodine 131; LymphoCide; ImmuRAIT-LL2	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer	

MAB, LYM-1-iodine 131; LYM 1; ONCOLYM	Phase III		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, MAB fragment, REC A33-TFM-nuclide; CDP 833	Discontinued		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, NRLU13-streptavidin + biotin-yttrium 90; AVICIDIN	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, OKB7-iodine 131; OKB7	Phase I		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, pan-B-yttrium; MAB, B-cell radiation therapy; IDEC Y2B8	Phase III		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, PEM-antisense oligonucleotide-radionuclide; AS 102	Preclinical		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, PF1-A; MAB, squamous cell carcinoma; AS 114	Preclinical		biotechnology; monoclonal antibody; radiotherapeutic	cancer
MAB, UJ13A yttrium 90	Discontinued		biotechnology; monoclonal antibody; radiotherapeutic	cancer
yttrium Y 90 capromab; MAB, CYT 356-yttrium 90; MAB, 7E11C5-yttrium 90; MAB, prostate cancer; OncoRad PR	Phase II		biotechnology; monoclonal antibody; radiotherapeutic	cancer

MAb, 4B5; MAb, anti-GD2 anti-idiotypic; NOVOVAC-M1	Preclinical		biotechnology; monoclonal antibody; vaccine	cancer
MAb, BEC-2; vaccine, BEC-2; EMD 60205; BEC2	Phase III		biotechnology; monoclonal antibody; vaccine	cancer
MAb, CA 125; vaccine, cancer; B43.13; OvaRex	Phase III		biotechnology; monoclonal antibody; vaccine	cancer
MAb, CA19.9; AR 44.6; GivaRex	Preclinical		biotechnology; monoclonal antibody; vaccine	cancer
MAb, idiotypic CEA; vaccine, cancer; cancer vaccine; Cea Vac	Phase II		biotechnology; monoclonal antibody; vaccine	cancer
MAb, idiotypic GD2; vaccine, cancer; cancer vaccine; TriGem	Phase II		biotechnology; monoclonal antibody; vaccine	cancer; psoriasis
MAb, idiotypic, MUC1; vaccine, cancer; cancer vaccine; TriAb	Phase II		biotechnology; monoclonal antibody; vaccine	cancer
MAb, MUC1; vaccine, cancer; AR 20.5; BrevaRex	Phase I		biotechnology; monoclonal antibody; vaccine	cancer
MAb, PSA; ProstaRex	Preclinical		biotechnology; monoclonal antibody; vaccine	cancer

monoclonal antibody, anti-idiotypic, cancer	Clinicals		biotechnology; monoclonal antibody; vaccine	cancer
antisense oligonucleotide, B cell lymphoma	Preclinical		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer
antisense oligonucleotide, c-myc	Preclinical		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer
antisense oligonucleotide, cancer	Discontinued		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer
antisense oligonucleotide, cancer; mRNA translation inhibitor, cancer	Preclinical		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer
antisense oligonucleotide, Ha-ras; ISIS 2503	Phase II		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer
antisense oligonucleotide, Kaposi's sarcoma	Discontinued		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer

antisense oligonucleotide, Philadelphia chromosome; antisense oligonucleotide, chronic myelogenous leukemia; G 1128	Phase II		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer
antisense oligonucleotides, Ki- ras	Preclinical		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer
GPs 0193; NAVIN	Discontinued		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	HIV infection; cancer
LR 3523	Discontinued		biotechnology; mRNA translation inhibitor; antisense; oligonucleotide	cancer
BCG A4	Preclinical		biotechnology; oligonucleotide	cancer
LR 5165	Discontinued		biotechnology; oligonucleotide	cancer
oligonucleotide directed DNA therapy	Discontinued		biotechnology; oligonucleotide	cancer; genetic disorder; viral infection; bacterial infection
oligonucleotide, cancer, Kimeragen	Preclinical		biotechnology; oligonucleotide	cancer
oligonucleotide, chronic myelogenous leukemia, Kimeragen	Preclinical		biotechnology; oligonucleotide	cancer

antisense oligonucleotide, bcl- 2; ODN 2009	Preclinical		biotechnology; oligonucleotide; antisense	cancer
antisense oligonucleotide, cancer, GeneSense Technologies; GTI 2040	Preclinical		biotechnology; oligonucleotide; antisense	cancer
antisense oligonucleotide, cancer, GeneSense Technologies; GTI 2501	Preclinical		biotechnology; oligonucleotide; antisense	cancer
antisense oligonucleotide, cancer, Isis/AstraZeneca	Preclinical		biotechnology; oligonucleotide; antisense	cancer
antisense oligonucleotide, raf kinase; antisense oligonucleotide, cancer; ISIS 5132; CGP 69846A; CGP 69846A; ODN 698	Phase II	d(P-thio) (T-C-C-C- G-C-C-T-G-T-G-A- C-A-T-G-C-A-T-T-)	biotechnology; oligonucleotide; antisense	cancer
antisense oligonucleotide, TAG 6; TAG 6	Preclinical		biotechnology; oligonucleotide; antisense	cancer
antisense oligonucleotides, non- Hodgkins lymphoma, Fox Chase Cancer Center	Preclinical		biotechnology; oligonucleotide; antisense	cancer

oligonucleotides, VimRx	Preclinical		biotechnology; oligonucleotide; ribozyme	cancer; psoriasis
ribozyme, bcl-2, Ribozyme	Preclinical		biotechnology; oligonucleotide; ribozyme	cancer
ribozyme, europium-texaphyrin, cancer; ribozyme, europium texaphyrin, viral infection	Preclinical		biotechnology; oligonucleotide; ribozyme	cancer; viral infection
ribozyme, K-ras	Preclinical		biotechnology; oligonucleotide; ribozyme	cancer
sense oligonucleotides, GenSet; transcription factor decoys, GenSet	Discontinued		biotechnology; oligonucleotide; transcription factor regulator	cancer; viral infection
polyethylene glycol uricase; PEG-uricase; uricase macrogol	Discontinued		biotechnology; oxidoreductase; uricase	gout; cancer
class II restricted melanoma antigens, National Institutes of Health	Preclinical		biotechnology; peptide	cancer
urokinase receptor antagonists, Chiron	Preclinical		biotechnology; peptide	cancer; inflammation
interferon-inducible protein-10; IP-10	Preclinical		biotechnology; peptide; chemokine	cancer
interferon-inducible protein-10; IP-10	Preclinical		biotechnology; peptide; chemokine	cancer; eye disease

antibody-derived anticancer peptides, Antisoma	Discontinued		biotechnology; peptide; contrast medium	cancer; diagnosis
RecepTox-GnRH	Preclinical		biotechnology; peptide; fusion toxin	cancer
chimeric peptides, National Institutes of Health	Preclinical		biotechnology; peptide; vaccine	cancer; viral infection
plasminogen activator inhibitor; PAI-2	Phase II		biotechnology; plasminogen activator inhibitor; cicatrizant	cancer; inflammation; skin ulcer
matrix metalloproteinase inhibitor	Discontinued		biotechnology; proteinase inhibitor; matrix metalloproteinase inhibitor; NSAID	arthritis; cancer; arthritis
maspin; mammary serine proteinase inhibitor; LXR 023; METAREX	Preclinical		biotechnology; proteinase inhibitor; serine proteinase inhibitor	cancer
neutral endopeptidase; NEP	Discontinued		biotechnology; proteinase; metalloproteinase	cancer; migraine; inflammatory bowel disease; inflammation; asthma; respiratory disease
oligonucleotides, acute promyelocytic leukemia	Preclinical		biotechnology; ribozyme; oligonucleotide	cancer
oligonucleotides, multiple drug resistance	Preclinical		biotechnology; ribozyme; oligonucleotide	cancer

ribozyme, BCR-ABL	Preclinical		biotechnology; ribozyme; oligonucleotide	cancer
ribozyme, ras, Ribozyme	Preclinical		biotechnology; ribozyme; oligonucleotide	cancer
ribozyme, vascular endothelial growth factor receptor; ribozyme, VEGF receptor; RPI 4610; ANGIOZYME	Phase I		biotechnology; ribozyme; oligonucleotide	retinopathy; cancer
screening technology, growth regulatory compounds	Preclinical		biotechnology; target based screening	drug design technology; cancer
drug delivery system, verotoxin fusion protein cancer vaccine; vaccine, cancer	Preclinical		biotechnology; vaccinecancer	
epidermal growth factor; EGF	Phase I		biotechnology; vaccinecancer	
MEDI 501	Phase I		biotechnology; vaccinecancer; viral infection	
MEDI 503	Preclinical		biotechnology; vaccinecancer	
MEDI 504	Preclinical		biotechnology; vaccinecancer	
tumor associated antigen; PP4X	Preclinical		biotechnology; vaccinecancer	
tumor associated antigen; CTAA 79 AV1017	Preclinical		biotechnology; vaccinecancer	

vaccine, B cell lymphoma specific idiotype-granulocyte macrophage colony stimulating factor; vaccine, Id/MoGM-CSF	Preclinical		biotechnology; vaccinecancer	
vaccine, breast cancer; immunotherapy, breast cancer; MUVAC	Preclinical		biotechnology; vaccinecancer	
vaccine, breast cancer	Preclinical		biotechnology; vaccinecancer	
vaccine, breast cancer, CelSci	Preclinical		biotechnology; vaccinecancer	
vaccine, canarypox CEA; vaccine, cancer; ALVAC-CEA	Phase I		biotechnology; vaccinecancer	
vaccine, cancer	Preclinical		biotechnology; vaccinecancer	
vaccine, cancer	Preclinical		biotechnology; vaccinecancer	
vaccine, cancer, MedImmune	Discontinued		biotechnology; vaccinecancer	
vaccine, cervical cancer; vaccine, Hsp65-HPV E7 fusion protein; Hsp65E7; HspE7; ONCOCINE	Phase I		biotechnology; vaccinecancer	
vaccine, colorectal and lung cancers; colorectal and lung cancers vaccine; Onco Vax-CL	Phase II		biotechnology; vaccinecancer	

vaccine, colorectal cancer	Preclinical		biotechnology; vaccinecancer	
vaccine, Epstein Barr viral coat protein; vaccine, EBV	Preclinical		biotechnology; vaccineglandular fever; cancer	
vaccine, Epstein-Barr virus gp 220-340; vaccine, EBV	Clinicals		biotechnology; vaccinecancer	
vaccine, gp75 antigen; vaccine, cancer	Preclinical		biotechnology; vaccinecancer	
vaccine, hepatitis B core antigen fusion proteins, National Institutes of Health; vaccine, cancer	Preclinical		biotechnology; vaccinecancer	
vaccine, HER/neu-2 oncogene; vaccine, breast cancer	Preclinical		biotechnology; vaccinecancer	
vaccine, human papilloma virus; vaccine, cervical cancer; vaccine, HPV	Phase I		biotechnology; vaccinecancer	
vaccine, human papillomavirus; therapeutic antigen, cervical cancer; vaccine, HPV; TA-HPV	Phase II		biotechnology; vaccinecancer; viral infection	

vaccine, human papillomavirus; therapeutic antigen, genital warts; vaccine, HPV; TA-GW	Phase II		biotechnology; vaccine	viral infection; cancer
vaccine, mage-1; vaccine, melanoma; TBC-Mage-1; MAGEVAC	Discontinued		biotechnology; vaccine	cancer
vaccine, MART-1; vaccine, melanoma	Phase I		biotechnology; vaccine	cancer
vaccine, mutant p53 and ras peptide activated monocytes	Phase I		biotechnology; vaccine	cancer
vaccine, neu; vaccine, breast and ovarian cancer; TBC-NEU	Preclinical		biotechnology; vaccine	cancer
vaccine, papilloma virus HPV 16; vaccine, cervical cancer	Discontinued		biotechnology; vaccine	cancer
vaccine, prostate cancer; immunotherapy, prostate cancer; PROSTVAC	Phase I		biotechnology; vaccine	cancer
vaccine, prostate cancer	Preclinical		biotechnology; vaccine	cancer
vaccine, prostate cancer; prostate cancer vaccine; NORELIN	Phase II		biotechnology; vaccine	cancer

vaccine, prostate cancer, CelSci	Preclinical		biotechnology; vaccine	cancer
vaccine, ras; vaccine, colorectal cancer; TBC-RAS; RASVAC	Discontinued		biotechnology; vaccine	cancer
vaccine, recombinant dendritic cells, Duke University	Phase I		biotechnology; vaccine	cancer
vaccine, TBC-CEA; vaccine, cancer; TBC-CEA	Phase II		biotechnology; vaccine	cancer
vaccine, tumor; tumor vaccine	Discontinued		biotechnology; vaccine	cancer
virus derived particles, human papillomavirus; VDPs, HPV	Discontinued		biotechnology; vaccine	cancer
thymalfasin; thymosin alpha-1; T-1; ZADAXIN	Marketed	(N-acetyl)-ser-asp-ala-ala-val-asp-thr-ser-ser-glu-ile-thr-lys-asp-leu-lys-glu-lys-lys-glu-val-val-glu-glu-ala-glu-asn-OH	biotechnology; vaccine; adjuvant; immunostimulant; peptide	cancer; viral infection
vaccine, human papilloma E7 antigen; vaccine, HPV; vaccine, cervical cancer	Preclinical		biotechnology; vaccine; biotechnology	cancer
vaccine, gene-based, cancer	Preclinical		biotechnology; vaccine; gene therapy	cancer

vaccine, gene-based, non-Hodgkin's B cell lymphoma; VAXID	Phase II		biotechnology; vaccine; gene therapy	cancer
vaccine, gene-based, T cell lymphoma; APL 400020; GENEVAX	Preclinical		biotechnology; vaccine; gene therapy	cancer
vaccine, ALVAC-hb7.1; vaccine, ovarian carcinoma; AUT-OV-ALVAC-hb7.1	Phase I		biotechnology; vaccine; immunostimulant	cancer
vaccine, cervical intraepithelial neoplasia; TA-CIN; TA-CIN	Preclinical		biotechnology; vaccine; immunostimulant	cancer
MAb, I-Mel-1; I-Mel-1; MELIMMUNE-1	Discontinued		biotechnology; vaccine; monoclonal antibody	cancer
MAb, I-Mel-1 + MAb, I-Mel-2; MAb, I-Mel-2 + MAb, I-Mel-1; MELIMMUNE	Discontinued		biotechnology; vaccine; monoclonal antibody	cancer
MAb, idiotypic 105AD7; MAb, anti-idiotypic gp72; 105AD7	Phase III		biotechnology; vaccine; monoclonal antibody	cancer
MAb, neuroblastoma/glioma; MAb, NG 1; MAb, cancer; NG 1; MONOPHARM G	Preclinical		biotechnology; vaccine; monoclonal antibody	cancer

vaccine, MAb, anti-idiotype, cancer; vaccine, cancer; MAb, cancer	Preclinical		biotechnology; vaccine; monoclonal antibody	cancer
vaccine, melanoma; MAb, MK2-23	Phase II		biotechnology; vaccine; monoclonal antibody	cancer
minodronic acid; YM 529; YH 529	Phase II	(1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethylidene)bisphosphonic acid	bisphosphonate	osteoporosis; hypercalcemia; cancer
meridronic acid; aminohexane diphosphonate; AHDP Na	Discontinued	(6-amino-1-hydroxyhexylidene)diphosphonic acid	bisphosphonate	Paget disease; osteoporosis; cancer
pamidronic acid; pamidronate disodium; APD; CGP 2339AE; AREDIA; OSTEOKIT	Marketed	(3-amino-1-hydroxypropylidene)bisphosphonic acid	bisphosphonate	osteoporosis; cancer
ibandronic acid; ibandronate sodium; BM 210955; BONDRONAT	Marketed	[1-hydroxy-3-(methylpentylamino)propylidene]bisphosphonic acid	bisphosphonate; postmenopausal osteoporosis	osteoporosis; cancer; hypercalcemia

RC 3095	Phase I	(3R)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxyl-L-glutaminy-L-tryptophyl-L-alanyl-L-valylglycyl-N-[(1S)-1-[[[(1S)-1-(aminocarbonyl)-3-methylbutyl]amino]methyl]-3-methylbutyl]-L-histidinamide	bombesin antagonist	cancer
ID 22213	Phase I	[[1(R),6[S-(R*,R*)]]-N2-[(2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-yl)carbonyl]-L-glutaminy-L-tryptophyl-L-alanyl-L-valylglycyl-N-[1-[[[1-(aminocarbonyl)-3-methylbutyl]amino]methyl]-3-methylbutyl]-L-histidinamide monoacetate	bombesin antagonist; peptide	cancer

PAK 200	Discontinued	5-(5,5-dimethyl-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dimethyl-1-[2-(4-morpholinyl)ethyl]-4-(3-nitrophenyl)-3-pyridinecarboxylic acid 2-[phenyl(phenylmethyl)amino]ethyl ester, P-oxide	calcium antagonist	cancer
dilazep; ANGOSIR IS	Marketed	tetrahydro-1H-1,4-diazepine-1,4(5H)-dipropanol 3,4,5-trimethoxybenzoate (diester)	calcium channel blocker; hematoprotectant; chemoprotectant	cancer; cardiac therapy
D 1465	Discontinued		calcium channel blocker; MDR inhibitor	cancer
CP 55940	Preclinical	(1alpha,2beta,5alpha)-(-)-5-(1,1-dimethylheptyl)-2-[5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]phenol	cannabinoid	cancer
casein kinase inhibitors, ICOS	Preclinical		casein kinase inhibitor; immunosuppressant; NSAID	inflammation; cancer
aragusterol A; YTA 0040	Preclinical		Cdk/cyclin inhibitor	cancer
ONCONEX	Preclinical		chelating agent	cancer

glucarolactam; ND 2001	Discontinued	5-amino-5-deoxy-D- glucosaccharic acid- delta-lactam	chemoprotectant	cancer
myeloid progenitor inhibitory factor; MPIF-1; HG 00300	Phase II		chemoprotectant; biotechnology; hematoprotectant; hematopoiesis inhibitor; stem cell division inhibitor; chemokine	cancer
dexrazoxane; razoxane (+), (S); ICRF 187; NSC 169780; ADR529; ICI 59118; CARDIOXANE; EUCARDION; RAZOXIN; ZINECORE; ZINECARD; ANTRAGARD	Marketed	(+)-(S)-4,4'- propylenedi-2,6- piperazinedione	chemoprotectant; cytoprotectant	cancer; heart failure
gamma-linolenic acid + eicosapentaenoic acid; EF 27; AMELORAD; TARAGAM	Discontinued		chemoprotectant; cytoprotectant	cancer
ICRF 197	Preclinical		chemoprotectant; cytoprotectant	cancer; heart failure
MGI 136	Discontinued	diethyldithiocarbamate	chemoprotectant; cytoprotectant	cancer

WR 151327; NSC 335662	Preclinical	3-[[3-(methylamino)propyl]amino]-1-propanethiol dihydrogen phosphate ester	chemoprotectant; cytoprotectant	cancer; HIV infection
amifostine; ethiofos; gammaphos; WR 2721; NSC 296961; YM 08310; WR 2721C; ETHYOL	Marketed	2-[(3-aminopropyl)amino]ethanethiol dihydrogen phosphate	chemoprotectant; cytoprotectant; radioprotectant	cancer
hematopoietic growth factor inhibitors, Ligand	Preclinical		chemoprotectant; hematopoiesis inhibitor	cancer
hematopoietic progenitor cell inhibitor, University of Indiana	Preclinical		chemoprotectant; hematoprotectant; hematopoiesis inhibitor; stem cell division inhibitor	cancer
stem-cell division inhibitors, Terry Fox Laboratory	Discontinued		chemoprotectant; stem cell division inhibitor; hematopoiesis inhibitor	cancer
stem cell inhibitory factor, natural; SCIF	Discontinued		chemoprotectant; stem cell division inhibitor; hematoprotectant; hematopoiesis inhibitor	cancer
CRL 1095	Discontinued		chemosensitizer	cancer
CRL 1605	Preclinical		chemosensitizer	cancer
glutathione-S-transferase inhibitors, Telik	Preclinical		chemosensitizer	cancer

napavin	Preclinical	3-[[[2-[(4-azido-2-nitrophenyl)amino]ethyl]amino]carbonyl]-O4-deacetyl-3-de(methoxycarbonyl)vincal leukoblastine	chemosensitizer	cancer
TER 199	Preclinical	(2R)-L-gamma-glutamyl-S-(phenylmethyl)-L-cysteiny]-2-phenylglycine	chemosensitizer	cancer
declopramide; OXI 104	Phase II		chemosensitizer; apoptosis inducer; radiosensitizer	cancer
CMDA; CJS 8	Preclinical	N-[4-[(2-chloroethyl)[2-(methylsulfonyl)oxy]ethyl]amino]benzoyl]-L-glutamic acid	chlormethine derivative; alkylating agent	cancer
galamustine; galactose-6-mustard; C6 GLM; G 6 M	Discontinued	6-[bis(2-chloroethyl)amino]-6-deoxy-D-galactopyranose	chlormethine derivative; alkylating agent	cancer
SN 23862	Preclinical	5-[bis(2-chloroethyl)amino]-2,4-dinitrobenzamide	chlormethine derivative; alkylating agent	cancer
spiromustine; spirohydantoin mustard; SHM; speratine; NSC 172112	Phase II	3-[2-[bis(2-chloroethyl)amino]ethyl]-1,3-diazaspiro[4.5]decane-2,4-dione	chlormethine derivative; alkylating agent	cancer

tallimustine; FCE 24517	Discontinued	N-[5-[[[(3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-4-[[[4-[[4-bis(2-chloroethyl)amino]benzoyl]amino]-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl-1H-pyrrole-2-carboxamide	chlormethine derivative; alkylating agent	cancer
veramine; RL 0017	Preclinical	(3beta,16beta,17beta,22S,25S)-17-methyl-18-norspirosola-5,12-dien-3-ol	chlormethine derivative; alkylating agent	cancer
linitript; SR 27897; SR 27897B	Phase II	2-[[[4-(2-chlorophenyl)-2-thiazolyl]amino]carbonyl]-1H-indole-1-acetic acid	cholecystokinin A antagonist; cholecystokinin antagonist	eating disorder; cancer
docosanol, n-; docosanol, l-; behenyl alcohol; LIDAKOL	Pre-registration	1-docosanol	cicatrizant	viral infection; skin ulcer; cancer
Myc/Max inhibitors, Apoptosis Technology; Myc/Max inhibitors, ICRF	Discontinued		cicatrizant	cancer; skin ulcer
OLX 501	Discontinued		collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor	septic shock; cancer; vascular leakage

OLX 514	Discontinued			collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor	septic shock; cancer
MAb, carcinoembryonic antigen; PRIA3	Phase I			contrast medium; monoclonal antibody; biotechnology; radiotherapeutic; radiodiagnostic	cancer; diagnosis
NLCQ 1	Preclinical	4-[3-(2-nitroimidazolyl)propylamino]-7-trifluoromethylquinoline hydrochloride		contrast medium; MRI contrast agent; imidazole	diagnosis; cancer
vasoactive intestinal peptide-iodine 123; VIP-I 123	Phase II			contrast medium; peptide	diagnosis; cancer
cancer therapy, Angstrom/Diatide	Preclinical			contrast medium; radiotherapeutic; radiodiagnostic	cancer
fludarabine + prednisone; prednisone + fludarabine	Discontinued			corticosteroid	cancer
ORG 6632	Discontinued	21-chloro-9alpha-fluoro-11beta-hydroxy-16alpha,17alpha-dimethylpregna-1,4-diene-3,20-dione		corticosteroid; immunosuppressant	cancer; rheumatoid arthritis

HX 0836	Preclinical	(E)-3-(3,4-dihydroxyphenyl)-1-(2,5-dimethoxyphenyl)-2-propen-1-one	COX inhibitor; 5-lipoxygenase inhibitor	cancer
celecoxib; SC 58635; YM 177; CELEBREX; CELEBRA	Marketed	4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	arthritis; pain; cancer
cyclocreatine; AM 285	Discontinued	2-amino-4,5-dihydro-1H-imidazole-1-acetic acid	creatine kinase modulator	cancer; viral infection
cdk2 inhibitors, Molecumetics	Preclinical		cyclin dependent kinase inhibitor	cancer
cyclin-dependent kinase inhibitor, Agouron; cancer therapy, Agouron	Preclinical		cyclin dependent kinase inhibitor	cancer
cyclin-dependent kinase/cyclin inhibitors, Mitotix; Cdk/cyclin inhibitors, Mitotix	Preclinical		cyclin dependent kinase inhibitor	cancer
cyclin-dependent kinase4 modulators, Pharmacopeia; cdk4 modulator, Pharmacopeia	Preclinical		cyclin dependent kinase inhibitor	cancer

flavopiridol; NSC 649890; HMR 1275	Phase II	cis-2-(2-chlorophenyl)-5,7-dihydroxy-8-(3-hydroxy-1-methyl-4-piperidinyl)-4H-1-benzopyran-4-one hydrochloride	cyclin dependent kinase inhibitor	cancer
CYC 202	Preclinical		cyclin dependent kinase inhibitor; apoptosis inducer	cancer
tumor necrosis factor alpha, natural; TNF alpha, natural; tonermin; MHR 24	Pre-registration		cytokine	cancer
granulocyte-colony stimulating factor agonists, Pharmacopeia; granulocyte-colony stimulating factor agonists, Regeneron	Preclinical		cytokine agonist	cancer
interferon agonists, Ligand	Preclinical		cytokine agonist; NSAID	cancer; viral infection; infectious disease; multiple sclerosis
cytokine trap, Regeneron	Preclinical		cytokine antagonist	cancer; asthma; rheumatoid arthritis; allergy
IL-6 receptor antagonist, Peptor	Preclinical		cytokine antagonist; peptide; NSAID	cancer

CNI 1493	Phase I	N,N'-bis[3,5-bis[1-[(aminoininomethyl)hydrazono]ethyl]phenyl]-decanediamide tetrahydrochloride	cytokine synthesis inhibitor	cancer
drug delivery system, IL-2, Biovector Therapeutics	Preclinical		cytokine; biotechnology	cancer
delivery system, gene therapy, IL-2, Biovector Therapeutics; gene therapy, IL-2, Biovector Therapeutics	Preclinical		cytokine; biotechnology; gene therapy; immunostimulant	cancer
cytotoxic lymphocyte maturation factor; CLMF	Discontinued		cytokine; immunostimulant	cancer
LY 295501; ILX 295501	Phase I	N-[[[(3,4-dichlorophenyl)amino]carbonyl]-2,3-dihydro-5-benzofuran-sulfonamide]	diaryl/sulfonylurea	cancer
sulofenur; LY 186641	Discontinued	N-[[[(4-chlorophenyl)amino]carbonyl]-2,3-dihydro-5H-indene-5-sulfonamide]	diaryl/sulfonylurea	cancer
AN 9; PIVANEX	Phase II	butanoic acid (2,2-dimethyl-1-oxopropoxy)methyl ester	differentiation inducer	cancer

CBHA	Preclinical	N-hydroxy-3-[3-(hydroxyamino)-3-oxo-1-propenyl]-benzamide	differentiation inducer	cancer
EMBA	Preclinical	diethyl bis-(pentamethylene-N,N-dimethylcarboxamide)malonate	differentiation inducer	cancer
hexamethylene bisacetamide; HMBA; NSC 95580; HEXABID	Phase II	N,N'-1,6-hexanediylobisacetamide	differentiation inducer	cancer
NF 036	Preclinical	8-[(7-chloro-4-quinolinyl)amino]-1,3,5-naphthalenetrisulfonic acid trisodium salt	differentiation inducer	cancer
SAHA; SW 064652	Preclinical	suberoylanilide hydroxamic acid	differentiation inducer	cancer
TI 66	Preclinical	6-fluoro-7,7,8,8-tetramethyl-2,4-bis(phenylmethyl)-2,4-diazabicyclo[4.2.0]octane-3,5-dione	differentiation inducer	cancer
CDDO	Preclinical	2-cyano-3,12-dioxoooleana-1,9(11)-dien-28-oic acid	differentiation inducer; antiproliferative agent	cancer

alitretinoin; LGD 1057; LG 1057; LGN 1057; ALRT 1057; NSC 659772; PANRETIN	Marketed	9-cis-retinoic acid	differentiation inducer; retinoid agonist; RXR agonist	cancer; psoriasis
AG 187	Discontinued	2,4-diamino-6-(N-(4-(phenylsulfonyl)benzyl)methylamino)quinazoline	dihydrofolate reductase inhibitor	cancer
LY 298207	Preclinical	N-[4-[4-(2,4-diamino-5-pyrimidinyl)butyl]benzoyl]-L-glutamic acid	dihydrofolate reductase inhibitor	cancer
LY 316373	Preclinical	N-[4-[3-(2,4-diamino-5-pyrimidinyl)propyl]benzoyl]-L-glutamic acid	dihydrofolate reductase inhibitor	cancer
trimetrexate; trimetrexate glucuronate; TMQ; NSC 249008; CI 898; NeuTrexin	Marketed	5-methyl-6-[[[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolin-6-ylidene]amino]quinazolin-2(1H)-one	dihydrofolate reductase inhibitor; antifolate; NSAID	cancer; psoriasis; rheumatoid arthritis; pneumocystis
drug delivery system, methotrexate; methotrexate Therapeutic Implant; MPI 5004; IntraDose-MTX; INTRADOSE-MTX	Discontinued		dihydrofolate reductase inhibitor; antimetabolite	cancer

MDAM	Phase I	N-[4-[2-(2,4-diamino-6-pteridiny)ethyl]benzoyl]-4-methylene-DL-glutamic acid	dihydrofolate reductase inhibitor; NSAID; immunosuppressant	cancer; transplant rejection; rheumatoid arthritis; asthma
eniluracil; 5-ethynyluracil; 5-EU; 776C85; BW 776C85	Phase III	5-ethynyl-2,4(1H,3H)-pyrimidinedione	dihydropyrimidine dehydrogenase inhibitor; antimetabolite	cancer
spirogermanium; NSC 192965; SPIRO-32	Discontinued	8,8-diethyl-1,N-dimethyl-2-aza-8-germaspiro[4.5]decan-2-propanamine	DMARD; NSAID	malaria; multiple sclerosis; rheumatoid arthritis; cancer
acridine-derived bisintercalators, NIH	Preclinical		DNA intercalator	cancer
anticancer agents, Kyowa Hakko	Discontinued		DNA intercalator	cancer
BBR 2778	Phase I	6,9-bis[(2-aminoethyl)amino]benz[g]isoquinoline-5,10-dione (Z)-2-butenedioate (1:2)	DNA intercalator	cancer
bisnafide; DMP 840	Phase II	[R-(R*,R*)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)dione]dimethanesulfonate	DNA intercalator	cancer
BW 7U85	Discontinued		DNA intercalator	cancer
BW A502U; BW 502U83	Discontinued		DNA intercalator	cancer

crisnatol; mesilate; BW 770U82; BWA 770U	Discontinued	2-[(6-chrysenylmethyl)amino]-2-methyl-1,3-propanediol	DNA intercalator	cancer
D 1411	Discontinued		DNA intercalator	cancer
DMP 315	Preclinical	[R-(R*,R*)]-5-[1-methyl-2-[[2-[[2-(5-nitro-1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl)propyl]amino]ethyl]amino]ethyl]-4H-benzo[de]pyrido[3,4-g]isoquinoline-4,6(5H)dione dimethanesulfonate	DNA intercalator	cancer
ledoxantrone; CI 958 isomer; PD 121373	Phase II	5-[(2-aminoethyl)amino]-2-[[2-(diethylamino)ethyl]-2H-[1]benzothiopyrano[4,3,2-cd]indazol-8-ol	DNA intercalator	cancer
mitonafide; NSC 3002888	Phase II	2-[2-(dimethylamino)ethyl]-5-nitro-1H-benz[de]isoquinoline-1,3(2H)-dione	DNA intercalator	cancer

S 160202; S 16020-2; S 16020; NSC 659687; NSC D659687	Phase II	N-[2-(dimethylamino)ethyl]-9-hydroxy-5,6-dimethyl-6H-pyrido[4,3-b]carbazole-1-carboxamide dihydrochloride	DNA intercalator	cancer
cyclopentantriquinones, Sloan Kettering Institute	Preclinical		DNA intercalator; anthraquinone	cancer
OC 4845	Preclinical	1,1a,2,2a,5,10-hexahydro-3[[[[(methylamino)carbonyl]oxy[methyl]-azirino[2',3':3,4]cyclopenta[1,2-a]anthracene-5,10-dione	DNA intercalator; anthraquinone	cancer
C 1311	Phase I	5-[[2-(diethylamino)ethyl]amino]-8-hydroxy-6H-imidazo[4,5,1-de]acridin-6-one	DNA intercalator; DNA topoisomerase inhibitor	cancer
NLP 1	Preclinical	5-[3-(2-nitro-1H-imidazol-1-yl)propyl]phenanthridinium bromide	DNA intercalator; radiosensitizer	cancer

aphidicolin glycinate; NSC 303812	Preclinical	glycine, (3 α ,4 α ,5 α ,17 α)- 3,17-dihydroxy-4- methyl-9,15-cyclo- C,18-dinor-14,15- secoandrostane-4,17- dimethanol ester hydrochloride	DNA polymerase inhibitor	cancer
DNA polymerase beta inhibitors, Agouron	Discontinued		DNA polymerase inhibitor; radiosensitizer; chemosensitizer	cancer
NU/ICRF 505	Discontinued		DNA topoisomerase inducer	cancer
UCT 4B; UCTB 4	Discontinued	2-[1-hydroxy-2- [1,2,3,4,4a,7,8,8a- octahydro-3-hydroxy- 5-(hydroxymethyl)- 1,2,4a-trimethyl-4- oxo-1- naphthalenyl]ethyl]- alpha-oxo- oxiraneacetaldehyde	DNA topoisomerase inducer; antibiotic	bacterial infection; cancer
9- aminocamptothecin; 9-AC; NSC 603071 (S); NSC 629971 (+, -); FCE 28044	Phase II	(S)-10-amino-4-ethyl- 4-hydroxy-1H- pyrano[3',4':6,7]indoli- zino[1,2-b]quinoline- 3,14(4H,12H)-dione	DNA topoisomerase inhibitor	cancer
AMP 53; azonafide 53	Discontinued		DNA topoisomerase inhibitor	cancer

asulacrine; amsalog; CI 921; NSC 343499; SN 21407	Phase I	9-[[2-methoxy-4- [(methylsulfonyl)ami- no]phenyl]amino]- N,5-dimethyl-4- acridinecarboxamide	DNA topoisomerase inhibitor	cancer
azatoxin; NSC 640737	Preclinical	(5R-cis)-5,6,11,11a- tetrahydro-5-(4- hydroxy-3,5- dimethoxyphenyl)- 1H,3H- oxazolo[3',4':1,6]pyri- do[3,4-b]indol-3-one	DNA topoisomerase inhibitor	cancer
BE 10988	Discontinued	2-(5-amino-4,7- dihydro-1-methyl- 4,7-dioxo-1H-indol- 3-yl)-4- thiazolecarboxamide	DNA topoisomerase inhibitor	cancer
BE 13793C	Discontinued	12,13-dihydro-1,11- dihydroxy-5H- indolo[2,3- a]pyrrolo[3,4- c]carbazole-5,7(6H)- dione	DNA topoisomerase inhibitor	cancer
BE 22179	Discontinued		DNA topoisomerase inhibitor	cancer
BN 80915	Phase I		DNA topoisomerase inhibitor	cancer
BNP 1350	Phase I		DNA topoisomerase inhibitor	cancer
BNPI 1100	Preclinical		DNA topoisomerase inhibitor	cancer

BO 2367	Discontinued	(-)-7-[1R*,2R*,6R*]-2-amino-8-azabicyclo[4.3.0.]non-3-en-8-yl]-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid	DNA topoisomerase inhibitor	cancer
camptothecin analogues, Research Triangle Institute	Preclinical		DNA topoisomerase inhibitor	cancer
camptothecin derivatives, Daiichi	Discontinued		DNA topoisomerase inhibitor	cancer
CKD 602	Phase I	4-ethyl-4-hydroxy-11-[2-[(1-methylethyl)amino]ethyl]-1H-pyranol[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione	DNA topoisomerase inhibitor	cancer
DM II 33	Preclinical		DNA topoisomerase inhibitor	cancer
DNA topoisomerase inhibitor, second generation, Xenova; XR 5942 series; XR 5942	Preclinical		DNA topoisomerase inhibitor	cancer
DRF 1042	Preclinical		DNA topoisomerase inhibitor	cancer

drug delivery system, camptothecin; camptothecin delivery system; MPI 5019	Preclinical		DNA topoisomerase inhibitor	cancer
drug delivery system, liposome lurtotecan; lurtotecan liposome; NX 211	Phase I		DNA topoisomerase inhibitor	cancer
drug delivery system, microsphere 10-hydroxycamptothecin; 10-hydroxycamptothecin microsphere	Preclinical		DNA topoisomerase inhibitor	cancer
DX 8951f; DX 8951f	Phase II	(1S-trans)-1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-10H,13H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-dione monomethanesulfonate	DNA topoisomerase inhibitor	cancer

ED 110	Discontinued	12-beta-D-glucopyranosyl-12,13-dihydro-1,11-dihydroxy-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6H)-dione	DNA topoisomerase inhibitor	cancer
ER 37328	Preclinical	12,13-dihydro-5-[2-(dimethylamino)ethyl]-4H-benzo[c]pyrimido[5,6,1-jk]carbazole-4,6,10(5H,11H)-trione	DNA topoisomerase inhibitor	cancer
F 11782; F 1267; L 0084	Preclinical	[5R-[5alpha,5abeta,8alpha,9beta(R*)]]-5-[3,5-dimethoxy-4-(phosphonoxy)phenyl]-9-[[4,6-O-ethylidene-2,3-bis-O-[(pentafluorophenoxy)acetyl]-beta-D-glucopyranosyl]oxy]-5,8,8a9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one	DNA topoisomerase inhibitor	cancer

fostriecin; NSC 339638; CI 920; CL 1565A	Phase I	5,6-dihydro-6- [3,6,13-trihydroxy-3- methyl-4- (phosphonoxy)- 1,7,9,11- tridecatetraenyl]-2H- pyran-2-one monosodium salt	DNA topoisomerase inhibitor	cancer
HAR 7	Preclinical		DNA topoisomerase inhibitor	cancer
intoplicine; RP 60475; NSC D645008	Phase I	11-[[3- (dimethylamino)prop yl]amino]-8-methyl- 7H- benzo[e]pyrido[4,3- b]indol-3-ol	DNA topoisomerase inhibitor	cancer
irinotecan; irinotecan hydrochloride; camptothecin 11; CPT 11; DQ 2805; SN 3811; U 101440E; CPT 11; CAMPTO; TOPOTECIN; CAMPTOSAR; IRKAN	Marketed	(1,4'-bipiperidine)-1'- carboxylic acid (S)- 4,11-diethyl- 3,4,12,14-tetrahydro- 4-hydroxy-3,14- dioxo-1H- pyrano(3',4':6,7)indoli zino(1,2-b)quinolin- 9-yl ester, monohydrochloride	DNA topoisomerase inhibitor	cancer

lurtotecan; lurtotecan dihydrochloride; GG 211; GI 147211; GI 147211A; GI 147211C	Suspended	(S)-8-ethyl-2,3-dihydro-8-hydroxy-15-[(4-methyl-1-piperazinyl)methyl]-11H-1,4-dioxino[2,3-g]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-9,12(8H,14H)-dione	DNA topoisomerase inhibitor	cancer
MPI 6003	Discontinued		DNA topoisomerase inhibitor	cancer
NB 506	Phase I	N-(12-beta-D-glucopyranosyl-5,7,12,13-tetrahydro-1,11-dihydroxy-5,7-dioxo-6H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-6-yl)-formamide	DNA topoisomerase inhibitor	cancer
NC 190; NCU 190	Discontinued	6-[[[2-(dimethylamino)ethyl]amino]carbonyl]-5-hydroxy-10-methoxybenzo[a]phenazine-9-carboxylic acid monosodium salt	DNA topoisomerase inhibitor	cancer
NCA 0465	Preclinical		DNA topoisomerase inhibitor	cancer
NK 109; NK 106	Phase I	1-Hydroxy-2-methoxy-12-methyl-[1,3]benzodioxolo[5,6-c]phenanthridinium, sulfate (1:1) (salt)	DNA topoisomerase inhibitor	cancer

NU/ICRF 500	Discontinued		DNA topoisomerase inhibitor	cancer	
NU/ICRF 506	Discontinued		DNA topoisomerase inhibitor	cancer	
polyethylene glycol-camptothecin; PEG-camptothecin; camptothecin macrogol; PROTHECAN	Preclinical		DNA topoisomerase inhibitor	cancer	
tubitecan; 9-nitrocamptothecin; RFS 2000	Phase III		DNA topoisomerase inhibitor	cancer	
sobuzoxane; MST 16; Marketed PERAZOLIN	Marketed	1,2-ethanedithylbis[(2,6-dioxo-4,1-piperazinediyl)methyl]ene]bis(2-methylpropyl) carbonic acid ester	DNA topoisomerase inhibitor	cancer	
TAN 1496	Discontinued		DNA topoisomerase inhibitor	cancer	

TAN 1518A	Discontinued	2-hydroxybenzoic acid 3-(aminocarbonyl)-8-[2,6-dideoxy-4-O-(2-methyl-1-oxo-2-butenyl)hexopyranosyl]-1,4,4a,6,11,11a,12,12a-octahydro-2,4a,5,7-tetrahydroxy-11-methoxy-11-methyl-4,6-dioxo-1-naphthaceny] ester	DNA topoisomerase inhibitor	cancer
TAS 103	Phase I	6-[[2-(dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one	DNA topoisomerase inhibitor	cancer
teniposide; VM 26; NSC 122819; VUMON; BEKNOS; VEHEM SANDOZ	Marketed	[5R-[5-alpha,5abeta,8aalpha,9beta(R*)]]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-(2-thienylmethylene)-beta-D-glucopyranosyl]oxy]furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one	DNA topoisomerase inhibitor	cancer

TOP 53	Phase I	[5R-(5alpha,5beta,8alpha,9beta)]-9-[2-[[2-(dimethylamino)ethyl]-[methylethylamino]ethyl]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one	DNA topoisomerase inhibitor	cancer
topoisomerase inhibitor, Biota	Preclinical		DNA topoisomerase inhibitor	cancer
topotecan; hycamtamine; SKF 104864; SKF 104864A; HYCAMTIN	Marketed	(S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione	DNA topoisomerase inhibitor	cancer
WIN 63320	Discontinued		DNA topoisomerase inhibitor	cancer
WIN 64593	Discontinued		DNA topoisomerase inhibitor	cancer
XR 5000; NSC 601316; DACA	Phase I	N-[2-(dimethylamino)ethyl]-4-acridinecarboxamide	DNA topoisomerase inhibitor	cancer

AD 312	Preclinical	(8S-cis)-8-acetyl-10-[[3-[[[(2-chloroethyl)nitrosoamino]carbonyl]amino]-2,3,6-trideoxy- α -L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione	DNA topoisomerase inhibitor; anthracycline; alkylating agent; antibiotic	cancer
elsamitrucin; elsamicin A; BMY 28090; NSC 369327; BMS 181171	Discontinued	10-[[2-O-(2-amino-2,6-dideoxy-3-O-methyl- α -D-galactopyranosyl)-6-deoxy-3-C-methyl-beta-D-galactopyranosyl]oxy]-6-hydroxy-1-methylbenzo[h][1]benzopyrano[5,4,3-cde][1]benzopyran-5,12-dione	DNA topoisomerase inhibitor; antibiotic	cancer
DNA topoisomerase inhibitors, AVAX Technologies	Preclinical		DNA topoisomerase inhibitor; antifungal	cancer; mycosis; parasitic infection
elinafide; LU 79553	Phase I	2,2'-[1,3-propanediylbis(imino-2,1-ethanediyl)]bis-1H-benz[de]isoquinolone-1,3(2H)-dione	DNA topoisomerase inhibitor; DNA intercalator	cancer

LU 55446	Discontinued			DNA topoisomerase inhibitor; DNA intercalator	cancer
doserogside; AF 1	Discontinued	[8beta(1S,2R,3E)]-N-[2-hydroxy-1-(hydroxymethyl)-3-heptadecenyl]-6-methylergoline-8-carboxamide		dopamine agonist	cancer; infertility
drug delivery system, bromocriptine; bromocriptine delivery system; ERGOSET	Pre-registration			dopamine agonist	diabetes; obesity; cancer
ST 557	Discontinued			dopamine agonist; immunostimulant	cancer
ST 570	Discontinued			dopamine agonist; immunostimulant	cancer
Pan-Her inhibitors, SUGEN; Her2 inhibitors, SUGEN	Preclinical			EGF receptor inhibitor	cancer
LFM A12	Preclinical	(Z)-2-cyano-3-hydroxy-N-[4-(trifluoromethoxy)phenyl]-2-butenamide		EGF receptor inhibitor; tyrosine kinase inhibitor	cancer

ABT 627; A 127722; A 147627	Phase II	[2S-(2alpha,3beta,4alpha)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-3-pyrrolidinecarboxylic acid	endothelin antagonist; endothelin A antagonist	cancer; restenosis; myocardial infarction
BE 14348B	Discontinued	2(S),3(S)-3-methyl-4',5,7-trihydroxy-flavanone	estrogen agonist	cancer
GW 5638	Preclinical	(E,Z)-3-[4-(1,2-diphenyl-1-butenyl)phenyl]-2-propenoic acid	estrogen agonist; antiestrogen	osteoporosis; cancer; coronary artery disease
CP 336156	Phase II	(5R,6S)-5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyloxy)phenyl]-2-naphthalenol (2S,3S)-2,3-dihydroxybutanedioate (1:1) (salt)	estrogen partial agonist	osteoporosis; cancer
2-methoxyestradiol; 2-ME	Preclinical		estrogen; angiogenesis inhibitor	cancer
estrogen receptor therapy, Ligand/Wyeth Ayerst	Preclinical		estrogen; hormone replacement therapy	hormone deficiency; contraception; cancer; osteoporosis
EMATE	Discontinued	3-[(aminosulfonyloxy)estra-1,3,5(10)trien-17-one	estrone sulfatase inhibitor	cancer

ara-CDP-DL-PTBA; CYTOROS	Preclinical	4-amino-1-[5-O-[1,3-dihydroxy-6-[(1-oxohexyloxy)]-2,4-dioxo-8-thia-1,3-diphosphahexacos-1-yl]-beta-D-arabinofuranosyl]-2(1H)-pyrimidinone P,P'-dioxide	ether lipid	cancer
edelfosine; ET 18-OCH ₃ ; ALP	Pre-registration	(+)-4-hydroxy-7-methoxy-N,N,N-trimethyl-3,5,9-trioxo-4-phosphahaptacosan-1-aminium hydroxide inner salt, 4-oxide	ether lipid	cancer
EG 6	Preclinical	1-[4-[2-[2-(octadecyloxy)ethoxy]ethoxy]butyl]pyridinium methanesulfonate	ether lipid	cancer
ether lipid, Roswell Park	Preclinical	ara-CDP-rac-1-S-tetradecyl-2-O-palmitoyl-1-thioglycerol	ether lipid	cancer
ether lipid, Vancouver University	Preclinical	4-(hexadecyloxy)-3-(S)-methoxybutyl phosphonylcholine	ether lipid	cancer

miltefosine; BM 41440; BM 21440	Discontinued	4-hydroxy-7-(methoxymethyl)-N,N,N-trimethyl-3,5-dioxo-9-thia-4-phosphapentacosan-1-aminium hydroxide, inner salt, 4-oxide	ether lipid	cancer
miltefosine; hexadecylphonylcholine; HPC; D 18506; MILTEX	Marketed	2-[[[(hexadecyloxy)hydroxyphosphinyloxy]-N,N,N-trimethylathanaminium, hydroxide, inner salt	ether lipid	cancer, leishmaniasis
perifosine; D 21266; NKA 17	Phase I	4-[[[hydroxy(octadecyloxy)phosphinyloxy]-1,1-dimethylpiperidinium inner salt	ether lipid	cancer
SRI 34234	Discontinued		ether lipid	cancer
SRI 62834	Discontinued	(+,-)-2-[[[hydroxy[[tetrahydro-2-[(octadecyloxy)methyl]-2-furanyl]methoxy]phosphinyloxy]-N,N,N-trimethyl-ethanaminium, inner salt.	ether lipid	cancer; multiple sclerosis
TLC ELL 12; ELL 12	Phase I		ether lipid	cancer

SDZ 62826	Discontinued		ether lipid; immunostimulant	cancer
etoposide phosphate; BMY 40481; ETOPOPHOS	Marketed	(5R,5aR,8aR,9S)-5-[3,5-dimethoxy-4-(phosphonoxy)phenyl]-9-[(4,6-O-(1R)-ethylidene-beta-D-glucopyranosyl)oxy]-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one	etoposide analogue	cancer
IGT 13	Preclinical		etoposide analogue	cancer
NK 611; VP 19; 2'-(dimethylamino)etoposide	Phase II	[5R-[5alpha,5a-beta,8a-alpha,9beta(R*)]]-9-[[2-deoxy-2-(dimethylamino)-4,6-O-ethylidene-beta-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one hydrochloride	etoposide analogue	cancer

GL 331	Phase II	[5R-(5alpha,5beta,8alpha,9beta)]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[(4-nitrophenyl)amino]furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one	etoposide analogue; DNA topoisomerase inhibitor	cancer
ARGLABIN	Registered		farnesyl protein transferase inhibitor	cancer
B 956	Preclinical	[2S-(2R*,3Z,5R*,6E,8S*)]-N-[8-amino-9-mercapto-5-(1-methylethyl)-1-oxo-2-(phenylmethyl)-3,6-nonadienyl]-L-methionine	farnesyl protein transferase inhibitor	cancer
farnesyl transferase inhibitors	Discontinued		farnesyl protein transferase inhibitor	cancer
L 639749	Preclinical		farnesyl protein transferase inhibitor	cancer

L 744832	Preclinical	[2S-[1[R*(R*),2R*(S),3R*]-2-[[2-[2-amino-3-mercaptopropyl]amino]-3-methylpentyl]oxy]-1-oxo-3-phenylpropyl]amino]-4-(methylsulfonyl)-butanoic acid, 1-methylethyl ester	farnesyl protein transferase inhibitor	cancer
L 778123	Phase I		farnesyl protein transferase inhibitor	cancer
PD 169451	Preclinical		farnesyl protein transferase inhibitor	cancer
perillyl alcohol; NSC 641066	Phase II	4-(1-methylethenyl)-1-cyclohexene-1-methanol	farnesyl protein transferase inhibitor	cancer
ras farnesyl protein transferase inhibitors, Parke Davis	Preclinical		farnesyl protein transferase inhibitor	cancer
ras farnesyl protein transferase inhibitors, University of Pittsburgh	Preclinical		farnesyl protein transferase inhibitor	cancer
RPR 115135	Preclinical		farnesyl protein transferase inhibitor	cancer

SCH 59228	Preclinical	1-(3-bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-4-[(1-oxido-4-pyridinyl)acetyl]piperazine	farnesyl protein transferase inhibitor	cancer
L 731734	Discontinued	[3S-[3R*[2R*[2R*(S*),3S*,3R*]]]-2-[(2-amino-3-mercaptopropyl)amino]-3-methylpentyl]amino]-3-methyl-N-(tetrahydro-2-oxo-3-furanyl)pentanamide	farnesyl protein transferase inhibitor; peptide	cancer
L 731735	Discontinued	[2S-[2R*(S*),3S*]]-N-[N-[2-(2-amino-3-mercaptopropyl)amino]-3-methylpentyl]-L-isoleucyl]-L-homoserine	farnesyl protein transferase inhibitor; peptide	cancer
R 115777	Phase II		farnesyl protein transferase inhibitor; signal transduction inhibitor	cancer
SCH 66336	Phase II		farnesyl protein transferase inhibitor; signal transduction inhibitor	cancer

TOP 53	Phase I	[5R-(5alpha,5abeta,8alpha,9beta))-9-[2-[(2-(dimethylamino)ethyl)-[methylamino]ethyl]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one]	DNA topoisomerase inhibitor	cancer
topoisomerase inhibitor, Biota	Preclinical		DNA topoisomerase inhibitor	cancer
topotecan; hycamtamine; SKF 104864; SKF 104864A; HYCAMTIN	Marketed	(S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione	DNA topoisomerase inhibitor	cancer
WIN 63320	Discontinued		DNA topoisomerase inhibitor	cancer
WIN 64593	Discontinued		DNA topoisomerase inhibitor	cancer
XR 5000; NSC 601316; DACA	Phase I	N-[2-(dimethylamino)ethyl]-4-acridinecarboxamide	DNA topoisomerase inhibitor	cancer

BIM 26028	Discontinued			gastrin antagonist; bombesin antagonist	cancer; cachexia; respiratory disease
CDP 845	Discontinued			gelatinase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor; angiogenesis inhibitor	cancer
CT 1746	Discontinued			gelatinase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor	cancer
gelatinase inhibitors, Celltech	Preclinical			gelatinase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor	cancer
basal cell carcinoma therapy, Ontogeny; patched gene; ptc gene	Preclinical			gene	cancer; skin disease
bcl-6-based non- Hodgkin's lymphoma therapy	Preclinical			gene	cancer
cancer therapy, cancer cell growth genes	Preclinical			gene	cancer
CDK4 based therapy, Axs; melanoma therapy, Axs	Preclinical			gene	cancer
HFE-based therapies, Progenitor	Preclinical			gene	iron overload; cancer

immune system modulators, Chiroscience	Preclinical		gene	autoimmune disease; rheumatoid arthritis; cancer; HIV infection
melanoma differentiation-associated genes	Discontinued		gene	cancer
MMAC1 based therapy, Myriad	Preclinical		gene	cancer
MTS2 based therapy, Myriad	Preclinical		gene	cancer
MTS3 based therapy, Myriad; cancer therapy, Myriad	Preclinical		gene	cancer
mum-1-based cancer therapy	Preclinical		gene	cancer
P-TEN-based cancer therapy, Amplicon	Preclinical		gene	cancer
prostate tumor-inducing genes	Discontinued		gene	cancer; diagnosis
gene therapy, ATase	Preclinical		gene therapy; biotechnology	cancer
gene therapy, C-CAM, Introgen; adenoviral C-CAM, Introgen; INGN 231	Preclinical		gene therapy; biotechnology	cancer
gene therapy, cancer	Preclinical		gene therapy; biotechnology	cancer
gene therapy, cancer; SMART GENETIC CONSTRUCTS	Preclinical		gene therapy; biotechnology	cancer
gene therapy, cancer	Preclinical		gene therapy; biotechnology	cancer

gene therapy, cancer	Preclinical		gene therapy; biotechnology	cancer
gene therapy, cancer, Cobra Therapeutics; CTL 102; TXS 0202	Preclinical		gene therapy; biotechnology	cancer
gene therapy, cancer, pulmonary disease	Preclinical		gene therapy; biotechnology	cancer; respiratory disease
gene therapy, hepatocellular carcinoma; HepXia	Preclinical		gene therapy; biotechnology	cancer
gene therapy, ovarian and pancreatic cancer	Preclinical		gene therapy; biotechnology	cancer
gene therapy, ovarian cancer; gene therapy, brca1, MB 700	Preclinical		gene therapy; biotechnology	cancer
gene therapy, p16, p27; gene therapy, restenosis; gene therapy, cancer	Preclinical		gene therapy; biotechnology	restenosis; cancer
gene therapy, p53; gene therapy, cancer	Phase I		gene therapy; biotechnology	cancer
gene therapy, scFV/gamma G250; gene therapy, renal carcinoma	Preclinical		gene therapy; biotechnology	cancer
gene therapy, stress proteins	Preclinical		gene therapy; biotechnology	cancer
gene therapy, thymidine kinase; gene therapy, cancer; gene therapy, HS-tk	Phase I		gene therapy; biotechnology	cancer

gene therapy, thymidine kinase; gene therapy, glioma	Preclinical		gene therapy; biotechnology	cancer
gene therapy, tumor antigens; gene therapy, cancer	Preclinical		gene therapy; biotechnology	cancer
gene therapy, ATF BTPI; gene therapy, cancer	Preclinical		gene therapy; biotechnology; angiogenesis inhibitor	cancer
gene therapy, colorectal cancer, Oxford BioMedica; CoRectoGen	Preclinical		gene therapy; biotechnology; angiogenesis inhibitor	cancer
gene therapy, glioma, Oxford Biomedica; GlioStat	Preclinical		gene therapy; biotechnology; angiogenesis inhibitor	cancer
gene therapy, ovarian cancer, Oxford BioMedica; BetOvaC	Preclinical		gene therapy; biotechnology; angiogenesis inhibitor	cancer
gene therapy, prostate cancer; ProCaStat	Preclinical		gene therapy; biotechnology; angiogenesis inhibitor	cancer
gene therapy, interleukin-2, Transgene; gene therapy, cancer	Phase I		gene therapy; biotechnology; cytokine; immunostimulant	cancer
gene therapy, wt p53; gene therapy, cancer	Preclinical		gene therapy; biotechnology; radiosensitizer; chemosensitizer	cancer

vaccine, gene-based, colorectal cancer; vaccine, gene-based, CO17-A/GA733; AV GA 7332	Phase I		gene therapy; biotechnology; vaccine	cancer
vaccine, gene-based, human papilloma virus	Preclinical		gene therapy; biotechnology; vaccine	cancer
progression elevated genes	Discontinued		gene; angiogenesis inhibitor	cancer
glutathione inhibitors, Telik	Discontinued		glutathione inhibitor	cancer
AG 2026	Discontinued		glycinamide ribotide formyltransferase inhibitor	cancer
AG 2032	Discontinued		glycinamide ribotide formyltransferase inhibitor	cancer
AG 2034	Phase I	(S)-N-[[5-[2-(2-amino-4,6,7,8-tetrahydro-4-oxo-1H-pyrimido[5,4-b][1,4]thiazin-6-yl)ethyl]-2-thienyl]carbonyl]-L-glutamic acid	glycinamide ribotide formyltransferase inhibitor	cancer
AG 2037	Preclinical		glycinamide ribotide formyltransferase inhibitor	cancer
contortrostatin; CN	Preclinical		glycoprotein IIb/IIIa antagonist; platelet antiaggregant; biotechnology	cancer; thrombosis

mannostatin A	Preclinical	[1R-(1alpha,2alpha,3alpha,4alpha,5beta)]-4-amino-5-(methylthio)-1,2,3-cyclopentanetriol	glycosidase inhibitor	cancer
glycosidase inhibitor, Oxford GlycoSciences	Preclinical		glycosidase inhibitor; NSAID	cancer; rheumatoid arthritis
drug delivery system, ATRIGEL sustained release leuporelin; leuporelin ATRIGEL	Preclinical		gonadorelin agonist	cancer
drug delivery system, microparticle buserelin; buserelin microparticle delivery system	Phase III		gonadorelin agonist	cancer; endometriosis
drug delivery system, sustained release LHRH analogue; LHRH analogue delivery system; ProMaxx, LHRH analogue; ProMaxx 100	Clinicals		gonadorelin agonist	cancer

goserelin; goserelin acetate; ICI 118630; ZOLADEX	Marketed	6-[O-(1,1-dimethylethyl)-D-serine]-1-9-luteinizing hormone-releasing factor (swine) 2-(aminocarbonyl)hydrazide	gonadorelin agonist	cancer; endometriosis; infertility
leuprorelin; leuprorelin acetate; leuprolide; TAP 144; TAP 144SR; ABBOTT 43818; LUPRON; CARCIN; LEUPLIN; LUPRON DEPOT; PROSTAP ST; PROSTAP SR; ENANTONE	Marketed	6-D-leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide luteinizing hormone-releasing factor (swine)	gonadorelin agonist	cancer; endometriosis
nafarelin; nafarelin acetate; D-Nal(2)6 LHRH; RS 94991; RS 94991 298; SAMYNAREL; SYNAREL; NASANYL	Marketed	6-[3-(2-naphthalenyl)-D-alanine]-luteinizing hormone-releasing factor (swine)	gonadorelin agonist	cancer; endometriosis; infertility
RL 0903	Phase II		gonadorelin agonist	cancer
triptorelin; BN 52014; BIM 21003; AY 25650; CL 118532; WY 42462; ARVECAP; DECAPEPTYL	Marketed	6-D-tryptophan-luteinizing hormone-releasing factor (swine)	gonadorelin agonist	cancer; precocious puberty; endometriosis

leuprolide + estrogen + progesterone	Phase I			gonadorelin agonist; estrogen; progestogen	contraception; cancer
gonadotropin releasing hormone analogue, conjugated; GnRH analogue copolymer conjugate	Preclinical			gonadorelin agonist; gonadorelin antagonist	cancer
avorelin	Phase II	5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-2-methyl-D-tryptophyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide		gonadorelin agonist; peptide	cancer; precocious puberty; endometriosis
drug delivery system, histrelin hydrogel implant; histrelin hydrogel implant	Phase I			gonadorelin agonist; peptide	precocious puberty; cancer
A 84861	Phase I			gonadorelin antagonist	cancer
abarelix; PPI 149; R 3827	Phase III	N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-N-methyl-L-tyrosyl-D-asparagyl-L-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide		gonadorelin antagonist cancer; benign prostate hypertrophy; endometriosis	

cetorelix; SB 75; SB 075; CETROTIDE	Registered	N-Acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N5-(aminocarbonyl)-D-ornithyl-L-leucyl-L-arginyl-L-prolyl-D-alaninamide	gonadorelin antagonist	infertility; cancer; endometriosis; benign prostate hypertrophy; contraception
D 20453	Discontinued		gonadorelin antagonist	cancer
D 21775; T 148	Discontinued	N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-[N-acetyl-3-(acetylamino)-L-alanyl]-D-lysyl-L-leucyl-L-arginyl-L-prolyl-D-alaninamide	gonadorelin antagonist	cancer
D 23487	Discontinued	Unspecified	gonadorelin antagonist	cancer
D 26344	Preclinical		gonadorelin antagonist	cancer; infertility

detirelix, RS 68439	Discontinued	N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-Phenylalanyl-D-tryptophyl-L-seryl-L-tyrosyl-N6-[bis(ethylamino)methylene]-D-lysyl-L-leucyl-L-arginyl-L-propyl-D-alaninamide	gonadorelin antagonist	gonadorelin antagonist; cancer
drug delivery system, ATRIGEL sustained release ganirelix; ganirelix ATRIGEL	Discontinued		gonadorelin antagonist	cancer; endometriosis
drug delivery system, ATRIGEL sustained release GnRH antagonists	Discontinued		gonadorelin antagonist	endometriosis; cancer
drug delivery system, microcapsule SB 75; SB 75 microcapsule	Preclinical		gonadorelin antagonist	cancer; contraception
gonadotropin releasing hormone antagonists, Alanex	Preclinical		gonadorelin antagonist	contraception; cancer
gonadotropin-releasing hormone antagonist, Agouron; GnRH antagonist, Agouron	Preclinical		gonadorelin antagonist	cancer
HOE 2013	Suspended		gonadorelin antagonist	cancer; endometriosis

ramorelix; HOE 013	Phase II	N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-D-typtophyl-L-seryl-L-tyrosyl-O-(6-deoxy-alpha-L-mannopyranosyl)-D-seryl-L-leucyl-L-arginyl-L-proline, 2-(aminocarbonyl)hydrazide	gonadorelin antagonist	cancer
A 76154	Preclinical	N-[3-(4-fluorophenyl)-1-oxopropyl]-3-(1-naphthalenyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-N6-(3-pyridinylcarbonyl)-D-lysyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide	gonadorelin antagonist; peptide	cancer; endometriosis; precocious puberty

teverelix; ANTARELIX	Phase I	N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-L-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-(aminocarbonyl)-D-lysyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide	gonadorelin antagonist; peptide	cancer; endometriosis; infertility
deslorelin; BACHEM 9022; SOMAGARD	Marketed	5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide	gonadorelin superagonist	cancer; precocious puberty
drug delivery system, deslorelin implant; deslorelin implant	Preclinical		gonadorelin superagonist	cancer; gynecological; infertility
hematology cytokines, AMRAD; hematology cytokines, Chugai	Discontinued		growth factor	cancer
hematopoietic growth factor mimetics, Ligand	Preclinical		growth factor	cancer; bacterial infection; anemia
GM 1306	Preclinical		growth factor modulator	diabetes; retinopathy; cancer
GM 1474	Preclinical	Unspecified	growth factor modulator	cancer
keratinocyte growth factor antagonist	Preclinical		growth factor modulator; peptide	cancer

hepatocyte growth factor related proteins; HGF-related proteins	Preclinical			growth factor; biotechnology; chemoprotectant; cytoprotectant	cancer
CMI SAF9	Preclinical			growth factor; hematopoietic factor	cancer
thrombopoietin; TPO	Phase II			growth factor; hematopoietic factor; biotechnology	cancer; thrombocytopenia
Tie-2 ligands, Regeneron; angiogenesis ligands, Regeneron	Preclinical			growth factor; hematopoietic factor; cicatrizant; angiogenesis inhibitor; angiogenesis inducer	cancer; restenosis; retinopathy; skin ulcer; atherosclerosis; peripheral vascular disease
SB 251353	Preclinical			growth factor; hematopoietic factor; immunostimulant	cancer
goralate; seraspemide; BN 52040; BIM 32001	Phase II		1-[N2-[N-(N-acetyl-L-seryl)-L-alpha-aspartyl]-L-lysyl]-L-proline	hematoprotectant; chemoprotectant; peptide	cancer
pentosan polysulfate sodium; SP 54; PZ 68; CARTROPHEN; LASONIL; ELMIRON; LE LONG MOUSSE	Marketed		(1-4)-beta-D-xylan 2,3-bis(hydrogen sulfate), sodium salt	heparinoid; vasodilator; NSAID	arthritis; angina; hyperlipidemia; rheumatoid arthritis; cancer; cystitis
MAXAMINE	Phase III			histamine agonist; histamine H2 agonist	cancer; viral infection; hepatitis

MAP 30	Preclinical	N2-[N-[N-[N2-(N-L-threonyl)-L-isoleucyl)-L-lysyl]-L-threonyl]-L-threonyl]-L-threonyl]-L-lysine	HIV integrase inhibitor	HIV infection; cancer
lovastatin; mevinolin; monakolin K; MK 803; MSD 803; MB 530B; L 154803; MEVACOR; MEVLOR; LOVACOL; HIPOVASTIN; DISLIPIN; LOVASTEROL; LINCIL	Marketed	(S)-2-methylbutyric acid, 8-ester with (4R,6R)-6-[2-[(1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl]ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one	HMG CoA reductase inhibitor	hyperlipidemia; cancer
cancer therapy, Oxis	Preclinical		hormone	cancer
drug delivery system, PEPITITROL	Preclinical		hormone	osteoporosis; Paget disease; cancer
calcitonin; calcitonin PEPITITROL				
drug delivery system, subcutaneous gonadotropin releasing hormone; gonadotropin releasing hormone subcutaneous implant; GnRH subcutaneous implant	Preclinical		hormone	precocious puberty; endometriosis; cancer; contraception
glycoprotein hormone superagonists, NIH	Preclinical		hormone	infertility; cancer

human chorionic gonadotropin beta; beta hCG	Preclinical			hormone	cancer
NV 06	Preclinical			hormone; apoptosis inhibitor; antiproliferative agent; differentiation inducer	cancer
gallium nitrate; NSC 15200; CALSTAT; GANITE	Marketed		gallium nitrate monohydrate	hypocalcemic; nitric oxide synthase inhibitor	hypercalcemia; cancer
AS 101; IVXQ 101; OSSIRENE	Phase II		(SP-5-22)-ammonium trichloro(1,2-ethanedithiolato(2-)-0,0')-tellurate	immunostimulant	HIV infection; cancer
BCH 1393	Suspended		N2-[[[5-[6-(dimethylamino)-9H-purin-9-yl]pentyl]oxy]carbon yl]-D-arginine	immunostimulant	cancer
beta-alethine; BETATHINE	Phase II		3-amino-N-(2-mercaptoethyl)-propanamide	immunostimulant	cancer
broprimine; ABPP; U 54461; U 54461S; NSC 149027; REMISAR	Pre-registration		2-amino-5-bromo-6-phenyl-4(1H)-pyrimidinone	immunostimulant	cancer; viral infection
CL 246738	Phase II		3,6-bis(2-piperidinoethoxy)acridine trihydrochloride	immunostimulant	viral infection; HIV infection; cancer
CL 870420	Discontinued			immunostimulant	cancer
conagenin	Preclinical		N-(3,5-dideoxy-3-methyl-D-xyloonyl)-2-methyl-L-serine	immunostimulant	cancer

DNA repair enhancers, OXiGENE	Preclinical			immunostimulant	cancer
drug delivery system, liposome muramyl tripeptide-phosphatidylethanolamine; drug delivery system, liposome MTP-PE; MTP-PE liposome	Phase III			immunostimulant	cancer
FCE 24578	Discontinued	alpha-cyano-1,4-dihydro-beta-oxo-N,1-diphenyl[1]benzothio pyrano[4,3-c]pyrazole-3-propanamide		immunostimulant	cancer; bacterial infection
FCE 25276	Suspended			immunostimulant	cancer; bacterial infection
FCE 25648	Suspended			immunostimulant	cancer; bacterial infection
FCE 25651	Suspended			immunostimulant	cancer; bacterial infection
FR 901235	Discontinued	(-)-2,4,9-trihydroxy-6-methoxy-7-methyl-2-(2-oxopropyl)-1H-phenalene-1,3(2H)-dione		immunostimulant	cancer
HAB 439	Discontinued	(4,5-dihydro-3-phenyl-5-isoxazolyl)phosphonic acid		immunostimulant	cancer; bacterial infection

icadamines, Cornell Research Foundation	Preclinical			immunostimulant	viral infection; cancer
idramantone; kemantane	Phase I	5-hydroxytricyclo[3.3.1.1(3,7)]decanone		immunostimulant	cancer
iniquimod; R 837; S 26308; DZ 2636; ALDARA; ZARTRA	Marketed	1-(2-methylpropyl)-1H-imadazo[4,5-c]quinolin-4-amine		immunostimulant	viral infection; cancer
immunostimulant, Repligen; immunostimulant, Pfizer	Preclinical			immunostimulant	cancer; infectious disease
immunostimulants, Massachusetts General Hospital	Preclinical			immunostimulant	cancer; autoimmune disease
JT 3002; CGP 40774	Preclinical			immunostimulant	cancer
KRN 7000	Phase I	[1S-(1R*,2R*,3S*)]-N-[1-[(alpha-D-galactopyranosyloxy)methyl]-2,3-dihydroxyheptadecyl]hexacosanamide		immunostimulant	cancer
large multivalent immunogen; LMI	Preclinical			immunostimulant	cancer
LC 9018; YIT 9018; DP 2202; PS PG; LIMONAL; LEMONAL	Pre-registration			immunostimulant	cancer; HIV infection
lentinan sulfate; lentinan; LENTINAN	Marketed			immunostimulant	HIV infection; cancer
LK 409	Preclinical	N-(1,7-dioxoctyl)-L-alanyl-D-alpha-glutamine		immunostimulant	cancer

loxoribine; RWJ 21757	Discontinued	7-allyl-8-oxoguanosine	immunostimulant	cancer
mirimostim; human urine derived stimulating factor inducer; CSF-HU; P 100; LEUKOPROL; COSTILATE	Marketed	l-214-colony-stimulating factor 1 (human clone p3ACSF-69 protein moiety reduced)	immunostimulant	cancer
MMS 2	Preclinical		immunostimulant	cancer
Nocardia-CWS; N-CWS; rubratine; RUBRATIN	Discontinued		immunostimulant	cancer
OM 163	Preclinical	Unspecified	immunostimulant	cancer
OM 174	Phase I		immunostimulant	cancer
RG 003; RG 136	Discontinued		immunostimulant	HIV infection; cancer
RM 06	Discontinued	N-[N-[[[5-(1,6-dihydro-6-oxo-9H-purin-9-yl)pentyl]oxy]carbon yl]-L-leucyl]-L-methionine	immunostimulant	cancer; transplant rejection
romurtide; muuroctasin; MDP-Lys (L18); MDP-Lys; DJ 7041; NOPIA	Marketed	2-acetamido-3-O-[(R)-1-[(S)-1-[(R)-1-carbamoyl-3-[(S)-1-carboxy-5-stearamidopentyl]carbamo yl]propyl]carbamo yl]ethyl]carbamo yl]ethyl]-2-deoxy-D-glucopyranose	immunostimulant	cancer; bacterial infection

RS 0481; S 0481	Discontinued	[R-(R*,R*)]-3-benzoyl-N-(1-phenylethyl)-4-thiazolidinecarboxamide	immunostimulant	cancer
S 27609	Discontinued	4-amino- α , α ,2-trimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol	immunostimulant	cancer
SRL 172	Phase III		immunostimulant	tuberculosis; cancer; asthma; bacterial infection; leprosy; rhinitis
ST 789; PCF 39	Phase I	N-[5-(hypoxanthin-9-yl)pentoxycarbonyl]-L-arginine	immunostimulant	cancer; bacterial infection
thymotrinan; thymopoietin 32-34; RGH 0205; TP3	Suspended	N-(N2-L-arginyl-L-lysyl)-L-aspartic acid	immunostimulant	cancer
vaccine, malignant melanoma; LP 2307	Phase II		immunostimulant	cancer
vaccine, Maruyama; Maruyama vaccine; SSM	Pre-registration		immunostimulant	cancer
vaccine, melanoma, University of Pittsburgh; melanoma vaccine	Phase I		immunostimulant	cancer
tiprotimod; HBW 538	Discontinued	2-[(3-carboxypropyl)thio]-4-methyl-5-thiazoleacetic acid	immunostimulant; antifungal	mycosis; cancer

MGN 3	Phase I	Unspecified	immunostimulant; biological response modifier	cancer
NSC 631570; E 09/029; NSC B238865; UKSR 222; W 122; UKRAIN	Pre- registration	5,5',5"- [phosphinothioylidyn etris(imino-2,1- ethanediy)]tris[5- methylchelidoninium]] trihydroxide	immunostimulant; biological response modifier	cancer
CD40 ligand, Immunex; CD40LT	Phase I		immunostimulant; biotechnology	cancer
prolactin	Preclinical		immunostimulant; biotechnology; hormone; vaccine adjuvant	cancer; infectious disease
pentoxifylline : ciprofloxacin; ciprofloxacin : pentoxifylline; CT 1500	Discontinued		immunostimulant; chemoprotectant; cytoprotectant	cancer
acemannan; CARN 1000; CARN 750; CARRASYN; ALIMINASE; VORALEX; CARRA VEX	Marketed	(1->4),(1->6)-alpha- D-galacto-beta-D- mannan acetate	immunostimulant; cicatrizant	inflammatory bowel disease; skin ulcer; inflammation; cancer
tetrachlorodecaoxide; TCDO; WF 10; OXOFERIN	Marketed		immunostimulant; cicatrizant	skin ulcer; HIV infection; cancer

granulocyte colony stimulating factor mimetic, Ligand/SmithKline Beecham; G-CSF mimetic, Ligand/SmithKline Beecham	Preclinical			immunostimulant; cytokine agonist	cancer; viral infection; bacterial infection
thiethazole	Preclinical	2-[1-(1,1-dioxothiethanyl-3)benzimidazolyl-2-thio] acetic acid	immunostimulant; immunosuppressant; antioxidant		cancer; rheumatoid arthritis; infectious disease; transplant rejection
tabilautide; RP 56142	Discontinued	threo-6-carbamoyl-N2-[N-(N-lauroyl-L-alanyl)-D-gamma-glutamyl]-L-lysine	immunostimulant; lipopeptide		bacterial infection; cancer
hemoregulatory peptide, Nycomed	Preclinical		immunostimulant; peptide		bacterial infection; cancer
immunostimulant peptides, BioChem Pharma	Discontinued		immunostimulant; peptide		cancer; viral infection
interleukin-2 receptor agonist; IL-2R agonist	Preclinical		immunostimulant; peptide		cancer; HIV infection
SUIS-gonadorelin; SUIS-LHRH	Phase I		immunostimulant; peptide		cancer
thymopietin receptor agonist	Preclinical		immunostimulant; peptide		cancer; HIV infection
ubenimex; bestatin; NK 421; BESTATIN	Marketed	(-)-N-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutyryl]-L-leucine	immunostimulant; peptide		cancer

ETHERAMIDE	Suspended		immunostimulant; peptide; oligosaccharide	cancer; infectious disease
monophosphoryl lipid A + myobacterium cell wall sk; myobacterium cell wall skeleton + monophosphoryl I; MPL + CWS; DETOX	Phase III		immunostimulant; vaccine adjuvant	cancer
D5; PM 92114	Discontinued		immunosuppressant	cancer
dehydrodidemnin B; DDB	Preclinical	N-[1-(1,2-dioxopropyl)-L-prolyl]didemnin A	immunosuppressant	viral infection; cancer
dinaline; GOE 1734; NSC 328786; AAPBA	Discontinued	4-amino-N-(2-aminophenyl)benzamide	immunosuppressant	cancer
fluasterone	Phase I		immunosuppressant	cancer; diabetes; systemic lupus erythematosus
gusperimus; gusperimus hydrochloride; deoxyspergualin, 15-; desoxyspergualin; DSG; NKT 01; NSC 356894; BMS 181173; BMY 42215- 1; SPANIDIN; SUPANIDIN	Marketed	(+,-)-7- [[[aminoiminomethyl] amino]-N-2-[[4-[(3-aminopropyl)amino]butyl]amino]-1-hydroxy-2-oxoethyl]heptanamide	immunosuppressant	transplant rejection; multiple sclerosis; cancer
promedulan; TERICIMUS	Discontinued		immunosuppressant	cancer

XENOJECT	Preclinical		immunosuppressant	cancer; autoimmune disease
protein A-based immune modulator	Preclinical		immunosuppressant; immunostimulant	autoimmune disease; cancer
signal transduction modulators, National Jewish Center for Immunology and Respiratory Medicine	Preclinical		immunosuppressant; immunostimulant; NSAID	autoimmune disease; cancer; inflammation
CI 972	Discontinued	2,6-diamino-1,5-dihydro-7-(3-thienylmethyl)-4H-pyrrolo[3,2-d]pyrimidin-4-one monohydrochloride	immunosuppressant; NSAID	rheumatoid arthritis; cancer; psoriasis
cladribine; 2-CdA; NSC 105014F; RWJ 26251; LEUSTATIN; LEUSTAT; MYLINAX	Marketed	2-chloro-2'-deoxyadenosine	immunosuppressant; nucleoside analogue; NSAID	cancer; multiple sclerosis; rheumatoid arthritis
T cell peptide, University of Illinois	Preclinical		immunosuppressant; peptide	autoimmune disease; cancer; bacterial infection
MAb, BR96 sFv-PE40; SGN 10; BMS 191352	Phase I		immunotoxin; biotechnology	cancer
MAb, TES-23-neocarzinostatin; TES-23-NCS	Discontinued		immunotoxin; biotechnology	cancer

MAb, TP3-pokeweed viral protein conjugate; immunotoxin, TP3- pokeweed viral protein conjugate; TP3-PAP	Preclinical		immunotoxin; biotechnology; monoclonal antibody	cancer
MAb, doxorubicin- CEA; DOX-CEA	Preclinical		immunotoxin; biotechnology; monoclonal antibody; anthracycline; antibiotic; DNA intercalator	cancer
drug delivery system, ANCHOR angiostatic agent	Preclinical		integrin antagonist; angiogenesis inhibitor; cell adhesion inhibitor	cancer
S 836	Discontinued		integrin antagonist; angiogenesis inhibitor; cell adhesion inhibitor; alpha5 beta3 integrin antagonist	cancer
CDP 850	Preclinical		integrin antagonist; biotechnology; cell adhesion inhibitor; immunosuppressant; monoclonal antibody; E selectin antagonist	cancer

cytostatin; MJ 654NF4	Preclinical	5,6-dihydro-6-[6- hydroxy-1,5- dimethyl-4- (phosphonoxy)- 7,9,11-tridecatrienyl]- 5-methyl-2H-pyran-2- one	integrin antagonist; cell adhesion inhibitor	cancer
SB 223245	Preclinical	(S)-7-[[[(1H- benzimidazol-2- yl)methyl]methylamin o]carbonyl]-2,3,4,5- tetrahydro-4-methyl- 3-oxo-1H-1,4- benzodiazepine-2- acetic acid	integrin antagonist; cell adhesion inhibitor	osteoporosis; restenosis; cancer
vitronectin receptor antagonists, DuPont	Preclinical		integrin antagonist; cell adhesion inhibitor; alpha5 beta3 integrin antagonist	osteoporosis; cancer; restenosis

IC 101	Preclinical	(alphaS,2R,5S,6R)-6-ethyltetrahydro-alpha-2-dihydroxy-alpha-methyl-5-(3-methylbutyl)-2H-pyran-2-acetyl-(3S)-3-hydroxy-L-leucyl-hexahydro-3-pyridazinecarbonyl-N-hydroxy-L-alanylglycyl-(3S)-hexahydro-3-pyridazinecarbonyl-N-hydroxy-D-Alanine (7->2)-lactone	integrin antagonist; cell adhesion inhibitor; immunostimulant; peptide; antibiotic	cancer; bacterial infection
anti-inflammatory agents, Chiroscience/Trega	Preclinical		integrin antagonist; cell adhesion inhibitor; NSAID	inflammation; cancer
cell adhesion inhibitor, GlycoTech/Novartis	Preclinical		integrin antagonist; cell adhesion inhibitor; NSAID	cancer; inflammation
drug delivery system, STEALTH cell adhesion inhibitors	Preclinical		integrin antagonist; cell adhesion inhibitor; NSAID	cancer; inflammation
GM 7050	Discontinued		integrin antagonist; cell adhesion inhibitor; NSAID	inflammation; cancer
RGD-based angiogenesis antagonists	Preclinical		integrin antagonist; NSAID; cell adhesion inhibitor	cancer; rheumatoid arthritis; eye disease

drug delivery system, interferon alfa; interferon alfa depot delivery; MPI 7057	Discontinued		interferon	cancer
drug delivery system, transdermal BIPHASIX interferon alfa; interferon alfa transdermal	Preclinical		interferon	cancer; viral infection
interferon alfa; BALL-1; MR 22; BALL 1; OIF; IFN ALPHA MOCHIDA	Marketed		interferon	cancer; viral infection; mucositis; musculoskeletal disorder
interferon alfa; Interferon Alfa native	Marketed		interferon	cancer; viral infection
interferon alfa-n3; KEMRON; ALFERON; ALFERON N; ALFERON LDO; ALTEMOL; REFERON	Marketed		interferon	viral infection; cancer
interferon beta; FRONE	Marketed		interferon	multiple sclerosis; cancer; eye disease
interferon gamma, natural; IFN gamma, natural; OH 6000; OGAMMA 100	Marketed		interferon	cancer
interferon-alpha; IFN-alpha	Preclinical		interferon; biotechnology	cancer; viral infection
interferon, modified, Tanox	Preclinical		interferon; biotechnology; immunosuppressant	cancer

leukocyte alpha interferon; ALFAFERONE; CILIFERON	Marketed		interferon; immunostimulant	viral infection; cancer
doretinel; BASF 47011; RWJ 20257; ORF 20257	Discontinued	(E)-1,2,3,4- tetrahydro-7-[2-[4- (hydroxymethyl)phen yl]-1-methylethenyl]- 1,1,4,4- tetramethylnaphthalen ol	keratolytic	cancer
U 74389	Preclinical	Unspecified	lazaroid	cancer
U 74500A	Preclinical	21-[4-[3,6- bis(diethylamino)-2- pyridinyl]-1- piperazinyl]-16- methylpregna- 1,4,9(11)-triene-3,20- dione hydrochloride	lazaroid	cerebrovascular disease; cancer
lysofylline; lisofylline; CT 1501R; ProTec	Phase III	(R)-1-(5- hydroxyhexyl)-3,7- dimethylxanthine	lysophosphatidate acyltransferase inhibitor; xanthine	cancer; cardiovascular disease; respiratory disease; mucositis
breflate; NSC 656202; NAS 656202	Preclinical	N,N-dimethyl- glycine, [1R- (1R*,2E,6S*,10E,11a S*,13S*,14aR*)]- 1,6,7,8,11a,12,13,14,1 4a-decahydro-1- hydroxy-6-methyl-4- oxo-4H- cyclopent[<i>f</i>]oxacyclot ridecin-13-yl ester	macrolide; antibiotic	cancer

duocarmycin SA; DC 113	Discontinued	(7bR)-1,2,4,5,8,8a-hexahydro-4-oxo-2-[(5,6,7-trimethoxy-1H-indol-2-yl)carbonyl]cyclopropa[c]pyrrolo[3,2-e]indole-6-carboxylic acid methyl ester	macrolide; antibiotic	bacterial infection; cancer
rhizoxin; lizoxine	Phase II		macrolide; antibiotic	cancer
drug delivery system, liposome CGP 31362; CGP 31362 liposome; MLV-CGP 31362	Discontinued		macrophage stimulator; immunostimulant	cancer
GPX 325	Preclinical		MAO inhibitor; chemoprotectant; cytoprotectant; radioprotectant	cancer
matrilysin inhibitors, Affymax	Preclinical		matrilysin inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor	cancer
matrix metalloproteinase inhibitors, OsteoArthritis; cartilage degrading enzyme inhibitors, OsteoArthritis; CHONDROPROTECTORS	Discontinued		matrix metalloproteinase inhibitor; cicatrizant; proteinase inhibitor; NSAID	arthritis; periodontal disease; skin ulcer; cancer

anticancer matrix metalloproteinase inhibitors	Preclinical		matrix metalloproteinase inhibitor	cancer
CMT 3; COL 3; NSC 683551; METASTAT	Phase I	(4aS,5aR,12aS)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-carboxamide	matrix metalloproteinase inhibitor	cancer
D 1927	Preclinical		matrix metalloproteinase inhibitor	cancer
D 2163	Phase I		matrix metalloproteinase inhibitor	cancer
ilomastat; GM 6001; CS 610; GALARDIN; GALARDIN MPI	Phase III	N4-hydroxy-N1-[1-(1H-indol-3-ylmethyl)-2-(methoxymethyl)-2-(2-methylpropyl)-butanediamide]	matrix metalloproteinase inhibitor	retinopathy; diabetes; cancer

marimastat; BB 2516; TA 2516	Phase III	(2S,3R)-N4-[(1R)-2,2-dimethyl-1-[(methylamino)carbonyl]propyl]-N1,,2-dihydroxy-3-(2-methylpropyl)butanamide	matrix metalloproteinase inhibitor; proteinase inhibitor	cancer
matrix metalloproteinase inhibitors, Agouron	Preclinical		matrix metalloproteinase inhibitor; proteinase inhibitor	cancer
S 3304	Phase I		matrix metalloproteinase inhibitor; proteinase inhibitor	cancer; inflammation
prinomastat; AG 3340	Phase III	Unspecified	matrix metalloproteinase inhibitor; proteinase inhibitor; angiogenesis inhibitor	cancer; retinopathy
CH 104	Discontinued		matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	cancer; inflammation
CH 715	Discontinued		matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	cancer; inflammation
matrix metalloproteinase inhibitor, State University of New York	Preclinical		matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	periodontal disease; kidney disease; cancer; arthritis; osteoporosis

matrix metalloproteinase inhibitors, ProScript	Preclinical		matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	cancer; arthritis
PI 88	Phase I		matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	inflammation; cancer
solimastat; BB 3644	Phase I	(2S,3R)-3-[(1S)-2,2-dimethyl-1-(2-pyridylcarbamoyl)propyl]carbamoyl-2-methoxy-5-methylhexanoic acid	matrix metalloproteinase inhibitor; TNF inhibitor; proteinase inhibitor	multiple sclerosis; rheumatoid arthritis; inflammatory bowel disease; cancer
BIBW 22; BIBW 22BS	Discontinued		MDR inhibitor	cancer
biricodar; biricodar dicitrate; VX 710; INCEL	Phase II	(S)-1-[oxo(3,4,5-trimethoxyphenyl)acetyl]-2-piperidinecarboxylic acid 4-(3-pyridinyl)-1-[3-(3-pyridinyl)propyl]butyl ester	MDR inhibitor	cancer
buthionine sulfoximine; BSO; NSC 326231	Phase I	(2S)-2-amino-4-(S-butylsulfonimidoyl)butanoic acid	MDR inhibitor	cancer

dexniguldipine; (+)-niguldipine; (R)-niguldipine; niguldipine; (R)-; B 8509035; BY 935	Discontinued	(R)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinecarboxylic acid 3-(4,4-diphenyl-1-piperidiny)propyl methyl ester	MDR inhibitor	cancer
drug delivery system, liposome ciclosporin; ciclosporin liposome; CYCLOXOME	Discontinued		MDR inhibitor	cancer
flezolastine; D 18024	Preclinical	4-((4-fluorophenyl)methyl)-2-(hexahydro-1H-(phenylethyl)-1H-azepin-4-yl)-1(2H)-phthalazinone monohydrochloride	MDR inhibitor	cancer
H 85	Preclinical	N-[2-[[3-(4-chlorophenyl)-2-propenyl]formylaminol-5-isoquinolinesulfonamide	MDR inhibitor	cancer
LU 49667	Discontinued		MDR inhibitor	cancer
LU 51903	Discontinued		MDR inhibitor	cancer
MDR inhibitor, BioNumerik	Preclinical		MDR inhibitor	cancer
MDR inhibitor, Xenova	Preclinical		MDR inhibitor	cancer
MDR inhibitors, Fox Chase Cancer Center	Preclinical		MDR inhibitor	cancer

MS 209	Phase II	4-(diphenylacetyl)- alpha-[(5- quinolinylloxy)methyl]-1-piperazineethanol, (E)-2-butenedioate (2:3)	MDR inhibitor	cancer
NA 382	Preclinical	N-(ethoxycarbonyl)- 7-oxostaurosporine	MDR inhibitor	cancer
PAK 104P	Preclinical	trans-5-(4,6-dimethyl-1- 2-oxido-1,3,2- dioxaphosphorinan-2- yl)-2,6-dimethyl-4-(3- nitrophenyl)-3- pyridinecarboxylic acid 2-[4- (diphenylmethyl)-1- piperazinyl]ethyl ester trihydrochloride	MDR inhibitor	cancer
propyl bis-acridone	Preclinical	1,3-bis(9-oxoacridin- 10-yl)propane	MDR inhibitor	cancer
R 101933	Phase I		MDR inhibitor	cancer
Ro 112933	Discontinued	N-[2-(3,4- dimethoxyphenyl)eth yl]-N-methyl-2-(2- naphthalenyl)-1,3- dithiane-2- propanamine hydrochloride	MDR inhibitor	cancer

S 16209	Preclinical	(+)-4-(2,3-dichlorophenyl)-1,4-dihydro-2-methyl-6-[[2-{2-[(4-nitrophenyl)methyl]amino}ethoxy]ethoxy]-3,5-pyridinedicarboxylic acid 5-ethyl 3-methyl ester	MDR inhibitor	cancer
S 16317	Preclinical	(+)-4-(2,3-dichlorophenyl)-1,4-dihydro-2-methyl-6-[[2-{2-[(4-pyridinylmethyl)amino]ethoxy}ethoxy]methyl]-3,5-pyridinedicarboxylic acid 5-ethyl 3-methyl ester	MDR inhibitor	cancer
S 16324	Preclinical	(+)-4-(2,3-dichlorophenyl)-1,4-dihydro-2-methyl-6-[[2-{2-[(3-thienylmethyl)amino]ethoxy}ethoxy]methyl]-3,5-pyridinedicarboxylic acid 5-ethyl 3-methyl ester	MDR inhibitor	cancer

S 9788	Discontinued	6-[4-[[2,2-bis(4-fluorophenyl)ethyl]amino]-1-piperidinyl]-N,N'-di-2-propenyl-1,3,5-triazine-2,4-diamine	MDR inhibitor	cancer
SB RA 31012	Preclinical		MDR inhibitor	cancer
SDZ 214103	Discontinued	2-(3-methyl-D-2-hydroxybutanoic acid)-4-L-leucine-7-L-threonine-10-L-leucine cyclosporin A	MDR inhibitor	cancer
XR 1500	Suspended		MDR inhibitor	cancer
CRL 1336	Discontinued		MDR inhibitor; chemosensitizer	cancer
valsopodar; SDZ PSC833; PSC 833; SDZ PSC 833; AMDRAY	Phase III	6-[[[R-(E)]-6,7-didehydro-N,4-dimethyl-3-oxo-L-2-aminooctanoic acid]-7-L-valine-cyclosporin A	MDR inhibitor; chemosensitizer; P-glycoprotein inhibitor	cancer
elacridar; GF 120918; GG 918	Suspended	N-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinoliny)ethyl]piperidin-1-yl]-9,10-dihydro-5-methoxy-9-oxo-4-acridinecarboxamide	MDR inhibitor; P-glycoprotein inhibitor	cancer

timecodar; timecodar dimesylate; VX 853	Phase II	(alphaS)-4-chloro-alpha-[methyl[oxo(3,4,5-trimethoxyphenyl)acetyl]amino]-N-(phenylmethyl)-N-[3-(4-pyridinyl)-1-[2-(4-pyridinyl)ethyl]propyl]benzenepropanamide	MDR inhibitor; P-glycoprotein inhibitor	cancer; neuropathy
XR 9051	Suspended	(Z,Z)-N-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-4-[[4-methyl-3,6-dioxo-5-(phenylmethylene)piperazinylidene]methyl]benzamide	MDR inhibitor; P-glycoprotein inhibitor	cancer
SDZ 280446	Discontinued	cyclo[N-methyl-L-alpha-Asp-N-methyl-L-Ile-N-methyl-L-Ile-Gly-N-methyl-L-Val-O-methyl-L-Tyr-(2S)-2-hydroxypropanoyl-(2S)-2-piperidinecarbonyl-N-methyl-L-Val-L-Val], 1,1-dimethylethyl ester	MDR inhibitor; peptide	cancer

melanostatin; BMY 28566; BU 3619E	Discontinued	(S)-3-[[1-carboxy-2-(1H-imidazol-4-yl)ethyl]amino]-N-(N-methyl-L-phenylalanyl)-L-alanine	melanin synthesis inhibitor	cancer
lithium gamma-linolenate; EF 13; GLAMOLEC	Discontinued		metalloproteinase inhibitor; proteinase inhibitor	cancer; HIV infection
PGE 2946979	Preclinical	3-[[[(hydroxyamino)carbonyl]-4-[(4-methoxyphenyl)sulfonyl]-1-piperazinecarboxylic acid phenylmethyl ester	metalloproteinase inhibitor; proteinase inhibitor	inflammation; cancer
metalloproteinase inhibitors, Syntem	Preclinical		metalloproteinase inhibitor; proteinase inhibitor; NSAID	cancer; arthritis
BW 1069C85	Suspended		microtubule assembly inhibitor	cancer
cryptophycin 52; LY 355703	Phase I	(2S)-3-chloro-N-[[[(2E,5S,6S)-5-hydroxy-1-oxo-6-[(2R,3R)-3-phenyloxiranyl]-2-heptenyl]-O-methyl-tyrosyl-2,2-dimethyl-beta-alanyl-2-hydroxy-4-methyl-pentanoic acid (3fwdarw)]-lactone	microtubule assembly inhibitor	cancer

cryptophycin 8	Preclinical	(2S)-3-chloro-N- [(2E,5S,6R,7R,8S)-8- chloro-5,7-dihydroxy- 6-methyl-1-oxo-8- phenyl-2-octenyl]-O- methyl-D-tyrosyl- (2R)-2-methyl-beta- alanyl-2-hydroxy-4- methylpentanoic acid (3->15)-lactone	microtubule assembly inhibitor	cancer
cryptophycin A derivatives, Wayne State University D 24851	Preclinical		microtubule assembly inhibitor	cancer
	Preclinical	1-[(4- chlorophenyl)methyl]- alpha-oxo-N-4- pyridinyl-1H-indole- 3-acetamide	microtubule assembly inhibitor	cancer
epothilone	Preclinical		microtubule assembly inhibitor	cancer

maitansine; maytansine; NSC 153858	Preclinical	N-acetyl-L-N-methyl-L-alanine [1S-(1R*,2S*,3R*,5R*,6R*,16E,18E,20S*,21R*)]-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxo-9,22-diazatetraacyclo[19.3.1.110,14.03.5]hexacos-10,12,14(26),16,18-pentaen-6-yl ester	microtubule assembly inhibitor	cancer
	Phase I	2-fluoro-1-methyl-4-pentafluorophenylsulfonamidobenzene	microtubule assembly inhibitor	cancer
	Preclinical		microtubule assembly inhibitor	cancer
	Preclinical		microtubule assembly inhibitor; angiogenesis inhibitor	cancer
	Preclinical		microtubule assembly inhibitor; antibiotic	cancer
epothilones, Society for Biotechnology Research cemadotin; LU 103793	Phase II	N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-N-(phenylmethyl)-L-prolinamide	microtubule assembly inhibitor; peptide	cancer

LU 223651	Preclinical	N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-L-prolin-Tert-butylamide	microtubule assembly inhibitor; peptide	cancer
epothilones	Preclinical	[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]-7,11-dihydroxy-8,8,10,12-tetramethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione (B is [1S-, 16-methyl])	microtubule assembly promoter	cancer
antimitotics, Nanodesign	Preclinical		mitosis inhibitor	cancer
TZT 1027	Phase I	[2S-N,N-dimethyl-L-valyl-N-[2-methoxy-4-[2-[1-methoxy-2-methyl-3-oxo-3-[(2-phenethyl)amino]propyl]-1-pyrrolidinyl]-1-(1-methylpropyl)-4-oxobutyl]-N-methyl-L-valinamide	mitosis inhibitor	cancer
mivobulin; CI 980; NSC 613862(-)	Phase II	(S)-(5-amino-1,2-dihydro-2-methyl-3-phenylpyrido(3,4-b)pyrazin-7-yl)carbamic acid ethyl ester	mitosis inhibitor; tubulin polymerase inhibitor	cancer

MAB, 81C6; MAb, cancer	Phase II		monoclonal antibody; biotechnology	cancer
MAB, alpha5 beta3 integrin	Discontinued		monoclonal antibody; biotechnology	cancer
MAB, boron complex, Strathclyde Institute for Drug Research	Preclinical		monoclonal antibody; biotechnology	cancer
MAB, cancer-beta glucosidase; AGENT	Preclinical		monoclonal antibody; biotechnology	cancer
MAB, epidermal growth factor receptor; MAB, EGFr; MAB, E7.6.3; ABX EGF; ABX EGFr	Preclinical		monoclonal antibody; biotechnology	cancer
MAB, HMF-1	Phase I		monoclonal antibody; biotechnology	cancer
MAB, platelet derived growth factor/basic fibroblast growth factor; MAB PDGF/bFGF; SMA PDGF/bFGF	Preclinical		monoclonal antibody; biotechnology	cancer; restenosis
MAB, tissue factor/factor VII; MAB, TF/factor VII; SMA TF/factor VII	Preclinical		monoclonal antibody; biotechnology	cancer
MABs, folate receptors & immune effector cells; bispecific monoclonal antibodies, folate receptors & immune effector cells	Preclinical		monoclonal antibody; biotechnology	cancer

tumor stroma specific antibody	Preclinical		monoclonal antibody; biotechnology	cancer
MAb, vascular endothelium growth factor; MAb, vEGF; SMA vEGF	Preclinical		monoclonal antibody; biotechnology; angiogenesis inhibitor	cancer
MAB, VEGF; MAb, vascular epithelial growth factor	Phase II		monoclonal antibody; biotechnology; angiogenesis inhibitor	cancer; retinopathy
MAB, endoglin-tTF; immunotoxin, endoglin-tTF	Preclinical		monoclonal antibody; biotechnology; coagulation factor; immunotoxin	cancer
MAB, endoglin-dgA; immunotoxin endoglin-dgA	Preclinical		monoclonal antibody; biotechnology; immunotoxin	cancer
MAB, HMFG-1 fragment-yttrium 90; TheraFab	Preclinical		monoclonal antibody; biotechnology; radiotherapeutic	cancer
MAB, LL2-yttrium-90; yttrium-90-LL2; LymphoCide	Phase I		monoclonal antibody; biotechnology; radiotherapeutic	cancer
MAB, polymorphic epithelial mucin-yttrium 90; MAB, human-milk fat globulin-1 (HMFG1); THERAGYN	Phase III		monoclonal antibody; biotechnology; radiotherapeutic	cancer

N 3554S; N 1554	Preclinical	[S-(all-E)]-3,7,11,15,19,23,27,31,35,39-decamethyl-6,10,14,18,22,26,30,34,38-tetracontanonaen-1-ol, dihydrogen phosphate	N glycosylation stimulator	cancer
SR 48692	Phase II	2-[[[1-(7-chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl]carbonyl]amino]tricyclo[3.3.1.1.3,7]decane-2-carboxylic acid	neurotensin antagonist	schizophrenia; cancer
NS 521	Discontinued		neurotrophic factor; growth factor	Alzheimer disease; neuropathy; cancer; diabetes
sodium borocaptate 10B; borocaptate sodium B 10; NASH; BSH; BOROLIFE	Suspended	1,2,3,4,5,6,7,8,9,10,11-undecahydro-12-mercaptododecaborate(2-)-10B12 disodium	neutron capture agent	cancer
nitric oxide-releasing anticancer agents, National Institutes of Health	Preclinical		nitric oxide donor	cancer
NCX 1101	Preclinical		nitric oxide donor; NSAID	cancer
hemoglobin-based scavenger; ENDOGLOBIN-HT; ENDOGLOBIN-CT	Discontinued		nitric oxide scavenger	hypotension; cancer

hemoglobin-based therapy, Apex	Preclinical		nitric oxide scavenger	cancer; hypotension; septic shock
NOX 100	Preclinical		nitric oxide scavenger	diabetes; cancer; trauma; transplant rejection; septic shock; cardiovascular disease
NOX 101	Discontinued	Unspecified	nitric oxide scavenger	stroke; diabetes; cancer; trauma; transplant rejection; septic shock; cardiovascular disease
NOX 51	Preclinical		nitric oxide scavenger	diabetes; cancer; cardiovascular disease; transplant rejection; septic shock
pyridoxylated hemoglobin polyoxyethylene conjugate; PHP-HT; PHP-CT	Phase II		nitric oxide scavenger	cancer; hypotension; septic shock
fotemustine; S 10036; MUPHORAN	Marketed	(+/-)-diethyl [1-[3-(2-chloroethyl)-3-nitrosoureido]ethyl]p hosphonate	nitrosurea; alkylating agent	cancer
nitruillyn; CRC 7805068	Phase II		nitrosurea; alkylating agent	cancer

SarCNU; NSC 364432	Preclinical	2-[[[(2-chloroethyl)nitrosoamino]carbonyl]methylamino]-acetamide	nitrosurea; alkylating agent	cancer
semustine; methyl CCNU; WR 220076; NSC 95441; ICIG 1110	Phase I	N-(2-chloroethyl)-N'-(4-methylcyclohexyl)-N-nitrosourea	nitrosurea; alkylating agent	cancer
TA 077	Phase III	N-(2-chloroethyl)-N'-(4-O- α -D-glucopyranosyl-beta-D-glucopyranosyl)-N'-(2-methylpropyl)-N-nitrosourea	nitrosurea; alkylating agent	cancer
taumustine; TCNU; LS 2667; TAURICYT	Phase III	2[[[(2-chloroethyl)nitrosoamino]carbonyl]amino)-N,N-dimethylethanesulfonamide	nitrosurea; alkylating agent	cancer
cell adhesion molecules intracellular inhibitors, ICOS/Abbott	Preclinical		NSAID	cancer; inflammation
drug discovery, Trega Biosciences; drug discovery, Chugai	Preclinical		NSAID	inflammation; diabetes; cardiovascular disease; neurological; cancer; infectious disease
G-protein therapy, Cadus/Bristol-Myers Squibb	Preclinical		NSAID	inflammation; cardiovascular disease; cancer

kinase modulators, ICOS	Preclinical		NSAID	cancer; inflammation
nitric oxide modulators, Duke University	Preclinical		NSAID	hypotension; cancer; rheumatoid arthritis
signal transduction modulators, Cancer Research Campaign	Preclinical		NSAID	cancer; inflammation; neurological
synthetic glycosaminoglycans	Preclinical		NSAID	inflammation; cancer; neuropathy
drug delivery system, HIT diclofenac; diclofenac HIT; HYAL AT2101; HYAL CT1101; HYAL AV2201; HYAL AT1201; HYANALGESE; HYANALGESE-D; SOLARASE; ORALEASE	Registered		NSAID; analgesic	pain; cancer; inflammation; skin disease; mucositis
P 54	Phase II		NSAID; analgesic	osteoarthritis; Crohn disease; cancer
apoptosis modulators, IDUN	Preclinical		NSAID; apoptosis inhibitor; apoptosis inducer; caspase inhibitor	cancer; neuropathy; inflammation
MDR inhibitors, BioResearch Ireland	Preclinical		NSAID; MDR inhibitor	cancer
proteasome inhibitors, inflammation, ProScript	Preclinical		NSAID; transcription factor regulator	inflammation; cancer
EPI 163; EpiCyte	Preclinical		nucleoside analogue	cancer

OGT 719	Phase I	5-fluoro-1-beta-L-galactopyranosyl-2,4(1H,3H)-pyrimidinone	nucleoside analogue	cancer
thio-cytarabine derivatives, Southern Research Institute; thio-araC derivatives, Southern Research Institute	Preclinical		nucleoside analogue	cancer
yunnannmycin	Preclinical		nucleoside analogue	cancer
8-chloro-cAMP; 8-Cl-cyclic adenosine monophosphate; 8-Cl-cAMP	Discontinued	8-chloro-cyclic adenosine 3',5'-monophosphate	nucleoside analogue; antimetabolite	cancer
anticancer, Camerino University	Preclinical	1-beta-D-ribofuranosyl-1H-pyrrolo[3,2-c]pyridine-4,6-diamine	nucleoside analogue; antimetabolite	cancer
CNDAC	Preclinical	4-amino-1-(2-cyano-2-deoxy-beta-D-arabinosylfuranosyl)-2(1H)-pyrimidinone	nucleoside analogue; antimetabolite	cancer
DMDC	Phase II	2'-deoxy-2'-methylene-cytidine	nucleoside analogue; antimetabolite	cancer
drug delivery system, 5 fluoropyrimidinone; 5 fluoropyrimidinone delivery system	Phase I		nucleoside analogue; antimetabolite	cancer; viral infection

fludarabine; F araAMP; fludarabine phosphate; SH 573; SH 584; SH 586; NSC 312887; NSC 328002; 2 F ara AMP; NSC 118218; NSC 118218-H; 2-F- araA; ZK 153851; FLUDARA	Marketed	9-beta-D- arabinofuranosyl-2- fluoroadenine-5'- (dihydrogen phosphate)	nucleoside analogue; antimetabolite	cancer
gemcitabine; dFdC; difluorodeoxycytidine; LY 188011; DDFC; GEMZAR	Marketed	2'-deoxy-2',2'- difluorocytidine	nucleoside analogue; antimetabolite	cancer
RL 0018; CYTOVERT	Preclinical		nucleoside analogue; antimetabolite	cancer
sulfinosine; fin; SULFINOSINE	Preclinical	2-amino-9-beta- ribofuranosyl-9H- purine-6-sulfonamide	nucleoside analogue; antimetabolite	cancer
UK 25	Preclinical	5-fluoro-3,4-dihydro- 2,4-dioxo-N-[6-[[[(1- oxo-2- propylpentyl)amino]a cetyl]amino]hexyl]- 1(2H)- pyrimidin-2-carboxami de	nucleoside analogue; antimetabolite	cancer
TPdR	Preclinical	5-iodo-pyrimidinone- 2-deoxyribose	nucleoside analogue; antimetabolite; radiosensitizer	cancer

troxacitabine; BCH 4556	Phase II	(2S-cis)-4-amino-1-[2-(hydroxymethyl)-1,3-dioxolan-4-yl]-2(1H)-pyrimidinone	nucleoside analogue; DNA polymerase inhibitor	cancer
N 10146	Phase I	5-amino-3-beta-D-ribofuranosylthiazolo[4,5-d]pyrimidine-2,7(3H,4H)-dione	nucleoside analogue; immunostimulant; biological response modifier	cancer; viral infection
nucleoside analogues, Nabi	Preclinical		nucleoside analogue; nucleotide analogue	viral infection; HIV infection; cancer
TAS 106	Preclinical		nucleoside analogue; RNA polymerase inhibitor; antimetabolite	cancer
FES 12	Preclinical		nucleoside; antimetabolite	cancer
CS 682	Phase I	N-[1-(2-cyano-2-deoxy-beta-D-arabino-furanosyl)-1,2-dihydro-2-oxo-4-pyrimidinyl]hexadecanamide	nucleoside; DNA polymerase inhibitor	cancer
adenosine triphosphate; ATP	Discontinued	adenosine 5'-(tetrahydrogen triphosphate)	nucleotide	cancer; cachexia
oligonucleotide, cancer immunotherapy	Preclinical		oligonucleotide; biotechnology; immunostimulant	cancer
ribozyme, dysprosium-tetraphyrin, cancer; Dy-Tex	Preclinical		oligonucleotide; biotechnology; ribozyme	cancer

drug delivery system, sustained release DepoFoam morphine; morphine DepoFoam; C 0401; DepoMorphine	Phase II		opiate agonist; mu agonist; analgesic	pain; cancer
naloxone + pentazocine; pentazocine + naloxone	Pre-registration		opiate agonist; opiate antagonist; analgesic	pain; cancer
CP 100356	Preclinical	4-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-6,7-dimethoxy-2-quinazolinamine	P glycoprotein inhibitor	cancer
LY 335979; RS 33295198; RS 33295	Phase II	[6(R)-(1a alpha,6alpha,10b alpha)]-4-(1,1-difluoro-1,1a,6,10b-tetrahydrodibenzol[a,e]cyclopropa[c]cyclohepten-6-yl)-alpha-[(5-quinolinyl)oxy)methyl]-1-piperazineethanol, trihydrochloride	P glycoprotein inhibitor	cancer

N 1379; L 623	Discontinued	hydroxybutanedioic acid cmpd with N,N'-bis[(3,4-dimethoxyphenyl)methyl]-N-(3,7,11,15,19,23,27,31,35-nonamethyl-2,6,10,14,18,22,26,30,34-hexatriacontanonyl)-1,2-ethanediamine (1:1)	P glycoprotein inhibitor	cancer
XR 9576	Phase II	N-2-[[[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinoliny)ethyl]phenyl]amino]carbonyl]-4,5-dimethoxyphenyl]-3-quinolinecarboxamide	P glycoprotein inhibitor; MDR inhibitor	cancer
rohitukine; L 868275	Preclinical	cis-5,7-dihydroxy-8-(3-hydroxy-1-methyl-4-piperidiny)-2-methyl-4H-1-benzopyran-4-one	p34 kinase inhibitor	cancer
SDZ 62434; SDZ 62-434	Discontinued	2,3-dihydro-5-[4-(1-piperidiny)methyl]phenyl]imidazo[2,1-a]isoquinoline dihydrochloride	PAF antagonist	cancer
plasminogen activator inhibitor antagonists, Corvas	Preclinical		PAI inhibitor	cancer

plasminogen activator inhibitor-1 inhibitor, Xenova; PAI-1 inhibitor, Xenova	Preclinical			PAI inhibitor	cancer
BIM 44002	Phase I			parathyroid hormone antagonist	hypercalcemia; cancer
antifreeze protein, cancer cryosurgery, A F Protein	Preclinical			peptide	cancer
axinastatin 1; malaysiatin; pseudoaxinellin	Preclinical	axinastatin 1		peptide	cancer
axinastatin 2	Preclinical	5-L-leucine-axinastatin 1		peptide	cancer
axinastatin 3	Preclinical	4-L-iso leucine-5-L-leucine-axinastatin 1		peptide	cancer
BST 1002	Preclinical			peptide	cancer
BST 1003; COLLAMER	Preclinical			peptide	cancer
cancer therapy, Aptein	Preclinical			peptide	cancer
cancer therapy, Magainin	Preclinical			peptide	cancer
cancer therapy, PSP 94, Procyon	Preclinical	beta-Inhibin (human reduced)		peptide	cancer
cell permeable peptides	Preclinical			peptide	cancer
corticotropin-releasing factor; corticotropin-releasing hormone; CRF; XERECEPT	Phase II			peptide	cancer; stroke; trauma
CYC 100	Preclinical			peptide	cancer

CYC 101	Preclinical		peptide	cancer
CYC 102	Preclinical		peptide	cancer
CYC 103	Preclinical		peptide	cancer
D 22631	Discontinued		peptide	cancer
drug delivery system, anticancer peptide	Preclinical		peptide	cancer
GPX 200	Phase I		peptide	cancer
GW 395058	Preclinical		peptide	cancer; thrombocytopenia
insulin-like growth factor-1 receptor inhibitor; IGF-1 receptor inhibitor; IGF-1 JB3	Preclinical		peptide	restenosis; cancer
laminin peptides, National Institutes of Health	Preclinical		peptide	cancer
MF 13	Preclinical	L-prolyl-3-[bis(2- chloroethyl)amino]- L-phenylalanyl-L- norvaline ethyl ester monohydrochloride	peptide	cancer
monocyte attracting peptide	Preclinical		peptide	cancer; bacterial infection
MSI 103	Discontinued	Lys Ile Ala Gly Lys Ile Ala Lys Ile Ala Gly Lys Ile Ala Lys Ile Ala Gly Lys Ile Alaninamide	peptide	cancer
MSI 500	Discontinued		peptide	cancer

NA 22598; NA 22598A1	Preclinical	N-[2,3-diamino-8-[2-amino-1-(aminocarbonyl)-4,5-dihydro-1H-imidazol-5-yl]-2,3,4,5,8-pentadeoxyoctonoyl]-L-alanyl-L-valine	peptide	cancer
NSC 630176; FR 901228	Phase I	N-[(3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteiny-(2Z)-2-amino-2-butenoyl-L-valine (4-1)-lactone cyclic (1-2)disulfide	peptide	cancer
p16 analogue	Preclinical		peptide	cancer
prohibitin	Preclinical		peptide	cancer
PTL 03001	Preclinical		peptide	cancer
somatoprim; PTR 3046	Preclinical	cyclo(Phe-N2-Tyr-D-Trp-Lys-Val-Phe-C3)Thr-NH2	peptide	pancreatitis; cancer; restenosis
thiocraline	Preclinical		peptide	cancer
urokinase receptor antagonist	Preclinical		peptide	cancer
cyclopeptide, Willex Biotechnology				
IM 862	Phase II		peptide; angiogenesis inhibitor	cancer
D2AT21	Preclinical		peptide; antibiotic	bacterial infection; trichomoniasis; cancer
breast cancer therapy, Cytoclonal	Preclinical		peptide; antiestrogen	cancer

BRCA1, recombinant	Preclinical			peptide; biotechnology	cancer
transcription factor, vascular endothelial growth factor gene	Preclinical			peptide; biotechnology	cancer; retinopathy
alpha-conopeptides	Preclinical			peptide; cholinergic agonist; nicotinic agonist	schizophrenia; Parkinson disease; cancer; urinary incontinence
fibroblast growth factor, basic, antagonists, NIH	Preclinical			peptide; FGF antagonist	cancer
fibroblast growth factor receptor inhibitor; FGF receptor inhibitor	Preclinical			peptide; FGF antagonist; angiogenesis inhibitor	restenosis; cancer
splenopentin; diacetylsplenopentin; berloptentin; DA SP5; DA-Sp 5; BCH 069	Preclinical	N2-acetyl-L-arginyl-N6-acetyl-L-lysyl-L-alpha-glutamyl-L-valyl-L-tyrosine		peptide; immunostimulant	cancer
integrin-specific peptides, Integra LifeSciences	Preclinical			peptide; integrin antagonist; cell adhesion inhibitor; angiogenesis inhibitor	osteoporosis; cancer; restenosis
antagonist D	Preclinical			peptide; substance P antagonist	cancer
auristatin PE	Preclinical			peptide; tubulin polymerase inhibitor	cancer
C3B	Preclinical	Unspecified		phosphatase inhibitor	cancer
Cdc25 inhibitors, Mitotix	Preclinical			phosphatase inhibitor	cardiovascular disease; cancer

CT 2584; APRA	Phase II	1-[11-(dodecylamino)-10-hydroxyundecyl]-3,7-dihydro-3,7-dimethyl-1H-purine-2,6-dione	phosphatidic acid inhibitor	cancer
benzochlorins	Preclinical		photosensitizer	cancer
benzophenothiazines, Rowland Institute; benzophenothiazines, Ergo Science	Preclinical		photosensitizer	cancer
benzoporphyrin derivatives, third generation; QLT 0074	Preclinical		photosensitizer	cancer
boronated porphyrin compounds; BOPP	Phase I		photosensitizer	cancer
chlorins	Preclinical		photosensitizer	cancer
cis-porphyrin	Preclinical	cis-meso-bis(N-methyl)-4-pyridinium)diphenyl porphyrin	photosensitizer	cancer
drug delivery system, liposome zinc phthalocyanine; zinc phthalocyanine liposome; CGP 55847	Discontinued		photosensitizer	cancer
drug delivery system, RFS aminolevulinic acid; 5-ALA RFS; aminolevulinic acid, RFS	Preclinical		photosensitizer	cancer

drug delivery system, transdermal 5-aminolevulinic acid; 5-aminolevulinic acid transdermal; drug delivery system, transdermal ALA PDT	Discontinued			photosensitizer	cancer
ER 470	Discontinued			photosensitizer	cancer
HAT D01	Preclinical			photosensitizer	cancer; diagnosis
HPHH	Phase I			photosensitizer	cancer
hypericin; VIMRxyn; CYCLO-WERROL; CYCLOSAN	Phase II	1,3,4,6,8,13-hexahydroxy-10,11-dimethylphenanthro[1,10,9,8-opqra]perylene-7,14-dione		photosensitizer	psoriasis; cancer
JM 2929	Discontinued	(OC-6-12)-bis[3-(diphenylphosphino-kappaP)benzenesulfonato][29H,31H-phthalocyaninato(2-)-kappaN29,kappaN30,kappaN31,kappaN32]ruthenate(2-), dipotassium		photosensitizer	cancer
lutetium texaphyrin; Lu Tex; PCI 0123; LUTRIN; Lu-Tex; OPTRIN; ANTRIN	Phase II			photosensitizer	cancer; atherosclerosis; eye disease; skin disease

NPc 6; NP c6; ME 2906	Phase II	N-[3-[(2S,3S)-18-carboxy-20-(carboxymethyl)-8-ethenyl-13-ethyl-2,3-dihydro-3,7,12,17-tetramethyl-21H,23H-porphin-2-yl]-1-oxopropyl]-L-aspartic acid tetrasodium salt	photosensitizer	cancer
photodynamic immunotherapy, Pacific; PDIT	Preclinical		photosensitizer	cancer
photodynamic therapy, Anutech; drug delivery system, photosensitizer	Preclinical		photosensitizer	cancer
photodynamic therapy, plant-derived, Steba Beher	Preclinical		photosensitizer	cancer; bacterial infection
porfimer sodium; polyporphyrin; CL 184116; PHOTOFRIN; PHOTOFRIN II	Marketed	photofrin porfimer sodium	photosensitizer	cancer
purpurins	Preclinical		photosensitizer	cancer
SC 102	Preclinical		photosensitizer	cancer
SQN 400; SQ 400	Preclinical		photosensitizer	cancer
tellurapyrylium; USB 006	Discontinued		photosensitizer	cancer
temoporfin; m-THPC; EF 9; FOSCAN	Phase III	3,3',3''-(2,3-dihydro-21H,23H-porphine-5,10,15,20-tetrayl)tetrakis phenol	photosensitizer	cancer

tin ethyl etiopurpurin; SnET2; PURLYTIN	Phase III	tin [ethyl 3,4,20,21-tetrahydro-4,9,14,19-tetraethyl-18,19-dihydro-3,8,13,18-tetramethyl-20-phorbinecarboxylato(2-)-kappa.N23,kappa.N24,kappa.N25,kappa.N26]-(SP-4-2)-	photosensitizer	cancer; benign prostate hypertrophy; retinopathy
verdins	Preclinical		photosensitizer	cancer
zinc phthalocyanine	Discontinued		photosensitizer	cancer
aminolevulinic acid, photodynamic therapy; 5-ALA PDT; LEVULAN	Pre-registration		photosensitizer; contrast medium	psoriasis; skin disease; endometriosis; cancer; diagnosis
verteporfin; benzoporphyrin derivative; BPD-MA; CL 318952; BPDR; VISUDYNE	Phase III	trans-18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-23H,25H-benzo[b]porphine-9,13-dipropionic acid monomethyl ester	photosensitizer; NSAID	cancer; psoriasis; arthritis; retinopathy
anagrelide; anagrelide hydrochloride; BL 4162A; AGRYLIN; AGRELIN	Marketed	6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2(3H)-one	platelet antiaggregant	thrombosis; cancer
AP 5070	Preclinical		platinum complex	cancer

B 850040	Discontinued	1,3-diamino-2-methoxymethyl-2-methyl-propan-N,N-platin (II)-0,0-cyclobutan-1,1-dicarboxylate	platinum complex	cancer
BBR 2207	Discontinued	hydrogen [mu-benzenepentacarboxylato(5-)-O1,O2:O4,O5]]bis(1,2-cyclohexanediamine-N,N')diplatinate (1-), stereoisomer	platinum complex	cancer
BBR 3464	Phase I		platinum complex	cancer
cisplatin analogue, II Yang	Preclinical		platinum complex	cancer
cycloplatin	Phase I	amine(cyclopentamine)[hydroxybutanedioato(2-)-O1,O4]-platinum	platinum complex	cancer
drug delivery system, ATRIGEL sustained release cisplatin; cisplatin ATRIGEL	Preclinical		platinum complex	cancer
drug delivery system, cisplatin; cisplatin Therapeutic Implant; MPI 5010; IntraDose INJECTABLE GEL; IntraDose-CDDP; INTRADOSE-CDDP; IntraDose	Phase III		platinum complex	cancer

drug delivery system, cisplatin biodegradable polymer implant; cisplatin biodegradable polymer implant	Preclinical			platinum complex	cancer
drug delivery system, liposomal L-NDDP; L-NDDP liposomes; AR 726; PLATAR	Phase II			platinum complex	cancer
drug delivery system, liposome carboplatin; carboplatin liposome	Preclinical			platinum complex	cancer
drug delivery system, liposome carboplatin; carboplatin liposome	Preclinical			platinum complex	cancer
drug delivery system, microsphere cisplatin; cisplatin microsphere	Preclinical			platinum complex	cancer
drug delivery system, NDDP liposome; NDDP liposome	Phase I			platinum complex	cancer
drug delivery system, STEALTH cisplatin; cisplatin STEALTH delivery system; SPI 77; SPI 077	Phase II			platinum complex	cancer
GB 21; W 164; E 92/114	Preclinical		poly-[(trans-1,2-diamino-cyclohexane)platinum]-carboxyamylose	platinum complex	cancer

JM 221	Discontinued	(OC-6-43)- amminebis(butanoato O)dichloro(cyclohexa namine)platinum	platinum complex	cancer
JM 335	Discontinued	(OC-6-12)- amminedichloro(cycl ohexanamine)dihydro xyplatinum	platinum complex	cancer
JM 473	Preclinical	(SP-4-3)- amminedichloro(2- methylpyridine)platin um	platinum complex	cancer
KHPC 001	Phase I	[SP-4-2-(1R-trans)]- (1,2- cyclohexanediamine- kappaN,kappaN')[1,3- propanediylbis[diphe nylphosphine- kappaP]]- platinum(2+),dinitrate	platinum complex	cancer
KHPC 002	Phase I		platinum complex	cancer
KI 30606	Preclinical	poly[[(+/-)-trans-1,2- diaminocyclohexane]] 1,3- dicarboxylatopropyla mido(nitrido)phospho ric acid]platinum (II)]	platinum complex	cancer

KP 1250	Preclinical	(SP-4-2)-dichloro(5,7,8,10,11,13,14,16,17,19,20,22-dodecahydro[1,4,7,10,13,16]hexaoxacyclodocosin o[19,18-b:20,21-b']dipyridine-N1,N26)platinum	platinum complex	cancer
lipophilic platinum compounds, Aronex	Discontinued		platinum complex	cancer
lobaplatin; D 19466	Registered	cis-(trans-1,2-cyclobutanediisothiocyanate N,N')(2-hydroxypropionate(2-O1,O2)platinum	platinum complex	cancer
miboplatin; loboplatin; DWA 2114R; DWA 2114A; NEOPLAT	Discontinued	[SP-4-3-(1R-cis)-[1,1-cyclobutanedicarboxylato(2-)](2-pyrrolidinemethanimine-Nalpha,N1)platinum	platinum complex	cancer
nedaplatin; latoplatin; S 254; 254 S; NSC 375101D; AQUPLA	Marketed	(SP-4-3)-diammine[(hydroxy-kappa.O)acetato(2-)-kappa.O]platinum	platinum complex	cancer
ornaplatin; tetraplatin; TCDCP; NSC 276017; NSC 363812; NSC 363812D; U 77233	Phase I	[OC-6-22-(trans)]-tetrachloro(1,2-cyclohexanediamine-N,N')platinum	platinum complex	cancer

oxaliplatin; oxalatoplatinum; L- OHP; ACT 078; ELOXATINE; L- OHP; TRANSPLATIN; ELOXATIN	Marketed	[SP-4-2-(1R-trans)]-(1,2-cyclohexanediamine)-N,N''[ethanedioato(2-O,O')]platinum	platinum complex	cancer
PADP	Phase I	phosphonoacetato-1,2-diaminocyclohexane platinum (II)	platinum complex	cancer
platinum complex, Cancer Research Center	Preclinical	cis-diamine(nitritotris(methyolphosphonato)(2-)-O1,N1)platinum II	platinum complex	cancer
platinum compounds, Georgetown University	Discontinued		platinum complex	cancer
platinum-triamine complex; DPR	Preclinical	(SP-4-3)-diamminechloro[2-(diethylamino)ethyl-4-aminobenzoate-N4]platinum(1+)chloride monohydrochloride	platinum complex	cancer
polymer platinate compounds, London School of Pharmacy	Preclinical		platinum complex	cancer

RL 0013; NSC 328005; Pt 268; CYPLATATE	Preclinical	(SP-4-3)-(1,2-cyclohexanediamine-N,N')[(phosphonoacetyl)-L-asparto(4-)-O1,O4]platinate(2-)-dihydrogen	platinum complex	cancer
satraplatin; JM 216; BMS 182751; BMY 45594	Phase III	(OC-6-43)-bis(acetato-O)amminedichloro(cyclohexanamine)platinum	platinum complex	cancer
sebriplatin; NK 121; CI 973; SEVRIPLATIN	Discontinued	[SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2-methyl-1,4-butanediamine-N,N')platinum	platinum complex	cancer
SKI 2034R	Discontinued		platinum complex	cancer
SKI 2053R; SK 12035R	Phase II	[SP-4-2-[4R-(2alpha,4alpha,5beta)]-[2-(1-methylethyl)-1,3-dioxolane-4,5-dimethanamine-kappaN4,kappaN5]]propanedioato(2-)-kappaO1,kappaO3]platinum	platinum complex	cancer
SM 11355; DACHPM	Discontinued	(trans-cyclohexanedi-1,2-diamine)bis(myristate)platinum (II)	platinum complex	cancer

TRK 710	Discontinued	[SP-4-3-1(S),3(1R-trans)]-(3-acetyl-5-methyl-2,4(3H,5H)-furanonato-O3,O4)(1,2-cyclohexanediamine-N,N')-platinum(1+), salt with (S)-3-acetyl-5-methyl-2,4(3H,5H)furanone (1:1), tetrahydrate	platinum complex	cancer
ZD 0473; AMD 473	Phase I	(SP-4-3)-amminedichloro(2-methylpyridine)platinum	platinum complex	cancer
zeniplatin; 2,2-bis(aminomethyl)-1,3-propanediol platinum complex; 1,1-cyclobutanedicarboxylic acid platinum complex; CL 286558	Phase II	(SP-4-2)-[2,2-bis(aminomethyl)-1,3-propanediol-N,N']-[1,1-cyclobutanedicarboxylato(2-)]platinum	platinum complex	cancer
PD 128763	Preclinical	3,4-dihydro-5-methyl-1(2H)-isoquinolinone	poly (ADP ribose) polymerase inhibitor	cancer
diethylhomospermine; DEHOP; DE 444	Phase II	N,N'-bis[4-(ethylamino)butyl]-1,4-butanediamine	polyamine analogue	diarrhea; hypertension; cancer; psoriasis; ulcerative colitis
diethylhomospermine; DENSPM; CI 1006; DE 333	Phase II	N1,N11-diethylhomospermine	polyamine analogue	cancer; psoriasis; Alzheimer disease

linear polyamine analogue, SunPharm	Preclinical			polyamine analogue	cancer; Alzheimer disease
MDL 28314	Discontinued		N,N'-bis[3-(ethylamino)propyl]-1,7-heptane diamine	polyamine analogue	cancer
polyamine analogues, National Institutes of Health	Preclinical			polyamine analogue	cancer
mitoguanzone; methylglyoxal bisguanyldrazone; MGBG; NSC 32946; ZYRKAMINE	Marketed		1,1'-[(methylethanediyli)diguanidine]	polyamine synthesis inhibitor	cancer
polyclonal antibody, complement inhibitor protein; gammaglobulin, complement inhibitor protein; PASS-CaB	Preclinical			polyclonal antibody; immunoglobulin	cancer
actinoplanone A; R 304G	Discontinued		[1S-(1 α ,3 α ,4 β ,8 α ,11 α)-13-amino-11-chloro-3,4,8a,13-tetrahydro-3,15,16-trihydroxy-1,4-dimethoxy-12-methyl-1H-xantheno[4',3',2':4,5][1,3]benzodioxino[7,6-g]isoquinoline-14,17(2H,9H)-dione	polycyclic xanthone; antibiotic	bacterial infection; cancer

actinoplanone B; R 304H	Discontinued	[1S-(1 α ,3 α ,4 β ,8 α)-11-chloro-3,4,8a,13-tetrahydro-3,15,16-trihydroxy-1,4-dimethoxy-12-methyl-1H-xantheno[4',3',2':4,5][1,3]benzodioxino[7,6-g]isoquinoline-14,17(2H,9H)-dione	polycyclic xanthone; antibiotic	bacterial infection; cancer
actinoplanone C; R 304J	Discontinued	[1S-(1 α ,3 α ,4 β ,8 α)-13-amino-3,4,8a,13-tetrahydro-3,15,16-trihydroxy-1,4-dimethoxy-12-methyl-1H-xantheno[4',3',2':4,5][1,3]benzodioxino[7,6-g]isoquinoline-14,17(2H,9H)-dione	polycyclic xanthone; antibiotic	bacterial infection; cancer

actinoplanone G; R 304F	Discontinued	[1S-(1 α ,3 α ,4 β ,8 α ,13 α)-3,4,8a,13-tetrahydro-3,15,16-trihydroxy-1,4-dimethoxy-12-methyl-13-[(1-methyl-2-oxopropylidene)amino]-1H-xantheno[4',3',2':4,5][1,3]benzodioxino[7,6-g]isoquinoline-14,17(2H,9H)-dione	polycyclic xanthone; antibiotic	bacterial infection; cancer
CARN 700; CARRAVEX	Phase I	Unspecified	polysaccharide	cancer
CKD 606	Preclinical		polysaccharide	cancer; liver disease
sizofiran; sizofilan; neoschizophyllan; SONIFILAN; SONIFIRAN	Marketed	poly[3--(O-beta-D-glucopyranosyl-(1--3)-O-[beta-D-glucopyranosyl-(1--6)]-O-beta-D-glucopyranosyl-(1--3)-O-beta-D-glucopyranosyl)--1]	polysaccharide; immunostimulant	cancer; viral infection
CM 101; ZD 0101	Phase II	Unspecified	polysaccharide; immunostimulant; angiogenesis inhibitor	cancer
AM 5	Discontinued		polysaccharide; radioprotectant	cancer
LG 2527; LG 2716	Preclinical		progestogen; hormone replacement therapy	hormone deficiency; cancer

progesterone receptor therapy, Ligand/Wyeth Ayerst	Preclinical		progestogen; hormone replacement therapy	hormone deficiency; contraception; cancer
prolyl hydroxylase inhibitor, Cornell Research Foundation	Preclinical		prolyl hydroxylase inhibitor; angiogenesis inhibitor	retinopathy; cancer; skin disease; atherosclerosis
TEI 9826	Preclinical		prostaglandin	cancer
OC 3186	Preclinical	(5Z,13E,15S)-15-hydroxy-9-oxo-prosta-5,8(12),13-trien-1-oic acid (acetyloxy)methyl ester homopolymer	prostanoid	cancer
prostaglandin J2; PG J2	Preclinical		prostanoid	cancer; viral infection
YM 11	Preclinical	(5S,6S,7Z,12alpha,14Z)-5,6-bis(acetyloxy)-10-chloro-12-hydroxy-9-oxoprostano-7,10,14-trien-1-oic acid methyl ester	prostanoid	cancer
YM 3	Preclinical	(7E,12xi)-10-chloro-12-hydroxy-9-oxoprost-7,10-dien-1-oic acid methyl ester	prostanoid	cancer

cicaprost; cicaprost clathrate; ZK 114923; SH 574; SH 490	Discontinued	[3aS- [2E,3alpha,4alpha(3 R*,4R*),5beta,6alpha a]]-[2-[hexahydro-5- hydroxy-4-(3- hydroxy-4-methyl- 1,6-nonadiynyl)- 2(1H)- pentalenylidene]ethox yl]acetic acid	prostanoid; vasodilator; platelet antiaggregant	thrombosis; peripheral vascular disease; cancer
bryostatins; bryostatins 1; BMY 45618; NSC 339555	Phase II	bryostatin 1	protein kinase activator; protein kinase C activator	cancer
hexamethylene bisacetamide derivative; HMBA derivative	Preclinical		protein kinase activator; protein kinase C activator	cancer
Y 27632	Preclinical	[4(R)-trans]-4-(1- aminoethyl)-N-4- pyridinylcyclohexane carboxamide	protein kinase inhibitor	hypertension; asthma; cancer
cancer therapy, Kinetix	Preclinical		protein kinase inhibitor; angiogenesis inhibitor	cancer
CP 564959	Preclinical		protein kinase inhibitor; angiogenesis inhibitor	cancer
H 87	Discontinued	N-[2-[[3-(4- bromophenyl)-2- propenyl]ethylamino] ethyl]-5- isquinolinesulfonam ide	protein kinase inhibitor; protein kinase A inhibitor; MDR inhibitor	cancer

BM 41400	Discontinued		protein kinase inhibitor; protein kinase C inhibitor	cancer
calphostin C; calphostin; UCN 1028C; UCN 1028	Discontinued	2-[12-[2-(benzyloxy)propyl]-3,10-dihydro-4,9-dihydroxy-2,6,7,11-tetramethoxy-3,10-dioxo-1-perylene]-1-methylethyl 4-hydroxyphenyl carbonic acid ester	protein kinase inhibitor; protein kinase C inhibitor	cancer
diacylglycerol analogues, National Institutes of Health	Preclinical		protein kinase inhibitor; protein kinase C inhibitor	cancer
midostaurin; benzoylstauroporine; N- benzoylstauroporin; CGP 41251; CGP 41231	Phase II	(9alpha,10beta,11beta,13alpha)-N-(2,3,10,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl)-N-methylbenzamide	protein kinase inhibitor; protein kinase C inhibitor	cancer
NK 860276	Discontinued		protein kinase inhibitor; protein kinase C inhibitor	cancer

NSC 646958	Preclinical		protein kinase inhibitor; protein kinase C inhibitor	cancer
protein kinase C inhibitor, microalgal, Martek	Preclinical		protein kinase inhibitor; protein kinase C inhibitor	cancer; psoriasis
protein kinase C inhibitor, Xenova	Discontinued		protein kinase inhibitor; protein kinase C inhibitor	cancer
safingol; safingol hydrochloride; SPC 100270; mSPC 100271; KYNAC; KYNACYTE	Phase II	(2S,3S)-2-amino-1,3-octadecanediol	protein kinase inhibitor; protein kinase C inhibitor	psoriasis; dermatitis; cancer
SPC 100221	Preclinical	[R-(R*,S*)]-2-amino-1,3-octadecanediol	protein kinase inhibitor; protein kinase C inhibitor	cancer
SPC 101591	Preclinical		protein kinase inhibitor; protein kinase C inhibitor	cancer; ischemia; reperfusion injury
RK 1409B	Preclinical	[9S-(9alpha,10alpha,11beta,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,270,271,272,273,274,275,276,277,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,297,298,299,300,301,302,303,304,305,306,307,308,309,310,311,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,327,328,329,330,331,332,333,334,335,336,337,338,339,340,341,342,343,344,345,346,347,348,349,350,351,352,353,354,355,356,357,358,359,360,361,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384,385,386,387,388,389,390,391,392,393,394,395,396,397,398,399,400,401,402,403,404,405,406,407,408,409,410,411,412,413,414,415,416,417,418,419,420,421,422,423,424,425,426,427,428,429,430,431,432,433,434,435,436,437,438,439,440,441,442,443,444,445,446,447,448,449,450,451,452,453,454,455,456,457,458,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478,479,480,481,482,483,484,485,486,487,488,489,490,491,492,493,494,495,496,497,498,499,500,501,502,503,504,505,506,507,508,509,510,511,512,513,514,515,516,517,518,519,520,521,522,523,524,525,526,527,528,529,530,531,532,533,534,535,536,537,538,539,540,541,542,543,544,545,546,547,548,549,550,551,552,553,554,555,556,557,558,559,560,561,562,563,564,565,566,567,568,569,570,571,572,573,574,575,576,577,578,579,580,581,582,583,584,585,586,587,588,589,590,591,592,593,594,595,596,597,598,599,600,601,602,603,604,605,606,607,608,609,610,611,612,613,614,615,616,617,618,619,620,621,622,623,624,625,626,627,628,629,630,631,632,633,634,635,636,637,638,639,640,641,642,643,644,645,646,647,648,649,650,651,652,653,654,655,656,657,658,659,660,661,662,663,664,665,666,667,668,669,670,671,672,673,674,675,676,677,678,679,680,681,682,683,684,685,686,687,688,689,690,691,692,693,694,695,696,697,698,699,700,701,702,703,704,705,706,707,708,709,710,711,712,713,714,715,716,717,718,719,720,721,722,723,724,725,726,727,728,729,730,731,732,733,734,735,736,737,738,739,740,741,742,743,744,745,746,747,748,749,750,751,752,753,754,755,756,757,758,759,760,761,762,763,764,765,766,767,768,769,770,771,772,773,774,775,776,777,778,779,780,781,782,783,784,785,786,787,788,789,790,791,792,793,794,795,796,797,798,799,800,801,802,803,804,805,806,807,808,809,810,811,812,813,814,815,816,817,818,819,820,821,822,823,824,825,826,827,828,829,830,831,832,833,834,835,836,837,838,839,840,841,842,843,844,845,846,847,848,849,850,851,852,853,854,855,856,857,858,859,860,861,862,863,864,865,866,867,868,869,870,871,872,873,874,875,876,877,878,879,880,881,882,883,884,885,886,887,888,889,890,891,892,893,894,895,896,897,898,899,900,901,902,903,904,905,906,907,908,909,910,911,912,913,914,915,916,917,918,919,920,921,922,923,924,925,926,927,928,929,930,931,932,933,934,935,936,937,938,939,940,941,942,943,944,945,946,947,948,949,950,951,952,953,954,955,956,957,958,959,960,961,962,963,964,965,966,967,968,969,970,971,972,973,974,975,976,977,978,979,980,981,982,983,984,985,986,987,988,989,990,991,992,993,994,995,996,997,998,999,1000,1001,1002,1003,1004,1005,1006,1007,1008,1009,1010,1011,1012,1013,1014,1015,1016,1017,1018,1019,1020,1021,1022,1023,1024,1025,1026,1027,1028,1029,1030,1031,1032,1033,1034,1035,1036,1037,1038,1039,1040,1041,1042,1043,1044,1045,1046,1047,1048,1049,1050,1051,1052,1053,1054,1055,1056,1057,1058,1059,1060,1061,1062,1063,1064,1065,1066,1067,1068,1069,1070,1071,1072,1073,1074,1075,1076,1077,1078,1079,1080,1081,1082,1083,1084,1085,1086,1087,1088,1089,1090,1091,1092,1093,1094,1095,1096,1097,1098,1099,1100,1101,1102,1103,1104,1105,1106,1107,1108,1109,1110,1111,1112,1113,1114,1115,1116,1117,1118,1119,1120,1121,1122,1123,1124,1125,1126,1127,1128,1129,1130,1131,1132,1133,1134,1135,1136,1137,1138,1139,1140,1141,1142,1143,1144,1145,1146,1147,1148,1149,1150,1151,1152,1153,1154,1155,1156,1157,1158,1159,1160,1161,1162,1163,1164,1165,1166,1167,1168,1169,1170,1171,1172,1173,1174,1175,1176,1177,1178,1179,1180,1181,1182,1183,1184,1185,1186,1187,1188,1189,1190,1191,1192,1193,1194,1195,1196,1197,1198,1199,1200,1201,1202,1203,1204,1205,1206,1207,1208,1209,1210,1211,1212,1213,1214,1215,1216,1217,1218,1219,1220,1221,1222,1223,1224,1225,1226,1227,1228,1229,1230,1231,1232,1233,1234,1235,1236,1237,1238,1239,1240,1241,1242,1243,1244,1245,1246,1247,1248,1249,1250,1251,1252,1253,1254,1255,1256,1257,1258,1259,1260,1261,1262,1263,1264,1265,1266,1267,1268,1269,1270,1271,1272,1273,1274,1275,1276,1277,1278,1279,1280,1281,1282,1283,1284,1285,1286,1287,1288,1289,1290,1291,1292,1293,1294,1295,1296,1297,1298,1299,1300,1301,1302,1303,1304,1305,1306,1307,1308,1309,1310,1311,1312,1313,1314,1315,1316,1317,1318,1319,1320,1321,1322,1323,1324,1325,1326,1327,1328,1329,1330,1331,1332,1333,1334,1335,1336,1337,1338,1339,1340,1341,1342,1343,1344,1345,1346,1347,1348,1349,1350,1351,1352,1353,1354,1355,1356,1357,1358,1359,1360,1361,1362,1363,1364,1365,1366,1367,1368,1369,1370,1371,1372,1373,1374,1375,1376,1377,1378,1379,1380,1381,1382,1383,1384,1385,1386,1387,1388,1389,1390,1391,1392,1393,1394,1395,1396,1397,1398,1399,1400,1401,1402,1403,1404,1405,1406,1407,1408,1409,1410,1411,1412,1413,1414,1415,1416,1417,1418,1419,1420,1421,1422,1423,1424,1425,1426,1427,1428,1429,1430,1431,1432,1433,1434,1435,1436,1437,1438,1439,1440,1441,1442,1443,1444,1445,1446,1447,1448,1449,1450,1451,1452,1453,1454,1455,1456,1457,1458,1459,1460,1461,1462,1463,1464,1465,1466,1467,1468,1469,1470,1471,1472,1473,1474,1475,1476,1477,1478,1479,1480,1481,1482,1483,1484,1485,1486,1487,1488,1489,1490,1491,1492,1493,1494,1495,1496,1497,1498,1499,1500,1501,1502,1503,1504,1505,1506,1507,1508,1509,1510,1511,1512,1513,1514,1515,1516,1517,1518,1519,1520,1521,1522,1523,1524,1525,1526,1527,1528,1529,1530,1531,1532,1533,1534,1535,1536,1537,1538,1539,1540,1541,1542,1543,1544,1545,1546,1547,1548,1549,1550,1551,1552,1553,1554,1555,1556,1557,1558,1559,1560,1561,1562,1563,1564,1565,1566,1567,1568,1569,1570,1571,1572,1573,1574,1575,1576,1577,1578,1579,1580,1581,1582,1583,1584,1585,1586,1587,1588,1589,1590,1591,1592,1593,1594,1595,1596,1597,1598,1599,1600,1601,1602,1603,1604,1605,1606,1607,1608,1609,1610,1611,1612,1613,1614,1615,1616,1617,1618,1619,1620,1621,1622,1623,1624,1625,1626,1627,1628,1629,1630,1631,1632,1633,1634,1635,1636,1637,1638,1639,1640,1641,1642,1643,1644,1645,1646,1647,1648,1649,1650,1651,1652,1653,1654,1655,1656,1657,1658,1659,1660,1661,1662,1663,1664,1665,1666,1667,1668,1669,1670,1671,1672,1673,1674,1675,1676,1677,1678,1679,1680,1681,1682,1683,1684,1685,1686,1687,1688,1689,1690,1691,1692,1693,1694,1695,1696,1697,1698,1699,1700,1701,1702,1703,1704,1705,1706,1707,1708,1709,1710,1711,1712,1713,1714,1715,1716,1717,1718,1719,1720,1721,1722,1723,1724,1725,1726,1727,1728,1729,1730,1731,1732,1733,1734,1735,1736,1737,1738,1739,1740,1741,1742,1743,1744,1745,1746,1747,1748,1749,1750,1751,1752,1753,1754,1755,1756,1757,1758,1759,1760,1761,1762,1763,1764,1765,1766,1767,1768,1769,1770,1771,1772,1773,1774,1775,1776,1777,1778,1779,1780,1781,1782,1783,1784,1785,1786,1787,1788,1789,1790,1791,1792,1793,1794,1795,1796,1797,1798,1799,1800,1801,1802,1803,1804,1805,1806,1807,1808,1809,1810,1811,1812,1813,1814,1815,1816,1817,1818,1819,1820,1821,1822,1823,1824,1825,1826,1827,1828,1829,1830,1831,1832,1833,1834,1835,1836,1837,1838,1839,1840,1841,1842,1843,1844,1845,1846,1847,1848,1849,1850,1851,1852,1853,1854,1855,1856,1857,1858,1859,1860,1861,1862,1863,1864,1865,1866,1867,1868,1869,1870,1871,1872,1873,1874,1875,1876,1877,1878,1879,1880,1881,1882,1883,1884,1885,1886,1887,1888,1889,1890,1891,1892,1893,1894,1895,1896,1897,1898,1899,1900,1901,1902,1903,1904,1905,1906,1907,1908,1909,1910,1911,1912,1913,1914,1915,1916,1917,1918,1919,1920,1921,1922,1923,1924,1925,1926,1927,1928,1929,1930,1931,1932,1933,1934,1935,1936,1937,1938,1939,1940,1941,1942,1943,1944,1945,1946,1947,1948,1949,1950,1951,1952,1953,1954,1955,1956,1957,1958,1959,1960,1961,1962,1963,1964,1965,1966,1967,1968,1969,1970,1971,1972,1973,1974,1975,1976,1977,1978,1979,1980,1981,1982,1983,1984,1985,1986,1987,1988,1989,1990,1991,1992,1993,1994,1995,1996,1997,1998,1999,2000,2001,2002,2003,2004,2005,2006,2007,2008,2009,2010,2011,2012,2013,2014,2015,2016,2017,2018,2019,2020,2021,2022,2023,2024,2025,2026,2027,2028,2029,2030,2031,2032,2033,2034,2035,2036,2037,2038,2039,2040,2041,2042,2043,2044,2045,2046,2047,2048,2049,2050,2051,2052,2053,2054,2055,2056,2057,2058,2059,2060,2061,2062,2063,2064,2065,2066,2067,2068,2069,2070,2071,2072,2073,2074,2075,2076,2077,2078,2079,2080,2081,2082,2083,2084,2085,2086,2087,2088,2089,2090,2091,2092,2093,2094,2095,2096,2097,2098,2099,2100,2101,2102,2103,2104,2105,2106,2107,2108,2109,2110,2111,2112,2113,2114,2115,2116,2117,2118,2119,2120,2121,2122,2123,2124,2125,2126,2127,2128,2129,2130,2131,2132,2133,2134,2135,2136,2137,2138,2139,2140,2141,2142,2143,2144,2145,2146,2147,2148,2149,2150,2151,2152,2153,2154,2155,2156,2157,2158,2159,2160,2161,2162,2163,2164,2165,2166,2167,2168,2169,2170,2171,2172,2173,2174,2175,2176,2177,2178,2179,2180,2181,2182,2183,2184,2185,2186,2187,2188,2189,2190,2191,2192,2193,2194,2195,2196,2197,2198,2199,2200,2201,2202,2203,2204,2205,2206,2207,2208,2209,2210,2211,2212,2213,2214,2215,2216,2217,2218,2219,2220,2221,2222,2223,2224,2225,2226,2227,2228,2229,2230,2231,2232,2233,2234,2235,2236,2237,2238,2239,2240,2241,2242,2243,2244,2245,2246,2247,2248,2249,2250,2251,2252,2253,2254,2255,2256,2257,2258,2259,2260,2261,2262,2263,2264,2265,2266,2267,2268,2269,2270,2271,2272,2273,2274,2275,2276,2277,2278,2279,2280,2281,2282,2283,2284,2285,2286,2287,2288,2289,2290,2291,2292,2293,2294,2295,2296,2297,2298,2299,2300,2301,2302,2303,2304,2305,2306,2307,2308,2309,2310,2311,2312,2313,2314,2315,2316,2317,2318,2319,2320,2321,2322,2323,2324,2325,2326,2327,2328,2329,2330,2331,2332,2333,2334,2335,2336,2337,2338,2339,2340,2341,2342,2343,2344,2345,2346,2347,2348,2349,2350,2351,2352,2353,2354,2355,2356,2357,2358,2359,2360,2361,2362,2363,2364,2365,2366,2367,2368,2369,2370,2371,2372,2373,2374,2375,2376,2377,2378,2379,2380,2381,2382,2383,2384,2385,2386,2387,2388,2389,2390,2391,2392,2393,2394,2395,2396,2397,2398,2399,2400,2401,2402,2403,2404,2405,2406,2407,2408,2409,2410,2411,2412,2413,2414,2415,2416,2417,2418,2419,2420,2421,2422,2423,2424,2425,2426,2427,2428,2429,2430,2431,2432,2433,2434,2435,2436,2437,2438,2439,2440,2441,2442,2443,2444,2445,2446,2447,2448,2449,2450,2451,2452,2453,2454,2455,2456,2457,2458,2459,2460,2461,2462,2463,2464,2465,2466,2467,2468,2469,2470,2471,2472,2473,2474,2475,2476,2477,2478,2479,2480,2481,2482,2483,2484,2485,2486,2487,2488,2489,2490,2491,2492,2493,2494,2495,2496,2497,2498,2499,2500,2501,2502,2503,2504,2505,2506,2507,2508,2509,2510,2511,2512,2513,2514,2515,2516,2517,2518,2519,2520,2521,2522,2523,2524,2525,2526,2527,2528,2529,2530,2531,2532,2533,2534,2535,2536,2537,2538,2539,2540,2541,2542,2543,2544,2545,2546,2547,2548,2549,2550,2551,2552,2553,2554,2555,2556,2557,2558,2559,2560,2561,2562,2563,2564,2565,2566,2567,2568,2569,2570,2571,2572,2573,2574,2575,2576,2577,2578,2579,2580,2581,2582,2583,2584,2585,2586,2587,2588		

CGP 60474	Phase I			protein kinase inhibitor; protein kinase C inhibitor; cyclin dependent kinase inhibitor	cancer
MLR 52; (+)-MLR-52	Discontinued	[9S-(9alpha,10beta,11alpha,12alpha,13alpha)]-2,3,10,11,12,13-hexahydro-11,12-dihydroxy-10-methoxy-9-methyl-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one		protein kinase inhibitor; protein kinase C inhibitor; immunosuppressant	cancer
balanol; (-)-balanol; azepinostatin; ophiocordin	Preclinical	(3R-trans)-4-(2-carboxy-6-hydroxybenzoyl)-3,5-dihydroxybenzoic acid 1-[hexahydro-3-[(4-hydroxybenzoyl)amino]-1H-azepin-4-yl] ester		protein kinase inhibitor; protein kinase C inhibitor; NSAID	cancer; inflammation; psoriasis
SPC 100840	Preclinical			protein kinase inhibitor; protein kinase C inhibitor; NSAID	ischemia; psoriasis; cancer; inflammation; reperfusion injury

UCN 01; UCN 1; KW 2401	Phase I	(3 α ,9 β ,10 α ,11 α ,13 β)-(+)-2,3,10,11,12,13-hexahydro-3-hydroxy-10-methoxy-9-methyl-11-(methoxylamino)-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-1-one	protein kinase inhibitor; protein kinase C inhibitor; NSAID	cancer; inflammation; allergy
MDL 27032	Suspended	4-propyl-5-(4-pyridinyl)-2(3H)oxazolone	protein kinase inhibitor; protein kinase C inhibitor; vasodilator	cancer
BE 23372M	Discontinued	(E)-5-(3,4-dihydroxyphenyl)-3-[(3,4-dihydroxyphenyl)methylene]-2(3H)-furanone	protein kinase inhibitor; tyrosine kinase inhibitor	cancer
CGP 53716	Phase II	N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide	protein kinase inhibitor; tyrosine kinase inhibitor	cancer
CGP 59326B	Preclinical		protein kinase inhibitor; tyrosine kinase inhibitor; EGF receptor inhibitor	cancer

KRN 5500	Phase I	4-deoxy-4-[[[(14-methyl-1-oxopentadecyl)amino]acetyl]amino]-N-1H-purin-6-yl-L-glycero-beta-L-manno-heptoipyranosylamine	protein synthesis inhibitor	cancer
Pseudomonas exotoxin A linked to F(ab') ₂ fragment of Mab 1H10-PE; 1H10-PE	Preclinical		protein synthesis inhibitor	cancer
didemnin B; NSC 325319; IND 24505	Phase II	(S)-N-[1-(2-hydroxy-1-oxopropyl)-L-prolyl]didemnin A	protein synthesis inhibitor; antifungal; peptide	cancer; bacterial infection; mycosis; viral infection
B 428	Preclinical	4-iodobenzo[b]thiophene-2-carboximidamide monohydrochloride	proteinase inhibitor	cancer
Bowman Birk inhibitor concentrate; BBIC	Phase II		proteinase inhibitor	benign prostate hypertrophy; cancer
KT 512	Preclinical		proteinase inhibitor	cancer
P 35011	Preclinical		proteinase inhibitor	cancer
urokinase inhibitor, 3 Dimensional Pharmaceuticals	Preclinical		proteinase inhibitor	cancer
urokinase inhibitors, Axys	Preclinical		proteinase inhibitor	cancer
urokinase inhibitors, Corvas	Preclinical		proteinase inhibitor	cancer

PS 341	Phase I	[S-(R*,S*)]-[3-methyl-1-[[1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid	proteinase inhibitor; apoptosis inducer	cancer
cathepsin B inhibitors, Axys AG 3433	Preclinical		proteinase inhibitor; cathepsin B inhibitor	cancer
	Preclinical		proteinase inhibitor; matrix metalloproteinase inhibitor	cancer
CGS 27023A	Phase II	(R)-N-hydroxy-2-[[[4-methoxyphenyl)sulfonyl](3-pyridinylmethyl)amino]-3-methylbutanamide	proteinase inhibitor; matrix metalloproteinase inhibitor	cancer
CH 4815	Preclinical		proteinase inhibitor; matrix metalloproteinase inhibitor	cancer
metalloproteinase inhibitors, Glycomed	Preclinical		proteinase inhibitor; metalloproteinase inhibitor	cancer
cysteine proteinase inhibitor, SynPhar/British Biotech	Preclinical		proteinase inhibitor; NSAID	rheumatoid arthritis; osteoporosis; cancer; osteoarthritis

peldesine; BCX 34; BCX 34B	Phase II	2-amino-1,5-dihydro-7-(3-pyridinylmethyl)-4H-pyrrolo[3,2-d]pyrimidin-4-one	purine nucleoside phosphorylase inhibitor; immunosuppressant; NSAID	cancer; psoriasis; rheumatoid arthritis; transplant rejection; eye disease; dermatitis; HIV infection
CH 799	Discontinued		purine nucleoside phosphorylase inhibitor; NSAID	rheumatoid arthritis; inflammatory bowel disease; cancer
CI 1000; PD 141955	Phase I	2-amino-1,5-dihydro-7-(3-thienylmethyl)-4H-pyrrolo[3,2-d]pyrimidin-4-one	purine nucleoside phosphorylase inhibitor; NSAID	cancer; psoriasis; rheumatoid arthritis
purine nucleoside phosphorylase inhibitors, Chiroscience; PNP inhibitors, Chiroscience	Discontinued		purine nucleoside phosphorylase inhibitor; NSAID	cancer; psoriasis; rheumatoid arthritis; transplant rejection
Helicobacter pylori therapy, RPMS Technology	Discontinued		quinoline; antibiotic	gastrointestinal ulcer; bacterial infection; cancer
A 84441	Preclinical	6-[3-[(2-amino-1-oxopentyl)amino]-1-pyrrolidinyl]-5-fluoro-3-oxo-3H-pyrido[3,2,1-k]phenoxazine-2-carboxylic acid	quinolone; antibiotic	cancer

KB 5246	Discontinued	6-fluoro-5-(4-methyl-1-piperazinyl)-8-oxo-3H,8H-4-oxa-1-thia-9b-azacyclopenta[cd]phenalene-9-carboxylic acid monohydrochloride	quinolone; antibiotic	cancer; pruritis; hypertension; HIV infection; gastrointestinal ulcer; hyperlipidemia; bacterial infection
quinaldopeptin; BMY 28662; BU 3845T	Discontinued		quinomycin; antibiotic	bacterial infection; cancer
WR 168643; NSC 333839	Preclinical	4,4'-trithiobis-1-butanedisulfonic acid, disodium salt	radioprotectant	cancer
anticancer radiosensitizers, Telik	Preclinical		radiosensitizer	cancer
AQ4N radiation enhancer; AQ4N	Preclinical	1,4-bis[[2-(dimethylamino)ethyl]amino]-5,8-dihydroxy-9,10-anthracenedione	radiosensitizer	cancer
broxuridine; BuDR; BROXINE; NEOMARK	Pre-registration		radiosensitizer	cancer; diagnosis
CT 2412	Preclinical		radiosensitizer	cancer
cuprinol; RL 5077; CUPRINYL	Discontinued	(2,2'-bipyridine-5,5'-diyl)bis[propanedioic acid (2-)-O,O'-copper	radiosensitizer	cancer
etanidazole; SR 2508; NSC 301467; RADINYL	Phase III	N-(2-hydroxyethyl)-2-nitro-1H-imidazole-1-acetamide	radiosensitizer	cancer
KIN 804	Preclinical	N-methoxy-2-nitro-1H-imidazole-1-acetamide	radiosensitizer	cancer

KIN 831	Preclinical	N-hydroxy-2-nitro-1H-imidazole-1-propanamide	radiosensitizer	cancer
KU 2285	Preclinical	alpha,alpha-difluoro-N-(2-hydroxyethyl)-2-nitro-1H-imidazole-1-propanamide	radiosensitizer	cancer
metoclopramide; AHR 3070 C; DEL 1267; SENSAMIDE; NEU-SENSAMIDE; AEROFLAT; ANANDA; ANASIN; ANTIMET; BENAGASTRON; PRIMPERAN; DIGENOR; REGLAN	Marketed	4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide	radiosensitizer	emesis; cancer
MPI 5020	Phase II		radiosensitizer	cancer
mimorazole	Discontinued	4-[2-(5-nitroimidazol-1-yl)-ethyl]morpholine	radiosensitizer	cancer
PD 130908	Preclinical	N-(2-bromoethyl)-2-nitro-1H-imidazole-1-propanamine monohydrobromide	radiosensitizer	cancer
radiosensitizer, NCI	Preclinical		radiosensitizer	cancer
RK 28	Discontinued	4-[(2-nitro-1H-imidazol-1-yl)methoxy]-2-buten-1-ol	radiosensitizer	cancer

RP 170	Preclinical	2-[2-nitro-1H-imidazol-1-yl)methoxy]-1,3-propanediol	radiosensitizer	cancer
RSU 1164	Discontinued	cis-alpha-[(2,3-dimethyl-1-aziridinyl)methyl]-2-nitro-1H-imidazole-1-ethanol	radiosensitizer	cancer
RSU 1165	Discontinued	trans-alpha-[(2,3-dimethyl-1-aziridinyl)methyl]-2-nitro-1H-imidazole-1-ethanol	radiosensitizer	cancer
SN 24699	Preclinical	N-[2-(2-methyl-5-nitro-1H-imidazolyl)ethyl]-4-(2-nitro-1H-imidazolyl)butanamide	radiosensitizer	cancer
SPI 40	Preclinical		radiosensitizer	cancer
SR 2545	Discontinued	N-[2-(acetyloxyethyl)-2-nitro-1H-imidazole-1-acetamide	radiosensitizer	cancer
SR 2555; NSC 314-055	Discontinued	N,N-bis(2-hydroxyethyl)-2-nitro-1H-imidazole-1-acetamide	radiosensitizer	cancer
tirapazamine; WIN 59075; SR 4233; TIRAZONE	Phase III	3-amino-1,2,4-benzotriazine-1,4-dioxide	radiosensitizer	cancer

SD-144110.1

gadolinium texaphyrin; Gd Tex; PCI 0120; Gd-TeX; XCYTRIN	Phase III	(PB-7-11-233'2'4)- bis(acetato-O)[9,10- diethyl-20,21-bis[2- [2-(2- methoxyethoxy)ethox y]ethoxy]-4,15- dimethyl-8,11-imino- 3,6:16,13-dinitrilo- 1,18- benzodiazacycloicos ine-5,14- dipropanolato- N1,N18,N23,N24,N2 5]-gadolinium	radiosensitizer; chemosensitizer	cancer
ioberguane; ioberguane sulfate I123; MIBG; MIBG-I 123	Marketed	[[3-(iodo- 131I)phenyl]methyl]g uanidine	radiosensitizer; contrast medium; radiodiagnostic; radiotherapeutic	cancer; diagnosis
PK 110	Preclinical	N-[(4- fluorophenyl)methyl]- 2-nitro-1H-imidazole- 1-acetamide	radiosensitizer; imidazole	cancer
PK 130	Preclinical	N-[(2-nitro-1H- imidazol-1-yl)acetyl]- L-phenylalanine, methyl ester	radiosensitizer; imidazole	cancer
RB 6145; PD 144872; PD 144871; PD 130571; CI 1010	Phase I	alpha-[[[(2- bromoethyl)amino]m ethyl]-2-nitro-1H- imidazole-1- ethanolmonohydrobro mide	radiosensitizer; imidazole	cancer

nitric oxide-releasing radiosensitizer, National Institutes of Health	Preclinical			radiosensitizer; nitric oxide donor	cancer
cytochlor	Preclinical	5-chloro-2'-deoxycytidine		radiosensitizer; nucleoside analogue	cancer
doranidazole; RP 343; PR 350	Phase I	(R*,S*)-3-[(2-nitro-1H-imidazol-1-yl)methoxy]-1,2,4-butanetriol		radiosensitizer; nucleoside analogue; antimetabolite	cancer
117m Sn DTPA; pentetate 117m Sn	Phase II			radiotherapeutic; analgesic	cancer; pain
rhodium Re 186 etidronate; 186-Re HEDP; 186-Re HEDP; BETAMET	Pre-registration			radiotherapeutic; analgesic	pain; cancer
strontium-89 chloride; METASTRON	Marketed	strontium chloride (89SrCl2)		radiotherapeutic; analgesic	pain; cancer
ALRT 1455	Preclinical			RAR agonist; retinoid agonist	cancer
AGN 192792; LG 100382	Preclinical			RAR agonist; RXR agonist; retinoid; retinoid agonist	cancer
CP 609754	Preclinical			RAS inhibitor	cancer
ras inhibitors, Agouron	Suspended			RAS inhibitor	cancer
Ras inhibitors, Bristol-Myers Squibb	Preclinical			RAS inhibitor	cancer
ras farnesyl transferase inhibitor, Xenova; XR 3005 series	Discontinued			RAS inhibitor; farnesyl protein transferase inhibitor	cancer

ras FT inhibitor, Genentech	Discontinued			RAS inhibitor; farnesyl protein transferase inhibitor	cancer
ras inhibitors, Onyx/Bayer	Preclinical			RAS inhibitor; signal transduction inhibitor	cancer
cancer therapy, retinoids, Cornell Research Foundation	Preclinical			retinoid	cancer; psoriasis
drug delivery system, liposome tretinoin; tretinoin liposome; AR 623; ATRAGEN	Pre- registration			retinoid	cancer
NIK 333	Preclinical			retinoid	cancer
polyprenoic acid; E 5166	Discontinued	(all-E)-3,7,11,15- tetramethyl- 2,4,6,10,14- hexadecapentaenoic acid		retinoid	cancer
RJI retinamide	Marketed			retinoid	cancer
tazarotene; AGN 190168; ZORAC; TAZORAC	Marketed	6-[(3,4-dihydro-4,4- dimethyl-2H-1- benzothiopyran-6- yl)ethynyl]-3-pyrid inecarboxylic acid ethyl ester		retinoid	acne; cancer; psoriasis
tretinoin; Ro 015488/115; NSC 122758; VESANOID	Marketed	(all-E)-3,7-dimethyl- 9-(2,6,6-trimethyl-1- cyclohexen-1-yl)- 2,4,6,8- nonatetraenoic acid		retinoid	acne; cancer

AM 580	Discontinued	4-[[[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbonyl]amino]benzoic acid	retinoid agonist	psoriasis; cancer
MX 33511; MX33511; MX 33501	Preclinical	6-(7-tricyclo[3.3.1.1 ^{3,7}]dec-1-yl-1,3-benzodioxol-5-yl)-2-naphthalenecarboxylic acid	retinoid agonist	cancer
tamibarotene; AM 80	Discontinued	4-[[[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)amino]carbonyl]benzoic acid	retinoid agonist	psoriasis; cancer
LGD 1550; ALRT 1550; LG 100550; AGN 193101; LG 1550; ALRT 550	Phase II	(all-E)-7-[3,5-bis(1,1-dimethylethyl)phenyl]-3-methyl-2,4,6-octatrienoic acid	retinoid agonist; RAR agonist	cancer; skin disease
AGN 190521; LG 030106	Preclinical	5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenecarboxylic acid 4-carboxyphenyl ester	retinoid agonist; RAR agonist; retinoid	cancer; skin disease
ER 38925	Preclinical	4-[5-(4,7-dimethyl-2-benzofuranyl)-1H-pyrrol-2-yl]benzoic acid	retinoid agonist; RARalpha agonist	cancer; psoriasis

ER 65250	Preclinical	4-[5-(7-ethyl-4-methyl-2-benzofuranyl)-1H-pyrrol-2-yl]benzoic acid	retinoid agonist; RARalpha agonist	cancer; psoriasis
ER 69029	Preclinical	4-[5-[7-fluoro-4-(trifluoromethyl)-2-benzofuranyl]-1H-pyrrol-2-yl]benzoic acid	retinoid agonist; RARalpha agonist	cancer; psoriasis
AGN 190121; LG 030042	Preclinical	(E)-4-[4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-buten-1-ynyl]benzoic acid	retinoid agonist; RARbeta agonist; RARgamma agonist; retinoid	cancer; viral infection
AGN 191379; LG 030053	Preclinical	4-[(3,4-dihydro-2,2,4,4-tetramethyl-2H-1-benzopyran-6-yl)ethynyl]benzoic acid	retinoid agonist; RARbeta agonist; RARgamma agonist; retinoid	cancer; skin disease
bexarotene; LGD 1069; LG 100069; LG 1069; LDG 1069; TARGRETIN	Phase III	4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthenyl)-1-ethenyl]-benzoic acid	retinoid agonist; retinoid; differentiation inducer; RXR agonist	cancer; diabetes; psoriasis; skin disease
LGD 1324; ALRT 324	Preclinical		retinoid agonist; RXR agonist	diabetes; cancer
AGN 4310; ALRT 4310	Preclinical		retinoid antagonist	psoriasis; cancer
TAC 101; AM 555s	Phase I	4-[[3,5-bis(trimethylsilyl)benzoyl]amino]benzoic acid	retinoid antagonist	cancer

fenretinide; HPR, 4; 4HPR; RAHA; McN R1967	Phase III	N-(4- hydroxyphenyl)retina mide	retinoid; NSAID	rheumatoid arthritis; cancer
apurinic acid	Preclinical		reverse transcriptase inhibitor	HIV infection; cancer
P 30 protein; P 30; ONCONASE	Phase III	ribonuclease (Rana pipiens reduced)	ribonuclease	cancer
LY 309887	Phase I	(R)-N-[[5-[2-(2- amino-1,4,5,6,7,8- hexahydro-4- oxopyrido[2,3- d]pyrimidin-6- yl)ethyl]-2- thienyl]carbonyl]-L- glutamic acid	ribonucleotide formyltransferase inhibitor; antifolate; antimetabolite	cancer
amidox; VF 236	Preclinical	N,3,4- trihydroxybenzenecar boximidamide	ribonucleotide reductase inhibitor	cancer
didox; VF 147; NSC 324360	Phase II	N,3,4- trihydroxybenzamide	ribonucleotide reductase inhibitor	cancer; HIV infection
OCX 189; OCX 0189	Discontinued		ribonucleotide reductase inhibitor	cancer
OCX 191; OCX 0191; 3AP; TRIAPINE	Phase I	2-[(3-amino-4- methyl-2- pyridinyl)methylene] hydrazinecarbothioam ide	ribonucleotide reductase inhibitor	cancer
OCX 191 prodrugs, Vion	Preclinical		ribonucleotide reductase inhibitor	cancer
trimidox	Preclinical		ribonucleotide reductase inhibitor	HIV infection; cancer

FMdC; MDL 101731; Phase II KW 2331		(E)-2'- fluoromethylene-2'- deoxycytidine (FMdc)	ribonucleotide reductase inhibitor; nucleoside analogue	cancer
parabactin	Preclinical		ribonucleotide reductase inhibitor; polyamine analogue	cancer
LGD 1268; ALRT 268	Preclinical		RXR agonist; retinoid agonist	diabetes; cancer
ALRT 620; AGN 192620; LG 100268	Preclinical	6-[1-(5,6,7,8- tetrahydro-3,5,8,8- pentamethyl-2- naphthalenyl)cyclopr opyl]-3- pyridinecarboxylic acid	RXR agonist; retinoid; retinoid agonist	cancer
CGP 35753	Discontinued	2-[[3- (aminoiminomethyl)p henyl]methylene]-N- hydroxyhydrazinecar boximidamide	S adenosylmethionine decarboxylase inhibitor	cancer
CGP 39937	Discontinued	[2,2'-bipyridine]-6,6'- dicarboximidamide	S adenosylmethionine decarboxylase inhibitor	cancer
sardomozide; CGP 48664; SAM 486	Phase II	2-[4- (aminoiminomethyl)- 2,3-dihydro-1H- inden-1- ylidene]hydrazinecarb oximidamide	S adenosylmethionine decarboxylase inhibitor	cancer
cancer therapy, Cortecs	Preclinical		signal transduction inhibitor	cancer

GW 7072	Preclinical		signal transduction inhibitor	cancer
signal transduction inhibitor, National Academy of Science	Preclinical		signal transduction inhibitor	cancer
signal transduction inhibitors, NCI	Preclinical		signal transduction inhibitor	cancer
signal transduction inhibitor, SUGEN/ArQule	Preclinical		signal transduction inhibitor; immunosuppressant	cancer; diabetes; neurological; autoimmune disease
BIBX 1382	Phase II		signal transduction inhibitor; tyrosine kinase inhibitor; EGF receptor inhibitor	cancer
lanreotide; BIM 23014; DC 13116; BIM 23014C; BN 52030; SOMATULINE; ANGIOPEPTIN; DERMOPEPTIN; IPSTYL	Marketed	3-(2-naphthalenyl)-D-alanyl-L-cysteiny-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteiny-L-threoninamide cyclic (2,7)-disulfide	somatostatin analogue	cancer; acromegaly; retinopathy; diabetes; psoriasis; restenosis
TT 232; TT 2-32	Preclinical	D-phenylalanyl-L-cysteiny-L-tyrosyl-D-tryptophyl-L-lysyl-L-cysteiny-L-threoninamide cyclic (2->6)-disulfide	somatostatin analogue	cancer

TT 250; TT 2-50	Preclinical	D-Phenylalanyl-L-cysteiny-L-tyrosyl-L-tryptophyl-L-lysyl-L-leucyl-L-cysteiny-L-threoninamide cyclic (2->7)-disulfide	somatostatin analogue	cancer
octreotide; octreotide acetate; SMS; SMS 201995; SMS 201995ac; SMS 995; SANDOSTATIN; SANDOSTATINE; SANDOSTATINA; LONGASTATINA; SAMILSTATINA	Marketed	[R-(R*,R*)]-D-phenylalanyl-L-cysteiny-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide cyclic (2-7)-disulfide	somatostatin analogue; analgesic	Alzheimer disease; cancer; viral infection; psoriasis; diarrhea; diabetes; pain; acromegaly
vapreotide; octastatin; RC 160; BMY 41606	Phase II	D-Phe-Cys-Trp-D-Trp-Lys-Val-Cys-Trp-NH2	somatostatin analogue; analgesic	cancer; pain
stem cell inhibitor	Preclinical		stem cell division inhibitor; hematopoiesis inhibitor; hematoprotectant; chemoprotectant	cancer
BAY 129566	Phase III	(S)-4'-chloro-gamma-oxo-alpha-[(phenylthio)methyl][1,1'-biphenyl]-4-butanoic acid	stromelysin inhibitor; proteinase inhibitor; matrix metalloproteinase inhibitor; NSAID	osteoarthritis; cancer

stromelysin inhibitors, Agouron	Preclinical		stromelysin inhibitor; proteinase inhibitor; matrix metalloproteinase inhibitor; NSAID	cancer; arthritis
antagonist G; PTL 68300B	Phase I	Arg-DTrp-NMePhe-DTrp-Leu-Met-NH2	substance P antagonist; peptide; growth factor modulator	cancer
DW 2282	Preclinical		sulfonylurea; antineoplasmon	cancer
LaneBase	Preclinical		target based screening	drug design technology; cancer
screening technology, cancer, Cellomics	Preclinical		target based screening	drug design technology; cancer
screening technology, granulocyte colony-stimulating factor mimetic	Discontinued		target based screening	drug design technology; cancer
screening technology, human papillomavirus therapy, Harvard Medical School	Preclinical		target based screening	drug design technology; viral infection; cancer
screening technology, NuMA	Preclinical		target based screening	drug design technology; cancer
screening technology, thrombopoietin mimetic	Discontinued		target based screening	drug design technology; cancer; thrombocytopenia
screening technology, cox-2 gene suppression	Preclinical		target based screening; biotechnology	drug design technology; inflammation; cancer

screening technology, MDR inhibitors	Preclinical		target based screening; MDR inhibitor	drug design technology; cancer
baccatin III derivatives, Indena	Preclinical	[2aR- (2aalpha,4beta,4abeta, 6beta,9alpha,10beta,1 1alpha,12alpha,12aal pha,12balpha)]-12b- (acetyloxy)-12- (benzoyloxy)- 1,2a,3,4,4a,6,9,10,11, 12,12a,12b- dodecahydro- 4,6,9,10,11- pentahydroxy- 4a,8,13,13- tetramethyl-7,11- methano-5H- cyclodeca[3,4]benz[1, 2-b]oxet-5-one	taxane	cancer
BMS 184476	Phase I		taxane	cancer

BP 179	Preclinical	[2aR- [2aalpha,4beta,4beta, 6beta,9alpha(alphaR*, betaS*),11alpha,12al pha,12aalpha,12balph a]]-[partial]-beta- (benzoylamino)- alpha- hydroxybenzenepropa noic acid, 6,12b- bis(acetyloxy)-12- (benzoyloxy)-4- [[[(2,3- dihydroxypropoxy)ca rbonyl]oxy]- 2a,3,4,4a,5,6,9,10,11, 12,12a,12b- dodecahydro-11- hydroxy-4a,8,13,13- tetramethyl-5-oxo- 7,11-methano-1H- cyclodeca[3,4]benz[1, 2-b]oxet-9-yl ester	taxane	cancer
--------	-------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------	--------

dihydrotaxol, 9-; 9- dihydrotaxol; TAXAN	Preclinical	[2aR- [2aalpha,4beta,4alpha, 5alpha,6beta,9alpha(a lphaR*,betaS*),11alp ha,12alpha,12aalpha, 12balpha]]-beta- benzoylamino)-alpha- hydroxy- benzenepropanoic acid, 6,12b- bis(acetyloxy)-12- (benzoyloxy)-12- 2a,3,4,4a,5,6,9,10,11, 12,12a,12b- dodecahydro-4,5,11- trihydroxy- 4a,8,13,13- tetramethyl-7,11- methano-1H- cyclodeca[3,4]benz[1, 2-b]oxet-9-yl ester	taxane	cancer
drug delivery system, LDS microemulsion paclitaxel; paclitaxel LDS microemulsion	Preclinical		taxane	cancer
drug delivery system, liposome paclitaxel; paclitaxel liposome	Phase I		taxane	cancer
IDN 5109; SB	Preclinical		taxane	cancer
T101131	Preclinical		taxane	cancer
paclitaxel analogues, Virginia Tech	Preclinical		taxane	cancer
RPR 109881	Phase I		taxane	cancer

TAXOPREXIN	Phase II		taxane	cancer
TDX 258	Phase I		taxane	cancer
bromotaxol	Preclinical		taxane; microtubule assembly promoter	cancer
docetaxel; RP 56976; NSC 628503; TAXOTERE	Marketed	beta-[[[(1,1-dimethylethoxy)carbonyl]amino]-alpha-hydroxybenzenepropanoic acid [2aR-[2alpha,4beta,6beta,9alpha(alphaR*,betaS*)-11alpha,12alpha,12alpha,12beta]]-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester	taxane; microtubule assembly promoter	cancer; malaria
drug delivery system, biodegradable polymer paste paclitaxel; paclitaxel biodegradable polymer paste	Preclinical		taxane; microtubule assembly promoter	cancer

drug delivery system, CYTOPORTER paclitaxel	Preclinical		taxane; microtubule assembly promoter	cancer
drug delivery system, intralesional paclitaxel; paclitaxel anhydrous delivery vehicle; ADV paclitaxel; MPI 5018	Preclinical		taxane; microtubule assembly promoter	cancer
drug delivery system, liposome paclitaxel; paclitaxel liposome	Discontinued		taxane; microtubule assembly promoter	cancer
drug delivery system, liposome paclitaxel; paclitaxel liposome	Preclinical		taxane; microtubule assembly promoter	cancer
drug delivery system, ONCHOLAB paclitaxel; paclitaxel ONCHOLAB	Discontinued		taxane; microtubule assembly promoter	cancer
drug delivery system, polyglutamic acid paclitaxel; paclitaxel polyglutamic acid; PG-TXL	Preclinical		taxane; microtubule assembly promoter	cancer
drug delivery system, polymer-bound paclitaxel; paclitaxel polymer-bound; PNU 166945	Phase I		taxane; microtubule assembly promoter	cancer
drug delivery system, polymeric micelle paclitaxel; paclitaxel polymeric micelle	Preclinical		taxane; microtubule assembly promoter	cancer

drug delivery system, PROCYTE microsphere paclitaxel; paclitaxel PROCYTE	Preclinical		taxane; microtubule assembly promoter	cancer
drug delivery system, ReGel paclitaxel; GENEXOL	Preclinical		taxane; microtubule assembly promoter	cancer
drug delivery system, vascular stent paclitaxel; paclitaxel vascular stent	Preclinical		taxane; microtubule assembly promoter	restenosis; cancer
paclitaxel; NSC 125973; BMS 181339; TAXOL; ANZATAX; YEW TAXAN	Marketed	[2aR[2aalpha,4beta,4 abeta,6beta,9alpha(al phaR*,betaS*),11beta ,12alpha,12aalpha,12 balpha]]-beta- (benzoylamino)- alpha- hydroxybenzenepropan oic acid 6,12b- bis(acetyloxy)-12- (benzoyloxy)- 2a,3,4,4a,5,6,9,10,11, 12,12a,12b- dodecahydro-4,11- dihydroxy- 4a,8,13,13- tetramethyl-5-oxo- 7,11-methano-1H- cyclodeca[3,4]benz[1, 2-b]oxet-9-yl ester	taxane; microtubule assembly promoter	cancer

paclitaxel analogue, Reading University	Preclinical		taxane; microtubule assembly promoter	cancer
paclitaxel derivatives, EnzyMed	Preclinical		taxane; microtubule assembly promoter	cancer
polyethylene glycol paclitaxel; PEG- paclitaxel; paclitaxel macrogol	Preclinical		taxane; microtubule assembly promoter	cancer
ZYN-LINKER conjugated paclitaxel	Suspended		taxane; microtubule assembly promoter	restenosis; cancer
drug delivery system, anticancer agents	Preclinical		taxane; microtubule assembly promoter; DNA topoisomerase inhibitor	cancer
telomerase inhibitor, Telik	Preclinical		telomerase inhibitor	cancer
telomerase inhibitors, Geron	Preclinical		telomerase inhibitor	cancer
telomerase inhibitors, University of Texas	Preclinical		telomerase inhibitor	cancer
telomerase inhibitors, Whitehead Institute for Biomedical Research	Preclinical		telomerase inhibitor	cancer
cancer therapy, Viscount Pharma	Preclinical		telomerase inhibitor; nucleoside analogue	cancer
acylfulvene, MGI Pharma/Dainippon	Phase I		terpene	cancer
betulinic acid; betulic acid	Preclinical	(3.beta.)-3-hydroxy- lup-20(29)-en-28-oic acid	terpene	cancer
caulerpenyne	Suspended		terpene	cancer

monoterpenes, Endorex	Preclinical		terpene	cancer
TGF beta antagonists, GLYCODesign; transforming growth factor beta antagonists	Preclinical		TGF beta antagonist; cicatrizant	cancer; viral infection; inflammation; skin ulcer
thrombospondin inhibitor, Allelix	Discontinued		thrombospondin inhibitor; peptide; NSAID	inflammation; cancer; sickle cell anemia
CV 6504	Preclinical	2,3,5-trimethyl-6-(3- pyridinylmethyl)-2,5- cyclohexadiene-1,4- dione	thromboxane antagonist; 5- lipoxigenase inhibitor	cancer
ICI D8322; ZD 8322	Discontinued		thymidylate synthase inhibitor	cancer
raltitrexid; paltitrexid; ZD 1694; ICI D1694; TOMUDEX	Marketed	N-[[5-[(1,4-dihydro- 2-methyl-4-oxo-6- quinazolinyl)methyl] methylamino]-2- thienyl]carbonyl]-L- glutamic acid	thymidylate synthase inhibitor; antifolate; antimetabolite	cancer
AG 250	Discontinued		thymidylate synthase inhibitor; antimetabolite	cancer
AG 341	Discontinued		thymidylate synthase inhibitor; antimetabolite	cancer
AG 394	Discontinued		thymidylate synthase inhibitor; antimetabolite	cancer

BW 1843U89	Suspended	(S)-2-(5-(((1,2-Dihydro-3-methyl-1-oxobenzof[quinazolin-9-yl)methyl]amino)-1-oxo-2-isoindolinyl)glutaric Acid	thymidylate synthase inhibitor; antimetabolite	cancer
FTC 092	Discontinued	alpha, alpha, alpha-trifluoro-3'-O-(phenylmethyl)thymidine	thymidylate synthase inhibitor; antimetabolite	cancer
metesind; AG 331	Suspended	4-[[4-[(2-aminobenz[cd]indol-6-yl)methylamino]methyl]phenyl]sulfonyl]morpholine	thymidylate synthase inhibitor; antimetabolite	cancer
molatrexed; molatrexed dihydrochloride; AG 337; THYMITAQ	Discontinued	2-amino-6-methyl-5-(4-pyridinylthio)-4(1H)-quinazolinone	thymidylate synthase inhibitor; antimetabolite	cancer
pemetrexed; pemetrexed disodium; LY 231514; MTA	Phase III	N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid	thymidylate synthase inhibitor; antimetabolite	cancer

ZD 9331	Phase II	(2S)-[4-[N-(2,7-dimethyl-4-oxo-3,4-dihydroquinazolin-6-ylmethyl)-N-(2-propynyl)amino]-2-fluorobenzamido]-4-(1H-tetrazol-5-yl)butyric acid	thymidylate synthase inhibitor; antimetabolite	cancer
titanocene dichloride	Phase II	CpTiCl ₂	titanium complex	cancer
budotitane	Discontinued	diethoxybis(1-phenyl-1,3-butanedionato-O,O')-titanium	titanium complex; alkylating agent	cancer
CC 1080	Preclinical		TNF inhibitor; NSAID	arthritis; cancer; multiple sclerosis
thalidomide; BMS 205935	Phase II	N-(2,6-dioxo-3-piperidyl)phthalimide	TNF modulator; angiogenesis inhibitor	retinopathy; cancer
thalidomide; SYNOVIR; THALOMID	Marketed	N-(2,6-dioxo-3-piperidyl)phthalimide	TNF modulator; immunosuppressant	cachexia; diarrhea; leprosy; rheumatoid arthritis; transplant rejection; cancer; Crohn disease
CC 1069	Preclinical	beta-(3,4-dimethoxyphenyl)-1,3-dihydro-1,3-dioxo-2H-isindole-2-propanamide	TNF modulator; NSAID	cachexia; arthritis; cancer
FRK inhibitor, Signal; fos regulating kinase inhibitor, Signal	Discontinued		transcription factor regulator; MAP kinase inhibitor	cancer; hypothyroidism; Paget disease; periodontal disease
NF-kappaB inhibitor, Signal	Preclinical		transcription factor regulator; NSAID	inflammation; ischemia; cancer; autoimmune disease

AP-1 inhibitor, Signal; JNK inhibitor, Signal	Preclinical			transcription factor regulator; NSAID; immunosuppressant	inflammation; autoimmune disease; cancer
SC 104	Discontinued			triglyceride	cancer
halichondrin B	Preclinical	halichondrin B		tubulin polymerase inhibitor	cancer
NSC 654261	Preclinical			tubulin polymerase inhibitor	cancer
spongistatin 1 analogues, Hughes Institute	Preclinical			tubulin polymerase inhibitor	cancer
combretastatin analogue	Preclinical	3,4,5-trimethoxy-N- (4- methylphenyl)benzen emethanamine		tubulin polymerase inhibitor; microtubule assembly inhibitor	cancer
DDE 261	Preclinical			tubulin polymerase inhibitor; microtubule assembly inhibitor	cancer
dolastatin 10; NSC 376128	Phase I	N,N-dimethyl-L- valyl-N-[(1S,2R)-2- methoxy-4-[(2S)-2- [(1R,2R)-1-methoxy- 2-methyl-3-oxo-3- [[[(1S)-2-phenyl-1-(2- thiazolyl)ethyl]amino]propyl]-1- pyrrolidinyl]-1-[(1S)- 1-methylpropyl]-4- oxobutyl]-N-methyl- L-valinamide		tubulin polymerase inhibitor; peptide	cancer

ALL-TK antagonists; acute lymphoblastic leukemia tyrosine kinase antagonists	Suspended		tyrosine kinase inhibitor	cancer
angelmicin B	Discontinued		tyrosine kinase inhibitor	cancer
BCR/ABL antagonists	Discontinued		tyrosine kinase inhibitor	cancer
CEP 2563; KT 8391	Phase I		tyrosine kinase inhibitor	cancer
CEP 701; KR 5555	Phase I		tyrosine kinase inhibitor	cancer
CEP 751; KT 6587	Suspended		tyrosine kinase inhibitor	cancer
CGP 52411	Discontinued	5,6- bis(phenylamino)-1H- isoindole-1,3(2H)- dione	tyrosine kinase inhibitor	cancer
CGP 53353	Discontinued	5,6-bis[(4- fluorophenyl)amino]- 1H-isoindole- 1,3(2H)-dione	tyrosine kinase inhibitor	cancer
CGP 57148; CGP 57148B	Phase I	4-[(4-methyl-1- piperazinyl)methyl]- N-[4-methyl-3-[[4-(3- pyridinyl)-2- pyrimidinyl]amino]ph enyl]-benzamide	tyrosine kinase inhibitor	cancer
FGF-1 receptor inhibitors, Parke Davis/Auckland University	Preclinical		tyrosine kinase inhibitor	cancer

GW 282974; GW 974	Preclinical	N6,N6-dimethyl-N4-[1-(phenylmethyl)-1H-indazol-5-yl]pyrido[3,4-d]pyrimidine-4,6-diamine monohydrochloride	tyrosine kinase inhibitor	cancer
LFM A13	Preclinical		tyrosine kinase inhibitor	cancer
Met tyrosine kinase antagonist	Preclinical		tyrosine kinase inhibitor	cancer
PD 157655	Preclinical		tyrosine kinase inhibitor	cancer
PD 158294	Preclinical		tyrosine kinase inhibitor	cancer
PD 158780	Preclinical	N4-(3-bromophenyl)-N6-methylpyrido[3,4-d]pyrimidine-4,6-diamine	tyrosine kinase inhibitor	cancer
PD 164199	Preclinical	6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7(8H)-one	tyrosine kinase inhibitor	cancer; atherosclerosis; restenosis
PD 164771	Preclinical	6-(2,6-dichlorophenyl)-8-methyl-2-(4-pyridinylamino)pyrido[2,3-d]pyrimidin-7(8H)-one	tyrosine kinase inhibitor	cancer; atherosclerosis; restenosis

PD 166285	Preclinical	6-(2,6-dichlorophenyl)-2-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one	tyrosine kinase inhibitor	cancer; atherosclerosis; restenosis
PD 167978	Preclinical		tyrosine kinase inhibitor	cancer
PD 173956	Preclinical		tyrosine kinase inhibitor	cancer
SU 101	Phase III	5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide	tyrosine kinase inhibitor	cancer
SU 101 analogues	Preclinical		tyrosine kinase inhibitor	cancer
SU 102	Preclinical		tyrosine kinase inhibitor	cancer
SU 65847	Preclinical		tyrosine kinase inhibitor	cancer
tyrosine kinase inhibitors, Cephalon	Discontinued		tyrosine kinase inhibitor	benign prostate hypertrophy; cancer
tyrosine kinase inhibitors, Novartis	Preclinical		tyrosine kinase inhibitor	cancer
tyrosine kinase inhibitors, Xenova	Discontinued		tyrosine kinase inhibitor	cancer
ZD 4190	Preclinical		tyrosine kinase inhibitor	cancer

SU 1433	Discontinued	4-(6,7-dimethyl-2-quinoxaliny)-1,2-benzenediol	tyrosine kinase inhibitor; angiogenesis inhibitor; signal transduction inhibitor	cancer; retinopathy
SU 1498	Discontinued	(E)-2-cyano-3-[4-hydroxy-3,5-bis(1-methylethyl)phenyl]-N-(3-phenylpropyl)-2-propenamide	tyrosine kinase inhibitor; angiogenesis inhibitor; signal transduction inhibitor	cancer; retinopathy
CGP 59326A	Phase I	N-(3-chlorophenyl)-5,6-dimethyl-1H-pyrrolo[2,3-d]pyrimidin-4-amine monohydrochloride	tyrosine kinase inhibitor; EGF receptor inhibitor	cancer
CP 358774	Phase II	N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine	tyrosine kinase inhibitor; EGF receptor inhibitor	cancer
PD 153035	Preclinical	N-(3-bromophenyl)-6,7-dimethoxy-4-quinazolinamine	tyrosine kinase inhibitor; EGF receptor inhibitor	cancer
PD 183805; CI 1033	Preclinical		tyrosine kinase inhibitor; EGF receptor inhibitor	cancer
ZD 1839	Phase I		tyrosine kinase inhibitor; EGF receptor inhibitor	cancer
tyrosine kinase inhibitors, AstraZeneca	Discontinued		tyrosine kinase inhibitor; signal transduction inhibitor	cancer
WHI P131	Preclinical		tyrosine kinase inhibitor; signal transduction inhibitor	cancer

WHI P154	Preclinical		tyrosine kinase inhibitor; signal transduction inhibitor	cancer
DAB 720	Preclinical		tyrosine kinase inhibitor; signal transduction inhibitor; EGF receptor inhibitor	cancer
PD 169540	Preclinical		tyrosine kinase inhibitor; signal transduction inhibitor; EGF receptor inhibitor	cancer
BMLOV	Discontinued	bis(maltolato) oxovanadium	tyrosine phosphatase inhibitor	cancer
cancer-associated protein tyrosine phosphatase inhibitor, Ontogen	Discontinued		tyrosine phosphatase inhibitor	cancer
AG 213; RG 50964; tyrphostin AG 213; RG 50864 (no stereo)	Phase I	(E)-2-cyano-3-(3,4-dihydroxyphenyl)-2-propenethioamide	tyrphostin	psoriasis; cancer; atherosclerosis
AG 555	Preclinical	(2E)-2-cyano-3-(3,4-dihydroxyphenyl)-N-(3-phenylpropyl)-2-propenamide	tyrphostin	psoriasis; cancer; atherosclerosis
tyrphostins	Preclinical		tyrphostin	psoriasis; cancer; atherosclerosis; septic shock
AG 490	Discontinued	(E)-2-Cyano-3-(3,4-dihydroxyphenyl)-N-(phenylmethyl)-2-propenamide	tyrphostin; tyrosine kinase inhibitor	cancer

UBC inhibitors, Mitotix; ubiquitin conjugating enzyme inhibitors	Preclinical		ubiquitin conjugating enzyme inhibitor; NSAID	cancer; inflammation
urate oxidase; SR 29142	Phase III		urate oxidase; biotechnology; enzyme	gout; cancer
eptaloprost; eptaprost; ZK 97959	Discontinued	3aS- [2E,3aalfa,4alfa(3R*, 4R*)5beta,6aalfa]-4- (2-hexahydro-5- hydroxy-4-(3- hydroxy-4-methyl- 1,6-nonadiynyl- 2(1H))- pentalenylidene)ethox y-butanedioic acid	vasodilator; prostanoid	thrombosis; peripheral vascular disease; cancer
SR 49059	Phase II	[2R- [2alfa(S*),3beta]]-1- [[5-chloro-3-(2- chlorophenyl)-1- [(3,4- dimethoxyphenyl)sulf onyl]-2,3-dihydro-3- hydroxy-1H-indol-2- yl]carbonyl]-2- pyrrolidinecarboxami de	vasopressin antagonist; diuretic	gynecological; cancer; hypertension; heart failure; emesis
VRCTC 310	Preclinical	Unspecified	venom	cancer
anhydrovinblastine	Phase I	3',4'-didehydro-4'- deoxyvincal leukoblast ine	vinca alkaloid	cancer

drug delivery system, liposome vincristine; vincristine liposome; VincaXome	Preclinical		vinca alkaloid	cancer
drug delivery system, ONCHOLAB vincristine; vincristine ONCHOLAB	Discontinued		vinca alkaloid	cancer
drug delivery system, STEALTH liposome vincristine; vincristine STEALTH	Preclinical		vinca alkaloid	cancer
drug delivery system, vinblastine; vinblastine Therapeutic Implant; MPI 5017	Discontinued		vinca alkaloid	cancer
drug delivery system, vincristine; vincristine drug delivery system; Onco TCS	Phase II		vinca alkaloid	cancer
vinflunine; F 12158; L 0070	Phase I	4'-deoxy-20',20'-difluoro-C'-norvincal leukoblastine	vinca alkaloid	cancer
vinorelbine; vinorelbine tartrate; PM 259; DC 1; KW 2307; BW 7Y89; KW 3407; NAVELBINE; EUNADES; NABELBIN	Marketed	3',4'-didehydro-4'deoxy-C'-norvincal leukoblastine	vinca alkaloid	cancer

vinxaltine; S 12363	Phase I	[3(S)]-O4-deacetyl-3-de(methoxycarbonyl)-3-[[[1-(diethoxyphosphinyl)-2-methylpropyl]amino]carbonyl]vincalcoloblastine	vinca alkaloid; microtubule assembly inhibitor	cancer
superactive vasoactive intestinal peptide antagonist, NCI	Preclinical		VIP antagonist	cancer
LR 103	Preclinical		vitamin D analogue	cancer
1alpha-hydroxyvitamin D2; 1alpha-D2; one-alpha D2; TSA 870; HECTOROL	Pre-registration		vitamin D2 analogue	osteoporosis; hyperparathyroidism; cancer
CB 1267	Discontinued	[1R-[1alpha(R*),3abeta,4E(1R*,3S*,5Z),7a]penta-4-methylene-5-[[[octahydro-7a-methyl-1-[1-methyl-2-[[[5,5,5-trifluoro-4-hydroxy-4-(trifluoromethyl)-2-pentynyl]oxy]ethyl]-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediol	vitamin D3 analogue	cancer

ILX 237553; ILX 23-7553	Preclinical	1,25(OH) ₂ -16ene-23yne-26,27-hexafluorovitamin D3	vitamin D3 analogue	cancer
seocalcitol; EB 1089	Phase II	1(S),3(R)-dihydroxy-20(R)-(5'-ethyl-5'-hydroxy-hepta-1'(E),3'(E)-dien-1'-yl)-9,10-secopregna-5(Z),7(E),10(19)-triene	vitamin D3 analogue	cancer
solverol; PRI 1901	Phase I	(1R,3S,5Z)-4-methylene-5-[(2E)-[(1R,3aS,7aR)-octahydro-1-[(1R,5E)-7-hydroxy-1,7-dimethyl-5-octeny]]-7a-methyl-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediol	vitamin D3 analogue; differentiation inducer	cancer; psoriasis

Table 25. Current Candidate Therapeutic Interventions for the Treatment of ALS

Product Name	Chemical Name	Action	Indication
EF 7412	N-3-[4-[4-(tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl)butyl]-1-piperazinyl]phenyl]ethanesulfonamide	5HT antagonist; 5HT1A antagonist; glutamate release inhibitor	Neurodegeneration; depression; cancer
AMPA antagonists	Unspecified	AMPA antagonist; glutamate antagonist	Neurodegeneration; eye disease
SPD 502; NS 1209	2-[[[5-[4-[(dimethylamino)sulfonyl]phenyl]-1,2,6,7,8,9-hexahydro-8-methyl-2-oxo-3H-pyrrolo[3,2-h]isoquinolin-3-ylidene]amino]oxy]-4-hydroxybutanoic acid monosodium salt	AMPA antagonist; glutamate antagonist	stroke; neurodegeneration
pirfenidone; MAR 01; AMR 69; DESKAR	5-methyl-1-phenyl-2(1H)-pyridinone	antifibrotic	skin disease; pulmonary fibrosis; neurodegeneration
dehydroascorbic acid	Unspecified	antioxidant	neurodegeneration; neurological
U 101033E	6,7,8,9-tetrahydro-9-[2-(4-morpholinyl)ethyl]-2,4-di-1-pyrrolidinyl-5H-pyrimido[4,5-b]indole dihydrochloride	antioxidant	stroke; neurodegeneration; brain ischemia
MDL 101002	3,4-dihydro-3,3-dimethylisoquinoline 2-oxide	antioxidant; free radical scavenger	stroke; neurodegeneration; septic shock
synthetic catalytic scavenger analogues; SCS analogues	Unspecified	antioxidant; free radical scavenger	stroke; trauma; atherosclerosis; neurodegeneration; asthma
neurodegenerative disease therapy	Unspecified	apoptosis inhibitor	neurodegeneration

neurodegeneration therapy	unspecified	apoptosis inhibitor	neurodegeneration; amyotrophic lateral sclerosis
apoptosis modulators	Unspecified	apoptosis inhibitor; apoptosis inducer	cancer; autoimmune disease; neurodegeneration
apoptosis inhibitors	Unspecified	apoptosis inhibitor; peptide	neurodegeneration
BAY Z 4406	Unspecified	calcium channel blocker	neurodegeneration; Alzheimer disease
cardiotrophin-1 secreting implant	Unspecified	Cardiotrophin-1 agonist	amyotrophic lateral sclerosis; neurodegeneration
caspase inhibitors	Unspecified	caspase inhibitor	neurodegeneration; myocardial infarction; rheumatoid arthritis; septic shock
CPP32 inhibitors, caspase 3 inhibitors,	unspecified	caspase inhibitor; apoptosis inhibitor	neurodegeneration
creb gene transcription modulators, CNS disorders	Unspecified	Creb gene transcription modulation	neurodegeneration; Alzheimer disease
Neurotransmitter transporter modulators	Unspecified	Excitatory amino acids transporter function	neurodegeneration
batyl alcohol; CPR 4001	Unspecified	free radical scavenger; ether lipid	skin disease; neurodegeneration
chimyl alcohol; CPR 4004	Unspecified	free radical scavenger; ether lipid	skin disease; neurodegeneration
free radical scavengers	Unspecified	free radical scavenger; NSAID	neurodegeneration; arthritis; reperfusion injury; psoriasis; stroke
SLH 301	Unspecified	free radical scavenger; NSAID	neurodegeneration; arthritis; reperfusion injury; psoriasis; stroke
growth and differentiation factor-1; GDF-1	Unspecified	GDF-1 agonist	neurodegeneration
LY 379268	(1R,4R,5S,6R)-4-amino-2-oxabicyclo[3.1.0]hexane-4,6-dicarboxylic acid	glutamate agonist; mGluR agonist; analgesic	neurodegeneration; pain

Excitatory amino acid antagonists	unspecified	glutamate antagonist; excitatory amino acid antagonist; NMDA antagonist	epilepsy; neurodegeneration
SIB 1757	Unspecified	glutamate antagonist; mGluR antagonist; analgesic	pain; neurological; neurodegeneration
SIB 1893	Unspecified	glutamate antagonist; mGluR antagonist; analgesic	pain; neurological; neurodegeneration
2-PMPA; GPI 5000	Unspecified	glutamate release inhibitor	stroke; neurodegeneration
NZ 093	Unspecified	IGF-1	brain ischemia; trauma; stroke; neurodegeneration
insulin-like growth factor-1; IGF-1	Unspecified	IGF-1 agonist	brain ischemia; trauma; stroke; neurodegeneration
insulin-like growth factor binding protein ligand inhibitors	Unspecified	IGFBP ligand inhibitors	stroke; neurodegeneration
ICE inhibitors	Unspecified	IL-1 beta converting enzyme inhibitor; caspase inhibitor	neurodegeneration
Neurodegenerative disease therapy	Unspecified	Immunomodulation, peptide mediated	neurodegeneration
MKK4 modulators	Unspecified	MAP kinase inhibitor; signal transduction inhibitor, NSAID	inflammation; neurodegeneration
Melatonin analogue	Unspecified	Melatonin agonist	neurodegeneration
Neurodegenerative disease therapy	Unspecified	monoclonal antibody immunomodulation	neurodegeneration; Alzheimer disease
neural progenitor regulatory factor	Unspecified	Neural progenitor regulation, growth factor; peptide; neurotrophic factor	multiple sclerosis; trauma; neurodegeneration
Neuroimmunophilin ligands	Unspecified	Neuroimmunophilins, growth factor; neurotrophic factor	neurodegeneration
Neuroimmunophilins	Unspecified	neurotrophic factor	neurodegeneration
nerve growth factor secreting implant	Unspecified	NGF agonist	neurodegeneration; neuropathy
nerve growth factor mimetics	Unspecified	NGF mimetics	neurodegeneration

CP 101606	[S-(R*,R*)]-4-hydroxy-alpha-(4-hydroxyphenyl)-beta-methyl-4-phenyl-1-piperidineethanol	NMDA antagonist; glutamate antagonist	stroke; trauma; neurodegeneration
Remacemide; FPL 12924; PR 934423; FPL 12924AA; PR 934423A; FPL 14144; PR 1032644; FPL 14145, PR 1032646	(+,-)-2-amino-N-(1-methyl-1,2-diphenylethyl)acetamide	NMDA antagonist; glutamate antagonist	epilepsy; Parkinson disease; neurodegeneration
Telomerase activators	Unspecified	NSAID	neurodegeneration; atherosclerosis; arthritis
Neurotrophin-4/5 secreting implant; NT-4/5 implant	Unspecified	NT-4/5 agonist	neurodegeneration; neuropathy; amyotrophic lateral sclerosis; eye disease
Synthetic opioid alkaloids	Unspecified	Opioid agonists	neurodegeneration
prion inhibiting peptides	Unspecified	Prion inhibition	neurodegeneration
taltirelin; TA 0910; CEREDIST	(S)-N-[(hexahydro-1-methyl-2,6-dioxo-4-pyrimidinyl)carbonyl]-L-histidyl-L-prolinamide	Protirelin analogue	neurodegeneration
telomere modulators	Unspecified	Telomere modulation	neurodegeneration; atherosclerosis; arthritis
NZ 097	Unspecified	TGF-b agonist	brain ischemia; trauma; stroke; neurodegeneration
Transforming growth factor beta; TGFbeta	Unspecified	TGF-b agonist	brain ischemia; trauma; stroke; neurodegeneration
CEP 3265; CB 1093	5-[[1-(2-ethoxy-6-ethyl-6-hydroxy-1-methyl-3-octynyl)octahydro-7a-methyl-4H-inden-4-ylidene]ethylidene]-4-methylene-1,3-cyclohexanediol	transcription activator	neurodegeneration; Alzheimer disease

Table 26. Current Candidate Therapeutic Interventions for the Treatment of Anxiety

Product Name	Chemical Name	Action	Indication
CGS 12066	4-(4-methyl-1-piperazinyl)-7-(trifluoromethyl)pyrrolo[1,2-a]quinoxaline	5HT agonist	anxiety
umespiron; KC 7218; KC 9172	3-butyl-7-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]-9,9-dimethyl-3,7-diazabicyclo[3.3.1]nonane-2,4,6,8-tetrone	5HT agonist	anxiety
CP 110330	N,N-dimethyl-5-[4-[(phenylamino)methyl]-2-thiazolyl]-1H-indole-3-ethanamine	5HT agonist; 5HT1 agonist	migraine; anxiety; depression
CP 119333	N,N-dimethyl-5-[4-(phenylmethyl)-2-thiazolyl]-1H-indole-3-ethanamine	5HT agonist; 5HT1 agonist	migraine; anxiety; depression
alnespiron; S 20499	(+)-8-[4-[(3,4-dihydro-5-methoxy-2H-1-benzopyran-3-yl)propylamino]butyl]-8-azaspiro[4.5]decane-7,9-dione	5HT agonist; 5HT1A agonist	anxiety
EMD 67478		5HT agonist; 5HT1A agonist	anxiety
F 12439		5HT agonist; 5HT1A agonist	depression; anxiety
flesinoxan; DU 29373	(+)-N-[2-[4-[2,3-dihydro-2-(hydroxymethyl)-1,4-benzodioxin-5-yl]-1-piperazinyl]ethyl]-4-fluorobenzamide	5HT agonist; 5HT1A agonist	anxiety; depression
gepirone; gepirone hydrochloride; MJ 13805; BMJ 13805; BMJ 138051	4,4-dimethyl-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,6-piperidinedione	5HT agonist; 5HT1A agonist	anxiety; depression

ipsapirone; BAY q 7821; TVX q 7821	2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2-benzisothiazol-3(2H)-one 1,1-dioxide	5HT agonist; 5HT1A agonist	depression; anxiety
lesopitron; E 4424	2-[4-[4-(4-chloro-1H-pyrazol-1-yl)butyl]-1-piperazinyl]pyrimidine dihydrochloride	5HT agonist; 5HT1A agonist	anxiety
LY 228729	4-(dipropylamino)-1,3,4,5-tetrahydrobenz[cd]indole-6-carboxamide	5HT agonist; 5HT1A agonist	anxiety; depression
MKC 242	(S)-N-[3-(1,3-benzodioxol-5-yl)oxy]propyl]-2,3-dihydro-1,4-benzodioxin-2-methanamine, hydrochloride	5HT agonist; 5HT1A agonist	anxiety
S 14506	4-fluoro-N-[2-[4-(7-methoxy-1-naphthalenyl)-1-piperazinyl]ethyl]benzamide hydrochloride	5HT agonist; 5HT1A agonist	anxiety
S 14671	N-[2-[4-(7-methoxy-1-naphthalenyl)-1-piperazinyl]ethyl]-2-thiophenecarboxamide	5HT agonist; 5HT1A agonist	anxiety; depression
SUN 8399	2,3,4,5-tetrahydro-4-(4-(4-(2-pyrimidinyl)piperazin-1-yl)butyl)-1,4-benzoxazepine-3,5-dione hydrochloride	5HT agonist; 5HT1A agonist	anxiety; emesis
Tandospirone; metanopirone; SM 3997; SEDIEL	3aalfa,4beta,7beta,7aalfa-hexahydro-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-4,7-methano-1H-isoindole-1,3(2H)-dione	5HT agonist; 5HT1A agonist	anxiety
U 92016A		5HT agonist; 5HT1A agonist	anxiety; depression

U 93385; U 93385E	(3aR-cis)-2,3,3a,4,5,9b-hexahydro-3-propyl-1H-benz[e]indole-9-carboxamide	5HT agonist; 5HT1A agonist	anxiety; depression
SL 870765		5HT agonist; 5HT1A agonist; 5HT antagonist; 5HT1D antagonist	anxiety; depression
adatanserin; adatanserin hydrochloride; WY 50324; WAY SEB 324; SEB 324	N-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]tricyclo[3.3.1.1(3,7)]decane-1-carboxamide	5HT agonist; 5HT1A agonist; 5HT antagonist; 5HT2 antagonist	anxiety; depression
FG 5865	2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide monohydrochloride	5HT agonist; 5HT1A agonist; 5HT antagonist; 5HT2 antagonist	anxiety; depression
FG 5893; FG 5974	(2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester)	5HT agonist; 5HT1A agonist; 5HT antagonist; 5HT2 antagonist	anxiety; depression
S 213571; S 21357-1	3-[2-[4-(4-fluorobenzoyl)-1-piperidinyl]ethyl]-6-[4-[4-(2-methoxyphenyl)-1-piperazinyl]-butyl]-2(3H)-benzothiazolone trihydrochloride	5HT agonist; 5HT1A agonist; 5HT antagonist; 5HT2 antagonist	anxiety
sunepitron; CP 93393; CP 93393-1	(7S-trans)-1-[[octahydro-2-(2-pyrimidinyl)-2H-pyrido[1,2-a]pyrazin-7-yl]methyl]-2,5-pyrrolidinedione	5HT agonist; 5HT1A agonist; alpha adrenergic antagonist; alpha2 adrenergic agonist	depression; anxiety
SB 236057		5HT agonist; 5HT1B agonist	anxiety
LY 293284	(R)-1-[4-(dipropylamino)-1,3,4,5-tetrahydrobenz[cd]indol-6-yl]ethanone	5HT agonist; 5HT1D agonist	anxiety

ICI 190622	4-amino-1-(3-pentynyl)-N-2-propenyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide	5HT antagonist	anxiety
5HT1B antagonists		5HT antagonist	depression; anxiety
BMY 7378	8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride	5HT antagonist	anxiety
DU 123015		5HT antagonist	anxiety; depression
DU 125530		5HT antagonist	depression; anxiety; psychosis
ICI 170809	N,N,2-trimethyl-1-[(3-phenyl-2-quinoliny)thio]-2-propanamine monohydrochloride	5HT antagonist	anxiety
RS 42358; RS 42358197	(S)-2-(1-azabicyclo[2.2.2]oct-3-yl)-2,4,5,6-tetrahydro-1-H-benz[de]isoquinolin-1-one monohydrochloride	5HT antagonist	anxiety; emesis
seganserin; R 56413	3-[2-[4-[bis(4-fluorophenyl)methylene]-1-piperidinyl]ethyl]-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one	5HT antagonist	anxiety
serazapine; CGS 15040A	1,3,4,16b-tetrahydro-2-methyl-2H,10H-indolo[2,1-c]pyrazino[1,2-a][1,4]benzodiazepine-16-carboxylic acid methyl ester	5HT antagonist	anxiety

5-HT antagonist; pindobind	2-bromo-N-[4-[1-[[2-hydroxy-3-(1H-indol-4-ylloxy)propyl]amino]-1-methylethyl]-1-methylcyclohexyl]acetamide	5HT antagonist; 5HT1A antagonist	anxiety; depression
Anxiolytic	(S)-5,6,6a,7-tetrahydro-6,10-dimethyl-4H-dibenzo[de,g]quinolin-11-ol	5HT antagonist; 5HT1A antagonist	anxiety
Binospirone; binospirone mesylate; MDL 73005EF	8-[2-[[[(2,3-dihydro-1,4-benzodioxan-2-yl)methyl]amino]ethyl]-8-azaspiro[4.5]decan-7,9-dione	5HT antagonist; 5HT1A antagonist	anxiety
F 8910RS		5HT antagonist; 5HT1A antagonist	anxiety
Robalzotan; NAD 299	(3R)-3-(dicyclobutylamino)-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide (2R,3R)-2,3-dihydroxybutanedioate (1:1)	5HT antagonist; 5HT1A antagonist	anxiety; depression
S 15535	1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-(2,3-dihydro-1H-inden-2-yl)piperazine	5HT antagonist; 5HT1A antagonist	anxiety; depression
SDZ 216525; SDZ 216-525	methyl 4-[4-[4-(1,1,3-trioxo-2H-1,2-benzisothiazol-2-yl)butyl]-1-piperazinyl]-1H-indole-2-carboxylate	5HT antagonist; 5HT1A antagonist	anxiety
UH 301	(+,-)-7-(dipropylamino)-4-fluoro-5,6,7,8-tetrahydro-1-naphthalenol	5HT antagonist; 5HT1A antagonist	anxiety

WAY 100135	N-(1,1-dimethylethyl)-4-(2-methoxyphenyl)-alpha-phenyl-1-piperazinepropanamide	5HT antagonist; 5HT1A antagonist	anxiety
WAY 100635	N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide trihydrochloride	5HT antagonist; 5HT1A antagonist	anxiety
Buspirone hydrochloride; MJ 40221; MJ 9022; BESPAR; BUSPAR; NORMATON; TUTRAN; NAROL; ANSIENON; ANSITEN; TRANBUS; SIMPLESS	8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-8-azaspiro[4,5]decane-7,9-dione hydrochloride	5HT antagonist; 5HT1A antagonist; dopamine agonist	anxiety; depression; dermatitis
drug delivery system, transdermal buspirone; buspirone transdermal		5HT antagonist; 5HT1A antagonist; dopamine agonist	anxiety; depression; attention deficit disorder
CR 1909		5HT antagonist; 5HT2 antagonist	anxiety
Glemanserin; MDL 11939	(+,-)-alpha-phenyl-1-(2-phenylethyl)-4-piperidinemethanol	5HT antagonist; 5HT2 antagonist	anxiety
ritanserin; R 55667	6-[2-[4-[bis(4-fluorophenyl)methylene]piperidino]ethyl]-7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one	5HT antagonist; 5HT2 antagonist	addiction; anxiety; schizophrenia
CGS 18102	trans-10-methoxy-4-propyl-1,3,4,4a,5,10b-hexahydro-2H-(1)benzopyrano(3,4-b)pyridine	5HT antagonist; 5HT2 antagonist; 5HT agonist; 5HT1A agonist	anxiety

HT 90B	(-)-N-[2-[(2,3-dihydro-8-methyl-1,4-benzodioxin-2-yl)methyl]amino]ethyl]tricyclo[3.3.1.1 ^{3,7}]decane-1-carboxamide	5HT antagonist; 5HT2 antagonist; 5HT agonist; 5HT1A agonist	anxiety; depression
Amesergide; amerserzide; LY 237733	8beta-N-cyclohexyl-6-methyl-1-(1-methylethyl)ergoline-8-carboxamide	5HT antagonist; 5HT2 antagonist; 5HT1C antagonist	sexual dysfunction; depression; anxiety
Deramciclane; EGIS 3886; EGYT 3886	(1R-exo)-N,N-dimethyl-2-[(1,7,7-trimethyl-2-phenylbicyclo[2.2.1]hept-2-yl)oxy]-ethanamine	5HT antagonist; 5HT2 antagonist; 5HT1C antagonist	anxiety
Ziprasidone; ziprasidone hydrochloride; CP 88059; CP 880591; CP 8805901; ZELDOX	5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one	5HT antagonist; 5HT2 antagonist; 5HT1C antagonist; dopamine antagonist; dopamine D2 antagonist; 5HT1A agonist; 5HT agonist	schizophrenia; anxiety
EGIS 8465		5HT antagonist; 5HT2C antagonist	anxiety
ORG 37415		5HT antagonist; 5HT2C antagonist	depression; anxiety
SB 200646A	N-(1-methyl-1H-indol-5-yl)-N'-(3-pyridinyl)urea monohydrochloride	5HT antagonist; 5HT2C antagonist	anxiety
SB 228357	N-[3-fluoro-5-(3-pyridinyl)phenyl]-2,3-dihydro-5-methoxy-6-(trifluoromethyl)-1H-indole-1-carboxamide	5HT antagonist; 5HT2C antagonist	anxiety; depression
ADR 851	(S)-4-amino-5-chloro-2,3-dihydro-N-(2-pyrrolidinylmethyl)-7-benzofurancarboxamide monohydrochloride	5HT antagonist; 5HT3 antagonist	anxiety; emesis

Antidepressant		5HT antagonist; 5HT3 antagonist	depression; anxiety
itasetron; DAU 6215; DAU 6215CL; DA 6215; U 98079; U 98079A	endo-2,3-dihydro-N- (8-methyl-8- azabicyclo[3.2.1]oct- 3-yl)-2-oxo-1H- benzimidazole-1- carboxamide	5HT antagonist; 5HT3 antagonist	emesis; anxiety
ricasetron; BRL 46470; BRL 46470A	endo-2,3-dihydro-3,3- dimethyl-N-(8- methyl-8- azabicyclo[3.2.1]oct- 3-yl)-1H-indole-1- carboxamide	5HT antagonist; 5HT3 antagonist	anxiety; schizophrenia; emesis
tropisetron; ICS 205930; NAVOBAN	1H-indole-3- carboxylic acid endo- 8-methyl-8- azabicyclo[3.2.1]oct- 3-yl ester	5HT antagonist; 5HT3 antagonist	emesis; anxiety
VA 21B7	2-[(4-piperonyl)-1- piperazinyl]-3- indolecarboxaldehyde	5HT antagonist; 5HT3 antagonist	anxiety
WAY 100289; WY 100289	(endo)-N-[[[(8-aza-8- methylbicyclo[3,2,1]o ctan-3- yl)amino]carbonyl]- 2- (cyclopropylmethoxy)benzamide	5HT antagonist; 5HT3 antagonist	anxiety
WAY 100579; SEC 579	endo-1-cyclohexyl- 1,4-dihydro-N-(8- methyl-8- azabicyclo[3.2.1]oct- 3-yl)-4-oxo-3- quinolinecarboxamid e (Z)-2-butenedioate	5HT antagonist; 5HT3 antagonist	anxiety
zacopride; zacopride hydrochloride; ZAP; AHR 11190B; AHR 11190; MD 78027	4-amino-N-1- azabicyclo[2.2.2]oct- 3-yl-5-chloro-2- methoxy-benzamide	5HT antagonist; 5HT3 antagonist	anxiety; emesis

zatosetron; LY 277359	endo-5-chloro-2,3- dihydro-2,2-dimethyl- N-(8-methyl-8- azabicyclo[3.2.1]oct- 3-yl)-7- benzofurancarboxami de	5HT antagonist; 5HT3 antagonist	emesis; anxiety
SB 204070	8-amino-7-chloro- 2,3-dihydro-1,4- benzodioxin-5- carboxylic acid (1- butyl-4- piperidiny)methyl ester	5HT antagonist; 5HT4 antagonist	anxiety; irritable bowel syndrome
SC 56184		5HT antagonist; 5HT4 antagonist	anxiety
THE JL3; JL 3	10-(4-methyl-1- piperaziny)- pyrido[4,3- b][1,4]benzothiazepi ne	5HT antagonist; dopamine antagonist	anxiety; depression
fluvoxamine; fluvoxamine maleate; DU 23000; MK 264; SME 3110; FEVARIN; FLOXYFRAL; LUVOX; DUMYROX; DUMIROX; FLAVOXYL; FAVERIN; DEPROMEL	5-methoxy-1-[4- (trifluoromethyl)phen yl]-1-pentanone (E)- O-(2- aminoethyl)oxime	5HT reuptake inhibitor	depression; anxiety; obsessive compulsive disorder
paroxetine hydrochloride; FR 7051; BRL 29060; BRL 29060A; SI 211103; SEROXAT; AROPAX; PAXIL; TAGONIS; FROSINOR; DEROXAT; SEREUPIN; MOTIVAN	(3S-trans)-3-[(1,3- benzodioxol-5- yloxy)methyl]-4-(4- fluorophenyl)piper idine	5HT reuptake inhibitor	depression; obsessive compulsive disorder; anxiety

sertraline; CP 51974; CP 519741; CP 5197401; LUSTRAL; ZOLOFT; ALTRULINE; TATIG; GLADEM	(1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthaleneamine	5HT reuptake inhibitor	depression; obsessive compulsive disorder; anxiety; sexual dysfunction; obesity
venlafaxine; WY 45030; EFFEXOR; EFEXOR; EFFEXOR XR; EFFEXOR XL	(+,-)-1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol	5HT reuptake inhibitor; noradrenalin reuptake inhibitor; dopamine reuptake inhibitor	depression; anxiety
ST 1112	2-acetyl-5-(4-methoxyphenyl)-3-oxo-1,2,4-triazine	5HT1/5HT2 ligand	anxiety
L 0068; F 11440	4-methyl-2-[4-(2-pyrimidinyl)-1-piperazinyl]butyl-1,2,4-triazine-3,5(2H,4H)-dione	5HT1A agonist; 5HT agonist	anxiety; depression
OPC 14523	1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4-dihydro-5-methoxy-2(1H)-quinolinone	5HT1A agonist; sigma agonist; 5HT agonist	depression; anxiety; obsessive compulsive disorder
F 92502CN	Unspecified	5HT1A ligand	anxiety
EGIS 9933	2-(2-[N-(3-trifluoromethylbenzyl)-N-piperazinyl]ethyl)mercapto-4,6-diamino-5-(2-methoxybenzyl)-pyrimidine hydrochloride	5HT2C antagonist; 5HT antagonist	anxiety
SB 243213	2,3-dihydro-5-methyl-N-[(6-[(2-methyl-3-pyridinyl)oxy]-3-pyridinyl]-6-(trifluoromethyl)-1H-indole-1-carboxamide	5HT2C antagonist; 5HT antagonist	depression; anxiety

zalospirone; WY 47846	(3aalfa,4beta,4aalfa,6aalfa,7beta,7aalfa)-3a,4,4a,6a,7,7a-hexahydro-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-4,7-etheno-1H-cyclobut[f]isoindole-1,3(2H)-dione	5HT3 antagonist	anxiety; depression
ceronapril; ceranapril; SQ 29852	(S)-1-[6-amino-2-[[hydroxy(4-phenylbutyl)phospinyl]oxy]-1-oxohexyl]-L-proline	ACE inhibitor	cognitive defect; hypertension; anxiety
drug delivery system; adenosine; adenosine drug delivery system; adenosine prodrug	adenosine 5'-(1,4-dihydrotrigonellinate)-2',3'-O-bis-benzoate	adenosine agonist	anxiety; depression
atipamezole; MPV 1248; ANTISEDAN	4-(2-ethyl-2,3-dihydro-1H-inden-2-yl)-1H-imidazole	alpha adrenergic antagonist; alpha2 adrenergic antagonist	sexual dysfunction; alcoholism; depression; hypotension; diabetes; anxiety
SNAP 5114	1-[2-[tris(4-methoxyphenyl)methoxy]ethyl]-3-piperidinecarboxylic acid	amine uptake inhibitor	epilepsy; anxiety; insomnia
gabapentin; CI 945; GO 3450; GOE 2450; NEURONTIN	1-(aminomethyl)cyclohexaneacetic acid	analgesic	epilepsy; anxiety; pain; neuropathy; psychosis; depression
losartan; losartan potassium; DUP 753; MK 954; DUP 89; E 3340; AVASTAR; COZAAR; LOORTAN; NULOTAN	2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol	angiotensin II antagonist	hypertension; anxiety; stroke; heart failure; myocardial infarction
AIT 084		antispasmodic	anxiety
alpidem; SL 80034200; ANANXYL	6-chloro-2-(4-chlorophenyl)-N,N-dipropylimidazo[1,2-a]pyridine-3-acetamide (imidazopyridine)	Anxiolytic activity with unspecified mechanism of action	anxiety

Anxiolytic	Ketisoaxalidine derivative	Anxiolytic activity with unspecified mechanism of action	anxiety
AP 521	Unspecified	Anxiolytic activity with unspecified mechanism of action	anxiety
BMS 181100	alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine-butanol	Anxiolytic activity with unspecified mechanism of action	anxiety
BMS 184111	Unspecified	Anxiolytic activity with unspecified mechanism of action	Anxiety
CEB 1128	Unspecified	Anxiolytic activity with unspecified mechanism of action	anxiety
CEB 1342	Unspecified	Anxiolytic activity with unspecified mechanism of action	anxiety
CEB 1459	Unspecified	Anxiolytic activity with unspecified mechanism of action	anxiety
CGS 13767	Unspecified	Anxiolytic activity with unspecified mechanism of action	anxiety
CL 870704	Unspecified	Anxiolytic activity with unspecified mechanism of action	anxiety
CNS 3	Unspecified	Anxiolytic activity with unspecified mechanism of action	anxiety
Co 2-6749; Co 26749	Synthetic epalons	Anxiolytic activity with unspecified mechanism of action	anxiety
transmucosal etomidate	Etomidate derivative	Anxiolytic activity with unspecified mechanism of action	anxiety
transdermal buspirone;	Buspirone	Anxiolytic activity with unspecified mechanism of action	anxiety
dulozafone; dicozafone; F 1933	2-[bis(2-hydroxyethyl)amino]-N-[4-chloro-2-(chlorobenzoyl)phenyl]-N-methylacetamide	Anxiolytic activity with unspecified mechanism of action	anxiety

enciprazine; D 13112; WY 48624	(+,-)-4-(2-methoxyphenyl)- alpha-[(3,4,5- trimethoxyphenoxy) methyl]-1- piperazineethanol	Anxiolytic activity with unspecified mechanism of action	anxiety
etizolam; Y 7131; DEPAS; PASADEN	4-(2-chlorophenyl)-2- ethyl-9-methyl-6H- thieno[3,2- f][1,2,4]triazolo[4,3- a][1,4]diazepine	Anxiolytic activity with unspecified mechanism of action	anxiety
F 2692	3-amino-6-methyl-1- [3- (trifluoromethyl)phen yl]-4(1H)- pyridazinone	Anxiolytic activity with unspecified mechanism of action	anxiety
mexidol	2-ethyl-6-methyl-3- hydroxypyridine succinate	Anxiolytic activity with unspecified mechanism of action	anxiety; cognitive defect
rilapine	(Z)-2-chloro-10-(4- methyl-1- piperazinyl)-5H- dibenzo[a,d]cyclohept ene-delta5,alfa- acetonitrile	Anxiolytic activity with unspecified mechanism of action	anxiety
SC 48274; BTG 1501	3-[3- (dimethylamino)prop yl]-3-(3- methoxyphenyl)-4,4- dimethyl-2,6- piperidinedione hydrochloride	Anxiolytic activity with unspecified mechanism of action	anxiety
sultopride; sultopride hydrochloride; LIN 1418; DAN 2163; BARNETIL	N-[(1-ethyl-2- pyrrolidiny)methyl]- 5-(ethylsulfonyl)-2- methoxybenzamide	Anxiolytic activity with unspecified mechanism of action	anxiety
suriclone; RP 31264; RP 006; SURIL	4-methyl-1- piperazinecarboxylic acid ester with 6-(7- chloro-1,8- naphthyridin-2-yl)- 2,3,6,7-tetrahydro-7- oxy-5H-1,4- dithiino[2,3- c]pyrrol-5-yl	Anxiolytic activity with unspecified mechanism of action	anxiety

TAS 401	Unspecified	Anxiolytic activity with unspecified mechanism of action	anxiety
NNC 138119	3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5,6-dihydro-5-methyl-6-oxo-4H-imidazo(1,5-a)(1,4)benzodiazepine	Benzodiazepine	epilepsy; anxiety
AD 8152		benzodiazepine	anxiety
adinazolam; adinazolam mesylate; adinazolam mesilate; U 41123F; U 41123; DERACYN	8-chloro-N,N-dimethyl-6-phenyl-4H-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine-1-methanamine	benzodiazepine	anxiety; depression
AHR 14749	5-chloro-N,N-dimethyl-2-(4-methylphenyl)-3H-imidazo[4,5-b]pyridine-3-acetamide	benzodiazepine	anxiety
CGS 20625	5,6,7,8,9,10-hexahydro-2-(4-methoxyphenyl)-cyclohepta[b]pyrazolo[3,4-d]pyridin-3(2H)-one	benzodiazepine	anxiety
clobazam; HR 376; H 4723; LM 2717; NH 15; FRISIUM; CLIDIZAN; GRIFOCLOBAM; URBADAM; FRISIN; URBANYL; URBANIL; MYSTAN	7-chloro-1-methyl-5-phenyl-1H-1,5-benzodiazepine-2,4-(3H,5H)-dione	benzodiazepine	anxiety; epilepsy
drug delivery system, intranasal benzodiazepines; benzodiazepine intranasal delivery system		benzodiazepine	anxiety; insomnia

drug delivery system, transdermal alprazolam; alprazolam transdermal		benzodiazepine	anxiety
drug delivery system, transdermal alprazolam; alprazolam transdermal		benzodiazepine	anxiety
EGIS 5278	3-amino-4-ethylthio- 7-chloro-quinolone hydrochloride	benzodiazepine	anxiety
EGIS 8858	5-[2-(4- fluorophenyl)ethenyl] -8-methyl-9H-1,3- dioxolo[4,5- h][2,3]benzodiazepin e	benzodiazepine	anxiety
girisopam; EGIS 5810; GYKI 51189	1-(m-chlorophenyl)- 7,8-dimethoxy-4- methyl-5H-2,3- benzodiazepine	benzodiazepine	anxiety
midazolam; Ro 213981/001; Ro 213981/003; HYPNOVEL; VERSED; DORMICUM	8-chloro-6-(2- fluorophenyl)-1- methyl-4H- imidazo[1,5- a][1,4]benzodiazepine	benzodiazepine	anxiety; epilepsy
nerisopam; EGIS 6775; GYKI 52232	4-(7,8-dimethoxy-4- methyl-5H-2,3- benzodiazepin-1-yl)- benzenamine	benzodiazepine	anxiety
panadiplon; U 78875; FG 10571	3-(5-cyclopropyl- 1,2,4-oxadiazol-3-yl)- 5-(1-methylethyl)- imidazo[1,5a]- quinoxalin-4(5H)-one	benzodiazepine	anxiety
RU 32759	[6-ethyl-5-methyl-7- (methylthio)imidazo[1,2-a]pyrimidin-2- yl]phenylmethanone	benzodiazepine	anxiety

tofisopam; EGYT 341; MER 19; MER 1961; GRANDAXIN; SERIEL; ISOTAN	1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine	benzodiazepine	anxiety; skin disease
abecarnil; ZK 112119; FG 7516; NNC 157516; SH 524; LADOTEC	4-(methoxymethyl)-6-(phenylmethoxy)-9H-pyrido[3,4-b]indole-3-carboxylic acid, 1-methylethyl ester	benzodiazepine partial agonist	anxiety
FG 8119	3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydro-5-methyl-6H-imidazo[1,5-a][1,4]benzodiazepin-6-one	benzodiazepine partial agonist	anxiety
FG 8205; L 663581	7-chloro-4,5-dihydro-5-methyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-6H-imidazo[1,5-a][1,4]benzodiazepin-6-one	benzodiazepine partial agonist	epilepsy; anxiety
ICI D7569		benzodiazepine partial agonist	anxiety
imidazenil; FGIN 2073; FID 02023; Ro 231412	6-(2-bromophenyl)-8-fluoro-4H-imidazol[1,5-a][1,4]benzodiazepine-3-carboxamide	benzodiazepine partial agonist	anxiety
Ro 198022	(R)-1-((10-chloro-4-oxo-3-phenyl-4H-benzo(a)quinolizin-1-yl)carbonyl)-2-pyrrolidine-methanol	benzodiazepine partial agonist	anxiety
saripidem; SL 850274	N-[[2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl]methyl]-N-methylbutyramide	benzodiazepine partial agonist	anxiety

Y 23684	2-(4-chlorophenyl)-5,6-dihydro-[1]benzothiepine[5,4-c]pyridazin-3(2H)-one 7-oxide	benzodiazepine partial agonist	anxiety
5HT4 human neuroreceptor; neuroreceptor, 5HT4		biotechnology	irritable bowel syndrome; cognitive defect; anxiety; arrhythmia; stroke; urinary incontinence; migraine; research tool
Cholecystokinin B antagonist		cholecystokinin antagonist; cholecystokinin B antagonist	schizophrenia; anxiety
CR 2622	[R-(R*,S*)]-4-[[5-(8-azaspiro[4.5]dec-8-yl)-4-[(3,5-dichlorobenzoyl)amino]-1,5-dioxopentyl]amino]-5-(1-naphthalenylamino)-5-oxo-pentanoic acid	cholecystokinin antagonist; cholecystokinin B antagonist	anxiety
GV 150013	(R)-N-phenyl-N'-[2,3,4,5-tetrahydro-2,4-dioxo-1-phenyl-5-(tricyclo[3.3.1.1 ^{3,7}]dec-1-ylmethyl)-1H-1,5-benzodiazepin-3-yl]urea	cholecystokinin antagonist; cholecystokinin B antagonist	anxiety
LY 288513		cholecystokinin antagonist; cholecystokinin B antagonist	schizophrenia; anxiety
CR 2345	N-[1-(8-azaspiro[4.5]dec-8-ylcarbonyl)-4-(4-methyl-1-piperazinyl)-4-oxobutyl]-3,5-dichlorobenzamide monohydrochloride	cholecystokinin antagonist; cholecystokinin B antagonist; gastrin antagonist	anxiety; gastrointestinal ulcer; bacterial infection

CR 2945		cholecystokinin antagonist; cholecystokinin B antagonist; gastrin antagonist	gastrointestinal ulcer; anxiety
L 740093	(R)-N-[5-(3-azabicyclo[3.2.2]nonan-3-yl)-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-N'-(3-methylphenyl)urea monohydrochloride	cholecystokinin B antagonist; cholecystokinin antagonist	anxiety
PD 134308; CI 988	[R-(R*,R*)]-4-[[2-[[3-(1H-indol-3-yl)-2-methyl-1-oxo-2-[[[(tricyclo[3.3.1.1sup 3,7]dec-2-yl)oxy]carbonyl]amino]propyl]amino]-1-phenylethyl]amino]-4-oxobutanoic acid compound with 1-deoxy-1-(methylamino)-D-glucitol (1:1)	cholecystokinin B antagonist; cholecystokinin antagonist	anxiety
PD 135158	[1S-[1 α ,2 β][S*(S*)],4 α]-4-[[2-[[3-(1H-indol-3-yl)-2-methyl-1-oxo-2-[[[(1,7,7-trimethylbicyclo[2.2.1]hept-2-yl)oxy]carbonyl]amino]propyl]amino]-1-phenylethyl]amino]-4-oxobutanoic acid cmpd with meglumine (1:1)	cholecystokinin B antagonist; cholecystokinin antagonist	anxiety

PD 145942	[2-[(hexahydro-1H-azepin-1-yl)amino]-1-(1H-indol-3-ylmethyl)-1-methyl-2-oxoethyl]carbamic acid tricyclo[3.3.1.1 ^{3,7}]dec-2-yl ester	cholecystokinin B antagonist; cholecystokinin antagonist	anxiety
AXC 2219		CRF antagonist	depression; anxiety
AXC 4007		CRF antagonist	depression; anxiety
CRA 1000	INDEX NAME NOT YET ASSIGNED	CRF antagonist	depression; anxiety
CRA 1001		CRF antagonist	depression; anxiety
CRF antagonist		CRF antagonist	depression; anxiety
CRF antagonists		CRF antagonist	depression; anxiety
CRF2 antagonists		CRF antagonist	depression; anxiety
NBI 27914	5-chloro-N-(cyclopropylmethyl)-2-methyl-N-propyl-N'-(2,4,6-trichlorophenyl)-4,6-pyrimidinediamine	CRF antagonist	anxiety
NBI 30545	3-(2,4-dimethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl-N-propylpyrazolo[1,5-a]pyrimidin-7-amine	CRF antagonist	anxiety; depression
NBI 30775; R 121919		CRF antagonist	anxiety; depression; addiction
NGD 981; NGD 98-1		CRF antagonist	depression; anxiety
PD 171729	butyl-[3[(2,4-dichloro-phenyl)-2,5-dimethyl-pyrazolo(1,5-a)pyrimidin-7-yl]-ethyl-amine	CRF antagonist	anxiety; depression
corticotropin releasing factor analogue	Unspecified	CRF ligand	anxiety; depression

DMP 695	N-(2-chloro-4,6-dimethylphenyl)-1-[2-methoxy-1-(methoxymethyl)ethyl]-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine monomethanesulfonate	CRH antagonist	anxiety; depression
SA 627	N-(2-bromo-4,6-dimethoxyphenyl)-N-ethyl-4-methyl-6-(4-morpholinyl)-1,3,5-triazin-2-amine	CRH antagonist	depression; anxiety
SC 241		CRH antagonist	anxiety; depression
RP 60503	4-(acetylamino)butanoic acid 2-(7-chloro-1,8-naphthyridin-2-yl)-2,3-dihydro-3-oxo-1H-isoindol-1-yl ester	Cyclic GMP modulation	anxiety
CCD 2034		GABA agonist	anxiety
GABA agonist, XR 368 series	(2aR*,5aR,7E,11E,14aS*,14bS*,14cS*)-2a,5a,6,9,10,13,14,14a,14b,14c-decahydro-4-hydroxy-5a,9,9,12-tetramethyl-1,5-dioxacyclopenta[cd]cycloundec[f]inden-3(2H)-one	GABA agonist	anxiety; epilepsy
RWJ 38293	1,2,3,5-tetrahydro-3-oxo-N-4-pyridinylpyrido[1,2-a]benzimidazole-4-carboxamide	GABA agonist	anxiety
U 91571	3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-N,N-dimethylimidazo[1,5-a]quinoxaline-5(4H)-carboxamide	GABA antagonist	anxiety
U 94625		GABA antagonist	anxiety

ocinaplon; CL 273547	2-pyridinyl[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone	GABA modulation	anxiety
pazinaclone; DN 2327; A 77000	8-[[2-(7-chloro-1,8-naphthyridin-2-yl)-2,3-dihydro-3-oxo-1H-isoindol-1-yl]acetyl]-1,4-dioxo-8-azaspiro[4.5]decane	GABA modulation	anxiety
Anxiolytics		GABA modulator	anxiety
AWD 131138; AWD 131-138	1-(4-chlorophenyl)-1,5-dihydro-4-(4-morpholinyl)-2H-imidazol-2-one	GABA modulator	epilepsy; anxiety
NGD 911; CP 409092		GABA modulator	anxiety
NGD 912; NGD 91-2		GABA modulator	anxiety
NGD 913; NGD 91-3		GABA modulator	anxiety
NS 2552		GABA modulator	anxiety; epilepsy
NS 2608		GABA modulator	epilepsy; anxiety
NS 2710; ME 3127		GABA modulator	anxiety
pagoclon; IP 456; RP 62955; (+)-RP 59037	(+)-2-(7-chloro-1,8-naphthyridin-2-yl)-2,3-dihydro-3-(5-methyl-2-oxohexyl)-1H-isoindol-1-one	GABA modulator	anxiety
RWJ 53050		GABA partial agonist	anxiety
U 101017; PNU 101017	cis-7-chloro-5-[(3,5-dimethyl-1-piperazinyl)carbonyl]imidazo[1,5-a]quinoline-3-carboxylic acid 1,1-dimethylethyl ester	GABA partial agonist	anxiety
RP 59037	2-(7-chloro-1,8-naphthyridin-2-yl)-2,3-dihydro-3-(5-methyl-2-oxohexyl)-1H-isoindol-1-one	GABA partial agonist; benzodiazepine partial agonist	anxiety
SNAP 5258	Unspecified	GAT1 transporter	epilepsy; anxiety; insomnia
SNAP 5294	Unspecified	GAT2 transporter	epilepsy; anxiety; insomnia

ACPC; cycloleucine; cycloleucin; NSC 1026; WR 14997	1-aminocyclopentanecarboxylic acid	glutamate antagonist; NMDA antagonist	coronary artery disease; anxiety; depression; stroke; epilepsy; addiction
HA 966	3-amino-1-hydroxy-2-pyrrolidone	glutamate antagonist; NMDA antagonist	anxiety
LY 354740	(1alpha,2beta,5alpha,6alpha)-2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid	glutamate release inhibitor	anxiety; nicotine withdrawal
hBGT1 transporter modulator	Unspecified	HBGT1 transporter modulator	epilepsy; anxiety; insomnia
GT 5140		histamine agonist; histamine H3 agonist	insomnia; anxiety
Methylhistamine, R-alpha; BP 2.94		histamine agonist; histamine H3 agonist	asthma; anxiety; gastrointestinal ulcer
SCH 49648	(2S-trans)-4-(2-methyl-3-pyrrolidinyl)-1H-imidazole	histamine agonist; histamine H3 agonist	asthma; anxiety; gastrointestinal ulcer
SCH 50971	(3R-trans)-4-(4-methyl-3-pyrrolidinyl)-1H-imidazole	histamine agonist; histamine H3 agonist	asthma; anxiety; gastrointestinal ulcer
CNS disorder modifiers	Unspecified	Ion channel modification	anxiety; schizophrenia; depression
Befloxatone; MD 370503	(R)-5-(methoxymethyl)-3-(p-((R)-4,4,4-trifluoro-3-hydroxybutoxy)phenyl)-2-oxazolidinone	MAO A inhibitor; MAO inhibitor	depression; anxiety; nicotine withdrawal
BW 1370U87	1-ethylphenoxathiin 10,10-dioxide	MAO A inhibitor; MAO inhibitor	depression; anxiety
Co 6-0549; Co 60549		neuroactive steroid	anxiety
MEN 10376		neurokinin antagonist; bronchodilator; neurokinin 2 antagonist	asthma; anxiety
CGP 60829		neurokinin antagonist; neurokinin 1 antagonist	anxiety

GR 100679	N-(cyclohexylcarbonyl)glycyl-L-alanyl-D-tryptophyl-N,N-dimethyl-L-phenylalaninamide	neurokinin antagonist; neurokinin 2 antagonist	anxiety
MEN 10207		neurokinin antagonist; neurokinin 2 antagonist	anxiety
osanetant; SR 142801	(R)-N-[1-[3-[1-benzoyl-3-(3,4-dichlorophenyl)-3-piperidinyl]propyl-4-phenyl-4-piperidinyl]-N-methylacetamide monohydrochloride	neurokinin antagonist; neurokinin 3 antagonist	schizophrenia; anxiety
Neuropeptide Y antagonists		neuropeptide Y antagonist; analgesic	obesity; cardiovascular disease; anxiety; pain
MDL 105519	(E)-3-(2-carboxy-2-phenylethenyl)-4,6-dichloro-1H-indole-2-carboxylic acid	NMDA antagonist; glutamate antagonist	anxiety; epilepsy
oxytocin antagonist		oxytocin antagonist; diuretic	anxiety; depression; obsessive compulsive disorder; epilepsy; heart failure
SNAP 1156		peptide	anxiety; hypertension; obesity; addiction
LU 28179	1'-[4-[1-(4-fluorophenyl)-1H-indol-3-yl]butyl]spiro[isobenzofuran-1(3H),4'-piperidine]	Sigma ligand	anxiety
CGP 49823	(2R-trans)-1-(3,5-dimethylbenzoyl)-2-(phenylmethyl)-N-(4-quinolinylmethyl)-4-piperidinamine	substance P antagonist	anxiety; asthma
MK 869		substance P antagonist	depression; anxiety; schizophrenia; emesis

vasopressin antagonist		vasopressin antagonist; diuretic	anxiety; depression; obsessive compulsive disorder; epilepsy; heart failure
------------------------	--	----------------------------------	-----------------------------------------------------------------------------

Table 27. Current Candidate Therapeutic Interventions for the Treatment of Dementia

Product Name	Chemical Name	Action	Indication
SR 57746; SR 57746A	1,2,3,6-tetrahydro-1-[2-(1-naphthalenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]pyridine	5HT agonist; 5HT1A agonist; growth factor modulator	Alzheimer disease; neuropathy
AP 159	N-cyclohexyl-1,2,3,4-tetrahydro-[1]benzothieno[2,3c]pyridine-3-carboxamide monohydrochloride	5HT antagonist; 5HT1A antagonist	cognitive defect
SL 880338		5HT antagonist; 5HT1A antagonist	cognitive defect
GYKI 46903	(1R-endo)-6-(4-fluorophenyl)-1-azabicyclo[3.3.1]non-6-en-4-ol propanoate hydrochloride	5HT antagonist; 5HT3 antagonist	cognitive defect
Ondansetron; GR 38032; GR 38032F; SN 307; ZOFRAN; ZOPHREN; ZOFRON	1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one	5HT antagonist; 5HT3 antagonist	emesis; cognitive defect
FG 7080	trans-(-)-4-(4-fluorophenyl)-3-[(4-methoxyphenoxy)methyl]piperidine hydrochloride	5HT reuptake inhibitor	cognitive defect
Fluoxetine, (R)-; (R)-fluoxetine	(R)-N-methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine	5HT reuptake inhibitor	migraine; cognitive defect; depression

Indeloxazine; ideloxazine; YM 08054; CI 874; ELEN; NOIN	(+,-)-2-[(indol-7- yloxy)methyl]morpho line	5HT reuptake inhibitor	cognitive defect
NS 2347		5HT reuptake inhibitor; dopamine reuptake inhibitor	depression; cognitive defect
SM 3163	3-((1,5- diphenylpentyl)oxy)- N,N-dimethyl-1- propanamine citrate	5HT reuptake inhibitor; vasodilator	cognitive defect; cerebrovascular disease
FK 960	N-(4-acetyl-1- piperazinyl)-4- fluorobenzamide	5HT, somatostatin	Alzheimer disease
SL 650102; SL 65.0102	(-)-8-amino-7-chloro- N-(1,4- diazabicyclo[2.2.2]oc t-2-ylmethyl)-2,3- dihydro-1,4- benzodioxin-5- carboxamide dihydrochloride	5HT4 agonist; 5HT agonist	Alzheimer disease
5HT4 human neuroreceptor		5HT4 human neuroreceptor	irritable bowel syndrome; cognitive defect; anxiety; arrhythmia; stroke; urinary incontinence; migraine; research tool
Ceranapril; ceranapril; SQ 29852	(S)-1-[6-amino-2- [[hydroxy(4- phenylbutyl)phospiny l]oxy]-1-oxohexyl]- L-proline	ACE inhibitor	cognitive defect; hypertension; anxiety
Alzheimer's disease therapy	1-[3,4- (methylenedioxy)ben zoyl]-3-[2-(1-benzyl- 4- piperidinyl)ethyl]thio urea	Acetylcholinesterase inhibitor	Alzheimer disease
NBI 117	Extracellular portion of activin receptor (soluble)	Activin soluble portion of receptor	Alzheimer disease
AD7C-NTP modulators, Alzheimer disease		AD7C-NTP modulation	Alzheimer disease

KF 15372	8-(3-dicyclopropylmethyl)-1,3-dipropylxanthine	adenosine antagonist	cognitive defect
KFM 19	3,7-dihydro-8-(3-oxocyclopentyl)-1,3-dipropyl-1H-purine-2,6-dione	adenosine antagonist; adenosine A1 antagonist	Alzheimer disease
MDL 102234	(R)-3,7-dihydro-8-(1-phenylpropyl)-1,3-dipropyl-1H-purine-2,6-dione	adenosine antagonist; adenosine A1 antagonist	cognitive defect
MDL 102503	(R)-3,7-dihydro-8-(1-methyl-2-phenylethyl)-1,3-dipropyl-1H-purin-2,6-dione	adenosine antagonist; adenosine A1 antagonist	cognitive defect
midaxifylline; IRFI 117	8-(1-aminocyclopentyl)-3,7-dihydro-1,3-dipropyl-1H-purine-2,6-dione	adenosine antagonist; adenosine A1 antagonist	cognitive defect; depression; kidney disease
apaxifylline; BIIP 20XX; U 98950; BIIP 20	(S)-3,7-dihydro-8-(3-oxocyclopentyl)-1,3-dipropyl 1H-purine-2,6-dione	adenosine antagonist; adenosine A1 antagonist; xanthine	cognitive defect
MAB, adrenomedullin	Unspecified	adrenomedullin monoclonal antibody	cancer; diabetes; Alzheimer disease; diagnosis
Alzheimer's disease therapy		Alpha 2 macroglobulin inhibitor	Alzheimer disease
RU 49041; RU 49067	(3alpha)-(+,-)-11-methyl-20,21-dinoreburnamenine	alpha adrenergic agonist; alpha2 adrenergic partial agonist	cognitive defect
RU 52583	(3alpha)-11-methyl-20,21-dinoreburnamenine	alpha adrenergic agonist; alpha2 adrenergic partial agonist	cognitive defect
NS 1201		AMPA antagonist; glutamate antagonist	cognitive defect
NS 377	7-ethyl-1,6,7,8-tetrahydro-5-phenylbenzo[2,1-b:3,4-c']dipyrrole-2,3-dione 3-oxime	AMPA antagonist; glutamate antagonist	cognitive defect

NS 420	4-[2,3,6,7,8,9-hexahydro-3-(hydroxyimino)-8-methyl-2-oxo-1H-pyrrolo[3,2-h]isoquinolin-5-yl]-N,N-dimethylbenzenesulfonamide	AMPA antagonist; glutamate antagonist	cognitive defect
S 18986; S 18986-1	(S)-2,3,3a,4-tetrahydro-1H-pyrrolo[2,1-c][1,2,4]benzothiadiazine 5,5-dioxide	AMPA antagonist; glutamate antagonist	cognitive defect
CX 691	Unspecified	AMPA glutaminergic receptor ligand	Alzheimer disease; schizophrenia
amyloid aggregation inhibitors	Unspecified	amyloid aggregation inhibitors	Alzheimer disease
antiamyloid	Unspecified	Amyloid antagonists	Alzheimer disease
GT 4001	Unspecified	Amyloid b destruction	Alzheimer disease
GT 4002	Unspecified	Amyloid b destruction	Alzheimer disease
GT 4003	Unspecified	Amyloid b destruction	Alzheimer disease
GT 4011	Unspecified	Amyloid b destruction	Alzheimer disease
GT 5011	Unspecified	Amyloid b destruction	Alzheimer disease
PTI 00703	Cats claw extract	Amyloid b protein deposition inhibitor	Alzheimer disease
amyloid enzyme inhibitors,	Unspecified	amyloid enzyme inhibitors	Alzheimer disease
amyloid inhibiting peptides	Unspecified	amyloid inhibiting peptides	Alzheimer disease
amyloid neurotoxicity antagonists,	Unspecified	amyloid neurotoxicity antagonists,	Alzheimer disease
CX 423	Unspecified	Amyloid neurotoxicity antagonist	Alzheimer disease
amyloid production inhibitors,	Unspecified	amyloid production inhibitors,	Alzheimer disease
amyloid production inhibitors,	Unspecified	amyloid production inhibitors,	Alzheimer disease; diabetes

FID 072021	3-atropanyl 2-(4-chlorophenoxy) butyrate maleate	analgesic	pain; cognitive defect
galanin modulators	Unspecified	galanin modulators analgesic	obesity; diabetes; cognitive defect; pain
galanin1 antagonists	Unspecified	galanin1 antagonists analgesic	obesity; pain; cognitive defect
metabotropic glutamate receptor modulators	Unspecified	metabotropic glutamate receptor modulators analgesic	pain; cognitive defect; schizophrenia; epilepsy
anatoxin analogue,	Unspecified	Anatoxin	Alzheimer disease
prasterone; dehydroepiandrosterone; DHEA; GL 701; NBI 106; PB 007; ASTENILE; DEANDROS; DIANDRON	(3beta)-3-hydroxyandrost-5-en-17-one	androgen; vaccine adjuvant; hormone replacement therapy; corticosteroid	systemic lupus erythematosus; hormone deficiency; Alzheimer disease; reperfusion injury; ischemia
nootropic,	2-(4-allyl-1-piperazinyl)-4-pentyloxyquinazoline	antihypoxic	cognitive defect
RU 35929	(+,-)-5-ethoxy-1-(phenylsulfonyl)-2-pyrrolidinone	antihypoxic	cognitive defect
tenilsetam; tenimal; PAS 997; CAS 997; HR 029	(+/-)-3-(2-thienyl)-2-piperazinone	antihypoxic	cognitive defect
RGH 5279	(3alpha)-eburnamenine-14-carboxylic acid 2-(acetyloxy)ethyl ester monohydrochloride	anti-ischemic	cognitive defect; brain ischemia
CPG 607	Unspecified	antioxidant	cognitive defect
Neurodegenerative disease therapy,	Unspecified	antioxidant	stroke; Alzheimer disease
antioxidant,	Unspecified	antioxidant; free radical scavenger	Alzheimer disease
VANTOX	Unspecified	antioxidant; NSAID	asthma; Parkinson disease; Alzheimer disease; stroke

antisense oligonucleotides, amyloid precursor/beta amyloid proteins; antisense oligonucleotides, Alzheimer's disease	Unspecified	antisense; oligonucleotide amyloid precursor/beta amyloid	Alzheimer disease
antisense oligonucleotide, APO-E4; antisense oligonucleotide, Alzheimer's disease	Unspecified	antisense; oligonucleotide APO-E4;	Alzheimer disease
Alzheimer's disease therapy	Unspecified	ApoE	Alzheimer disease
RU 34332	3-(cyclopropylcarbonyl)-7-fluoro-4,5-dihydro-5-methyl-6H-imidazo[1,5-a][1,4]benzodiazepine-6-one	benzodiazepine	cognitive defect
S 8510	1,6,7,9-tetrahydro-2-(3-isoxazolyl)imidazo[4,5-d]pyrano[4,3-b]pyridine phosphate (1:1)	benzodiazepine inverse agonist	cognitive defect; Alzheimer disease
SX 3933	5-(3-methoxyphenyl)-3-(5-methyl-1,2,4-oxadiazol-3-yl)-1,6-naphthyridin-2(1H)-one monohydrochloride	benzodiazepine inverse agonist	cognitive defect; Alzheimer disease
RU 33965	3-(cyclopropylcarbonyl)-4,5-dihydro-5-methyl-6H-imidazo[1,5-a][1,4]benzodiazepine-6-one	benzodiazepine partial agonist	cognitive defect
terbequinil; SR 25776	1,4-dihydro-1-(methoxymethyl)-4-oxo-N-propyl-3-quinolinecarboxamide	benzodiazepine partial agonist	cognitive defect

nimodipine; BAY e 9736; BAY N 5248; BAY N 5427; NIMOTOP; NIMOTAP; NIVAS; TROPOCER; EUGERIAL; NIMODILAT; CEBROFORT; KENESIL; GENOVOX	1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl 1-methylethyl ester	calcium antagonist	migraine; cognitive defect; Alzheimer disease; brain ischemia
RGH 2716; TDN 345	8-[4,4-bis(4-fluorophenyl)butyl]-3-(1,1-dimethylethyl)-4-methylene-1-oxa-3,8-diazaspiro[4.5]decan-2-one	calcium antagonist	cognitive defect
voltage-dependent calcium channel antagonists, VDCC antagonists	Unspecified	calcium antagonist	Alzheimer disease; neurological
sabeluzole; R 58735; JK 601	(+,-)-4-(2-benzothiazolylmethylamino)-alfa-[(4-fluorophenoxy)methyl]-1-piperidineethanol	calcium antagonist; antihypoxic	Alzheimer disease
Tamolarizine; tamolaridine hydrochloride; NC 1100; ZC 110	(+,-)-alfa-(3,4-dimethoxyphenyl)-2-(4-diphenylmethyl)-1-piperazineethanol	calcium antagonist; vasodilator	cognitive defect; cerebrovascular disease
BAY Z 4406	Unspecified	calcium channel blocker	neurodegeneration; Alzheimer disease
NS 649	1-(2,5-dimethoxyphenyl)-5-(trifluoromethyl)-1H-benzimidazol-2-amine	calcium channel blocker	cognitive defect
elziverine; Ro 224839	1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-4-[[4-(2-methoxyphenyl)-1-piperazinyl]methyl]isoquinoline	calmodulin antagonist; vasodilator	peripheral vascular disease; cognitive defect

drug delivery system, CDS sinnabidol; sinnabidol CDS	Unspecified	cannabinoid; glutamate antagonist; NMDA antagonist	cognitive defect; glaucoma
SK 067	Unspecified	Cerebral metabolic agent	cognitive defect
SNK 882	2-oxo-N-[(tetrahydro- 1H-pyrrolizin- 7a(5H)-yl)methyl]-1- pyrrolidin eacetamide, monohydrochloride	Cerebral metabolic agent	cognitive defect
vinconate; vincantenate; vintenate; OM 853; OC 340; OC 34; BRENAL	(+,-)-methyl 3-ethyl- 2,3,3a,4-tetrahydro- 1H-indolo[3,2,1- de][1,5] naphthyridine-6- carboxylate	Cerebral metabolite enhancer	cognitive defect
SUT 8701	N-[(1,1- dimethylethoxy)carbo nyl]-O- (dimethylphosiny)- L-tyrosyl-L- norleucylglycyl-L- tryptophyl-L- norleucyl-L-alfa- aspartyl-L- phenylalaninamide	cholecystokinin antagonist	Alzheimer disease
sibopirdine; DUP 921; X 9121; EXP 9121; EXP921	5,5-bis(4- pyridinylmethyl)-5H- cyclopenta-[2,1- b:3,4-b']dipyridine	Choline release stimulator	cognitive defect
choline alphoscerate; choline glycerophosphate; GLIATILIN; DELECIT; BREZAL	L-alpha- glycerylphosphorylch oline	Choline releasing agent	cognitive defect
MKC 231	2-oxo-N-(5,6,7,8- tetrahydro-2,3- dimethylfuro[2,3- b]quinolin-4-yl)-1- pyrrolidineacetamide	Choline uptake stimulation	cognitive defect; Alzheimer disease

bifemelane; bifemelane hydrochloride; MCI 2016; E 0687; CELEPORT; ALNERT; NEUROCINE; SURTONIL; CORDINAL	N-methyl-4-[2-(phenylmethyl)phenoxy]-1-butanamine	Cholinergic agent	cognitive defect
ABT 089	(R)-2-methyl-3-(2-pyrrolidinylmethoxy)pyridine	Cholinergic channel modifier	Alzheimer disease
stacofylline; S 9977; S 99772; SE 9977	N,N-diethyl-4-[3-(2,3,6,7-tetrahydro-1,3,7-trimethyl-2,6-dioxo-1H-purin-8-yl)propyl]-1-piperazinecarboxamide monohydrochloride	Cholinergic stimulation, 5HT uptake stimulation	Alzheimer disease
NS 2330	Unspecified	Cholinergic, adrenergic, noradrenergic	cognitive defect
choline derivatives, HOE 065	Choline derivatives	Cholinomimetic	cognitive defect
	[2S-[1[R*(R*)],2alpha,3alpha,beta,6alpha]]-1-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (Z)-2-butenedioate	Cholinomimetic	cognitive defect
acetyl-L-carnitine; acetylcarnitine, L-; ALC; ST 200; TA 803; NICETILE; BRANIGAN; ALCAR; NEUROACTIL; BRANIGEN	acetyl-L-carnitine	Cholinomimetic, stimulation of neuron growth and repair	Alzheimer disease; stroke; diabetes; neuropathy
Alzheimer's therapy,	Unspecified	Complement activation by beta-amyloid	Alzheimer disease

complement activation inhibitors	Unspecified	complement activation inhibitors	Alzheimer disease
Alzheimer's disease therapy,	Unspecified	Complex IV cytochrome oxidase function	Alzheimer disease
ebiratide; ACTH (4-9) analogue; corticotropin (4-9) analogue; HOE 427	4-(methylsulfonyl)-L-2-aminobutanoyl-L-alpha-glutamyl-L-histidyl-L-phenylalanyl-D-lysyl-N-alpha-(8-aminooctyl)-L-phenylalaninamide	corticotropin analogue	Alzheimer disease
GR 253035	Unspecified	COX inhibitor; COX 2 inhibitor; analgesic	pain; Alzheimer disease
rofecoxib; MK 966; VIOXX	4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; rheumatoid arthritis; osteoarthritis; pain; Alzheimer disease
creb gene transcription modulators, CNS disorders,	Unspecified	creb gene transcription modulators	neurodegeneration; Alzheimer disease
CRF1 partial agonist	Unspecified	CRF1 partial agonist	Alzheimer disease; Crohn disease
differentiation-inducing factor; DIF	Unspecified	differentiation-inducing factor; DIF; growth factor; neurotrophic factor	cognitive defect
Alzheimer's disease therapy,	Unspecified	Disease specific protein targets	Alzheimer disease
Alzheimer's disease therapy,	Unspecified	Disease specific protein targets	Alzheimer disease
Alzheimer's disease therapy	Unspecified	Disease specific protein targets	Alzheimer disease
Alzheimer's therapy,	Unspecified	Disease specific protein targets	Alzheimer disease
NDD 094; SDZ NDD094	Unspecified	Disease specific targets	Alzheimer disease
alaptide; VUFB 15754	8-methyl-6,9-diazaspiro[4.5]decane-7,10-dione	dopamine agonist; cicatrizant; peptide	Alzheimer disease; skin ulcer; gastrointestinal ulcer
dihydropyridine; IP 202	trans-5,6,6a,7,8,12b-hexahydro-benzo[a]phenanthridine-10,11-diol	dopamine agonist; dopamine D1 agonist	Parkinson disease; Alzheimer disease

voxergolide; RU 41656	(8beta)-(+,-)-6-methyl-8-[(methylthio)methyl]-9-oxaergoline	dopamine agonist; dopamine D2 agonist	cognitive defect
estrogens,	Estrogens	estrogen	Alzheimer disease
estrogens,	Estrogens	estrogen	neuropathy; Alzheimer disease
ABPI 124	Unspecified	estrogen agonist	Alzheimer disease
17alpha estradiol	estra-1,3,5(10)-triene-3,17alpha-diol	estrogen; hormone replacement therapy	hormone deficiency; cognitive defect
estrogen,	Estrogen	estrogen; neuroactive steroid	Alzheimer disease
estrogen + medroxyprogesterone acetate; PREMPRO; PREMPHASE; PREMARIN MPA; PREMIQUE; PREMIQUE CYCLE	estrogen + medroxyprogesterone acetate	estrogen; progestogen; hormone replacement therapy	hormone deficiency; Alzheimer disease
excitatory amino acid antagonists,	Unspecified	excitatory amino acid antagonist	epilepsy; Alzheimer disease; stroke
carboxylated buckminsterfullerenes; carboxyfullerenes	Carboxylated buckminsterfullerenes; carboxyfullerenes	free radical scavenger; apoptosis inhibitor	amyotrophic lateral sclerosis; Alzheimer disease; Parkinson disease
nefiracetam; feniracetam; DM 9384; DMPPA; TRANSLON	N-(2,6-dimethylphenyl)-2-oxo-1-pyrrolidineacetamide	GABA agonist	cognitive defect
ZK 95962; ZK 45962	ethyl 5-isopropoxy-4-methoxymethyl-beta-carboline-3-carboxylate	GABA agonist	epilepsy; cognitive defect
CGP 36742	(3-aminopropyl)butylphosphinic acid	GABA antagonist	epilepsy; Alzheimer disease
cognition enhancer,	Unspecified	GABA inverse agonist	Alzheimer disease
NGD 971; NGD 97-1	Unspecified	GABA inverse agonist	cognitive defect
suritozole; MDL 26479	2,4-dimethyl-5-(3-fluorophenyl)-3H-1,2,4-triazole-3-thione	GABA inverse agonist	depression; cognitive defect

valproate sodium; sodium valproate; NIK 240; SENITA; SELENICA	2-propylpentanoic acid sodium salt	GABA release enhancer	Alzheimer disease; epilepsy
siagoside; AGF 2	[R-[R*,S*-(E)]]-N- [1-[[[O-[1',2- anhydro]-N-acetyl- alpha-neuraminosyl- (2->3)-O-[O-beta-D- galactopyranosyl-(1- >3)-2-(acetyl-amino)- 2-deoxy-beta-D- galactopyranosyl-(1- >4)-O-beta-D- galactopyranosyl-(1- >4)-beta-D- glucopyranosyl]oxy] methyl]-2-hydroxy-3- heptadecenyl]octadec anamide	ganglioside	cognitive defect; stroke
Dimethylhomospermi ne; DMHSPM	Dimethylhomospermi ne	gastroprokinetic; polyamine analogue	gastrointestinal motility disease; Alzheimer disease
Alzheimer disease therapy,	Unspecified	gene	Alzheimer disease
Alzheimer's disease therapy,	Unspecified	Gene transcription based drugs	Alzheimer disease
ALT 766	Unspecified	Glucose derived cross-link breaker	diabetes; cardiovascular disease; Alzheimer disease
riluzole; PK 26124; RP 54274; RILUTEK	6-(trifluoromethoxy)- 2-benzothiazolamine	glutamate antagonist	amyotrophic lateral sclerosis; Alzheimer disease; Parkinson disease
sinnabidol; HU 211; PA 50211; DEXANABINOL	(6aS-trans)-3-(1,1- dimethylheptyl)- 6a,7,10,10a- tetrahydro-1- hydroxy-6,6- dimethyl-6H- dibenzo[b,d]pyran-9- methanol	glutamate antagonist; cannabinoid; NMDA antagonist; free radical scavenger	cognitive defect; stroke; trauma; myocardial infarction; glaucoma

LY 341495	[1S-[1alpha(R*),2beta]]-alpha-amino-alpha-(2-carboxycyclopropyl)-9H-xanthene-9-propanoic acid	glutamate antagonist; mGluR antagonist	psychosis; cognitive defect
PD 129653; SC 46643	(+)-alpha-amino-4-(phosphonomethyl)benzeneacetic acid	glutamate antagonist; NMDA antagonist	cognitive defect
PD 130527	3-(phosphonomethyl)phenylalanine	glutamate antagonist; NMDA antagonist	cognitive defect
dimiracetam; ISF 4185	dihydro-1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione	Glutaminergic, cholinergic pathways, inhibition of hippocampal serotonergic activity	cognitive defect
glycine transporter modulator,	Unspecified	glycine antagonist	epilepsy; cognitive defect
gene therapy, nerve growth factor	Unspecified	growth factor	Alzheimer disease
BU 4514N	Unspecified	growth factor	cognitive defect
CX 438	Unspecified	growth factor	Alzheimer disease
nerve growth factor inducer, NGF inducer,	Unspecified	growth factor	Alzheimer disease
drug delivery system, polymer pellet nerve growth factor; NGF polymer pellet	NGF polymer pellet	growth factor;	Alzheimer disease
neurodegenerative disease therapy,	Unspecified	growth factor; growth factor modulator	cognitive defect; Alzheimer disease; neuropathy
GPI 1046	1-(3,3-dimethyl-1,2-dioxopentyl)-L-proline 3-(3-pyridinyl)propyl ester	growth factor; neurotrophic factor	Alzheimer disease; Parkinson disease; multiple sclerosis; neuropathy
neurotrophin agonist,	Unspecified	growth factor; neurotrophic factor	Alzheimer disease; Parkinson disease; neuropathy
NIL-A	Unspecified	growth factor; neurotrophic factor	Alzheimer disease; Parkinson disease; multiple sclerosis; neuropathy

drug delivery system, neurotrophin-3 secreting implant; NT-3 implant	NT-3	growth factor; neurotrophic factor; biotechnology	Alzheimer disease; Parkinson disease; neuropathy
ciproxifan; compound 359; BP 2359	Cyclopropyl[4-[3-(1H-imidazol-4-yl)propoxyl]phenyl]methanone	histamine antagonist; histamine H3 antagonist	Alzheimer disease; schizophrenia; cognitive defect
compound 421	Unspecified	histamine antagonist; histamine H3 antagonist	Alzheimer disease; schizophrenia; cognitive defect
GR 175737	Unspecified	histamine antagonist; histamine H3 antagonist	Alzheimer disease; cognitive defect
GT 2016	1-(5-cyclohexyl-1-oxopentyl)-4-(1H-imidazol-4-yl)piperidine	histamine antagonist; histamine H3 antagonist	cognitive defect; stroke; attention deficit disorder
GT 2227	1-[1H-imidazol-4-yl]-6-cyclohexyl-cis-hex-3-ene	histamine antagonist; histamine H3 antagonist	cognitive defect; attention deficit disorder
GT 2331	4-[(1R,2R)-2-(5,5-dimethyl-1-hexynyl)cyclopropyl]-1H-imidazole	histamine antagonist; histamine H3 antagonist	cognitive defect; attention deficit disorder; Alzheimer disease
thioperamide; MR 12842	N-cyclohexyl-4-(1H-imidazol-4-yl)-1-piperidinecarbothioamide	histamine antagonist; histamine H3 antagonist	cognitive defect
drug delivery system, thyrotropin releasing hormone; TRH-SR; HILTONIN SR	Unspecified	hormone	cognitive defect
ICE inhibitors,	Unspecified	IL-1 beta converting enzyme inhibitor; caspase inhibitor; NSAID	endotoxic shock; rheumatoid arthritis; Alzheimer disease
AIT 083	Unspecified	immunostimulant	cognitive defect

CEP 1347; KT 7515	[9S-(9alpha,10beta,12alpha)-5,16-bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, methyl ester	Kinase inhibitor, jnk inhibitor	Alzheimer disease
m-NBA	2-amino-3-(3-nitrobenzoyl)propanoic acid	kynurenine 3 hydroxylase inhibitor	epilepsy; Parkinson disease; Alzheimer disease
Maillard reaction inhibitors	Unspecified	Maillard reaction ; blocks glycated proteins	atherosclerosis; Alzheimer disease
drug delivery system, transdermal selegiline; selegiline transdermal	Selgiline	MAO B inhibitor; MAO inhibitor	Alzheimer disease; depression
lazabemide; Ro 196327; PAKIO; TEMPIUM	N-(2-aminoethyl)-5-chloro-2-pyridine-carboxamide	MAO B inhibitor; MAO inhibitor	Parkinson disease; Alzheimer disease
LU 53439	3,4-dimethyl-7-(2-isopropyl-1,3,4-thiadiazol-5-yl)-methoxy-coumarin	MAO B inhibitor; MAO inhibitor	Parkinson disease; cognitive defect
rasagiline; rasagiline mesylate; TVP 1012; TV 1012	(R)-2,3-dihydro-N-2-propynyl-1H-inden-1-amine	MAO inhibitor; MAO B inhibitor	Parkinson disease; Alzheimer disease
SL 251188	Unspecified	MAO inhibitor; MAO B inhibitor	Alzheimer disease; nicotine withdrawal
neurodegenerative disease therapy	Unspecified	monoclonal antibody; biotechnology	neurodegeneration; Alzheimer disease
BY 1949	3-methoxy-11-methyl-dibenz(b,f)(1,4)oxazepine-8-carboxylic acid	Na ⁺ , K ⁺ ATPase activation	cerebrovascular disease; cognitive defect
SR 57667	Unspecified	Neurodegeneration protection agent	Alzheimer disease; Parkinson disease

memory enhancer,	Unspecified	Neuron enhancement at hippocampus	cognitive defect
neurophilins	Neurophilins	Neurophilin receptor ligand	Alzheimer disease; Parkinson disease; neuropathy
lubeluzole; R 87926; PROSYNAP	(S)-4-(2-benzothiazolylmethylamino)-alpha-[(3,4-difluorophenoxy)methyl]-1-piperidineethanol	Neuroprotectant	stroke; Alzheimer disease
CX 417	Unspecified	Neurotransmitter receptro modulator	Alzheimer disease
DMP 543	10,10-bis[(2-fluoro-4-pyridinyl)methyl]-9(10H)-anthracenone	Neurotransmitter release	Alzheimer disease
leteprinin; leteprinin potassium; AIT 082; NEOTROFIN	4-[[3-(1,6-dihydro-6-oxo-9H-purin-9-yl)-1-oxopropyl]amino]benzoic acid	Neurotrophic factor production stimulation	cognitive defect; Alzheimer disease
CEP 427	Unspecified	neurotrophic factor; growth factor	Alzheimer disease
K 252a derivative	[(9S-(9alpha,10beta,12alpha))-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo3,4-i][1,6]benzodiazocine-10-carboxylic acid methyl ester	neurotrophic factor; growth factor	neuropathy; Alzheimer disease
NS 506	Unspecified	neurotrophic factor; growth factor	cognitive defect
NS 521	Unspecified	neurotrophic factor; growth factor	Alzheimer disease; neuropathy; cancer; diabetes

ST 857	[R-(R*,S*)]-2-(acetyloxy)-4-[[4-[(aminoiminomethyl)amino]-1-carboxybutyl]amino]-N,N,N-trimethyl-4-oxo-1-butanaminium chloride	neurotrophic factor; growth factor	cognitive defect
eurystatin A; Bu 4164EA	[3S-[3R*,7R*,10R*(E)]]-6-methyl-N-[7-methyl-3-(2-methylpropyl)-2,5,6,9-tetraoxo-1,4,8-triazacyclotridec-10-yl]-2-heptenamide	neutral endopeptidase inhibitor	Alzheimer disease
eurystatin B; Bu 4164EB	[3S-[3R*,7R*,10R*(E)]]-6-methyl-N-[7-methyl-3-(2-methylpropyl)-2,5,6,9-tetraoxo-1,4,8-triazacyclotridec-10-yl]-2-octenamide	neutral endopeptidase inhibitor	Alzheimer disease
Y 29794	[2-[[8-(dimethylamino)octyl]thio]-6-(1-methylethyl)-3-pyridinyl]-2-thienylmethanone	neutral endopeptidase inhibitor	cognitive defect; Alzheimer disease
neurodegeneration therapy	Unspecified	Nicotinic compounds	Alzheimer disease; Parkinson disease
memantine; D 145; NMI 131; AKATINOL	3,5-dimethyl-1-adamantanamine	NMDA antagonist; analgesic; glutamate antagonist	cognitive defect; pain; glaucoma; neuropathy
CR 2249	(S)-4-amino-5-[(4,4-dimethylcyclohexyl)amino]-5-oxopentanoic acid	NMDA modulator	Alzheimer disease
GVS 111	1-(phenylacetyl)-L-prolylglycine ethyl ester	NMDA modulator	cognitive defect

adafenoxate; WON 150	4-chlorophenoxyacetic acid 2-(1-adamantylamino)ethyl ester	Nootropic agent	cognitive defect
ALE 26015	Unspecified	Nootropic agent	cognitive defect; Alzheimer disease
aloracetam; CAS 493	N-[2-(3-formyl-2,5-dimethylpyrrol-1-yl)ethyl]acetamide	Nootropic agent	cognitive defect
Alzheimer's disease therapy,	Unspecified	Nootropic agent	Alzheimer disease
AWD 5239	9,10-dihydrolysergic acid bis-(beta-acetoxyethyl)amide monotartrate	Nootropic agent	cognitive defect
bacoside A	3-[(O-alfa-L-arabinosyl-beta-D-glucosyl)oxy]-19,20-dihydroxydammar-24-en-16-one	Nootropic agent	cognitive defect
bacoside A + bacoside B	Unspecified	Nootropic agent	cognitive defect
bacoside B	3-[(O-L-arabinosyl-D-glucosyl)oxy]-19,20-dihydroxydammar-24-en-16-one	Nootropic agent	cognitive defect
BDP	(11beta,16beta)-9-chloro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)pregna-1,4-diene-3,20-dione	Nootropic agent	Alzheimer disease
BMY 21502; BMS 181168	1-[[1-[2-(trifluoromethyl)-4-pyrimidinyl]-4-piperidinyl]methyl]-2-pyrrolidinone	Nootropic agent	cognitive defect
BR 16A	Unspecified	Nootropic agent	cognitive defect
CGP 34735	Unspecified	Nootropic agent	cognitive defect
CGP 50068A	Unspecified	Nootropic agent	cognitive defect

CL 275838	4,5-dihydro-4-((4-(phenylmethyl)-1-piperazinyl)acetyl)-7-(3-(trifluoromethyl)phenyl)pyrazolo(1,5-a)pyrimidine-3-carbonitrile	Nootropic agent	cognitive defect
CX 516; AMPALEX	1-(6-quinoxalinylnylcarbonyl)piperidine	Nootropic agent	Alzheimer disease; schizophrenia
cycloserine-D; cycloserine; SC 49088	4-amino-3-isoxazolidinone	Nootropic agent	Alzheimer disease
dabelotine; S 12024; S 120242	(S)-1,2,3,4-tetrahydro-1-methyl-8-(2-morpholinylmethoxy)quinoline monomethanesulfonate	Nootropic agent	Alzheimer disease
exifone; ADLONE	2,3,3',4,4',5'-hexahydroxybenzophenone	Nootropic agent	cognitive defect
fasoracetam; NS 105; LAM 105	(R)-1-[(5-oxo-2-pyrrolidinyl)carbonyl]piperidine	Nootropic agent	cerebrovascular disease; cognitive defect
FR 121196	1-acetyl-4-[[4-(fluorophenyl)sulfonyl]amino]piperazine	Nootropic agent	cognitive defect; sexual dysfunction
gedocarnil; SH 530; ZK 113315	5-(4-chlorophenoxy)-4-(methoxymethyl)-9H-pyrido[3,4-b]indole-3-carboxylic acid 1-methylethyl ester	Nootropic agent	cognitive defect
idebenone; CV 2619; AVAN; LUCEBANOL; GENICERAL; MNESIS; DARUMA; NEMOCEBRAL; KEDANON; ARZKAT; DAYSTROM	2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione	Nootropic agent	cognitive defect

IDRA 21	7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide	Nootropic agent	cognitive defect
KI 711	Sialic acid derivative	Nootropic agent	Alzheimer disease
KW 6055	N-[3-nitro-4-(2-pyridinylmethyl)phenyl]butanamide	Nootropic agent	cognitive defect
mexidol	2-ethyl-6-methyl-3-hydroxypyridine succinate	Nootropic agent	anxiety; cognitive defect
oxiracetam; ISF 2522; CT 848; CGP 21690; NEUROMET; NEURACTIV; SENEX	4-hydroxy-2-oxo-1-pyrrolidineacetamide	Nootropic agent	cognitive defect
P 128	Unspecified	Nootropic agent	cognitive defect
P 58	Unspecified	Nootropic agent	Alzheimer disease; cognitive defect
P 867493	Unspecified	Nootropic agent	cognitive defect
P 878184	Unspecified	Nootropic agent	cognitive defect
PPRT 424	Ginko bilboa extract	Nootropic agent	cognitive defect
pramiracetam; amacetam; CI 879; CNS 1879; ECTAPRAM; NEUPRAMIR; REMEM	N-[2-[bis-(1-methylethyl)amino]ethyl]-2-oxo-1-pyrrolidineacetamide	Nootropic agent	Alzheimer disease
prisotinol; prisotinal; CGS 5649B	(+,-)-6-[2-(isopropylamino)propyl]-3-pyridinol	Nootropic agent	cognitive defect
RU 47067	5-(1-methylethoxy)-1,3-(trifluoromethyl)phenylsulfonyl-2-pyrrolidinone	Nootropic agent	cognitive defect
SC 110	Unspecified	Nootropic agent	Alzheimer disease
SEE 405	Unspecified	Nootropic agent	Alzheimer disease
South American frog toxins	Histrionicotoxin	Nootropic agent	Alzheimer disease
UCB 11056	Unspecified	Nootropic agent	Alzheimer disease
UCB 29427	Unspecified	Nootropic agent	cognitive defect
UCB 29536	Unspecified	Nootropic agent	cognitive defect

Z 4105	N-(3-carboxypropyl)-3-methylisoxazole-5-carboxamide	Nootropic agent	cognitive defect
T 588	(R)-1-alfa-[[2-(diethylamino)ethoxy]methyl]benzo[b]thiophene-5-methanol hydrochloride	Nootropic agent, neurodegeneration protection	cognitive defect
VA 045	(3alpha,16alpha)-eburnamenine-14-carboxylic acid 2-(nitrooxy)ethylester, apovincaminic acid derivative	Nootropic agent, neuroprotective agent	cognitive defect
nebracetam; WEB 1881; WEB 1881FU; MEMOLOG	4-aminomethyl-1-benzylpyrrolidin-2-one hemifumarate	Nootropic agent, unknown mechanism	Alzheimer disease
DQ-CER	des-Gln2-[Leu5,Nle8]-cerulein	Nootropic agent	cognitive defect
MCI 225	4-(2-fluorophenyl)-2-methyl-6-(piperazin-1-yl)-3a,7a-dihydrothieno[2,3-d]pyrimidine	Noradrenergic, serotonergic reuptake inhibitors	cognitive defect; depression
notch signalling pathway modulators	Unspecified	notch signalling pathway modulators	stroke; cognitive defect; cancer
CPH 82; REUMACON; COMIHOG	Unspecified	NSAID	inflammation; Alzheimer disease
HCT 1026	Unspecified	NSAID; nitric oxide donor	urinary incontinence; Alzheimer disease; osteoporosis
quadazocine; WIN 444413; WIN 44441	(-)-(2R,6S,11S)-1-cyclopentyl-5-(1,2,3,4,5,6-hexahydro-8-hydroxy-3,6,11-trimethyl-2,6-methano-3-benzazocin-11-yl)-3-pentanone	opiate antagonist; kappa antagonist	cognitive defect
MAb, OX 26-nerve growth factor conjugate; MAb, OX 26-NGF conjugate; OX 26-NGF	Unspecified	OX 26-nerve growth factor conjugate monoclonal antibody	cognitive defect

ACTH (4-10); SEMAX	Unspecified	peptide	cognitive defect; trauma; stroke
Alzheimer disease therapy,	Unspecified	peptide	Alzheimer disease
beta-sheet breaker,	Unspecified	peptide	Alzheimer disease
Transglutaminase inhibitor	Unspecified	peptide; transglutaminase inhibitor	psoriasis; Alzheimer disease
KS 505a	2,3,4,4a,4b,5,6,6a,6b, 7,8,8a,8b,9,10,10a,16, 16a,16b,17,18,18a,18 b,19,2 0,20a,20b,21,22,22a,- triacontahydro- 8a,10a- bis(hydroxymethyl)- 14-(4-methoxy-1,4- dioxobutyl)1,4,4a,6,6 a,16b,18b,20b- octamethyl-2-((2-O - methyl-beta-D- glucopyranuronosyl)o xy)-1H- benzo(9,10)picen o(3,4-a)xanthene- 1,15-dicarboxylic acid	phosphodiesterase inhibitor	cognitive defect
Rolipram; ZK 62711; ME 3167; ADEO	4-[3- (cyclopentyloxy)-4- methoxyphenyl]-2- pyrrolidinone	phosphodiesterase inhibitor	cognitive defect; multiple sclerosis
Propentofylline; HWA 285; HEXTOL; BRAINORM; VIVIQ	3-methyl-1-(5-oxo- hexyl)-7- propylxanthine	phosphodiesterase inhibitor; xanthine	Alzheimer disease
Diethylnorspermine; DENSPM; CI 1006; DE 333	N1,N11- diethylnorspermine	polyamine analogue	cancer; psoriasis; Alzheimer disease
Dipropylnorspermine; DPNSPM	Dipropylnorspermine	polyamine analogue	diarrhea; Alzheimer disease
linear polyamine analogue	linear polyamine analogue	polyamine analogue	cancer; Alzheimer disease
Polymerization inhibitor	Unspecified	polymerization inhibitor	Alzheimer disease

Clausenamide	(3R,4S,5S)-rel-3-hydroxy-5-[(R)-hydroxyphenylmethyl]-1-methyl-4-phenyl-2-pyrrolidinone	potassium channel blocker	cognitive defect
Potassium channel modulators,	Unspecified	potassium channel modulator	cognitive defect; attention deficit disorder; depression; asthma; diabetes
Alzheimer's disease therapy	Unspecified	Presenilins	Alzheimer disease
JTP 3399	Unspecified	prolyl endopeptidase inhibitor	cognitive defect
JTP 4819	[S-(R*,R*)]-2-[[2-(hydroxyacetyl)-1-pyrrolidinyl]carbonyl]-N-(phenylmethyl)-1-pyrrolidinecarboxamide	prolyl endopeptidase inhibitor	Alzheimer disease; cognitive defect
ONO 1603	(S)-N-[(4-chlorophenyl)methyl]-2-formyl-gamma-oxo-1-pyrrolidinebutanamide	prolyl endopeptidase inhibitor	Alzheimer disease
S 17092	Unspecified	prolyl endopeptidase inhibitor	Alzheimer disease; cognitive defect
Z 321	(4R)-3-(2-indanyl-2-ylacetyl)-4-(1-pyrrolidinylcarbonyl)-1,3-thiazolidine	prolyl endopeptidase inhibitor	cerebrovascular disease; cognitive defect; Alzheimer disease
CEP 431	Unspecified	proteinase inhibitor	Alzheimer disease
proteinase inhibitors,	Unspecified	proteinase inhibitor	cognitive defect
SIB T1980	Unspecified	proteinase inhibitor	Alzheimer disease
azetirelin; YM 14673	(S)-N-[(4-oxo-2-azetidiny]carbonyl]-L-histidyl-L-prolinamide	protirelin analogue	cognitive defect
JTP 2942	(1S-cis)-N-[(2-methyl-4-oxocyclopentyl)carbonyl]-L-histidyl-L-prolinamide	protirelin analogue	cognitive defect

posatirelin; RGH 2202	(S)-N-[(6-oxo-2-piperidinyl)carbonyl]-L-leucyl-L-prolinamide	protirelin analogue	cognitive defect; obesity
Alzheimer's disease therapy,	Unspecified	Serum amyloid p component	Alzheimer disease
igmesine; igmacine; JO 1784	(+)-N-(1,4-diphenyl-3-butenyl)-N-methylcyclopropane methanamine	sigma agonist	depression; cognitive defect; diarrhea
SA 4503	1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride	sigma agonist	Alzheimer disease; depression; cognitive defect; stroke
octreotide; octreotide acetate; SMS; SMS 201995; SMS 201995ac; SMS 995; SANDOSTATIN; SANDOSTATINE; SANDOSTATINA; LONGASTATINA; SAMILSTATINA	[R-(R*,R*)]-D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide cyclic (2-7)-disulfide	somatostatin analogue; analgesic	Alzheimer disease; cancer; viral infection; psoriasis; diarrhea; diabetes; pain; acromegaly
NX D2858; NXD 2858	Unspecified	Spherons, inhibition of spherons into plaques	Alzheimer disease
screening technology, ADAP	Unspecified	target based screening	drug design technology; Alzheimer disease
drug delivery system, thyroid stimulating hormone;	Unspecified	thyroid stimulating hormone delivery system	cognitive defect
thalidomide; NSC 66847	N-(2,6-dioxo-3-piperidyl)phthalimide	TNF modulator; immunosuppressant	HIV infection; Crohn disease; multiple sclerosis; Alzheimer disease; transplant rejection

CEP 3265; CB 1093	5-[[1-(2-ethoxy-6-ethyl-6-hydroxy-1-methyl-3-octynyl)octahydro-7a-methyl-4H-inden-4-ylidene]ethylidene]-4-methylene-1,3-cyclohexanediol	transcription activator	neurodegeneration; Alzheimer disease
ademetonine; FO 1561; GUMBARAL; DONAMET; TRANSMETIL; CERITAN; ERGEN; TWIN; SAMY R	(3S)-5'-[(3-amino-3-carboxypropyl)methylsulfonio]-5'-deoxyadenosine hydroxide inner salt	transmethylator; NSAID	inflammation; cognitive defect; cholestasis
AIT 034; AIT 34	1,6-dihydro-6-oxo-N-[3-(2-oxo-1-pyrrolidiny)propyl]9H-purine-9-propanamide	Unknown	cognitive defect
BTG 1640	Heterocyclic compound	unknown	cognitive defect; Alzheimer disease
cebaracetam; ZY 15119	(+,-)-4-[[4-(p-chlorophenyl)-2-oxo-1-pyrrolidiny]acetyl]-2-piperazinone	Unknown	cognitive defect
fatty acids, microalgal	Unspecified	Unknown	hyperlipidemia; Parkinson disease; Alzheimer disease; eye disease
NBI 107	Unspecified	vaccine adjuvant; immunostimulant; neuroactive steroid	infectious disease; Alzheimer disease
NBI 108	Unspecified	vaccine adjuvant; immunostimulant; neuroactive steroid	Alzheimer disease; infectious disease; multiple sclerosis
pregnenolone; NBI 113	Unspecified	vaccine adjuvant; immunostimulant; neuroactive steroid	infectious disease; Alzheimer disease

vinpocetine; AY 27255; CAVINTON; CERACTON; AIRPACIL; MEDICHILL; NAIKINOL TEISAN; NAIKINOL IWAKI	(3alpha,16alpha)-eburnamenine-14-carboxylic acid ethyl ester	vasodilator	peripheral vascular disease; cognitive defect
vasoactive intestinal peptide analogue; [stearyl norleucine17]VIP; [St-Nle17]VIP	Unspecified	VIP agonist	Alzheimer disease

Table 28. Current Candidate Therapeutic Interventions for the Treatment of Depression

Product Name	Chemical Name	Action	Indication
CP 110330	N,N-dimethyl-5-[4-[(phenylamino)methyl]-2-thiazolyl]-1H-indole-3-ethanamine	5HT agonist; 5HT1 agonist	migraine; anxiety; depression
CP 119333	N,N-dimethyl-5-[4-(phenylmethyl)-2-thiazolyl]-1H-indole-3-ethanamine	5HT agonist; 5HT1 agonist	migraine; anxiety; depression
F 12439		5HT agonist; 5HT1A agonist	depression; anxiety
Flesinoxan; DU 29373	(+)-N-[2-[4-[2,3-dihydro-2-(hydroxymethyl)-1,4-benzodioxin-5-yl]-1-piperazinyl]ethyl]-4-fluorobenzamide	5HT agonist; 5HT1A agonist	anxiety; depression
Gepirone; gepirone hydrochloride; MJ 13805; BMY 13805; BMY 138051	4,4-dimethyl-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,6-piperidinedione	5HT agonist; 5HT1A agonist	anxiety; depression
Ipsapirone; BAY q 7821; TVX q 7821	2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2-benzisothiazol-3(2H)-one 1,1-dioxide	5HT agonist; 5HT1A agonist	depression; anxiety

LY 228729	4-(dipropylamino)-1,3,4,5-tetrahydrobenz[cd]indole-6-carboxamide	5HT agonist; 5HT1A agonist	anxiety; depression
ORG 13011		5HT agonist; 5HT1A agonist	depression
S 14671	N-[2-[4-(7-methoxy-1-naphthalenyl)-1-piperazinyl]ethyl]-2-thiophenecarboxamide	5HT agonist; 5HT1A agonist	anxiety; depression
U 92016A		5HT agonist; 5HT1A agonist	anxiety; depression
U 93385; U 93385E	(3aR-cis)-2,3,3a,4,5,9b-hexahydro-3-propyl-1H-benz[e]indole-9-carboxamide	5HT agonist; 5HT1A agonist	anxiety; depression
WY 48723	octahydro-3-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,5-methano-6,7,9-metheno-2H-pentaleno[1,2-a]azepin-2,4(3H,5H)-dione dihydrochloride	5HT agonist; 5HT1A agonist	depression
SL 870765		5HT agonist; 5HT1A agonist; 5HT antagonist; 5HT1D antagonist	anxiety; depression
Adatanserin; adatanserin hydrochloride; WY 50324; WAY SEB 324; SEB 324	N-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]tricyclo[3.3.1.1(3,7)]decane-1-carboxamide	5HT agonist; 5HT1A agonist; 5HT antagonist; 5HT2 antagonist	anxiety; depression
FG 5865	2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxamide monohydrochloride	5HT agonist; 5HT1A agonist; 5HT antagonist; 5HT2 antagonist	anxiety; depression
FG 5893; FG 5974	(2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-3-pyridinecarboxylic acid methyl ester)	5HT agonist; 5HT1A agonist; 5HT antagonist; 5HT2 antagonist	anxiety; depression

AF 2968	(S)-[R-(R*,R*)]-2,3-2-[3-[4-(3-chlorophenyl)-2-methyl-1-piperazinyl]propyl]-1,2,4-triazolo[4,3-a]pyridin-3(2H)-one dihydroxybutanedioate (1:1)	5HT agonist; 5HT1A agonist; 5HT antagonist; 5HT2A antagonist; 5HT2C antagonist	depression
Sunepitron; CP 93393; CP 93393-1	(7S-trans)-1-[[octahydro-2-(2-pyrimidinyl)-2H-pyrido[1,2-a]pyrazin-7-yl]methyl]-2,5-pyrrolidinedione	5HT agonist; 5HT1A agonist; alpha adrenergic antagonist; alpha2 adrenergic agonist	depression; anxiety
Aromatic triflates,		5HT agonist; 5HT1D agonist	depression; migraine
GMC 2020		5HT agonist; 5HT1D agonist	depression; migraine
GMC 2021	trifluoromethanesulfonic acid 3-[2-(dimethylamino)ethyl]-1H-indol-5-yl ester (1:1) ethanedioate	5HT agonist; 5HT1D agonist	depression; migraine
ORG 12962		5HT agonist; 5HT2C agonist	depression
ORG 37684		5HT agonist; 5HT2C agonist	depression
Ro 600175; Ro 60-0175	(alphaS)-6-chloro-5-fluoro-alpha-methyl-1H-indole-1-ethanamine (2E)-2-butenedioate (1:1)	5HT agonist; 5HT2C agonist	depression; obsessive compulsive disorder
SR 57227; CM 57277	1-(6-chloro-2-pyridinyl)-4-piperidinamine	5HT agonist; 5HT3 agonist	depression
5HT1B antagonists, BN 50156	3-(4-chlorophenyl)-alpha-[3-(dimethylamino)-1-propenyl]-1,3-dihydro-7-hydroxyfuro[3,4-c]pyridine-6-methanol	5HT antagonist	depression; anxiety
DU 123015		5HT antagonist	anxiety; depression

DU 125530		5HT antagonist	depression; anxiety; psychosis
Moxymetin		5HT antagonist	depression
SB 245570		5HT antagonist	depression
5-HT antagonist, pindobind	2-bromo-N-[4-[1-[[2-hydroxy-3-(1H-indol-4-ylloxy)propyl]amino]-1-methylethyl]-1-methylcyclohexyl]acetamide	5HT antagonist; 5HT1A antagonist	anxiety; depression
Robalzotan; NAD 299	(3R)-3-(dicyclobutylamino)-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide (2R,3R)-2,3-dihydroxybutanedioate (1:1)	5HT antagonist; 5HT1A antagonist	anxiety; depression
S 14063	1-(2-benzothiazolyl)-N-[2-(2-methoxyphenoxy)ethyl]-4-piperidinemethanamine dihydrochloride	5HT antagonist; 5HT1A antagonist	depression
S 15535	1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-(2,3-dihydro-1H-inden-2-yl)piperazine	5HT antagonist; 5HT1A antagonist	anxiety; depression
Buspirone hydrochloride; MJ 40221; MJ 9022; BESPAR; BUSPAR; NORMATON; TUTRAN; NAROL; ANSIENON; ANSITEN; TRANBUS; SIMPLESS	8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-8-azaspiro[4,5]decane-7,9-dione hydrochloride	5HT antagonist; 5HT1A antagonist; dopamine agonist	anxiety; depression; dermatitis
Drug delivery system, transdermal buspirone; buspirone transdermal		5HT antagonist; 5HT1A antagonist; dopamine agonist	anxiety; depression; attention deficit disorder

EF 7412	N-3-[4-[4-(tetrahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H-yl)butyl]-1-piperazinyl]phenyl]ethanesulfonamide	5HT antagonist; 5HT1A antagonist; glutamate release inhibitor	neurodegeneration; depression; cancer
L 694247	N-[4-[[5-[3-(2-aminoethyl)-1H-indol-5-yl]-1,2,4-oxadiazol-3-yl]methyl]phenyl]methanesulfonamide	5HT antagonist; 5HT1D antagonist	depression
GR 127935	N-(4-methoxy-3-(4-methyl-1-piperazinyl)phenyl-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-5-yl)-1H-indole-3-yl)ethylamine	5HT antagonist; 5HT1Dbeta antagonist	depression
Flibanserin; BIMT 17	1,3-dihydro-1-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-2H-benzimidazol-2-one	5HT antagonist; 5HT2 antagonist; 5HT agonist; 5HT1A agonist	depression
HT 90B	(-)-N-[2-[[[(2,3-dihydro-8-methyl-1,4-benzodioxin-2-yl)methyl]amino]ethyl]tricyclo[3.3.1.1 ^{3,7}]decane-1-carboxamide	5HT antagonist; 5HT2 antagonist; 5HT agonist; 5HT1A agonist	anxiety; depression
Nefazodone; MJ 13754; MS 13754; BMY 13754; BMY 137541; SERZONE; DUTONIN; RESERIL; NEFADAR; NIFEREL; MENFAZONA; RULIVAN; DEPREFAX; SERZONIL	2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-2,4-dihydro-4-(2-phenoxyethyl)-3H-1,2,4-triazol-3-one	5HT antagonist; 5HT2 antagonist; 5HT reuptake inhibitor; alpha adrenergic antagonist; alpha1 adrenergic antagonist	depression

Amesergide; amerserzide; LY 237733	8beta-N-cyclohexyl- 6-methyl-1-(1- methylethyl)ergoline- 8-carboxamide	5HT antagonist; 5HT2 antagonist; 5HT1C antagonist	sexual dysfunction; depression; anxiety
Mirtazapine; mepirzepine; azamianserin; ORG 3770; REMERON; ZISPIN	1,2,3,4,10,14b- hexahydro-2- methylpyrazino[2,1- a]pyrido[2,3- c][2]benzaz epine	5HT antagonist; 5HT2 antagonist; 5HT3 antagonist; alpha2 adrenergic antagonist; alpha adrenergic antagonist	depression
Olanzapine; LY 170053; ZYPREX; ZYPREXA; OLANZEK	2-methyl-4-(4- methyl-1- piperazinyl)-10H- thieno[2,3- b][1,5]benzodiazepi ne	5HT antagonist; 5HT2 antagonist; dopamine antagonist; dopamine D2 antagonist	schizophrenia; psychosis; depression
ORG 37415		5HT antagonist; 5HT2C antagonist	depression; anxiety
SB 228357	N-[3-fluoro-5-(3- pyridinyl)phenyl]- 2,3-dihydro-5- methoxy-6- (trifluoromethyl)-1H- indole-1-carboxamide	5HT antagonist; 5HT2C antagonist	anxiety; depression
Antidepressant		5HT antagonist; 5HT3 antagonist	depression; anxiety
5HT7 receptor antagonists,		5HT antagonist; 5HT7 antagonist	depression; insomnia; schizophrenia
DR 4004		5HT antagonist; 5HT7 antagonist	depression; insomnia
THE JL3; JL 3	10-(4-methyl-1- piperazinyl)- pyrido[4,3- b][1,4]benzothiazepi e	5HT antagonist; dopamine antagonist	anxiety; depression
BMS 181101; BMY 42569	5-fluoro-3-[3-[4- (1,4,5,6- tetrahydropyrimidin- 4-yl)-2,3- dihydropyrazin-1- yl]propyl]-2,3- dihydro-1H-indole	5HT reuptake inhibitor	depression

Cericlamine; JO 1017(+,-); JO 1239(-); JO 1240(+)	(+,-)-3,4-dichloro-beta-(dimethylamino)-beta-methylbenzenepropanol	5HT reuptake inhibitor	depression
CGP 6085A	4-(5,6-dimethyl-2-benzofuranyl)piperidine hydrochloride	5HT reuptake inhibitor	depression
Citalopram; nitalopram; nitalapram; ZD 211; LU 10171; CIPRAMIL; SEROPRAM; CIPRAM; ELOPRAM; CELEXA	1-[3-(dimethylamino)propyl]-1-4-fluorophenyl)-5-isobenzofurancarbonitrile	5HT reuptake inhibitor	depression
Citalopram, (S); (+)-citalopram	(S)-1-[3-(dimethylamino)propyl]-1-4-fluorophenyl)-5-isobenzofurancarbonitrile	5HT reuptake inhibitor	depression
Dapoxetine; LY 210448	(S)-N,N-dimethyl-alpha-[2-(1-naphthalenyloxy)ethyl]benzenemethanamine	5HT reuptake inhibitor	depression
Depression therapy,		5HT reuptake inhibitor	depression
Dexfenfluramine; dexfenfluramine hydrochloride; S 5614; IP 001; ISOMERIDE; ADIFAX; ARDIX; ISOLIPAN; SIRAN; OBESINE; FLURIL; DISPONDAL; REDUX	(S)-N-ethyl-alpha-methyl-3-(trifluoromethyl)benzeneethanamine	5HT reuptake inhibitor	obesity; depression; nicotine withdrawal

Drug delivery system, controlled release GEOMATRIX paroxetine; paroxetine GEOMATRIX; PAXIL CR		5HT reuptake inhibitor	depression
FCE 25876	(E)-N-methyl-3- phenyl-3-(4- trifluoromethylpheno xy)-2-propen-1-ami ne	5HT reuptake inhibitor	depression
FI 4500		5HT reuptake inhibitor	depression
FI 4501		5HT reuptake inhibitor	depression
FI 4503		5HT reuptake inhibitor	depression
Fluoxetine, (R)-; (R)- fluoxetine	(R)-N-methyl- gamma-[4- (trifluoromethyl)phen oxy]benzenepropana mine	5HT reuptake inhibitor	migraine; cognitive defect; depression
Fluvoxamine; fluvoxamine maleate; DU 23000; MK 264; SME 3110; FEVARIN; FLOXYFRAL; LUVOX; DUMYROX; DUMIROX; FLAVOXYL; FAVERIN; DEPROMEL	5-methoxy-1-[4- (trifluoromethyl)phen yl]-1-pentanone (E)- O-(2- aminoethyl)oxime	5HT reuptake inhibitor	depression; anxiety; obsessive compulsive disorder
Litoxetine; SL 810385	4-(2- naphthalenylmethoxy)piperidine	5HT reuptake inhibitor	depression
LY 280253	Unspecified	5HT reuptake inhibitor	depression
LY 285974	Unspecified	5HT reuptake inhibitor	depression

Paroxetine hydrochloride; FR 7051; BRL 29060; BRL 29060A; SI 211103; SEROXAT; AROPAX; PAXIL; TAGONIS; FROSINOR; DEROXAT; SEREUPIN; MOTIVAN	(3S-trans)-3-[(1,3-benzodioxol-5-yl)oxy)methyl]-4-(4-fluorophenyl)piperidine	5HT reuptake inhibitor	depression; obsessive compulsive disorder; anxiety
Sertraline; CP 51974; CP 519741; CP 5197401; LUSTRAL; ZOLOFT; ALTRULINE; TATIG; GLADEM	(1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine	5HT reuptake inhibitor	depression; obsessive compulsive disorder; anxiety; sexual dysfunction; obesity
Tianeptine; S 1574; STABLON	7-[(3-chloro-6,11-dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide	5HT reuptake inhibitor	depression
EMD 68843	5-[4-[4-(5-cyano-3-indolyl)-butyl]-1-piperazinyl]benzofuran-2-carboxamide hydrochloride	5HT reuptake inhibitor; 5HT agonist; 5HT1A agonist	depression
YM 992; YM 35992	(S)-2-[[[(7-fluoro-2,3-dihydro-1H-inden-4-yl)oxy)methyl]morpholine hydrochloride	5HT reuptake inhibitor; 5HT antagonist; 5HT2A antagonist	depression
A 80426	(R)-N-methyl-N-[(1,2,3,4-tetrahydro-5-methoxy-1-naphthalenyl)methyl]-6-benzofuranethanamine	5HT reuptake inhibitor; alpha adrenergic antagonist; alpha2 adrenergic antagonist	depression
Antidepressants		5HT reuptake inhibitor; alpha adrenergic antagonist; alpha2 adrenergic antagonist	depression

NS 2347		5HT reuptake inhibitor; dopamine reuptake inhibitor	depression; cognitive defect
NS 2389		5HT reuptake inhibitor; dopamine reuptake inhibitor; noradrenalin reuptake inhibitor	depression
Drug delivery system, OROS oral controlled release venlafaxine; venlafaxine OROS; EFFEXOR XL		5HT reuptake inhibitor; noradrenalin reuptake inhibitor	depression
Duloxetine; LY 248686	(S)-N-methyl-gamma-(1-naphthalenyloxy)-2-thiophenepropanamine	5HT reuptake inhibitor; noradrenalin reuptake inhibitor	depression; urinary incontinence
Venlafaxine; WY 45030; EFFEXOR; EFFEXOR XR; EFFEXOR XL	(+,-)-1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol	5HT reuptake inhibitor; noradrenalin reuptake inhibitor; dopamine reuptake inhibitor	depression; anxiety
Ebalzotan; NAE 086	(R)-3,4-dihydro-N-(1-methylethyl)-3-[(1-methylethyl)propylamino]-2H-1-benzopyran-5-carboxamide	5HT1A agonist; 5HT agonist	depression
L 0068; F 11440	4-methyl-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2,4-triazine-3,5(2H,4H)-dione	5HT1A agonist; 5HT agonist	anxiety; depression
LY 274600	(S)-1,2,3,4-tetrahydro-8-(methylthio)-N,N-dipropyl-2-naphthalenamine hydrochloride	5HT1A agonist; 5HT agonist	sexual dysfunction; depression; irritable bowel syndrome
LY 274601	(R)-1,2,3,4-tetrahydro-8-(methylthio)-N,N-dipropyl-2-naphthalenamine hydrochloride	5HT1A agonist; 5HT agonist	sexual dysfunction; depression; irritable bowel syndrome

OPC 14523	1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4-dihydro-5-methoxy-2(1H)-quinolinone	5HT1A agonist; sigma agonist; 5HT agonist	depression; anxiety; obsessive compulsive disorder
F 12682; F 14258	N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-4-(2-phenylethyl)-1-piperazinecarboxamide	5HT1B/5HT1D inverse agonist	depression
GMC 5036	Mirtazepine analogue	5HT2, 5HT3 antagonist; alpha 2 adrenergic antagonist; histaminergic antagonism;	depression
Levoprotiline; levo-oxaprotiline; oxaprotiline, R-(-) enantiomer; CGP 12103A; CONSONAR	(R)-alpha-[(methylamino)methyl]-9,10-ethanoanthracene-9(10H)-ethanol	5HT2A, 5HT2C 5HT1A agonist alpha adrenergic agonist; 5HT1D and histaminergic antagonist	depression
SB 243213	2,3-dihydro-5-methyl-N-[(6-[(2-methyl-3-pyridinyl)oxy]-3-pyridinyl]-6-(trifluoromethyl)-1H-indole-1-carboxamide	5HT2C antagonist; 5HT antagonist	depression; anxiety
Zalospirone; WY 47846	(3aalfa,4beta,4aalfa,6aalfa,7beta,7aalfa)-3a,4,4a,6a,7,7a-hexahydro-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-4,7-etheno-1H-cyclobut[f]isoindole-1,3(2H)-dione	5HT3 antagonist	anxiety; depression
Drug delivery system, adenosine; adenosine drug delivery system; adenosine prodrug	adenosine 5'-(1,4-dihydrotrigonellinate)-2',3'-O-bis-benzoate	adenosine agonist	anxiety; depression

Midaxifylline; IRFI 117	8-(1-aminocyclopentyl)-3,7-dihydro-1,3-dipropyl-1H-purine-2,6-dione	adenosine antagonist; adenosine A1 antagonist	cognitive defect; depression; kidney disease
MCI 225	4-(2-fluorophenyl)-2-methyl-6-(piperazin-1-yl)-3a,7a-dihydrothieno[2,3-d]pyrimidine	Adrenergic and serotonergic reuptake inhibitor	cognitive defect; depression
Adrafinil; adrafinal; CRL 40028; OLMIFON	2-[(diphenylmethyl)sulfinyl]-N-hydroxyacetamide	alpha adrenergic agonist	neurological depression
Modafinil; CRL 40476; CEP 1538; MODIODAL; PROVIGIL; ALERTEC; MODASOMIL	2-[(diphenylmethyl)sulfinyl]acetamide	alpha adrenergic agonist	neurological depression
SDZ NVI085	(-)-(4aR,10aR)-3,4,4a,5,10,10a-hexahydro-6-methoxy-4-methyl-9-methylthio-2H-naphth[2,3,b]-1,4-oxazine	alpha adrenergic agonist; alpha1 adrenergic agonist	neurological depression; depression
Imiloxan; RS 21361	2-[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]-1-ethyl-1H-imidazole	alpha adrenergic antagonist	depression
ORG 6906		alpha adrenergic antagonist	depression
Setiptiline; teciptiline; MO 8282; ORG 8282; TECIPUL	2,3,4,9-tetrahydro-2-methyl-1H-dibenzo[3,4:6,7]cyclohepta[1,2-c]pyridine	alpha adrenergic antagonist	depression
Atipamezole; MPV 1248; ANTISEDAN	4-(2-ethyl-2,3-dihydro-1H-inden-2-yl)-1H-imidazole	alpha adrenergic antagonist; alpha2 adrenergic antagonist	sexual dysfunction; alcoholism; depression; hypotension; diabetes; anxiety

CH 38083	[8aS-(8aalpha,11alpha,12aalpha,13aalpha)]-5,8,8a,9,10,11,12,12a,13,13a-decahydro-6H-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizin-11-ol hydrochloride	alpha adrenergic antagonist; alpha2 adrenergic antagonist	depression
MK 912; L 657743	(2S-trans)-1,3,4,5',6,6',7,12b-octahydro-1',3'-dimethylspiro[2H-benzofuro[2,3-a]quinolizine-2,4'(1'H)-pyrimidin]-2'(3'H)-one monohydrochloride	alpha adrenergic antagonist; alpha2 adrenergic antagonist	depression
Idazoxan; RX 781094; RX 781094 A	2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole	alpha adrenergic antagonist; alpha2 adrenergic antagonist; antiproliferative agent	Parkinson disease; depression; cardiovascular disease; retinopathy
A 75200	(R*,R*)-(+,-)-3-phenyl-1-[(6,7,8,9-tetrahydronaphtho[1,2-d]-1,3-dioxol-6-yl)methyl]pyrrolidine	alpha adrenergic antagonist; alpha2 adrenergic antagonist; noradrenalin reuptake inhibitor	depression
Napitane; ABT 200; A 75200	(R*,R*)-(+,-)-3-phenyl-1-[(6,7,8,9-tetrahydronaphtho[1,2-d]-1,3-dioxol-6-yl)methyl]pyrrolidine	alpha adrenergic antagonist; alpha2 adrenergic antagonist; noradrenalin reuptake inhibitor	depression
ORG 9768		alpha adrenergic antagonist; alpha2 adrenergic antagonist; noradrenalin reuptake inhibitor	depression
Reboxetine; FCE 20124; FCE 21684; EDRONAX; PROLIFT	(R*,S*)-2-[(2-ethoxyphenoxy)phenylmethyl]morpholine	alpha adrenergic antagonist; alpha2 adrenergic antagonist; noradrenalin reuptake inhibitor	depression
AMPA receptor modulators,		AMPA receptor modulators	schizophrenia; depression

Dehydroepiandrosterone analogues; DHEA analogues,		androgen	atherosclerosis; depression
Drug delivery system, dehydroepiandrosterone; dehydroepiandrosterone delivery system; drug delivery system, DHEA		androgen	atherosclerosis; depression
Adinazolam; adinazolam mesylate; adinazolam mesilate; U 41123F; U 41123; DERACYN	8-chloro-N,N-dimethyl-6-phenyl-4H-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine-1-methanamine	benzodiazepine	anxiety; depression
Flumazenil; flumazepil; flumenazil; Ro 151788; ANEXATE; MAZICON; LANEXAT; ROMAZICON	8-fluoro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid ethyl ester	benzodiazepine antagonist	neurological depression; liver disease
Flerobuterol	alpha-[[[(1,1-dimethylethyl)amino]methyl]-2-fluorobenzenemethanol	beta adrenergic agonist	depression
SR 56811; SR 58611A; SR 58611; ME 3411	[R-(R*,S*)]-[[7-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]acetic acid ethyl ester hydrochloride	beta adrenergic agonist; beta3 adrenergic agonist	irritable bowel syndrome; obesity; depression
KP 840	diethyl 1,4-dihydro 2,6-dimethyl-4-(3-ethynyl phenyl)-3,5-pyridine-dicarboxylic acid	calcium antagonist	ischemia; depression
Topiramate; KW 6485; McN 4853; RWJ 17021; TOPAMAX	2,3:4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate	carbonate dehydratase inhibitor; sodium channel blocker; AMPA antagonist; GABA agonist; glutamate antagonist	epilepsy; psychosis; depression

CMI 477	(1S-exo)-2-(6-chloro-3-pyridinyl)-7-azabicyclo[2.2.1]heptane	cholinergic agonist; nicotinic agonist; analgesic	obesity; depression; Alzheimer disease; nicotine withdrawal
Corticotropin releasing factor analogue		CRF analogue	anxiety; depression
AXC 2219		CRF antagonist	depression; anxiety
AXC 4007		CRF antagonist	depression; anxiety
CRA 1000	INDEX NAME NOT YET ASSIGNED	CRF antagonist	depression; anxiety
CRA 1001		CRF antagonist	depression; anxiety
CRF antagonist,		CRF antagonist	depression; anxiety
CRF antagonists		CRF antagonist	depression; anxiety
CRF receptor antagonist; corticotropin releasing factor antagonist		CRF antagonist	depression
CRF2 antagonists,		CRF antagonist	depression; anxiety
NBI 103		CRF antagonist	depression; eating disorder
NBI 104		CRF antagonist	depression; stroke
NBI 30545	3-(2,4-dimethoxyphenyl)-N-(2-methoxyethyl)-2,5-dimethyl-N-propylpyrazolo[1,5-a]pyrimidin-7-amine	CRF antagonist	anxiety; depression
NBI 30775; R 121919		CRF antagonist	anxiety; depression; addiction
NGD 981; NGD 98-1		CRF antagonist	depression; anxiety
PD 171729	butyl-[3[(2,4-dichloro-phenyl)-2,5-dimethyl-pyrazolo(1,5-a)pyrimidin-7-yl]-ethyl-amine	CRF antagonist	anxiety; depression
Pivagabine; PG 2; TONERG	4-[(2,2-dimethyl-1-oxopropyl)amino]butanoic acid	CRF modulation	depression

DMP 695	N-(2-chloro-4,6-dimethylphenyl)-1-[2-methoxy-1-(methoxymethyl)ethyl]-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine monomethanesulfonate	CRH antagonist	anxiety; depression
SA 627	N-(2-bromo-4,6-dimethoxyphenyl)-N-ethyl-4-methyl-6-(4-morpholinyl)-1,3,5-triazin-2-amine	CRH antagonist	depression; anxiety
SC 241		CRH antagonist	anxiety; depression
Etrabamine; JL 14839	4,5,6,7-tetrahydro-N-methyl-6-benzothiazolamine	dopamine agonist	depression
MR 708	N-acetyl-DL-phenylalanine with tricyclo[3.3.1.1 ^{3,7}]decan-1-amine (1:1)	dopamine agonist	depression
Roxindole; EMD 62100; EMD 49980; EMD 62080	3-(4-(3,6-dihydro-4-phenyl-1(2H)-pyridyl)butyl)indol-5-ol	dopamine agonist; 5HT reuptake inhibitor	depression
Amisulpride; aminosultopride; AST; DAN 2163; SOCIAN; SOLIAN; ENORDEN; DENIBAN; SULAMID	4-amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxy benzamide	dopamine agonist; dopamine antagonist	schizophrenia; depression
Pergolide; pergolide mesylate; LY 141B; LY 127809; PERMAX; CELANCE; PHARKEN; PARKOTIL	(8beta)-8-[(methylthio)methyl]-6-propylergoline	dopamine agonist; dopamine D1 agonist; dopamine D2 agonist	Parkinson disease; depression

Pramipexole; pramipexole dihydrochloride; SND 919; U 98528E; SND919CL2Y; PNU 98528E; SIFROL; MIRAPEX; DAQUIRAN; MIRAPEXIN; FIROL	(S)-2-amino-4,5,6,7- tetrahydro-6- (propylamino)- benzothiazole	dopamine agonist; dopamine D2 agonist; dopamine D3 agonist	Parkinson disease; schizophrenia; depression
GYKI 52895	4-(8-methyl-9H-1,3- dioxolo[4,5- h][2,3]benzodiazepin- 5-yl)-benzodiazepine	dopamine reuptake inhibitor	depression
HOE 249	(+)-2-[(3- chlorophenyl)-1H- imidazol-1- ylmethyl]tricyclo[3.3. 1.1(3,7)]decan-2-ol	dopamine reuptake inhibitor	depression
NS 2200		dopamine reuptake inhibitor	Parkinson disease; depression; addiction
OPC 14117	N-(2,3-dihydro-7- hydroxy-2,2,4,6- tetramethyl-1H- inden-1-yl)-4-(3- methoxyphenyl)-1- piperazineacetamide	free radical scavenger	neurological depression
GABA-based depression therapy,		GABA agonist	depression
CGP 35348	(3- aminopropyl)(diethox ymethyl)phosphinic acid	GABA antagonist	depression
Suritozole; MDL 26479	2,4-dimethyl-5-(3- fluorophenyl)-3H- 1,2,4-triazole-3- thione	GABA inverse agonist	depression; cognitive defect
Valproate semisodium; divalproex sodium; semisodium valproate; AB 50711; DEPAKOTE; EPIVAL; VALCOTE	2-propylpentanoic acid sodium salt (2:1)	GABA receptor	epilepsy; migraine; schizophrenia; depression

Gabapentin; CI 945; GO 3450; GOE 2450; NEURONTIN	1-(aminomethyl)cyclohexaneacetic acid	GABA release; analgesic	epilepsy; anxiety; pain; neuropathy; psychosis; depression
ACPC; cycloleucine; cycloleucin; NSC 1026; WR 14997	1-aminocyclopentanecarboxylic acid	glutamate antagonist; NMDA antagonist	coronary artery disease; anxiety; depression; stroke; epilepsy; addiction
BN 50043	N-allyl N-isopropyl (p-chlorophenyl-4- piperidino)-2- acetamide hydrochloride	Imipramine binding site	depression
L 671776	3',4',4'a,5',6',7',8',8'a- octahydro-4,6'- dihydroxy-6- (hydroxymethyl)- 2',5',5',8'a- tetramethylspiro[benz ofuran-2(3H),1'(2'H)- naphthalene]-5- carboxaldehyde	inositol monophosphatase inhibitor	depression
Befloxatone; MD 370503	(R)-5- (methoxymethyl)-3- (p-((R)-4,4,4- trifluoro-3- hydroxybutoxy)phenyl)-2-oxazolidinone	MAO A inhibitor; MAO inhibitor	depression; anxiety; nicotine withdrawal
Brofaromine; CGP 11305A; CONSONAR	4-(7-bromo-5- methoxy-2- benzofuranyl)piperidine	MAO A inhibitor; MAO inhibitor	depression
BW 1370U87	1-ethylphenoxathiin 10,10-dioxide	MAO A inhibitor; MAO inhibitor	depression; anxiety
CS 8359; RS 8359	(+,-)-4-[(6,7-dihydro- 7-hydroxy-5H- cyclopentapyrimidin- 4- yl)amino]benzonitrile	MAO A inhibitor; MAO inhibitor	depression
E 2011	[R-(R*,S*)]-gamma- hydroxy-6-[5- (methoxymethyl)-2- oxo-3-oxazolidinyl]- 2- benzothiazolebutanenitrile	MAO A inhibitor; MAO inhibitor	depression

Esuprone; LU 43839	ethanesulfonic acid 3,4-dimethyl-2-oxo- 2H-1-benzopyran-7- yl ester	MAO A inhibitor; MAO inhibitor	depression
Moclobemide; Ro 111163; Ro 111163/000; AURORIX; MANERIX; ACUILIX; MOCLAMINE	4-chloro-N-[2-(4- morpholinyl)ethyl]be nzamide	MAO A inhibitor; MAO inhibitor	depression
Pirlindole; pyrasidol; pyrazidol; pyrazidole; LIFRIL; PYRAZIDOL; EUTHYM	2,3,3a,4,5,6- hexahydro-8-methyl- 1H-pyrazino[3,2,1- jk]carbazole	MAO A inhibitor; MAO inhibitor	depression
Drug delivery system, controlled release selegiline; selegiline		MAO B inhibitor; MAO inhibitor	depression
Drug delivery system, transdermal selegiline; selegiline transdermal		MAO B inhibitor; MAO inhibitor	Alzheimer disease; depression
MDL 72145	(E)-(beta- fluoromethylene)-3,4- dimethoxybenzeneeth anamine hydrochloride	MAO B inhibitor; MAO inhibitor	depression; Parkinson disease
KP 157		MAO inhibitor; MAO A inhibitor	depression
KP 9		MAO inhibitor; MAO A inhibitor	depression
T 794	(R)-3-[6- (cyclopropylmethoxy)2-naphthalenyl]-5- (methoxymethyl)-2- oxazolidinone	MAO inhibitor; MAO A inhibitor	depression
SL 650477; SL 65.0477	[R-(R*,R*)]-5- (methoxymethyl)-3- [6-(4,4,4-trifluoro-3- hydroxybutoxy)-3- benzofuranyl]-2- oxazolidinone	MAO inhibitor; MAO A inhibitor; MAO B inhibitor; oxazolidinone	depression; Parkinson disease
Agomelatine; S 20098	N-[2-(7-methoxy-1- naphthalenyl)ethyl]ac etamide	melatonin agonist	depression; insomnia

Melatonin modulators; melatonin analogues		Melatonin analogues	depression; infertility
Neuropeptide Y antagonists		neuropeptide Y antagonist; neuropeptide Y2 antagonist	hypotension; obesity; depression
RB 101	N-[2-[[[2-amino-4-(methylthio)butyl]dit hio]methyl]-1-oxo-3-phenylpropyl]-L-phenylalanine phenylmethyl ester	neutral endopeptidase inhibitor	addiction; depression
EGYT 4201	ethanesulfonic acid compd. with 5-chloro-2-(2-imino-3-thiazolidinyl)benzami ne (2:1)	Nonmomoaminergic action	depression
COR 3224	4,5-dihydro-5-((4-phenyl-1-piperazinyl)methyl)-2-oxazolamine	Nontricyclic action	depression
Minaprine; minaprine hydrochloride; minaprina; CB 30038; 30038 CB; AGR 1240; CANTOR; KANTOR; ALCAS; NORTIMIC; BRANTUR; ISOPULSAN	4-[2-[(4-methyl-6-phenyl-3-pyridazinyl)amino]et hyl]morpholine	Nontricyclic action	depression
Amfebutamone; bupropion hydrochloride; bupropion; bupropin; BW 323U; WELLBUTRIN; ZYBAN	(+,-)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone	noradrenalin reuptake inhibitor	depression; nicotine withdrawal; obesity
Beloxepin; ORG 4428	cis-2,10-dimethyl-1,2,3,4,4a,13b-hexahydrodibenz-[2,3:6,7]oxepino [4,5-c]pyridin-4a-ol	noradrenalin reuptake inhibitor	depression

Dexnafenodone; LU 43706	(S)-2-[2-(dimethylamino)ethyl]-3,4-dihydro-2-phenyl-1(2H)-naphthalenone	noradrenalin reuptake inhibitor	depression
Hydroxynortriptyline	(E)-10-11-dihydro-5-[3-(methylamino)propylidene]-5H-dibenzo-[a,d]cyclohepten-10-ol	noradrenalin reuptake inhibitor	depression
Drug delivery system, sustained release milnacipran; milnacipran sustained release		noradrenalin reuptake inhibitor; 5HT reuptake inhibitor	depression
Milnacipran; midalcipran; midacipran; F 2207; TN 912; DALCIPRAN; IXEL	cis-(+,-)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide	noradrenalin reuptake inhibitor; 5HT reuptake inhibitor	depression
1555; 1555U88; BW 1555U88	[2S-(2alpha,3alpha,5alpha)]-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol hydrochloride	noradrenalin reuptake inhibitor; dopamine reuptake inhibitor	attention deficit disorder; nicotine withdrawal; depression; psychosis
Nalmefene; nalmetrene; JF 1; INCYSTENE; ARTHENE; FENARC; CERVENE; REVEX	17-(cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol	opiate antagonist; NSAID	intoxication; alcoholism; pruritis; obesity; neurological depression; rheumatoid arthritis; cystitis; trauma
Oxytocin antagonist		oxytocin antagonist; diuretic	anxiety; depression; obsessive compulsive disorder; epilepsy; heart failure
NS 1546		potassium channel modulator	depression
Potassium channel modulators		potassium channel modulator	cognitive defect; attention deficit disorder; depression; asthma; diabetes

Igmesine; igmacine; JO 1784	(+)-N-(1,4-diphenyl-3-butenyl)-N-methylcyclopropane methanamine	sigma agonist	depression; cognitive defect; diarrhea
SA 4503	1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride	sigma agonist	Alzheimer disease; depression; cognitive defect; stroke
GW 273293		sodium channel blocker	epilepsy; depression
Lamotrigine; BW 430C; LAMICTAL	6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine	sodium channel blocker	epilepsy; psychosis; depression
MK 869		substance P antagonist	depression; anxiety; schizophrenia; emesis
Sifaprazine; FI 4303	1-(2-(phenylmethyl)phenyl)-4-methylpiperazine hydrochloride	Tricyclic antidepressant activity	depression
Antidepressant	N'-[5-[(2-chlorophenyl)methylene]-4,5-dihydro-6-methyl-3-pyridazinyl]-N,N-dimethyl-1,2-ethanediamine	Unknown	depression
Antidepressant, PPRT 152	St. John's Wort herbal remedy extract	Unknown	depression
ATX 70	(SP-4-2)-[[N,N'-[[7,12-bis[1-(decyloxy)ethyl]-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-diyl-kappaN21,kappaN22,kappaN23,kappaN24]bis(1-oxo-3,1-propanediyl)]bis[L-aspartato]](6-)]gallate (3-) trihydrogen	Unknown	depression; cancer
Bipenamol; BW 647U	2-[[2-(aminomethyl)phenyl]thio]benzenemethanol	Unknown	depression

BW 403U76		Unknown	depression
CGP 25454		Unknown	depression
CS 2232		Unknown	depression
Delfaprazine; FI 4310	1-(alpha2-phenyl-2,5-xylyl)-piperazine	Unknown	depression
Depression therapy		Unknown	depression
E 5505		Unknown	depression
ORG 12437		Unknown	depression
ORG 20091	5-chloro-4-(1,2,5,6-tetrahydro-1-methyl-3-pyridinyl)-2-thiazolamine (Z)-2-butenedioate (2:1)	Unknown	depression
YKP 10A		Unknown	depression
DGAVP; ORG 5667	8-L-arginine-9-deglycinamidevasopressin	Vasopressin	depression
Vasopressin antagonist,		vasopressin antagonist; diuretic	anxiety; depression; obsessive compulsive disorder; epilepsy; heart failure

Table 29. Current Candidate Therapeutic Interventions for the Treatment of Epilepsy

Product Name	Chemical Name	Action	Indication
MMPQ; SRC 820; SRC 820R	2-methyl-3-(3-methyl-2-pyridinyl)-4(3H)-quinazolinone	5HT neuromodulation	epilepsy
Adenosine regulating agents, epilepsy	Unspecified	adenosine regulating agent	epilepsy
Adenosine utilization inhibitors, epilepsy	Unspecified	adenosine regulating agent	epilepsy
GP 3269; GP 13269	7-(5-deoxy-beta-D-ribofuranosyl)-N-(4-fluorophenyl)-5-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine	adenosine regulating agent	epilepsy
SNAP 5114	1-[2-[tris(4-methoxyphenyl)methoxy]ethyl]-3-piperidinecarboxylic acid	amine uptake inhibitor	epilepsy; anxiety; insomnia

LY 215490	(3alpha,4alpha,6beta,8alpha)-decahydro-6-[2-(1H-tetrazol-5-yl)ethyl]-3-isoquinolinecarboxylic acid	AMPA antagonist; glutamate antagonist	epilepsy
LY 293558	[3S-(3alpha,4alpha,6beta,8alpha)]-decahydro-6-[2-(1H-tetrazol-5-yl)ethyl]-3-isoquinolinecarboxylic acid	AMPA antagonist; glutamate antagonist	heart ischemia; epilepsy
SYM 2189	Unspecified	AMPA antagonist; glutamate antagonist	stroke; epilepsy
SYM 2206	8-(4-aminophenyl)-5-methyl-N-propyl-1,3-dioxolo[4,5-g]phthalazine-6(5H)-carboxamide	AMPA antagonist; glutamate antagonist	stroke; epilepsy
Pregabalin; CI 1008; PD 144723	(S)-3-(aminomethyl)-5-methyl-hexanoic acid	analgesic	epilepsy; pain
mu-conopeptides	Unspecified	analgesic; peptide; sodium channel blocker	pain; epilepsy
ADD 196022	4-[(4-chlorophenyl)amino]-6-methyl-2-oxo-3-cyclohexene-1-carboxylic acid methyl ester	Antiepileptic agent with unspecified mechanism of action	epilepsy
ADD 55051	4-chlorobenzenesulfonamide	Antiepileptic agent with unspecified mechanism of action	epilepsy
AHN 649	(9alpha,13alpha,14alpha)-17-methyl-morphinan-3-amine	Antiepileptic agent with unspecified mechanism of action	epilepsy; neuropathy
Ameltolide; LY 201116; ADD 75073	4-amino-N-(2,6-dimethylphenyl)benzamide	Antiepileptic agent with unspecified mechanism of action	epilepsy
Anticonvulsant	(R)-7-[1-(4-chlorophenoxy)ethyl]-[1,2,4]triazolo[1,5-a]pyrimidine	Antiepileptic agent with unspecified mechanism of action	epilepsy

Anticonvulsants	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
Antiepileptic	4-phenoxy-2-(4-propyl-1-piperazinyl)quinazoline	Antiepileptic agent with unspecified mechanism of action	epilepsy
Antiepileptic	(S)-2-amino-4,5-dihydro-5-(2-methylpropyl)-4-oxo-1H-imidazole-1-carboxylic acid phenylmethyl ester	Antiepileptic agent with unspecified mechanism of action	epilepsy
Antiepileptics	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
B 974	N-(alpha,alpha,alpha-trifluoro-m-tolyl)piperazino-2-acetamido-4-methylthiazole	Antiepileptic agent with unspecified mechanism of action	epilepsy
Benzoidazoxan	6,7-benzoidazoxan	Antiepileptic agent with unspecified mechanism of action	epilepsy
Carabersat; SB 204269; SB 204269EO	(3R-trans)-N-(6-acetyl-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-4-fluorobenzamide	Antiepileptic agent with unspecified mechanism of action	epilepsy
CGS 18416	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
CHF 2993	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
CHF 3381	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
D 20443	[2-amino-4-[[[4-fluorophenyl)methyl]amino]phenyl]carbamic acid ethyl ester dihydrochloride	Antiepileptic agent with unspecified mechanism of action	epilepsy

D 2624	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
Endixaprine; SR 41378	1-[6-(2,4-dichlorophenyl)-3-pyridazinyl]-4-piperidinol	Antiepileptic agent with unspecified mechanism of action	epilepsy
F 721	5-[4-(trifluoromethyl)phenyl]-3-(diethylamino)-2,2-dimethylpropyl 2-furancarboxylic acid ester hydrochloride	Antiepileptic agent with unspecified mechanism of action	epilepsy
FCE 23819	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
Harkoseride; ADD 234037	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
Lodaxaprine; CM 40907	1-(6-(2-chlorophenyl)-3-pyridazinyl)-4-piperidinol	Antiepileptic agent with unspecified mechanism of action	epilepsy
Loreclezole; R 72063	(Z)-1-[2-chloro-2-(2,4-dichlorophenyl)ethenyl]-1H-1,2,4-triazole	Antiepileptic agent with unspecified mechanism of action	epilepsy
LY 193453	Amelotide derivative	Antiepileptic agent with unspecified mechanism of action	epilepsy
LY 228721	Bentamide amelotide derivative	Antiepileptic agent with unspecified mechanism of action	epilepsy
LY 274959	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
MS 16056	1-(3-phenyl-5-isoxazolyl)-3-(1-imidazolyl)-methylindole hydrochloride	Antiepileptic agent with unspecified mechanism of action	epilepsy
NPS 1776	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy

Oxcarbazepine; CGP 47680; KIN 493; GP 47680; TRILEPTAL; TOXECAR	10,11-dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide	Antiepileptic agent with unspecified mechanism of action	epilepsy; diabetes; neuropathy
Ro 70213	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
RWJ 37868	2-(4-chlorobenzoyl)-4-[(1-piperidinyl)acetyl]-1,3,5-trimethylpyrrole	Antiepileptic agent with unspecified mechanism of action	epilepsy
RX 751067	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
SL 900571	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
Soretolide; D 2916	2,6-dimethyl-N-(5-methyl-3-isoxazolyl)benzamide; aryl-isoxazole carboxamide derivative	Antiepileptic agent with unspecified mechanism of action	epilepsy
Stiripentol; BCX 2600	4,4-dimethyl-1-[(3,4-methylenedioxy)phenyl]-1-penten-3-ol	Antiepileptic agent with unspecified mechanism of action	epilepsy
TV 141	Unspecified	Antiepileptic agent with unspecified mechanism of action	epilepsy
TV 1901	Unspecified	Antiepileptic agent with unspecified mechanism of action	Epilepsy
Clobazam; HR 376; H 4723; LM 2717; NH 15; FRISIUM; CLIDIZAN; GRIFOCLOBAM; URBADAM; FRISIN; URBANYL; URBANIL; MYSTAN	7-chloro-1-methyl-5-phenyl-1H-1,5-benzodiazepine-2,4-(3H,5H)-dione	benzodiazepine	anxiety; epilepsy
GYKI 52466	1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine	benzodiazepine	epilepsy

Midazolam; Ro 213981/001; Ro 213981/003; HYPNOVEL; VERSED; DORMICUM	8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine	benzodiazepine	anxiety; epilepsy
Ro 417812	Unspecified	benzodiazepine	epilepsy
Ro 428773	Unspecified	benzodiazepine	epilepsy
FG 8205; L 663581	7-chloro-4,5-dihydro-5-methyl-3-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]-6H-imidazo[1,5-a][1,4]benzodiazepin-6-one	benzodiazepine partial agonist	epilepsy; anxiety
CNS 1067	Unspecified	calcium antagonist	epilepsy
U 54494A	cis-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidiny)cyclohexyl]benzamide monohydrochloride	calcium antagonist	epilepsy
NPS 846	Unspecified	calcium antagonist; analgesic	stroke; epilepsy; pain
Flunarizine; R 14950; FLUZINA; SIBELIUM; ZINASEN; SESNARBO; RIZENA; SINAZINE; HEADACHE; FLORIRATO; DIESPRUDEL	Unspecified	calcium antagonist; vasodilator	peripheral vascular disease; cerebrovascular disease; migraine; epilepsy
CNS 2103	Unspecified	calcium antagonist; venom	epilepsy
CPC 8027	Unspecified	calcium channel blocker	stroke; epilepsy
CPC 8029	Unspecified	calcium channel blocker	stroke; epilepsy
NS 696	Unspecified	calcium channel blocker	epilepsy
drug delivery system, conopeptides	Unspecified	calcium channel blocker; sodium channel blocker; potassium channel blocker; analgesic	epilepsy; Parkinson disease; stroke; pain; brain ischemia

DP 16	Acylglycerol derivative of BAPTA	Calcium chelation	epilepsy; stroke; heart ischemia
AO 78	Tetronic acid derivative, unspecified	Calcium ion modulator	epilepsy
Topiramate; KW 6485; McN 4853; RWJ 17021; TOPAMAX	2,3:4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate	carbonate dehydratase inhibitor; sodium channel blocker; AMPA antagonist; GABA agonist; glutamate antagonist	epilepsy; psychosis; depression
Losigamone; AO 33	5-[(2-chlorophenyl)hydroxymethyl]-4-methoxy-2(5H)-furanon; tetronic acid derivative	Chloride ion influx by GABA sensitive mechanism at a site distant from GABA	epilepsy
Levetiracetam; etiracetam, (S); UCB L059 (S); SIB S1 (S); UCB L060 (R); UCB 6474 (no stereo, etiracetam)	(S)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide	cholinergic agonist	epilepsy
Dopamine D4 receptor ligands	Unspecified	dopamine antagonist; dopamine D4 antagonist	attention deficit disorder; epilepsy; addiction
ADD 17014	4-[1-(4-chlorophenyl)-4,5-dihydro-1H-1,2,3-triazol-5-yl]pyridine	excitatory amino acid antagonist	epilepsy
Excitatory amino acid antagonists	Unspecified	excitatory amino acid antagonist	epilepsy; Alzheimer disease; stroke
NPC 18123	Unspecified	excitatory amino acid antagonist; glutamate antagonist	epilepsy; stroke
Dezinamide; AN 051; AHR 11748; ADD 94057	3-[(3-trifluoromethyl)phenoxy]-1-azetidinecarboxamide (desmethyl metabolite of fluzinamide)	Fluzinamide derivative	epilepsy
1-decylpyrrolidinone	1-decanoyl-2-pyrrolidinone	GABA agonist	epilepsy
1-dodecylpyrrolidinone	1-dodecanoyl-2-pyrrolidinone	GABA agonist	epilepsy

GABA agonist, XR 368 series	(2aR*,5aR,7E,11E,14aS*,14bS*,14cS*)-2a,5a,6,9,10,13,14,14a,14b,14c-decahydro-4-hydroxy-5a,9,9,12-tetramethyl-1,5-dioxacyclopenta[cd]cycloundec[f]inden-3(2H)-one	GABA agonist	anxiety; epilepsy
Ganaxolone; CCD 1042	(3alpha,5alpha)-3-hydroxy-3-methylpregnan-20-one	GABA agonist	epilepsy; migraine
MDL 27192	5-(4-chlorophenyl)-4-ethyl-2,4-dihydro-3H-1,2,4-triazol-3-one	GABA agonist	epilepsy
PD 144550	(R)-3-(aminomethyl)-5-methylhexanoic acid	GABA agonist	epilepsy
R 7621	N1-(3-trifluoromethylphenyl)N2-nicotinoyl piperazine hydrochloride	GABA agonist	epilepsy
Vigabatrin; gamma vinyl GABA; GVG; RMI 71754; MDL 71754; RMI 71890; RMI 71894; SABRIL; SABRILEX	4-amino-5-hexenoic acid	GABA agonist	epilepsy; addiction
ZK 95962; ZK 45962	ethyl 5-isopropoxy-4-methoxymethyl-beta-carboline-3-carboxylate	GABA agonist	epilepsy; cognitive defect
Milacemide; CP 15525; CP 1552S	2-(pentylamino)acetamide	GABA agonist; MAO B inhibitor; MAO inhibitor	epilepsy; Parkinson disease
CGP 36742	(3-aminopropyl)butylphosphinic acid	GABA antagonist	epilepsy; Alzheimer disease
Rufinamide; CGP 33101; RUF 331	1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-triazole-4-carboxamide	GABA antagonist	epilepsy

Gabapentin; CI 945; GO 3450; GOE 2450; NEURONTIN	1-(aminomethyl)cyclohexaneacetic acid	GABA modulation	epilepsy; anxiety; pain; neuropathy; psychosis; depression
NNC 138119	3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5,6-dihydro-5-methyl-6-oxo-4H-imidazo(1,5-a)(1,4)benzodiazepine derivative	GABA modulation	epilepsy; anxiety
AWD 131138; AWD 131-138	1-(4-chlorophenyl)-1,5-dihydro-4-(4-morpholinyl)-2H-imidazol-2-one	GABA modulator	epilepsy; anxiety
Co 21068	(3 α ,5 β)-3-[(4-acetylphenyl)ethynyl]-21-(3-carboxy-1-oxopropoxy)-3-hydroxypregnan-20-one sodium salt	GABA modulator	epilepsy
NNC 140189	3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-7-fluoro-5-(4-methyl-1-piperazinyl)-imidazo[1,5-a]quinazoline	GABA modulator	epilepsy
NS 2552	Unspecified	GABA modulator	anxiety; epilepsy
NS 2608	Unspecified	GABA modulator	epilepsy; anxiety
NS 2664	Unspecified	GABA modulator	epilepsy
Retigabine; D 23129; GKE 841	[2-amino-4-[(4-fluorophenyl)methyl]amino]phenyl]carbamic acid ethyl ester	GABA modulator; potassium channel activator	epilepsy
Co 21970	(3 α ,5 α)-3-hydroxy-3-(trifluoromethyl)-pregnan-20-one	GABA partial agonist; neuroactive steroid	epilepsy
Valproate magnesium; magnesium valproate; DEPAMAG; VALPAMAG	2-propylpentanoic acid magnesium salt	GABA release	epilepsy

Valproate semisodium; divalproex sodium; semisodium valproate; ABBOTT 50711; DEPAKOTE; EPIVAL; VALCOTE	2-propylpentanoic acid sodium salt (2:1)	GABA release	epilepsy; migraine; schizophrenia; depression
Valproate sodium; sodium valproate; NIK 240; SENITA; SELENICA	2-propylpentanoic acid sodium salt	GABA release	Alzheimer disease; epilepsy
CI 966	1-[2-[bis[4-(trifluoromethyl)phenyl]methoxy]ethyl]-1,2,5,6-tetrahydro-3-pyridinecarboxylic acid	GABA uptake inhibitor	epilepsy
NNC 711	1,2,5,6-tetrahydro-1-[2-[[[(diphenylmethylene)amino]oxy]ethyl]-3-pyridinecarboxylic acid monohydrochloride	GABA uptake inhibitor	epilepsy
Tiagabine; tiagabine hydrochloride; NO 050328; A 70569; NO 328; NNC 050328; NNC 328; NN 301; ABT 569; GABITRIL; TIABIX	(R)-1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-3-piperidinecarboxylic acid	GABA uptake inhibitor	epilepsy
3-isobutyl GABA	3-(aminoethyl)-5-methylhexanoic acid	GAD modulation, L-glutamic acid decarboxylase	Epilepsy
SNAP 5294	Unspecified	GAT1 transporter	epilepsy; anxiety; insomnia
SNAP 5258	Unspecified	GAT3 transporter	epilepsy; anxiety; insomnia
NNC 079202; FG 9202	1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-benzo(f)quinoxaline-7-sulfon amide	glutamate antagonist	epilepsy; stroke

Talampanel; LY 300164	(R)-7-acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine	glutamate antagonist; AMPA antagonist	epilepsy; amyotrophic lateral sclerosis
Excitatory amino acid antagonists	Unspecified	glutamate antagonist; excitatory amino acid antagonist; NMDA antagonist	epilepsy; neurodegeneration
CNS 2	Unspecified	glutamate antagonist; mGluR antagonist	epilepsy
NPS 2390	Unspecified	glutamate antagonist; mGluR antagonist	pain; epilepsy
ACPC; cycloleucine; cycloleucin; NSC 1026; WR 14997	1-aminocyclopentanecarboxylic acid	glutamate antagonist; NMDA antagonist	coronary artery disease; anxiety; depression; stroke; epilepsy; addiction
Dizocilpine; dizocilpine maleate; MK 801	(+)-10,11-dihydro-5-methyl-5H-dibenzo[a,d]cyclohepten-5,10-imine	glutamate antagonist; NMDA antagonist	epilepsy; stroke; neuropathy
drug delivery system, felbamate; felbamate drug delivery system	unspecified	glutamate antagonist; NMDA antagonist	epilepsy
Felbamate; W 554; ADD 03055; FELBATOL; FELBAMYL; TALOXIA	2-phenyl-1,3-propanediol dicarbamate	glutamate antagonist; NMDA antagonist	epilepsy
GPI 3000; NPC 17742	[1R-[1alpha(R*),2alpha]]-alpha-amino-2-(2-phosphonoethyl)cyclohexane propanoic acid	glutamate antagonist; NMDA antagonist	epilepsy; stroke; neuropathy
L 701324	7-chloro-4-hydroxy-3-(3-phenoxyphenyl)-2(1H)-quinolinone	glutamate antagonist; NMDA antagonist	epilepsy; stroke
MDL 27266	5-(4-chlorophenyl)-4-ethyl-2,4-dihydro-2-methyl-3H-1,2,4-triazol-3-one	glutamate antagonist; NMDA antagonist	epilepsy
RPR 118723	Unspecified	glutamate antagonist; NMDA antagonist	epilepsy

YKP 509	Unspecified	glutamate antagonist; NMDA antagonist	epilepsy
Metabotropic glutamate receptor modulators	Unspecified	Glutamate receptor modulation	pain; cognitive defect; schizophrenia; epilepsy
CNS 1145	N,N'-bisacenaphth-5- ylguanidine	glutamate release inhibitor	epilepsy
glycine transporter modulator	Unspecified	glycine antagonist	epilepsy; cognitive defect
MDL 100458	3- (benzoylmethylamino)-6-chloro-1H-indole- 2-carboxylic acid	glycine antagonist	epilepsy
L 687414	(3R-cis)-3-amino-1- hydroxy-4-methyl-2- pyrrolidone	glycine partial agonist	epilepsy
hBGT1 transporter modulator	Unspecified	hBGT1 transporter modulator	epilepsy; anxiety; insomnia
AQ 0145	4-[1-[(adamant-3- yl)iminomethyl]piperi din-4-yl]imidazole	histamine antagonist; histamine H3 antagonist	epilepsy
m-NBA	2-amino-3-(3- nitrobenzoyl)propano ic acid	kynurenine 3 hydroxylase inhibitor	epilepsy; Parkinson disease; Alzheimer disease
FCE 26743	(S)-2-[[[4-[(3- fluorophenyl)methox y]phenyl]methyl]ami no]propanamide	MAO B inhibitor; MAO inhibitor	epilepsy
Remacemide, (-); FPL 14145; PR 1032646; PR 1032- 646	(-)-2-amino-N-(1- methyl-1,2- diphenylethyl)acetam ide	NMDA antagonist	epilepsy
NMDA antagonists	Unspecified	NMDA antagonist; analgesic; glutamate antagonist	epilepsy; pain; brain ischemia
ACEA 1011	Unspecified	NMDA antagonist; glutamate antagonist	ischemia; epilepsy
CGP 37849	(E)-(+,-)-2-amino-4- methyl-5-phosphono- 3-pentenoic acid	NMDA antagonist; glutamate antagonist	epilepsy
CGP 39551	(E)-(+,-)-2-amino-4- methyl-5-phosphono- 3-pentenoic acid 1- ethyl ester	NMDA antagonist; glutamate antagonist	epilepsy

CGP 40116	[R-(E)]-2-amino-4-methyl-5-phosphono-3-pentenoic acid	NMDA antagonist; glutamate antagonist	epilepsy; stroke
D-CPP	(R)-4-(3-phosphonopropyl)-2-piperazinecarboxylic acid	NMDA antagonist; glutamate antagonist	epilepsy
FR 115427	(+)-1-methyl-1-phenyl-1,2,3,4-tetrahydroisoquinoline hydrochloride	NMDA antagonist; glutamate antagonist	epilepsy
L 701252	Unspecified	NMDA antagonist; glutamate antagonist	epilepsy
L 703717	7-chloro-4-hydroxy-3-[3-(4-methoxyphenyl)methyl]phenyl]-2(1H)-quinolinone	NMDA antagonist; glutamate antagonist	epilepsy; stroke
L 708541	Unspecified	NMDA antagonist; glutamate antagonist	epilepsy; stroke
LY 233536	(3R-(3 α ,4 α ,6 β ,8 α))-decahydro-6-(1H-tetrazol-5-ylmethyl)-3-isoquinolinecarboxylic acid	NMDA antagonist; glutamate antagonist	epilepsy
LY 235723	(2R-cis)-4-(1H-tetrazol-5-ylmethyl)-2-piperidinecarboxylic acid	NMDA antagonist; glutamate antagonist	epilepsy
LY 274614	(3 α ,4 α ,6 β ,8 α))-decahydro-6-(phosphonomethyl)-3-isoquinolinecarboxylic acid	NMDA antagonist; glutamate antagonist	epilepsy; neuropathy
MDL 100453	4-oxo-5-phosphono-D-norvaline	NMDA antagonist; glutamate antagonist	epilepsy; neuropathy; stroke
MDL 104653	7-chloro-4-hydroxy-3-phenyl-2(1H)-quinolinone	NMDA antagonist; glutamate antagonist	epilepsy

MDL 105519	(E)-3-(2-carboxy-2-phenylethenyl)-4,6-dichloro-1H-indole-2-carboxylic acid	NMDA antagonist; glutamate antagonist	anxiety; epilepsy
MDL 29814	5,7 dichlorokynurenic acid	NMDA antagonist; glutamate antagonist	epilepsy
NMDA antagonist	Unspecified	NMDA antagonist; glutamate antagonist	epilepsy; stroke; neuropathy
NPS 1387	Unspecified	NMDA antagonist; glutamate antagonist	epilepsy
Remacemide; FPL 12924; PR 934423; FPL 12924AA; PR 934423A; FPL 14144; PR 1032644; FPL 14145, PR 1032646	(+,-)-2-amino-N-(1-methyl-1,2-diphenylethyl)acetamide	NMDA antagonist; glutamate antagonist	epilepsy; Parkinson disease; neurodegeneration
RPR 104632; RPR 110754	2-[(3-bromophenyl)methyl]-6,8-dichloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-3-carboxylic acid 1,1-dioxide	NMDA antagonist; glutamate antagonist	epilepsy
ACEA 1416; NMCQX	5-nitro-6-methyl-7-chloro-2,3-quinoxalinedione	NMDA antagonist; glutamate antagonist; analgesic	epilepsy; pain; brain ischemia
Conantokins	Unspecified	NMDA antagonist; glutamate antagonist; peptide; analgesic	epilepsy; stroke; schizophrenia; pain; ischemia
ADCI; SGB 017; ADCI	10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine-5-carboxamide	NMDA antagonist; glutamate antagonist; sodium channel blocker	epilepsy; stroke
oxytocin antagonist	Unspecified	oxytocin antagonist; diuretic	anxiety; depression; obsessive compulsive disorder; epilepsy; heart failure
Conantokin G	Unspecified	peptide; glutamate antagonist; NMDA antagonist	stroke; brain ischemia; epilepsy

Fosphenytoin; fosphenytoin sodium; prophenytoin; ACC 9653; CI 982; PD 135711-15B; CEREBYX; PRO-EPANUTIN	5,5-diphenyl-3-[(phosphonoxy)methyl]-2,4-imidazolidinedione	Phenytoin prodrug; fosphenytoin converted to phenytoin by endogenous phosphatases	epilepsy
proline transport inhibitors	Unspecified	Proline transporter inhibitor	epilepsy; stroke
JNK 3 inhibitors	Unspecified	signal transduction inhibitor	epilepsy
Zonisamide; fenisoxine; AD 810; CI 912; PD 110843; EXCEGRAN; EXEGRAN; ZONEGRAN	1,2-benzisoxazole-3-methansulfonamide	Sodium and calcium voltage sensitive channel blockade	epilepsy
534U87; BW 534U87	Unspecified	sodium channel blocker	epilepsy
AWD 140190	4-(4-bromophenyl)-3-(4-morpholinyl)-1H-pyrrole-2-carboxylic acid, methyl ester	sodium channel blocker	epilepsy
Co 102862	2-[[4-(4-fluorophenoxy)phenyl]methylene]hydrazinecarboxamide	sodium channel blocker	epilepsy
GW 273293	Unspecified	sodium channel blocker	epilepsy; depression
Lamotrigine; BW 430C; LAMICTAL	6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine	sodium channel blocker	epilepsy; psychosis; depression
PNU 151774E	(2S)-2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]propanamide monomethanesulfonate	sodium channel blocker; calcium channel blocker; MAO B inhibitor; MAO inhibitor	epilepsy; Parkinson disease; brain ischemia
taurine transporter modulator	Unspecified	Taurine transporter inhibitor	epilepsy; brain ischemia
MDL 27531	4-methyl-3-(methylsulphonyl)-5-phenyl-4H-1,2,4-triazole	triazole	epilepsy

A 76895; ABBOTT 76895	Unspecified	Valproic acid derivative	epilepsy
Anticonvulsants	Unspecified	Valproic acid derivative	epilepsy
Antiepileptics	Unspecified	Valproic acid derivative	epilepsy
CHF 1504	Unspecified	Valproic acid derivative	epilepsy
RAP-valproic acid; DP VPA	Unspecified	Valproic acid derivative	epilepsy
ABS 103; ABS-103R	Unspecified	Valproic acid derivative	epilepsy
CHF 1355	Unspecified	Valproic acid derivative	epilepsy
Vasopressin antagonist	Unspecified	vasopressin antagonist; diuretic	anxiety; depression; obsessive compulsive disorder; epilepsy; heart failure

Table 30. Current Candidate Therapeutic Interventions for the Treatment of Huntington's Disease

Product Name	Chemical Name	Action	Indication
Neurodegenerative disease therapy	Unspecified	apoptosis inhibitor	Neurodegeneration
Brain-derived neurotrophic factor; BDNF;	BDNF, and derivatives	BDNF, growth factor; neurotrophic factor	amyotrophic lateral sclerosis; neuropathy
Dopamine release inhibitor	Unspecified	Calcium antagonist	schizophrenia
Cardiotrophin-1 secreting implant; cardiotrophin-1 secreting implant	Cardiotrophin-1 and derivatives	Cardiotrophin-1; growth factor	amyotrophic lateral sclerosis; neurodegeneration
Tacrine; THA; tetrahydroaminacrine; CI 970; COGNEX	1,2,3,4-tetrahydro-9-acridinamine	cholinesterase inhibitor	Alzheimer disease
AXOKINE	Ciliary neurotrophic factor derivative	CNTF, growth factor	amyotrophic lateral sclerosis; obesity; eye disease
Ciliary neurotrophic factor; CNTF; CNTF delivery system	CNTF and derivatives	CNTF, growth factor	amyotrophic lateral sclerosis; neuropathy

Estrogens	Estrogen and derivatives	estrogen	neuropathy; Alzheimer disease
SYM 2101	Unspecified	glutamate agonist; AMPA partial agonist	neurological
SYM 2250	Unspecified	glutamate agonist; AMPA partial agonist	neurological
SYM 2007	Unspecified	glutamate agonist; kainate partial agonist	neurological
SYM 2192	Unspecified	glutamate agonist; kainate partial agonist	neurological
SYM 1010	Unspecified	glutamate agonist; NMDA partial agonist	neurological
SYM 2315	Unspecified	glutamate agonist; NMDA partial agonist	neurological
Riluzole; PK 26124; RP 54274; RILUTEK	6-(trifluoromethoxy)-2-benzothiazolamine	glutamate antagonist	amyotrophic lateral sclerosis; Alzheimer disease; Parkinson disease
MAB, major histocompatibility complex I; F(ab') ₂ , MHC I	Monoclonal antibody fragment	Immunomodulation	transplant rejection
Nerve growth factor secreting implant	NGF and derivatives	NGF, growth factor	Neurodegeneration; neuropathy
Remacemide; FPL 12924; PR 934423; FPL 12924AA; PR 934423A; FPL 14144; PR 1032644; FPL 14145, PR 1032646	(+,-)-2-amino-N-(1-methyl-1,2-diphenylethyl)acetamide	NMDA antagonist; glutamate antagonist	epilepsy; Parkinson disease; neurodegeneration
Idebenone; CV 2619; AVAN; LUCEBANOL; GENICERAL; MNESIS; DARUMA; NEMOCEBRAL; KEDANON; ARZKAT; DAYSTROM	2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione	Nootropic agent	cognitive defect
Neurotrophin-3 secreting implant	NT-3 and derivatives	NT-3, growth factor	Alzheimer disease; Parkinson disease; neuropathy
Neurotrophin-4; NT-4	NT-4 and derivatives	NT-4, growth factor	neuropathy; diabetes

Nalmefene; nalmetrene; JF 1; INCYSTENE; ARTHENE; FENARC; CERVENE; REVEX	17-(cyclopropylmethyl)- 4,5alpha-epoxy-6- methylenemorphinan- 3,14-diol	opiate antagonist; NSAID	intoxication; alcoholism; pruritis; obesity; neurological depression; rheumatoid arthritis; cystitis; trauma
Synthetic opioid alkaloids	Unspecified	Opioid ligand	Neurodegeneration

Table 31. Current Candidate Therapeutic Interventions for the Treatment of Migraine

Product Name	Chemical Name	Action	Indication
ALX 0646	Unspecified	5HT agonist	migraine
CP 122288	(R)-N-methyl-3-[(1-methyl-2-pyrrolidinyl)methyl]-1H-indole-5-methanesulfonamide	5HT agonist	migraine
IS 159	Unspecified	5HT agonist	migraine
avatriptan; avatriptan fumarate; BMS 180048; BMS 18004802	3-[3-[4-(5-methoxy-4-pyrimidinyl)-1-piperazinyl]propyl]-N-methyl-1H-indole-5-methanesulfonamide	5HT agonist; 5HT1 agonist	migraine
BW 324C91	Unspecified	5HT agonist; 5HT1 agonist	migraine
CP 110330	N,N-dimethyl-5-[4-[(phenylamino)methyl]-2-thiazolyl]-1H-indole-3-ethanamine	5HT agonist; 5HT1 agonist	migraine; anxiety; depression
CP 119333	N,N-dimethyl-5-[4-(phenylmethyl)-2-thiazolyl]-1H-indole-3-ethanamine	5HT agonist; 5HT1 agonist	migraine; anxiety; depression
D 1997	2-quinolineethanamine	5HT agonist; 5HT1 agonist	migraine
GR 127607	Unspecified	5HT agonist; 5HT1 agonist	migraine
GR 40370	Unspecified	5HT agonist; 5HT1 agonist	migraine

Naratriptan; naratriptan hydrochloride; GR 85548; GR 85548A; GR 85548X; NARAMIG; AMERGE	N-methyl-3-(1- methyl-4- piperidinyl)-1H- indole-5- ethanesulfonamide	5HT agonist; 5HT1 agonist	migraine
Sumatriptan; GR 43175; GR 43175X; GR 43175A; GR 43175C; SN 308; GW 102; IMIGRAN; IMITREX; SUMADOL; IMIJECT; ARCOIRAN	3-[2- (dimethylamino)ethyl]-N-methyl-1H- indole-5- methanesulfonamide	5HT agonist; 5HT1 agonist	migraine
tonabersat; SB 220453	(3S-cis)-N-(6-acetyl- 3,4-dihydro-3- hydroxy-2,2- dimethyl-2H-1-benz pyran-4-yl)-3-chloro- 4-fluorobenzamide	5HT agonist; 5HT1 agonist	migraine
CP 93129	1,4-dihydro-3- (1,2,3,6-tetrahydro-4- pyridinyl)-5H- pyrrolo[3,2-b]pyridin- 5-one	5HT agonist; 5HT1B agonist	migraine
Frovatriptan; VML 251; SB 209509; MIGUARD	(R)-2,3,4,9- tetrahydro-3- (methylamino)-1H- carbazole-6- carboxamide	5HT agonist; 5HT1B agonist; 5HT1D agonist	migraine
rizatriptan; rizatriptan benzoate; rizatriptan sulfate; MK 462; MAXALT	N,N-dimethyl-5-(1H- 1,2,4-triazol-1- ylmethyl)-1H-indole- 3-ethanamine	5HT agonist; 5HT1B agonist; 5HT1D agonist	migraine
Almotriptan; LAS 31416	1-[[[3-[2- (dimethylamino)ethyl]-1H-indol-5- yl]methyl]sulfonyl]py rrolidine	5HT agonist; 5HT1D agonist	migraine

alniditan; R 91274; PASMIGREN; PASMIGRINE	(R)-N-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-N'-(1,4,5,6-tetrahydropyrimidin-2-yl)propane-1,3-diamine	5HT agonist; 5HT1D agonist	migraine
ALX 1323	Unspecified	5HT agonist; 5HT1D agonist	migraine
aromatic triflates,	Unspecified	5HT agonist; 5HT1D agonist	depression; migraine
eletriptan; UK 116044; RELPAX	(R)-3-[(1-methyl-2-pyrrolidinyl)methyl]-5-[2-(phenylsulfonyl)ethyl]-1H-indole	5HT agonist; 5HT1D agonist	migraine
GMC 2020	Unspecified	5HT agonist; 5HT1D agonist	depression; migraine
GMC 2021	Trifluoromethanesulfonic acid 3-[2-(dimethylamino)ethyl]-1H-indol-5-yl ester (1:1) ethanedioate	5HT agonist; 5HT1D agonist	depression; migraine
L 741519	3-(1-methyl-4-piperidinyl)-5-(4H-1,2,4-triazol-4-yl)-1H-indole	5HT agonist; 5HT1D agonist	migraine
L 741604	N,N-dimethyl-5-(4H-1,2,4-triazol-4-yl)-1H-indole-3-ethanamine	5HT agonist; 5HT1D agonist	migraine
LAS 31727	Unspecified	5HT agonist; 5HT1D agonist	migraine
VS 395	3-[3-[4-(5,6-dimethoxy-4-pyrimidinyl)-1-piperazinyl]propyl]-N-methyl-1H-indole-5-methanesulfonamide	5HT agonist; 5HT1D agonist	migraine

F 11356; L 0076	1-[[[3-(2-aminoethyl)-1H-indol-5-yl]oxy]acetyl]-4-(4-cyanophenyl)piperazine monohydrochloride	5HT agonist; 5HT1D agonist; 5HT1B agonist	migraine
Zolmitriptan; 311C90; BW 311C90; ZOMIG	(S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone	5HT agonist; 5HT1Dalpha agonist; 5HT1Dbeta agonist; 5HT1B agonist	migraine
LY 334370	4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]benzamide	5HT agonist; 5HT1F agonist	migraine
selective serotonin 1F receptor agonists,	Unspecified	5HT agonist; 5HT1F agonist	migraine
Sergolexole; LY281067	trans-4-methoxycyclohexyl 1-isopropyl-6-methylergoline-8beta-carboxylate	5HT antagonist; 5HT2 antagonist	migraine
tropoxin	O-(3,4,5-trimethoxybenzoyl)oxime-8-methyl-8-azabicyclo[3.2.1]octan-3-one monohydrochloride	5HT antagonist; 5HT2 antagonist	migraine
dotarizine; FI 6026	1-(diphenylmethyl)-4-[3-(2-phenyl-1,3-dioxolan-2-yl)propyl]piperazine	5HT antagonist; 5HT2 antagonist; 5HT1C antagonist; calcium antagonist	migraine
Bemesetron; MDL 72222	3,5-dichlorobenzoic acid, endo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester	5HT antagonist; 5HT3 antagonist	emesis; migraine
LY 53857	(8beta)-6-methyl-1-(1-methylethyl)ergoline-8-carboxylic acid 2-hydroxy-1-methylpropyl ester, (Z)-2-butenedioate (1:1)	5HT antagonist; vasodilator	migraine

fluoxetine, (R)-; (R)-fluoxetine	(R)-N-methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine	5HT reuptake inhibitor	migraine; cognitive defect; depression
fluoxetine, (S)-; (S)-fluoxetine	(S)-N-methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine	5HT reuptake inhibitor	migraine
5HT4 human neuroreceptor; neuroreceptor, 5HT4	Unspecified	5HT4 human neuroreceptor;	Irritable bowel syndrome; cognitive defect; anxiety; arrhythmia; stroke; urinary incontinence; migraine; research tool
drug delivery system, transdermal lidocaine; PAINtrol TW; PAINtrol HM; PAINtrol TV	unspecified	analgesic	pain; migraine
CNS 5161	N'-[2-chloro-5-(methylthio)phenyl]-N-methyl-N-[3-(methylthio)phenyl]guanidine monohydrochloride	analgesic; NMDA antagonist; glutamate antagonist	pain; migraine; neuropathy
nebivolol; narbivolol; R 67555; R 65824; ME 3255; R 67138; R 67145; R 065824; NEBILET; LOBIVON	[2R*[R*[R*(S*)]]]-alpha, alpha'-[iminobis(methylene)]bis[6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol]	beta adrenergic antagonist; beta1 adrenergic antagonist; nitric oxide activator; vasodilator	hypertension; migraine; heart failure
drug delivery system, intranasal propranolol; propranolol intranasal; MIGRASTAT	Unspecified	beta adrenergic antagonist; beta2 adrenergic antagonist	migraine
Bradykinin antagonist/mu agonist,	Unspecified	bradykinin antagonist; mu agonist; opiate agonist; analgesic; NSAID	Inflammation; pain; migraine

calcitonin gene-related peptide (CGRP) receptor modulators,	Unspecified	Calcitonin gene related peptide modulation	migraine; diabetes
Nimodipine; BAY e 9736; BAY N 5248; BAY N 5427; NIMOTOP; NIMOTAP; NIVAS; TROPOCER; EUGERIAL; NIMODILAT; CEBROFORT; KENESIL; GENOVOX	1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl 1-methylethyl ester	calcium antagonist	migraine; cognitive defect; Alzheimer disease; brain ischemia
Flunarizine; R 14950; FLUZINA; SIBELIUM; ZINASEN; SESNARBO; RIZENA; SINAZINE; HEADACHE; FLORIRATO; DIESPRUDEL	Unspecified	calcium antagonist; vasodilator	peripheral vascular disease; cerebrovascular disease; migraine; epilepsy
Lomerizine; KB 2796; TERRANAS TAB; MIGSIS	1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine	calcium antagonist; vasodilator	hypertension; migraine
BIBN 4096	Unspecified	CGRP antagonist	migraine
botulinum toxin type A; Clostridium botulinum toxin type A; OCULINUM; BOTOX	botulin A	cholinergic antagonist; muscle relaxant	muscle spasm; eye disease; migraine
Ganaxolone; CCD 1042	(3 α ,5 α)-3-hydroxy-3-methylpregnan-20-one	GABA agonist	epilepsy; migraine
valproate semisodium; divalproex sodium; semisodium valproate; ABBOTT 50711; DEPAKOTE; EPIVAL; VALCOTE	2-propylpentanoic acid sodium salt (2:1)	GABA releasing agent	epilepsy; migraine; schizophrenia; depression

4991W93	Unspecified	Inflammation inhibitor	migraine
FK 888	trans-4-hydroxy-1-[(1-methyl-1H-indol-3-yl)carbonyl]-L-propyl-N-methyl-3-(2-naphthalenyl)-N-(phenylmethyl)-L-alaninamide	neurokinin antagonist	asthma; migraine
lanepitant; LY 303870	(R)-N-[2-acetyl[(2-methoxyphenyl)methyl]amino]-1-(1H-indol-3-ylmethyl)ethyl]-[1,4'-bipiperidine]-1'-acetamide	neurokinin antagonist; analgesic; neurokinin 1 antagonist	asthma; pain; migraine
GR 205171	(2S-cis)-N-[[2-methoxy-5-[5-(trifluoromethyl)-1H-tetrazol-1-yl]phenyl]methyl]-2-phenyl-3-piperidinamine	neurokinin antagonist; neurokinin 1 antagonist	emesis; migraine
neutral endopeptidase; NEP	Unspecified	neutral endopeptidase; proteinase; metalloproteinase	cancer; migraine; inflammatory bowel disease; inflammation; asthma; respiratory disease
nitric oxide inhibitor, diclofenac potassium; CGP 45840B; CATAFLAM; CATAFLAN; DICLOFEN; VOLTAREN	unspecified potassium (o-(2,6-dichloroanilino)-phenyl)acetate	nitric oxide inhibitor NSAID	migraine Inflammation; migraine; surgery
dapitant; RPR 100893	[3aS-[2(R*),3aalpha,4beta,7aalpha]]-octahydro-4-(2-methoxyphenyl)-2-[2-(2-methoxyphenyl)-1-oxopropyl]-7,7-diphenyl-1H-isoindol-4-ol	substance P antagonist; NSAID	asthma; inflammation; migraine

BMS 182246	Unspecified	Sumitripan-like activity	migraine
ALX 0625	Unspecified	Unspecified	migraine
BMS 181885	3-[[3-[3-[4-(5-methoxy-4-pyrimidinyl)-1-piperazinyl]propyl]-1H-indol-5-yl]amino]-4-methyl-3-cyclobutene-1,2-dione	Unspecified	migraine
drug delivery system, solid liquid polymer, migraine therapy	Unspecified	Unspecified	migraine
migraine therapy	Unspecified	Unspecified	migraine
Parthenolide	Unspecified	Unspecified	migraine
SB 218842	Unspecified	unspecified	migraine

Table 32. Current Candidate Therapeutic Interventions for the Treatment of Multiple Sclerosis

Product Name	Chemical Name	Action	Indication
RG 13577	(4-hydroxyphenoxy)acetic acid, polymer with formaldehyde monoammoniate	angiogenesis inhibitor; FGF antagonist	restenosis; multiple sclerosis
VLA4 integrin antagonist,	unspecified	cell adhesion inhibitor; integrin antagonist; VLA 4 antagonist; NSAID	asthma; rheumatoid arthritis; multiple sclerosis
drug delivery system, corticotropin; corticotropin delivery system; drug delivery system, ACTH	Unspecified	Corticotropin; hormone	multiple sclerosis
interferon agonists,	Unspecified	cytokine agonist; NSAID	cancer; viral infection; infectious disease; multiple sclerosis
gene therapy, cytokines,	Unspecified	cytokine; immunosuppressant	autoimmune disease; rheumatoid arthritis; diabetes; multiple sclerosis

Interleukin-10; IL-10; cytokine synthesis inhibitory factor; CSIF; SCH 52000; TENOVIL	interleukin 10 (human clone pH15C)	cytokine; vaccine adjuvant; immunosuppressant; NSAID	autoimmune disease; inflammatory bowel disease; rheumatoid arthritis; multiple sclerosis; psoriasis; HIV infection; viral infection
Spirogermanium; NSC 192965; SPIRO-32	8,8-diethyl-N,N-dimethyl-2-aza-8-germaspiro[4.5]decan-2-propanamine	DMARD; NSAID	malaria; multiple sclerosis; rheumatoid arthritis; cancer
SRI 62834	(+,-)- 2-[[[hydroxy[[[tetrahydro-2-[(octadecyloxy)methyl]-2-furanyl]methoxy]phosphinyl]oxy]-N,N,N-trimethyl-ethananium, inner salt.	ether lipid	cancer; multiple sclerosis
Transforming growth factor beta 2; TGF beta2; FOVALIN; BetaKine	Unspecified	growth factor; cicatrizant	retinopathy; osteoporosis; skin ulcer; multiple sclerosis
GPI 1046	1-(3,3-dimethyl-1,2-dioxopentyl)-L-proline 3-(3-pyridinyl)propyl ester	growth factor; neurotrophic factor	Alzheimer disease; Parkinson disease; multiple sclerosis; neuropathy
NIL-A	Unspecified	growth factor; neurotrophic factor	Alzheimer disease; Parkinson disease; multiple sclerosis; neuropathy
neural progenitor regulatory factor	Unspecified	growth factor; peptide; neurotrophic factor	multiple sclerosis; trauma; neurodegeneration
AG 284	MHC molecule with myelin basic protein	Immunomodulation	multiple sclerosis
Multiple sclerosis therapy	Chimeric virus particles	Immunomodulation	multiple sclerosis
Oligodendroglial trophic factor; OTF	Peptide	Immunomodulation	multiple sclerosis
RecepTox-MBP	peptide; fusion toxin	Immunomodulation	multiple sclerosis

MAB, 23F2G; MAB, leukointegrin; Hu 23F2G; LeukArrest	23F2G; MAB, leukointegrin monoclonal antibody	Immunomodulation;	multiple sclerosis; cardiovascular disease; myocardial infarction; stroke
MAB, OX40-ricin A; immunotoxin OX40-ricin A	Immunotoxin monoclonal antibody;	Immunomodulation;	multiple sclerosis
MAB, alpha4beta1 integrin; AN 100226; ANTEGREN	Unspecified	Immunomodulation; monoclonal antibody	multiple sclerosis; Crohn disease; ulcerative colitis
MAB, M1	Unspecified	Immunomodulation; monoclonal antibody	trauma; multiple sclerosis
MAB, humanized, leukemia; MAB, IgG2B; LDP 03; BW 7U; CAMPATH; CAMPATH-1H	Unspecified	Immunomodulation; monoclonal antibody; NSAID	rheumatoid arthritis; cancer; multiple sclerosis; transplant rejection
ABR 215062	Unspecified	Immunomodulator	multiple sclerosis
Glatiramer acetate; copolymer 1; COP 1; COPAXONE	L-glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt)	Immunomodulator	multiple sclerosis
PA 1093	Herpes virus 6 protein derivative	Immunomodulator	multiple sclerosis
Roquinimex; LS 2616; FCF 89; LINOMIDE	1,2-dihydro-4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide	immunostimulant	multiple sclerosis
AI 101	Unspecified	immunosuppressant	multiple sclerosis
AI 102	Unspecified	immunosuppressant	multiple sclerosis
Galaptin L-14-1; immunomodulatory lectin-1; IML-1	Unspecified	immunosuppressant	transplant rejection; multiple sclerosis
PEPTIMER	Unspecified	immunosuppressant	autoimmune disease; multiple sclerosis; rheumatoid arthritis; diabetes
AI 100; MYLORAL	Unspecified	immunosuppressant	multiple sclerosis

Gusperimus; gusperimus hydrochloride; hydroxyspergualin, 15-; desoxyspergualin; DSG; NKT 01; NSC 356894; BMS 181173; BMY 42215- 1; SPANIDIN; SUPANIDIN	(+,-)-7- [(aminoiminomethyl) amino]-N-[2-[[4-[(3- aminopropyl)amino]b utyl]amino]-1- hydroxy-2- oxoethyl]heptanamid e	immunosuppressant	transplant rejection; multiple sclerosis; cancer
MAb, gamma interferon, humanized; SMART anti-gamma interferon	Unspecified	immunosuppressant monoclonal antibody;	systemic lupus erythematosus; multiple sclerosis
Lymphocyte activation gene 3 protein; LAG 3 protein	Unspecified	immunosuppressant; biotechnology	transplant rejection; multiple sclerosis
MP 4	Unspecified	immunosuppressant; biotechnology; apoptosis inducer	multiple sclerosis
ATP 012; TP 12	Unspecified	immunosuppressant; biotechnology; peptide	multiple sclerosis
MAb, T cell antigen receptor; ATM 027; TM 27	Unspecified	Immunosuppressant; monoclonal antibody;	multiple sclerosis
Priliximab; MAb, humanized CD4; cM- T412; CEN 000029; CENTARA	Immunoglobulin G1 (human-mouse monoclonal cm-T412 anti-human antigen CD 4), disulfide with human-mouse monoclonal cm- T412.kappa.-chain, dimer	immunosuppressant; monoclonal antibody; NSAID	multiple sclerosis; autoimmune disease; rheumatoid arthritis
Lenercept; tumor necrosis factor receptor fusion protein; TNF receptor fusion protein; Ro 452081; TENEFUSE	Unspecified	immunosuppressant; NSAID	rheumatoid arthritis; asthma; septic shock; multiple sclerosis

MAb, CD40 ligand; 5C8; ANTOVA	Unspecified	immunosuppressant; NSAID	inflammation; systemic lupus erythematosus; multiple sclerosis
Autoimmune disease therapy,	Unspecified	immunosuppressant; NSAID	rheumatoid arthritis; multiple sclerosis; systemic lupus erythematosus
Cladribine; 2-CdA; NSC 105014F; RWJ 26251; LEUSTATIN; LEUSTAT; MYLINAX	2-chloro-2'- deoxyadenosine	immunosuppressant; nucleoside analogue; NSAID	cancer; multiple sclerosis; rheumatoid arthritis
ZAP inhibitors, Ariad	unspecified	immunosuppressant; protein kinase inhibitor; tyrosine kinase inhibitor; NSAID	transplant rejection; rheumatoid arthritis; inflammatory bowel disease; systemic lupus erythematosus; multiple sclerosis
alpha4beta1 integrin antagonist	Unspecified	integrin antagonist; cell adhesion inhibitor; alpha4 beta1 integrin antagonist	multiple sclerosis
VLA-4 antagonists, inflammatory diseases; BIO 1211	N-[[4-[[[(2- methylphenyl)amino] carbonyl]amino]phen yl]acetyl]-L-leucyl-L- alpha-aspartyl-L- valyl-L-proline	integrin antagonist; VLA 4 antagonist	asthma; multiple sclerosis
Interferon beta-1a; IFN beta; AVONEX	interferon beta-1a	interferon	viral infection; multiple sclerosis; cancer
Interferon beta-1a; interferon beta; IFN- beta; REBIF	Unspecified	interferon	cancer; viral infection; multiple sclerosis; inflammatory bowel disease
Interferon beta-1b; interferon beta-serine; SH 579; ZK 157046; BETASERON; BENESERON; BETA FERON	2-166-interferon beta 1 (human fibroblast reduced)	interferon	multiple sclerosis; cancer; viral infection
Interferon tau	Unspecified	interferon	multiple sclerosis

alpha interferon, natural; OMNIFERON	Unspecified	interferon	multiple sclerosis; viral infection
Interferon beta; FRONE	Unspecified	interferon	multiple sclerosis; cancer; eye disease
Solimastat; BB 3644	(2S,3R)-3-[(1S)-2,2-dimethyl-1-(2-pyridylcarbamoyl)propyl]carbamoyl-2-methoxy-5-methylhexanohydroxamic acid	matrix metalloproteinase inhibitor; TNF inhibitor; proteinase inhibitor	multiple sclerosis; rheumatoid arthritis; inflammatory bowel disease; cancer
LG 21101	Unspecified	NSAID	inflammation; multiple sclerosis
NBI 116	Unspecified	NSAID	multiple sclerosis; rheumatoid arthritis
PKC-RACK interaction inhibitors,	Unspecified	NSAID, PKC-RACK interaction inhibitors	arthritis; multiple sclerosis; asthma
white blood cell migration inhibitors,	Unspecified	NSAID, white blood cell migration inhibitors,	inflammation; multiple sclerosis
Neurotactin blockers	Unspecified	NSAID; chemokine antagonist; gene	multiple sclerosis; inflammation
Lexipafant; BB 882; DO 6; GR 167089; ZACUTEX	N-methyl-N[[4-(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]phenyl]sulfonyl]-L-leucine ethyl ester	PAF antagonist	thrombosis; endotoxic shock; pancreatitis; eye disease; multiple sclerosis
Ginkgolide B; BN 52021	hexacyclic trilactone	PAF antagonist; platelet antiaggregant	thrombosis; dermatitis; asthma; multiple sclerosis; septic shock
CGP 77116	Unspecified	peptide	multiple sclerosis
Multiple sclerosis therapy	Unspecified	peptide	multiple sclerosis
Multiple sclerosis therapy	Unspecified	peptide	multiple sclerosis
Multiple sclerosis therapy	Unspecified	peptide	multiple sclerosis
NBI 114	Unspecified	peptide	multiple sclerosis
NBI 115	Unspecified	peptide	multiple sclerosis

NBI 5788; MSP 771	D-ala-L-lys-L-pro-L-val-L-val-L-his-L-leu-L-phe-L-ala-L-asp-L-ile-L-val-L-thr-L-pro-L-arg-L-thr-L-pro	peptide	multiple sclerosis
rD-mPGPtide	Unspecified	peptide; immunosuppressant	transplant rejection; multiple sclerosis
TNF receptor antagonist; TNF receptor antagonist,	Unspecified	peptide; NSAID	rheumatoid arthritis; multiple sclerosis
rolipram; ZK 62711; ME 3167; ADEO	4-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone	phosphodiesterase inhibitor	cognitive defect; multiple sclerosis
SH 636	Unspecified	phosphodiesterase inhibitor; phosphodiesterase IV inhibitor	multiple sclerosis
drug delivery system, IPDAS fampridine; fampridine IPDAS	Unspecified	potassium channel blocker	multiple sclerosis; neuropathy
Fampridine; EL 970; AVITROL	4-pyridinamine	potassium channel blocker	multiple sclerosis
adapalene; CD 271; DIFFERINE; DIFFERIN	6-(4-methoxy-3-tricyclo[3.3.1.1(3,7)]dec-1-ylphenyl)-2-naphthalenecarboxylic acid	retinoid agonist; retinoid; RAR agonist; RARbeta agonist	acne; multiple sclerosis
drug delivery system, biodegradable micellar paclitaxel; paclitaxel micellar	Unspecified	Taxane; DMARD; NSAID; microtubule inhibitor	rheumatoid arthritis; multiple sclerosis
CC 1080	Unspecified	TNF inhibitor; NSAID	arthritis; cancer; multiple sclerosis
MNX 160	Unspecified	TNF inhibitor; NSAID	rheumatoid arthritis; diabetes; multiple sclerosis
Thalidomide; NSC 66847	N-(2,6-dioxo-3-piperidyl)phthalimide	TNF modulator; immunosuppressant	HIV infection; Crohn disease; multiple sclerosis; Alzheimer disease; transplant rejection

Mitoxantrone; CL 232315; NSC 279836; NSC 301739; DHAQ; DHAD; NOVANTRONE; NOVATRON	1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione	Topoisomerase inhibitor	cancer; multiple sclerosis
TCR peptide, multiple sclerosis	Vaccine	vaccine	multiple sclerosis
vaccine, activated T cells; vaccine, multiple sclerosis	Vaccine	vaccine	multiple sclerosis
vaccine, multiple sclerosis; vaccine, Vbeta6.2/6.5 T cell receptor; AI 208; IR 208	Vaccine	vaccine	multiple sclerosis
NBI 108	Unspecified	vaccine adjuvant; immunostimulant; neuroactive steroid	Alzheimer disease; infectious disease; multiple sclerosis
VCAM antagonists	Unspecified	vascular cell adhesion molecule inhibitor; NSAID	atherosclerosis; rheumatoid arthritis; multiple sclerosis
TBC 609	Unspecified	vascular cell adhesion molecule inhibitor; NSAID; peptide	atherosclerosis; rheumatoid arthritis; multiple sclerosis
TBC 772	Unspecified	vascular cell adhesion molecule inhibitor; NSAID; peptide	atherosclerosis; rheumatoid arthritis; multiple sclerosis
ZD 7349	Unspecified	VLA 4 antagonist; integrin antagonist; NSAID; cell adhesion inhibitor	multiple sclerosis; arthritis

Table 33. Current Candidate Therapeutic Interventions for the Treatment of Pain

Product Name	Chemical Name	Action	Indication
anpirtoline	4-[(6-chloro-2-pyridyl)thio]piperidine	5HT agonist; 5HT1B agonist; analgesic	pain
5HT antagonists	Unspecified	5HT antagonist; 5HT1A antagonist; analgesic	pain
SP 186	Unspecified	5HT reuptake inhibitor; analgesic	pain

AAL 13	2-[4-(3-chloropropyl)-1-piperazinyl]quinoline	5HT reuptake inhibitor; analgesic; NSAID	inflammation; pain
GR 79236	(1S-trans)-N-(2-hydroxycyclopentyl)adenosine	adenosine agonist; adenosine A1 agonist	pain; coronary artery disease
UP 20232	Unspecified	adenosine agonist; analgesic	pain; neuropathy
adenosine analogues	Unspecified	adenosine analogues analgesic	pain
analgesic adenosine regulating agents	Unspecified	adenosine regulating agent	pain
GP 1683	Unspecified	adenosine regulating agent; analgesic	pain
adrenergic alpha2 human neuroreceptors; neuroreceptors, adrenergic alpha2 human	Unspecified	adrenergic alpha2 human neuroreceptors analgesic	research tool; pain; hypertension; glaucoma
S 18616	8-chloro-3,4-dihydrospiro[naphthalene-2(1H),4'(5'H)-oxazol]-2'-amine	alpha adrenergic agonist; alpha2 adrenergic agonist; analgesic	pain
SNAP 5143	Unspecified	alpha adrenergic agonist; alpha2 adrenergic agonist; analgesic	pain; glaucoma
RWJ 52807	Unspecified	alpha2 adrenergic agonist; alpha adrenergic agonist; analgesic	pain
ABT 594	(R)-2-chloro-5-(2-azetidinylmethoxy)pyridine	analgesic	pain
analben	Unspecified	analgesic	rheumatoid arthritis; pain
analgesic,	2-phenylimidazo[2,1-b]benzothiazole-3-propanoic acid 9,9-dioxide	analgesic	pain
analgesic,	9-phenyl-9H-thioxanthen-9-ol propanoate	analgesic	pain

analgesic	N-[4-(4-methyl-2-thiazolyl)-1-[2-(1H-pyrazol-1-yl)ethyl]-4-piperidiny]N-phenylpropanamide	analgesic	pain; anesthesia
analgesic,	Unspecified	analgesic	pain
analgesic	(R)-3-amino-2,3,4,9-tetrahydrothiopyrano(2,3-b)indole	analgesic	pain
analgesic	(R)-3-methylamino-2,3,4,9-tetrahydrothiopyrano(2,3-b)indole	analgesic	pain
analgesic	(R)-3-dimethylamino-2,3,4,9-tetrahydrothiopyrano(2,3-b)indole	analgesic	pain
analgesic,	Unspecified	analgesic	pain
analgesic	5-(4-methylbenzoyl)-6-(methylthio)-1,2-dihydro-3H-pyrrolo(1,2-a)pyrrole-1-carboxylic acid	analgesic	pain
analgesics	Unspecified	analgesic	pain
Analgesics	Unspecified	analgesic	pain; neuropathy
BCH 1788	Unspecified	analgesic	pain
buprenorphine + naloxone; naloxone + buprenorphine	Unspecified	analgesic	pain
capsaicin; ZOSTRIX; ZOTRIX HP; THERAGEN; THERAGEN HP; CAPSIDOL;	(E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-6-nonenamide	analgesic	pain; neuropathy; diabetes
cizolirtine; E 4018	N,N-dimethyl-2-[(1-methyl-1H-pyrazol-5-yl)phenylmethoxy]ethanamine	analgesic	pain
D 20450	Unspecified	analgesic	pain
D 21151	1-phenoxyphthalazine	analgesic	pain
dexpemmedolac; PEM 420; WAY PEM 420	(1S-cis)-1-ethyl-1,3,4,9-tetrahydro-4-(phenylmethyl)pyran-3-ylidene-1H-indole-1-acetic acid	analgesic	pain

dezocine; WY 16225; DALGAN	[5R-(5 α ,11 α ,13S*)]-13-amino-5,6,7,8,9,10,11,12-octahydro-5-methyl-11-methanobenzocyclodecen-3-ol	analgesic	pain
F 9004T	Unspecified	analgesic	pain
FID 072021	3-atropanyl 2-(4-chlorophenoxy)butyrate maleate	analgesic	pain; cognitive defect
filenadol; FI 2024	(R*,S*)-(+,-)-beta-1,3-benzodioxol-5-yl-alpha-methyl-4-morpholineethanol	analgesic	pain
flubichin	Unspecified	analgesic	pain
flupirtine; D 998; W 2964M; KATADOLON	[2-amino-6-[[4-fluorophenyl)methyl]amino]-3-pyridinyl]-ethyl ester, carbamic acid	analgesic	pain; neurological
gapxavanyl; DA 5018; DA 50018; KR 25018	4-(2-aminoethoxy)-N-[3-(3,4-dimethylphenyl)propyl]-3-methoxybenzeneacetamide	analgesic	pain
GW 275919	Unspecified	analgesic	pain
JTC 801	Unspecified	analgesic	pain
KR 25018	4-(2-aminoethoxy)-N-[3-(3,4-dimethylphenyl)propyl]-3-methoxybenzeneacetamide	analgesic	pain
pain therapy	Unspecified	analgesic	pain
pain therapy	Unspecified	analgesic	pain
pemedolac; AY 30715	cis-(+,-)-1-ethyl-1,3,4,9-tetrahydro-4-(phenylmethyl)pyran o[3,4-b]indole-1-acetic acid	analgesic	pain
peripheral nervous system therapy	Unspecified	analgesic	pain; urinary tract disorder

phenaridine; fenaridin	N-[2,5-dimethyl-1-(2-phenylethyl)-4-piperidinyl]-N-phenylpropanamide	analgesic	pain
pregabalin; CI 1008; PD 144723	(S)-3-(aminomethyl)-5-methyl-hexanoic acid	analgesic	epilepsy; pain
Ro 158081	Unspecified	analgesic	pain
ruizadolane; UP 2691	3-[[2-[4-(2,4-difluorophenyl)-1-piperazinyl]ethyl]thio]-1,2,4-triazolo[4,3-a]pyridine	analgesic	pain
S 01	5,6-dihydro-9,10,14-trimethoxy-8H-1,3-dioxolo[4,5-h]isoindolo[1,2-b][3]benzazepine-8-one	analgesic	pain
S 14080	benzoyl-6 dihydro-2,3-benzothiazole	analgesic	pain
S 8117	Unspecified	analgesic	pain
sameridine; LPB 139	N-ethyl-1-hexyl-N-methyl-4-phenyl-4-piperidinecarboxamide	analgesic	local anesthesia; pain
SJ 2321	Unspecified	analgesic	pain
SYM 2081	(4R)-4-methyl-L-glutamic acid	analgesic	pain
tramadol analogues	Unspecified	analgesic	pain
UP 52204	Unspecified	analgesic	pain
V 2	Unspecified	analgesic	pain
NC 164	Unspecified	analgesic	pain
dynorphin A; dynorphin A (1-13)	Unspecified	analgesic; peptide	pain
bradykinin antagonists	Unspecified	bradykinin antagonist; analgesic; NSAID	pain; inflammation; septic shock
bradykinin antagonist/mu agonist, Cortech	Unspecified	bradykinin antagonist; mu agonist; opiate agonist; analgesic; NSAID	inflammation; pain; migraine

CP 0880; CP 880	N-[[3-[[1-oxo-3-[4- [(1-oxopropyl)phenylamino]-1-(2-phenylethyl)-3-piperidinyl]propyl]amino]phenyl]acetyl]-beta-alanyl-D-arginyl-L-arginyl-L-prolyl-(4R)-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-(3R)-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-N-cyclohexylglycyl-L-arginine	bradykinin antagonist; mu agonist; opiate agonist; analgesic; NSAID	inflammation; pain
FR 173657	(E)-3-[6-(acetylamino)-3-pyridinyl]-N-[2-[[2,4-dichloro-3-[(2-methyl-8-quinolinyl)oxy]methyl]phenyl]methylamino]-2-oxoethyl-2-propenamide	bradykinin antagonist; NSAID; analgesic	asthma; inflammation; pain
NPS 846	Unspecified	calcium antagonist; analgesic	stroke; epilepsy; pain
ziconotide; SNX 111; CI 1009	omega-conotoxin MVIIA	calcium antagonist; analgesic; peptide	stroke; pain; brain ischemia
AM 336	Unspecified	calcium channel blocker; analgesic	pain
calcium channel blockers,	Unspecified	calcium channel blocker; analgesic	pain
SNX 239	Unspecified	calcium channel blocker; analgesic	pain; neuropathy
drug delivery system, conopeptides	Unspecified	calcium channel blocker; sodium channel blocker; potassium channel blocker; analgesic	epilepsy; Parkinson disease; stroke; pain; brain ischemia
NE 21610	(Z)-N-[[4-(2-aminoethoxy)-3-methoxyphenyl]methyl]-9-octadecenamide	capsaicin analogue; analgesic	pain

L 365031	4-bromo-N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)benzamide	cholecystokinin A antagonist; cholecystokinin antagonist	pain
L 156586	Unspecified	cholecystokinin antagonist	gastrointestinal ulcer; pain
L 156587	14,15-didehydro-14-deoxyvirginiamycin M1	cholecystokinin antagonist	gastrointestinal ulcer; pain
L 156588	14-deoxyvirginiamycin M1	cholecystokinin antagonist	gastrointestinal ulcer; pain
L 156906	Unspecified	cholecystokinin antagonist	gastrointestinal ulcer; pain
devazepide; L 364718; MK 329	(S)-N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-1H-indole-2-carboxamide	cholecystokinin antagonist; cholecystokinin A antagonist; analgesic	pain
L 365260	(R)-N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-methylphenyl)urea	cholecystokinin B antagonist; cholecystokinin antagonist; analgesic	pain
vedaclidine; NNC 111053; LY 297802	(S)-3-[4-(butylthio)-1,2,5-thiadiazol-3-yl]-1-azabicyclo[2.2.2]octane	cholinergic agonist; muscarinic agonist; analgesic	pain
CMI 980	Unspecified	cholinergic agonist; nicotinic agonist; analgesic	pain
nicotinic agonists	Unspecified	cholinergic agonist; nicotinic agonist; analgesic	cognitive defect; pain; nicotine withdrawal
SIB T1887	Unspecified	cholinergic antagonist; nicotinic antagonist; analgesic	pain
RU 54808	Unspecified	COX inhibitor; 5 lipoxxygenase inhibitor	pain

drug delivery system, transdermal ketorolac; ketorolac transdermal	Unspecified	COX inhibitor; analgesic	pain
ketorolac; ketorolac trometamol; BPPC; RS 37619; RS 3761900313; TORADOL; TARASYN; TORATEX; ACULAR; LIDIXOL; TORA DOL; TORA-DO; TONUM; KETRODOL	(+,-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid	COX inhibitor; analgesic	pain
meloxicam; UH AC62; UH AC26XX; MOBIC; MOBICOX; MOBEC; MOVALIS; MOVATEC	4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide	COX inhibitor; analgesic; COX 2 inhibitor; NSAID	rheumatoid arthritis; inflammation; pain; osteoarthritis
AHR 10037	2-amino-3-(4-chlorobenzoyl)benzenecetamide	COX inhibitor; analgesic; NSAID	inflammation; pain
D 1367	Unspecified	COX inhibitor; analgesic; NSAID	pain; inflammation
T 614	N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl]-methanesulfonamide	COX inhibitor; analgesic; NSAID; DMARD	inflammation; pain
GR 253035	Unspecified	COX inhibitor; COX 2 inhibitor; analgesic	pain; Alzheimer disease
L 783003	Unspecified	COX inhibitor; COX 2 inhibitor; analgesic	pain
parecoxib; SC 69124A	N-[[4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl]sulfonyl]propanamide	COX inhibitor; COX 2 inhibitor; analgesic	pain
celecoxib; SC 58635; YM 177	4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	arthritis; pain; cancer

CT 3	Unspecified	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	pain; inflammation
JTE 522	4-(4-cyclohexyl-2-methyl-5-oxazolyl)-2-fluorobenzenesulfonamide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; pain
L 745337	N-[6-[(2,4-difluorophenyl)thio]-2,3-dihydro-1-oxo-1H-inden-5-yl]methanesulfonamide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	pain; inflammation
L 752860	unspecified	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; pain
MK 663	Unspecified	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; pain
NS 398	N-[2-(cyclohexyloxy)-4-nitrophenyl]methanesulfonamide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; pain
Rofecoxib; MK 966; VIOXX	4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; rheumatoid arthritis; osteoarthritis; pain; Alzheimer disease
Valdecoxib; SC 65872	4-(5-methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	arthritis; pain
COX 2 inhibitors,	Unspecified	COX inhibitor; COX 2 inhibitor; NSAID; analgesic	inflammation; osteoarthritis; pain
Lornoxicam; chlortenoxicam; Ro 139297; TS 110; CTX; SAFEM; XEFO; LORCAM	6-chloro-4-hydroxy-2-methyl-N-2-pyridinyl-2H-thieno[2,3-e]-1,2-thiazin e-3-carboxamide 1,1-dioxide	COX inhibitor; NSAID; analgesic	inflammation; pain
E 5090	(Z)-3-[4-(acetyloxy)-5-ethyl-3-methoxy-1-naphthalenyl]-2-methyl-2-propenoic acid	cytokine inhibitor; analgesic; NSAID	inflammation; pain

TAN 67	trans-3-(1,3,4,5,12,12a-hexahydro-2-methylpyrido[3,4-b]acridin-4a(2H)-yl)phenol	delta agonist; opiate agonist; analgesic	pain
Prinomide; prinomide tromethamine; CGS 10787; CGS 10787B	alpha-cyano-1-methyl-beta-oxopyrrole-2-propionanilide with 2-amino-2-(hydroxymethyl)-1,3-propanediol	DMARD; analgesic; immunosuppressant; NSAID	inflammation; pain; rheumatoid arthritis
FR 64822	N-(3,6-dihydro-1(2H)-pyridinyl)-N'-4-pyridinylurea	dopamine agonist; dopamine D2 agonist; analgesic	pain
BW 443C	L-tyrosyl-D-arginylglycyl-4-nitro-L-phenylalanyl-L-prolinamide diacetate (salt)	enkephalinase inhibitor; analgesic	asthma; pain; cough
KK 3	[S-(R*,R*)]-alfa-amino-4-hydroxy-N-[4-[[1-(hydroxymethyl)-2-phenylethyl]amino]-4-oxobutyl]-N-methyl-benzenepropanamide	enkephalinase inhibitor; analgesic	pain
ONO 9902	[1S-[1R*[R*(R*)]]]-4-[[2-[[[(1,3-dihydro-3-oxo-1-isobenzofuranyl)thio]methyl]-1-oxo-3-phenylpropyl]amino]-5-oxo-5-(phenylamino)pentanoic acid	enkephalinase inhibitor; analgesic	pain
Excitatory amino acid antagonist	Unspecified	excitatory amino acid antagonist; analgesic	pain
CGP 29030A	1-[2-(4-chlorophenyl)ethyl]-4-(3,5-dimethoxybenzoyl)-piperazine, monohydrochloride	GABA agonist; analgesic	pain

Gabapentin; CI 945; GO 3450; GOE 2450; NEURONTIN	1-(aminomethyl)cyclohexaneacetic acid	GABA release analgesic	epilepsy; anxiety; pain; neuropathy; psychosis; depression
galanin1 antagonists,	Unspecified	Galanin 1 antagonists	obesity; pain; cognitive defect
galanin modulators,	Unspecified	Galanin modulation analgesic	obesity; diabetes; cognitive defect; pain
Mipragoside; AGF 44	[R-[R*,S*-(E)]]-N-[1-[[[O-[N-acetyl-1-(1-methylethyl)-alfa-neuraminosyl]-(2-3)-O-[O-beta-D-galactopyranosyl-(1-3)-2-(acetylamino)-2-deoxy-beta-D-galactopyranosyl-(1-4)-O-beta-D-galactopyranosyl-(1-4)-beta-D-glucopyranosyl]oxy]methyl]-2-hydroxy-3-heptadecenyl]octadecanamide	ganglioside analogue; analgesic; NSAID	inflammation; pain
LY 379268	(1R,4R,5S,6R)-4-amino-2-oxabicyclo[3.1.0]hexane-4,6-dicarboxylic acid	glutamate agonist; mGluR agonist; analgesic	neurodegeneration; pain
BW 524C79	Unspecified	glutamate antagonist; analgesic	pain
NPS 2390	Unspecified	glutamate antagonist; mGluR antagonist	pain; epilepsy
SIB 1757	Unspecified	glutamate antagonist; mGluR antagonist; analgesic	pain; neurological; neurodegeneration
SIB 1893	Unspecified	glutamate antagonist; mGluR antagonist; analgesic	pain; neurological; neurodegeneration
GV 196771; GV 196771A	E-4,6-dichloro-3-[(2-oxo-1-phenyl-3-pyrrolidinylidene)methyl]-1H-indole-2-carboxylic acid monosodium salt	glutamate antagonist; NMDA antagonist; analgesic	pain

CP 331; CP 6	1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid 2-[[2-oxo-2-[[3-[3-(1-piperidinylmethyl)phenoxy]propyl]amino]ethyl]thio]ethyl ester	histamine antagonist; histamine H2 antagonist; analgesic; NSAID	inflammation; pain
Melanocortin receptor-1 modulators	Unspecified	melanocortin agonist; melanocortin MC1 agonist	asthma; pain; nephritis
Metabotropic glutamate receptor modulators	Unspecified	metabotropic glutamate receptor modulators analgesic	pain; cognitive defect; schizophrenia; epilepsy
remifentanyl; GI 87084; GI 87084B; GI 87084X; ULTIVA	4-(methoxycarbonyl)-4-[(1-oxopropyl)phenylamino]-1-piperidinepropanoic acid methyl ester	mu agonist; opiate agonist; analgesic	pain
trefentanyl; trefentanyl hydrochloride; A 3665	N-(1-(2-(4-ethyl-4,5-dihydro-5-oxo-1H-tetrazol-1-yl)ethyl)-4-phenyl-4-piperidinyl)-N-(2-fluorophenyl)propanamide monohydrochloride	mu agonist; opiate agonist; analgesic	pain
BCH 150	Unspecified	mu agonist; opiate agonist; peptide; analgesic	pain
mirfentanyl; mirfentanyl hydrochloride; A 3508	N-[1-(2-phenethyl)-4-piperidinyl]-N-pyrazinyl-2-furancarboxamide	mu antagonist; opiate antagonist; analgesic	anesthesia; pain
Narcotics	Unspecified	Narcotics analgesic	pain; addiction; intoxication
WIN 64821	(2alpha,2'beta,5beta,5'alpha)-2,5:2',5'-dide(epidithio)-3,3'-didemethyl-19,19'-dideoxy-19,19'-diphenylchaetocin	neurokinin antagonist; analgesic	pain

GR 82334	9-deglycine-10-[(5S)-6-oxo-L-alfa--(2-methylpropyl)-1,7-diazaspiro[4.4]nonane-7-acetic acid]-11-L-tryptophanamidephysalemin	neurokinin antagonist; analgesic; neurokinin 1 antagonist	pain
lanepitant; LY 303870	(R)-N-[2-acetyl[(2-methoxyphenyl)methyl]amino]-1-(1H-indol-3-ylmethyl)ethyl]-[1,4'-bipiperidine]-1'-acetamide	neurokinin antagonist; analgesic; neurokinin 1 antagonist	asthma; pain; migraine
L 733060	(2S-cis)-3-[[3,5-bis(trifluoromethyl)phenyl]methoxy]-2-phenylpiperidine	neurokinin antagonist; analgesic; neurokinin 1 antagonist; NSAID	inflammation; pain; asthma
CP 96345	(2S,3S)-cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine	neurokinin antagonist; analgesic; neurokinin 1 antagonist; NSAID; substance P antagonist	inflammation; pruritis; pain
saredutant; SR 48968	(S)-N-[4-(4-acetylamino-4-phenyl-1-piperidinyl)-2-(3,4-dichlorophenyl)butyl]-N-methyl-benzamide	neurokinin antagonist; analgesic; neurokinin 2 antagonist	asthma; pain; urinary incontinence
neurokinin antagonists	Unspecified	neurokinin antagonist; analgesic; NSAID	pain; inflammation
CP 99994	(2S-cis)-N-[(2-methoxyphenyl)methyl]-2-phenyl-3-piperidinamine	neurokinin antagonist; neurokinin 1 antagonist; analgesic	asthma; pain
SR 144190	(R)-4-benzoyl-2-(3,4-difluorophenyl)-2-[2-[4-[[[(dimethylamino)carbonyl]amino]-4-phenyl-1-piperidinyl]ethyl]morpholine	neurokinin antagonist; neurokinin 2 antagonist; analgesic	asthma; urinary incontinence; asthma; pain

neuropeptide Y antagonists	Unspecified	neuropeptide Y antagonist; analgesic	obesity; cardiovascular disease; anxiety; pain
JMV 449	(S)-1-de-L-lysine-2-[N2-(2,6-diaminohexyl)-L-lysine]neuromedin N (pig spinal cord)	neurotensin analogue; analgesic	pain
nitroglycerin; glyceryl trinitrate; trinitrin; ANOGESIC	Unspecified	nitrate; cicatrizant; analgesic	skin ulcer; angina; pain
memantine; D 145; NMI 131; AKATINOL	3,5-dimethyl-1-adamantanamine	NMDA antagonist; analgesic; glutamate antagonist	cognitive defect; pain; glaucoma; neuropathy
NMDA antagonists	Unspecified	NMDA antagonist; analgesic; glutamate antagonist	epilepsy; pain; brain ischemia
CNS 5161	N'-[2-chloro-5-(methylthio)phenyl]-N-methyl-N-[3-(methylthio)phenyl]guanidine monohydrochloride	NMDA antagonist; glutamate antagonist	pain; migraine; neuropathy
ACEA 1328	5-nitro-6,7-dimethyl-2,3-quinoxalinedione	NMDA antagonist; glutamate antagonist; analgesic	pain
ACEA 1416; NMCQX	5-nitro-6-methyl-7-chloro-2,3-quinoxalinedione	NMDA antagonist; glutamate antagonist; analgesic	epilepsy; pain; brain ischemia
aptiganel; CNS 1102; CDD 2515A; CERESTAT	N-(3-ethylphenyl)-N-methyl-N'-1-naphthalenyl-guanidine	NMDA antagonist; glutamate antagonist; analgesic	stroke; neuropathy; trauma; Parkinson disease; pain
budipine; budipine hydrochloride; BY 701; PARKINSAN	1-(1,1-dimethylethyl)-4,4-diphenylpiperidine	NMDA antagonist; glutamate antagonist; analgesic	Parkinson disease; pain
NMDA antagonists,	Unspecified	NMDA antagonist; glutamate antagonist; analgesic	pain
conantokins	Unspecified	NMDA antagonist; glutamate antagonist; peptide; analgesic	epilepsy; stroke; schizophrenia; pain; ischemia
nociceptor blockers, NB 1	Unspecified	nociceptor blockers analgesic	pain
non-narcotic analgesic	Unspecified	non-narcotic analgesic analgesic	pain

2-halopyridine	Unspecified	NSAID	inflammation; pain; insomnia
Analgesic	3-methyl-5-oxobenzo(b)thieno(2,3-d)thiazolo(3,2-a)pyrimidine-2-carboxylic acid ethyl ester	NSAID	pain; inflammation; gastrointestinal ulcer
BN 50370	1,3-dihydro-3,6-dimethyl-7-hydroxy-furo(3,4)pyridine hydrochloride	NSAID	inflammation; pain
Diaveridine; EGIS 5645	5-[(3,4-dimethoxyphenyl)methyl]-2,4-pyrimidinediamine	NSAID	inflammation; pain
drug delivery system, hydrogel diclofenac; diclofenac hydrogel; DICLOFENAC HYCORE-R	Unspecified	NSAID	pain; inflammation
drug delivery system, OSAT diclofenac; diclofenac sustained release	Unspecified	NSAID	pain; inflammation
drug delivery system, OSAT ibuprofen; ibuprofen sustained release	Unspecified	NSAID	pain; rheumatoid arthritis; osteoarthritis; inflammation
drug delivery system, sustained release microsphere flurbiprofen; flurbiprofen, sustained release	Unspecified	NSAID	pain; inflammation
DTA	4'-methyl-[1,1':3',1''-terphenyl]-5'-acetic acid	NSAID	inflammation; pain
FA 401	1-(4-fluorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid carboxymethyl ester	NSAID	pain; inflammation

Flurbiprofen axetil; LFP 83; ROPION; LIPFEN	2-fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic acid, 1-(acetyloxy)ethyl ester	NSAID	pain; inflammation
HU 239	(6aR-trans)-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-carboxylic acid	NSAID	inflammation; pain
LA 351	5H-(1)-benzopyrano(2,3-b)pyridin-5-one	NSAID	inflammation; pain; asthma
M 5011; T 3788	alpha-2-[4-(3-methylthienyl)phenyl]propionic acid	NSAID	inflammation; pain
Proglumetacin; protacine; CR 604; IMPETIN; PROXIL; PROXATIL; AFLOXAN; TOLINDOL; BRUXEL; MIRIDACIN	1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid 2-[4-[3-[[4-(benzoylamino)-5-(dipropylamino)-1,5-dioxopentyl]oxy]propyl]-1-piperazinyl]ethyl ester, (+,-)-	NSAID	inflammation; pain
RP 67580	(3aR-cis)-octahydro-2-[1-imino-2-(2-methoxyphenyl)ethyl]-7,7-diphenyl-4H-isoindol-4-one	NSAID	pain; inflammation
SC 107	Unspecified	NSAID	arthritis; pain
TZI 41078	Unspecified	NSAID	inflammation; pain
Aceclofenac; YT 919; AIRTAL; GERBIN; FALCOL; BRISTAFLAM; PRESERVEX; BIOFENAC; BARRACAN	2-[(2,6-dichlorophenyl)amino]benzeneacetic acid, carboxymethyl ester	NSAID; analgesic	pain; inflammation

Amtolmetin guacil; ST 679; MED 15; ARTROMED; EUFANS	N-[[1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl]acetyl]glycine 2-methoxyphenyl ester	NSAID; analgesic	arthritis; rheumatoid arthritis; inflammation; pain
bromfenac; bromfenac sodium; AHR 10282; DURACT	2-amino-3-(4-bromobenzoyl)benzoic acid	NSAID; analgesic	inflammation; pain
CHF 2003	Unspecified	NSAID; analgesic	pain; inflammation
Dexketoprofen trometamol; LM 1158; TRIS; D 1158; ENANTYUM; QUIRALAM; KETESSE	(S)-3-benzoyl-alpha-methylbenzeneacetic acid cpd with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)	NSAID; analgesic	pain; inflammation
Esflurbiprofen; flurbiprofen, (S)-; (S)-flurbiprofen; BTS 24332	(S)-2-fluoro-alpha-methyl-4-biphenylacetic acid	NSAID; analgesic	pain
florifenine; FI 2522	2-(1-pyrrolidinyl)ethyl-N-[7-(trifluoromethyl)-4-quinolyl]anthranilate	NSAID; analgesic	inflammation; pain
flosulide; ZK 38997; CGP 28238; CGS 28238; SH 459	N-[6-(2,4-difluorophenoxy)-2,3-dihydro-1-oxo-1H-inden-5-yl]methanesulfonamide	NSAID; analgesic	inflammation; pain
FS 205397	6-ethoxy-2,3-dihydro-3,3-dimethyl-1H-indole methanesulfonate	NSAID; analgesic	pain
HAI 105	6,11-dihydro-2-methoxy-alpha-methyl-11-oxodibenz[b,e]oxepin-3-acetic acid	NSAID; analgesic	pain; inflammation
HN 3392	N-(4-(4-methoxyphenyl)-5-phenylthiazolyl)	NSAID; analgesic	inflammation; pain
mofezolac; N 22; DISOPAIN	3,4-bis(4-methoxyphenyl)-5-isoxazoleacetic acid	NSAID; analgesic	inflammation; pain

Nabumetone; BRL 14777; RELIFEN; RELIFEX; LISTRAN; PRODAG; BALMOX; NABUMETON; RELAFEN	4-(6-methoxy-2-naphthyl)-2-butanone	NSAID; analgesic	pain; inflammation
olvanil; oluvamil; NE 19550	N-vanillyloleamide	NSAID; analgesic	pain; inflammation; viral infection
Pelubiprofen; CS 670; RS 2131	alpha-methyl-4-[(2-oxocyclohexyllidene)methyl]benzeneacetic acid	NSAID; analgesic	inflammation; pain
piroxicam betadex; piroxicam cyclodextrin; CHF 1194; BREXIN; BREXINE; BREXIDOL; CYCLADOL; BREXICAM; BREXINIL	4-hydroxy-2-methyl-N-(2-pyridinyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide compound with beta-cyclodextrin	NSAID; analgesic	pain; inflammation
Polyunsaturated fatty acids, PUFA	Unspecified	NSAID; analgesic	inflammation; pain
Tenosal; MR Y134	2-thiophenecarboxylic acid, ester with salicylic acid	NSAID; analgesic	pain
Tifurac; RS 82917; RS 82917030	7-[4-(methylthio)benzoyl]-5-benzofuranacetic acid	NSAID; analgesic	inflammation; pain
Tilnoprofen arbamel; Y 23023	(+/-)-alpha-2-methyl-5H-[1]benzopyran[2,3-b]pyridine-7-acetic acid, 2-(dimethylamino)-2-oxoethyl ester	NSAID; analgesic	inflammation; pain
HCT 3012	Unspecified	NSAID; nitric oxide donor	pain; inflammation
HCT 6015	Unspecified	NSAID; nitric oxide donor	pain

NCX 4016	2-(acetyloxy)benzoic acid, 2-[(nitrooxy)methyl]phenylester	NSAID; nitric oxide donor; platelet antiaggregant; analgesic	thrombosis; pain
HP 228	N-acetyl-Nleu-Gln-His-Phe-Arg-Trp-Gly-amide	NSAID; peptide; melanocortin agonist	pain; inflammation; asthma; cachexia
Samarium 153 Sm lexidronam; Sm 153-EDTMP; samarium 153-EDTMP; samarium EDTMP; CYT 424;	(OC-6-21)-[[[1,2-ethanediylbis[nitrilobis(methylene)]tetrakis(phosphonato)](8-)-N,N',OP,OP',OP'',OP''']-samarate(5-)-153Sm	NSAID; radiotherapeutic	cancer; pain; rheumatoid arthritis
Analgesic, human serum albumin conjugated opioid peptide	Unspecified	opiate agonist	pain
AXC 3742	Unspecified	opiate agonist	pain
AXC 3943	Unspecified	opiate agonist	pain
drug delivery system, hydrogel pethidine; pethidine hydrogel	Unspecified	opiate agonist	pain
Oxycodone + ibuprofen; ibuprofen + oxycodone	Unspecified	opiate agonist	pain
ADL 21294	Unspecified	opiate agonist; analgesic	pain; corneal abrasion
Analgesic	Unspecified	opiate agonist; analgesic	pain
Brifentanil; A 3331	(+,-)-cis-N-[1-[2-(4-ethyl-5-oxo-2-tetrazolin-1-yl)ethyl]-3-methyl-4-piperidyl]-2'-fluoro-2-methoxyacetanilide	opiate agonist; analgesic	pain
drug delivery system, ANCHOR opioid agonist	Unspecified	opiate agonist; analgesic	pain

drug delivery system, transdermal fentanyl; TTS-fentanyl; fentanyl transdermal; KJK 4263; SUBLIMAZE; DURAGESIC; DUROGESIC	Unspecified	opiate agonist; analgesic	pain
LEF 576; BCH 3963	Unspecified	opiate agonist; analgesic	pain
ocfentanil; A 3217	N-(2-fluorophenyl)-2-methoxy-N-[1-(2-phenylethyl)-4-piperidinyl]acetamide	opiate agonist; analgesic	pain
TRK 820	(2E)-N-[(5alpha,6beta)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]-3-(3-furanyl)-N-methyl-2-propenamide monohydrochloride	opiate agonist; analgesic; kappa agonist	pain
BW 373U86	[1(S*),2alpha,5beta]-(+,-)-4-[[2,5-dimethyl-4-(2-propenyl)-1-piperazinyl](3-hydroxyphenyl)methyl]-N,N-diethylbenzamide	opiate agonist; delta agonist; analgesic	pain
SB 235863	Unspecified	opiate agonist; delta agonist; analgesic	pain
SNF 8912	(H2N-(CH2)7-CO-NH)Asp-Tyr-(N-Me)Nle-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2	opiate agonist; delta agonist; analgesic	pain
SNF 9007	L-alpha-aspartyl-L-tyrosyl-D-phenylalanyl-glycyl-L-tryptophyl-N-methyl-L-norleucyl-L-alpha-aspartyl-L-phenylalaninamide	opiate agonist; delta agonist; analgesic	pain

opioid mimetic peptides	Unspecified	opiate agonist; delta agonist; analgesic; peptide	pain; addiction
Apadoline; RP 60180; RP 60180A; RPR 60180	(R)-10-[1-methyl-2-(1-pyrrolidinyl)ethyl]-N-propyl-10H-phenothiazine-2-carboxamide	opiate agonist; kappa agonist; analgesic	pain
BRL 53001A	(2S)-1-(1-oxo-3,4-dihydro-(2H)-naphth-6-yl)acetyl-2-dimethyl-aminomethyl piperidine hydrochloride	opiate agonist; kappa agonist; analgesic	pain
CL 891601	Unspecified	opiate agonist; kappa agonist; analgesic	pain
DUP 747	trans-(+,-)-3,4-dichloro-N-methyl-N-[1,2,3,4-tetrahydro-5-methoxy-2-(1-pyrrolidinyl)-1-naphthalenyl]benzene acetamide	opiate agonist; kappa agonist; analgesic	pain
E 2078; 66A078	N-methyl-L-tyrosylglycylglycyl-L-phenylalanyl-L-leucyl-L-arginyl-N2-methyl-L-arginyl-N-ethyl-D-leucinamide	opiate agonist; kappa agonist; analgesic	pain
EMD 60400	N-methyl-N((1S))-1-phenyl-2-((3S)-3-hydroxypyrrolidine-1-yl)-ethyl-2-amino-phenylacetamide	opiate agonist; kappa agonist; analgesic	pain
GR 102908	Unspecified	opiate agonist; kappa agonist; analgesic	pain
GR 107537	[S-(R*,R*)]-5-[(3,4-dichlorophenyl)acetyl]-4,5,6,7-tetrahydro-4-[(3-hydroxy-1-pyrrolidinyl)methyl]furo[3,2-c]pyridine	opiate agonist; kappa agonist; analgesic	pain

ICI 197067	(S)-3,4-dichloro-N-methyl-N-[2-methyl-1-(1-pyrrolidinylmethyl)propyl]benzeneacetamide monohydrochloride	opiate agonist; kappa agonist; analgesic	pain
ICI 204448	(+,-)-[3-[1-[(3,4-dichlorophenyl)acetyl]methylamino]-2-(1-pyrrolidinyl)ethyl]phenoxylacetic acid monohydrochloride	opiate agonist; kappa agonist; analgesic	pain
R 84760	(3R)-4-[[[(1S)-5,6-dichloro-2,3-dihydro-1H-inden-1-yl]carbonyl]-3-(1-pyrrolidinylmethyl)thiomorpholine monohydrochloride	opiate agonist; kappa agonist; analgesic	pain
Asimadoline; EMD 61753	[S-(R*,R*)]-N-[2-(3-hydroxy-1-pyrrolidinyl)-1-phenylethyl]-N-methyl-.alpha.-phenyl-, benzeneacetamide	opiate agonist; kappa agonist; analgesic; NSAID	pain
opiate analgesic,	Unspecified	opiate agonist; mu agonist	pain
BCH 2687; LEF 553	Unspecified	opiate agonist; mu agonist; analgesic	pain
drug delivery system, hydrogel morphine; morphine hydrogel; MORAXEN; MORPHINE HYCORE-R	Unspecified	opiate agonist; mu agonist; analgesic	pain
drug delivery system, oral sustained release morphine; morphine sustained release; KAPANOL; KADIAN; MORCAP SR	Unspecified	opiate agonist; mu agonist; analgesic	pain

drug delivery system, oral transmucosal fentanyl; fentanyl OTFC; ACTIQ; FENTANYL ORALET	Unspecified	opiate agonist; mu agonist; analgesic	anesthesia; pain
drug delivery system, OROS oral controlled release hydrocodone; hydrocodone OROS	Unspecified	opiate agonist; mu agonist; analgesic	pain
drug delivery system, OROS oral controlled release hydromorphone; hydromorphone OROS	Unspecified	opiate agonist; mu agonist; analgesic	pain
drug delivery system, OROS oral controlled release morphine; morphine OROS	Unspecified	opiate agonist; mu agonist; analgesic	pain
drug delivery system, OSAT morphine; morphine sustained release	Unspecified	opiate agonist; mu agonist; analgesic	pain
drug delivery system, subcutaneous hydromorphone; hydromorphone subcutaneous implant	Unspecified	opiate agonist; mu agonist; analgesic	pain
drug delivery system, sustained release DepoFoam morphine; morphine DepoFoam; C 0401; DepoMorphine	Unspecified	opiate agonist; mu agonist; analgesic	pain; cancer
drug delivery system, transdermal buprenorphine; buprenorphine transdermal	Unspecified	opiate agonist; mu agonist; analgesic	pain
drug delivery system, transdermal fentanyl; fentanyl transdermal	Unspecified	opiate agonist; mu agonist; analgesic	pain

HP 736	cis-7-bromo-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-ol (E)-2-butenedioate (1:1) (salt)	opiate agonist; mu agonist; analgesic	pain
morphine-6-glucuronide; CEE 04410; HN 33169; CAP	morphine-6-glucuronide	opiate agonist; mu agonist; analgesic	pain
pentamorphone; RX 77989; A 4492	7,8-didehydro-4,5a-epoxy-3-hydroxy-17-methyl-14-(pentylamino)morphinan-6-one	opiate agonist; mu agonist; analgesic	pain
DPI 3290	[2S-[1(S*),2alpha,5beta]]-3-[[2,5-dimethyl-4-(2-propenyl)-1-piperazinyl](3-hydroxyphenyl)methyl]-N-(3-fluorophenyl)-N-methylbenzamide monohydrochloride	opiate agonist; mu agonist; delta agonist; analgesic	pain
OHM 3295; ANQ 3295	Unspecified	opiate agonist; mu agonist; kappa agonist; analgesic	pain
SK 9709	Tyr-D-Ala-Phe-Leu-Arg (CH ₂ NH) Arg-NH ₂	opiate agonist; mu agonist; kappa agonist; peptide	pain
naloxone + pentazocine; pentazocine + naloxone	Unspecified	opiate agonist; opiate antagonist; analgesic	pain; cancer
tonazocine; WIN 42156; WIN 42156 2	(+,-)-(2alpha,6alpha,11S*)-1-(1,2,3,4,5,6-hexahydro-8-hydroxy-3,6,11-trimethyl-2,6-methano-3-benzazocin-11-yl)-3-octanone	opiate agonist; opiate antagonist; mu agonist; delta agonist; analgesic	pain

picecadol; LY 150720	trans-(+,-)-3-(1,3-dimethyl-4-propyl-4-piperidiny)phenol	opiate agonist; opiate antagonist; mu agonist; mu antagonist; analgesic	pain
acetylmethadol; levomethadyl acetate hydrochloride; L-alpha acetylmethadol; LAAM; methadyl acetate; LAAM; MK 790; ORLAAM	beta-[2-(dimethylamino)propyl]-alfa-ethyl-beta-phenylbenzeneethanol acetate (ester)	opiate antagonist; analgesic	pain; addiction
SNC 80	[2S-[1(S*),2alpha,5beta]]-4-[[2,5-dimethyl-4-(2-propenyl)-1-piperazinyl](3-methoxyphenyl)methyl]-N,N-diethylbenzamide	opiate antagonist; delta antagonist; analgesic	pain
ibuprofen + propiram; propiram + ibuprofen; DIRATAB	Unspecified	opiate antagonist; opiate partial agonist; mu agonist; mu antagonist; analgesic	pain
propiram; propiram fumarate; BAY 4503; FBA 4503; DIRAME; ALGERIL	N-(1-methyl-2-piperidinoethyl)-N-2-pyridyl-propionamide fumarate	opiate antagonist; opiate partial agonist; mu agonist; mu antagonist; analgesic	pain
propiram + paracetamol; propiram + acetaminophen; paracetamol + propiram; acetaminophen + propiram; DIRAMAX	Unspecified	opiate antagonist; opiate partial agonist; mu agonist; mu antagonist; analgesic	pain
drug delivery system, transdermal buprenorphine; buprenorphine transdermal	Unspecified	opiate partial agonist; analgesic	pain
MR 2264	Unspecified	opiate partial agonist; analgesic	pain
analgesics,	Unspecified	peptide	pain
CEE 04420	Unspecified	peptide	pain
CEE 04421	Unspecified	peptide	pain

drug delivery system, analgesic, oral transmucosal	Unspecified	peptide	pain
drug delivery system, Polyfunctional Molecular Modification, enkephalin; enkephalin Polyfunctional Molecular Modification	Unspecified	peptide; analgesic	pain
MER W8020	Unspecified	peptide; analgesic; NSAID	inflammation; pain
drug delivery system, MICROPUMP oral controlled release aspirin; aspirin MICROPUMP; ASACARD	Unspecified	platelet antiaggregant; thromboxane synthetase inhibitor; analgesic; NSAID	thrombosis; pain; inflammation
ZD 4953	Unspecified	prostaglandin antagonist; prostaglandin endoperoxide 1 antagonist	pain
ZD 6416	Unspecified	prostaglandin endoperoxide 1 antagonist; analgesic	pain
ZD 6804	Unspecified	prostaglandin endoperoxide 1 antagonist; analgesic	pain
limaprost; limeprost; limaprost alfadex; OP 1206; ONO 1206; OPALMON; PRORENAL	(E)-7-[(1R,2R,3R)-3-hydroxy-2-[(E)-(3S,5S)-3-hydroxy-5-methyl-1-nonenyl]-5-oxocyclopentyl]-2-heptenoic acid	prostanoid; analgesic	cardiovascular disease; pain
SC 42867	8-chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid 2-[3-(ethylsulfonyl)-1-oxopropyl]hydrazide	prostanoid; analgesic	pain

SCH 34826	N-[N-[2-[(2,2-dimethyl-1-3-dioxolan-4-yl)methoxy]-2-oxo-1-(phenylmethyl)ethyl]-L-phenylalanyl]-beta-alanine	proteinase inhibitor; analgesic	pain; hypertension
117m Sn DTPA; pentetate 117m Sn	Unspecified	radiotherapeutic; analgesic	cancer; pain
rhenium Re 186 etidronate; 186-Re HEDP; 186-Re HEDP; BETAMET	Unspecified	radiotherapeutic; analgesic	pain; cancer
Sm 153 hydroxyapatite; Sm 153 HA; samarium 153 hydroxyapatite	Unspecified	radiotherapeutic; analgesic	pain
strontium-89 chloride; METASTRON	strontium chloride (89SrCl ₂)	radiotherapeutic; analgesic	pain; cancer
PD 144418	1,2,3,6-tetrahydro-5-[3-(4-methylphenyl)-5-isoxazolyl]-1-propylpyridine	sigma antagonist; analgesic	pain
mu-conopeptides	Unspecified	sodium channel blocker	pain; epilepsy
4030W92; BW 4030W92	(5R)-5-(2,3-dichlorophenyl)-6-(fluoromethyl)-2,4-pyrimidinediamine	sodium channel blocker	pain
GW 286103	Unspecified	sodium channel blocker; analgesic	pain
LTA	Unspecified	sodium channel blocker; analgesic	pain
sodium channel blockers	Unspecified	sodium channel blocker; analgesic	pain
sodium channel blockers	Unspecified	sodium channel blocker; analgesic	pain

Octreotide; octreotide acetate; SMS; SMS 201995; SMS 201995ac; SMS 995; SANDOSTATIN; SANDOSTATINE; SANDOSTATINA; LONGASTATINA; SAMILSTATINA	[R-(R*,R*)]-D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide cyclic (2-7)-disulfide	somatostatin analogue; analgesic	Alzheimer disease; cancer; viral infection; psoriasis; diarrhea; diabetes; pain; acromegaly
Vapreotide; octastatin; RC 160; BMY 41606	D-Phe-Cys-Trp-D-Trp-Lys-Val-Cys-Trp-NH ₂	somatostatin analogue; analgesic	cancer; pain
NKT 343; SDZ NKT 343	1-[[2-(nitrophenyl)amino]carbonyl]-L-prolyl-N-methyl-3-(2-naphthalenyl)-N-(phenylmethyl)-L-alaninamide	substance P antagonist; analgesic	pain
Etanercept; tumor necrosis factor receptor; TNFr; TNF 001;	Unspecified	TNF inhibitor; immunosuppressant; NSAID; analgesic	rheumatoid arthritis; heart failure; diabetes; pain; endometriosis; autoimmune disease

Table 34: Current Candidate Therapeutic Interventions for the Treatment of Parkinson's Disease

Product Name	Chemical Name	Action	Indication
KF 17837	(E)-8-[2-(3,4-dimethoxyphenyl)ethenyl]-3,7-dihydro-7-methyl-1,3-dipropyl-1H-purine-2,6-dione	adenosine antagonist	Parkinson disease
KW 6002	Unspecified	adenosine antagonist	Parkinson disease
Parkinson's disease therapy	Unspecified	adenosine antagonist	Parkinson disease
SCH 58261	2-(2-furanyl)-7-(2-phenylethyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine	adenosine antagonist; adenosine A ₂ antagonist	Parkinson disease

Idazoxan; RX 781094; RX 781094 A	2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole	alpha adrenergic antagonist; alpha2 adrenergic antagonist; antiproliferative agent	Parkinson disease; depression; cardiovascular disease; retinopathy
alpha2 adrenoceptor antagonists,	Unspecified	alpha2 adrenergic antagonist; alpha adrenergic antagonist	Parkinson disease
SR 57667	Unspecified	Antineurodegenerative	Alzheimer disease; Parkinson disease
Parkinson's disease therapy,	Unspecified	antioxidant	Parkinson disease
VANTOX	Unspecified	antioxidant; NSAID	asthma; Parkinson disease; Alzheimer disease; stroke
CNS therapy, IDUN; CNS therapy	Unspecified	apoptosis inhibitor; caspase inhibitor	stroke; Parkinson disease; amyotrophic lateral sclerosis
CNS 1237	N-5-acenaphthylenyl-N'-(4-methoxy-1-naphthalenyl)-guanidine	Calcium channel blocker; glutamate release inhibitor	brain ischemia; Parkinson disease; neuropathy
drug delivery system, conopeptides	Unspecified	calcium channel blocker; sodium channel blocker; potassium channel blocker; analgesic	epilepsy; Parkinson disease; stroke; pain; brain ischemia
SIB 1508Y	(S)-3-ethynyl-5-(1-methyl-2-pyrrolidinyl)pyridine	cholinergic agonist; nicotinic agonist	Parkinson disease
SIB S1663; S 1663	2,3,3a,4,5,9b-hexahydro-7-methoxy-1-methyl-1H-pyrrolo[3,2-b]isoquinoline	cholinergic agonist; nicotinic agonist	Parkinson disease
CGP 28014	N'-(1,6-dihydro-6-oxo-2-pyridinyl)-N,N-dipropylmethanimidamide	COMT inhibitor	Parkinson disease
Entacapone; OR 611; COMTAN; COMTESS	(E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide	COMT inhibitor	Parkinson disease

Tolcapone; Ro 407592; TASMAR	(3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone	COMT inhibitor	Parkinson disease
drug delivery system, controlled release carbidopa + levodopa; carbidopa + levodopa	Unspecified	decarboxylase inhibitor; dopamine agonist	Parkinson disease
Dopaminergic neurotrophic factor; DNTF	Unspecified	DNTF growth factor	Parkinson disease
JA 116a; JA 116	1,2,6,7,8,8a-hexahydro-1-acenaphthylenamine hydrochloride	dopamine agonist	Parkinson disease
levodopa methyl; CHF 1301	Unspecified	dopamine agonist	Parkinson disease
levodopa methyl + carbidopa; carbidopa + levodopa methyl; CHF 1512	Unspecified	dopamine agonist	Parkinson disease
Moxiraprime; 4-hydroxyminaprime; CM 30366	p-[5-methyl-6-[(2-morpholinoethyl)amino]-3-pyridazinyl]phenol	dopamine agonist	Parkinson disease
naxagolide; PHNO; dopazinol; MK 458; L 647339	(4aR-trans)-3,4,4a,5,6,10b-hexahydro-4-propyl-2H-naphth[1,2-b]-1,4-oxazin-9-ol	dopamine agonist	Parkinson disease
U 86170F	(R)-5-(dipropylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one monohydrobromide	dopamine agonist	Parkinson disease
WAY 124486	(S)-3-[[[3-(3-aminophenoxy)propyl]amino]methyl]-2,3-dihydro-1,4-benzodioxin-6-ol	dopamine agonist	Parkinson disease

Quinelorane; quinelorane hydrochloride; LY 163502	(5aR-trans)- 5,5a,6,7,8,9,9a,10- octahydro-6- propylpyrido[2,3- g]quinazolin-2-amine	dopamine agonist	Parkinson disease; hyperprolactinemia; hypertension
HW 165	trans-(+/-)- 1,2,3,4,4a,5,6,10b- octahydrobenzo(f)qui nolin-7-ol, hydrobromide	dopamine agonist	Parkinson disease; schizophrenia
Apomorphine; apomorphine hydrochloride; UPRIMA	(R)-5,6,6a,7- tetrahydro-6-methyl- 4H- dibenzo[de,g]quinolin e-10,11- diol hydrochloride hydrate (2:1)	dopamine agonist	sexual dysfunction; Parkinson disease
talipexole; BHT 920; DOMINE; DOMIN	6-allyl-2-amino- 5,6,7,8-tetrahydro- 4H-thiazolo[4,5- d]azepine	dopamine agonist; alpha adrenergic agonist; alpha2 adrenergic agonist	Parkinson disease; glaucoma
drug delivery system, benserazide + levodopa; benserazide + levodopa, levodopa + benserazide; MADOPAR DR	Unspecified	dopamine agonist; decarboxylase inhibitor	Parkinson disease
A 68930	(1R,3S)-1- aminomethyl-5,6- dihydroxy-3- phenylisochroman	dopamine agonist; dopamine D1 agonist	hypertension; Parkinson disease
A 77636	(1R-cis)-1- (aminomethyl)-3,4- dihydro-3- tricyclo[3.3.1.1 ^{3,7}]de c-1-yl-1H-2- benzopyran-5,6-diol hydrochloride	dopamine agonist; dopamine D1 agonist	Parkinson disease
A 86929	trans-4,5,5a,6,7,11b- hexahydro-2- propylbenzo[f]thieno[2,3-c]quinoline-9,10- diol hydrochloride	dopamine agonist; dopamine D1 agonist	Parkinson disease

ABT 431	(5aR-trans)-4,5,5a,6,7,11b-hexahydro-2-benzo[f]thieno[2,3-c]quinoline-9,10-diol, diacetate (ester), hydrochloride	dopamine agonist; dopamine D1 agonist	Parkinson disease
dopamine agonist	Unspecified	dopamine agonist; dopamine D1 agonist	Parkinson disease
dopamine-D1 agonists, BLSI	Unspecified	dopamine agonist; dopamine D1 agonist	Parkinson disease
dihydroxidine; IP 202	trans-5,6,6a,7,8,12b-hexahydro-benzo[a]phenanthridine-10,11-diol	dopamine agonist; dopamine D1 agonist	Parkinson disease; Alzheimer disease
BAM 1110	(8 beta)-6-methyl-8-(1H-1,2,4-triazol-1-ylmethyl)ergoline (Z)-2-butenedioate	dopamine agonist; dopamine D1 agonist; dopamine D2 agonist	Parkinson disease
drug delivery system, transdermal pergolide; pergolide transdermal	Unspecified	dopamine agonist; dopamine D1 agonist; dopamine D2 agonist	Parkinson disease
pergolide; pergolide mesylate; LY 141B; LY 127809; PERMAX; CELANCE; PHARKEN; PARKOTIL	(8beta)-8-[(methylthio)methyl]-6-propylergoline	dopamine agonist; dopamine D1 agonist; dopamine D2 agonist	Parkinson disease; depression
CQA 206291	Unspecified	dopamine agonist; dopamine D2 agonist	Parkinson disease
drug delivery system, transdermal N 0923; N 0923 transdermal delivery system; N 0923; SPM 962	(S)-5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-1-naphthalenol	dopamine agonist; dopamine D2 agonist	Parkinson disease
ropinirole; ropinirole hydrochloride; ropinerole; SKF 101468; SKF 101468A;	(4-2(-dipropylamino)ethyl)-1,3-dihydro-2H-indol-2-one monohydrochloride	dopamine agonist; dopamine D2 agonist	Parkinson disease

U 91356A	(R)-5,6-dihydro-5-(propylamino)-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one monohydrochloride	dopamine agonist; dopamine D2 agonist	Parkinson disease
Cabergoline; FCE 21336; CG 101; DOSTINEX; SOGILEN; CABASER	(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)ergoline-8-carboxamide	dopamine agonist; dopamine D2 agonist	Parkinson disease; hyperprolactinemia
PNU 95666; U 95666A	(R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one	dopamine agonist; dopamine D2 agonist; 5HT agonist; 5HT1A agonist	Parkinson disease
Pramipexole; pramipexole dihydrochloride; SND 919; U 98528E; SND919CL2Y; PNU 98528E; SIFROL; MIRAPEX; DAQUIRAN; MIRAPEXIN; FIROL	(S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)-benzothiazole	dopamine agonist; dopamine D2 agonist; dopamine D3 agonist	Parkinson disease; schizophrenia; depression
LEK 8829	(8beta)-9,10-didehydro-N,6-dimethyl-N-2-propynylergoline-8-methanamine	dopamine D1 agonist; dopamine D2 antagonist; 5HT antagonist; 5HT2A antagonist; dopamine agonist; dopamine antagonist	schizophrenia; Parkinson disease
Brasofensine; NS 2214; BMS 204756	[1R-[1alpha,2beta(E),3alpha,5alpha]]-3-(3,4-dichlorophenyl)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxaldehyde O-methyloxime	dopamine reuptake inhibitor	Parkinson disease
NS 2141	Unspecified	dopamine reuptake inhibitor	Parkinson disease
NS 2200	Unspecified	dopamine reuptake inhibitor	Parkinson disease; depression; addiction

drug delivery system, dopamine secreting implant; dopamine secreting implant; NeuroCRIB	Unspecified	Dopaminergic agonist	Parkinson disease
drug delivery system, dopamine secreting implants, Parkinson's disease; SPHERAMINE	Unspecified	Dopaminergic agonist	Parkinson disease
NB 355	3-hydroxy-L-tyrosine, 4-(2,2,-dimethylpropanoate)	Dopaminergic agonist, L-dopa prodrug	Parkinson disease
epidermal growth factor; EGF	epidermal growth factor	EGF growth factor	eye disease; Parkinson disease
Carboxylated buckminsterfullerenes; carboxyfullerenes	Unspecified	free radical scavenger; apoptosis inhibitor	amyotrophic lateral sclerosis; Alzheimer disease; Parkinson disease
Milacemide; CP 15525; CP 1552S	2-(pentylamino)acetamide	GABA agonist; MAO B inhibitor; MAO inhibitor	epilepsy; Parkinson disease
glial cell line-derived neurotrophic factor; GDNF	Unspecified	GDNF growth factor; neurotrophic factor	Parkinson disease; amyotrophic lateral sclerosis
glial-cell-line-derived neurotrophic factor; GDNF	Unspecified	GDNF growth factor; neurotrophic factor	Parkinson disease; amyotrophic lateral sclerosis
drug delivery system, neurturin secreting implant; neurturin secreting implant; GDNF secreting implant	Unspecified	GDNF; neurotrophic factor; growth factor	Parkinson disease
riluzole; PK 26124; RP 54274; RILUTEK	6-(trifluoromethoxy)-2-benzothiazolamine	glutamate antagonist	amyotrophic lateral sclerosis; Alzheimer disease; Parkinson disease
NS 072	Unspecified	glutamate antagonist	Parkinson disease
MRZ 2579; MRZ 2/579	Unspecified	glutamate antagonist; NMDA antagonist	Parkinson disease; addiction; stroke
CNS 5065	N-(2-chloro-5-ethylphenyl)-N'-(3-ethylphenyl)-N'-methylguanidine	glutamate antagonist; NMDA antagonist	Parkinson disease; neuropathy; brain ischemia

CP 283097	(3R-cis)-3-[4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]-3,4-dihydro-2H-1-benzopyran-4,7-diol	glutamate antagonist; NMDA antagonist	Parkinson disease; stroke; trauma
GPI 1046	1-(3,3-dimethyl-1,2-dioxopentyl)-L-proline 3-(3-pyridinyl)propyl ester	growth factor; neurotrophic factor	Alzheimer disease; Parkinson disease; multiple sclerosis; neuropathy
NIL-A	Unspecified	growth factor; neurotrophic factor	Alzheimer disease; Parkinson disease; multiple sclerosis; neuropathy
Neurotrophin agonist	Unspecified	growth factor; neurotrophic factor	Alzheimer disease; Parkinson disease; neuropathy
V 10367; VA 10367	Unspecified	growth factor; neurotrophic factor	Parkinson disease
drug delivery system, neurotrophin-3 secreting implant; NT-3 implant	Unspecified	growth factor; neurotrophic factor; biotechnology	Alzheimer disease; Parkinson disease; neuropathy
m-NBA	2-amino-3-(3-nitrobenzoyl)propanoic acid	kynurenine 3 hydroxylase inhibitor	epilepsy; Parkinson disease; Alzheimer disease
MDL 72145	(E)-(beta-fluoromethylene)-3,4-dimethoxybenzeneethanamine hydrochloride	MAO B inhibitor; MAO inhibitor	depression; Parkinson disease
2 HxMP	N-(2-hexyl)-N-methylpropargylamine	MAO B inhibitor; MAO inhibitor	Parkinson disease
drug delivery system, transdermal selegiline; selegiline transdermal	Unspecified	MAO B inhibitor; MAO inhibitor	Parkinson disease
M 2 PP	N-(2-pentyl)-N-methylpropargylamine	MAO B inhibitor; MAO inhibitor	Parkinson disease
mofegiline; MDL 72974A; MDL 72974	(E)-4-fluoro-beta-(fluoromethylene)benzenebutanamine	MAO B inhibitor; MAO inhibitor	Parkinson disease

selegiline; selegiline hydrochloride; deprenyl; E 250; FPF 1100; ELDEPRYL; DEPRENYL; JULAP; NIAR; SELEDAT; DEPRILAN; SELEPARKIN; KINABIDE; NOVO-SELEGILINE; MOVERDIN	(R)-N,α-dimethyl-N-2-propynylbenzeneethanamine	MAO B inhibitor; MAO inhibitor	Parkinson disease
lazabemide; Ro 196327; PAKIO; TEMPIUM	N-(2-aminoethyl)-5-chloro-2-pyridine-carboxamide	MAO B inhibitor; MAO inhibitor	Parkinson disease; Alzheimer disease
LU 53439	3,4-dimethyl-7-(2-isopropyl-1,3,4-thiadiazol-5-yl)-methoxy-coumarin	MAO B inhibitor; MAO inhibitor	Parkinson disease; cognitive defect
SL 650477; SL 65.0477	[R-(R*,R*)]-5-(methoxymethyl)-3-[6-(4,4,4-trifluoro-3-hydroxybutoxy)-3-benzofuranyl]-2-oxazolidinone	MAO inhibitor; MAO A inhibitor; MAO B inhibitor; oxazolidinone	depression; Parkinson disease
SL 340026; SL 34.0026	3-(2-methoxyethyl)-5-[4-(4,4,4-trifluorobutoxy)phenyl]-1,3,4-oxadiazol-2(3H)-one	MAO inhibitor; MAO B inhibitor	Parkinson disease
rasagiline; rasagiline mesylate; TVP 1012; TV 1012	(R)-2,3-dihydro-N-2-propynyl-1H-inden-1-amine	MAO inhibitor; MAO B inhibitor	Parkinson disease; Alzheimer disease
fatty acids, microalgal,	Unspecified	Microalgal extracts	hyperlipidemia; Parkinson disease; Alzheimer disease; eye disease
Neurophilins	Unspecified	Neurophilins	Alzheimer disease; Parkinson disease; neuropathy

LIGA 20; FID 012020	[R-[R*,S*-(E)]]-N-[1-[[[O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 3)-O-[O-beta-D-galactopyranosyl-(1 \rightarrow 3)-2-(acetylamino)-2-deoxy-beta-D-galactopyranosyl-(1 \rightarrow 4)]-O-beta-D-galactopyranosyl-(1 \rightarrow 4)-beta-D-glucopyranosyl]oxy]methyl]-2-hydroxy-3-heptadecenyl]-2,2-dichloroacetamide	Neuroprotectant	Parkinson disease
neurturin	Unspecified	Neurturin; growth factor; neurotrophic factor	Parkinson disease; amyotrophic lateral sclerosis
SIB 1765F; SIB 1765	3-ethynyl-5-(1-methyl-2-pyrrolidinyl)pyridine, (E)-2-butenedioate (1:1)	nicotinic agonist; cholinergic agonist	Parkinson disease
neurodegeneration therapy	Unspecified	Nicotinic cholinergic receptor ligands	Alzheimer disease; Parkinson disease
nitric oxide synthase inhibitors,	Unspecified	nitric oxide synthase inhibitor	Parkinson disease; stroke
remacemide; FPL 12924; PR 934423; FPL 12924AA; PR 934423A; FPL 14144; PR 1032644; FPL 14145, PR 1032646	(+,-)-2-amino-N-(1-methyl-1,2-diphenylethyl)acetamide	NMDA antagonist; glutamate antagonist	epilepsy; Parkinson disease; neurodegeneration
CO 101244	1-[2-(4-hydroxyphenoxy)ethyl]-4-[(4-methylphenyl)methyl]-4-piperidinol hydrochloride	NMDA antagonist; glutamate antagonist	Parkinson disease
PD 158473	3-(1-naphthalenyl)-5-(phosphonomethyl)-L-phenylalanine	NMDA antagonist; glutamate antagonist	Parkinson disease; stroke
PD 159913	Unspecified	NMDA antagonist; glutamate antagonist	Parkinson disease; stroke
Ro 256981	Unspecified	NMDA antagonist; glutamate antagonist	Parkinson disease; stroke

budipine; budipine hydrochloride; BY 701; PARKINSAN	1-(1,1-dimethylethyl)-4,4-diphenylpiperidine	NMDA antagonist; glutamate antagonist; analgesic	Parkinson disease; pain
aptiganel; CNS 1102; CDD 2515A; CERESTAT	N-(3-ethylphenyl)-N-methyl-N'-1-naphthalenyl-guanidine	NMDA antagonist; glutamate antagonist; analgesic	stroke; neuropathy; trauma; Parkinson disease; pain
antisense oligonucleotide, p75	Unspecified	P75 transcriptional coactivator antisense; oligonucleotide	Parkinson disease
alpha-conopeptides	Unspecified	peptide; cholinergic agonist; nicotinic agonist	schizophrenia; Parkinson disease; cancer; urinary incontinence
PNU 151774E	(2S)-2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]propanamide monomethanesulfonate	sodium channel blocker; calcium channel blocker; MAO B inhibitor; MAO inhibitor	epilepsy; Parkinson disease; brain ischemia
CEB 1097	Unspecified	Unknown	Parkinson disease
TV 1203	Unspecified	Unknown	Parkinson disease

Table 35. Current Candidate Therapeutic Interventions for the Treatment of Schizophrenia (and Other Psychoses)

Product Name	Chemical Name	Action	Indication
BW 1192U90; 1192U90	2-amino-N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]benzamide	5HT agonist; 5HT1A agonist; dopamine antagonist; dopamine D2 antagonist; 5HT antagonist; 5HT2 antagonist	schizophrenia
Ritanserlin; R 55667	6-[2-[4-[bis(4-fluorophenyl)methylene]piperidino]ethyl]-7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one	5HT antagonist; 5HT2 antagonist	addiction; anxiety; schizophrenia

Ziprasidone; ziprasidone hydrochloride; CP 88059; CP 880591; CP 8805901; ZELDOX	5-[2-[4-(1,2- benzothiazol-3-yl)- 1-piperazinyl]ethyl]- 6-chloro-1,3-dihydro- 2H-indol-2-one	5HT antagonist; 5HT2 antagonist; 5HT1C antagonist; dopamine antagonist; dopamine D2 antagonist; 5HT1A agonist; 5HT agonist	schizophrenia; anxiety
Ocaperidone; R 79598	3-[2-[4-(6-fluoro-1,2- benzoxazol-3-yl)-1- piperidinyl]ethyl]- 2,9-dimethyl-4H- pyrido[1,2- a]pyrimidin-4-one	5HT antagonist; 5HT2 antagonist; dopamine antagonist; dopamine D2 antagonist	schizophrenia
Olanzapine; LY 170053; ZYPREX; ZYPREXA; OLANZEK	2-methyl-4-(4- methyl-1- piperazinyl)-10H- thieno[2,3-b][1,5] benzodiazepine	5HT antagonist; 5HT2 antagonist; dopamine antagonist; dopamine D2 antagonist	schizophrenia; psychosis; depression
Perospirone; SM 9018; LULLAN	cis-2-[4-[4-(1,2- benzothiazol-3-yl)- 1-piperazinyl]butyl]- hexahydro-1H-isoin- dole-1,3(2H)-dione	5HT antagonist; 5HT2 antagonist; dopamine antagonist; dopamine D2 antagonist	schizophrenia
Risperidone; R 64766; RISPERDAL; BELIVON	3-[2-[4-(6-fluoro-1,2- benzoxazol-3- yl)piperidinyl]ethyl]- 6,7,8,9-tetrahydro-2- methyl-4H-pyrido[1, 2-a]pyrimidin-4-one	5HT antagonist; 5HT2 antagonist; dopamine antagonist; dopamine D2 antagonist	schizophrenia
Eplivanserin; SR 46349; SR 46349B	(1Z,2E)-1-(2- fluorophenyl)-3-(4- hydroxyphenyl)-2- propen-1-one (2E)-2- butenedioate (2:1) salt	5HT antagonist; 5HT2 antagonist; platelet antiaggregant	schizophrenia; insomnia; thrombosis
M 100907; MDL 100907	(R)-alpha-(2,3- dimethoxyphenyl)-1- [2-(4- fluorophenyl)ethyl]- 4-piperidinemethanol	5HT antagonist; 5HT2A antagonist	schizophrenia
Sertindole; LU 23174; S 1991; SERDOLECT	1-[2-[4-[5-chloro-1- (4-fluorophenyl)-1H- indol-3-yl]-1- piperidinyl]ethyl]-2- imidazolidinone	5HT antagonist; 5HT2A antagonist; 5HT2C antagonist; dopamine antagonist; dopamine D2 antagonist	schizophrenia

AS 5370	N-[hexahydro-1-methyl-4-[(3-methylphenyl)methyl]-1H-1,4-diazepin-6-yl]-1H-indazole-3-carboxamide dihydrochloride	5HT antagonist; 5HT3 antagonist	emesis; schizophrenia
BMV 33426		5HT antagonist; 5HT3 antagonist	schizophrenia
BMV 33462	(4-amino-N-(1-azabicyclo-[2,2,2]oct-3-yl)-2-(butan-2-one-3-yl)oxy-5-chlorobenzamine 1.25 fumerate hydrate	5HT antagonist; 5HT3 antagonist	schizophrenia
Ricasetron; BRL 46470; BRL 46470A	endo-2,3-dihydro-3,3-dimethyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1H-indole-1-carboxamide	5HT antagonist; 5HT3 antagonist	anxiety; schizophrenia; emesis
5HT7 receptor antagonists		5HT antagonist; 5HT7 antagonist	depression; insomnia; schizophrenia
BTS 79018		5HT antagonist; dopamine antagonist	schizophrenia
Schizophrenia therapy,		AMPA receptor modulators	schizophrenia; depression
bretazenil; Ro 166028; Ro 166028001	(S)-8-bromo-11,12,13,13a-tetrahydro-9-oxo-9H-imidazo[1,5-a]pyrrolo[2,1-c][1,4]benzodiazepine-1-carboxylic acid 1,1-dimethylethyl ester	benzodiazepine partial agonist	schizophrenia
dopamine release inhibitor,		calcium antagonist; dopamine release inhibitor	schizophrenia
SR 141716; SR 141716A	5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide	cannabinoid antagonist	schizophrenia

Cholecystokinin B antagonist		cholecystokinin antagonist; cholecystokinin B antagonist	schizophrenia; anxiety
LY 288513		cholecystokinin antagonist; cholecystokinin B antagonist	schizophrenia; anxiety
LY 262691	trans-N-(4-bromophenyl)-3-oxo-4,5-diphenyl-1-pyrazolidinecarboxamide	cholecystokinin B antagonist; cholecystokinin antagonist	schizophrenia
Alentemol; alentemol hydrobromide; U 68553B	(+)-2-(dipropylamino)-2,3-dihydrophenalen-5-ol	dopamine agonist	schizophrenia
CGS 15873A	trans-(+,-)-1,3,4,4a,5,10b-hexahydro-4-propyl-2H-[1]benzopyrano[3,4-b]pyridin-7-ol hydrochloride	dopamine agonist	schizophrenia
HW 165	trans-(+/-)-1,2,3,4,4a,5,6,10b-octahydrobenzo(f)quinolin-7-ol, hydrobromide	dopamine agonist	Parkinson disease; schizophrenia
Amisulpride; aminosultopride; AST; DAN 2163; SOCIAN; SOLIAN; ENORDEN; DENIBAN; SULAMID	4-amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxy benzamide	dopamine agonist; dopamine antagonist	schizophrenia; depression
terguride; TDHL; VUFB 6638; ZK 31224; SH 406; DIRONYL; TELURON; TERULON	1,1-diethyl-3-(6-methylergolin-8alpha-yl)urea	dopamine agonist; dopamine antagonist	schizophrenia; hyperprolactinemia

Pramipexole; pramipexole dihydrochloride; SND 919; U 98528E; SND919CL2Y; PNU 98528E; SIFROL; MIRAPEX; DAQIRAN; MIRAPEXIN; FIROL	(S)-2-amino-4,5,6,7- tetrahydro-6- (propylamino)- benzothiazole	dopamine agonist; dopamine D2 agonist; dopamine D3 agonist	Parkinson disease; schizophrenia; depression
PD 158771	trans-N-[4-[2-(4- phenyl-1- piperazinyl)ethyl]cyclohexyl]-2- pyrimidinamine	dopamine agonist; dopamine D2 partial agonist; 5HT1A partial agonist; 5HT agonist	schizophrenia
CI 1007; PD 143188	(R)-1,2,3,6- tetrahydro-4-phenyl- 1-[(3-phenyl-3- cyclohexen-1-yl)m ethyl]pyridine	dopamine agonist; dopamine D2 partial agonist; dopamine D3 partial agonist	schizophrenia
GYKI 22441; BRENFUMOD	2-(4-chlorophenoxy)- 2-methylpropanoic acid 2-[4-[3-[2- (trifluoromethyl)- 10H-phenothiazin-10- yl]propyl]-1- piperazinyl]ethyl ester	Dopamine antagonist Phenothiazine ester	schizophrenia
Isofloxythepin; VUFB 10662	4-[3-fluoro-10,11- dihydro-8-(1- methylethyl)dibenzo[b,f]thiepin-10-yl]-1- piperazineethanol	Dopamine antagonist	schizophrenia
Bromperidol; R 11333; IMPROMEN; BRIDOL; IMPROMEN DECANOAS; ERODIUM; LUNAPRON; PRINDRIL; ROPEL	4-[4-(4- bromophenyl)-4- hydroxy-1- piperidinyl]-1-(4- fluorophenyl)-1- butanone	dopamine antagonist	schizophrenia
dopamine D4 antagonists, Taisho		dopamine antagonist	schizophrenia

Nemonapride; Nemonapride; YM 09151; YM 091512; EMILACE; SEPAN; NEPONID	cis-5-chloro-2- methoxy-4- (methylamino)-N-[2- methyl-1- (phenylmethyl)-3- pyrrolidinyl]benzami de	dopamine antagonist	schizophrenia
Savoxepin; cipazoxapine; CGP 19486	3- (cyclopentylmethyl)- 2,3,4,5-tetrahydro- 1H- dibenz[2,3:6,7]oxepin o[4,5-d]azepine-7- carbonitrile	dopamine antagonist	schizophrenia
NGD 931; NGB 566		dopamine antagonist, 5HT agonist, adrenergic agonist; Atypical neuroleptic,	schizophrenia
Quetiapine; quetiapine fumarate; ZD 5077; Zeneca 204636; ICI 204636; SEROQUEL	2-[2-(4- dibenzo[b,f][1,4]thiaz epin-11-yl-1- piperazinyl)ethoxy]et hanol	dopamine antagonist; 5HT antagonist; 5HT2 antagonist	schizophrenia
Berupipam; NNC 220010	(S)-8-chloro-5(5- bromo-2,3- dihydrobenzofuran-7- yl)-7-hydroxy-3- methyl-2,3,4,5- tetrahydro-1H-3- benzazepine	dopamine antagonist; dopamine D1 antagonist	schizophrenia
CEE 03310; NNC 010687; NNC 687; NO 687; NNC 01- 0687	(S)-5-(2,3-dihydro-7- benzofuranyl)- 2,3,4,5-tetrahydro-3- methyl-8-nitro-1H-3- benzazepin-7-ol	dopamine antagonist; dopamine D1 antagonist	schizophrenia; insomnia
CEE 03320; NNC 220215	Unspecified	dopamine antagonist; dopamine D1 antagonist	schizophrenia
ecopipam; SCH 39166	(6aS-trans)-11- chloro-6,6a,7,8,9,13b- hexahydro-7-methyl- 5H- benzo[d]naphth[2,1- b]azepin-12-ol	dopamine antagonist; dopamine D1 antagonist	schizophrenia

ZD 3638; M 275562	4-[2-(ethylsulfinyl)-3-pyridinyl]-1-(9,10-methanoanthracen-9(10H)-ylmethyl)-4-piperidinol	dopamine antagonist; dopamine D1 antagonist; dopamine D2 antagonist; 5HT antagonist; 5HT2 antagonist	schizophrenia
zotepine; LODOPIN; NIPOLEPT; ZOLEPTIL; ZOPITE; SETOUS; MAJORPIN	2-[(8-chlorodibenzo[b,f]thi-epin-10-yl)oxy]-N,N-dimethylethylamine	dopamine antagonist; dopamine D1 antagonist; dopamine D2 antagonist; 5HT antagonist; 5HT2 antagonist; noradrenalin reuptake inhibitor	schizophrenia
Mosapramine; closipramine; Y 516; CREMIN	(+,-)-1'-[3-(3-chloro-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)propyl]hexahydros piro[imidazo[1,2-a]pyridine-3(2H),4'-piperidin]-2-one	dopamine antagonist; dopamine D2 antagonist	schizophrenia
Remoxipride; remoxipride hydrochloride; FLA 731; A 33547; ROXIAM	(S)-3-bromo-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenzamide	dopamine antagonist; dopamine D2 antagonist	schizophrenia
RWJ 25730	1-[[1-methyl-5-[[4-[2-(1-methylethoxy)phenyl]-1-piperazinyl]methyl]-1H-pyrrol-2-yl]methyl-2-piperidinone	dopamine antagonist; dopamine D2 antagonist	schizophrenia
DU 29894		dopamine antagonist; dopamine D2 antagonist; 5HT antagonist; 5HT1A antagonist	schizophrenia
Blonanserin; AD 5423	2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine	dopamine antagonist; dopamine D2 antagonist; 5HT antagonist; 5HT2 antagonist	schizophrenia

ORG 5222	trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole maleate (1:1)	dopamine antagonist; dopamine D2 antagonist; 5HT antagonist; 5HT2 antagonist	schizophrenia
Amisulpride, (S); (-)-amisulpride	(S)-4-amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide	dopamine antagonist; dopamine D2 antagonist; dopamine D3 antagonist	schizophrenia
RGH 1756	6-[4-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butoxy]phenyl]imidazo[2,1-b]thiazole	dopamine antagonist; dopamine D3 antagonist	schizophrenia; psychosis
YM 43611	(S)-5-chloro-4-[(cyclopropylcarbonyl)amino]-2-methoxy-N-[1-(phenylmethyl)-3-pyrrolidinyl]benzamide	dopamine antagonist; dopamine D3 antagonist; dopamine D4 antagonist	schizophrenia
CP 293019	7-[(4-fluorophenoxy)methyl]-2-(5-fluoro-2-pyrimidinyl)octahydro-2H-pyrido[1,2-a]pyrazine	dopamine antagonist; dopamine D4 antagonist	schizophrenia
L 745870	3-[[4-(4-chlorophenyl)-1-piperazinyl)methyl]-1H-pyrrolo[2,3-b]pyridine	dopamine antagonist; dopamine D4 antagonist	schizophrenia
NGD 941	2-[4-[(2-phenyl-1H-imidazol-4-yl)methyl]-1-piperazinyl]pyrimidine	dopamine antagonist; dopamine D4 antagonist	schizophrenia
NGD 944; NGD 94-4		dopamine antagonist; dopamine D4 antagonist	schizophrenia

PD 172760	7-[[4-(4-chlorophenyl)-1-piperazinyl]methyl-2H-1,4-benzoxazin-3(4H)-one	dopamine antagonist; dopamine D4 antagonist	schizophrenia
Sonepiprazole; PNU 101387; U 101387G	(S)-4-[4-[2-(3,4-dihydro-1H-2-benzopyran-1-yl)ethyl]-1-piperazinyl]benzenesulfonamide	dopamine antagonist; dopamine D4 antagonist	schizophrenia
Belaperidone; LU 111995	(1 α ,5 α ,6 α)-3-[2-[6-(4-fluorophenyl)-3-azabicyclo[3.2.0]hept-3-yl]ethyl]-2,4(1H,3H)-quinazolinedione	dopamine antagonist; dopamine D4 antagonist; 5HT antagonist; 5HT2 antagonist	schizophrenia
dopamine antagonist		dopamine antagonist; dopamine D4 antagonist; dopamine D2 antagonist	schizophrenia; psychosis
HMR 2934		dopamine antagonist; dopamine D4 antagonist; dopamine D2 antagonist; 5HT antagonist	schizophrenia
LEK 8829	(8 β)-9,10-didehydro-N,6-dimethyl-N-2-propynylergoline-8-methanamine	dopamine D1 agonist; dopamine D2 antagonist; 5HT antagonist; 5HT2A antagonist; dopamine agonist; dopamine antagonist	schizophrenia; Parkinson disease
levosulpiride; LEVOPRAID	(S)-5-(aminosulfonyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxybenzamide	dopamine D2 antagonist; dopamine antagonist	emesis; schizophrenia
LU 201640		dopamine D3 antagonist; dopamine antagonist	schizophrenia

fananserine; RP 62203	2-[3-[4-(4-fluorophenyl)-1-piperazinyl]propyl]-2H-naphth[1,8-cd]isothiazole, 1,1-dioxide	dopamine D4 antagonist; dopamine antagonist; 5HT antagonist; 5HT2A antagonist	schizophrenia
valproate semisodium; divalproex sodium; semisodium valproate; AB 50711; DEPAKOTE; EPIVAL; VALCOTE	2-propylpentanoic acid sodium salt (2:1)	GABAergic agonist	epilepsy; migraine; schizophrenia; depression
glycine reuptake inhibitors,		Glycine reuptake inhibitors, GlyT-1	schizophrenia
ciproxifan; compound 359; BP 2359	cyclopropyl[4-[3-(1H-imidazol-4-yl)propoxyl]phenyl]methanone	histamine antagonist; histamine H3 antagonist	Alzheimer disease; schizophrenia; cognitive defect
compound 421		histamine antagonist; histamine H3 antagonist	Alzheimer disease; schizophrenia; cognitive defect
metabotropic glutamate receptor modulators		metabotropic glutamate receptor modulators, analgesic	pain; cognitive defect; schizophrenia; epilepsy
osanetant; SR 142801	(R)-N-[1-[3-[1-benzoyl-3-(3,4-dichlorophenyl)-3-piperidinyl]propyl-4-phenyl-4-piperidinyl]-N-methylacetamide monohydrochloride	neurokinin antagonist; neurokinin 3 antagonist	schizophrenia; anxiety
SR 48692	2-[[[1-(7-chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl]carbonyl]amino]tricyclo[3.3.1.1 ^{3,7}]decane-2-carboxylic acid	neurotensin antagonist	schizophrenia; cancer
conantokins		NMDA antagonist; glutamate antagonist; peptide; analgesic	epilepsy; stroke; schizophrenia; pain; ischemia

alpha-conopeptides		peptide; cholinergic agonist; nicotinic agonist	schizophrenia; Parkinson disease; cancer; urinary incontinence
lithium gamolenic acid; SC 111	(Z,Z,Z)-6,9,12-octadecatrienoic acid lithium salt	phospholipase inhibitor	schizophrenia
panamesine; EMD 57445	(S)-5-[[4-(1,3-benzodioxol-5-yl)-4-hydroxy-1-piperidinyl]methyl]-3-(4-methoxyphenyl)-2-oxazolidinone	sigma agonist; dopamine antagonist	schizophrenia
BMY 14802; BMY 148021	alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol	sigma antagonist	schizophrenia
CNS 1044		sigma antagonist	schizophrenia
CNS 1169		sigma antagonist	schizophrenia
CNS 1307		sigma antagonist	schizophrenia
CNS 3040		sigma antagonist	schizophrenia
MS 355		sigma antagonist	schizophrenia
NPC 16316		sigma antagonist	schizophrenia
MK 869		substance P antagonist	depression; anxiety; schizophrenia; emesis
CX 516; AMPALEX	1-(6-quinoxalinylicarbonyl)piperidine	Unknown	Alzheimer disease; schizophrenia
Maroxepine; CGP 13442A	2,3,4,5-tetrahydro-3-methyl-1H-dibenz[2,3:6,7]oxepino[4,5-d]azepine	Unknown	schizophrenia

Table 36. Current Candidate Therapeutic Interventions for the Treatment of Spasticity

Product Name	Chemical Name	Action	Indication
Tizanidine; tizanidine hydrochloride; AN 021A; DS 103 282 CH; SIRDALUD; ZANAFLEX; TEMELIN	5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine	alpha adrenergic agonist; alpha2 adrenergic agonist; antispasmodic; muscle relaxant	muscle spasm

botulinum A toxin; Clostridium botulinum toxin type A; DYSPORT	Botulinum toxin A	cholinergic antagonist; muscle relaxant	muscle spasm; eye disease
botulinum toxin type A; Clostridium botulinum toxin type A; OCULINUM; BOTOX	Botulin A	cholinergic antagonist; muscle relaxant	muscle spasm; eye disease; migraine
riluzole; PK 26124; RP 54274; RILUTEK	6-(trifluoromethoxy)-2-benzothiazolamine	glutamate antagonist	amyotrophic lateral sclerosis; Alzheimer disease; Parkinson disease
GRI 2	Unspecified	Glycine reuptake inhibitors	muscle spasm
afloqualone; HQ 495; AROFUTO; ALOFT; PLENCO; AFROBARON	6-amino-2-(fluoromethyl)-3-o-tolyl-4(3H)-quinazolinone	muscle relaxant	surgery
lanperisone; lanperisone hydrochloride; NK 433	2-methyl-3-(1-pyrrolidinyl)-1-[4-(trifluoromethyl)phenyl]-1-propa none	muscle relaxant	muscle spasm; urinary incontinence
MS 322	(R)-(+)-3-phenyl-5-(2-(1-pyrrolidinylmethyl)butyryl)isoxazole hydrochloride	muscle relaxant	muscle spasm
threonine, L-; L-threonine; IP 204	L-threonine	unknown	muscle spasm

Table 37. Current Candidate Therapeutic Interventions for the Treatment of Stroke

Product Name	Chemical Name	Action	Indication
repinotan; BAY x 3702	(R)-2-[4-[[[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]amino]butyl]-1,2-benzisothiazol-3(2H)-one 1,1-dioxide	5HT agonist; 5HT1A agonist	stroke; trauma
Levemopamil; emopamil, (S)	(2S)-2-isopropyl-5-(methylphenethylamino)-2-phenylvaleronitrile	5HT antagonist; 5HT2 antagonist; calcium antagonist; antihypoxic	stroke

5HT4 human neuroreceptor; neuroreceptor, 5HT4		5HT4 human neuroreceptor	irritable bowel syndrome; cognitive defect; anxiety; arrhythmia; stroke; urinary incontinence; migraine; research tool
A3 receptor regulator		Adenosine 3 receptor ligand	stroke
Adenosine A1 agonists		adenosine A1 agonist	stroke
AMP 579		adenosine agonist; adenosine A1 agonist; adenosine A2 agonist	myocardial infarction; stroke
GP 04012		adenosine antagonist; adenosine A1 antagonist	stroke; trauma
Adenosine allosteric modulators		adenosine regulating agent	cardiovascular disease; cancer; stroke
Adenosine regulating agents, stroke		adenosine regulating agent	stroke
CPC 407		adenosine regulating agent	stroke
GP 1668; GP 668	5-amino-1-[beta-D-5-phosphoribofuranosyl]-imidazole-1-N-[(4-nitrophenyl)methyl]carboxamide)	adenosine regulating agent	angina; stroke
NS 257		AMPA antagonist; glutamate antagonist	stroke
NS 479		AMPA antagonist; glutamate antagonist	stroke; neuropathy
S 176252; S 17625	(6,7-dichloro-1,2-dihydro-2-oxo-3-quinolinyloxy)phosphonic acid	AMPA antagonist; glutamate antagonist	stroke
SH 608		AMPA antagonist; glutamate antagonist	stroke

SPD 502; NS 1209	2-[[[5-[4- [(dimethylamino)sulf onyl]phenyl]- 1,2,6,7,8,9- hexahydro-8-methyl- 2-oxo-3H- pyrrolo[3,2- h]isoquinolin-3- ylidene]amino]oxy]- 4-hydroxybutanoic acid monosodium salt	AMPA antagonist; glutamate antagonist	stroke; neurodegeneration
SYM 2189		AMPA antagonist; glutamate antagonist	stroke; epilepsy
SYM 2206	8-(4-aminophenyl)-5- methyl-N-propyl-1,3- dioxolo[4,5- g]phthalazine-6(5H)- carboxamide	AMPA antagonist; glutamate antagonist	stroke; epilepsy
YM 872	3,4-dihydro-7-(1H- imidazol-1-yl)-6- nitro-2,3-dioxo- 1(2H)- quinoxalineacetic acid	AMPA antagonist; glutamate antagonist	stroke
losartan; losartan potassium; DUP 753; MK 954; DUP 89; E 3340; AVASTAR; COZAAR; LOORTAN; NULOTAN	2-butyl-4-chloro-1- [[[2'-(1H-tetrazol-5- yl)[1,1'-biphenyl]-4- yl]methyl]-1H- imidazole-5-methanol	angiotensin II antagonist	hypertension; anxiety; stroke; heart failure; myocardial infarction
TN 871	1-(6-butyl-6,7- dihydro-5H- indeno[5,6-d]-1,3- dioxol-5-yl)-4-methyl piperazine dihydrochloride	Anoxia protection	stroke
apocuanzine; IDB 1057	(3alfa,16alfa,17alfa)- 17,21-epoxy-12- methoxy- eburnamenine-14- carboxylic acid methyl ester	antihypoxic	stroke
hypoxia therapy		antihypoxic	heart ischemia; stroke
KF 17329		antihypoxic	stroke; brain ischemia
KF 19863		antihypoxic	stroke

MS 153	(-)-1-nicotinoyl-5-methyl-2-pyrazoline	anti-ischemic	stroke
YM 737	N-(N-L-gamma-glutamyl-L-cysteinyl)-glycine, 1-(1-methyl)ester	anti-ischemic	stroke
BXT 51072	3,4-dihydro-4,4-dimethyl-2H-1,2-benzoselenazine	antioxidant	stroke; inflammatory bowel disease
CEB 1370		antioxidant	stroke
LY 231617	2,6-bis(1,1-dimethylethyl)-4-[(ethylamino)methyl]phenol hydrochloride	antioxidant	stroke
Neurodegenerative disease therapy		antioxidant	stroke; Alzheimer disease
U 101033E	6,7,8,9-tetrahydro-9-[2-(4-morpholinyl)ethyl]-2,4-di-1-pyrrolidinyl-5H-pyrimido[4,5-b]indole dihydrochloride	antioxidant	stroke; neurodegeneration; brain ischemia
MDL 101002	3,4-dihydro-3,3-dimethylisoquinoline 2-oxide	antioxidant; free radical scavenger	stroke; neurodegeneration; septic shock
synthetic catalytic scavenger analogues; SCS analogues		antioxidant; free radical scavenger	stroke; trauma; atherosclerosis; neurodegeneration; asthma
VANTOX		antioxidant; NSAID	asthma; Parkinson disease; Alzheimer disease; stroke
secreted apoptosis related proteins; SARPS		apoptosis inducer; apoptosis inhibitor	cancer; myocardial infarction; stroke
CNS therapy, IDUN; CNS therapy		apoptosis inhibitor; caspase inhibitor	stroke; Parkinson disease; amyotrophic lateral sclerosis
VM 201		blood clotting factor IXa inhibitor; proteinase inhibitor	thrombosis; stroke
factor Xa inhibitor		blood clotting factor Xa inhibitor; proteinase inhibitor	thrombosis; stroke; myocardial infarction

JTV 803		blood clotting factor Xa inhibitor; proteinase inhibitor	stroke; myocardial infarction; thrombosis
deltibant; CP 0127; SB 238592; BRADYCOR	hexamethylene-bis- (succinimido- Cys(Leu)-Phe-Gly- Hyp-Pro-Arg)	bradykinin antagonist; cicatrizant	trauma; stroke
AJ 3941	11-(4-cinnamyl-1- piperazyl)-3-fluoro- 6,11- dihydrodibenzo[6,e]o xepine-2 maleate	calcium antagonist	stroke
calcium antagonist		calcium antagonist	stroke
lifarizine; RS 87476; RS 87476000	1-(diphenylmethyl)- 4-[[5-methyl-2-(4- methylphenyl)-1H- imidazol-4- yl]methyl]piperazine	calcium antagonist	stroke; brain ischemia
NCC 161; LY 042826		calcium antagonist	ischemia; stroke
S 830256	3-cyclo-pentyl-5- cyclo- pentyloxyethoxycarb onyl-4,7-dihydro-1,6- di methyl-4-(2-nitro- phenyl)pyrazolo-(3,4- b)pyridine hydrochloride	calcium antagonist	stroke
S 830327	methyl-4,7-dihydro- 3-n-butyl-6-methyl-4- (3- nitrophenyl)thieno(2, 3 -b)pyridine-5- carboxylate	calcium antagonist	stroke
NPS 846		calcium antagonist; analgesic	stroke; epilepsy; pain
ziconotide; SNX 111; CI 1009	omega-conotoxin MVIIA	calcium antagonist; analgesic; peptide	stroke; pain; brain ischemia
rumbrin	(1Z,3E,5E,7E)-6-(8- (3-chloro-1H-pyrrol- 2-yl)-1-methyl- 1,3,5,7-octatetraenyl)- 4-methoxy-3-methyl- 2H-pyran-2-one	calcium antagonist; free radical scavenger	stroke

F 0401; D 31D	(E)-3-[4-(1H-imidazol-1-ylmethyl)phenyl]-2-propenyl-methyl-1,4-dro-2,6-dimethyl-4-(3-nitrophenyl) 3,5-pyridinedicarboxylate	calcium antagonist; PAF antagonist; thromboxane synthetase inhibitor; vasodilator	stroke
S 312; S 312d; S 830312	4,7-dihydro-6-methyl-3-(2-methylpropyl)-4-(3-nitrophenyl)-thieno[2,3-b]pyridine-5-carboxylic acid methyl ester	calcium antagonist; vasodilator	stroke
U 92032	7-[[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]methyl]-2-[(2-hydroxyethyl)amino]-4-(1-methylethyl)-2,4,6-cycloheptatrien-1-one	calcium antagonist; vasodilator	stroke
calcium channel blocker		calcium channel blocker	stroke
Calcium channel blockers		calcium channel blocker	stroke
calcium channel blockers		calcium channel blocker	stroke
CPC 301		calcium channel blocker	stroke
CPC 304		calcium channel blocker	stroke
CPC 317		calcium channel blocker	stroke
CPC 8027		calcium channel blocker	stroke; epilepsy
CPC 8029		calcium channel blocker	stroke; epilepsy
NS 3034		calcium channel blocker	stroke
NS 638		calcium channel blocker	stroke

SB 201823A	4-[2(3,4-dichlorophenoxy)ethyl]-1-pentyl piperidine hydrochloride	calcium channel blocker	stroke
drug delivery system, conopeptides		calcium channel blocker; sodium channel blocker; potassium channel blocker; analgesic	epilepsy; Parkinson disease; stroke; pain; brain ischemia
DP 16	Acylglycerol derivative of BAPTA	Calcium chelator	epilepsy; stroke; heart ischemia
stroke therapy	N-1-naphthalenyl-1-(3-phenoxypropyl)-4-piperidinamine	Calcium lowering agent	stroke
DY 9760	3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-1-(1H-imidazol-4-ylmethyl)-5,6-dimethoxy-1H-indazole	calmodulin antagonist	brain ischemia; stroke
calpain inhibitors		calpastatin	stroke
calpain inhibitors,		calpastatin; proteinase inhibitor	stroke
caspase antagonists		caspase inhibitor; apoptosis inhibitor	stroke; myocardial infarction
KF 10632; IKY 432	2-methyl-1-[1-oxo-3-[4-(trifluoromethyl)phenyl]-2-propenyl]piperidine	Cerebroprotectant	stroke
acetyl-L-carnitine; acetylcarnitine, L-; ALC; ST 200; TA 803; NICETILE; BRANIGAN; ALCAR; NEUROACTIL; BRANIGEN	acetyl-L-carnitine	Cholinergic agonist stimulation of nerve growth	Alzheimer disease; stroke; diabetes; neuropathy
Aniracetam; Ro 135057; SARPUL; DRAGANON; APAMET; RESET	1-(4-methoxybenzoyl)-2-pyrrolidinone	cholinergic antagonist	cognitive defect; stroke

Citicoline; citicoline sodium; cytidil diphosphocholine; CDP choline; IP 302; NEUROX; ALPHACOLIN; HIPERCOL; NEUREX; SOMAZINA; TRAUSAN	P'-[2-(trimethylammonio)ethyl] citidine 5'-(trihydrogen diphosphate)	cholinesterase inhibitor	stroke
Fibroblast growth factor agonist,		cicatrizant; FGF agonist	skin ulcer; stroke
MAB, C5 single chain; Mab, complement C5; 5G1.1-SC		complement inhibitor; monoclonal antibody; NSAID	inflammation; myocardial infarction; stroke; ischemia
NBI 102		CRF antagonist	stroke
NBI 104		CRF antagonist	depression; stroke
interleukin-8 antagonists; IL-8 antagonists		cytokine antagonist	myocardial infarction; stroke; respiratory distress syndrome
endothelin B antagonist,		endothelin B antagonist; endothelin antagonist	stroke
Endothelium-associated disease therapy,		Endothelin receptor ligand	stroke; asthma
ABPI 126		estrogen agonist	stroke
ABPI 127		estrogen agonist	stroke
excitatory amino acid antagonists		excitatory amino acid antagonist	epilepsy; Alzheimer disease; stroke
NPC 18123		excitatory amino acid antagonist; glutamate antagonist	epilepsy; stroke
excitatory amino acid receptor modulators		Excitatory amino acid receptor ligand	stroke
APO 99		free radical scavenger	stroke; ischemia; reperfusion injury
K 7259	hexahydro-1,4-bis[4-(3,4,5-trimethoxyphenyl)butyl]-1H-1,4-diazepine dihydrochloride	free radical scavenger	stroke
NXY 059		free radical scavenger	stroke

Pyrrolostatin	4-geranylpyrrole-2-carboxylic acid	free radical scavenger	stroke
resorstatin		free radical scavenger	stroke
stobadine; DH 1101; DP 1031	(4aR,9bS)-2,3,4,4a,5,9b-hexahydro-2,8-dimethyl-1H-pyrido[4,3-b]indole dihydrochloride	free radical scavenger	ischemia; stroke
TAK 218	(S)-2,3-dihydro-2,4,6,7-tetramethyl-2-[[4-phenyl-1-piperidinyl)methyl]-5-benzofuranamine dihydrochloride	free radical scavenger	stroke; trauma
EUK 134	(SP-5-13)-chloro[[2,2'-[1,2-ethanediylbis[(nitrilo-kappaN)methylidyne]]bis[6-methoxyphenolato-kappaO1]]]-manganese	free radical scavenger; antioxidant	stroke
free radical scavengers		free radical scavenger; NSAID	neurodegeneration; arthritis; reperfusion injury; psoriasis; stroke
SLH 301		free radical scavenger; NSAID	neurodegeneration; arthritis; reperfusion injury; psoriasis; stroke
EPC K1; CHX 3107	[2R-[2R*(4R*,8R*)]]-2-[3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl hydrogen phosphate] L-ascorbic acid esters, monopotassium salt	free radical scavenger; phospholipase inhibitor; cytokine antagonist; NSAID	stroke

OC 5186	(5Z,13E,15S)-15-hydroxy-9-oxo-prosta-5,8(12),13-trien-1-oic acid, homopolymer, ester with L-ascorbic acid	free radical scavenger; prostanoid	cancer; stroke; malaria
BMS 183729; BMY 20862	5,6-dihydro-11-methyl-11H-pyrimido[4,5-6][1,4]benzodiazepine	GABA agonist	neuropathy; stroke
clomethiazole; CMZ; HEMINEVRIN; ZENDRA		GABA modulator	insomnia; stroke
GM-1; ganglioside GM-1;	monosialotetrahexosylganglioside	ganglioside	stroke
siagoside; AGF 2	[R-[R*,S*-(E)]]-N-[1-[[[O-[1',2-anhydro]-N-acetyl-alpha-neuraminosyl-(2->3)-O-[O-beta-D-galactopyranosyl-(1->3)-2-(acetyl-amino)-2-deoxy-beta-D-galactopyranosyl-(1->4)-O-beta-D-galactopyranosyl-(1->4)-beta-D-glucopyranosyl]oxy]methyl]-2-hydroxy-3-heptadecenyl]octadecanamide	ganglioside	cognitive defect; stroke
stroke therapy		glutamate agonist; mGluR agonist	stroke
HF 7		glutamate antagonist	stroke
NNC 079202; FG 9202	1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-benzo(f)quinoxaline-7-sulfon amide	glutamate antagonist	epilepsy; stroke
NS 409; PD 152247; PNQX	1,4,7,8,9,10-hexahydro-9-methyl-6-nitro-pyrido[3,4-f]quinoxaline-2,3-dione	glutamate antagonist	stroke
AMPA antagonist		glutamate antagonist; AMPA antagonist	stroke

CP 465022	3-(2-chlorophenyl)-2-[2-[6-[(diethylamino)methyl]-2-pyridinyl]ethenyl]-6-fluoro-4(3H)-quinazolinone (Z)-2-butenedioate (1:1)	glutamate antagonist; AMPA antagonist	stroke
NNC 070775		glutamate antagonist; AMPA antagonist	stroke
YM 90K; YM 900	1,4-dihydro-6-(1H-imidazol-1-yl)-7-nitro-2,3-quinoxalinedione monohydrochloride	glutamate antagonist; AMPA antagonist	stroke
sinnabidol; HU 211; PA 50211; DEXANABINOL	(6aS-trans)-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol	glutamate antagonist; cannabinoid; NMDA antagonist; free radical scavenger	cognitive defect; stroke; trauma; myocardial infarction; glaucoma
ACPC; cycloleucine; cycloleucin; NSC 1026; WR 14997	1-aminocyclopentanecarboxylic acid	glutamate antagonist; NMDA antagonist	coronary artery disease; anxiety; depression; stroke; epilepsy; addiction
CP 283097	(3R-cis)-3-[4-(4-fluorophenyl)-4-hydroxy-1-piperidinyl]-3,4-dihydro-2H-1-benzopyran-4,7-diol	glutamate antagonist; NMDA antagonist	Parkinson disease; stroke; trauma
dizocilpine; dizocilpine maleate; MK 801	(+)-10,11-dihydro-5-methyl-5H-dibenzo[a,d]cyclohepten-5,10-imine	glutamate antagonist; NMDA antagonist	epilepsy; stroke; neuropathy
EAA 090	[2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)ethyl]phosphonic acid	glutamate antagonist; NMDA antagonist	stroke

GPI 3000; NPC 17742	[1R-[1alpha(R*),2alpha]]-alpha-amino-2-(2-phosphonoethyl)cyclohexane propanoic acid	glutamate antagonist; NMDA antagonist	epilepsy; stroke; neuropathy
L 701324	7-chloro-4-hydroxy-3-(3-phenoxyphenyl)-2(1H)-quinolinone	glutamate antagonist; NMDA antagonist	epilepsy; stroke
MRZ 2579; MRZ 2/579		glutamate antagonist; NMDA antagonist	Parkinson disease; addiction; stroke
2-PMPA; GPI 5000		glutamate release inhibitor	stroke; neurodegeneration
BW 1003C87	Ethanesulfonic acid cmpd. with 5-(2,3,5-trichlorophenyl)-2,4-pyrimidinediamine (1:1)	glutamate release inhibitor	stroke
sipatrigine; BW 619C89; BW 619C	2-(4-methyl-1-piperazinyl)-5-(2,3,5-trichlorophenyl)-4-pyrimidinamine	glutamate release inhibitor	stroke
ACEA 1031		glycine antagonist	stroke
gavestinel; GV 150526; GV 150526A; GV 150526X; GG 526; GV 526A	(E)-4,6-dichloro-3-[3-oxo-3-(phenylamino)-1-propenyl]-1H-indole-2-carboxylic acid	glycine antagonist	stroke
HMR 2371		glycine antagonist	stroke
M 241247		glycine antagonist	stroke
M 244249		glycine antagonist	stroke
ZD 9379	7-chloro-3,5-dihydro-2-(4-methoxy-2-methylphenyl)-pyridazino[4,5-b]quinoline-1,4-10(5H)-trione, base and salts	glycine antagonist	stroke
glycoprotein IIb/IIIa antagonist; P246		glycoprotein IIb/IIIa antagonist; peptide; platelet antiaggregant	thrombosis; heart ischemia; stroke
cromafiban		glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis; stroke

EMD 122347; YM 028		glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis; angina; stroke
MK 852; L 367073	N-acetyl-L-cysteinyl-L-asparaginy-(4R)-5,5-dimethyl-4-thiazolidinecarbonyl-4-(aminomethyl)-L-phenylalanyl-glycyl-L-alpha-aspartyl-L-cysteine, cyclic (1-7)-disulfide	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	stroke; thrombosis
SDZ GPI562	Unspecified	glycoprotein IIb/IIIa antagonist; platelet antiaggregant	thrombosis; stroke
pimagedine; pimagedine hydrochloride; aminoguanidine; GER 11; YM 585	aminoguanidine	Glycosylation end-product inhibitor	diabetes; kidney disease; retinopathy; atherosclerosis; neuropathy; stroke
fibroblast growth factor-10		Growth factor, fibroblast growth factor-10	stroke; trauma
insulin-like growth factor-1; IGF-1		Growth factor, IGF-1	brain ischemia; trauma; stroke; neurodegeneration
transforming growth factor beta; TGFbeta		Growth factor, TGF-beta	brain ischemia; trauma; stroke; neurodegeneration
ersofermin; fibroblast growth factor, basic; basic fibroblast growth factor; bFGF; TROFAK	N-(N-glycyl-L-threonyl)-basic fibroblast growth factor (human clone lambdaKB7/lambdaHFL1 precursor reduced)	growth factor; cicatrizant	stroke
trafermin; fibroblast growth factor, basic; basic fibroblast growth factor; bFGF; trofermin; KCB 1; CAB 2001; FIBLAST	2-155-fibroblast growth factor, basic (human clone lambdaKB7/lambda HFL 1 precursor reduced)	growth factor; cicatrizant	skin ulcer; osteoporosis; stroke; neuropathy; peripheral vascular disease; coronary artery disease

drug delivery system; proteinase inhibitor and trophic factor secreting implant; proteinase inhibitor secreting implant; trophic factor secreting implant		growth factor; neurotrophic factor; proteinase inhibitor	stroke
heat shock transcription factor modulators, ischemia; heat shock transcription factor modulators, cancer		heat shock transcription factor modulators	stroke; ischemia; reperfusion injury; cancer
RSR 13	2-[4-[2-[(3,5- dimethylphenyl)amino]-2- oxoethyl]phenoxy]-2- methylpropanoic acid	Hemoglobin, allosteric modification	surgery; heart ischemia; stroke
RSR 4	2-[4-[2-[(3,5- dichlorophenyl)amino]-2- oxoethyl]phenoxy]-2- methylpropanoic acid	Hemoglobin, allosteric modification	cancer; surgery; heart ischemia; stroke
RSR 46	2-[4-[2-[(2,3-dihydro- 1H-inden-5- yl)amino]-2- oxoethyl]phenoxy]-2- methylpropanoic acid	Hemoglobin, allosteric modification	cancer; surgery; heart ischemia; stroke
JP 7		Hemoglobin, synthetic allosteric modifiers of	cancer; surgery; heart ischemia; stroke
enoxaparin sodium; low molecular weight heparin; enoxaparin; enoxaparine; PK 10169; RPY 005; RP 54563; LOVENOX; CLEXAN; CLEXANE	heparin sodium salt	heparinoid	thrombosis; angina; stroke; myocardial infarction
GT 2016	1-(5-cyclohexyl-1- oxopentyl)-4-(1H- imidazol-4- yl)piperidine	histamine antagonist; histamine H3 antagonist	cognitive defect; stroke; attention deficit disorder
MAB, 1A29; MAB, ICAM-1		ICAM monoclonal antibody	stroke

NZ 097		IGF-1 ligand	brain ischemia; trauma; stroke; neurodegeneration
antibody-mediated stroke inhibitor		immunosuppressant; biotechnology	gynecological; stroke; thrombosis; myocardial infarction
insulin-like growth factor binding protein ligand inhibitors, IGFBP ligand inhibitors		insulin-like growth factor binding protein ligand inhibitors	stroke; neurodegeneration
neutrophil inhibitory factor; NIF; CORLEUKIN NIF		integrin antagonist; cell adhesion inhibitor; NSAID	reperfusion injury; inflammation; stroke
AM 36		Ion channel blocker	stroke; trauma
cation channel blocker		Ion channel blocker, cation channel blocker	stroke
Tirilazad; tirilazad mesylate; trilazad; U 74006F; FREDOX	21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-16-alpha-methyl-pregn-1,4,9-(11)-triene-3,20-dione	lazaroid	brain ischemia; stroke; trauma; heart ischemia; kidney disease
MAbs, leukocytes		Leukocytes monoclonal antibody	stroke
MAb, 23F2G; MAb, leukointegrin; Hu 23F2G		leukointegrin monoclonal antibody	multiple sclerosis; cardiovascular disease; myocardial infarction; stroke
stroke and trauma therapy, morphogenic proteins,		morphogenic proteins	trauma; stroke
Lubeluzole; R 87926; PROSYNAP	(S)-4-(2-benzothiazolylmethylamino)-alpha-[(3,4-difluorophenoxy)methyl]-1-piperidineethanol	Neuroprotectant	stroke; Alzheimer disease
drug delivery system, neurotrophic peptide; neurotrophic peptide delivery system; TROFEXIN-A	Trofexin-A	Neurotrophic factor	stroke

Neurotrophic peptide; TROFEXIN		neurotrophic factor; peptide; growth factor	stroke
NOX 101	Unspecified	nitric oxide scavenger	stroke; diabetes; cancer; trauma; transplant rejection; septic shock; cardiovascular disease
NOX 151		nitric oxide scavenger	stroke
A 84643	[S-(E)]-N-(4-amino- 5-hydroxy-2- pentenyl)-N'- nitroguanidine	nitric oxide synthase inhibitor	stroke; ischemia
Neuronal nitric oxide synthase inhibitors		nitric oxide synthase inhibitor	stroke; trauma
nitric oxide synthase inhibitors		nitric oxide synthase inhibitor	Parkinson disease; stroke
nitric oxide inhibitors,		nitric oxide synthetase inhibitor; NSAID	stroke; rheumatoid arthritis
ARL 15896; FPL 15896; ARL 15896AR; FPL15896AR	(S)-alpha-phenyl-2- pyridineethanamine	NMDA antagonist; glutamate antagonist	stroke
BIII 277; BIII 277CL	[2R- [2alpha,3(R*),6alpha[[1,2,3,4,5,6- hexahydro-3-(2- methoxypropyl)- 6,11,11-trimethyl-2,6- methano-3- benzazocin-9-ol hydrochloride	NMDA antagonist; glutamate antagonist	stroke
CGP 40116	[R-(E)]-2-amino-4- methyl-5-phosphono- 3-pentenoic acid	NMDA antagonist; glutamate antagonist	epilepsy; stroke
CNS 1118	N,N'-dimethyl-N,N'- bis(1- naphthyl)guanidine	NMDA antagonist; glutamate antagonist	stroke
CNS 1531	(+)-3-fluoro-10,5- iminomethano-10,11- dihydro-5H- dibenzo(a,d)cyclohept ane	NMDA antagonist; glutamate antagonist	stroke

CP 101606	[S-(R*,R*)]-4-hydroxy-alpha-(4-hydroxyphenyl)-beta-methyl-4-phenyl-1-piperidineethanol	NMDA antagonist; glutamate antagonist	stroke; trauma; neurodegeneration
eliprodil; SL 820715	(+,-)-alpha-(4-chlorophenyl)-4-[(4-fluorophenyl)methyl]-1-piperidineethanol	NMDA antagonist; glutamate antagonist	neuropathy; stroke; trauma
ES 2421		NMDA antagonist; glutamate antagonist	stroke
L 703717	7-chloro-4-hydroxy-3-[3-(4-methoxyphenyl)methyl]phenyl]-2(1H)-quinolinone	NMDA antagonist; glutamate antagonist	epilepsy; stroke
L 708541		NMDA antagonist; glutamate antagonist	epilepsy; stroke
licostinel; ACEA 1021; CGP 63446	6,7-dichloro-5-nitro-1,4-dihydro-2,3-quinoxalinedione	NMDA antagonist; glutamate antagonist	stroke; trauma
MDL 100453	4-oxo-5-phosphono-D-norvaline	NMDA antagonist; glutamate antagonist	epilepsy; neuropathy; stroke
NMDA antagonist		NMDA antagonist; glutamate antagonist	epilepsy; stroke; neuropathy
NMDA antagonist, subtype specific, SSNRA		NMDA antagonist; glutamate antagonist	stroke; trauma
NPS 1506		NMDA antagonist; glutamate antagonist	stroke; trauma
P 7189	2-amino-N-methyl-alpha-(3-methyl-2-thienyl)benzeneethanamine hydrochloride	NMDA antagonist; glutamate antagonist	stroke; neuropathy
PD 158473	3-(1-naphthalenyl)-5-(phosphonomethyl)-L-phenylalanine	NMDA antagonist; glutamate antagonist	Parkinson disease; stroke
PD 159913		NMDA antagonist; glutamate antagonist	Parkinson disease; stroke
Ro 256981		NMDA antagonist; glutamate antagonist	Parkinson disease; stroke
selfotel; CGS 19755	cis-4-(phosphonomethyl)-2-piperidinecarboxylic acid	NMDA antagonist; glutamate antagonist	stroke; trauma

SM 18400		NMDA antagonist; glutamate antagonist	stroke
aptiganel; CNS 1102; CDD 2515A; CERESTAT	N-(3-ethylphenyl)-N-methyl-N'-1-naphthalenyl-guanidine	NMDA antagonist; glutamate antagonist; analgesic	stroke; neuropathy; trauma; Parkinson disease; pain
conantokins		NMDA antagonist; glutamate antagonist; peptide; analgesic	epilepsy; stroke; schizophrenia; pain; ischemia
ADCI; SGB 017; ADCI	10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine-5-carboxamide	NMDA antagonist; glutamate antagonist; sodium channel blocker	epilepsy; stroke
ABS 401		Nonglutaminergic neuromodulators	neuropathy; stroke
notch signalling pathway modulators PS 519		notch signalling pathway modulators	stroke; cognitive defect; cancer
		NSAID; anti- ischemic; proteinase inhibitor	inflammation; stroke
BB 823		PAF antagonist	septic shock; stroke
BN 50739	6-(2-chlorophenyl)-9-[2-[(3,4-dimethoxyphenyl)thio]-1-thioxoethyl]-7,8,9,10-tetrahydro-1-methyl-4H-pyrido[4',3':4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine	PAF antagonist	hypotension; septic shock; stroke
ACTH (4-10); SEMAX		peptide	cognitive defect; trauma; stroke
corticotropin- releasing factor; corticotropin- releasing hormone; CRF; XERECEPT		peptide	cancer; stroke; trauma
pituitary adenylate cyclase activating polypeptide; PACAP	Unspecified	peptide	stroke
conantokin G		peptide; glutamate antagonist; NMDA antagonist	stroke; brain ischemia; epilepsy

denbufylline; BRL 30892	1,3-dibutyl-3,7-dihydro-7-(2-oxopropyl)-1H-purine-2,6-dione	phosphodiesterase inhibitor; vasodilator; xanthine	stroke
coronary artery disease therapy,		platelet antiaggregant	stroke; coronary artery disease
clopidogrel; clopidogrel bisulfate; SR 25990; SR 25990C; DV 7314; PCR 4099; SR 25990B; SR 25990A; SR 25990D; SR 25990E; PLAVIX; ISCOVER	(S)-alfa-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetic acid methyl ester	platelet antiaggregant	thrombosis; stroke; ischemia
ticlopidine; ticlopidine hydrochloride; 5332 C; 4 C 32; PCR 5332; PICLODIN; PICLONADINE; PROPACALL; TICLID; PANALDINE; ROBETARL; RONDORIN	5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridine	platelet antiaggregant; calcium antagonist	stroke; thrombosis
abciximab; abciximab; MAb, F(ab') ₂ fragment platelet; MAb, 7E3; c7E3 FAb; c7E3; ReoPro; CENTORX	immunoglobulin G1, (human-mouse monoclonal c7E3 clone p7E3VHhC.gamma.1 Fab fragment anti-human glycoprotein IIb/IIIa receptor), disulfide with human-mouse monoclonal c7E3 clone p7E3V.kappa.hc.kappa.alpha.light chain	platelet antiaggregant; monoclonal antibody	thrombosis; restenosis; angina; stroke; myocardial infarction
GPI 6000		poly (ADP ribose) polymerase inhibitor	stroke
GPI 6150		poly (ADP ribose) polymerase inhibitor	stroke; myocardial infarction

KC 399	[N-(2-cyanoethyl)-2,2-bisfluoromethyl-6-nitro-2H-1-benzopyran-4-carbothioamide]	potassium channel activator	angina; stroke
LOE 908	3,4-dihydro-6,7-dimethoxy-alpha-phenyl-N,N-bis[2-(2,3,4-trimethoxyphenyl)ethyl]-1-isoquinolineacetamide	potassium channel blocker	stroke
BMS 204352		potassium channel modulator	stroke
NS 1619	1,3-dihydro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-2H-benzimidazol-2-one	potassium channel modulator; bronchodilator	stroke; asthma
proline transport inhibitors		Proline transport inhibitor	epilepsy; stroke
drug delivery system, lipid microsphere, clinprost; clinprost lipid microsphere; TTC 909; ARTEON	[3aS-[3aalpha,5beta,6alpha(1E,3R*),6aalpha]]-1,3a,4,5,6,6a-hexahydro-5-hydroxy-6-(3-hydroxy-1-octenyl)-2-pentalenepentanoic acid methyl ester	prostanoid; platelet antiaggregant	thrombosis; stroke
fasudil; fasudil hydrochloride; AT 877; HA 1077; HA 004; ERIL	hexahydro-1-(5-isoquinolylsulfonyl)-1H-1,4-diazepine	protein kinase inhibitor; protein kinase C inhibitor; vasodilator	brain ischemia; stroke; angina; HIV infection
CPC 211; CERESINE		Pyruvate dehydrogenase activation to reduce lactic acid	stroke; trauma
SA 4503	1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride	sigma agonist	Alzheimer disease; depression; cognitive defect; stroke

BIII 890		sodium channel blocker	stroke
sodium channel blocker		sodium channel blocker	stroke
SL 34082908; SL 34.0829-08; SL 34.0829		sodium channel blocker; calcium channel blocker	stroke; brain ischemia
BIIR 561		sodium channel blocker; glutamate antagonist; AMPA antagonist	stroke
BM 27	4-(cycloheptylamino)-N-[(cycloheptylamino)carbonyl]-3-pyridinesulfonamide	sulfonylurea	stroke
SNO-tissue plasminogen activator; NMI 106		thrombolytic	stroke; myocardial infarction
Tisokinase; tissue plasminogen activator, natural; tPA, natural; AK 124; PLASVATA; HAPASE		thrombolytic	thrombosis; stroke
Prourokinase; PUK; rProUK; A 74187; PROLYSE		thrombolytic; plasminogen activator	thrombosis; stroke
Alteplase; tissue plasminogen activator; tPA; ACTIVASE; ACTILYSE; ACTIVACIN; GRTPA		thrombolytic; plasminogen activator; cicatrizant	thrombosis; skin ulcer; stroke
KT 2962; KT 2-962	3-[4-[(4-chlorophenyl)sulfonylamino]butyl]-6-(1-methylethyl)-1-azulene sulfonic acid monosodium salt	thromboxane antagonist; platelet antiaggregant	stroke; asthma; kidney disease; thrombosis
Isbogrel; CV 4151; A 66900; ANTEXAN	(E)-7-phenyl-7-(3-pyridyl)-6-heptenoic acid	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; stroke

Ozagrel; ozagrel sodium; OKY 046; DOMENAN; CATACLOT; XANBON; VEGA	(E)-3-[4-(1H-imidazol-1-ylmethyl)phenyl]-2-propenoic acid	thromboxane synthetase inhibitor; platelet antiaggregant	stroke; thrombosis; asthma; cough
Y 20811	4-(hydroxy(5-(1H-imidazol-1-yl)-2-methylphenyl)methyl)-3,5-dimethylbenzoic acid, monosodium salt	thromboxane synthetase inhibitor; platelet antiaggregant	thrombosis; asthma; stroke
NZ 093		Undisclosed receptor ligand	brain ischemia; trauma; stroke; neurodegeneration
CNS 1		Unknown	stroke
EAB 318		Unknown	stroke
ONO 2506		unknown	stroke
SB 221420		Unknown	stroke
SPI 29		Unknown	myocardial infarction; stroke
SPI 42		Unknown	myocardial infarction; stroke
ST 765		Unknown	stroke
stroke therapy		Unknown	stroke; trauma
TV 2711; 2711	Polyamine	Unknown	stroke; trauma
Pentoxifylline; oxpentifylline; EBISANIN; SEVSTAN; TRENTAL; TORENTAL	3,7-dimethyl-1-(5-oxo-hexyl)xanthine	xanthine; vasodilator	peripheral vascular disease; stroke; atherosclerosis

Table 38. Current Candidate Therapeutic Interventions for the Treatment of Arthritis.

Product Name	Chemical Name	Action	Indication
BW 4C; BW A4C; BW 4C86	N-(3-phenoxy-phenyl)-2-propenyl)acetohydroxamic acid	5 lipoxygenase inhibitor; chelating agent; NSAID	arthritis; psoriasis
tenidap; tenidap sodium; CP 66248; CP 6624842; KENIDA; ENABLE; ENABLEX; REUMATEN	(Z)-5-chloro-2,3-dihydro-3-(hydroxy-2-thienylmethylene)-2-oxo-1H-indole-1-carboxamide	5 lipoxygenase inhibitor; COX inhibitor; NSAID	rheumatoid arthritis; arthritis
flobufen; VUFB 16066	2',4'-difluoro-alpha-methyl-gamma-oxo-[1,1'-biphenyl]-4-butanoic acid	5 lipoxygenase inhibitor; COX inhibitor; NSAID	rheumatoid arthritis
ZD 2138; ICI D2138	6-[[[3-fluoro-5-(tetrahydro-4-methoxy-2H-pyran-4-yl)phenoxy]methyl]-1-methyl-2(1H)-quinolinone	5 lipoxygenase inhibitor; NSAID	arthritis; asthma
AKI 1	unspecified	adenosine regulating agent; NSAID	inflammation; arthritis
AKI 2	unspecified	adenosine regulating agent; NSAID	inflammation; arthritis
analben	unspecified	analgesic	rheumatoid arthritis; pain
drug delivery system, OSAT ibuprofen; ibuprofen sustained release	unspecified	analgesic; NSAID	pain; rheumatoid arthritis; osteoarthritis; inflammation
SC 107	unspecified	analgesic; NSAID	arthritis; pain
samarium 153 Sm lexidronam; Sm 153-EDTMP; samarium 153-EDTMP; samarium EDTMP; CYT 424; QUADRAMET	(OC-6-21)-[[[1,2-ethanediylbis[nitrilobis(methylene)]tetrakis(phosphonato]](8-)-N,N',OP,OP',OP'',OP''']-samarate(5-)-153Sm	analgesic; NSAID; radiotherapeutic	cancer; pain; rheumatoid arthritis
AE 941; NEOVASTAT; NEORETNA; PSOVASCAR; ARTHROVAS	unspecified	angiogenesis inhibitor; NSAID	cancer; psoriasis; rheumatoid arthritis; eye disease; retinopathy

FR 111142; WF 2015A	4,5-dihydroxy-2-hexenoic acid 5-methoxy-4-[2-methyl-3-(3-methyl-2-butenyl)oxiranyl]-1-oxaspiro[2.5]oct-6-yl ester	angiogenesis inhibitor; NSAID	cancer; rheumatoid arthritis; retinopathy
troponin I; cartilage derived inhibitor	unspecified	angiogenesis inhibitor; NSAID; biotechnology	cancer; rheumatoid arthritis; eye disease
MHC II peptidomimetic, rheumatoid arthritis	unspecified	Antagonists of MHC	rheumatoid arthritis
SB 226882	4-[4-(4-fluorophenyl)-1-(4-piperidinyl)-1H-imidazol-5-yl]-N-methyl-2-pyrimidinamine	antifungal; MAP kinase inhibitor; signal transduction inhibitor; imidazole	inflammation; asthma; rheumatoid arthritis
ZYN-LINKER conjugated methotrexate	unspecified	antimetabolite; NSAID	cancer; rheumatoid arthritis; psoriasis
TRK 530	[[[4-(methylthio)phenyl]thio]methylene]bisphosphonic acid disodiumsalt	antioxidant; bisphosphonate	rheumatoid arthritis
LY 221068	5-[[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-3-(dimethylamino)-4-thiazolidinone	antioxidant; NSAID	arthritis
LY 269415	5-[[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-3-(methylamino)-4-thiazolidinone	antioxidant; NSAID	arthritis
AHR 15010	1-[(2-methoxyphenoxy)methyl]-1,2-ethanediyl ester of sulfamic acid	carbonate dehydratase inhibitor; NSAID	arthritis

caspase inhibitors, Cytovia	unspecified	caspase inhibitor	neurodegeneration; myocardial infarction; rheumatoid arthritis; septic shock
ICE inhibitor, IDUN	unspecified	caspase inhibitor; apoptosis inhibitor; IL-1 beta converting enzyme inhibitor; immunosuppressant	transplant rejection; septic shock; rheumatoid arthritis; inflammatory bowel disease; diabetes
VLA4 integrin antagonist, Cytel	unspecified	cell adhesion inhibitor; integrin antagonist; VLA 4 antagonist; NSAID	asthma; rheumatoid arthritis; multiple sclerosis
drug delivery system, somatomedin C; drug delivery system, insulin-like growth factor-1; somatomedin C DepoFoam; Depo IGF-1	unspecified	cicatrizant; hormone; NSAID; growth factor	rheumatoid arthritis; osteoporosis
fibroblast anticollagenase; FIBAC; anticollagenase fibroblast	unspecified	cicatrizant; NSAID	arthritis; cancer; skin ulcer; arthritis
BB 926	unspecified	collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	arthritis; eye disease
collagenase inhibitors, Affymax	unspecified	collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	arthritis; inflammation
collagenase inhibitors, Xenova; XR 168 series	unspecified	collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	rheumatoid arthritis

Ro 319790	unspecified	collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	rheumatoid arthritis; arthritis
GR 129574A	(R)-N-[1-carboxy-3-(1,3-dihydro-1,3-dioxo-2H-benz[f]isoindol-2-yl)propyl]-L-leucyl-N-methyl-L-phenylalaninamide mono(trifluoroacetate)	collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	arthritis
Ro 323555; TROCADE	beta-(cyclopentylmethyl)-N-hydroxy-gamma-oxo-alfa-[(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)methyl]-1-piperidinebutanamide	collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	arthritis
WY 46135	N-[[[(5-chloro-2-benzothiazolyl)thio]phenylacetyl]-L-cysteine	collagenase inhibitor; matrix metalloproteinase inhibitor; proteinase inhibitor; NSAID	arthritis
MAB, C5; MAb, complement C5; 5G1.1	unspecified	complement inhibitor; monoclonal antibody; immunosuppressant; NSAID	rheumatoid arthritis; systemic lupus erythematosus
hyaluronic acid 6- alpha-methylprednisolone ester; HYC 141	unspecified	corticosteroid	rheumatoid arthritis
MYC 2095	unspecified	corticosteroid	arthritis
rimexolone; trimexolone; ORG 6216; RIMEXEL; VEXOL	(11beta,16alpha,17beta)-11-hydroxy-16,17-dimethyl-17-(1-oxopropyl)androst-1,4-dien-3-one	corticosteroid	rheumatoid arthritis; inflammation; eye disease

deflazacort; azacort; L 5458; MDL 458; AZACORTID; CALCORT; LANTADIN; DEFLAN; FLANTADIN; DEZACOR; ZAMENE; ROSILIN; DEFLAMON; PRANDIN	(11beta,16beta)-21-(acetyloxy)-11-hydroxy-2'-methyl-5'H-pregna-1,4-diene-3,20-dione	corticosteroid	rheumatoid arthritis; skin disease; asthma
prednisolone farnesylate; PNF 21; FARNESONE; FARNERATE GEL; FARNEZONE GEL	[11beta,21(2E,6E)]-11,17-dihydroxy-21-[(3,7,11-trimethyl-1-oxo-2,6,10-dodecatrienyl)oxy]-pregna-1,4-diene-3,20-dione	corticosteroid	rheumatoid arthritis; osteoarthritis
ORG 6632	21-chloro-9alpha-fluoro-11beta-hydroxy-16alpha,17alpha-dimethylpregna-1,4-diene-3,20-dione	corticosteroid; immunosuppressant	cancer; rheumatoid arthritis
RU 46057	2-[1,2-bis(1-oxopropoxy)ethyl]-4-hydroxy-N-2-thiazolyl-8-(trifluoromethyl)-3-quinolinecarboxamide	COX inhibitor; 5-lipoxygenase inhibitor; NSAID	arthritis; psoriasis
meloxicam; UH AC62; UH AC26XX; MOBIC; MOBICOX; MOBEC; MOVALIS; MOVATEC	4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide	COX inhibitor; analgesic; COX 2 inhibitor; NSAID	rheumatoid arthritis; inflammation; pain; osteoarthritis
SD 8381	unspecified	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	arthritis
SC 57666	1-(4-fluorophenyl)-2-(4-methylsulphonylphenyl)cyclopentene	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	arthritis

valdecoxib; SC 65872	4-(5-methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	arthritis; pain
rofecoxib; MK 966; VIOXX	4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	inflammation; rheumatoid arthritis; osteoarthritis; pain; Alzheimer disease
celecoxib; SC 58635; YM 177; CELEBREX; CELEBRA	4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide	COX inhibitor; COX 2 inhibitor; analgesic; NSAID	arthritis; pain; cancer
LAS 33826	unspecified	COX inhibitor; COX 2 inhibitor; NSAID	rheumatoid arthritis
pranoprofen; Y 8004; ITEOPAN; NIEFTOP; NIFLAN; CESFLAN; ELICAPRIL; MABUL; FLANIN; PRAFEN; PRANOX; DIFEN	alpha-methyl-5H[1]benzopyrano[2,3-b]pyridine-7-acetic acid	COX inhibitor; NSAID	rheumatoid arthritis; eye disease
lipophosphoglycan analogue	unspecified	Cytokine antagonist	atherosclerosis; arthritis; septic shock; HIV infection
cytokine trap, Regeneron	unspecified	cytokine antagonist	cancer; asthma; rheumatoid arthritis; allergy
interleukin-12 signal transduction antagonists, Ligand	unspecified	cytokine antagonist; immunosuppressant; NSAID	autoimmune disease; transplant rejection; rheumatoid arthritis
RP 54745	4-chloro-5-(3,4-dihydro-1-methyl-2(1H)-isoquinoliny)-3H-1,2-dithiol-3-one	cytokine antagonist; immunosuppressant; NSAID	rheumatoid arthritis; inflammatory bowel disease; psoriasis
interleukin-8 receptor; IL-8r	unspecified	cytokine antagonist; NSAID	psoriasis; rheumatoid arthritis; respiratory distress syndrome; septic shock